{
  "category": "Clinical Pathology",
  "subject": {
    "name": "Transfusion Medicine",
    "url": "https://app.pathprimer.com/curriculum/dca180d7-168d-4fda-b798-968c1f7c0dc6",
    "lessons": {
      "Regulatory Issues in Transfusion Medicine": {
        "name": "Regulatory Issues in Transfusion Medicine",
        "url": "https://app.pathprimer.com/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
        "topics": {
          "Regulatory Issues in Blood Banking": {
            "name": "Regulatory Issues in Blood Banking",
            "url": "https://app.pathprimer.com/document/a5fd2947-caa2-4804-9f06-ccb7f7a0d476/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Clinical laboratories are highly regulated and transfusion services within clinical laboratory experience most regulatory requirements"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "Transfusion-related fatalities must be reported to FDA as soon as possible (initial notification)/within 7 days (written evaluation)"
                  },
                  {
                    "text": "Transfusion services and blood collection centers can be warned, face sanctions, or be closed by FDA for noncompliances"
                  },
                  {
                    "text": "Transfusion-associated sentinel event"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion Medicine/Blood Bank Regulation and Accreditation": [
                  {
                    "text": "Clinical laboratories are highly regulatedTransfusion services within clinical laboratory experience most regulatory requirements",
                    "sub_points": [
                      "Transfusion services within clinical laboratory experience most regulatory requirements"
                    ]
                  },
                  {
                    "text": "Over past > 100 yr, blood transfusion has grown from transfusion of small amounts of fresh whole blood to one of most common medical procedures"
                  },
                  {
                    "text": "Safe, reliable, and available blood supply is critical to modern health care"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "US Code of Federal Regulations Title 21 (21 CFR)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Center for Biologics Evaluation and Research (CBER)"
                  },
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Center for Medicare and Medicaid Services (CMS)"
                  },
                  {
                    "text": "Clinical Laboratory Improvement Amendments of 1988 (CLIA)"
                  },
                  {
                    "text": "College of American Pathologists (CAP)"
                  },
                  {
                    "text": "The Joint Commission (TJC)"
                  },
                  {
                    "text": "Nuclear Regulatory Commission (NRC)"
                  },
                  {
                    "text": "Department of Transportation (DOT)"
                  },
                  {
                    "text": "Occupational Safety and Health Administration (OSHA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Blood establishment manufactures blood products"
                  },
                  {
                    "text": "Blood establishment computer system includes computer hardware, computer software, peripheral devices, networks, personnel, and documentationUser’s Manuals and Standard Operating Procedures",
                    "sub_points": [
                      "User’s Manuals and Standard Operating Procedures"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Food and Drug Administration": [
                  {
                    "text": "Oversees blood product collection, manufacturing, storage, and distribution by 21 CFR"
                  },
                  {
                    "text": "21 CFR lists current good manufacturing practices applicable to blood centers and transfusion servicesEnsures blood products are manufactured in a way that protects safety, quality, identity, and purity of product",
                    "sub_points": [
                      "Ensures blood products are manufactured in a way that protects safety, quality, identity, and purity of product"
                    ]
                  },
                  {
                    "text": "Within FDA, CBER is primary regulator of blood products"
                  },
                  {
                    "text": "FDA regulations on blood industry are binding"
                  },
                  {
                    "text": "FDA guidances do not carry weight of law but are generally followed by all blood establishments"
                  },
                  {
                    "text": "Blood is considered a drug as it is intended to cure, mitigate, treat, or prevent disease"
                  },
                  {
                    "text": "FDA ensures safety and efficacy of US blood supply by focusing onDonor screeningDonor IDM testingDonor deferral and deferred donor managementQuarantine of unacceptable blood productsInvestigation of deviations",
                    "sub_points": [
                      "Donor screening",
                      "Donor IDM testing",
                      "Donor deferral and deferred donor management",
                      "Quarantine of unacceptable blood products",
                      "Investigation of deviations"
                    ]
                  },
                  {
                    "text": "Transfusion-related fatalities must be reported to FDA as soon as possible (initial notification) within 7 days (written evaluation)"
                  },
                  {
                    "text": "FDA registration and license of transfusion services and blood collection centersLicensed organizationsBlood collection services that ship products across states linesRegistered organizationsTransfusion services that substantially modify blood (leukoreduction, irradiation, washing, and freezing blood products)Blood collection services that do not ship across state linesTransfusion services that routinely forward blood to other hospitalsExempt organizationsTransfusion services that do not manufacture or substantially modify blood",
                    "sub_points": [
                      "Licensed organizationsBlood collection services that ship products across states lines",
                      "Blood collection services that ship products across states lines",
                      "Registered organizationsTransfusion services that substantially modify blood (leukoreduction, irradiation, washing, and freezing blood products)Blood collection services that do not ship across state linesTransfusion services that routinely forward blood to other hospitals",
                      "Transfusion services that substantially modify blood (leukoreduction, irradiation, washing, and freezing blood products)",
                      "Blood collection services that do not ship across state lines",
                      "Transfusion services that routinely forward blood to other hospitals",
                      "Exempt organizationsTransfusion services that do not manufacture or substantially modify blood",
                      "Transfusion services that do not manufacture or substantially modify blood"
                    ]
                  },
                  {
                    "text": "FDA inspects registered and licensed organizations every 2 yrInspections are unannounced and review operational processes involved with following safety areasQuality assuranceDonor screeningDonor testingProduct testingQuarantine/inventory managementComponent production/processingTransfusion services and blood collection centers can be warned, face sanctions, or be closed by FDA for noncompliance",
                    "sub_points": [
                      "Inspections are unannounced and review operational processes involved with following safety areasQuality assuranceDonor screeningDonor testingProduct testingQuarantine/inventory managementComponent production/processing",
                      "Quality assurance",
                      "Donor screening",
                      "Donor testing",
                      "Product testing",
                      "Quarantine/inventory management",
                      "Component production/processing",
                      "Transfusion services and blood collection centers can be warned, face sanctions, or be closed by FDA for noncompliance"
                    ]
                  },
                  {
                    "text": "Unlicensed blood products can be shipped across state lines only for infrequent medical emergencies"
                  }
                ],
                "Center for Medicare and Medicaid Services and Clinical Laboratory Improvement Amendments of 1988": [
                  {
                    "text": "CMS regulates all US clinical laboratories"
                  },
                  {
                    "text": "Laws establishing CMS authority over clinical laboratoriesCLIA 1988Public Health Service Act of 1944CFR 42 (Public Health)",
                    "sub_points": [
                      "CLIA 1988",
                      "Public Health Service Act of 1944",
                      "CFR 42 (Public Health)"
                    ]
                  },
                  {
                    "text": "CLIA certification requiresAdequate facilities, equipment, personnel, and supervisionQuality management system (including proficiency testing)",
                    "sub_points": [
                      "Adequate facilities, equipment, personnel, and supervision",
                      "Quality management system (including proficiency testing)"
                    ]
                  },
                  {
                    "text": "Inspections under CLIA occur at least every 2 yrInspections involve sample misidentification, blood administration, blood utilization, and transfusion reaction investigation",
                    "sub_points": [
                      "Inspections involve sample misidentification, blood administration, blood utilization, and transfusion reaction investigation"
                    ]
                  },
                  {
                    "text": "Transfusion services perform immunohematology/compatibility testing, categorized as high-complexity testing"
                  },
                  {
                    "text": "All transfusion services must be CLIA certifiedBy state health departmentBy deemed accreditation agency (e.g., AABB, CAP, TJC)",
                    "sub_points": [
                      "By state health department",
                      "By deemed accreditation agency (e.g., AABB, CAP, TJC)"
                    ]
                  }
                ],
                "AABB and College of American Pathologists Accreditation": [
                  {
                    "text": "AABB inspections ensure compliance with current AABB Standards for Blood Banks and Transfusion Services"
                  },
                  {
                    "text": "CAP inspections ensure compliance with current CAP Transfusion Medicine Checklist"
                  }
                ],
                "The Joint Commission": [
                  {
                    "text": "Inspections involve sample misidentification, blood administration, blood utilization, and transfusion reaction investigation"
                  },
                  {
                    "text": "TJC sentinel events require immediate investigation and responseExample: Hemolytic transfusion reaction involving administration of blood or blood products having major blood group incompatibilities (ABO, Rh, other blood groups)Root cause analysis must be completed within 45 days",
                    "sub_points": [
                      "Example: Hemolytic transfusion reaction involving administration of blood or blood products having major blood group incompatibilities (ABO, Rh, other blood groups)",
                      "Root cause analysis must be completed within 45 days"
                    ]
                  }
                ],
                "Other Regulatory Agencies": [
                  {
                    "text": "NRC for radioactive source material used for irradiation"
                  },
                  {
                    "text": "DOT and OSHA regulate areas of blood center and hospital transfusion services"
                  }
                ]
              },
              "LABORATORY INFORMATICS": {
                "Blood Establishment Computer Systems": [
                  {
                    "text": "FDA regulated as medical devices"
                  },
                  {
                    "text": "Ensure safe transfusion practice and proper record retention and are usedTo determine donor eligibility and release of blood components as suitable for transfusion or further manufacture (electronic crossmatch)To perform compatibility testing and other related functionsTo establish positive patient identification before transfusion by scanning machine readable informationBarcodes on patient wristbands, specimen containers, and blood product labelsTo perform other functions associated with transfusionRecording patient vital signs and tracking blood products",
                    "sub_points": [
                      "To determine donor eligibility and release of blood components as suitable for transfusion or further manufacture (electronic crossmatch)",
                      "To perform compatibility testing and other related functions",
                      "To establish positive patient identification before transfusion by scanning machine readable informationBarcodes on patient wristbands, specimen containers, and blood product labels",
                      "Barcodes on patient wristbands, specimen containers, and blood product labels",
                      "To perform other functions associated with transfusionRecording patient vital signs and tracking blood products",
                      "Recording patient vital signs and tracking blood products"
                    ]
                  },
                  {
                    "text": "Subject to FDA 510(k) premarket clearance and must be validated according to CFR and FDA regulations"
                  },
                  {
                    "text": "Use algorithmic approach to ensure safe and properly documented blood issue"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Quality Systems in Blood Banking": {
            "name": "Quality Systems in Blood Banking",
            "url": "https://app.pathprimer.com/document/0f5ac023-446d-4eee-a0e3-343b1c59f261/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Quality in transfusion medicine involves continual focus on eliminating errors and nonconformances with goal to prospectively respond to problems and challenges before they impact blood product safety/conformance to requirements or blood donor safety"
                  },
                  {
                    "text": "Quality is also focused on maximizing efficiencies in processes"
                  },
                  {
                    "text": "Quality is a journey, not a destination"
                  },
                  {
                    "text": "Product recall is removal or correction of marketed product whose distribution was major violation of FDA regulation"
                  },
                  {
                    "text": "Lookback is process initiated after donor tests positive for infectious disease to identify previous blood product donations from that donor that may have been during infectious window period"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Current good manufacturing processes (CGMP)"
                  },
                  {
                    "text": "Center for Biologics Evaluation and Research (CBER)"
                  },
                  {
                    "text": "Office of Compliance and Biologics Quality (OCBQ)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Code of Federal Regulation (CFR)"
                  },
                  {
                    "text": "Quality control (QC)"
                  },
                  {
                    "text": "Quality System Essentials (QSE)"
                  },
                  {
                    "text": "Quality Management System (QMS)"
                  },
                  {
                    "text": "Standard operating procedures (SOP)"
                  },
                  {
                    "text": "Corrective and preventive action (CAPA)"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Biologic Product Deviation Report to Food and Drug Administration": [
                  {
                    "text": "21 CFR 606.171 requires reporting of any event causing deviation from CGMP associated with manufacturing (testing, processing, packing, labeling, or storage or with holding or distribution) of licensed biologic product or blood or blood component, in which safety, purity, or potency of distributed product may be affected"
                  },
                  {
                    "text": "Blood establishments and transfusion services are required to report to CBER/OCBQ as soon as possibleNot to exceed 45 calendar days from date of discovery of information reasonably suggesting reportable event has occurred",
                    "sub_points": [
                      "Not to exceed 45 calendar days from date of discovery of information reasonably suggesting reportable event has occurred"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Current Good Manufacturing Processes": [
                  {
                    "text": "FDA regulations for blood establishments in CFR focus primarily on CGMP"
                  },
                  {
                    "text": "CGMP requirements are set forth to ensure safety, quality, identity, potency, and purity of drugs and biologics"
                  },
                  {
                    "text": "CGMP standards include mandates that address issues such as personnel, training, competency, record keeping, documentation systems, electronic records, facilities, equipment management (including validation), labeling, and error investigation/management"
                  },
                  {
                    "text": "CGMP are intended to maximize quality of blood collection and blood components"
                  },
                  {
                    "text": "Manufacturers of reagents, devices, and computer software used in transfusion medicine are regulated by FDA and must follow CGMP"
                  },
                  {
                    "text": "CFR requires independent QC/quality assurance unit that has responsibility and authority over blood manufactureShould report directly to executive managementShould have authority to initiate corrective action",
                    "sub_points": [
                      "Should report directly to executive management",
                      "Should have authority to initiate corrective action"
                    ]
                  }
                ],
                "Quality System Essentials/Quality Management System": [
                  {
                    "text": "FDA “Guideline for Quality Assurance in Blood Establishments” (60 FR 36290, July 14, 1995) required that blood facility’s quality program must include processes to prevent, detect, and correct deficiencies that could compromise blood product qualityThis ensures prospective assurance of quality rather than reactive retrospective response to errors",
                    "sub_points": [
                      "This ensures prospective assurance of quality rather than reactive retrospective response to errors"
                    ]
                  },
                  {
                    "text": "There are 10 AABB QSEAll derived from ISO 9000 system, which originated in industrial manufacturing quality assuranceOrganizationOrganizational reporting chart, regular review of QMSResourcesJob descriptions, hiring plan, training, competency assessmentEquipmentValidation, calibration, preventive maintenance, monitoring, investigation of failuresSupplier and customer issuesQualification of critical supplies/vendorsCritical inputs must beQualified before useGoverned by agreementsInspected and tested at receiptProcess controlValidation plansProcess/test method validationAnnually review SOPAdhere to manufacturer’s recommendationsRegular QCProficiency testingTraceable recordsDocuments and recordsLevel 1—Policies: \"What to do\"In response to various situationsLevel 2—Processes: \"How it happens\"Development of a methodLevel 3—Procedures: \"Steps to do it\"Course of actionLevel 4—Forms/Records: “How you did it”Supporting documents that need to be completed when performing procedures and following processes and policiesOnly current documents should be usedThere must be control over document distributionManagement of deviationsDeviation: A departure from SOPs, regulation, or industry standardRespond to deviations byDocument and classify eventDetermine effect of event on qualityRoot cause analysisCAPAInternal event report: who, what, when, where, why/how, follow-upReport to external agencies when requiredEvaluate effectiveness of CAPATrack and trend reported eventsAssessmentsInternalQuality indicators (i.e., blood outdating rate)Blood utilization assessmentInternal inspectionsExternalProficiency testingExternal inspections and accreditationProcess improvement through CAPAAnalysis of findings from internal or external assessmentsAnalysis or trending of variance and incident reportsSystematically investigate near misses and sentinel events with focus on root cause analysis and systems changeDonor and customer feedbackJoint Commission requires data monitoring for blood component use and transfusion reactionsFacilities and safetyClean and well-maintained work space that is conducive to performing required workAccess limited to include only necessary personnel",
                    "sub_points": [
                      "All derived from ISO 9000 system, which originated in industrial manufacturing quality assurance",
                      "OrganizationOrganizational reporting chart, regular review of QMS",
                      "Organizational reporting chart, regular review of QMS",
                      "ResourcesJob descriptions, hiring plan, training, competency assessment",
                      "Job descriptions, hiring plan, training, competency assessment",
                      "EquipmentValidation, calibration, preventive maintenance, monitoring, investigation of failures",
                      "Validation, calibration, preventive maintenance, monitoring, investigation of failures",
                      "Supplier and customer issuesQualification of critical supplies/vendorsCritical inputs must beQualified before useGoverned by agreementsInspected and tested at receipt",
                      "Qualification of critical supplies/vendors",
                      "Critical inputs must beQualified before useGoverned by agreementsInspected and tested at receipt",
                      "Qualified before use",
                      "Governed by agreements",
                      "Inspected and tested at receipt",
                      "Process controlValidation plansProcess/test method validationAnnually review SOPAdhere to manufacturer’s recommendationsRegular QCProficiency testingTraceable records",
                      "Validation plans",
                      "Process/test method validation",
                      "Annually review SOP",
                      "Adhere to manufacturer’s recommendations",
                      "Regular QC",
                      "Proficiency testing",
                      "Traceable records",
                      "Documents and recordsLevel 1—Policies: \"What to do\"In response to various situationsLevel 2—Processes: \"How it happens\"Development of a methodLevel 3—Procedures: \"Steps to do it\"Course of actionLevel 4—Forms/Records: “How you did it”Supporting documents that need to be completed when performing procedures and following processes and policiesOnly current documents should be usedThere must be control over document distribution",
                      "Level 1—Policies: \"What to do\"In response to various situations",
                      "In response to various situations",
                      "Level 2—Processes: \"How it happens\"Development of a method",
                      "Development of a method",
                      "Level 3—Procedures: \"Steps to do it\"Course of action",
                      "Course of action",
                      "Level 4—Forms/Records: “How you did it”Supporting documents that need to be completed when performing procedures and following processes and policies",
                      "Supporting documents that need to be completed when performing procedures and following processes and policies",
                      "Only current documents should be used",
                      "There must be control over document distribution",
                      "Management of deviationsDeviation: A departure from SOPs, regulation, or industry standardRespond to deviations byDocument and classify eventDetermine effect of event on qualityRoot cause analysisCAPAInternal event report: who, what, when, where, why/how, follow-upReport to external agencies when requiredEvaluate effectiveness of CAPATrack and trend reported events",
                      "Deviation: A departure from SOPs, regulation, or industry standard",
                      "Respond to deviations byDocument and classify eventDetermine effect of event on qualityRoot cause analysisCAPAInternal event report: who, what, when, where, why/how, follow-upReport to external agencies when requiredEvaluate effectiveness of CAPATrack and trend reported events",
                      "Document and classify event",
                      "Determine effect of event on quality",
                      "Root cause analysis",
                      "CAPA",
                      "Internal event report: who, what, when, where, why/how, follow-up",
                      "Report to external agencies when required",
                      "Evaluate effectiveness of CAPA",
                      "Track and trend reported events",
                      "AssessmentsInternalQuality indicators (i.e., blood outdating rate)Blood utilization assessmentInternal inspectionsExternalProficiency testingExternal inspections and accreditation",
                      "InternalQuality indicators (i.e., blood outdating rate)Blood utilization assessmentInternal inspections",
                      "Quality indicators (i.e., blood outdating rate)",
                      "Blood utilization assessment",
                      "Internal inspections",
                      "ExternalProficiency testingExternal inspections and accreditation",
                      "Proficiency testing",
                      "External inspections and accreditation",
                      "Process improvement through CAPAAnalysis of findings from internal or external assessmentsAnalysis or trending of variance and incident reportsSystematically investigate near misses and sentinel events with focus on root cause analysis and systems changeDonor and customer feedbackJoint Commission requires data monitoring for blood component use and transfusion reactions",
                      "Analysis of findings from internal or external assessments",
                      "Analysis or trending of variance and incident reports",
                      "Systematically investigate near misses and sentinel events with focus on root cause analysis and systems change",
                      "Donor and customer feedback",
                      "Joint Commission requires data monitoring for blood component use and transfusion reactions",
                      "Facilities and safetyClean and well-maintained work space that is conducive to performing required workAccess limited to include only necessary personnel",
                      "Clean and well-maintained work space that is conducive to performing required work",
                      "Access limited to include only necessary personnel"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Blood Product Labeling": {
            "name": "Blood Product Labeling",
            "url": "https://app.pathprimer.com/document/5dabe499-eed1-4e0a-8023-696e3f3b58cb/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Implementation of ISBT 128 blood labeling system was required by AABB Standards on May 1, 2008ISBT 128 significantly improved blood component traceabilitySole global standard for identification, labeling, and information transfer for medical products of human origin (MPHO)Allows continued traceability of MPHO across international borders and disparate health care systemsEnsures globally unique identificationBuilt on internationally agreed upon terminology available in a public document",
                    "sub_points": [
                      "ISBT 128 significantly improved blood component traceabilitySole global standard for identification, labeling, and information transfer for medical products of human origin (MPHO)Allows continued traceability of MPHO across international borders and disparate health care systemsEnsures globally unique identificationBuilt on internationally agreed upon terminology available in a public document",
                      "Sole global standard for identification, labeling, and information transfer for medical products of human origin (MPHO)",
                      "Allows continued traceability of MPHO across international borders and disparate health care systems",
                      "Ensures globally unique identification",
                      "Built on internationally agreed upon terminology available in a public document"
                    ]
                  }
                ],
                "Terminology": [
                  {
                    "text": "Donation identification number (DIN)"
                  },
                  {
                    "text": "International Council for Commonality in Blood Banking Automation (ICCBBA)Nongovernmental organization affiliated with WHO that manages ISBT 128",
                    "sub_points": [
                      "Nongovernmental organization affiliated with WHO that manages ISBT 128"
                    ]
                  },
                  {
                    "text": "International Society for Blood Transfusion/Information Standard for Blood and Transplant (ISBT)"
                  },
                  {
                    "text": "Medical products of human origin (MPHO)"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Blood Product Labeling Requirements": [
                  {
                    "text": "Labels and bar codes: Machine-readable representations of informationLabels and bar codes include critical information necessary to accurately identify, store, ship, track, and distribute blood productsMachine-readable labels increase transfusion service efficiency, accuracy, and safety",
                    "sub_points": [
                      "Labels and bar codes include critical information necessary to accurately identify, store, ship, track, and distribute blood products",
                      "Machine-readable labels increase transfusion service efficiency, accuracy, and safety"
                    ]
                  },
                  {
                    "text": "Federal Drug Administration (FDA) recognizes 2 blood product labeling languagesCodabarISBT 128",
                    "sub_points": [
                      "Codabar",
                      "ISBT 128"
                    ]
                  },
                  {
                    "text": "FDA does not specify which language should be used, only that eye-readable and machine-readable information must be available on labelFDA label requirements for blood productsUnique facility identifierLot number relating to donorProduct codeABO and Rh of donor",
                    "sub_points": [
                      "FDA label requirements for blood productsUnique facility identifierLot number relating to donorProduct codeABO and Rh of donor",
                      "Unique facility identifier",
                      "Lot number relating to donor",
                      "Product code",
                      "ABO and Rh of donor"
                    ]
                  },
                  {
                    "text": "AABB Standards and Accreditation program requires that facilities comply with ISBT 128 labeling for blood and blood productsImproves unit traceability and lookback tracking due to unique numerical identificationEach and every blood product worldwide can be identified and traced back to blood collection facility and individual blood donorPrevents errors in data entry through use of data identifiers and check charactersSpecial testing results can be stored on label",
                    "sub_points": [
                      "Improves unit traceability and lookback tracking due to unique numerical identificationEach and every blood product worldwide can be identified and traced back to blood collection facility and individual blood donor",
                      "Each and every blood product worldwide can be identified and traced back to blood collection facility and individual blood donor",
                      "Prevents errors in data entry through use of data identifiers and check charactersSpecial testing results can be stored on label",
                      "Special testing results can be stored on label"
                    ]
                  },
                  {
                    "text": "Implementation of ISBT 128Implementation in blood establishments took many years and significant revisions to computer information systemsISBT 128 replaced Codabar (prior labeling system)ISBT 128 label includes more information than Codabar label, and in less spaceISBT 128 improved on Codabar system by including internal check digit to prevent bar-code misreadsBlood banks that store or receive cryopreserved red cells may still encounter Codabar labelsMust have process to manage such units within their ISBT 128-based laboratory information system",
                    "sub_points": [
                      "Implementation in blood establishments took many years and significant revisions to computer information systems",
                      "ISBT 128 replaced Codabar (prior labeling system)ISBT 128 label includes more information than Codabar label, and in less spaceISBT 128 improved on Codabar system by including internal check digit to prevent bar-code misreadsBlood banks that store or receive cryopreserved red cells may still encounter Codabar labelsMust have process to manage such units within their ISBT 128-based laboratory information system",
                      "ISBT 128 label includes more information than Codabar label, and in less space",
                      "ISBT 128 improved on Codabar system by including internal check digit to prevent bar-code misreads",
                      "Blood banks that store or receive cryopreserved red cells may still encounter Codabar labelsMust have process to manage such units within their ISBT 128-based laboratory information system",
                      "Must have process to manage such units within their ISBT 128-based laboratory information system"
                    ]
                  },
                  {
                    "text": "ISBT 128 label components: 4 bar codes in 4 standardized quadrants(1) DIN: Located in upper left quadrantIdentifies individual donation eventComponents of that donation event will have same DIN but different ISBT 128 product codeCombination of same DIN and product code should never be duplicated(2) ABO/Rh type: Located in upper right quadrant(3) Product code: Located in lower left quadrantProduct codes are based on definitions that allow common understanding of colloquial terms (e.g., leukodepleted)(4) Expiration date/time: Located in lower right quadrant",
                    "sub_points": [
                      "(1) DIN: Located in upper left quadrantIdentifies individual donation eventComponents of that donation event will have same DIN but different ISBT 128 product codeCombination of same DIN and product code should never be duplicated",
                      "Identifies individual donation event",
                      "Components of that donation event will have same DIN but different ISBT 128 product codeCombination of same DIN and product code should never be duplicated",
                      "Combination of same DIN and product code should never be duplicated",
                      "(2) ABO/Rh type: Located in upper right quadrant",
                      "(3) Product code: Located in lower left quadrantProduct codes are based on definitions that allow common understanding of colloquial terms (e.g., leukodepleted)",
                      "Product codes are based on definitions that allow common understanding of colloquial terms (e.g., leukodepleted)",
                      "(4) Expiration date/time: Located in lower right quadrant"
                    ]
                  },
                  {
                    "text": "Individual product codes are determined by integration of numerous product propertiesComponent class: Red blood cellsModifier: NoneCore conditions: CPDA-1 (anticoagulant)450 mL (nominal collection volume)Refrigerated (storage condition)Attribute: Irradiated",
                    "sub_points": [
                      "Component class: Red blood cells",
                      "Modifier: None",
                      "Core conditions: CPDA-1 (anticoagulant)",
                      "450 mL (nominal collection volume)",
                      "Refrigerated (storage condition)",
                      "Attribute: Irradiated"
                    ]
                  },
                  {
                    "text": "ISBT 128 labels also capture other informationType of donation (e.g., volunteer, directed, autologous)Collection date/timeRed cell phenotyping informationHuman leukocyte antigen (HLA) typing informationCytomegalovirus (CMV) and other test resultsCollection container catalog and lot numberPatient date of birth and identification number",
                    "sub_points": [
                      "Type of donation (e.g., volunteer, directed, autologous)",
                      "Collection date/time",
                      "Red cell phenotyping information",
                      "Human leukocyte antigen (HLA) typing information",
                      "Cytomegalovirus (CMV) and other test results",
                      "Collection container catalog and lot number",
                      "Patient date of birth and identification number"
                    ]
                  },
                  {
                    "text": "Transfusion services that alter or pool a blood product must be able to label that product with any modifications in an ISBT printable label, thereby maintaining ISBT 128 format at every level of the process"
                  },
                  {
                    "text": "Any important blood component information that does not fit on ISBT 128 label may be affixed using tie-tag labelsIn the future, ISBT 128 may also allow radio-frequency ID tags",
                    "sub_points": [
                      "In the future, ISBT 128 may also allow radio-frequency ID tags"
                    ]
                  },
                  {
                    "text": "Bedside bar-code transfusion administration systems that link to hospital information systems offer significant benefits related to documentation, error detection, and patient safetyISBT 128 offers a universal standard that can work with such systems",
                    "sub_points": [
                      "ISBT 128 offers a universal standard that can work with such systems"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Role of the Blood Bank Physician": {
            "name": "Role of the Blood Bank Physician",
            "url": "https://app.pathprimer.com/document/66cbbdb0-b187-4ed0-b92f-d4a498e83bf8/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
            "content": {
              "OVERVIEW": {
                "Requirements": [
                  {
                    "text": "Blood centers and transfusion services are required to have qualified medical directors"
                  },
                  {
                    "text": "Blood bank/transfusion medicine-certified physicians have extremely variable range of professional roles and responsibilities"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "American Association of Blood Banks (AABB)"
                  },
                  {
                    "text": "Clinical Laboratory Improvement Amendments (CLIA)"
                  },
                  {
                    "text": "Code of Federal Regulations (CFR)"
                  },
                  {
                    "text": "College of American Pathologists (CAP)"
                  },
                  {
                    "text": "Human leukocyte antigen (HLA)"
                  },
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Transfusion-related acute lung injury (TRALI)"
                  },
                  {
                    "text": "US Food and Drug Association (FDA)"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Medical Director Requirements": [
                  {
                    "text": "AABB Standards for Blood Banks and Transfusion Services designates that blood collection establishments and transfusion services must be under supervision of licensed, qualified physicianPhysician must be readily available to blood establishmentQualification can be by education, experience, or training",
                    "sub_points": [
                      "Physician must be readily available to blood establishment",
                      "Qualification can be by education, experience, or training"
                    ]
                  },
                  {
                    "text": "Medical director has range of responsibilitiesAll medical and technical policies/processes/proceduresConsultative service, as related to blood donor and recipient care",
                    "sub_points": [
                      "All medical and technical policies/processes/procedures",
                      "Consultative service, as related to blood donor and recipient care"
                    ]
                  },
                  {
                    "text": "Medical directors referred to as “conscience” of organization"
                  },
                  {
                    "text": "Medical director responsibilities at blood collection centerPolicies and proceduresEnsuring accurate and up-to-date policies/procedures that meet regulatory requirementsBlood collectionDonor recruitmentDonor eligibilityOverseeing autologous collectionsDonor care and donation reaction investigationDetermination of donor deferralsCounseling of deferred donorsBlood processingComponent processingProduct testing, including IDMsInvestigating nonconformances and determining if product is acceptableManagement of specialty products and rare unitsMedical direction (CLIA license holder)Immunohematology reference labDiagnostic testing laboratoriesIDM testingRBC or HLA genetic testingQuality systems, accreditation, and registration/licensureBlood collection center leadership and managementBudgetStaffing planEnsure appropriate staffing levelsEnsure adequately trained staffSelect new equipmentReview results of proficiency testingClinical consultation to optimize transfusion clinical careAdvise on transfusion indications and product manipulationsInvestigate adverse events related to transfusionEnsure proper quarantine of split units implicated in TRALI or septic transfusion reactionsTriage blood requests in times of shortageDirect patient careApheresisTherapeutic phlebotomyCellular therapiesMedical directors of blood collection centers may also have roles as surgical pathologists or pursue research",
                    "sub_points": [
                      "Policies and proceduresEnsuring accurate and up-to-date policies/procedures that meet regulatory requirements",
                      "Ensuring accurate and up-to-date policies/procedures that meet regulatory requirements",
                      "Blood collectionDonor recruitmentDonor eligibilityOverseeing autologous collectionsDonor care and donation reaction investigationDetermination of donor deferralsCounseling of deferred donors",
                      "Donor recruitment",
                      "Donor eligibility",
                      "Overseeing autologous collections",
                      "Donor care and donation reaction investigation",
                      "Determination of donor deferrals",
                      "Counseling of deferred donors",
                      "Blood processingComponent processingProduct testing, including IDMsInvestigating nonconformances and determining if product is acceptableManagement of specialty products and rare units",
                      "Component processing",
                      "Product testing, including IDMs",
                      "Investigating nonconformances and determining if product is acceptable",
                      "Management of specialty products and rare units",
                      "Medical direction (CLIA license holder)Immunohematology reference labDiagnostic testing laboratoriesIDM testingRBC or HLA genetic testing",
                      "Immunohematology reference lab",
                      "Diagnostic testing laboratoriesIDM testingRBC or HLA genetic testing",
                      "IDM testing",
                      "RBC or HLA genetic testing",
                      "Quality systems, accreditation, and registration/licensure",
                      "Blood collection center leadership and managementBudgetStaffing planEnsure appropriate staffing levelsEnsure adequately trained staffSelect new equipmentReview results of proficiency testing",
                      "Budget",
                      "Staffing plan",
                      "Ensure appropriate staffing levels",
                      "Ensure adequately trained staff",
                      "Select new equipment",
                      "Review results of proficiency testing",
                      "Clinical consultation to optimize transfusion clinical careAdvise on transfusion indications and product manipulationsInvestigate adverse events related to transfusionEnsure proper quarantine of split units implicated in TRALI or septic transfusion reactionsTriage blood requests in times of shortageDirect patient careApheresisTherapeutic phlebotomyCellular therapies",
                      "Advise on transfusion indications and product manipulations",
                      "Investigate adverse events related to transfusionEnsure proper quarantine of split units implicated in TRALI or septic transfusion reactions",
                      "Ensure proper quarantine of split units implicated in TRALI or septic transfusion reactions",
                      "Triage blood requests in times of shortage",
                      "Direct patient careApheresisTherapeutic phlebotomyCellular therapies",
                      "Apheresis",
                      "Therapeutic phlebotomy",
                      "Cellular therapies",
                      "Medical directors of blood collection centers may also have roles as surgical pathologists or pursue research"
                    ]
                  },
                  {
                    "text": "Medical director responsibilities at hospital transfusion servicePolicies and proceduresEnsuring accurate and up-to-date policies/procedures that meet regulatory requirementsClinical consultationAdvise on transfusion indications and product manipulationsInvestigate adverse events related to transfusionEnsure proper blood supplier notification and/or quarantine of split units implicated in TRALI or septic transfusion reactionsTriage blood requests in times of shortageDirect patient careApheresisTherapeutic phlebotomyPreop anemia management clinicCellular therapiesLiaison between transfusion service and hospitalWorking with transfusion committee to be good stewards of hospital-wide blood useEffective transfusion audit system: Prospective review and retrospective reviewMaximize hospital-wide patient blood managementEstablish maximal surgical blood order scheduleEnsure adequately trained transfusionistsLaboratory leadership and managementBudgetStaffing planEnsure appropriate staffing levelsEnsure adequately trained staffQuality oversightQualify blood component supplierSelect new equipmentReview validation of new proceduresDevelop standard operating proceduresInvestigate errors and procedure deviationsReview results of proficiency testingEnsure success in inspections by AABB/CAP and FDAMedical directors of hospital transfusion services may also have roles as surgical pathologists or laboratory directors of other clinical laboratories (often coagulation or stem cell processing labs), or pursue research",
                    "sub_points": [
                      "Policies and proceduresEnsuring accurate and up-to-date policies/procedures that meet regulatory requirements",
                      "Ensuring accurate and up-to-date policies/procedures that meet regulatory requirements",
                      "Clinical consultationAdvise on transfusion indications and product manipulationsInvestigate adverse events related to transfusionEnsure proper blood supplier notification and/or quarantine of split units implicated in TRALI or septic transfusion reactionsTriage blood requests in times of shortageDirect patient careApheresisTherapeutic phlebotomyPreop anemia management clinicCellular therapies",
                      "Advise on transfusion indications and product manipulations",
                      "Investigate adverse events related to transfusionEnsure proper blood supplier notification and/or quarantine of split units implicated in TRALI or septic transfusion reactions",
                      "Ensure proper blood supplier notification and/or quarantine of split units implicated in TRALI or septic transfusion reactions",
                      "Triage blood requests in times of shortage",
                      "Direct patient careApheresisTherapeutic phlebotomyPreop anemia management clinicCellular therapies",
                      "Apheresis",
                      "Therapeutic phlebotomy",
                      "Preop anemia management clinic",
                      "Cellular therapies",
                      "Liaison between transfusion service and hospitalWorking with transfusion committee to be good stewards of hospital-wide blood useEffective transfusion audit system: Prospective review and retrospective reviewMaximize hospital-wide patient blood managementEstablish maximal surgical blood order scheduleEnsure adequately trained transfusionists",
                      "Working with transfusion committee to be good stewards of hospital-wide blood useEffective transfusion audit system: Prospective review and retrospective review",
                      "Effective transfusion audit system: Prospective review and retrospective review",
                      "Maximize hospital-wide patient blood management",
                      "Establish maximal surgical blood order schedule",
                      "Ensure adequately trained transfusionists",
                      "Laboratory leadership and managementBudgetStaffing planEnsure appropriate staffing levelsEnsure adequately trained staffQuality oversightQualify blood component supplierSelect new equipmentReview validation of new proceduresDevelop standard operating proceduresInvestigate errors and procedure deviationsReview results of proficiency testingEnsure success in inspections by AABB/CAP and FDA",
                      "Budget",
                      "Staffing planEnsure appropriate staffing levelsEnsure adequately trained staff",
                      "Ensure appropriate staffing levels",
                      "Ensure adequately trained staff",
                      "Quality oversightQualify blood component supplierSelect new equipmentReview validation of new proceduresDevelop standard operating proceduresInvestigate errors and procedure deviationsReview results of proficiency testingEnsure success in inspections by AABB/CAP and FDA",
                      "Qualify blood component supplier",
                      "Select new equipment",
                      "Review validation of new procedures",
                      "Develop standard operating procedures",
                      "Investigate errors and procedure deviations",
                      "Review results of proficiency testing",
                      "Ensure success in inspections by AABB/CAP and FDA",
                      "Medical directors of hospital transfusion services may also have roles as surgical pathologists or laboratory directors of other clinical laboratories (often coagulation or stem cell processing labs), or pursue research"
                    ]
                  }
                ],
                "Blood Bank and Transfusion Medicine Specialty Training": [
                  {
                    "text": "Specialty certification is offered by American Board of PathologySpecialty can be pursued through various disciplinesPathologyHematology-oncologyAnesthesiaPediatricsSurgeryObstetrical training routes",
                    "sub_points": [
                      "Specialty can be pursued through various disciplinesPathologyHematology-oncologyAnesthesiaPediatricsSurgeryObstetrical training routes",
                      "Pathology",
                      "Hematology-oncology",
                      "Anesthesia",
                      "Pediatrics",
                      "Surgery",
                      "Obstetrical training routes"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lookbacks and Product Recalls": {
            "name": "Lookbacks and Product Recalls",
            "url": "https://app.pathprimer.com/document/ed16b515-8160-4b5e-842a-5f84347ed6d1/lesson/b4f59b57-1741-4ae6-ab07-ed703e287c3b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "If repeat donor is IDM positive (i.e., found to have evidence of infectious disease requiring deferral) onsubsequentdonation, there is risk that previous donations with negative IDM were within window period for infectious disease"
                  },
                  {
                    "text": "Lookbacks into prior donations from seroconverting blood donors are required by CFR, FDA, and AABB. Lookback processes must be followed exactlyDescriptions of lookback procedures are described for educational purposes. Refer to FDA Guidances for clinical lookback cases",
                    "sub_points": [
                      "Descriptions of lookback procedures are described for educational purposes. Refer to FDA Guidances for clinical lookback cases"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Lookback": [
                  {
                    "text": "Why have a lookback?If repeat donor is IDM positive, there is risk that previous donations with negative IDM were within window period for infectious diseaseIDM-positive donor is one who is found to have evidence of infectious disease requiring deferralPreviously released products with negative IDM testing could be infectious",
                    "sub_points": [
                      "If repeat donor is IDM positive, there is risk that previous donations with negative IDM were within window period for infectious diseaseIDM-positive donor is one who is found to have evidence of infectious disease requiring deferralPreviously released products with negative IDM testing could be infectious",
                      "IDM-positive donor is one who is found to have evidence of infectious disease requiring deferral",
                      "Previously released products with negative IDM testing could be infectious"
                    ]
                  },
                  {
                    "text": "What is a lookback?Retrieval and quarantine of prior donations and notification of prior recipients of their risk for TTI",
                    "sub_points": [
                      "Retrieval and quarantine of prior donations and notification of prior recipients of their risk for TTI"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Transfusion-transmitted infection (TTI)"
                  },
                  {
                    "text": "Code of Federal Regulations (CFR)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Human immunodeficiency virus (HIV)"
                  },
                  {
                    "text": "Hepatitis C virus (HCV)"
                  },
                  {
                    "text": "Hepatitis B surface antigen (HBsAg)"
                  },
                  {
                    "text": "Hepatitis B core antibody (HBcAb)"
                  },
                  {
                    "text": "Human T-lymphotropic virus (HTLV)"
                  },
                  {
                    "text": "Hepatitis B virus (HBV)"
                  },
                  {
                    "text": "West Nile virus (WNV)"
                  },
                  {
                    "text": "Individual donor nucleic acid testing (ID-NAT)"
                  }
                ]
              },
              "LIMITATIONS": {
                "Lookbacks Based on Newly Implemented IDM Testing/Assays": [
                  {
                    "text": "When new IDM testing is initiated, significant number of positive donors may be identifiedThese donors may have donated many times in the past with potential of transmitting TTI to multiple recipients",
                    "sub_points": [
                      "These donors may have donated many times in the past with potential of transmitting TTI to multiple recipients"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Lookback": [
                  {
                    "text": "Lookbacks are required by CFR, FDA, and AABBLookback processes must be followed exactly",
                    "sub_points": [
                      "Lookback processes must be followed exactly"
                    ]
                  },
                  {
                    "text": "Lookbacks generally require retrieval and quarantine of all in-date units from the implicated donorFDA and AABB (30th, Standard 5.8.7) require that retrieval begin as soon as repeatedly reactive result is obtained despite availability of confirmatory testing resultsRetrieval required within 3 days of positive screening test for HIV, HCV, Chagas diseaseWithin 7 days of HBsAg, HBcAb, anti-HTLV repeat reactive screening testIf confirmatory testing is negative, FDA guidances may allow re-release of quarantined units",
                    "sub_points": [
                      "FDA and AABB (30th, Standard 5.8.7) require that retrieval begin as soon as repeatedly reactive result is obtained despite availability of confirmatory testing resultsRetrieval required within 3 days of positive screening test for HIV, HCV, Chagas diseaseWithin 7 days of HBsAg, HBcAb, anti-HTLV repeat reactive screening testIf confirmatory testing is negative, FDA guidances may allow re-release of quarantined units",
                      "Retrieval required within 3 days of positive screening test for HIV, HCV, Chagas disease",
                      "Within 7 days of HBsAg, HBcAb, anti-HTLV repeat reactive screening test",
                      "If confirmatory testing is negative, FDA guidances may allow re-release of quarantined units"
                    ]
                  },
                  {
                    "text": "AABB requires collection facilities to have process to notify blood consignees that donors were subsequently found to have, or be at risk for, relevant infectious disease (30th ed, Standard 7.5.5.1)"
                  },
                  {
                    "text": "AABB requires transfusion services to have process to identify blood recipients from donors who were subsequently found to have, or be at risk for, relevant infectious disease (30th ed, Standard 7.5.5.2.1)Transfusion services must follow FDA Guidances about notification of blood recipient's physician &/or recipient (30th ed, Standard 7.5.5.2.2)Notification must occur within 12 weeks of final data allowing time for results confirmatory testing",
                    "sub_points": [
                      "Transfusion services must follow FDA Guidances about notification of blood recipient's physician &/or recipient (30th ed, Standard 7.5.5.2.2)Notification must occur within 12 weeks of final data allowing time for results confirmatory testing",
                      "Notification must occur within 12 weeks of final data allowing time for results confirmatory testing"
                    ]
                  },
                  {
                    "text": "HIV/HCV lookback required by law (21 CFR 610.46-610.47)Lookback at all donations from 12 months before last IDM negative donationFor HIV lookback, must notify decedent’s next of kin",
                    "sub_points": [
                      "Lookback at all donations from 12 months before last IDM negative donation",
                      "For HIV lookback, must notify decedent’s next of kin"
                    ]
                  },
                  {
                    "text": "HBVRetrieve and quarantine in-date productsLookback not required by FDA but represents the best-practice standard",
                    "sub_points": [
                      "Retrieve and quarantine in-date products",
                      "Lookback not required by FDA but represents the best-practice standard"
                    ]
                  },
                  {
                    "text": "HTLVRetrieve and quarantine in-date productsLookback not required by FDA and likely very low yieldPublic health benefit of HTLV lookback is questionable",
                    "sub_points": [
                      "Retrieve and quarantine in-date products",
                      "Lookback not required by FDA and likely very low yieldPublic health benefit of HTLV lookback is questionable",
                      "Public health benefit of HTLV lookback is questionable"
                    ]
                  },
                  {
                    "text": "WNVRetrieve and quarantine in-date products from prior collections dating back 120 days before donation that is ID-NAT-reactiveShort period is due to acute nature of WNV infection without generally accepted chronic carriage state",
                    "sub_points": [
                      "Retrieve and quarantine in-date products from prior collections dating back 120 days before donation that is ID-NAT-reactive",
                      "Short period is due to acute nature of WNV infection without generally accepted chronic carriage state"
                    ]
                  },
                  {
                    "text": "Chagas diseaseRetrieve and quarantine in-date productsIdentify all blood components previously donated by such donor, going back either 10 yr (or indefinitely where electronic records are available) or, in previously tested donor, 12 months before donor’s most recent negative test result with licensed test forTrypanosoma cruziantibody, whichever is the lesser period (lookback period)Repeatedly reactive donor who has risk factors forT. cruziinfectionFDA recommends notify recipients for all previously distributed blood and blood components collected during lookback period",
                    "sub_points": [
                      "Retrieve and quarantine in-date products",
                      "Identify all blood components previously donated by such donor, going back either 10 yr (or indefinitely where electronic records are available) or, in previously tested donor, 12 months before donor’s most recent negative test result with licensed test forTrypanosoma cruziantibody, whichever is the lesser period (lookback period)",
                      "Repeatedly reactive donor who has risk factors forT. cruziinfectionFDA recommends notify recipients for all previously distributed blood and blood components collected during lookback period",
                      "FDA recommends notify recipients for all previously distributed blood and blood components collected during lookback period"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Blood Donation": {
        "name": "Blood Donation",
        "url": "https://app.pathprimer.com/lesson/da50ece8-9627-41a4-b178-b906e0818703",
        "topics": {
          "Donor Selection and the Donor History Questionnaire": {
            "name": "Donor Selection and the Donor History Questionnaire",
            "url": "https://app.pathprimer.com/document/506a7666-9b1d-4364-ab9d-6ef619b2a8a8/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "OVERVIEW": {
                "Safe and Reliable Blood Supply Has Transformed Modern Medicine": [
                  {
                    "text": "Approximately 15 million WB donations are collected per year in United States"
                  },
                  {
                    "text": "40%-50% of adult population is eligible3%-5% donate",
                    "sub_points": [
                      "3%-5% donate"
                    ]
                  },
                  {
                    "text": "Blood donation is overseen by licensed, qualified physician and is regulated by FDA"
                  },
                  {
                    "text": "Responsibility of transfusion medicine field to ensure patients continued access to safe blood (despite continual emergence of new infectious diseases) as well as ensure well-being of blood donors"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Whole blood (WB)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Donor History Questionnaire (DHQ)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Blood Donation Requirements": [
                  {
                    "text": "Purpose of all blood donation requirements and testing isTo ensure safe and adequate blood supply using volunteer altruistic donorsTo do minimal harm to blood donors",
                    "sub_points": [
                      "To ensure safe and adequate blood supply using volunteer altruistic donors",
                      "To do minimal harm to blood donors"
                    ]
                  },
                  {
                    "text": "AABB and FDA require donor to beEducated about donation procedureConsented for phlebotomy (reaction risks, notification of public health bodies about positive test results)Educated about risk of transmitting HIV and toldnotto donate as a means of obtaining HIV testEducated about donation-related iron deficiencyEducated about medications on deferral listGiven reasonable accommodation for language barrier, hearing impairment, disability",
                    "sub_points": [
                      "Educated about donation procedure",
                      "Consented for phlebotomy (reaction risks, notification of public health bodies about positive test results)",
                      "Educated about risk of transmitting HIV and toldnotto donate as a means of obtaining HIV test",
                      "Educated about donation-related iron deficiency",
                      "Educated about medications on deferral list",
                      "Given reasonable accommodation for language barrier, hearing impairment, disability"
                    ]
                  },
                  {
                    "text": "Donors must register with blood collection establishment and donor identity must be verifiedNeed photo ID with name matching name donor is using to donateDonor birth date and contact information (e.g., address, phone number, e-mail) requiredNo duplicate donor recordsAll previous donations must be linked togetherFor postdonation deferrals, donor must be notified within 8 weeks (CFR 630.40)—need accurate contact information",
                    "sub_points": [
                      "Need photo ID with name matching name donor is using to donate",
                      "Donor birth date and contact information (e.g., address, phone number, e-mail) required",
                      "No duplicate donor recordsAll previous donations must be linked together",
                      "All previous donations must be linked together",
                      "For postdonation deferrals, donor must be notified within 8 weeks (CFR 630.40)—need accurate contact information"
                    ]
                  },
                  {
                    "text": "Blood collection records are retained 10 yr"
                  },
                  {
                    "text": "Blood donor permanent/indefinite deferral records retained indefinitely"
                  },
                  {
                    "text": "Blood donors must use DHQ based on AABB/FDA-approved DHQBlood collection establishments can make DHQ more stringent by adding their own questionsQuestions cannot be removedOrder of DHQ should not be changedAABB/FDA DHQ was developed using psychologists and social scientists to ensure optimal donor understanding and capture of positive responses",
                    "sub_points": [
                      "Blood collection establishments can make DHQ more stringent by adding their own questions",
                      "Questions cannot be removed",
                      "Order of DHQ should not be changedAABB/FDA DHQ was developed using psychologists and social scientists to ensure optimal donor understanding and capture of positive responses",
                      "AABB/FDA DHQ was developed using psychologists and social scientists to ensure optimal donor understanding and capture of positive responses"
                    ]
                  },
                  {
                    "text": "Blood donation eligibility must be determined on day of donationIncomplete DHQ and clarification of ambiguous statements must be rectified on the day of collectionThese items should have been addressedbeforedonation",
                    "sub_points": [
                      "Incomplete DHQ and clarification of ambiguous statements must be rectified on the day of collectionThese items should have been addressedbeforedonation",
                      "These items should have been addressedbeforedonation"
                    ]
                  },
                  {
                    "text": "Deferred donors may become angry or confusedBlood collection establishments should have processes in place to address concerns of deferred donors and explain regulatory requirements",
                    "sub_points": [
                      "Blood collection establishments should have processes in place to address concerns of deferred donors and explain regulatory requirements"
                    ]
                  },
                  {
                    "text": "Rare products can be collected without meeting all typical allogeneic donor requirements in situations of exceptional medical needRBC antigen negative units, products from IgA-deficient donors, and products from HLA-matched donorsTransfusion medicine physician oversight and documentation required in these situations",
                    "sub_points": [
                      "RBC antigen negative units, products from IgA-deficient donors, and products from HLA-matched donors",
                      "Transfusion medicine physician oversight and documentation required in these situations"
                    ]
                  },
                  {
                    "text": "Apheresis donation requirementsApheresis donors must meet same requirements as allogeneic WB donors with additional requirementsApheresis RBC collection (or \"double red\" collection) requires higher hemoglobin concentration and higher donor weights and heightsManufacturer's instructions should be followedPlateletpheresis donors cannot have received recent antiplatelet medicationPeripheral blood platelet count is not required before first plateletpheresis or if 4 weeks have elapsed since last platelet donationSubsequent platelet donations can be qualified from platelet count drawn immediately before previous donationPlateletpheresis should not generally be performed if starting platelet count is < 150,000/μLConcomitant plasma collection during plateletpheresis is governed by the same rules as infrequent plasma donorsRBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeksPlasmapheresis is divided into infrequent and frequentInfrequent—collected by blood collection establishmentsFrequent—collected from paid donors as source plasma centersRBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                    "sub_points": [
                      "Apheresis donors must meet same requirements as allogeneic WB donors with additional requirements",
                      "Apheresis RBC collection (or \"double red\" collection) requires higher hemoglobin concentration and higher donor weights and heightsManufacturer's instructions should be followed",
                      "Manufacturer's instructions should be followed",
                      "Plateletpheresis donors cannot have received recent antiplatelet medicationPeripheral blood platelet count is not required before first plateletpheresis or if 4 weeks have elapsed since last platelet donationSubsequent platelet donations can be qualified from platelet count drawn immediately before previous donationPlateletpheresis should not generally be performed if starting platelet count is < 150,000/μLConcomitant plasma collection during plateletpheresis is governed by the same rules as infrequent plasma donorsRBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                      "Peripheral blood platelet count is not required before first plateletpheresis or if 4 weeks have elapsed since last platelet donation",
                      "Subsequent platelet donations can be qualified from platelet count drawn immediately before previous donation",
                      "Plateletpheresis should not generally be performed if starting platelet count is < 150,000/μL",
                      "Concomitant plasma collection during plateletpheresis is governed by the same rules as infrequent plasma donors",
                      "RBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                      "If ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                      "Plasmapheresis is divided into infrequent and frequentInfrequent—collected by blood collection establishmentsFrequent—collected from paid donors as source plasma centersRBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                      "Infrequent—collected by blood collection establishments",
                      "Frequent—collected from paid donors as source plasma centers",
                      "RBC losses must be trackedIf ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks",
                      "If ≥ 200 mL of RBCs are lost, donor is deferred for 8 weeks"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Donor Deferrals": {
            "name": "Donor Deferrals",
            "url": "https://app.pathprimer.com/document/6e3e155a-5038-4102-bce8-12c379825b8b/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "OVERVIEW": {
                "Blood Donor Deferrals": [
                  {
                    "text": "Ensure blood donor safety"
                  },
                  {
                    "text": "Ensure blood product SQPP"
                  }
                ],
                "Blood Donor History Questionnaire": [
                  {
                    "text": "Questions dealing with infectious risks to recipient are highly regulated by FDA"
                  },
                  {
                    "text": "Questions dealing with risks to donor are mostly left to discretion of local medical director"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Safety, quality, purity, and potency (SQPP)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Full-length donor history questionnaire (DHQ)"
                  },
                  {
                    "text": "Human papillomavirus (HPV)"
                  },
                  {
                    "text": "Hepatitis A virus (HAV)"
                  },
                  {
                    "text": "Hepatitis B virus (HBV)"
                  },
                  {
                    "text": "Hepatitis B surface antigen (HBsAg)"
                  },
                  {
                    "text": "Hepatitis B immunoglobulin (HBIg)"
                  },
                  {
                    "text": "Variant Creutzfeldt-Jakob disease (vCJD)"
                  },
                  {
                    "text": "Bovine spongiform encephalopathy (BSE)"
                  },
                  {
                    "text": "Creutzfeldt-Jakob disease (CJD)"
                  },
                  {
                    "text": "West Nile virus (WNV)"
                  },
                  {
                    "text": "Human immunodeficiency virus (HIV)"
                  },
                  {
                    "text": "Men who have sex with men (MSM)"
                  },
                  {
                    "text": "Intravenous drug abuse (IVDA)"
                  },
                  {
                    "text": "Hepatitis C virus (HCV)"
                  },
                  {
                    "text": "Human T-lymphotropic virus (HTLV)"
                  },
                  {
                    "text": "Transfusion-related acute lung injury (TRALI)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  },
                  {
                    "text": "Human leukocyte antigen (HLA)"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Basic Blood Donor Deferrals": [
                  {
                    "text": "Deferred if donor isUnder age limitUnder weight limitAnemicFebrileWithin donation interval from previous donations",
                    "sub_points": [
                      "Under age limit",
                      "Under weight limit",
                      "Anemic",
                      "Febrile",
                      "Within donation interval from previous donations"
                    ]
                  }
                ],
                "Full-Length Donor History Questionnaire Deferrals": [
                  {
                    "text": "DHQ developed by AABB and FDA"
                  },
                  {
                    "text": "Day of donation, donor should beFeeling wellOf generally good healthFree of major diseaseHeart/lung diseaseLiver diseaseOncologic diseaseHistory of bleeding disorder",
                    "sub_points": [
                      "Feeling well",
                      "Of generally good healthFree of major diseaseHeart/lung diseaseLiver diseaseOncologic diseaseHistory of bleeding disorder",
                      "Free of major diseaseHeart/lung diseaseLiver diseaseOncologic diseaseHistory of bleeding disorder",
                      "Heart/lung disease",
                      "Liver disease",
                      "Oncologic disease",
                      "History of bleeding disorder"
                    ]
                  },
                  {
                    "text": "Oncologic disease is permanent deferral for hematolymphoid malignancy"
                  },
                  {
                    "text": "Other cancers (much less likely to be transfusion-transmitted) are deferred at discretion of local medical directorFrequently provides 1- to 5-year deferral from date donor has been declared disease-free",
                    "sub_points": [
                      "Frequently provides 1- to 5-year deferral from date donor has been declared disease-free"
                    ]
                  },
                  {
                    "text": "Potential donors with bleeding disorders require deferralFor their own safetyFor product potency",
                    "sub_points": [
                      "For their own safety",
                      "For product potency"
                    ]
                  },
                  {
                    "text": "Medication deferralsDonors must be given list of relevant medications to reviewAntibioticsDeferred if treating active infectionAnticoagulantsDeferral periods at discretion of local medical directorOften deferred due to medical reason that requires anticoagulantDonation for which platelet product will be manufacturedDefer at least 2 days for aspirin or aspirin-containing products, piroxicamDeferral periods for other antiplatelet agents at discretion of local medical directorFrequently deferred 7 days for prasugrel/ticagrelorFrequently deferred 14 days for clopidogrel/ticlodipineRetinoids (potent teratogens, particularly in first trimester)Deferral period varies due to extremely variable half-lives1 month: Finasteride (Propecia), isotretinoin (Accutane)Used for acne or prostatic hypertrophy6 months: dutasteride (Avodart)Used for acne or prostatic hypertrophy3 years: acitretin (Soriatane)Used for psoriasisPermanent deferral: Etretinate (Tegison)Used for psoriasisBovine insulin manufactured in United KingdomPermanent deferral",
                    "sub_points": [
                      "Donors must be given list of relevant medications to review",
                      "AntibioticsDeferred if treating active infection",
                      "Deferred if treating active infection",
                      "AnticoagulantsDeferral periods at discretion of local medical directorOften deferred due to medical reason that requires anticoagulantDonation for which platelet product will be manufacturedDefer at least 2 days for aspirin or aspirin-containing products, piroxicamDeferral periods for other antiplatelet agents at discretion of local medical directorFrequently deferred 7 days for prasugrel/ticagrelorFrequently deferred 14 days for clopidogrel/ticlodipine",
                      "Deferral periods at discretion of local medical director",
                      "Often deferred due to medical reason that requires anticoagulant",
                      "Donation for which platelet product will be manufacturedDefer at least 2 days for aspirin or aspirin-containing products, piroxicamDeferral periods for other antiplatelet agents at discretion of local medical directorFrequently deferred 7 days for prasugrel/ticagrelorFrequently deferred 14 days for clopidogrel/ticlodipine",
                      "Defer at least 2 days for aspirin or aspirin-containing products, piroxicam",
                      "Deferral periods for other antiplatelet agents at discretion of local medical director",
                      "Frequently deferred 7 days for prasugrel/ticagrelor",
                      "Frequently deferred 14 days for clopidogrel/ticlodipine",
                      "Retinoids (potent teratogens, particularly in first trimester)Deferral period varies due to extremely variable half-lives1 month: Finasteride (Propecia), isotretinoin (Accutane)Used for acne or prostatic hypertrophy6 months: dutasteride (Avodart)Used for acne or prostatic hypertrophy3 years: acitretin (Soriatane)Used for psoriasisPermanent deferral: Etretinate (Tegison)Used for psoriasis",
                      "Deferral period varies due to extremely variable half-lives",
                      "1 month: Finasteride (Propecia), isotretinoin (Accutane)Used for acne or prostatic hypertrophy",
                      "Used for acne or prostatic hypertrophy",
                      "6 months: dutasteride (Avodart)Used for acne or prostatic hypertrophy",
                      "Used for acne or prostatic hypertrophy",
                      "3 years: acitretin (Soriatane)Used for psoriasis",
                      "Used for psoriasis",
                      "Permanent deferral: Etretinate (Tegison)Used for psoriasis",
                      "Used for psoriasis",
                      "Bovine insulin manufactured in United KingdomPermanent deferral",
                      "Permanent deferral"
                    ]
                  },
                  {
                    "text": "Immunization deferralsSynthetic vaccine or killed vaccine requires no deferralHPV, influenza, pertussis, HAV, HBVSome blood collection establishments defer in case of HBV for ≤ 1 week to prevent false-positive results on HBsAg testingNo deferral: Nasal influenza vaccination (live attenuated)2-week deferral (live attenuated vaccine): Measles (rubeola), mumps, yellow fever, oral polio, oral typhoid4-week deferral (live attenuated vaccine): Rubella, varicellaSmallpox vaccine (vaccinia) deferralRefer to FDA for more details, including how to deal with donor who contracted vaccinia infection through close contact with vaccineUncomplicated vaccination: 21 days from vaccination or from when scab falls off, whichever is laterComplicated vaccination: 14 days from when all vaccine complications have completely resolvedHBIg deferral: 1 yearDue to reason for HBIg administration",
                    "sub_points": [
                      "Synthetic vaccine or killed vaccine requires no deferralHPV, influenza, pertussis, HAV, HBVSome blood collection establishments defer in case of HBV for ≤ 1 week to prevent false-positive results on HBsAg testing",
                      "HPV, influenza, pertussis, HAV, HBVSome blood collection establishments defer in case of HBV for ≤ 1 week to prevent false-positive results on HBsAg testing",
                      "Some blood collection establishments defer in case of HBV for ≤ 1 week to prevent false-positive results on HBsAg testing",
                      "No deferral: Nasal influenza vaccination (live attenuated)",
                      "2-week deferral (live attenuated vaccine): Measles (rubeola), mumps, yellow fever, oral polio, oral typhoid",
                      "4-week deferral (live attenuated vaccine): Rubella, varicella",
                      "Smallpox vaccine (vaccinia) deferralRefer to FDA for more details, including how to deal with donor who contracted vaccinia infection through close contact with vaccineUncomplicated vaccination: 21 days from vaccination or from when scab falls off, whichever is laterComplicated vaccination: 14 days from when all vaccine complications have completely resolved",
                      "Refer to FDA for more details, including how to deal with donor who contracted vaccinia infection through close contact with vaccineUncomplicated vaccination: 21 days from vaccination or from when scab falls off, whichever is laterComplicated vaccination: 14 days from when all vaccine complications have completely resolved",
                      "Uncomplicated vaccination: 21 days from vaccination or from when scab falls off, whichever is later",
                      "Complicated vaccination: 14 days from when all vaccine complications have completely resolved",
                      "HBIg deferral: 1 yearDue to reason for HBIg administration",
                      "Due to reason for HBIg administration"
                    ]
                  },
                  {
                    "text": "Childbirth deferral: 6 weeks"
                  },
                  {
                    "text": "Travel deferralsZika-related deferrals are 28 daysFrom return from travel to Zika-endemic areaFrom last sexual encounter with man carrying Zika within last 3 monthsFrom becoming asymptomatic after Zika infectionMalaria-related1-year deferral for travel to malaria-endemic region3-year deferral for having malaria (3 years from becoming asymptomatic)3-year deferral from date of leaving malaria-endemic region only ifDonor was born thereDonor lived there for at least 5 yearsvCJD relatedvCJD is transmitted through ingestion of infected tissue of cows with BSEBSE was much more common in UK and western Europe, although cases were described in Asia and AmericasRare transfusion-transmitted cases of vCJD have been describedDefer permanently for vCJD risk all donors whoLived > 3 months in United Kingdom 1980-1996Lived > 5 years in Europe, 1980 to present timeMilitary personnel (current and former) and their dependents who spent > 6 months on military bases in northern Europe (Germany, United Kingdom, Belgium, Netherlands) 1980-1990 or southern Europe (Greece, Turkey, Spain, Portugal, Italy) 1980-1996Received transfusion in United Kingdom and France since 1980Received bovine insulin from United Kingdom since 1980Have family members with vCJD",
                    "sub_points": [
                      "Zika-related deferrals are 28 daysFrom return from travel to Zika-endemic areaFrom last sexual encounter with man carrying Zika within last 3 monthsFrom becoming asymptomatic after Zika infection",
                      "From return from travel to Zika-endemic area",
                      "From last sexual encounter with man carrying Zika within last 3 months",
                      "From becoming asymptomatic after Zika infection",
                      "Malaria-related1-year deferral for travel to malaria-endemic region3-year deferral for having malaria (3 years from becoming asymptomatic)3-year deferral from date of leaving malaria-endemic region only ifDonor was born thereDonor lived there for at least 5 years",
                      "1-year deferral for travel to malaria-endemic region",
                      "3-year deferral for having malaria (3 years from becoming asymptomatic)",
                      "3-year deferral from date of leaving malaria-endemic region only ifDonor was born thereDonor lived there for at least 5 years",
                      "Donor was born there",
                      "Donor lived there for at least 5 years",
                      "vCJD relatedvCJD is transmitted through ingestion of infected tissue of cows with BSEBSE was much more common in UK and western Europe, although cases were described in Asia and AmericasRare transfusion-transmitted cases of vCJD have been describedDefer permanently for vCJD risk all donors whoLived > 3 months in United Kingdom 1980-1996Lived > 5 years in Europe, 1980 to present timeMilitary personnel (current and former) and their dependents who spent > 6 months on military bases in northern Europe (Germany, United Kingdom, Belgium, Netherlands) 1980-1990 or southern Europe (Greece, Turkey, Spain, Portugal, Italy) 1980-1996Received transfusion in United Kingdom and France since 1980Received bovine insulin from United Kingdom since 1980Have family members with vCJD",
                      "vCJD is transmitted through ingestion of infected tissue of cows with BSEBSE was much more common in UK and western Europe, although cases were described in Asia and Americas",
                      "BSE was much more common in UK and western Europe, although cases were described in Asia and Americas",
                      "Rare transfusion-transmitted cases of vCJD have been described",
                      "Defer permanently for vCJD risk all donors whoLived > 3 months in United Kingdom 1980-1996Lived > 5 years in Europe, 1980 to present timeMilitary personnel (current and former) and their dependents who spent > 6 months on military bases in northern Europe (Germany, United Kingdom, Belgium, Netherlands) 1980-1990 or southern Europe (Greece, Turkey, Spain, Portugal, Italy) 1980-1996Received transfusion in United Kingdom and France since 1980Received bovine insulin from United Kingdom since 1980Have family members with vCJD",
                      "Lived > 3 months in United Kingdom 1980-1996",
                      "Lived > 5 years in Europe, 1980 to present time",
                      "Military personnel (current and former) and their dependents who spent > 6 months on military bases in northern Europe (Germany, United Kingdom, Belgium, Netherlands) 1980-1990 or southern Europe (Greece, Turkey, Spain, Portugal, Italy) 1980-1996",
                      "Received transfusion in United Kingdom and France since 1980",
                      "Received bovine insulin from United Kingdom since 1980",
                      "Have family members with vCJD"
                    ]
                  },
                  {
                    "text": "CJDFamilial (genetic) formCase of transfusion-transmitted classical CJD has never been reportedTransmissible formTransmitted through direct neural or blood contact with infected human neural tissueDefer permanently for CJD risk all donors whoReceived dura mater transplant or human pituitary-derived growth hormoneHave family members with CJD",
                    "sub_points": [
                      "Familial (genetic) formCase of transfusion-transmitted classical CJD has never been reported",
                      "Case of transfusion-transmitted classical CJD has never been reported",
                      "Transmissible formTransmitted through direct neural or blood contact with infected human neural tissue",
                      "Transmitted through direct neural or blood contact with infected human neural tissue",
                      "Defer permanently for CJD risk all donors whoReceived dura mater transplant or human pituitary-derived growth hormoneHave family members with CJD",
                      "Received dura mater transplant or human pituitary-derived growth hormone",
                      "Have family members with CJD"
                    ]
                  },
                  {
                    "text": "WNV deferralHistory of WNV: deferred 120 days after becoming asymptomaticHistory of asymptomatic positive WNV test: Deferred 120 days from test",
                    "sub_points": [
                      "History of WNV: deferred 120 days after becoming asymptomatic",
                      "History of asymptomatic positive WNV test: Deferred 120 days from test"
                    ]
                  },
                  {
                    "text": "HIV risk deferral1-year deferral for following risks≥ 72 hours in jail (due to risk of sexual assault)Transfusion (blood or factor concentrate) or transplantSex with someone at risk of HIV (i.e., donor's sexual partner had MSM contact within 1 year, was IVDA, prostitute, or hemophiliac &/or recipient of factor concentrates)MSM in last year (recent change from permanent deferral)Exposure to someone else’s blood/infectious body fluids viaMucous membrane/broken skin blood exposure or needlestick/gross cutTattoo or piercing in non-state licensed facility that did not use autoclaved/disposable tattoo or piercing instrumentsPermanent deferral for following risksIVDAReceiving payment for sex since 1977",
                    "sub_points": [
                      "1-year deferral for following risks≥ 72 hours in jail (due to risk of sexual assault)Transfusion (blood or factor concentrate) or transplantSex with someone at risk of HIV (i.e., donor's sexual partner had MSM contact within 1 year, was IVDA, prostitute, or hemophiliac &/or recipient of factor concentrates)MSM in last year (recent change from permanent deferral)Exposure to someone else’s blood/infectious body fluids viaMucous membrane/broken skin blood exposure or needlestick/gross cutTattoo or piercing in non-state licensed facility that did not use autoclaved/disposable tattoo or piercing instruments",
                      "≥ 72 hours in jail (due to risk of sexual assault)",
                      "Transfusion (blood or factor concentrate) or transplant",
                      "Sex with someone at risk of HIV (i.e., donor's sexual partner had MSM contact within 1 year, was IVDA, prostitute, or hemophiliac &/or recipient of factor concentrates)",
                      "MSM in last year (recent change from permanent deferral)",
                      "Exposure to someone else’s blood/infectious body fluids viaMucous membrane/broken skin blood exposure or needlestick/gross cutTattoo or piercing in non-state licensed facility that did not use autoclaved/disposable tattoo or piercing instruments",
                      "Mucous membrane/broken skin blood exposure or needlestick/gross cut",
                      "Tattoo or piercing in non-state licensed facility that did not use autoclaved/disposable tattoo or piercing instruments",
                      "Permanent deferral for following risksIVDAReceiving payment for sex since 1977",
                      "IVDA",
                      "Receiving payment for sex since 1977"
                    ]
                  },
                  {
                    "text": "Viral hepatitis risk deferral1-year deferral: Living with or sexual contact with person who hasActive HBV (HBsAg+)Symptomatic HCVSymptomatic other viral hepatitisPermanent deferral for history of HBV/HCV infection or following hepatitis riskViral hepatitis after age 11 years",
                    "sub_points": [
                      "1-year deferral: Living with or sexual contact with person who hasActive HBV (HBsAg+)Symptomatic HCVSymptomatic other viral hepatitis",
                      "Active HBV (HBsAg+)",
                      "Symptomatic HCV",
                      "Symptomatic other viral hepatitis",
                      "Permanent deferral for history of HBV/HCV infection or following hepatitis riskViral hepatitis after age 11 years",
                      "Viral hepatitis after age 11 years"
                    ]
                  },
                  {
                    "text": "Syphilis/gonorrhea1-year deferral from completion of treatment",
                    "sub_points": [
                      "1-year deferral from completion of treatment"
                    ]
                  },
                  {
                    "text": "Permanent deferral for history ofHTLV infectionBabesiosisChagas diseaseXenotransplantation",
                    "sub_points": [
                      "HTLV infection",
                      "Babesiosis",
                      "Chagas disease",
                      "Xenotransplantation"
                    ]
                  },
                  {
                    "text": "Previous donor questions about travel or residence in Africa can be deleted if blood collection establishment HIV serologic testing allows detection of HIV group OMuch more common in Africa and not well detected by older generations of HIV antibody tests",
                    "sub_points": [
                      "Much more common in Africa and not well detected by older generations of HIV antibody tests"
                    ]
                  },
                  {
                    "text": "TRALI mitigation deferrals for plasma-rich productsPlasma, apheresis platelets, WB for transfusionPlasma-rich products are to be manufactured only from men, not previously pregnant women, or previously pregnant women who are tested and negative for anti-HLA antibodyPlatelet portion of this requirement is new with AABB Blood Bank and Transfusion Services Standards, 30th edition",
                    "sub_points": [
                      "Plasma, apheresis platelets, WB for transfusion",
                      "Plasma-rich products are to be manufactured only from men, not previously pregnant women, or previously pregnant women who are tested and negative for anti-HLA antibodyPlatelet portion of this requirement is new with AABB Blood Bank and Transfusion Services Standards, 30th edition",
                      "Platelet portion of this requirement is new with AABB Blood Bank and Transfusion Services Standards, 30th edition"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Apheresis Blood Component Collections": {
            "name": "Apheresis Blood Component Collections",
            "url": "https://app.pathprimer.com/document/7d5ddd6d-6103-4ea5-bf9d-aa982739e23d/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Most RBC and plasma components are manufactured from whole-blood collections in United States"
                  },
                  {
                    "text": "Most platelets are collected via apheresis"
                  },
                  {
                    "text": "Most regulations and standards applicable for whole-blood collections are also applicable to apheresis collections"
                  },
                  {
                    "text": "Apheresis blood component collections are less time-consuming and labor-intensive from start of collection to final product"
                  },
                  {
                    "text": "Multiple components can be collected during 1 collection: 2 RBC units, 1 RBC unit and 1 plasma component, 1 RBC unit and 1 platelet component, 2 platelet components"
                  },
                  {
                    "text": "Disadvantages of apheresis blood component collections are increased cost of apheresis collection kits, increased phlebotomist training required, and increased time of collection"
                  }
                ]
              },
              "OVERVIEW": {
                "Overview": [
                  {
                    "text": "Most RBC and plasma components are manufactured from whole-blood collections in United States"
                  },
                  {
                    "text": "Most platelets are collected via apheresis"
                  },
                  {
                    "text": "Most regulations and standards applicable for whole-blood collections are also applicable to apheresis collections"
                  }
                ],
                "Advantages of Apheresis Blood Component Collections": [
                  {
                    "text": "Less time-consuming and labor-intensive from start of collection to final product"
                  },
                  {
                    "text": "Able to collect multiple components during 1 collection2 RBC units1 RBC unit and 1 plasma component1 RBC unit and 1 platelet component2 platelet components",
                    "sub_points": [
                      "2 RBC units",
                      "1 RBC unit and 1 plasma component",
                      "1 RBC unit and 1 platelet component",
                      "2 platelet components"
                    ]
                  },
                  {
                    "text": "Decrease in blood donor adverse reactionsDecreased incidence of hypovolemia and resultant vasovagal reactions due to saline replacement and reinfusion of blood components not collected",
                    "sub_points": [
                      "Decreased incidence of hypovolemia and resultant vasovagal reactions due to saline replacement and reinfusion of blood components not collected"
                    ]
                  },
                  {
                    "text": "Potential decrease in infectious disease marker testing costs"
                  }
                ],
                "Disadvantages of Apheresis Blood Component Collections": [
                  {
                    "text": "Increased cost of apheresis collection kits"
                  },
                  {
                    "text": "Requires increased phlebotomist training"
                  },
                  {
                    "text": "Increased time of collection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Human leukocyte antigen (HLA)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "American Association of Blood Banks (AABB)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Apheresis Red Blood Cell Collections": [
                  {
                    "text": "Frequently 2 RBC units collected during 1 procedure"
                  },
                  {
                    "text": "Minimum hemoglobin and hematocrit requirements are 13.3 g/dL and 40%"
                  },
                  {
                    "text": "Deferral period is increased to 16 weeks"
                  },
                  {
                    "text": "Minimum height and weight requirements are 130 lb and 5'5\" for men and 150 lb and 5'5\" for women"
                  },
                  {
                    "text": "Expect loss of 400-500 mg of iron per collection"
                  }
                ],
                "Plateletpheresis Collections": [
                  {
                    "text": "Apheresis platelet components allow for transfusion of single donor plateletsEliminates need for platelet poolingDecreases donor exposures",
                    "sub_points": [
                      "Eliminates need for platelet pooling",
                      "Decreases donor exposures"
                    ]
                  },
                  {
                    "text": "Allows for easy provision of HLA matched and crossmatched plateletsFor patients refractory to platelet transfusion",
                    "sub_points": [
                      "For patients refractory to platelet transfusion"
                    ]
                  },
                  {
                    "text": "Donors must meet whole-blood donation criteria"
                  },
                  {
                    "text": "Donation criteria specific to plateletpheresis collectionsDonors can donate 72 hr after whole-blood collectionDonors can donate up to 24 times/yrDonors can donate up to 2 times/weekThere must be at least 2 days between donationsIf the donor loses > 100 mL of RBCs, deferral period is 8 weeksDonation criteria may be waived with medical director approval",
                    "sub_points": [
                      "Donors can donate 72 hr after whole-blood collection",
                      "Donors can donate up to 24 times/yr",
                      "Donors can donate up to 2 times/week",
                      "There must be at least 2 days between donations",
                      "If the donor loses > 100 mL of RBCs, deferral period is 8 weeks",
                      "Donation criteria may be waived with medical director approval"
                    ]
                  },
                  {
                    "text": "If donation interval is < 4 weeks, platelet count must be at least 150,000/μL before collection"
                  },
                  {
                    "text": "If repeat donor has platelet count < 150,000/μL, new count must be drawn before next procedure and demonstrated to be > 150,000/μL"
                  },
                  {
                    "text": "Donor is deferred from future donations until count of 150,000/μL is achieved"
                  },
                  {
                    "text": "Plasma collected during plateletpheresis should not be > 500 mL in donors weighing ≤ 175 lb or > 600 mL in donors weighing > 175 lb"
                  },
                  {
                    "text": "Detailed records for each plateletpheresis procedure should be maintained by collection facilityRecords should be reviewed at least once every 4 months by donor center medical director",
                    "sub_points": [
                      "Records should be reviewed at least once every 4 months by donor center medical director"
                    ]
                  }
                ],
                "Plasmapheresis Collections": [
                  {
                    "text": "May be collected as transfusable plasma or source plasmaTransfusable plasmaPlasma componentsSource plasmaPlasma used to manufacture plasma derivativesAlbumin, intravenous immunoglobulin, factor concentrates",
                    "sub_points": [
                      "Transfusable plasmaPlasma components",
                      "Plasma components",
                      "Source plasmaPlasma used to manufacture plasma derivativesAlbumin, intravenous immunoglobulin, factor concentrates",
                      "Plasma used to manufacture plasma derivativesAlbumin, intravenous immunoglobulin, factor concentrates",
                      "Albumin, intravenous immunoglobulin, factor concentrates"
                    ]
                  },
                  {
                    "text": "Infrequent plasmapheresis donationDefined as donation interval every 4 months or longerDonors subject to whole-blood deferral criteria",
                    "sub_points": [
                      "Defined as donation interval every 4 months or longer",
                      "Donors subject to whole-blood deferral criteria"
                    ]
                  },
                  {
                    "text": "Frequent plasmapheresis donation or serial plasmapheresisDefined as donation interval more than once every 4 weeksPrograms subject to different FDA requirementsOverseen by Plasma Protein Therapeutics AssociationRequirementsRBC loss must not be > 25 mL/weekDonors may donate every 2 days or 2 times/week at maximumUnless approved by physician when donor has plasma with specific therapeutic valueVolume of plasma collected must not be > 12,000 mL annually for donors who weigh ≤ 175 lb and > 14,400 mL for donors weighing > 175 lbTotal protein level and serum plasma electrophoresis must be performedAt first donationAt 4-month intervals",
                    "sub_points": [
                      "Defined as donation interval more than once every 4 weeks",
                      "Programs subject to different FDA requirementsOverseen by Plasma Protein Therapeutics Association",
                      "Overseen by Plasma Protein Therapeutics Association",
                      "RequirementsRBC loss must not be > 25 mL/weekDonors may donate every 2 days or 2 times/week at maximumUnless approved by physician when donor has plasma with specific therapeutic valueVolume of plasma collected must not be > 12,000 mL annually for donors who weigh ≤ 175 lb and > 14,400 mL for donors weighing > 175 lbTotal protein level and serum plasma electrophoresis must be performedAt first donationAt 4-month intervals",
                      "RBC loss must not be > 25 mL/week",
                      "Donors may donate every 2 days or 2 times/week at maximumUnless approved by physician when donor has plasma with specific therapeutic value",
                      "Unless approved by physician when donor has plasma with specific therapeutic value",
                      "Volume of plasma collected must not be > 12,000 mL annually for donors who weigh ≤ 175 lb and > 14,400 mL for donors weighing > 175 lb",
                      "Total protein level and serum plasma electrophoresis must be performedAt first donationAt 4-month intervals",
                      "At first donation",
                      "At 4-month intervals"
                    ]
                  }
                ],
                "Granulocyte Collections": [
                  {
                    "text": "Granulocytes collected only via apheresis"
                  },
                  {
                    "text": "Granulocytes not licensed by FDA"
                  },
                  {
                    "text": "AABB Standards requires that granulocyte yield is at least 1 x 10¹⁰ granulocytes per bag in > 75% of products collected"
                  },
                  {
                    "text": "Minimum of 1 x 10¹⁰ granulocytes per bag necessary for efficacy"
                  },
                  {
                    "text": "Collection yield depends on donor WBC count and total volume of blood processedDonors are stimulated with corticosteroids ± G-CSF to increase WBC countsIncreasing density gradients in apheresis instrument through use of pentastarch or hetastarch improves separation between RBC and granulocyte layers, improving efficiency",
                    "sub_points": [
                      "Donors are stimulated with corticosteroids ± G-CSF to increase WBC counts",
                      "Increasing density gradients in apheresis instrument through use of pentastarch or hetastarch improves separation between RBC and granulocyte layers, improving efficiency"
                    ]
                  },
                  {
                    "text": "Sedimenting agentsPentastarch and hetastarchAct as volume expanders in donorMay cause peripheral edema, headaches, coagulopathy, allergic reactions",
                    "sub_points": [
                      "Pentastarch and hetastarch",
                      "Act as volume expanders in donorMay cause peripheral edema, headaches, coagulopathy, allergic reactions",
                      "May cause peripheral edema, headaches, coagulopathy, allergic reactions"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Whole Blood Donation": {
            "name": "Whole Blood Donation",
            "url": "https://app.pathprimer.com/document/767d4084-f70e-46d2-8a64-b53b9572a2c2/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Regulation": [
                  {
                    "text": "Volume limitations for WB collection ensure donor safety as well as potent product for recipientPacked RBC units collected from WB do not have FDA or AABB required hemoglobin contentMechanism for ensuring product potency is minimum WB volume requirements",
                    "sub_points": [
                      "Packed RBC units collected from WB do not have FDA or AABB required hemoglobin content",
                      "Mechanism for ensuring product potency is minimum WB volume requirements"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Citrate phosphate dextrose (CPD)"
                  },
                  {
                    "text": "Citrate phosphate dextrose adenine (CPDA)"
                  },
                  {
                    "text": "Citrate phosphate double dextrose (CP2D)"
                  },
                  {
                    "text": "Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Whole Blood Collection": [
                  {
                    "text": "Most blood collection establishments use blood bags designed to collect 500 mL for routine WB collectionsBlood bags designed to collect 450 mL are also available and may be desirable for use in autologous donors or underweight donors",
                    "sub_points": [
                      "Blood bags designed to collect 450 mL are also available and may be desirable for use in autologous donors or underweight donors"
                    ]
                  },
                  {
                    "text": "Collection of 500 mL WB generally should take 4-10 minutesLonger collections imply slow flow rates, which can contribute to clotsShorter flow rates can be associated with syncopal reactions",
                    "sub_points": [
                      "Longer collections imply slow flow rates, which can contribute to clots",
                      "Shorter flow rates can be associated with syncopal reactions"
                    ]
                  },
                  {
                    "text": "Anticoagulant solutions (CPD, CP2D, CPDA) are in collection bag"
                  },
                  {
                    "text": "Collection bag should be thoroughly mixed intermittently (~ every 30 seconds) during donation to ensure thorough mixing of anticoagulant and prevent clottingMixing can be done by hand or with FDA-approved continuous mechanical mixingSuch mechanical mixers can also have features such as scales and tubing clamps to prevent over-collection",
                    "sub_points": [
                      "Mixing can be done by hand or with FDA-approved continuous mechanical mixing",
                      "Such mechanical mixers can also have features such as scales and tubing clamps to prevent over-collection"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "WB Collection Volume Requirements": [
                  {
                    "text": "No more than 10.5 mL/kg of WB is to be collected, including specimens for IDM testing and ABO and antibody screen testing"
                  },
                  {
                    "text": "Density of WB is approximately 1.053 g/mLInformation allows conversion of more frequently measured product weights into required volumes for regulatory compliance",
                    "sub_points": [
                      "Information allows conversion of more frequently measured product weights into required volumes for regulatory compliance"
                    ]
                  },
                  {
                    "text": "Collection volumes must be within bag manufacturer's specified range to ensure correct WB:anticoagulant ratioRoutine collections for 500 mL bags are 450-550 mL of WB﻿",
                    "sub_points": [
                      "Routine collections for 500 mL bags are 450-550 mL of WB﻿"
                    ]
                  },
                  {
                    "text": "Low-volume collections (333-449 mL WB for 500 mL bags)﻿Red cell product can be manufactured from these products﻿Products must be labeled as \"Red Blood Cells, Low Volume\"﻿\"Red Blood Cells, Low Volume\" cannot have additive solutions, per AABB Circular of Information, to prevent further dilution of RBCThere does not appear to be any harm in storage properties of red cells collected from low-volume collections﻿Plasma-rich products cannot be manufactured from low-volume collections, due to presence of excess anticoagulant solution that could cause recipient reaction",
                    "sub_points": [
                      "Red cell product can be manufactured from these products﻿",
                      "Products must be labeled as \"Red Blood Cells, Low Volume\"﻿\"Red Blood Cells, Low Volume\" cannot have additive solutions, per AABB Circular of Information, to prevent further dilution of RBCThere does not appear to be any harm in storage properties of red cells collected from low-volume collections﻿",
                      "\"Red Blood Cells, Low Volume\" cannot have additive solutions, per AABB Circular of Information, to prevent further dilution of RBC",
                      "There does not appear to be any harm in storage properties of red cells collected from low-volume collections﻿",
                      "Plasma-rich products cannot be manufactured from low-volume collections, due to presence of excess anticoagulant solution that could cause recipient reaction"
                    ]
                  },
                  {
                    "text": "Overweight collections (> 550 mL WB for 500 mL bags)Should not be collectedIf volume collected represents > 10.5 mL/kg from donor and product is manufactured and distributed, event report should be made to FDA",
                    "sub_points": [
                      "Should not be collected",
                      "If volume collected represents > 10.5 mL/kg from donor and product is manufactured and distributed, event report should be made to FDA"
                    ]
                  }
                ]
              },
              "WORKFLOW": {
                "Blood Donation Workflow": [
                  {
                    "text": "Once donor has passed all physical exam and Donor History Questionnaire requirements, they are brought to donation area"
                  },
                  {
                    "text": "Donor identification is assured, and all collection bags are labeled with correct ISBT 128 label, which is cross-listed with donor's record"
                  },
                  {
                    "text": "Antecubital fossae are inspected and, if acceptable, sterilely preparedSterile prep must be according to manufacturer's guidelines and properly documented",
                    "sub_points": [
                      "Sterile prep must be according to manufacturer's guidelines and properly documented"
                    ]
                  },
                  {
                    "text": "Tourniquet (frequently, blood pressure cuff inflated to 40-60 mm Hg) is applied, and phlebotomy is performed using sterile technique and 15-17 gauge steel needleLess mobile median vein is generally best phlebotomy choice",
                    "sub_points": [
                      "Less mobile median vein is generally best phlebotomy choice"
                    ]
                  },
                  {
                    "text": "After completion of phlebotomy, needle is withdrawn and pressure is held over siteOnce hemostasis is achieved, pressure dressing is appliedHeavy lifting with arm should be delayed several hours",
                    "sub_points": [
                      "Once hemostasis is achieved, pressure dressing is appliedHeavy lifting with arm should be delayed several hours",
                      "Heavy lifting with arm should be delayed several hours"
                    ]
                  },
                  {
                    "text": "Donor is hydrated and given post-donation salty snacks"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Autologous and Directed Donations": {
            "name": "Autologous and Directed Donations",
            "url": "https://app.pathprimer.com/document/471eecad-88f2-4375-9e64-645eef89d8b7/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Directed donations are units collected for use by intended recipient, usually relative or friend"
                  },
                  {
                    "text": "Autologous donations are units collected for use by donor and are usually collected prior to scheduled surgery"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Directed Donations": [
                  {
                    "text": "Donors who donate for specified patient who may be relative or friend"
                  },
                  {
                    "text": "Must meet all requirements for allogeneic blood donation"
                  },
                  {
                    "text": "Donors must be ABO and Rh compatible with their intended recipient"
                  },
                  {
                    "text": "Risk of positive infectious disease marker testing is increased compared with general donor population, as these are often first-time blood donors"
                  },
                  {
                    "text": "Cellular blood components must be irradiated if recipient is blood relative, due to risk of transfusion-associated graft-versus-host disease"
                  },
                  {
                    "text": "Directed donor units may be released into general inventory if unused by intended recipient"
                  },
                  {
                    "text": "Directed donations are not encouraged at this time"
                  }
                ],
                "Autologous Donations": [
                  {
                    "text": "Autologous donors donate their own blood for their own use"
                  },
                  {
                    "text": "Should be reserved for patients who would like to donate blood for their own use prior to scheduled surgery with high likelihood of transfusion"
                  },
                  {
                    "text": "Patients with multiple alloantibodies or antibodies to high frequency antigens for whom finding compatible blood may prove difficult may be encouraged to donate prior to scheduled surgery"
                  },
                  {
                    "text": "Transfusion of autologous blood mitigates risk of some but not all transfusion reactionsSeptic reactions, febrile nonhemolytic transfusion reactions, and transfusion-associated circulatory overload may still occur",
                    "sub_points": [
                      "Septic reactions, febrile nonhemolytic transfusion reactions, and transfusion-associated circulatory overload may still occur"
                    ]
                  },
                  {
                    "text": "Physician's order must be received, specifying products to be collected and anticipated date of transfusion"
                  }
                ],
                "Criteria for Autologous Donations": [
                  {
                    "text": "Age: As defined by medical director"
                  },
                  {
                    "text": "Whole blood volume collected: ≤ 10 mL/kg, including samplesCollection of small volume units require adjustment of anticoagulant volume in order to obtain appropriate ratio",
                    "sub_points": [
                      "Collection of small volume units require adjustment of anticoagulant volume in order to obtain appropriate ratio"
                    ]
                  },
                  {
                    "text": "Hemoglobin: 11.0 g/dL"
                  },
                  {
                    "text": "Hematocrit: 33%"
                  },
                  {
                    "text": "Intervals between donations of RBCs: 72 hours after each whole blood donationLast donation no fewer than 72 hours prior to date and time of need",
                    "sub_points": [
                      "Last donation no fewer than 72 hours prior to date and time of need"
                    ]
                  },
                  {
                    "text": "Blood pressure: As defined by medical director"
                  },
                  {
                    "text": "Donor history: Abbreviated, as defined by medical directorHeart and lung diseasesBlood disordersBleeding conditionsPregnancy",
                    "sub_points": [
                      "Heart and lung diseases",
                      "Blood disorders",
                      "Bleeding conditions",
                      "Pregnancy"
                    ]
                  },
                  {
                    "text": "Medication and vaccination deferrals: As defined by medical director"
                  },
                  {
                    "text": "Temperature: As defined by medical director; defer for conditions that present risk of bacteremia"
                  },
                  {
                    "text": "Pregnancy: As defined by medical director"
                  },
                  {
                    "text": "Transfusion history: As defined by medical director"
                  },
                  {
                    "text": "Venipuncture site: As defined by medical director"
                  },
                  {
                    "text": "Platelet count (for platelet donors): As defined by medical director"
                  },
                  {
                    "text": "Contraindications: As defined by medical director, likely including certain conditionsUnstable anginaRecent myocardial infarction or cerebrovascular accidentSymptomatic heart or lung diseaseUntreated aortic stenosis",
                    "sub_points": [
                      "Unstable angina",
                      "Recent myocardial infarction or cerebrovascular accident",
                      "Symptomatic heart or lung disease",
                      "Untreated aortic stenosis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Adverse Donor Reactions": {
            "name": "Adverse Donor Reactions",
            "url": "https://app.pathprimer.com/document/b3ed746b-5044-40ae-b331-821de0bcebd1/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Adverse reactions occur in ~ 2-5% of donations"
                  },
                  {
                    "text": "Small hematomas and minor vasovagal reactions are most common"
                  },
                  {
                    "text": "Approximately 60% of reactions occur postdonation in canteen"
                  },
                  {
                    "text": "Reactions requiring medical care are rare (~ 1 per 3400)"
                  },
                  {
                    "text": "Reactions most commonly occur in young, 1st-time, female blood donors"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hematomas and Infiltrations": [
                  {
                    "text": "Occur in ~ 75 per 10,000 donations"
                  },
                  {
                    "text": "Related to needle insertion"
                  },
                  {
                    "text": "Pain, redness, warmth, and swelling are seen around needle insertion site"
                  },
                  {
                    "text": "Hematomas may be more severe with apheresis collections due to positive pressure with blood return"
                  },
                  {
                    "text": "TreatmentRestAnalgesicsWarm compresses",
                    "sub_points": [
                      "Rest",
                      "Analgesics",
                      "Warm compresses"
                    ]
                  },
                  {
                    "text": "Symptoms generally resolve within 1-2 weeks"
                  }
                ],
                "Nerve Injury": [
                  {
                    "text": "Rare reaction related to needle insertion"
                  },
                  {
                    "text": "Numbness, weakness, radiating pain, and sensory changes in forearm, hand, wrist, or shoulder"
                  },
                  {
                    "text": "Often seen in combination with hematoma and may be due to compression by large hematoma"
                  },
                  {
                    "text": "Symptoms generally resolve within 1 month, but may last up to 1 year"
                  },
                  {
                    "text": "Permanent nerve damage is rare"
                  }
                ],
                "Vasovagal Reactions": [
                  {
                    "text": "Most common donor reactionOccurs in ~ 2.5% of donations",
                    "sub_points": [
                      "Occurs in ~ 2.5% of donations"
                    ]
                  },
                  {
                    "text": "Due to excessive parasympathetic outflow"
                  },
                  {
                    "text": "More common in donors donating for 1st time, who are low weight, and have history of adverse reaction during blood donation"
                  },
                  {
                    "text": "Anxiety regarding needles &/or donation process predispose to vasovagal reactions and can lead to multiple fainting events in blood donors at blood drive (seen most commonly in high school blood drives)"
                  },
                  {
                    "text": "SymptomsPallorDizzinessChillsFeeling warmNauseaVomitingWeaknessSweatingHypotensionBradycardia",
                    "sub_points": [
                      "Pallor",
                      "Dizziness",
                      "Chills",
                      "Feeling warm",
                      "Nausea",
                      "Vomiting",
                      "Weakness",
                      "Sweating",
                      "Hypotension",
                      "Bradycardia"
                    ]
                  },
                  {
                    "text": "Syncope and convulsions with possible injury can be seen in more severe vasovagal reactions"
                  },
                  {
                    "text": "TreatmentRespond calmly and reassure donorDiscontinue donationImmediately place donor in recumbent positionElevate legs above heartMonitor vital signsApply cold damp cloth to donor’s foreheadLoosen tight clothingHave donor breath into paper bagPrevent injury due to loss of consciousnessSeek medical attention when loss of consciousness occurs or if donor has prolonged symptoms (30 minutes to 1 hour)",
                    "sub_points": [
                      "Respond calmly and reassure donor",
                      "Discontinue donation",
                      "Immediately place donor in recumbent position",
                      "Elevate legs above heart",
                      "Monitor vital signs",
                      "Apply cold damp cloth to donor’s forehead",
                      "Loosen tight clothing",
                      "Have donor breath into paper bag",
                      "Prevent injury due to loss of consciousness",
                      "Seek medical attention when loss of consciousness occurs or if donor has prolonged symptoms (30 minutes to 1 hour)"
                    ]
                  },
                  {
                    "text": "Vasovagal reactions are less commonly seen with apheresis collections"
                  }
                ],
                "Arterial Puncture": [
                  {
                    "text": "Relatively rare reactionOccurs in < 1% of reactions",
                    "sub_points": [
                      "Occurs in < 1% of reactions"
                    ]
                  },
                  {
                    "text": "Bright red blood and rapid bag filling is seen"
                  },
                  {
                    "text": "More common with inexperienced collection staff"
                  },
                  {
                    "text": "TreatmentImmediately remove needle and apply pressure at site",
                    "sub_points": [
                      "Immediately remove needle and apply pressure at site"
                    ]
                  }
                ],
                "Anemia": [
                  {
                    "text": "200-250 mg of iron are lost with each whole blood donation"
                  },
                  {
                    "text": "Repeat blood donations can lead to iron deficiency and resultant loss of iron stores and iron-deficiency anemia"
                  },
                  {
                    "text": "SymptomsFatigueWeaknessDifficulty concentratingRestless legsPica",
                    "sub_points": [
                      "Fatigue",
                      "Weakness",
                      "Difficulty concentrating",
                      "Restless legs",
                      "Pica"
                    ]
                  },
                  {
                    "text": "Females and males who donate blood frequently are at increased risk"
                  }
                ],
                "Rashes": [
                  {
                    "text": "Donors may have reactions due to allergies or sensitivity to skin preparation solutions (iodine, chlorhexidine) or bandages used postdonation"
                  }
                ],
                "Apheresis-Specific Donation Reactions": [
                  {
                    "text": "Hypocalcemia reactions due to citrate anticoagulationSymptomsNumbnessTingling around lips, face, and fingertipsNauseaRarely: Confusion, tetany, chest pain, and cardiac arrhythmiasTreatmentSlow procedure downProvide oral calcium supplementationDiscontinue procedure",
                    "sub_points": [
                      "SymptomsNumbnessTingling around lips, face, and fingertipsNauseaRarely: Confusion, tetany, chest pain, and cardiac arrhythmias",
                      "Numbness",
                      "Tingling around lips, face, and fingertips",
                      "Nausea",
                      "Rarely: Confusion, tetany, chest pain, and cardiac arrhythmias",
                      "TreatmentSlow procedure downProvide oral calcium supplementationDiscontinue procedure",
                      "Slow procedure down",
                      "Provide oral calcium supplementation",
                      "Discontinue procedure"
                    ]
                  },
                  {
                    "text": "Machine malfunctionCan lead to early procedure termination and inability to return donor’s blood within machineMay lead to thrombosis, hemolysis, and air embolus",
                    "sub_points": [
                      "Can lead to early procedure termination and inability to return donor’s blood within machine",
                      "May lead to thrombosis, hemolysis, and air embolus"
                    ]
                  }
                ],
                "Prevention of Adverse Reactions": [
                  {
                    "text": "Educate donor regarding expectations during donation process"
                  },
                  {
                    "text": "Hydrate with or without provision of salty snacks prior to donation"
                  },
                  {
                    "text": "Use distraction and relaxation techniques"
                  },
                  {
                    "text": "Establish weight limits for blood donors"
                  },
                  {
                    "text": "Request muscle tension or sequential muscle tensing during phlebotomy"
                  }
                ],
                "Adverse Reaction Reporting": [
                  {
                    "text": "Federal Drug Administration’s Code of Federal Regulations mandates that donor centers notify the FDA Center for Biologics Evaluation and Research (CBER) as soon as possible after confirming a donation-related fatalityWritten report must be submitted to CBER within 7 days of fatality",
                    "sub_points": [
                      "Written report must be submitted to CBER within 7 days of fatality"
                    ]
                  },
                  {
                    "text": "Department of Health and Human Services Biovigilance Network has established standardized criteria for reporting adverse donor reactionsVasovagal reactionsPrefaint, no loss of consciousnessLoss of consciousness, uncomplicated (no injury, seizure, need for medical attention)Loss of consciousness, complicated (seizure, need for medical attention)InjuryNeedle-related injuryHematomaNerve irritationArterial punctureApheresisCitrate-relatedHematomaAir embolusAllergicLocalSystemicAnaphylaxisOther",
                    "sub_points": [
                      "Vasovagal reactionsPrefaint, no loss of consciousnessLoss of consciousness, uncomplicated (no injury, seizure, need for medical attention)Loss of consciousness, complicated (seizure, need for medical attention)Injury",
                      "Prefaint, no loss of consciousness",
                      "Loss of consciousness, uncomplicated (no injury, seizure, need for medical attention)",
                      "Loss of consciousness, complicated (seizure, need for medical attention)",
                      "Injury",
                      "Needle-related injuryHematomaNerve irritationArterial puncture",
                      "Hematoma",
                      "Nerve irritation",
                      "Arterial puncture",
                      "ApheresisCitrate-relatedHematomaAir embolus",
                      "Citrate-related",
                      "Hematoma",
                      "Air embolus",
                      "AllergicLocalSystemicAnaphylaxis",
                      "Local",
                      "Systemic",
                      "Anaphylaxis",
                      "Other"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Donation Intervals": {
            "name": "Donation Intervals",
            "url": "https://app.pathprimer.com/document/ee03f190-57a6-4323-a871-d06b53ef37f5/lesson/da50ece8-9627-41a4-b178-b906e0818703",
            "content": {
              "OVERVIEW": {
                "Allowed Minimal Interval Between Blood Donation Differs Between Types of Blood Donation": [
                  {
                    "text": "Regulations on donor intervalsProtect blood donor from iron deficiency/cytopeniaEnsure recipient potent product that meets minimal regulatory requirements",
                    "sub_points": [
                      "Protect blood donor from iron deficiency/cytopenia",
                      "Ensure recipient potent product that meets minimal regulatory requirements"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Serum protein electrophoresis (SPEP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Minimal Donation Intervals Help Ensure Minimal Required Component Content and Clinical Efficacy": [
                  {
                    "text": "RBC unit hemoglobin content is not regulated in United StatesVaries as a function of donor's hemoglobin and exact donation volumeApproximately 2 × 10¹¹ new erythrocytes are generated dailyApproximately 1% of total red cell mass, given red cell half-life of 120 daysProduction increases several-fold after blood lossRemoving 500 mL WB represents approximately 14% of RBCs in donor with hemoglobin of 12.5 g/dLThis would be regenerated within approximately 14 days with adequate iron storesDonation interval of 8 weeks generally prevents iron deficiency anemia in most nonvegetarian donorsThis interval optimizes chances that repeat donor would have hemoglobin at least 12.5 g/dL (female) or 13.0 g/dL (male) and would be able to donate 500 mL of WB",
                    "sub_points": [
                      "Varies as a function of donor's hemoglobin and exact donation volume",
                      "Approximately 2 × 10¹¹ new erythrocytes are generated dailyApproximately 1% of total red cell mass, given red cell half-life of 120 daysProduction increases several-fold after blood lossRemoving 500 mL WB represents approximately 14% of RBCs in donor with hemoglobin of 12.5 g/dLThis would be regenerated within approximately 14 days with adequate iron stores",
                      "Approximately 1% of total red cell mass, given red cell half-life of 120 days",
                      "Production increases several-fold after blood loss",
                      "Removing 500 mL WB represents approximately 14% of RBCs in donor with hemoglobin of 12.5 g/dL",
                      "This would be regenerated within approximately 14 days with adequate iron stores",
                      "Donation interval of 8 weeks generally prevents iron deficiency anemia in most nonvegetarian donors",
                      "This interval optimizes chances that repeat donor would have hemoglobin at least 12.5 g/dL (female) or 13.0 g/dL (male) and would be able to donate 500 mL of WB"
                    ]
                  },
                  {
                    "text": "Apheresis platelet products must contain 3 x 10¹¹ platelets per unitWB-derived platelet products must contain 5.5 x 10¹⁰ platelets per unitHealthy human marrow produces approximately 4 x 10⁹ platelets/hr (9.6 x 10¹⁰ platelets/day)With normal platelet production rate, 3 x 10¹¹ platelets would be regenerated in 3.1 days",
                    "sub_points": [
                      "WB-derived platelet products must contain 5.5 x 10¹⁰ platelets per unit",
                      "Healthy human marrow produces approximately 4 x 10⁹ platelets/hr (9.6 x 10¹⁰ platelets/day)With normal platelet production rate, 3 x 10¹¹ platelets would be regenerated in 3.1 days",
                      "With normal platelet production rate, 3 x 10¹¹ platelets would be regenerated in 3.1 days"
                    ]
                  },
                  {
                    "text": "Plasma has no regulatory requirement for coagulation factor or plasma protein contentPlasma proteins have variable production rate/half-lifeAlbumin has fractional synthetic rate of 6%/dayFibrinogen has fractional synthetic rate of 18%/dayWith plasma unit being 250-300 mL (approximately 14% of circulating plasma), albumin loss would be replaced in approximately 2.3 days, and fibrinogen loss would be replaced in < 1 dayIgG production rate is approximately 860 mg/dayLoss would be replaced in approximately 4 days",
                    "sub_points": [
                      "Plasma proteins have variable production rate/half-lifeAlbumin has fractional synthetic rate of 6%/dayFibrinogen has fractional synthetic rate of 18%/dayWith plasma unit being 250-300 mL (approximately 14% of circulating plasma), albumin loss would be replaced in approximately 2.3 days, and fibrinogen loss would be replaced in < 1 dayIgG production rate is approximately 860 mg/dayLoss would be replaced in approximately 4 days",
                      "Albumin has fractional synthetic rate of 6%/dayFibrinogen has fractional synthetic rate of 18%/dayWith plasma unit being 250-300 mL (approximately 14% of circulating plasma), albumin loss would be replaced in approximately 2.3 days, and fibrinogen loss would be replaced in < 1 day",
                      "Fibrinogen has fractional synthetic rate of 18%/day",
                      "With plasma unit being 250-300 mL (approximately 14% of circulating plasma), albumin loss would be replaced in approximately 2.3 days, and fibrinogen loss would be replaced in < 1 day",
                      "IgG production rate is approximately 860 mg/dayLoss would be replaced in approximately 4 days",
                      "Loss would be replaced in approximately 4 days"
                    ]
                  },
                  {
                    "text": "Granulocyte products do not have regulatory requirement for cellular contentA dose of 1 x 10¹⁰ granulocytes per unit is reportedly associated with improved response in adult neutropenic recipientsNeutrophils are produced at rate of 5-10 × 10¹⁰ cells/day (approximately 1 × 10⁹ cells/kg)This rate is increased by corticosteroids or G-CSF administration to granulocyte donorsNeutrophils are replaced within < 1 day in mobilized donors",
                    "sub_points": [
                      "A dose of 1 x 10¹⁰ granulocytes per unit is reportedly associated with improved response in adult neutropenic recipients",
                      "Neutrophils are produced at rate of 5-10 × 10¹⁰ cells/day (approximately 1 × 10⁹ cells/kg)This rate is increased by corticosteroids or G-CSF administration to granulocyte donors",
                      "This rate is increased by corticosteroids or G-CSF administration to granulocyte donors",
                      "Neutrophils are replaced within < 1 day in mobilized donors"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Donation Intervals by Type of Donation": [
                  {
                    "text": "WB donation: 8 weeks"
                  },
                  {
                    "text": "Apheresis RBC donation (or \"double red\" donation): 16 weeksMust have hemoglobin 13.3 g/dLConfirm with specific apheresis instrument operator manualSex-based height/weight requirementsConfirm with specific apheresis instrument operator manualMen 130 lb, 5'1\"Women 150 lb, 5'5\"",
                    "sub_points": [
                      "Must have hemoglobin 13.3 g/dLConfirm with specific apheresis instrument operator manual",
                      "Confirm with specific apheresis instrument operator manual",
                      "Sex-based height/weight requirementsConfirm with specific apheresis instrument operator manualMen 130 lb, 5'1\"Women 150 lb, 5'5\"",
                      "Confirm with specific apheresis instrument operator manual",
                      "Men 130 lb, 5'1\"",
                      "Women 150 lb, 5'5\""
                    ]
                  },
                  {
                    "text": "Single plateletpheresis, leukocytopheresis: 2 daysNo more than 2 donations/week and no more than 24 donations in rolling 12-month period< 200 mL RBC loss within 8 weeksPlasma loss not to exceed that for infrequent plasma donors",
                    "sub_points": [
                      "No more than 2 donations/week and no more than 24 donations in rolling 12-month period",
                      "< 200 mL RBC loss within 8 weeks",
                      "Plasma loss not to exceed that for infrequent plasma donors"
                    ]
                  },
                  {
                    "text": "Double or triple plateletpheresis: 7 daysNo more than 24 donations in rolling 12-month period< 200 mL RBC loss within 8 weeksPlasma loss not to exceed that for infrequent plasma donors",
                    "sub_points": [
                      "No more than 24 donations in rolling 12-month period",
                      "< 200 mL RBC loss within 8 weeks",
                      "Plasma loss not to exceed that for infrequent plasma donors"
                    ]
                  },
                  {
                    "text": "Infrequent plasmapheresis: 4 weeks< 200 mL RBC loss within 8 weeks",
                    "sub_points": [
                      "< 200 mL RBC loss within 8 weeks"
                    ]
                  },
                  {
                    "text": "Frequent (i.e., paid) plasma donor (product used for source plasma): 2 daysNo more than 2 donations per week< 200 mL RBC loss within 8 weeksTotal protein and SPEP)/quantitative immunoglobulin levels must be performed every 4 monthsTotal protein must be > 6.0 g/dLSPEP pattern must be normalImmunoglobulin levels must be normalMust have physical examination by apheresis service physician every year",
                    "sub_points": [
                      "No more than 2 donations per week",
                      "< 200 mL RBC loss within 8 weeks",
                      "Total protein and SPEP)/quantitative immunoglobulin levels must be performed every 4 monthsTotal protein must be > 6.0 g/dLSPEP pattern must be normalImmunoglobulin levels must be normal",
                      "Total protein must be > 6.0 g/dL",
                      "SPEP pattern must be normal",
                      "Immunoglobulin levels must be normal",
                      "Must have physical examination by apheresis service physician every year"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Component Manufacturing": {
        "name": "Component Manufacturing",
        "url": "https://app.pathprimer.com/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
        "topics": {
          "Component Processing and Manufacturing": {
            "name": "Component Processing and Manufacturing",
            "url": "https://app.pathprimer.com/document/6a270f2c-b15c-46e7-90dc-df7309503478/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Component therapy better matches needs of most patients in modern medical care"
                  },
                  {
                    "text": "Platelets, pRBC, plasma, and cryoprecipitate are made from processing WB"
                  },
                  {
                    "text": "In-line LR filters allow for prestorage leukoreduction"
                  },
                  {
                    "text": "WB may be transfused directly to neonates or to military personnel for treatment of trauma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Additive solution (AS)"
                  },
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Leukoreduction (LR)"
                  },
                  {
                    "text": "Packed red blood cells (pRBC)"
                  },
                  {
                    "text": "Platelet-poor plasma (PPP)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Blood Component Processing From WB": [
                  {
                    "text": "WB is drawn into primary (\"mother\") bag from donorPrimary bag contains anticoagulant preservative solutionUp to 3 secondary (\"daughter\") bags are integrally attached to primary bag and are utilized for further sterile component manufactureOne of daughter bags intended for RBC storage may contain AS",
                    "sub_points": [
                      "Primary bag contains anticoagulant preservative solution",
                      "Up to 3 secondary (\"daughter\") bags are integrally attached to primary bag and are utilized for further sterile component manufacture",
                      "One of daughter bags intended for RBC storage may contain AS"
                    ]
                  },
                  {
                    "text": "LR filters are often included \"in-line\" as part of integral tubing in blood collection bag setLR is performed on WB as it flows by gravity from primary bag to secondary bagLR may be performed prestorage with in-line LR filter or at bedside during transfusionPrestorage LR is preferred, as it prevents accumulation of cytokines from WBCs during storageMost common cause of LR filter failure is sickle cell trait",
                    "sub_points": [
                      "LR is performed on WB as it flows by gravity from primary bag to secondary bag",
                      "LR may be performed prestorage with in-line LR filter or at bedside during transfusion",
                      "Prestorage LR is preferred, as it prevents accumulation of cytokines from WBCs during storage",
                      "Most common cause of LR filter failure is sickle cell trait"
                    ]
                  },
                  {
                    "text": "WB for transfusion is stored at 1-6°C"
                  },
                  {
                    "text": "WB for platelet manufacture should not be cooled to less than 20°C"
                  },
                  {
                    "text": "WB for component manufacture other than platelets must be cooled to 1-10°C"
                  },
                  {
                    "text": "WB products with visible clots (often detected during LR step) should not be manufactured for transfusion"
                  },
                  {
                    "text": "WB is centrifuged with hard spin to create pRBC and PPPCentrifuges must maintain appropriate temperature, be validated, and properly maintained",
                    "sub_points": [
                      "Centrifuges must maintain appropriate temperature, be validated, and properly maintained"
                    ]
                  },
                  {
                    "text": "Manual plasma expressors or FDA-approved automated devices may be used to physically separate plasma from pRBC"
                  },
                  {
                    "text": "pRBC, plasma, platelets, and cryoprecipitate are further manufactured from WB (See individual topics)"
                  },
                  {
                    "text": "After separation of products into different component bags, tubing should be clamped, heat sealed, and separated"
                  }
                ],
                "WB for Transfusion": [
                  {
                    "text": "ABO-matched WB may be used for transfusion for neonates and in military settings for trauma"
                  },
                  {
                    "text": "Fresh, warm WB is used by military and provides functional platelets"
                  },
                  {
                    "text": "WB is stored at 1-6°C and does not provide functional platelets"
                  },
                  {
                    "text": "Minimum hematocrit is about 33% due to anticoagulant in collection bag"
                  },
                  {
                    "text": "More frequently, WB is reconstituted for specific patient populations (i.e., neonates requiring WB exchange) by combining RBCs with FFP to achieve specific hematocrit"
                  },
                  {
                    "text": "Reconstituted WB may be stored at 1-6°C for 24 hours"
                  },
                  {
                    "text": "Levels of factor V and factor VIII decrease over time of storage"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Red Blood Cell Components": {
            "name": "Red Blood Cell Components",
            "url": "https://app.pathprimer.com/document/962a865e-2612-40c9-b903-aa408c721428/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "RBCs may be collected for transfusion by apheresis or manufactured from whole blood"
                  },
                  {
                    "text": "Shelf-life of RBC unit is dependent upon anticoagulant preservative solution and additive solutionCPD/CP2D/ACD: 21 daysCDPA-1: 35 daysAS: 42 days",
                    "sub_points": [
                      "CPD/CP2D/ACD: 21 days",
                      "CDPA-1: 35 days",
                      "AS: 42 days"
                    ]
                  },
                  {
                    "text": "RBCs are stored at 1-6 °C"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Additive solution (AS)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "Anticoagulant citrate dextrose (ACD)"
                  },
                  {
                    "text": "Citrate phosphate dextrose (CPD)"
                  },
                  {
                    "text": "Citrate phosphate dextrose adenine (CPDA)"
                  },
                  {
                    "text": "Citrate phosphate dextrose dextrose (CP2D)"
                  },
                  {
                    "text": "Food and Drug Association (FDA)"
                  },
                  {
                    "text": "Packed red blood cells (PRBC)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "White blood cells (WBC)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Red Blood Cell Components": [
                  {
                    "text": "WB is drawn from donor into primary (\"mother\") bag containing anticoagulant preservative solution"
                  },
                  {
                    "text": "Mother bag is centrifuged to separate RBCs from plasma via density gradient"
                  },
                  {
                    "text": "Plasma is expressed off either using manual plasma expressor or FDA-approved automated device"
                  },
                  {
                    "text": "Tubing should be clamped, heat sealed, and separated"
                  },
                  {
                    "text": "Retention segments are made by heat sealing tubing containing RBC product to create multiple segments containing small aliquotsAliquots are stored to be used for compatibility testing and phenotyping",
                    "sub_points": [
                      "Aliquots are stored to be used for compatibility testing and phenotyping"
                    ]
                  },
                  {
                    "text": "RBC units may be prestorage leukoreduced via gravity filtration through in-line leukoreduction filter"
                  }
                ],
                "Apheresis RBC Components": [
                  {
                    "text": "RBCs may be collected via apheresis"
                  },
                  {
                    "text": "Leukoreduced RBCs collected via apheresis may be collected either by method that collects < 5 x 10⁶ WBCs per unit or with in-line leukoreduction filter"
                  },
                  {
                    "text": "Apheresis method must be validated to generate average collection containing ≥ 60 g hemoglobin per unit"
                  },
                  {
                    "text": "Quality control requirement is for at least 95% of tested units to have > 50 g hemoglobin per unit"
                  }
                ],
                "Storage and Transportation Requirements": [
                  {
                    "text": "PRBCs are stored at 1-6 °C"
                  },
                  {
                    "text": "PRBCs are transported at 1-10 °C"
                  },
                  {
                    "text": "Issued PRBCs must be returned to blood bank within validated time frame (often 20-30 minutes) that does not allow unit temperature to rise about 10 °C to be returned to inventory"
                  },
                  {
                    "text": "Irradiated PRBCs have shelf life of 28 days from time of irradiation or original expiration date, whichever comes first"
                  }
                ],
                "Anticoagulant Preservative Solutions": [
                  {
                    "text": "All anticoagulant preservative solutions use citrate for anticoagulation and dextrose as energy source"
                  },
                  {
                    "text": "Phosphate may be added as buffer"
                  },
                  {
                    "text": "PRBC shelf-lifeACD: 21-day outdate, generally only used for apheresis RBC collectionCPD/CP2D: 21-day outdate, unit hematocrit generally 70-80%CPDA-1: 35-day outdateAdenine allows extra 2 weeks of storage due to adenine’s effect of maintaining RBC ATP levels and, hence, maintaining cellular metabolism",
                    "sub_points": [
                      "ACD: 21-day outdate, generally only used for apheresis RBC collection",
                      "CPD/CP2D: 21-day outdate, unit hematocrit generally 70-80%",
                      "CPDA-1: 35-day outdateAdenine allows extra 2 weeks of storage due to adenine’s effect of maintaining RBC ATP levels and, hence, maintaining cellular metabolism",
                      "Adenine allows extra 2 weeks of storage due to adenine’s effect of maintaining RBC ATP levels and, hence, maintaining cellular metabolism"
                    ]
                  }
                ],
                "Additive Solutions": [
                  {
                    "text": "AS for PRBCs are added to PRBCs after plasma is expressed off"
                  },
                  {
                    "text": "Blood collection sets designed for production of AS PRBC use CPD or CP2D for their anticoagulant preservative solution"
                  },
                  {
                    "text": "AS allows extension of PRBC outdate from 21 days to 42 days"
                  },
                  {
                    "text": "AS unit hematocrit generally 55-65%; contain less residual donor plasma than CPDA-1 units"
                  },
                  {
                    "text": "All contain NaCl, adenine, glucose, +/- phosphate, +/- mannitol, +/- citric acid/citrate"
                  },
                  {
                    "text": "AS-3 does not contain mannitolSome neonatologists previously worried about using mannitol-containing AS products, due to concern regarding osmotic diuresis and changes in intracerebral pressureProbably only problem for large-volume transfusion > 15 mL/kgMannitol stabilizes RBC membrane and reduces hemolysis",
                    "sub_points": [
                      "Some neonatologists previously worried about using mannitol-containing AS products, due to concern regarding osmotic diuresis and changes in intracerebral pressure",
                      "Probably only problem for large-volume transfusion > 15 mL/kg",
                      "Mannitol stabilizes RBC membrane and reduces hemolysis"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA": [
                  {
                    "text": "Licensing requirements for anticoagulant preservative solutions and AS< 1% hemolysis at end of storage periodSurvival of > 75% of transfused cells at 24 hours after transfusion",
                    "sub_points": [
                      "< 1% hemolysis at end of storage period",
                      "Survival of > 75% of transfused cells at 24 hours after transfusion"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasma Components": {
            "name": "Plasma Components",
            "url": "https://app.pathprimer.com/document/229b3945-0d02-4eb8-a23f-7fac45881e8c/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Plasma may be obtained from centrifugation of whole blood or via automated apheresis"
                  },
                  {
                    "text": "Plasma components have different names based on time from donor phlebotomy to plasma freezing"
                  },
                  {
                    "text": "FFP is frozen within 6-8 hours of collection"
                  },
                  {
                    "text": "Plasma frozen within 24 hours of phlebotomy is frozen 8-24 hours after collection and has decreased levels of factor V and factor VIII"
                  },
                  {
                    "text": "Plasma products are stored at or less than 18°C for up to 1 year"
                  },
                  {
                    "text": "Plasma products are thawed at 30-37°C and stored at 1-6°C prior to transfusion"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anticoagulant citrate phosphate dextrose (CPD)"
                  },
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Plasma frozen within 24 hours of phlebotomy (FP24)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Thawed plasma (TP)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Plasma Manufacture": [
                  {
                    "text": "Manufactured from whole blood or collected via automated apheresis (See Apheresis Blood Component Collections)"
                  },
                  {
                    "text": "Whole blood is centrifuged to separate RBCs and PRP in United States"
                  },
                  {
                    "text": "Initial centrifugation to create platelet-poor plasma is used in Europe"
                  },
                  {
                    "text": "Manual plasma expressors or FDA-approved automated devices may be used to physically separate plasma from RBCs"
                  },
                  {
                    "text": "Expression of plasma off whole blood collection bag must stop before RBCs contaminate plasma"
                  },
                  {
                    "text": "Plasma can be pathogen-reduced prior to freezing, using FDA-approved pathogen reduction method"
                  },
                  {
                    "text": "Plasma is then frozen at or less than -18°C for up to 1 year"
                  },
                  {
                    "text": "Plasma is thawed at 30-37°C and stored at 1-6°C prior to transfusion"
                  }
                ],
                "Fresh Frozen Plasma": [
                  {
                    "text": "Must be frozen within 8 hours of collection if prepared with CPD, CP2D, CPDA-1 anticoagulants or within 6 hours of collection if prepared with anticoagulant citrate dextrose solution"
                  },
                  {
                    "text": "FFP must be transfused within 24 hours post thawing"
                  }
                ],
                "Plasma Frozen Within 24 Hours of Phlebotomy": [
                  {
                    "text": "Requires freezing plasma within 24 hours of phlebotomy"
                  },
                  {
                    "text": "FP24 has lower levels of factor V and factor VIII, though this difference is generally clinically insignificant"
                  },
                  {
                    "text": "FP24 must be transfused within 24 hours post thawing"
                  }
                ],
                "Thawed Plasma": [
                  {
                    "text": "FFP and FP24 thawed and not transfused within 24 hours may be converted to TP"
                  },
                  {
                    "text": "TP is stored at 1-6°C for up to 5 days post initial thawing"
                  },
                  {
                    "text": "Factor VIII levels continue to decline over length of storage by about 30%"
                  }
                ],
                "Cryoprecipitate-Reduced Plasma": [
                  {
                    "text": "Plasma that is residual plasma after manufacture of cryoprecipitate"
                  },
                  {
                    "text": "Contains decreased levels of von Willebrand factor, factor VII, factor XIII, and fibrinogen"
                  },
                  {
                    "text": "Stored at or less than -18°C for up to 1 year"
                  },
                  {
                    "text": "Thawed at 30-37°C and stored for up to 5 days at 1-6°C prior to transfusion"
                  }
                ],
                "Recovered Plasma": [
                  {
                    "text": "Plasma used to manufacture plasma derivatives such as factor concentrates, albumin, and intravenous immunoglobulin"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cryoprecipitate": {
            "name": "Cryoprecipitate",
            "url": "https://app.pathprimer.com/document/28c0a291-9369-4c95-8d3f-95610a143e5f/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Used to replace fibrinogen in patients with hypofibrinogenemia (fibrinogen < 100 mg/dL)"
                  },
                  {
                    "text": "Contains certain concentrated amounts of factor VIII and fibrinogen in a smaller volume than FFP"
                  },
                  {
                    "text": "Usually prepared as small pool from multiple donors instead of being issued in single units"
                  }
                ],
                "Processing": [
                  {
                    "text": "To manufacture 1 unit of cryo, 1 unit of FFP is used"
                  }
                ]
              },
              "OVERVIEW": {
                "Uses for Cryoprecipitate": [
                  {
                    "text": "Used to replace fibrinogenUsually due to acquired coagulopathiesCardiac surgeryTraumaLiver transplantationObstetric hemorrhage",
                    "sub_points": [
                      "Usually due to acquired coagulopathiesCardiac surgeryTraumaLiver transplantationObstetric hemorrhage",
                      "Cardiac surgery",
                      "Trauma",
                      "Liver transplantation",
                      "Obstetric hemorrhage"
                    ]
                  },
                  {
                    "text": "In some developing nations, where expensive factor concentrates are not feasible, cryo is still commonly used for treatment of factor VIII-deficient hemophiliacs"
                  }
                ],
                "High-Yield Facts": [
                  {
                    "text": "cryo is pooled productPathogen inactivation is not performed during preparation",
                    "sub_points": [
                      "Pathogen inactivation is not performed during preparation"
                    ]
                  },
                  {
                    "text": "cryo is produced by further processing of FFPcryo contains certain concentrated amounts of factor VIII and fibrinogen in a smaller volume than FFPWhen 1 unit of FFP is allowed to thaw slowly at 1°-6°C, 1 unit of cryo forms",
                    "sub_points": [
                      "cryo contains certain concentrated amounts of factor VIII and fibrinogen in a smaller volume than FFP",
                      "When 1 unit of FFP is allowed to thaw slowly at 1°-6°C, 1 unit of cryo forms"
                    ]
                  },
                  {
                    "text": "Per AABB standards, each cryo bag should contain80-100 U of concentrated factor VIII150-250 mL of fibrinogenAlso contains von Willebrand factor, factor XIII, and fibronectin",
                    "sub_points": [
                      "80-100 U of concentrated factor VIII",
                      "150-250 mL of fibrinogen",
                      "Also contains von Willebrand factor, factor XIII, and fibronectin"
                    ]
                  }
                ],
                "Alternatives to Cryoprecipitate": [
                  {
                    "text": "Commercial fibrinogen preparations are available for fibrinogen replacement therapy"
                  },
                  {
                    "text": "cryoNot quickly availableMust be ordered from blood bank, thawed, and pooled, which can take 25-45 minTransfusion of standard dose takes another 30 minContains varying concentrations of fibrinogen",
                    "sub_points": [
                      "Not quickly availableMust be ordered from blood bank, thawed, and pooled, which can take 25-45 minTransfusion of standard dose takes another 30 min",
                      "Must be ordered from blood bank, thawed, and pooled, which can take 25-45 min",
                      "Transfusion of standard dose takes another 30 min",
                      "Contains varying concentrations of fibrinogen"
                    ]
                  },
                  {
                    "text": "Commercial fibrinogen concentrateCommercial fibrinogen concentrate is reconstituted at smaller volume so that large doses can be administered in a few minutesCommercial fibrinogen concentrate has standardized levels of fibrinogen",
                    "sub_points": [
                      "Commercial fibrinogen concentrate is reconstituted at smaller volume so that large doses can be administered in a few minutes",
                      "Commercial fibrinogen concentrate has standardized levels of fibrinogen"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cryoprecipitate (cryo)"
                  },
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  },
                  {
                    "text": "Antihemophilic factor (AHF)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  }
                ]
              },
              "PROCESSING": {
                "Overview": [
                  {
                    "text": "To manufacture 1 unit of cryo, 1 unit of FFP is usedIf within 1 yr of FFP collection date",
                    "sub_points": [
                      "If within 1 yr of FFP collection date"
                    ]
                  },
                  {
                    "text": "FFP is obtained either from whole blood or plasmapheresis"
                  }
                ],
                "Manufacturing Steps": [
                  {
                    "text": "FFP is thawed slowly at 1°-6°C"
                  },
                  {
                    "text": "White precipitate forms and is centrifuged to bottom of bag (done in refrigerated centrifuge)"
                  },
                  {
                    "text": "Precipitate is separated from supernatant plasma"
                  },
                  {
                    "text": "cryo (should contain 15-20 mL in volume) is refrozen within 1 hr"
                  },
                  {
                    "text": "Component is stored frozen at -18°C or colder"
                  },
                  {
                    "text": "Must be used within 12 months of original FFP collection date"
                  }
                ],
                "Cryoprecipitate-Reduced Plasma": [
                  {
                    "text": "Supernatant plasma removed during cryo preparation is refrozen within 24 hr of thawing FFP and relabeled \"plasma, cryoprecipitate reduced\""
                  },
                  {
                    "text": "Used for treatment of TTP"
                  }
                ],
                "Storage": [
                  {
                    "text": "Stored at -18°C or colder for up to 1 yr after original collection date"
                  }
                ],
                "Pooling": [
                  {
                    "text": "cryo is usually prepared as small pool from multiple donors instead of being issued in single units"
                  },
                  {
                    "text": "Typically, 5 single units are pooled into 1 bag before issue"
                  },
                  {
                    "text": "If pooled at collection facilityUsually 5 single cryo bags are pooled immediately after production (before freezing) from thawed FFPMust be transfused within 4 hr of thawing",
                    "sub_points": [
                      "Usually 5 single cryo bags are pooled immediately after production (before freezing) from thawed FFP",
                      "Must be transfused within 4 hr of thawing"
                    ]
                  },
                  {
                    "text": "If pooled at transfusing facility/hospitalFrozen cryo bags are thawed in a 30°-37°C water bath for up to 15 min (unit placed in overwrap)5-10 thawed bags are pooled into transfer bagPooled bags must be administered within 4 hr and should be stored at room temperature (20°-24°C) until transfused",
                    "sub_points": [
                      "Frozen cryo bags are thawed in a 30°-37°C water bath for up to 15 min (unit placed in overwrap)",
                      "5-10 thawed bags are pooled into transfer bag",
                      "Pooled bags must be administered within 4 hr and should be stored at room temperature (20°-24°C) until transfused"
                    ]
                  },
                  {
                    "text": "cryo must be transfused within 6 hr of thawing (single units) or 4 hr of pooling"
                  }
                ],
                "Available Components, as Labeled": [
                  {
                    "text": "Cryoprecipitated AHF"
                  },
                  {
                    "text": "Pooled cryoprecipitated AHF"
                  },
                  {
                    "text": "Plasma, cryoprecipitate reduced"
                  }
                ],
                "FDA Quality Control": [
                  {
                    "text": "Factor VIII and fibrinogen assays are conducted on representative units"
                  },
                  {
                    "text": "Average potency level of factor VIII = 80 U and fibrinogen = 150 mg per container"
                  }
                ]
              },
              "POINT OF CARE": {
                "Transfusing Facility/Hospital Considerations": [
                  {
                    "text": "Components do not need to be crossmatchedUnits contain negligible amount of RBCs and isohemagglutinins (anti-A and anti-B)If large volume of ABO-incompatible cryo is used, there is potential for recipient to develop positive DAT and mild hemolysis (rare)ABO-compatible components are preferred, especially in neonates because of their small plasma volume",
                    "sub_points": [
                      "Units contain negligible amount of RBCs and isohemagglutinins (anti-A and anti-B)",
                      "If large volume of ABO-incompatible cryo is used, there is potential for recipient to develop positive DAT and mild hemolysis (rare)",
                      "ABO-compatible components are preferred, especially in neonates because of their small plasma volume"
                    ]
                  },
                  {
                    "text": "Rh type need not be considered when using cryoRhD-positive plasma components may be given to RhD-negative recipients without need for prophylaxis with RhoGAM",
                    "sub_points": [
                      "RhD-positive plasma components may be given to RhD-negative recipients without need for prophylaxis with RhoGAM"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Components": {
            "name": "Platelet Components",
            "url": "https://app.pathprimer.com/document/8adccdd9-b491-4edb-8fd1-e3fa82d71cf5/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Platelet concentrates (PC) are manufactured from whole blood and are transfused in pools of 4-6 units"
                  },
                  {
                    "text": "Single donor platelets (SDP) are collected via automated apheresis and are transfused as 1 dose of platelets"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "Random donor platelets must contain greater than 5.5 x 10¹⁰ platelets"
                  },
                  {
                    "text": "SDPs must contain 3.0 x 10¹¹ platelets"
                  },
                  {
                    "text": "All platelets are stored at 20-24°C for 5-7 days"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Platelet concentrates (PC)"
                  },
                  {
                    "text": "Platelet-rich plasma (PRP)"
                  },
                  {
                    "text": "Single donor platelets (SDP)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Whole-Blood-Derived Platelets": [
                  {
                    "text": "Known as whole-blood-derived platelets, PC, and random donor platelets"
                  },
                  {
                    "text": "Development of new prestorage pooled, leukoreduced, and bacterial detection systems in United States is expected to increase use of whole-blood-derived platelets"
                  },
                  {
                    "text": "PRP method is primary method used to manufacture PCsWhole blood is centrifuged at low speed to produce PRPPRP is centrifuged at high speed to create platelet pelletPlatelet pellet is resuspended in plasma",
                    "sub_points": [
                      "Whole blood is centrifuged at low speed to produce PRP",
                      "PRP is centrifuged at high speed to create platelet pellet",
                      "Platelet pellet is resuspended in plasma"
                    ]
                  },
                  {
                    "text": "Final volume is 40-70 mL"
                  },
                  {
                    "text": "Random donor platelets must contain greater than 5.5 x 10¹⁰ platelets"
                  },
                  {
                    "text": "Adult dose is 4-6 pooled random donor platelets"
                  }
                ],
                "Apheresis Single Donor Platelets": [
                  {
                    "text": "Collected via automated apheresis technology (See Apheresis Blood Component Collections)"
                  },
                  {
                    "text": "Contain average of 300 mL of platelets suspended in either plasma or platelet additive solution"
                  },
                  {
                    "text": "Must contain greater than 3.0 x 10¹¹ platelets in 75% of products tested"
                  },
                  {
                    "text": "SDPs are leukoreduced during collection; WBC count must be less than 5 x 10⁶"
                  }
                ],
                "Storage": [
                  {
                    "text": "All platelet components are stored at 20-24°C with gentle agitation"
                  },
                  {
                    "text": "Storage duration is 5 days, unless collected in FDA-approved 7-day platelet collection apheresis systems used in conjunction with Verax Platelet PGD test for bacterial contamination"
                  },
                  {
                    "text": "If open system is created, platelet component must be transfused within 4 hours"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Granulocytes": {
            "name": "Granulocytes",
            "url": "https://app.pathprimer.com/document/3a10f0e2-5815-42d9-8317-8f34b04047b6/lesson/5fda5872-0212-4f22-b8d1-6ab08bd02146",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Granulocyte transfusion may be used in treatment of patients with bacterial or fungal infections and neutrophil defects or neutropenia"
                  },
                  {
                    "text": "Standards requires yield of at least 1 x 10^10 in 75% of components tested"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Transfused daily until infection resolved or neutrophil count is recovered"
                  },
                  {
                    "text": "Granulocytes should be CMV negative when transfused to CMV negative patients"
                  },
                  {
                    "text": "Must be irradiated to prevent TA-GVHD"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "Must be transfused within 24 hours of collection"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Granulocytes protect against bacterial and fungal infections"
                  },
                  {
                    "text": "Granulocyte transfusion may be used in treatment of patients with bacterial or fungal infections and neutrophil defects or neutropenia"
                  },
                  {
                    "text": "Granulocytes are collected through apheresis procedures and may be collected using various apheresis instrumentation"
                  },
                  {
                    "text": "Collected for transfusion to patient; remaining blood components are returned to donor"
                  },
                  {
                    "text": "Standards requires yield of at least 1 x 10^10 in 75% of components tested"
                  },
                  {
                    "text": "To meet this goal, red cell sedimenting agents (hetastarch, pentastarch) must be used to improve separation between red cell and granulocyte layers and improve efficiency of granulocyte collection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cytomegalovirus (CMV)"
                  },
                  {
                    "text": "Granulocyte-colony stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Hydroxyethyl starch (HES)"
                  },
                  {
                    "text": "Transfusion-associated graft-versus-host disease (TA-GVHD)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "Donor Center Testing": [
                  {
                    "text": "Granulocytes are released from inventory prior to obtaining results of infectious disease markers"
                  },
                  {
                    "text": "Granulocytes are frequently collected from repeat platelet donors recently tested for infectious disease markers to reduce risk"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "Preparation for Testing": [
                  {
                    "text": "Granulocytes contain 20-50 mL of red blood cells and require ABO group testing and crossmatch prior to release and transfusion"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Granulocyte Products": [
                  {
                    "text": "Dose should be > 4 x 10^10"
                  },
                  {
                    "text": "Transfused daily until infection resolved or neutrophil count is recovered"
                  },
                  {
                    "text": "Granulocytes should be CMV negative when transfused to CMV negative patients"
                  },
                  {
                    "text": "Must be irradiated to prevent TA-GVHD"
                  }
                ],
                "Granulocyte Collection": [
                  {
                    "text": "Granulocytes are collected using apheresis technology"
                  },
                  {
                    "text": "Increasing density gradients in apheresis instrument through use of pentastarch or hetastarch improves collection efficiency"
                  },
                  {
                    "text": "Donor stimulation with G-CSF and/or corticosteroids improves yields"
                  }
                ],
                "Sedimenting Agents": [
                  {
                    "text": "HetastarchCauses red cell aggregation, improving red cell and granulocyte separationVolume expander; may cause adverse effectsPeripheral edemaHeadachesCoagulopathyAllergic reactions",
                    "sub_points": [
                      "Causes red cell aggregation, improving red cell and granulocyte separation",
                      "Volume expander; may cause adverse effectsPeripheral edemaHeadachesCoagulopathyAllergic reactions",
                      "Peripheral edema",
                      "Headaches",
                      "Coagulopathy",
                      "Allergic reactions"
                    ]
                  },
                  {
                    "text": "PentastarchLow molecular weight version of hetastarchThought to decrease risks associated with hetastarchFaster renal elimination than hetastarchLower collection efficiency when compared with high molecular weight sedimenting agent",
                    "sub_points": [
                      "Low molecular weight version of hetastarch",
                      "Thought to decrease risks associated with hetastarch",
                      "Faster renal elimination than hetastarch",
                      "Lower collection efficiency when compared with high molecular weight sedimenting agent"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards": [
                  {
                    "text": "Standards require minimum granulocyte yield to be 1.0 x 10^10 in at least 75% of units tested"
                  },
                  {
                    "text": "Yield for neonates is determined by donor center medical director"
                  },
                  {
                    "text": "Must be transfused within 24 hours of collection"
                  },
                  {
                    "text": "Granulocytes are stored at 20-24°C, without agitation"
                  }
                ]
              },
              "QUALITY": {
                "Quality Assurance": [
                  {
                    "text": "Granulocyte products are not licensed by FDA"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Donor Testing": {
        "name": "Donor Testing",
        "url": "https://app.pathprimer.com/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
        "topics": {
          "Overview of Infectious Disease Testing": {
            "name": "Overview of Infectious Disease Testing",
            "url": "https://app.pathprimer.com/document/bce6ff5e-afa8-44e8-8d88-4b1da016d121/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "IDM testing has been tremendously effective in reducing risk of transfusion-transmitted diseases"
                  },
                  {
                    "text": "New emerging diseases that threaten blood supply cannot be tested for immediately and require test development"
                  },
                  {
                    "text": "Window period is time between infection with infectious disease and first detectable laboratory evidence of infection"
                  },
                  {
                    "text": "CFR, FDA, and AABB require blood donors to be tested for HIV, HCV, HBV, HTLV, WNV, syphilis, and Chagas disease"
                  },
                  {
                    "text": "FDA recommends that donors be tested for Babesia in 15 designated Babesia-risk states"
                  }
                ]
              },
              "OVERVIEW": {
                "Clinical Applications": [
                  {
                    "text": "Blood safety is of utmost importance to safe and effective medical care"
                  },
                  {
                    "text": "Implementation of infectious disease testing of blood components helps to ensure safe blood supply"
                  },
                  {
                    "text": "IDM testing has been tremendously effective in reducing risk of transfusion-transmitted diseases"
                  },
                  {
                    "text": "TTIs are so rare that risks must be calculated using statistical models"
                  },
                  {
                    "text": "Impossible to test for all possible transfusion-transmitted infectious diseasesOther screening methods must be usedBlood supply is protected from malaria and prions by donor questioning onlyNew emerging diseases that threaten blood supply cannot be tested for immediately and require test development",
                    "sub_points": [
                      "Other screening methods must be used",
                      "Blood supply is protected from malaria and prions by donor questioning only",
                      "New emerging diseases that threaten blood supply cannot be tested for immediately and require test development"
                    ]
                  },
                  {
                    "text": "Implementation of pathogen reduction technology has potential ability to further reduce TTIs"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Transfusion-transmitted infection (TTI)"
                  },
                  {
                    "text": "Nucleic acid amplification testing (NAT)"
                  },
                  {
                    "text": "Human immunodeficiency virus (HIV)"
                  },
                  {
                    "text": "Hepatitis C virus (HCV)"
                  },
                  {
                    "text": "Hepatitis B virus (HBV)"
                  },
                  {
                    "text": "Hepatitis B surface antigen (HBsAg)"
                  },
                  {
                    "text": "Hepatitis B core antibody (HBcAb)"
                  },
                  {
                    "text": "Human T-lymphotropic virus (HTLV)"
                  },
                  {
                    "text": "Rapid plasma reagin (RPR)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Immunofluorescence assay﻿ (IFA)"
                  },
                  {
                    "text": "West Nile virus (WNV)﻿"
                  },
                  {
                    "text": "Mini-pool (MP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Infectious Disease Marker Testing of Donors": [
                  {
                    "text": "Window periodPeriod between infection with infectious disease and first detectable laboratory evidence of infectionBlood donated during this window period has negative IDM but can transmit diseaseWindow period includes \"eclipse phase\"Earliest period after infection before there is detectable viremiaWindow periods are generally shortest for NAT, longer for serologic antigen assays, and longest for serologic antibody assays",
                    "sub_points": [
                      "Period between infection with infectious disease and first detectable laboratory evidence of infection",
                      "Blood donated during this window period has negative IDM but can transmit disease",
                      "Window period includes \"eclipse phase\"Earliest period after infection before there is detectable viremia",
                      "Earliest period after infection before there is detectable viremia",
                      "Window periods are generally shortest for NAT, longer for serologic antigen assays, and longest for serologic antibody assays"
                    ]
                  },
                  {
                    "text": "Serologic assays have higher false-positive rate than NAT testing and require confirmatory testingCause of serologic false positives are often autoantibodies, rheumatoid factor, human antimouse antibodies, or heterophile antibodiesAmong donors, positive HIV antibodies are confirmed by Western blot < 20% of time",
                    "sub_points": [
                      "Cause of serologic false positives are often autoantibodies, rheumatoid factor, human antimouse antibodies, or heterophile antibodies",
                      "Among donors, positive HIV antibodies are confirmed by Western blot < 20% of time"
                    ]
                  },
                  {
                    "text": "Transfusion-transmitted syphilis has not been reported since 1966Likely due to conversion to blood component therapy and ubiquitous refrigeration of packed red blood cell and plasma componentsTreponema pallidumis not infectious after ~ 72 hr of refrigerationTransfusion-transmitted syphilis manifests as secondary syphilis",
                    "sub_points": [
                      "Likely due to conversion to blood component therapy and ubiquitous refrigeration of packed red blood cell and plasma componentsTreponema pallidumis not infectious after ~ 72 hr of refrigeration",
                      "Treponema pallidumis not infectious after ~ 72 hr of refrigeration",
                      "Transfusion-transmitted syphilis manifests as secondary syphilis"
                    ]
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "Infectious Disease Marker Testing as Required by 21 CFR 610.40, FDA, and AABB": [
                  {
                    "text": "Donor testing performed on samples collected at time of blood donation"
                  },
                  {
                    "text": "HIVScreening: anti-HIV 1/2 antibody (IgG and IgM)If HIV 1/2 screening test also detects HIV 1 group O (much more common in West/Central Africa), donor deferrals for travel/residence in Africa are not requiredConfirmatory testing: HIV-1 Western blotHIV RNA by NAT",
                    "sub_points": [
                      "Screening: anti-HIV 1/2 antibody (IgG and IgM)If HIV 1/2 screening test also detects HIV 1 group O (much more common in West/Central Africa), donor deferrals for travel/residence in Africa are not required",
                      "If HIV 1/2 screening test also detects HIV 1 group O (much more common in West/Central Africa), donor deferrals for travel/residence in Africa are not required",
                      "Confirmatory testing: HIV-1 Western blot",
                      "HIV RNA by NAT"
                    ]
                  },
                  {
                    "text": "HCVScreening: Anti-HCV IgG antibodyConfirmatory testing: HCV NAT or variance to use second anti-HCV antibody screening assayHCV RNA by NAT",
                    "sub_points": [
                      "Screening: Anti-HCV IgG antibody",
                      "Confirmatory testing: HCV NAT or variance to use second anti-HCV antibody screening assay",
                      "HCV RNA by NAT"
                    ]
                  },
                  {
                    "text": "HBVHBsAg: Screening immunoassay and confirmation by HBsAg neutralizationIf HBV NAT is positive, neutralization is not requiredHBcAb (IgG and IgM) screening immunoassayNo confirmatory testing is availableHBV DNA by NAT",
                    "sub_points": [
                      "HBsAg: Screening immunoassay and confirmation by HBsAg neutralizationIf HBV NAT is positive, neutralization is not required",
                      "If HBV NAT is positive, neutralization is not required",
                      "HBcAb (IgG and IgM) screening immunoassayNo confirmatory testing is available",
                      "No confirmatory testing is available",
                      "HBV DNA by NAT"
                    ]
                  },
                  {
                    "text": "HTLV I/IIHTLV I/II IgG antibody screening immunoassay",
                    "sub_points": [
                      "HTLV I/II IgG antibody screening immunoassay"
                    ]
                  },
                  {
                    "text": "SyphilisScreening: Spirochete-specific testing (IgG or IgG+IgM toT. pallidum) or non-spirochete-specific testing (RPR)Spirochete-specific testing is preferred by most blood centers due to its automation and lack of biologic false positivesConfirmatory testing:T. pallidum-specific IFA or agglutination assays",
                    "sub_points": [
                      "Screening: Spirochete-specific testing (IgG or IgG+IgM toT. pallidum) or non-spirochete-specific testing (RPR)Spirochete-specific testing is preferred by most blood centers due to its automation and lack of biologic false positives",
                      "Spirochete-specific testing is preferred by most blood centers due to its automation and lack of biologic false positives",
                      "Confirmatory testing:T. pallidum-specific IFA or agglutination assays"
                    ]
                  },
                  {
                    "text": "Chagas disease (Trypanosoma cruzi﻿)﻿Screening: anti-T. cruziIgG antibodyConfirmatory testing: Enzyme strip assay (FDA approved)",
                    "sub_points": [
                      "Screening: anti-T. cruziIgG antibody",
                      "Confirmatory testing: Enzyme strip assay (FDA approved)"
                    ]
                  },
                  {
                    "text": "WNVWNV RNA by NATWNV infection can be associated with low levels of viremiaAt time of high WNV activity in geographic region, all WNV NAT testing is done on individual samples rather than MPThis switch to testing individual samples must occur within 48 hr of triggerWNV activity trigger is identification of 1 positive donor in geographic regionDe-escalation back to MP testing is at discretion of blood collection establishment medical director",
                    "sub_points": [
                      "WNV RNA by NATWNV infection can be associated with low levels of viremiaAt time of high WNV activity in geographic region, all WNV NAT testing is done on individual samples rather than MPThis switch to testing individual samples must occur within 48 hr of triggerWNV activity trigger is identification of 1 positive donor in geographic regionDe-escalation back to MP testing is at discretion of blood collection establishment medical director",
                      "WNV infection can be associated with low levels of viremiaAt time of high WNV activity in geographic region, all WNV NAT testing is done on individual samples rather than MPThis switch to testing individual samples must occur within 48 hr of triggerWNV activity trigger is identification of 1 positive donor in geographic regionDe-escalation back to MP testing is at discretion of blood collection establishment medical director",
                      "At time of high WNV activity in geographic region, all WNV NAT testing is done on individual samples rather than MP",
                      "This switch to testing individual samples must occur within 48 hr of trigger",
                      "WNV activity trigger is identification of 1 positive donor in geographic region",
                      "De-escalation back to MP testing is at discretion of blood collection establishment medical director"
                    ]
                  },
                  {
                    "text": "BabesiaFDA  May 2019 guidance calls for regional testing or pathogen reduction (for those products where licensed devices are available) in 15 identified Babesia-risk statesFDA licensed Babesia antibody assay and NAT in March 2018; these assays were discontinued and replaced by FDA-licensed NAT assay for Babesia RNA in January 2019FDA has approved reduction devices for effective pathogen reduction for Babesia microti for plasma and platelet products; similar devices for whole blood or RBC products are not available at this time",
                    "sub_points": [
                      "FDA  May 2019 guidance calls for regional testing or pathogen reduction (for those products where licensed devices are available) in 15 identified Babesia-risk statesFDA licensed Babesia antibody assay and NAT in March 2018; these assays were discontinued and replaced by FDA-licensed NAT assay for Babesia RNA in January 2019FDA has approved reduction devices for effective pathogen reduction for Babesia microti for plasma and platelet products; similar devices for whole blood or RBC products are not available at this time",
                      "FDA licensed Babesia antibody assay and NAT in March 2018; these assays were discontinued and replaced by FDA-licensed NAT assay for Babesia RNA in January 2019",
                      "FDA has approved reduction devices for effective pathogen reduction for Babesia microti for plasma and platelet products; similar devices for whole blood or RBC products are not available at this time"
                    ]
                  }
                ],
                "Approach to Testing": [
                  {
                    "text": "Donated blood and required testing are considered biologics by FDAAll testing performed on blood and blood components must be FDA licensed",
                    "sub_points": [
                      "All testing performed on blood and blood components must be FDA licensed"
                    ]
                  },
                  {
                    "text": "Donor testing workflowBlood sample is drawn from every blood donor at each presentation for blood donation for IDM testingAll IDM tests are performed at each donation except for test forT. cruzi, which may be performed only on first donationAll components manufactured from collection are placed in quarantine until results are received, determined to be negative, and reviewed by blood center personnelAt this time, components from that donation may be placed into inventory",
                    "sub_points": [
                      "Blood sample is drawn from every blood donor at each presentation for blood donation for IDM testing",
                      "All IDM tests are performed at each donation except for test forT. cruzi, which may be performed only on first donation",
                      "All components manufactured from collection are placed in quarantine until results are received, determined to be negative, and reviewed by blood center personnel",
                      "At this time, components from that donation may be placed into inventory"
                    ]
                  },
                  {
                    "text": "Donor testing methodologySerologic testsPerformed on individual samplesNonreactive tests are considered to be negativeReactive tests are repeated in duplicateIf one or both of repeated tests are reactive, unit is considered repeatedly reactive and discardedIf both repeated tests are nonreactive, unit is considered negative and released into inventoryConfirmatory testing is performed on repeatedly reactive testsResults of confirmatory tests are used for donor counselingNATMay be performed on MP of 6-16 samples to reduce costs without affecting test sensitivityMay be performed on multiplex platforms testing for HCV, HBV, and HIV concurrentlyIf MP is positive, individual NAT is performed on all samplesComponents from positive individual NAT are discardedIf multiplex testing is used, discriminatory NAT must be performed to identify cause of positive result",
                    "sub_points": [
                      "Serologic testsPerformed on individual samplesNonreactive tests are considered to be negativeReactive tests are repeated in duplicateIf one or both of repeated tests are reactive, unit is considered repeatedly reactive and discardedIf both repeated tests are nonreactive, unit is considered negative and released into inventoryConfirmatory testing is performed on repeatedly reactive testsResults of confirmatory tests are used for donor counseling",
                      "Performed on individual samples",
                      "Nonreactive tests are considered to be negative",
                      "Reactive tests are repeated in duplicate",
                      "If one or both of repeated tests are reactive, unit is considered repeatedly reactive and discarded",
                      "If both repeated tests are nonreactive, unit is considered negative and released into inventory",
                      "Confirmatory testing is performed on repeatedly reactive tests",
                      "Results of confirmatory tests are used for donor counseling",
                      "NATMay be performed on MP of 6-16 samples to reduce costs without affecting test sensitivityMay be performed on multiplex platforms testing for HCV, HBV, and HIV concurrentlyIf MP is positive, individual NAT is performed on all samplesComponents from positive individual NAT are discardedIf multiplex testing is used, discriminatory NAT must be performed to identify cause of positive result",
                      "May be performed on MP of 6-16 samples to reduce costs without affecting test sensitivity",
                      "May be performed on multiplex platforms testing for HCV, HBV, and HIV concurrently",
                      "If MP is positive, individual NAT is performed on all samples",
                      "Components from positive individual NAT are discarded",
                      "If multiplex testing is used, discriminatory NAT must be performed to identify cause of positive result"
                    ]
                  }
                ],
                "Donor Management": [
                  {
                    "text": "Donors with repeatedly reactive serologic IDM testing or positive NAT are deferred"
                  },
                  {
                    "text": "Blood components from donation with positive IDMs are discarded"
                  },
                  {
                    "text": "Donors must be notified of deferral and positive testing within 8 weeks"
                  },
                  {
                    "text": "Depending on the positive IDM, donors may return for additional testing and be re-entered into donor pool"
                  },
                  {
                    "text": "Blood collection establishments must have systems that prevent future collections from ineligible donors"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Residual Infectious Risks of Transfusion": [
                  {
                    "text": "Transfusion transmission of diseases covered by tested IDM is rare"
                  },
                  {
                    "text": "Rates of transfusion transmission are not directly knownEstimated through modeling after considering disease incidence and window periods",
                    "sub_points": [
                      "Estimated through modeling after considering disease incidence and window periods"
                    ]
                  },
                  {
                    "text": "Emerging infectious disease risks to blood supply are not covered by IDM immediatelyDonor testing must be developed and approved by FDADonor questioning and deferral based on risk factors have been the last, best protection in these casesPathogen reduction has been approved and has capability of revolutionizing reactive donor testing system",
                    "sub_points": [
                      "Donor testing must be developed and approved by FDA",
                      "Donor questioning and deferral based on risk factors have been the last, best protection in these casesPathogen reduction has been approved and has capability of revolutionizing reactive donor testing system",
                      "Pathogen reduction has been approved and has capability of revolutionizing reactive donor testing system"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Infectious Disease Marker Testing Regulation": [
                  {
                    "text": "IDM tests must be approved by FDA for donor testingIDM testing must be performed exactly as recommended by manufacturer",
                    "sub_points": [
                      "IDM testing must be performed exactly as recommended by manufacturer"
                    ]
                  },
                  {
                    "text": "Laboratories performing IDM testing must be registered with FDA as biologics manufacturers as they are qualifying raw materials for manufacture into drug"
                  },
                  {
                    "text": "Blood components cannot be distributed or issued unless results of IDM tests are negativeOnly exception is biologic false-positive result for syphilis, in which case unit must be labeled with that informationBiologic false-positive result is positive when using non-treponemal-specific assay such as RPRIn setting of emergency need for blood components, products can be issued before IDM testing is complete if label states that testing is incomplete",
                    "sub_points": [
                      "Only exception is biologic false-positive result for syphilis, in which case unit must be labeled with that informationBiologic false-positive result is positive when using non-treponemal-specific assay such as RPR",
                      "Biologic false-positive result is positive when using non-treponemal-specific assay such as RPR",
                      "In setting of emergency need for blood components, products can be issued before IDM testing is complete if label states that testing is incomplete"
                    ]
                  },
                  {
                    "text": "For dedicated granulocyte or platelet donors, testing need only be performed at first donation and every 30 days thereafter"
                  },
                  {
                    "text": "Autologous donations shipped to another facility require same IDM testing as allogeneic testingTesting must be performed at least once in a 30-day period (if multiple donations)Autologous donor and his/her physician must be informed of positive IDM testingAutologous units with positive IDM testing can be transfused with physician approvalMust carry biohazard label and be stored separately from uninfected blood products",
                    "sub_points": [
                      "Testing must be performed at least once in a 30-day period (if multiple donations)",
                      "Autologous donor and his/her physician must be informed of positive IDM testing",
                      "Autologous units with positive IDM testing can be transfused with physician approvalMust carry biohazard label and be stored separately from uninfected blood products",
                      "Must carry biohazard label and be stored separately from uninfected blood products"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Serologic Testing of Blood Products": {
            "name": "Serologic Testing of Blood Products",
            "url": "https://app.pathprimer.com/document/bcbb0ebd-b1b4-4d5d-bdb0-891b4606d605/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Allogeneic Donor Testing": [
                  {
                    "text": "All blood components must be ABO and RhD typed and screened for unexpected RBC alloantibodies"
                  },
                  {
                    "text": "RBC units may be further phenotyped for RBC antigens for matching with recipients who require matched RBC units (e.g., patients who are high alloimmunized or have sickle cell anemia or warm autoimmune hemolytic anemia)"
                  },
                  {
                    "text": "Group O single-donor apheresis platelets may be titered for anti-A and anti-B antibodies to prevent hemolytic transfusion reactionsThis practice is inconsistent among blood centers and transfusion services",
                    "sub_points": [
                      "This practice is inconsistent among blood centers and transfusion services"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "ABO Group Typing": [
                  {
                    "text": "Front and back typing for ABO antigens are performed on all blood donors"
                  },
                  {
                    "text": "ABO discrepancies must be resolved prior to labeling"
                  },
                  {
                    "text": "RBC genotyping may be used if needed to resolve discrepancies"
                  },
                  {
                    "text": "ABO typing is repeated on all units by transfusion service, but only RhD-negative units must be retyped for RhD"
                  }
                ],
                "D Antigen Phenotype": [
                  {
                    "text": "Blood centers must perform D antigen typing that can detect presence of weak D"
                  },
                  {
                    "text": "Weak D testing can be performed by using typing reagents that can detect weak D, including antihuman globulin phase of testing, or by molecular methods that can detect weak D"
                  },
                  {
                    "text": "Donor centers must ensure that all Rh-negative blood products are correctly labeled to prevent alloimmunization to D antigen"
                  },
                  {
                    "text": "Rh-negative recipients of weak D blood products can become sensitized to D antigen"
                  }
                ],
                "Unexpected RBC Antibody Screening": [
                  {
                    "text": "AABB standards require that blood from donors with history of pregnancy or transfusion be antibody tested"
                  },
                  {
                    "text": "Blood centers often screen serum or plasma from all blood donors for unexpected RBC antibodies"
                  },
                  {
                    "text": "Antibody screening of donors may be performed on pooled or individual reagent RBCs of known phenotype"
                  },
                  {
                    "text": "ABO and RhD typing and antibody screening may be performed on automated platforms"
                  },
                  {
                    "text": "Antibody identification is performed on donors with positive screening results"
                  },
                  {
                    "text": "Products from these donors may be used for transfusion if transfusion service has policies in place for these productsSuch products may be transfused to either antigen-negative recipients or washed prior to transfusion",
                    "sub_points": [
                      "Such products may be transfused to either antigen-negative recipients or washed prior to transfusion"
                    ]
                  }
                ],
                "Anti-A and Anti-B Titers": [
                  {
                    "text": "Group O donors may have high titers of anti-A and anti-B antibodies"
                  },
                  {
                    "text": "Single-donor apheresis products may be titered to prevent hemolytic transfusion reactions due to preexisting anti-A (more common) and anti-B antibodies"
                  },
                  {
                    "text": "Performing anti-A and anti-B antibody titers is not done consistently among blood centers and transfusion centers"
                  },
                  {
                    "text": "Cut-off values to define high-titer products are not defined or consistent among transfusion services and collection centers"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "Phenotyping of RBC Products": [
                  {
                    "text": "Collection centers maintain inventories of commonly requested antigen-negative RBC units"
                  },
                  {
                    "text": "These units are often provided to patients that require multiple antigen-negative RBC unitsPatients with multiple RBC alloantibodiesChronically transfused patient populations (e.g., those with sickle cell anemia and thalassemia)",
                    "sub_points": [
                      "Patients with multiple RBC alloantibodies",
                      "Chronically transfused patient populations (e.g., those with sickle cell anemia and thalassemia)"
                    ]
                  },
                  {
                    "text": "Donors of certain ethnicities, along with donors who have made alloantibodies to high-frequency antigens, may be screened for rare RBC phenotypesRBC units from these donors may be frozen as part of rare RBC unit inventories",
                    "sub_points": [
                      "RBC units from these donors may be frozen as part of rare RBC unit inventories"
                    ]
                  },
                  {
                    "text": "High-throughput automated instruments are available to type for C, E, and K antigens"
                  },
                  {
                    "text": "American Rare Donor Program and International Society for Blood Transfusion maintain list of donors with blood types that occur in < 1 per 10,000 individuals to supply rare units to patients worldwideLarge-scale genotyping methods are now available to increase ease of identification of these donors and RBC units",
                    "sub_points": [
                      "Large-scale genotyping methods are now available to increase ease of identification of these donors and RBC units"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Human Immunodeficiency Virus Screening": {
            "name": "Human Immunodeficiency Virus Screening",
            "url": "https://app.pathprimer.com/document/4fd9f597-e015-4ab5-9dc9-da424d453b16/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "All allogeneic donors are tested for anti-HIV-1/2 and HIV NAT"
                  },
                  {
                    "text": "All autologous units transfused outside of the collection facility are tested for anti-HIV-1/2 and HIV NAT"
                  },
                  {
                    "text": "The current window period for HIV testing is 11 days"
                  },
                  {
                    "text": "The current residual risk of transfusion-transmitted HIV is about 1:2 million to 1:5 million blood products transfused"
                  }
                ]
              },
              "OVERVIEW": {
                "Human Immunodeficiency Virus": [
                  {
                    "text": "HIV is a retrovirus and the cause of AIDS"
                  },
                  {
                    "text": "Retroviruses are RNA viruses that enter and infect host CD4+ T-helper lymphocytes"
                  },
                  {
                    "text": "HIV uses reverse transcriptase to convert viral RNA to cDNA which is incorporated into the T-helper lymphocyte DNA"
                  },
                  {
                    "text": "The CD4+ T-helper lymphocyte transcribes and translates viral cDNA to viral RNA and proteins producing new virions which are released and infect other host cells"
                  },
                  {
                    "text": "HIV also spreads via mediating fusion of infected and uninfected cells and by replication of viral cDNA during meiosis and mitosis"
                  },
                  {
                    "text": "CD4+ T-helper lymphocytes are killed in the process leading to development of opportunistic infections"
                  },
                  {
                    "text": "Transmission of HIV is via sexual contact, childbirth, breastfeeding, and parental exposure including blood transfusion"
                  }
                ],
                "Transfusion-Transmitted HIV": [
                  {
                    "text": "Current window period is about 11 days"
                  },
                  {
                    "text": "Current residual risk is about 1:2 million to 1:5 million blood products transfused"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "HIV: Human immunodeficiency virus"
                  },
                  {
                    "text": "AIDS: Acquired immune deficiency syndrome"
                  },
                  {
                    "text": "cDNA: Complementary double stranded DNA"
                  },
                  {
                    "text": "EIA: Enzyme immunoassay"
                  },
                  {
                    "text": "ELISA: Enzyme-linked immunosorbent assay"
                  },
                  {
                    "text": "PCR: Polymerase chain reaction"
                  },
                  {
                    "text": "TMA: Transcription mediated amplification"
                  },
                  {
                    "text": "HBV: Hepatitis B virus"
                  },
                  {
                    "text": "HCV: Hepatitis C virus"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Window period: Time from exposure to an infectious agent to the time the test is reliably reactive"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "Anti-HIV Testing": [
                  {
                    "text": "Performed by either EIA or ELISA"
                  },
                  {
                    "text": "Repeatedly reactive assays are confirmed by immunofluorescence assays or western blot"
                  },
                  {
                    "text": "Units repeatedly reactive with EIA or ELISA are discarded despite the results of confirmatory testing"
                  },
                  {
                    "text": "Window period for serologic testing is about 22 days"
                  }
                ],
                "HIV NAT": [
                  {
                    "text": "Either PCR or TMA is usedHIV-1 RNA is copied and amplified by reverse transcriptase",
                    "sub_points": [
                      "HIV-1 RNA is copied and amplified by reverse transcriptase"
                    ]
                  },
                  {
                    "text": "Performed on pools of 16-24 samples as mini-pool NAT"
                  },
                  {
                    "text": "Individual NAT is performed on all samples part of a reactive mini-pool NAT"
                  },
                  {
                    "text": "May be performed on multiplex platforms in conjunction with HCV and HBV testing"
                  },
                  {
                    "text": "Discriminatory testing must be performed on positive samples to determine the source of the reactive result"
                  },
                  {
                    "text": "All units that are reactive by NAT are discarded"
                  },
                  {
                    "text": "Window period for HIV NAT is about 11 days"
                  }
                ],
                "Donor Management": [
                  {
                    "text": "All donors with repeatedly reactive results with anti-HIV-1/2 testing and reactive confirmatory testing are permanently deferred"
                  },
                  {
                    "text": "Donors who are negative or indeterminate on confirmatory testing and nonreactive for HIV NAT or reactive for HIV NAT and nonreactive on EIA/ELISA are indefinitely deferredThese donors may be retested 8 weeks after the positive test resultIf anti-HIV-1/2 and individual NAT are nonreactive, they may be re-entered into the donor pool",
                    "sub_points": [
                      "These donors may be retested 8 weeks after the positive test result",
                      "If anti-HIV-1/2 and individual NAT are nonreactive, they may be re-entered into the donor pool"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards and FDA Code of Federal Regulations": [
                  {
                    "text": "Requires that all allogeneic blood donors are tested for anti-HIV-1/2 and HIV-1 RNA"
                  },
                  {
                    "text": "Requires that all autologous units transfused outside of the collection facility are tested for anti-HIV-1/2 and HIV-1 RNA"
                  },
                  {
                    "text": "Donors must be notified of any abnormal test results"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hepatitis B Virus Screening": {
            "name": "Hepatitis B Virus Screening",
            "url": "https://app.pathprimer.com/document/e4317e95-5147-4f86-94cf-f918541c070e/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "TT-HBV occurs in about 1 in 250,000-488,000 transfusions, but this number is likely overestimated"
                  }
                ],
                "Allogeneic Donor Testing": [
                  {
                    "text": "All allogeneic donors are tested for HBsAg, anti-HBc antibody, and HBV NAT"
                  },
                  {
                    "text": "Window period is about 40-50 days for all testing"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "FDA requires that all allogeneic donors are tested for HBV infection"
                  },
                  {
                    "text": "AABB Standards requires that all allogeneic donations and autologous donations transfused outside of collection facility are tested for HBsAg, anti-HBc antibody, and HBV NAT"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-Transmitted HBV": [
                  {
                    "text": "Was common cause of post-transfusion hepatitis prior to advent of testing"
                  },
                  {
                    "text": "High-risk donors were removed from donor pool by switching to 100% volunteer donors and deferring donors with high-risk behaviors"
                  },
                  {
                    "text": "Currently, all allogeneic donors are tested for HBsAg and anti-HBc, and HBV NAT is performed"
                  },
                  {
                    "text": "Estimated residual risk in United States is 1 in 250,000-488,000, but this number is likely falsely elevated"
                  },
                  {
                    "text": "Transfusion transmission occurs when donors are negative for HBsAg but infected with HBV not detected by NAT"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anti-hepatitis B core antigen antibody (Anti-HBc)"
                  },
                  {
                    "text": "Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Hepatitis B surface antigen (HBsAg)"
                  },
                  {
                    "text": "Hepatitis B virus (HBV)"
                  },
                  {
                    "text": "Hepatitis C virus (HCV)"
                  },
                  {
                    "text": "Nucleic acid testing (NAT)"
                  },
                  {
                    "text": "Transfusion-transmitted HBV (TT-HBV)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Window period: Interval from initial infection until test will reliably detect infection"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "HBsAg": [
                  {
                    "text": "HBsAg is antigen on viral coat produced in large quantities in patients with chronic, active HBV infection"
                  },
                  {
                    "text": "Detected via enzyme immunoassays and chemiluminescent immunoassays"
                  },
                  {
                    "text": "Has high sensitivity and specificity for HBV infection, but positive predictive value is low due to low prevalence of HBsAg in volunteer blood donors"
                  },
                  {
                    "text": "Repeatedly reactive samples are confirmed with neutralizationAnti-HBsAg is added to positive donor serumGreater than 50% decrease in HBsAg signal is observed when neutralization occurs",
                    "sub_points": [
                      "Anti-HBsAg is added to positive donor serum",
                      "Greater than 50% decrease in HBsAg signal is observed when neutralization occurs"
                    ]
                  },
                  {
                    "text": "Window period for HBsAg testing is about 42-59 days"
                  }
                ],
                "Anti-HBc Antibody": [
                  {
                    "text": "Anti-HBc antibody is detected in patients with acute resolving infection and chronic carriers"
                  },
                  {
                    "text": "Serologic testing is performed for both IgG and IgM by solid phase immunoassays or direct antiglobulin assays"
                  },
                  {
                    "text": "Confirmatory tests are not available"
                  },
                  {
                    "text": "Donors are permitted to donate with 1 repeatedly reactive sample but are indefinitely deferred with 2 repeatedly reactive samples"
                  }
                ],
                "NAT": [
                  {
                    "text": "Performed on multiplex platforms in conjunction with HIV and HCV in pools of 6 or 16 samplesSamples are tested individually if pool is reactiveDiscriminatory NAT testing is performed on positive sample to determine cause of reactive result",
                    "sub_points": [
                      "Samples are tested individually if pool is reactive",
                      "Discriminatory NAT testing is performed on positive sample to determine cause of reactive result"
                    ]
                  },
                  {
                    "text": "Window period for multiplex pooled NAT is 40-50 days"
                  },
                  {
                    "text": "Window period for individual NAT is 15-34 days"
                  },
                  {
                    "text": "TT-HBV occurs when virus mutates and is not detected by current testing or from donations during window period"
                  },
                  {
                    "text": "HBV NAT detects breakthrough infections that occur in previously vaccinated donorsThese donors have no clinical symptoms but are positive for HBV on NAT with anti-HBsAg antibodies and low viral loadTesting may be negative for HBsAg and anti-HBc antibodies",
                    "sub_points": [
                      "These donors have no clinical symptoms but are positive for HBV on NAT with anti-HBsAg antibodies and low viral load",
                      "Testing may be negative for HBsAg and anti-HBc antibodies"
                    ]
                  }
                ],
                "Donor Deferral": [
                  {
                    "text": "Permanent deferralDonors with repeatedly reactive HbsAg testing and positive neutralizationDonors with repeatedly reactive HbsAg testing and negative neutralization are permanently deferred if anti-HBc antibody testing is positive on concurrent or any future donations",
                    "sub_points": [
                      "Donors with repeatedly reactive HbsAg testing and positive neutralization",
                      "Donors with repeatedly reactive HbsAg testing and negative neutralization are permanently deferred if anti-HBc antibody testing is positive on concurrent or any future donations"
                    ]
                  },
                  {
                    "text": "Indefinite deferralDonors with 2 repeated reactive anti-HBc antibody tests, but negative HBV NAT and HBsAgDonors with positive HBV NAT",
                    "sub_points": [
                      "Donors with 2 repeated reactive anti-HBc antibody tests, but negative HBV NAT and HBsAg",
                      "Donors with positive HBV NAT"
                    ]
                  },
                  {
                    "text": "Donor re-entryDonors with repeatedly reactive anti-HBc antibody testing but negative for HBsAg and HBV NAT may be re-entered if non-donation sample is negative for all testing 8 weeks laterDonors with positive HBV NAT may be retested with individual NAT on non-donation sample 6 months later and re-entered if all testing is negative",
                    "sub_points": [
                      "Donors with repeatedly reactive anti-HBc antibody testing but negative for HBsAg and HBV NAT may be re-entered if non-donation sample is negative for all testing 8 weeks later",
                      "Donors with positive HBV NAT may be retested with individual NAT on non-donation sample 6 months later and re-entered if all testing is negative"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA": [
                  {
                    "text": "Code of Federal Regulations requires that all blood products from allogeneic donors be tested for HBV infection"
                  }
                ],
                "AABB Standards": [
                  {
                    "text": "Requires that all allogeneic donors are tested for HBsAg, anti-HBc antibody, and HBV NAT"
                  },
                  {
                    "text": "All positive donations must not be issued for transfusion"
                  },
                  {
                    "text": "Autologous units that will be transfused outside of collection facility must be tested for HBsAg, anti-HBc antibody, and HBV NAT"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hepatitis C Virus Screening": {
            "name": "Hepatitis C Virus Screening",
            "url": "https://app.pathprimer.com/document/9e625268-77a1-4ad5-b8b0-4d873fc6fb9c/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Pretransfusion Laboratory Testing": [
                  {
                    "text": "All allogeneic donations are tested for anti-HCV antibody and HCV NAT"
                  },
                  {
                    "text": "Window period is about 11 days"
                  },
                  {
                    "text": "Estimated residual risk is about 1 in 1,800,000 units transfused"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "FDA and AABB Standards require anti-HCV antibody and HCV RNA testing of allogeneic donors"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-Transmitted HCV": [
                  {
                    "text": "Risk of TT-HCV is mitigated by combination of deferral of high-risk donors and testing"
                  },
                  {
                    "text": "High-risk donors were removed from donor pool by switching to 100% volunteer donors and deferring donors with high-risk behaviors"
                  },
                  {
                    "text": "Currently, all allogeneic donors are tested for anti-HCV antibody and HBV NAT"
                  },
                  {
                    "text": "Estimated residual risk is about 1 in 1,800,000 units transfused"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hepatitis C virus (HCV)"
                  },
                  {
                    "text": "Nucleic acid testing (NAT)"
                  },
                  {
                    "text": "Recombinant immunoblot assay (RIBA)"
                  },
                  {
                    "text": "Repeatedly reactive (RR)"
                  },
                  {
                    "text": "Transfusion-transmitted HCV (TT-HCV)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Window period: Interval from initial infection until test will reliably detect infection"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "Anti-HCV Antibody Testing": [
                  {
                    "text": "Enzyme immunoassay or chemiluminescent immunoassay for antibodies to HCV antigen present in donor"
                  },
                  {
                    "text": "Sensitivity is about 98%"
                  },
                  {
                    "text": "Window period is about 10 weeks"
                  },
                  {
                    "text": "Reactive tests are repeated in duplicate"
                  },
                  {
                    "text": "Repeatedly reactive tests (2 of 3 tests are positive) are considered reactive"
                  },
                  {
                    "text": "Repeatedly reactive products may not be used for transfusion despite results of RIBA testing"
                  }
                ],
                "HCV NAT": [
                  {
                    "text": "Performed concurrently with anti-HCV antibody testing"
                  },
                  {
                    "text": "Two assays are FDA-approved for allogeneic blood-donor testingPCR for HCV RNATranscription-mediated amplification for HCV RNA",
                    "sub_points": [
                      "PCR for HCV RNA",
                      "Transcription-mediated amplification for HCV RNA"
                    ]
                  },
                  {
                    "text": "Window period is about 11 days"
                  },
                  {
                    "text": "Can be performed on multiplex platformsTesting is performed on pools of 6 or 16 samplesSamples are tested individually if pool is reactiveHCV NAT is combined with NAT for HIV and HBVDiscriminatory NAT testing is performed on positive sample to determine cause of reactive result",
                    "sub_points": [
                      "Testing is performed on pools of 6 or 16 samplesSamples are tested individually if pool is reactive",
                      "Samples are tested individually if pool is reactive",
                      "HCV NAT is combined with NAT for HIV and HBVDiscriminatory NAT testing is performed on positive sample to determine cause of reactive result",
                      "Discriminatory NAT testing is performed on positive sample to determine cause of reactive result"
                    ]
                  },
                  {
                    "text": "Positive results indicate persistent HCV infection"
                  },
                  {
                    "text": "Reactive products may not be used for transfusion"
                  }
                ],
                "Supplemental Testing": [
                  {
                    "text": "RIBA against HCV antigens is only FDA-approved supplemental test"
                  },
                  {
                    "text": "Performed on samples that are RR but NAT negative"
                  },
                  {
                    "text": "Positive RIBA with RR anti-HCV antibody testing and negative HCV NAT likely indicates resolved infection"
                  }
                ],
                "Donor Re-Entry": [
                  {
                    "text": "Donors who are RR on screening test, RIBA negative, and NAT negative may be re-entered if all testing is repeated and is negative"
                  },
                  {
                    "text": "Donors who are reactive for HCV NAT but negative for anti-HCV antibodies may be re-entered if all testing is repeated and is negative"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA and AABB Standards": [
                  {
                    "text": "Require anti-HCV antibody and HCV RNA testing of allogeneic donors"
                  },
                  {
                    "text": "If either test is reactive, all blood products must be discarded"
                  },
                  {
                    "text": "Donor must be notified and counseled on results of testing"
                  },
                  {
                    "text": "Donor is permanently deferred from future donations"
                  },
                  {
                    "text": "Lookback and recall must be performed for pretransfusion laboratory testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "West Nile Virus Screening": {
            "name": "West Nile Virus Screening",
            "url": "https://app.pathprimer.com/document/ca88deb5-6d12-4ccf-ab39-79c49760abd5/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "OVERVIEW": {
                "West Nile Virus": [
                  {
                    "text": "Single-stranded RNA flavivirus primarily transmitted via mosquitoes, usually during summer and early fall"
                  },
                  {
                    "text": "Most infections are asymptomatic but may present with fever, myalgia, headache, nausea, and vomiting"
                  },
                  {
                    "text": "Severe disease may occur presenting with encephalitis or meningitis"
                  },
                  {
                    "text": "Death is rare"
                  },
                  {
                    "text": "Transfusion-associated WNV was first confirmed in 2002"
                  }
                ],
                "Transfusion-Associated West Nile Virus": [
                  {
                    "text": "All allogeneic donations are tested for WNV RNA"
                  },
                  {
                    "text": "Low viral load in some donors may result in false-negative testing on minipool NAT"
                  },
                  {
                    "text": "During times of increased prevalence, conversion to individual NAT decreases risk of transfusion-associated WNV"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nucleic acid testing (NAT)"
                  },
                  {
                    "text": "West Nile virus (WNV)"
                  }
                ]
              },
              "ALLOGENEIC DONOR TESTING": {
                "West Nile Virus Nucleic Acid Testing": [
                  {
                    "text": "Minipool NAT is performed year-round on all donor samplesIndividual NAT is performed on samples comprising reactive pool to identify positive sample",
                    "sub_points": [
                      "Individual NAT is performed on samples comprising reactive pool to identify positive sample"
                    ]
                  },
                  {
                    "text": "Individual NAT is performed if epidemiological trigger occurs based on geographic prevalence"
                  },
                  {
                    "text": "Blood centers must define what epidemiological trigger will define when individual NAT is performed on all donations and when minipool testing may resume"
                  },
                  {
                    "text": "Individual NAT must be performed on all donations within 48 hours of identification of presumptive viremic donation"
                  },
                  {
                    "text": "All reactive units may not be used for transfusion"
                  }
                ],
                "Donor Management": [
                  {
                    "text": "All positive donations may not be used for transfusion"
                  },
                  {
                    "text": "All prior in-date components from positive donor should be discarded"
                  },
                  {
                    "text": "Positive donors are deferred for 120 days"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Federal Drug Administration and American Association of Blood Banks Standards": [
                  {
                    "text": "All allogeneic donors must be tested for WNV RNA"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Screening for Other Infectious Diseases": {
            "name": "Screening for Other Infectious Diseases",
            "url": "https://app.pathprimer.com/document/4a226518-f778-4c29-9cc8-f08eada8f5fe/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Transfusion transmission of malaria, Chagas disease,Babesia, syphilis, variant Creutzfeldt-Jacob disease (vCJD), and human T-cell lymphotropic virus (HTLV) have been documented"
                  },
                  {
                    "text": "At-risk donors are deferred based on history for malaria and vCJD"
                  },
                  {
                    "text": "Donors are tested for Chagas disease at initial presentation for donation"
                  },
                  {
                    "text": "All donors are tested for human T-cell lymphotropic virus (HTLV) and syphilis at each donation"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Malaria": [
                  {
                    "text": "Mosquito-borne parasitic disease spread by bite of femaleAnophelesmosquito"
                  },
                  {
                    "text": "Most cases in United States are seen in recent travelers to endemic areas"
                  },
                  {
                    "text": "SpeciesPlasmodium falciparumPlasmodium vivaxPlasmodium malariaePlasmodium ovalePlasmodium knowelsi",
                    "sub_points": [
                      "Plasmodium falciparum",
                      "Plasmodium vivax",
                      "Plasmodium malariae",
                      "Plasmodium ovale",
                      "Plasmodium knowelsi"
                    ]
                  },
                  {
                    "text": "Nonspecific symptoms include fever, chills, malaise, tachycardia, arthralgia, headache, sweats, and abdominal pain"
                  },
                  {
                    "text": "Transmission: May be transmitted through transfusion from infected blood donorBlood donations depend on careful donor history (no sensitive blood test is available for malaria)1-year deferral for travel3-year deferral for habitation in country where malaria is found",
                    "sub_points": [
                      "Blood donations depend on careful donor history (no sensitive blood test is available for malaria)1-year deferral for travel3-year deferral for habitation in country where malaria is found",
                      "1-year deferral for travel",
                      "3-year deferral for habitation in country where malaria is found"
                    ]
                  }
                ],
                "Chagas Disease": [
                  {
                    "text": "Caused by parasiteTrypanosoma cruziPrevalent in Central and South America",
                    "sub_points": [
                      "Prevalent in Central and South America"
                    ]
                  },
                  {
                    "text": "TransmissionInfected triatomine bug (a.k.a. kissing bug)Pregnancy (vertical transmission)Consumption of undercooked meat contaminated with infected feces of triatomine bugOrgan transplantationBlood transfusion",
                    "sub_points": [
                      "Infected triatomine bug (a.k.a. kissing bug)",
                      "Pregnancy (vertical transmission)",
                      "Consumption of undercooked meat contaminated with infected feces of triatomine bug",
                      "Organ transplantation",
                      "Blood transfusion"
                    ]
                  },
                  {
                    "text": "Acute phase of infection: Lymphadenopathy, malaise, fever, facial and lower extremity edema, and hepatosplenomegalyResolves spontaneously",
                    "sub_points": [
                      "Resolves spontaneously"
                    ]
                  },
                  {
                    "text": "Chronic phase of infection: Arrhythmias, cardiomyopathy, heart failure, megaesophagus, and megacolonDevelops decades after initial infection in ~ 30%",
                    "sub_points": [
                      "Develops decades after initial infection in ~ 30%"
                    ]
                  },
                  {
                    "text": "Blood donors are screened once at initial donation"
                  },
                  {
                    "text": "Screening testEnzyme-linked immunoassay to screen donors for antibodiesNo FDA confirmatory test available",
                    "sub_points": [
                      "Enzyme-linked immunoassay to screen donors for antibodies",
                      "No FDA confirmatory test available"
                    ]
                  },
                  {
                    "text": "Donors with history of Chagas disease or who are repeatedly reactive are deferred indefinitely"
                  }
                ],
                "Babesiosis": [
                  {
                    "text": "Tick-borne parasitic illness transmitted byIxodes scapularis﻿found in United States and Asia﻿"
                  },
                  {
                    "text": "Babesiaspp. that are pathogenic to humans includeB. microti(US)B. odocoilei(US)B. burgdorferi(US)B. divergens(Asia)Endemic areas include Connecticut, Maine, and other northeastern states, as well as Minnesota and Wisconsin",
                    "sub_points": [
                      "B. microti(US)",
                      "B. odocoilei(US)",
                      "B. burgdorferi(US)",
                      "B. divergens(Asia)",
                      "Endemic areas include Connecticut, Maine, and other northeastern states, as well as Minnesota and Wisconsin"
                    ]
                  },
                  {
                    "text": "TransmissionBlood productsTransplacental/congenital (vertical)Solid organ transplant",
                    "sub_points": [
                      "Blood products",
                      "Transplacental/congenital (vertical)",
                      "Solid organ transplant"
                    ]
                  },
                  {
                    "text": "Flu-like symptoms, including fever, chills, night sweats, weight loss, vomiting"
                  },
                  {
                    "text": "Intraerythrocytic and extraerythrocytic ring forms \"Maltese cross\" formation"
                  },
                  {
                    "text": "FDA-approved screening tests are currently availableInitial FDA approved tests in March 2018 included NAT assay for Babesia microti DNA and arrayed fluorescent immunoassay (AFIA) for Babesia microti antibody detectionThese tests were subsequently discontinued, replaced by FDA-licensed test in January 2019, NAT assay for detection of Babesia sp. RNA in whole-blood specimens",
                    "sub_points": [
                      "Initial FDA approved tests in March 2018 included NAT assay for Babesia microti DNA and arrayed fluorescent immunoassay (AFIA) for Babesia microti antibody detection",
                      "These tests were subsequently discontinued, replaced by FDA-licensed test in January 2019, NAT assay for detection of Babesia sp. RNA in whole-blood specimens"
                    ]
                  },
                  {
                    "text": "AABB Standards call for indefinite deferral for history of babesiosisFDA has offered guidance on requalification of deferred donors in May 2019 Guidance Statement",
                    "sub_points": [
                      "FDA has offered guidance on requalification of deferred donors in May 2019 Guidance Statement"
                    ]
                  }
                ],
                "Syphilis": [
                  {
                    "text": "Highly contagious sexually-transmitted disease caused by bacteriaTreponema pallidum"
                  },
                  {
                    "text": "Transmission: Transfusion transmission has been documented"
                  },
                  {
                    "text": "Presents in 4 stagesPrimary stage: ChancreSecondary stage: Diffuse macular rash involving palms and soles of feet, malaise, fever, myalgias, lymphadenopathyLatent syphilis: Asymptomatic phase of infection; symptoms of secondary syphilis can recurTertiary syphilis: Rare; can present as gummatous syphilis, cardiovascular syphilis, and neurosyphilis",
                    "sub_points": [
                      "Primary stage: Chancre",
                      "Secondary stage: Diffuse macular rash involving palms and soles of feet, malaise, fever, myalgias, lymphadenopathy",
                      "Latent syphilis: Asymptomatic phase of infection; symptoms of secondary syphilis can recur",
                      "Tertiary syphilis: Rare; can present as gummatous syphilis, cardiovascular syphilis, and neurosyphilis"
                    ]
                  },
                  {
                    "text": "Donor testingSpirochete-specific testing (IgG or IgG+IgM toTreponema pallidum)Preferred by most blood centers due to availability of automated testing and lack of biologic false-positivesScreeningMicrohemagglutination or enzyme immunoassay (EIA) for antibodies (spirochete-specific)Solid-phase red cell adherence or particle agglutinationConfirmatory testingTreponema pallidum-specific immunofluorescence assay (IFA)Agglutination assays",
                    "sub_points": [
                      "Spirochete-specific testing (IgG or IgG+IgM toTreponema pallidum)Preferred by most blood centers due to availability of automated testing and lack of biologic false-positives",
                      "Preferred by most blood centers due to availability of automated testing and lack of biologic false-positives",
                      "ScreeningMicrohemagglutination or enzyme immunoassay (EIA) for antibodies (spirochete-specific)Solid-phase red cell adherence or particle agglutination",
                      "Microhemagglutination or enzyme immunoassay (EIA) for antibodies (spirochete-specific)",
                      "Solid-phase red cell adherence or particle agglutination",
                      "Confirmatory testingTreponema pallidum-specific immunofluorescence assay (IFA)Agglutination assays",
                      "Treponema pallidum-specific immunofluorescence assay (IFA)",
                      "Agglutination assays"
                    ]
                  },
                  {
                    "text": "Repeat reactive screening for syphilis with reactive confirmatory test calls for indefinite deferral"
                  },
                  {
                    "text": "Donors may reenter donor pool 1 year from completion of treatment"
                  }
                ],
                "Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease": [
                  {
                    "text": "Rare prion (proteinaceous infectious particles) diseasesCause neurodegenerative diseases called transmissible spongiform encephalopathies (TSEs)Classic Creutzfeldt-Jakob disease (CJD)Familial CJD: Associated with gene mutation and is responsible for up to 15% of casesSporadic CJD: Responsible for majority of remaining casesCJD is not known to be transmitted through blood transfusion; however, it has been transmitted through transplant of tissues from central nervous system of infected individualsVariant Creutzfeldt-Jakob disease (vCJD)Affects younger individuals; related to bovine spongiform encephalopathyTransmissible though transfusion of blood products",
                    "sub_points": [
                      "Cause neurodegenerative diseases called transmissible spongiform encephalopathies (TSEs)Classic Creutzfeldt-Jakob disease (CJD)Familial CJD: Associated with gene mutation and is responsible for up to 15% of casesSporadic CJD: Responsible for majority of remaining casesCJD is not known to be transmitted through blood transfusion; however, it has been transmitted through transplant of tissues from central nervous system of infected individualsVariant Creutzfeldt-Jakob disease (vCJD)Affects younger individuals; related to bovine spongiform encephalopathyTransmissible though transfusion of blood products",
                      "Classic Creutzfeldt-Jakob disease (CJD)Familial CJD: Associated with gene mutation and is responsible for up to 15% of casesSporadic CJD: Responsible for majority of remaining casesCJD is not known to be transmitted through blood transfusion; however, it has been transmitted through transplant of tissues from central nervous system of infected individuals",
                      "Familial CJD: Associated with gene mutation and is responsible for up to 15% of cases",
                      "Sporadic CJD: Responsible for majority of remaining cases",
                      "CJD is not known to be transmitted through blood transfusion; however, it has been transmitted through transplant of tissues from central nervous system of infected individuals",
                      "Variant Creutzfeldt-Jakob disease (vCJD)Affects younger individuals; related to bovine spongiform encephalopathyTransmissible though transfusion of blood products",
                      "Affects younger individuals; related to bovine spongiform encephalopathy",
                      "Transmissible though transfusion of blood products"
                    ]
                  },
                  {
                    "text": "Leukoreduction of blood products may decrease risk of prion transmission due to prion association with leukocytesOther prion affinity filters are currently under investigation",
                    "sub_points": [
                      "Other prion affinity filters are currently under investigation"
                    ]
                  },
                  {
                    "text": "No FDA-approved screening test exists for diagnosis of vCJD or CJD"
                  },
                  {
                    "text": "Screening for risk of vCJD and CJD done through use of donor history questionnaireFamily history of CJDHistory of human growth hormone usageHistory of dura mater graftResidency in endemic areas",
                    "sub_points": [
                      "Family history of CJD",
                      "History of human growth hormone usage",
                      "History of dura mater graft",
                      "Residency in endemic areas"
                    ]
                  },
                  {
                    "text": "History of, or risk of, CJD or vCJD results in indefinite deferral from blood donation"
                  }
                ],
                "Human T-Cell Lymphotrophic Virus": [
                  {
                    "text": "Retrovirus that can cause adult T-cell leukemia/lymphoma and HTLV-I–associated myelopathy/tropical spastic paraparesis"
                  },
                  {
                    "text": "Most cases are asymptomatic"
                  },
                  {
                    "text": "TransmissionCongenitalSexual contactNeedle sharingBreastfeedingTransfusion",
                    "sub_points": [
                      "Congenital",
                      "Sexual contact",
                      "Needle sharing",
                      "Breastfeeding",
                      "Transfusion"
                    ]
                  },
                  {
                    "text": "All blood donors are tested at each donation"
                  },
                  {
                    "text": "Screening: HTLV I/II IgG AbNo licensed confirmatory testing is available. Licensed supplemental testing is available",
                    "sub_points": [
                      "No licensed confirmatory testing is available. Licensed supplemental testing is available"
                    ]
                  },
                  {
                    "text": "Repeat-reactive anti-HTLV Ab result without confirmatory testing requires permanent deferral of donors after 2nd donation with repeat-reactive anti-HTLV Ab test"
                  },
                  {
                    "text": "Repeat-reactive anti-HTLV Ab result with confirmatory testing by unlicensed confirmatory test results in permanent deferral"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Emerging Infectious Diseases": {
            "name": "Emerging Infectious Diseases",
            "url": "https://app.pathprimer.com/document/d6e98d8d-13d5-4a9e-bf98-5f205f79426e/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Emerging infectious diseases pose potential threat to blood supply"
                  },
                  {
                    "text": "Effect of dengue, Zika, and chikungunya viruses on blood supply are of current concern"
                  },
                  {
                    "text": "Cases of transfusion transmission of dengue virus have been documented"
                  },
                  {
                    "text": "Cases of potential transfusion transmission of Zika virus are currently being investigated"
                  },
                  {
                    "text": "No reported cases of transfusion transmission of chikungunya virus have been reported to date"
                  },
                  {
                    "text": "There are no FDA-approved screening tests for dengue, Zika, and chikungunya viruses"
                  },
                  {
                    "text": "Blood donors in United States are screened by questioning regarding recent and current illness and signs and symptoms of infection"
                  },
                  {
                    "text": "Implementation of pathogen reduction technology has potential to significantly reduce risk of emerging infectious diseases on blood supply"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Chikungunya": [
                  {
                    "text": "Symptoms occur 3 days to 1 week post mosquito biteFever and arthralgias (more common)Headaches, swollen joints, rash, muscle pain",
                    "sub_points": [
                      "Fever and arthralgias (more common)",
                      "Headaches, swollen joints, rash, muscle pain"
                    ]
                  },
                  {
                    "text": "Symptoms may resemble cold/fluHowever, most infected people are asymptomatic",
                    "sub_points": [
                      "However, most infected people are asymptomatic"
                    ]
                  },
                  {
                    "text": "To date, there has not been documented case of transfusion-transmitted Chikungunya, but this is thought to be possible"
                  }
                ],
                "Dengue": [
                  {
                    "text": "Symptoms occur 4 days to 1 week post mosquito bite and last for 3-10 days"
                  },
                  {
                    "text": "Present as classic dengue fever (milder form), dengue hemorrhagic fever, or dengue shock syndrome"
                  },
                  {
                    "text": "Infected individuals may be asymptomatic"
                  },
                  {
                    "text": "SymptomsHeadacheArthralgiasMuscle painBone painRashMucous membrane hemorrhageLeukopenia",
                    "sub_points": [
                      "Headache",
                      "Arthralgias",
                      "Muscle pain",
                      "Bone pain",
                      "Rash",
                      "Mucous membrane hemorrhage",
                      "Leukopenia"
                    ]
                  },
                  {
                    "text": "Fatalities seen more often in children"
                  },
                  {
                    "text": "Cases of transfusion transmission have been reported"
                  }
                ],
                "Zika": [
                  {
                    "text": "Symptoms occur 3-12 days post mosquito bite and last up to 1 weekFeverJoint painRashConjunctivitis",
                    "sub_points": [
                      "Fever",
                      "Joint pain",
                      "Rash",
                      "Conjunctivitis"
                    ]
                  },
                  {
                    "text": "Less common symptomsMucous membrane ulcerationPruritusGastrointestinal symptomsNeurologic symptomsCongenital abnormalities",
                    "sub_points": [
                      "Mucous membrane ulceration",
                      "Pruritus",
                      "Gastrointestinal symptoms",
                      "Neurologic symptoms",
                      "Congenital abnormalities"
                    ]
                  },
                  {
                    "text": "To date, there have been no cases of transfusion transmission in United States, but cases of potential transfusion transmission have been reported in Brazil"
                  }
                ],
                "Testing": [
                  {
                    "text": "There are no FDA-approved screening tests for Zika, dengue, or chikungunya, but nucleic acid amplification tests and serology are available for all 3 viruses"
                  },
                  {
                    "text": "Screening for blood donor acceptability achieved through donor health history questionnaire"
                  },
                  {
                    "text": "FDA guidance for Zika defers donors with history of Zika for 4 weeks"
                  },
                  {
                    "text": "Implementation of pathogen reduction technology has potential to significantly reduce risk of emerging infectious diseases on blood supply, negating need for testing"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bacterial Detection": {
            "name": "Bacterial Detection",
            "url": "https://app.pathprimer.com/document/4439c28a-5005-4974-8285-8d9608f8ebe4/lesson/f16bced4-e87d-40db-a10a-0f493cbb52cb",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Platelet components are most commonly implicated in septic transfusion reactions"
                  },
                  {
                    "text": "Platelets are stored at room temperature in aerobic environment, facilitating bacterial growth in contaminated products"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Apheresis platelets and whole blood-derived platelets are cultured prior to release to transfusion services"
                  },
                  {
                    "text": "Point of issue testing is available to further decrease risk of transfusion of contaminated unit"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "AABB Standards and CAP regulations require use of FDA approved or validated enhanced methods of detecting bacterial contamination of platelet products"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-Associated Sepsis": [
                  {
                    "text": "Transfusion of platelet products is associated with increased risk of septic transfusion reactions"
                  },
                  {
                    "text": "Platelets are stored at room temperature allowing for bacterial growth and proliferation"
                  },
                  {
                    "text": "Other blood components are stored at refrigerated temperatures or frozenDecreases risk of bacterial growth",
                    "sub_points": [
                      "Decreases risk of bacterial growth"
                    ]
                  },
                  {
                    "text": "Gram-positive aerobic bacteria, most commonly skin flora, are most commonly implicated"
                  },
                  {
                    "text": "Gram-negative bacteria are most commonly implicated in fatal cases of transfusion-transmitted sepsis"
                  }
                ],
                "Bacterial Detection": [
                  {
                    "text": "All platelet products are cultured prior to release to transfusion services"
                  },
                  {
                    "text": "Point of issue tests may be used to detect bacterial growth prior to release"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "College of American Pathologists (CAP)"
                  },
                  {
                    "text": "Food and Drug Administration (FDA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Platelet Collection": [
                  {
                    "text": "Donor history questionnaire screens and excludes donors with possible infection"
                  },
                  {
                    "text": "Donors are excluded if they have fever or other symptoms of infection or if they are currently taking antibiotics for infection"
                  },
                  {
                    "text": "Donors who are asymptomatic at time of collection will not be detected, allowing for possible contamination of blood product"
                  },
                  {
                    "text": "Prior to needle insertion, skin is cleansed with iodine, or chlorhexidine for donors with iodine allergies, to decontaminate needle insertion siteAbout 80% of contaminated units contain skin flora",
                    "sub_points": [
                      "About 80% of contaminated units contain skin flora"
                    ]
                  },
                  {
                    "text": "First few milliliters of blood collected are collected into diversion pouch to decrease risk of unit contamination by deep-seated skin flora found in skin plugSamples for bacteria culture are taken from blood in diversion pouch, increasing likelihood of detecting contamination by skin flora",
                    "sub_points": [
                      "Samples for bacteria culture are taken from blood in diversion pouch, increasing likelihood of detecting contamination by skin flora"
                    ]
                  }
                ],
                "Culture-Based Methods": [
                  {
                    "text": "Two bacterial detection systems are FDA approved for quality control testing of leukoreduced apheresis plateletsBacT/ALERT from bioMerieux and eBDS from Pall",
                    "sub_points": [
                      "BacT/ALERT from bioMerieux and eBDS from Pall"
                    ]
                  },
                  {
                    "text": "eBDS may also be used to culture leukoreduced whole blood-derived platelet components"
                  },
                  {
                    "text": "BacT/ALERT from bioMerieuxDetects increase in carbon dioxide in culture bottleAerobic bottles are inoculated 24 hours after collectionProduct may be released if negative at 16 hours of incubationCulture bottle must be incubated until expiration date of product or it becomes positiveAnaerobic bottles are not typically used, as anaerobes are infrequently implicated in transfusion-associated sepsis",
                    "sub_points": [
                      "Detects increase in carbon dioxide in culture bottle",
                      "Aerobic bottles are inoculated 24 hours after collection",
                      "Product may be released if negative at 16 hours of incubation",
                      "Culture bottle must be incubated until expiration date of product or it becomes positive",
                      "Anaerobic bottles are not typically used, as anaerobes are infrequently implicated in transfusion-associated sepsis"
                    ]
                  },
                  {
                    "text": "eBDS from PallDetects decrease in oxygen concentrationBottles are incubated for 24 hours prior to being read, at which point negative product may be released",
                    "sub_points": [
                      "Detects decrease in oxygen concentration",
                      "Bottles are incubated for 24 hours prior to being read, at which point negative product may be released"
                    ]
                  },
                  {
                    "text": "Slow-growing bacteria such asPropionibacterium acnesmay be missed by both culture-based methods"
                  },
                  {
                    "text": "Blood centers must notify transfusion services of positive cultures so that units can be discarded or clinical team can be notified of possibility of transfusion of contaminated product"
                  },
                  {
                    "text": "Positive cultures require identification of organism and reporting to transfusion service"
                  }
                ],
                "Immunoassays": [
                  {
                    "text": "Platelet Pan Genera (PGD) detection test by Verax Biomedical, Inc.FDA-approved rapid qualitative immunoassayDetects lipoteichoic acid and lipopolysaccharide antigens on aerobic and anaerobic gram-positive and gram-negative bacteriaMay be used as standalone quality control bacterial testing for leukocyte-reduced whole blood-derived platelet componentsMay be used as adjunctive testing to culture-based methods for quality control bacterial testing of leukoreduced apheresis plateletsTest uses 0.5 mL of sample and takes 30 minutes to runTest is used as point of issue test prior to release of platelets",
                    "sub_points": [
                      "FDA-approved rapid qualitative immunoassay",
                      "Detects lipoteichoic acid and lipopolysaccharide antigens on aerobic and anaerobic gram-positive and gram-negative bacteria",
                      "May be used as standalone quality control bacterial testing for leukocyte-reduced whole blood-derived platelet components",
                      "May be used as adjunctive testing to culture-based methods for quality control bacterial testing of leukoreduced apheresis platelets",
                      "Test uses 0.5 mL of sample and takes 30 minutes to run",
                      "Test is used as point of issue test prior to release of platelets"
                    ]
                  },
                  {
                    "text": "BacTx Assay System by ImmuneticsFDA-approved for bacterial testing of leukocyte-reduced whole blood-derived platelet componentsDetects peptidoglycan from cell wall of gram-positive and gram-negative bacteriaTest uses 0.5 mL of sample and takes 45 minutes to runTest is used as point of issue test prior to release of platelets",
                    "sub_points": [
                      "FDA-approved for bacterial testing of leukocyte-reduced whole blood-derived platelet components",
                      "Detects peptidoglycan from cell wall of gram-positive and gram-negative bacteria",
                      "Test uses 0.5 mL of sample and takes 45 minutes to run",
                      "Test is used as point of issue test prior to release of platelets"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards and CAP Regulations": [
                  {
                    "text": "Require enhanced methods of bacterial detection in platelet products that are either FDA approved or validated"
                  },
                  {
                    "text": "AABB Standard 5.1.5.1 \"The blood bank or transfusion service shall have methods to limit and to detect or inactivate bacteria in all platelet components\""
                  },
                  {
                    "text": "AABB Standard 5.1.5.1.1 \"Detection methods shall either be approved by the FDA or be validated to provide sensitivity equivalent to FDA-approved methods\""
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Pretransfusion Testing and Transfusion Practice": {
        "name": "Pretransfusion Testing and Transfusion Practice",
        "url": "https://app.pathprimer.com/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
        "topics": {
          "Overview of Transfusion Medicine Testing": {
            "name": "Overview of Transfusion Medicine Testing",
            "url": "https://app.pathprimer.com/document/dfe6acb9-01cd-4c95-b3ea-57feea5e71eb/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Pretransfusion testing includes immunohematologic testing needed for proper patient blood typing, blood component selection, and compatibility testing"
                  }
                ]
              },
              "OVERVIEW": {
                "Pretransfusion Testing Includes Immunohematologic Testing for Proper Patient Blood Typing, Blood Component Selection, and Compatibility Testing": [
                  {
                    "text": "Number of tests required, their frequency, and their methodology differ based on type of patient and component to be issued"
                  },
                  {
                    "text": "Accurate detection of antibodies and antigens are key biologic units of immunohematologic testing"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Antihuman globulin (AHG)"
                  },
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  },
                  {
                    "text": "Indirect antiglobulin test (IAT)"
                  },
                  {
                    "text": "Immediate spin (IS)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Key Immunoglobulin Classes": [
                  {
                    "text": "IgMClassically expressed early in immune response before B-cell class switchingIs pentavalent immunoglobulin that contains 5 subunits, each with 2 F(ab) domainsIs extensively disulfide linkedIts activity can be destroyed by reducing agent treatment (e.g., dithiothreitol or 2-mercaptoethanol)Is most commonly active at room temperature/cool temperaturesAfter binding its target epitope, it undergoes a conformational change that results in very potent activation of complement",
                    "sub_points": [
                      "Classically expressed early in immune response before B-cell class switching",
                      "Is pentavalent immunoglobulin that contains 5 subunits, each with 2 F(ab) domains",
                      "Is extensively disulfide linkedIts activity can be destroyed by reducing agent treatment (e.g., dithiothreitol or 2-mercaptoethanol)",
                      "Its activity can be destroyed by reducing agent treatment (e.g., dithiothreitol or 2-mercaptoethanol)",
                      "Is most commonly active at room temperature/cool temperatures",
                      "After binding its target epitope, it undergoes a conformational change that results in very potent activation of complement"
                    ]
                  },
                  {
                    "text": "IgGIs a bivalent immunoglobulin that is classically expressed later in an immune response after B-cell class switchingCan be divided into 4 subclassesIgG1, IgG2, IgG3, IgG4IgG1 and IgG3 strongly activate complement when bound to antigen and can bind Fc receptors on phagocytesIgG2 and IgG4 cause weak to no complement binding or Fc receptor bindingMost warm autoantibodies are IgG1Most commonly active at body temperature",
                    "sub_points": [
                      "Is a bivalent immunoglobulin that is classically expressed later in an immune response after B-cell class switching",
                      "Can be divided into 4 subclassesIgG1, IgG2, IgG3, IgG4IgG1 and IgG3 strongly activate complement when bound to antigen and can bind Fc receptors on phagocytesIgG2 and IgG4 cause weak to no complement binding or Fc receptor bindingMost warm autoantibodies are IgG1",
                      "IgG1, IgG2, IgG3, IgG4",
                      "IgG1 and IgG3 strongly activate complement when bound to antigen and can bind Fc receptors on phagocytes",
                      "IgG2 and IgG4 cause weak to no complement binding or Fc receptor binding",
                      "Most warm autoantibodies are IgG1",
                      "Most commonly active at body temperature"
                    ]
                  }
                ],
                "Key Antigen Classes": [
                  {
                    "text": "Carbohydrate antigens (e.g., A, B, H, I, i, Lewis)Are synthesized by enzymes that add specific monosaccharides to glycoproteins and glycolipidsImportant antigen differences are usually due to presence or absence of these specific enzymes (i.e., FUT3 and Lewis antigens)Incompatible carbohydrate antigens classically stimulate naturally occurring IgM antibodies",
                    "sub_points": [
                      "Are synthesized by enzymes that add specific monosaccharides to glycoproteins and glycolipids",
                      "Important antigen differences are usually due to presence or absence of these specific enzymes (i.e., FUT3 and Lewis antigens)",
                      "Incompatible carbohydrate antigens classically stimulate naturally occurring IgM antibodies"
                    ]
                  },
                  {
                    "text": "Amino-acid antigens (e.g., Rh, K, Kidd, Duffy)Are cell surface proteins that are synthesized by ribosomesImportant antigen differences are usually due to genetic single nucleotide polymorphisms (i.e., Jka vs. Jkb antigens) or deletions (i.e., D antigen)Incompatible amino-acid antigens classically stimulate exposure (transfusion/pregnancy)-induced IgG antibodies",
                    "sub_points": [
                      "Are cell surface proteins that are synthesized by ribosomes",
                      "Important antigen differences are usually due to genetic single nucleotide polymorphisms (i.e., Jka vs. Jkb antigens) or deletions (i.e., D antigen)",
                      "Incompatible amino-acid antigens classically stimulate exposure (transfusion/pregnancy)-induced IgG antibodies"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Transfusion Medicine Services Perform Following Functions": [
                  {
                    "text": "Correctly identify patient and corresponding blood specimen"
                  },
                  {
                    "text": "Determine ABO and D type of patient specimen"
                  },
                  {
                    "text": "Test patient's plasma for unexpected, clinically significant RBC antibodies"
                  },
                  {
                    "text": "Compare current findings with previous results from same patient"
                  },
                  {
                    "text": "Confirm ABO and D group of RBC components"
                  },
                  {
                    "text": "Select ABO and D appropriate components for patient"
                  },
                  {
                    "text": "Crossmatch selected units for patient"
                  },
                  {
                    "text": "Inspect and label components correctly before issue"
                  }
                ],
                "Basics of Serologic Testing": [
                  {
                    "text": "Most in vitro tests in transfusion medicine require antibody-antigen interactionCommon methods include tube testing, gel testing, and solid phase testingMany laboratories now automate these tests",
                    "sub_points": [
                      "Common methods include tube testing, gel testing, and solid phase testing",
                      "Many laboratories now automate these tests"
                    ]
                  },
                  {
                    "text": "Final endpoint of most tests in transfusion medicine is red cell agglutinationVisual lumping of RBCs together from RBC-antibody interactionsMost IgM antibodies can cause direct agglutinationNo need to add anything to make RBCs to stick togetherMost IgG antibodies cannot cause direct agglutination and require secondary antibody (AHG) for visualization of agglutination",
                    "sub_points": [
                      "Visual lumping of RBCs together from RBC-antibody interactions",
                      "Most IgM antibodies can cause direct agglutinationNo need to add anything to make RBCs to stick together",
                      "No need to add anything to make RBCs to stick together",
                      "Most IgG antibodies cannot cause direct agglutination and require secondary antibody (AHG) for visualization of agglutination"
                    ]
                  },
                  {
                    "text": "Standard blood bank serologic tests mainly differ in where RBCs and antigens come fromDAT used to detect antibodies or complement proteins that are bound to surface of RBCsIAT used to detect antibodies against RBCs that are present unbound in plasma or serumAntibody screens and antibody panels are examples of IATs",
                    "sub_points": [
                      "DAT used to detect antibodies or complement proteins that are bound to surface of RBCs",
                      "IAT used to detect antibodies against RBCs that are present unbound in plasma or serumAntibody screens and antibody panels are examples of IATs",
                      "Antibody screens and antibody panels are examples of IATs"
                    ]
                  },
                  {
                    "text": "Standard blood bank serologic tests also differ based on when and how red cell agglutination is evaluatedIS testing evaluates red cell agglutination after quick centrifugation at room temperatureAgglutination at room temperature often implies cold-reacting or IgM antibodyAHG testing evaluates red cell agglutination after warming sample to 37°C and adding secondary antibody that binds Fc region of other antibodies (AHG or Coombs reagent) togetherAgglutination at AHG often implies warm-reacting or IgG antibody",
                    "sub_points": [
                      "IS testing evaluates red cell agglutination after quick centrifugation at room temperatureAgglutination at room temperature often implies cold-reacting or IgM antibody",
                      "Agglutination at room temperature often implies cold-reacting or IgM antibody",
                      "AHG testing evaluates red cell agglutination after warming sample to 37°C and adding secondary antibody that binds Fc region of other antibodies (AHG or Coombs reagent) togetherAgglutination at AHG often implies warm-reacting or IgG antibody",
                      "Agglutination at AHG often implies warm-reacting or IgG antibody"
                    ]
                  }
                ],
                "Basics of Molecular Testing": [
                  {
                    "text": "Not routinely used as part of standard pretransfusion testing"
                  },
                  {
                    "text": "DNA-based methods for blood typing are now used in certain clinical situations where serologic tests alone are insufficient"
                  },
                  {
                    "text": "Current techniques exploit the fact that many differences in key blood types differ by a single nucleotide polymorphism"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Blood Group Typing": {
            "name": "Blood Group Typing",
            "url": "https://app.pathprimer.com/document/3c56b07c-f9d1-4fd9-a5f0-2dc6313ca9a2/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Antibodies to antithetical ABO antigens are naturally occurring and do not require previous exposure"
                  },
                  {
                    "text": "Standard ABO and D testing requires forward type and reverse type"
                  },
                  {
                    "text": "Any discrepancy between results of front type and reverse type must be resolved before interpretation is recorded and type-specific blood is offered"
                  },
                  {
                    "text": "Discrepancies between historical and current typing must be resolved prior to issuing type-specific blood"
                  }
                ]
              },
              "OVERVIEW": {
                "ABO Antigens and Antibodies": [
                  {
                    "text": "ABO antigens and antibodies are most clinically significant of all red cell antigens and antibodies in transfusion practice"
                  },
                  {
                    "text": "Antibodies to antithetical ABO antigens are naturally occurring and do not require previous exposure"
                  },
                  {
                    "text": "These antibodies are generally IgM that can result in severe intravascular hemolysis after transfusion of ABO-incompatible units"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "ABO Group Typing": [
                  {
                    "text": "Forward type2-5% suspension of patient red cells is incubated with reagent anti-A, anti-B, and anti-DReagent anti-A solution is always blueReagent anti-B solution is always yellowAnti-D reagent solution is always clearPositive result occurs when hemolysis or agglutination is observed",
                    "sub_points": [
                      "2-5% suspension of patient red cells is incubated with reagent anti-A, anti-B, and anti-DReagent anti-A solution is always blueReagent anti-B solution is always yellowAnti-D reagent solution is always clear",
                      "Reagent anti-A solution is always blue",
                      "Reagent anti-B solution is always yellow",
                      "Anti-D reagent solution is always clear",
                      "Positive result occurs when hemolysis or agglutination is observed"
                    ]
                  },
                  {
                    "text": "Reverse (back) typePatient plasma is incubated with 2-5% suspension of reagent group A1 and B red cellsPositive result occurs when hemolysis or agglutination is observed",
                    "sub_points": [
                      "Patient plasma is incubated with 2-5% suspension of reagent group A1 and B red cells",
                      "Positive result occurs when hemolysis or agglutination is observed"
                    ]
                  },
                  {
                    "text": "Transfusion service must compare current patient ABO and Rh typing to any prior typing (and document comparison)"
                  },
                  {
                    "text": "Any discrepancy between results of front type and back type or between historical type and current type must be resolved before interpretation is recorded and type-specific blood is offeredO red cells and AB plasma can be offered in emergency",
                    "sub_points": [
                      "O red cells and AB plasma can be offered in emergency"
                    ]
                  }
                ],
                "ABO Discrepancies": [
                  {
                    "text": "Unexpected reactions with anti-A and anti-B (forward type)B(A) phenotype: Will have unexpected agglutination with anti-ASome group B individuals have excessive levels of B-associated galactosyltransferase, leading to reactivity with anti-A reagentUsing anti-A reagent that lacks MH04 can resolve discrepancyAcquired B phenotype: Will have unexpected agglutination with anti-BGroup A1 individuals who have bacteremia develop unexpected anti-B agglutination due to effect of circulating microbial deacetylating enzymes (enzyme makes A sugar look like B sugar)Polyagglutination: Will have unexpected agglutination with anti-A and anti-BRed cells agglutinate with all human sera due to presence of neuraminidase, which cleaves N-acetylneuraminic acid and exposes hidden T-antigen on red cells (cryptantigens)Neuraminidase can be produced by bacterial or viral infection (T antigen exposure can also be genetic)Proteolytic enzymes should degrade these exposed antigens and remove excess reactivityLectins can be used to characterize offending polyagglutinable antigenMixed-field agglutinationOccurs when 2 or more populations of red cellsPrevious transfusion of group O red cells in non-group O patientStem cell transplant recipient when donor has different ABO group from patientPatient who is A3 subtypeAntibody-coated red cellsPatient red cells heavily coated with IgG may agglutinate spontaneouslyExcess IgG can be removed with chloroquine diphosphate, and red cells can be retestedWeak/absent anti-A or anti-B agglutinationAcquired loss or weakened A and B antigens can be seen in patients with hematologic diseases or malignanciesIncreasing incubation time may enhance appropriate reactivity",
                    "sub_points": [
                      "B(A) phenotype: Will have unexpected agglutination with anti-ASome group B individuals have excessive levels of B-associated galactosyltransferase, leading to reactivity with anti-A reagentUsing anti-A reagent that lacks MH04 can resolve discrepancy",
                      "Some group B individuals have excessive levels of B-associated galactosyltransferase, leading to reactivity with anti-A reagent",
                      "Using anti-A reagent that lacks MH04 can resolve discrepancy",
                      "Acquired B phenotype: Will have unexpected agglutination with anti-BGroup A1 individuals who have bacteremia develop unexpected anti-B agglutination due to effect of circulating microbial deacetylating enzymes (enzyme makes A sugar look like B sugar)",
                      "Group A1 individuals who have bacteremia develop unexpected anti-B agglutination due to effect of circulating microbial deacetylating enzymes (enzyme makes A sugar look like B sugar)",
                      "Polyagglutination: Will have unexpected agglutination with anti-A and anti-BRed cells agglutinate with all human sera due to presence of neuraminidase, which cleaves N-acetylneuraminic acid and exposes hidden T-antigen on red cells (cryptantigens)Neuraminidase can be produced by bacterial or viral infection (T antigen exposure can also be genetic)Proteolytic enzymes should degrade these exposed antigens and remove excess reactivityLectins can be used to characterize offending polyagglutinable antigen",
                      "Red cells agglutinate with all human sera due to presence of neuraminidase, which cleaves N-acetylneuraminic acid and exposes hidden T-antigen on red cells (cryptantigens)",
                      "Neuraminidase can be produced by bacterial or viral infection (T antigen exposure can also be genetic)",
                      "Proteolytic enzymes should degrade these exposed antigens and remove excess reactivity",
                      "Lectins can be used to characterize offending polyagglutinable antigen",
                      "Mixed-field agglutinationOccurs when 2 or more populations of red cellsPrevious transfusion of group O red cells in non-group O patientStem cell transplant recipient when donor has different ABO group from patientPatient who is A3 subtype",
                      "Occurs when 2 or more populations of red cellsPrevious transfusion of group O red cells in non-group O patientStem cell transplant recipient when donor has different ABO group from patientPatient who is A3 subtype",
                      "Previous transfusion of group O red cells in non-group O patient",
                      "Stem cell transplant recipient when donor has different ABO group from patient",
                      "Patient who is A3 subtype",
                      "Antibody-coated red cellsPatient red cells heavily coated with IgG may agglutinate spontaneouslyExcess IgG can be removed with chloroquine diphosphate, and red cells can be retested",
                      "Patient red cells heavily coated with IgG may agglutinate spontaneously",
                      "Excess IgG can be removed with chloroquine diphosphate, and red cells can be retested",
                      "Weak/absent anti-A or anti-B agglutinationAcquired loss or weakened A and B antigens can be seen in patients with hematologic diseases or malignanciesIncreasing incubation time may enhance appropriate reactivity",
                      "Acquired loss or weakened A and B antigens can be seen in patients with hematologic diseases or malignancies",
                      "Increasing incubation time may enhance appropriate reactivity"
                    ]
                  },
                  {
                    "text": "Unexpected reactions with reagent A and B red cells (reverse type)Immunodeficient or elderly patients may not produce enough anti-A or anti-B to lead to measurable agglutinationAnti-A1 may be present in A2 or A2B patientsDolichos bifloruslectin can be used to resolve this discrepancyStrongly reacting cold antibodies can agglutinate reagent A and B red cellsCommon examples include anti-I, -IH, P1, and MUse of prewarming technique or adsorption may resolve discrepancyHigh concentrations of serum proteins can lead to rouleaux, or irregular clumpsSaline can resolve this form of red cell agglutination",
                    "sub_points": [
                      "Immunodeficient or elderly patients may not produce enough anti-A or anti-B to lead to measurable agglutination",
                      "Anti-A1 may be present in A2 or A2B patientsDolichos bifloruslectin can be used to resolve this discrepancy",
                      "Dolichos bifloruslectin can be used to resolve this discrepancy",
                      "Strongly reacting cold antibodies can agglutinate reagent A and B red cellsCommon examples include anti-I, -IH, P1, and MUse of prewarming technique or adsorption may resolve discrepancy",
                      "Common examples include anti-I, -IH, P1, and M",
                      "Use of prewarming technique or adsorption may resolve discrepancy",
                      "High concentrations of serum proteins can lead to rouleaux, or irregular clumpsSaline can resolve this form of red cell agglutination",
                      "Saline can resolve this form of red cell agglutination"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "RhD Typing": {
            "name": "RhD Typing",
            "url": "https://app.pathprimer.com/document/6305e1ed-52b0-49a1-8f00-67104bd4694c/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "All blood donations and patient samples must be typed for D antigen using anti-D reagent"
                  },
                  {
                    "text": "RhD typing is complex; several types of variants have been identified, each with different risks (weak D, DEL, partial D)"
                  },
                  {
                    "text": "Molecular techniques have increasing value in solving discordant RhD typing results"
                  }
                ]
              },
              "OVERVIEW": {
                "Aims and Techniques": [
                  {
                    "text": "RhD typing is highly regulated due to antigen's known high immunogenicity and severity of anti-D associated HDFNRhD is complex, and several types of variants have been identifiedWeak DDELPartial DMolecular testing is best way to identify partial D as well as weak D patients who should be treated as D-negativeTreating patient with discrepant D typing as D-negative is always safest approachMain goal of D-typing practices is to protect D-negative persons from inadvertent alloimmunization to D antigen by exposure to D-positive RBCs, including from RBCs expressing serological weak D phenotype",
                    "sub_points": [
                      "RhD is complex, and several types of variants have been identifiedWeak DDELPartial D",
                      "Weak D",
                      "DEL",
                      "Partial D",
                      "Molecular testing is best way to identify partial D as well as weak D patients who should be treated as D-negative",
                      "Treating patient with discrepant D typing as D-negative is always safest approach",
                      "Main goal of D-typing practices is to protect D-negative persons from inadvertent alloimmunization to D antigen by exposure to D-positive RBCs, including from RBCs expressing serological weak D phenotype"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "College of American Pathologists (CAP)"
                  },
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "RhD Antigen Typing Requirements": [
                  {
                    "text": "RhD typing reagents, which are monoclonal or monoclonal blends of anti-D, may type weak D or partial D phenotypes differentlyWeak D is classically detected by incubating patient red cells with anti-D reagent at 37°C for 15-60 min, and then adding anti-human globulin to enhance agglutinationPartial D is suggested when D typing results are positive with one reagent and negative with another using same incubation methods",
                    "sub_points": [
                      "Weak D is classically detected by incubating patient red cells with anti-D reagent at 37°C for 15-60 min, and then adding anti-human globulin to enhance agglutination",
                      "Partial D is suggested when D typing results are positive with one reagent and negative with another using same incubation methods"
                    ]
                  },
                  {
                    "text": "Testing of blood products/blood donorsAll blood donations must be typed for D antigenKey goal: To detect weak D phenotype donors as D-positiveAll D antigen-negative donors must be typed for weak D antigens (see below) using more sensitive testAssay used must be proven to have sufficient sensitivity to identify weak D donorsD antigen status (either \"Rh positive\" or \"Rh negative\") is required part of blood donor product ISBT 128 labelComponents labeled Rh negative must be negative for both initial D typing and weak D testingBefore issuing red cell, whole blood, or granulocyte product, D status must be again confirmed by transfusion service",
                    "sub_points": [
                      "All blood donations must be typed for D antigenKey goal: To detect weak D phenotype donors as D-positive",
                      "Key goal: To detect weak D phenotype donors as D-positive",
                      "All D antigen-negative donors must be typed for weak D antigens (see below) using more sensitive testAssay used must be proven to have sufficient sensitivity to identify weak D donors",
                      "Assay used must be proven to have sufficient sensitivity to identify weak D donors",
                      "D antigen status (either \"Rh positive\" or \"Rh negative\") is required part of blood donor product ISBT 128 labelComponents labeled Rh negative must be negative for both initial D typing and weak D testing",
                      "Components labeled Rh negative must be negative for both initial D typing and weak D testing",
                      "Before issuing red cell, whole blood, or granulocyte product, D status must be again confirmed by transfusion service"
                    ]
                  },
                  {
                    "text": "Testing of transfusion recipientsType and screen, and type and cross, must include testing for D antigenKey goal 1: To detect weak and partial D phenotype recipients and label them as D-negativeKey goal 2: To determine need for Rh immune globulin in pregnant womenIf blood recipient's D type cannot be resolved, especially in female patients of childbearing potential, they should be issued D-negative blood productsSpecific testing of patient for weak D is not required, unless patient is neonateDetermines D-negative mother's need for Rh immune globulin)CAP/AABB Working Group now recommendsRHDgenotyping be performed when discordant RhD typing results are encountered and/or when serological weak D is identified in female patient of childbearing potential",
                    "sub_points": [
                      "Type and screen, and type and cross, must include testing for D antigenKey goal 1: To detect weak and partial D phenotype recipients and label them as D-negativeKey goal 2: To determine need for Rh immune globulin in pregnant women",
                      "Key goal 1: To detect weak and partial D phenotype recipients and label them as D-negative",
                      "Key goal 2: To determine need for Rh immune globulin in pregnant women",
                      "If blood recipient's D type cannot be resolved, especially in female patients of childbearing potential, they should be issued D-negative blood productsSpecific testing of patient for weak D is not required, unless patient is neonateDetermines D-negative mother's need for Rh immune globulin)CAP/AABB Working Group now recommendsRHDgenotyping be performed when discordant RhD typing results are encountered and/or when serological weak D is identified in female patient of childbearing potential",
                      "Specific testing of patient for weak D is not required, unless patient is neonateDetermines D-negative mother's need for Rh immune globulin)",
                      "Determines D-negative mother's need for Rh immune globulin)",
                      "CAP/AABB Working Group now recommendsRHDgenotyping be performed when discordant RhD typing results are encountered and/or when serological weak D is identified in female patient of childbearing potential"
                    ]
                  },
                  {
                    "text": "Typing requirements are highly effectiveEstimated 98.4-99.0% successful in preventing D alloimmunization and anti-D-related HDFN",
                    "sub_points": [
                      "Estimated 98.4-99.0% successful in preventing D alloimmunization and anti-D-related HDFN"
                    ]
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "D Variants: Weak D, DEL, and Partial D": [
                  {
                    "text": "Weak DDefined as expression of D antigen at low enough level that weak (≤ 2 +) or no agglutination is seen upon testing with typical monoclonal anti-D reagentMore than 100 weak D alleles have been identifiedWeak D is caused by variety of different point mutations inRHDgene, which cause amino acid changes on intracellular or transmembrane portion of proteinChanges cause inefficient processing of protein from endoplasmic reticulum to cell surfaceMost do not cause changes in extracellular epitopesWeak D types 1, 2, 3 are most common types of weak D (making up ~ 90% of weak D phenotypes in people of European descent)Classic weak D patients do not produce anti-D when exposed to D+ red cellsPatients can receive D-positive red cells without concernPregnant patients do not need Rh immune globulinIncludes weak D type 1, 2, 3Some types of weak D alleles can potentially lead to anti-D formationPatients should not receive D-positive red cells, and should be treated as D-negativePregnant patients do need Rh immune globulinIncludes weak D type 4.0, 4.1, 4.2, DAR, type 11, type 15, type 21, and type 57",
                    "sub_points": [
                      "Defined as expression of D antigen at low enough level that weak (≤ 2 +) or no agglutination is seen upon testing with typical monoclonal anti-D reagent",
                      "More than 100 weak D alleles have been identifiedWeak D is caused by variety of different point mutations inRHDgene, which cause amino acid changes on intracellular or transmembrane portion of proteinChanges cause inefficient processing of protein from endoplasmic reticulum to cell surfaceMost do not cause changes in extracellular epitopesWeak D types 1, 2, 3 are most common types of weak D (making up ~ 90% of weak D phenotypes in people of European descent)",
                      "Weak D is caused by variety of different point mutations inRHDgene, which cause amino acid changes on intracellular or transmembrane portion of protein",
                      "Changes cause inefficient processing of protein from endoplasmic reticulum to cell surfaceMost do not cause changes in extracellular epitopes",
                      "Most do not cause changes in extracellular epitopes",
                      "Weak D types 1, 2, 3 are most common types of weak D (making up ~ 90% of weak D phenotypes in people of European descent)",
                      "Classic weak D patients do not produce anti-D when exposed to D+ red cellsPatients can receive D-positive red cells without concernPregnant patients do not need Rh immune globulinIncludes weak D type 1, 2, 3",
                      "Patients can receive D-positive red cells without concern",
                      "Pregnant patients do not need Rh immune globulin",
                      "Includes weak D type 1, 2, 3",
                      "Some types of weak D alleles can potentially lead to anti-D formationPatients should not receive D-positive red cells, and should be treated as D-negativePregnant patients do need Rh immune globulinIncludes weak D type 4.0, 4.1, 4.2, DAR, type 11, type 15, type 21, and type 57",
                      "Patients should not receive D-positive red cells, and should be treated as D-negative",
                      "Pregnant patients do need Rh immune globulin",
                      "Includes weak D type 4.0, 4.1, 4.2, DAR, type 11, type 15, type 21, and type 57"
                    ]
                  },
                  {
                    "text": "DEL phenotypeExtreme version of weak D, where D antigen is expressed at such low density that even weak D testing is negativeDEL patients have 26 D antigens/cell (D+ has 10,000-30,000 D antigens/cell, and weak D type 1 has 967 D antigens/cell, for comparison)DEL phenotypes have been implicated as cause of RhD alloimmunization when RhD-negative/DEL-positive red cells were unknowingly transfused to RhD-negative recipientsDEL phenotypes are found more commonly among persons of Asian ancestry (10-30% of all D- Asians)",
                    "sub_points": [
                      "Extreme version of weak D, where D antigen is expressed at such low density that even weak D testing is negativeDEL patients have 26 D antigens/cell (D+ has 10,000-30,000 D antigens/cell, and weak D type 1 has 967 D antigens/cell, for comparison)",
                      "DEL patients have 26 D antigens/cell (D+ has 10,000-30,000 D antigens/cell, and weak D type 1 has 967 D antigens/cell, for comparison)",
                      "DEL phenotypes have been implicated as cause of RhD alloimmunization when RhD-negative/DEL-positive red cells were unknowingly transfused to RhD-negative recipients",
                      "DEL phenotypes are found more commonly among persons of Asian ancestry (10-30% of all D- Asians)"
                    ]
                  },
                  {
                    "text": "Partial DReactivity, and strength of reactivity, of partial D patient/donor red cells with anti-D reagents depends on D-epitopes present as well as particular D reagent usedPartial D patients often type as D+, but then form anti-D from exposure to D+ red cells (of normal phenotype) and can cause clinically significant HDFNPartial D phenotypes are associated with amino acid substitutions in RhD protein on extracellular surface of RhD protein, leading to lack of common D epitopes~ 30 immunogenic epitopes on DDIIIa, DVI, DBT, and DFR are common partial D phenotypesIn United States, most persons expressing partial D phenotypes are of African ancestryMost common partial D phenotype in African Americans is DIIIa, which provides strong reactions with commonly used anti-D reagentsPartial DVI is most common partial D phenotype in people of European descentCommercially marketed panels of monoclonal reagents are available to differentiate number of partial D types, but D genotyping is superior technique for identification and discrimination of partial DMonoclonal anti-D reagents licensed in United States for patient testing intentionally do not detect partial DVI as RhD-positive by initial testing, due to known anti-D alloimmunization riskPatients with DVI are typed as D-negative",
                    "sub_points": [
                      "Reactivity, and strength of reactivity, of partial D patient/donor red cells with anti-D reagents depends on D-epitopes present as well as particular D reagent used",
                      "Partial D patients often type as D+, but then form anti-D from exposure to D+ red cells (of normal phenotype) and can cause clinically significant HDFN",
                      "Partial D phenotypes are associated with amino acid substitutions in RhD protein on extracellular surface of RhD protein, leading to lack of common D epitopes~ 30 immunogenic epitopes on DDIIIa, DVI, DBT, and DFR are common partial D phenotypesIn United States, most persons expressing partial D phenotypes are of African ancestryMost common partial D phenotype in African Americans is DIIIa, which provides strong reactions with commonly used anti-D reagentsPartial DVI is most common partial D phenotype in people of European descent",
                      "~ 30 immunogenic epitopes on D",
                      "DIIIa, DVI, DBT, and DFR are common partial D phenotypesIn United States, most persons expressing partial D phenotypes are of African ancestryMost common partial D phenotype in African Americans is DIIIa, which provides strong reactions with commonly used anti-D reagentsPartial DVI is most common partial D phenotype in people of European descent",
                      "In United States, most persons expressing partial D phenotypes are of African ancestry",
                      "Most common partial D phenotype in African Americans is DIIIa, which provides strong reactions with commonly used anti-D reagents",
                      "Partial DVI is most common partial D phenotype in people of European descent",
                      "Commercially marketed panels of monoclonal reagents are available to differentiate number of partial D types, but D genotyping is superior technique for identification and discrimination of partial DMonoclonal anti-D reagents licensed in United States for patient testing intentionally do not detect partial DVI as RhD-positive by initial testing, due to known anti-D alloimmunization riskPatients with DVI are typed as D-negative",
                      "Monoclonal anti-D reagents licensed in United States for patient testing intentionally do not detect partial DVI as RhD-positive by initial testing, due to known anti-D alloimmunization riskPatients with DVI are typed as D-negative",
                      "Patients with DVI are typed as D-negative"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Proficiency Testing": [
                  {
                    "text": "Clinical Laboratory Improvement Amendments of 1988 regulates ABO group and D typing"
                  },
                  {
                    "text": "Proficiency testing must be performed at least twice/year with 100% success required for compliance"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Antibody Screening and Identification": {
            "name": "Antibody Screening and Identification",
            "url": "https://app.pathprimer.com/document/a20bd10a-154a-4363-a5e6-98953a08cc75/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Classical endpoint for detecting RBC-antibody interaction is RBC agglutination (e.g., clumping)"
                  },
                  {
                    "text": "Indirect antiglobulin testing can be performed with or without potentiators (substances that favor agglutination of RBC)"
                  },
                  {
                    "text": "Common antibody screening methods include tube, gel, and solid phase methods"
                  }
                ]
              },
              "OVERVIEW": {
                "Antibody Screen Is Required Component of Pretransfusion Testing": [
                  {
                    "text": "Detection and identification of unexpected clinically significant alloantibodies or autoantibodies is primary objective of antibody screening"
                  },
                  {
                    "text": "Testing for unexpected red cell antibodies focuses on clinically significant antibodies that react at 37°C and at AHG (Coombs) phase"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antihuman globulin (AHG)"
                  },
                  {
                    "text": "Hemolytic disease of the fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Indirect antiglobulin test (IAT)"
                  },
                  {
                    "text": "Low ionic strength saline (LISS)"
                  },
                  {
                    "text": "Polyethylene glycol (PEG)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "Antibody Screen/IAT": [
                  {
                    "text": "Test must use at least 2 screening red cells, though many laboratories use 3 cells"
                  },
                  {
                    "text": "Reagent RBCs used for antibody detection must express and have known D, C, c, E, e, M, N, S, s, P1, Le(a), Le(b), K, k, Fy(a), Fy(b), Jk(a), Jk(b) phenotypeAntibody screening cells are always type O, because goal of indirect antiglobulin test is to detect non-ABO antibodies known to cause hemolytic transfusion reactions of HDFNMost common red cell screen combination: (1) R1R1, (2) R2R2, (3) rr",
                    "sub_points": [
                      "Antibody screening cells are always type O, because goal of indirect antiglobulin test is to detect non-ABO antibodies known to cause hemolytic transfusion reactions of HDFN",
                      "Most common red cell screen combination: (1) R1R1, (2) R2R2, (3) rr"
                    ]
                  },
                  {
                    "text": "Positive result in any of screening cells and in any method requires further testing using antibody identification technique (antibody panel)"
                  },
                  {
                    "text": "Classical endpoint for detecting this interaction is RBC agglutination (e.g., clumping), although some antibodies (such as anti-Jk) can cause in vitro hemolysis so this should also be watched for"
                  },
                  {
                    "text": "Current methods: Both gel and solid phase technologies have been automatedTube testing (gold standard test)Test can be performed with or without potentiators or substances that favor agglutination of RBCsPEG excludes water from around RBC and therefore concentrates antibodies around RBCAlbumin and LISS neutralize RBC-negative zeta potential that normally repels RBC from each otherReagent RBCs are allowed to incubate at 37°C with patient plasma or serum (with or without antibodies)After incubation, unbound patient antibodies are washed offRed cell-bound antibodies are detected using anti-IgG (AHG or Coombs reagent) and observed for red cell agglutinationGrading schema for agglutination when using tube technique4+ is all RBC forming one solid agglutinate (e.g., background is clear)3+ is RBC forming several large agglutinates (e.g., background is clear)2+ is RBC forming medium-sized agglutinates (e.g., background is clear)1+ is most RBC forming small-sized agglutinates (e.g., background is turbid red color)0 is no RBC agglutination; background is smooth turbid red without any \"chunkiness\"Gel testingReagent RBCs are allowed to interact with patient plasma or serum at top of column filled with gel matrix or beadsAfter incubation, centrifugation step forces red cells into column mediaAgglutinated red cells will be unable to move deeply into gel matrix due to size and will stay at top of column (positive test)Free red cells will be able to move deeply into gel matrix and will fall to bottom of column (negative test)Gel reactions are stable up to 24 hours and can be reviewed at later time by other staff or supervisorsSolid phase testing (does not require detection of red cell agglutination)Intact red cells or red cell membranes of known phenotype are immobilized to microplate wells, and patient serum or plasma is addedAfter incubation, unbound patient antibodies are washed offRed cell-bound antibodies are detected using anti-IgG-coated indicator red cellsPositive result is reported if indicator red cells adhere diffusely over wellWell reactions can be photographed or scanned electronically and can be reviewed at later time by other staff or supervisors",
                    "sub_points": [
                      "Tube testing (gold standard test)Test can be performed with or without potentiators or substances that favor agglutination of RBCsPEG excludes water from around RBC and therefore concentrates antibodies around RBCAlbumin and LISS neutralize RBC-negative zeta potential that normally repels RBC from each otherReagent RBCs are allowed to incubate at 37°C with patient plasma or serum (with or without antibodies)After incubation, unbound patient antibodies are washed offRed cell-bound antibodies are detected using anti-IgG (AHG or Coombs reagent) and observed for red cell agglutinationGrading schema for agglutination when using tube technique4+ is all RBC forming one solid agglutinate (e.g., background is clear)3+ is RBC forming several large agglutinates (e.g., background is clear)2+ is RBC forming medium-sized agglutinates (e.g., background is clear)1+ is most RBC forming small-sized agglutinates (e.g., background is turbid red color)0 is no RBC agglutination; background is smooth turbid red without any \"chunkiness\"",
                      "Test can be performed with or without potentiators or substances that favor agglutination of RBCsPEG excludes water from around RBC and therefore concentrates antibodies around RBCAlbumin and LISS neutralize RBC-negative zeta potential that normally repels RBC from each other",
                      "PEG excludes water from around RBC and therefore concentrates antibodies around RBC",
                      "Albumin and LISS neutralize RBC-negative zeta potential that normally repels RBC from each other",
                      "Reagent RBCs are allowed to incubate at 37°C with patient plasma or serum (with or without antibodies)",
                      "After incubation, unbound patient antibodies are washed off",
                      "Red cell-bound antibodies are detected using anti-IgG (AHG or Coombs reagent) and observed for red cell agglutination",
                      "Grading schema for agglutination when using tube technique4+ is all RBC forming one solid agglutinate (e.g., background is clear)3+ is RBC forming several large agglutinates (e.g., background is clear)2+ is RBC forming medium-sized agglutinates (e.g., background is clear)1+ is most RBC forming small-sized agglutinates (e.g., background is turbid red color)0 is no RBC agglutination; background is smooth turbid red without any \"chunkiness\"",
                      "4+ is all RBC forming one solid agglutinate (e.g., background is clear)",
                      "3+ is RBC forming several large agglutinates (e.g., background is clear)",
                      "2+ is RBC forming medium-sized agglutinates (e.g., background is clear)",
                      "1+ is most RBC forming small-sized agglutinates (e.g., background is turbid red color)",
                      "0 is no RBC agglutination; background is smooth turbid red without any \"chunkiness\"",
                      "Gel testingReagent RBCs are allowed to interact with patient plasma or serum at top of column filled with gel matrix or beadsAfter incubation, centrifugation step forces red cells into column mediaAgglutinated red cells will be unable to move deeply into gel matrix due to size and will stay at top of column (positive test)Free red cells will be able to move deeply into gel matrix and will fall to bottom of column (negative test)Gel reactions are stable up to 24 hours and can be reviewed at later time by other staff or supervisors",
                      "Reagent RBCs are allowed to interact with patient plasma or serum at top of column filled with gel matrix or beads",
                      "After incubation, centrifugation step forces red cells into column media",
                      "Agglutinated red cells will be unable to move deeply into gel matrix due to size and will stay at top of column (positive test)Free red cells will be able to move deeply into gel matrix and will fall to bottom of column (negative test)",
                      "Free red cells will be able to move deeply into gel matrix and will fall to bottom of column (negative test)",
                      "Gel reactions are stable up to 24 hours and can be reviewed at later time by other staff or supervisors",
                      "Solid phase testing (does not require detection of red cell agglutination)Intact red cells or red cell membranes of known phenotype are immobilized to microplate wells, and patient serum or plasma is addedAfter incubation, unbound patient antibodies are washed offRed cell-bound antibodies are detected using anti-IgG-coated indicator red cellsPositive result is reported if indicator red cells adhere diffusely over wellWell reactions can be photographed or scanned electronically and can be reviewed at later time by other staff or supervisors",
                      "Intact red cells or red cell membranes of known phenotype are immobilized to microplate wells, and patient serum or plasma is added",
                      "After incubation, unbound patient antibodies are washed off",
                      "Red cell-bound antibodies are detected using anti-IgG-coated indicator red cells",
                      "Positive result is reported if indicator red cells adhere diffusely over well",
                      "Well reactions can be photographed or scanned electronically and can be reviewed at later time by other staff or supervisors"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Antibody screening is required, with new patient sample every 3 days when there is history of transfusion or pregnancy in past 3 months"
                  },
                  {
                    "text": "Patient samples must be retained for 7 days after transfusion in blood bank"
                  }
                ],
                "Proficiency Testing": [
                  {
                    "text": "Proficiency testing for immunohematology encompasses ABO/Rh typing, unexpected antibody detection, compatibility testing, and antibody identificationTransfusion services are required to achieve 100% score in order to have satisfactory performance",
                    "sub_points": [
                      "Transfusion services are required to achieve 100% score in order to have satisfactory performance"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Direct Antibody Testing and Elutions": {
            "name": "Direct Antibody Testing and Elutions",
            "url": "https://app.pathprimer.com/document/923e7f3a-1092-447b-9518-4020c915f28c/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "DAT detects antibodies or complement coating patient or recently transfused red cells"
                  },
                  {
                    "text": "Eluate is performed when DAT is positive for IgG defines specificity of IgG antibody coating cells"
                  },
                  {
                    "text": "Clinical significance of positive DAT is determined by analysis of hemolysis laboratory results (i.e., complete blood count, haptoglobin, lactate dehydrogenase) and clinical context"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antihuman globulin (AHG)"
                  },
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Test Methodology": [
                  {
                    "text": "DAT: Detects antibodies or complement coating patient or recently transfused red cellsSpecimen: Patient blood sample in EDTA (prevents complement fixation in collection tube)Step 1: Incubate patient red cells with polyspecific AHG that binds IgG and C3Positive test: Patient red cells visually agglutinateStep 2: If step 1 is positive, incubate patient red cells with monospecific AHG: (1) anti-IgG only and (2) anti-C3 onlyPositive test: Patient red cells visually agglutinatePositive agglutination with anti-IgG reagent implies IgG is coating patient red cells, and eluate procedure is subsequently performedControl steps6% albumin or saline without AHG (negative control): If positive, test is invalid as it implies spontaneous red cell agglutinationCheck red cells (positive control): Used to validate that AHG reagent is actually working (when results are negative); if negative, test is invalid",
                    "sub_points": [
                      "Specimen: Patient blood sample in EDTA (prevents complement fixation in collection tube)Step 1: Incubate patient red cells with polyspecific AHG that binds IgG and C3Positive test: Patient red cells visually agglutinateStep 2: If step 1 is positive, incubate patient red cells with monospecific AHG: (1) anti-IgG only and (2) anti-C3 onlyPositive test: Patient red cells visually agglutinatePositive agglutination with anti-IgG reagent implies IgG is coating patient red cells, and eluate procedure is subsequently performedControl steps6% albumin or saline without AHG (negative control): If positive, test is invalid as it implies spontaneous red cell agglutinationCheck red cells (positive control): Used to validate that AHG reagent is actually working (when results are negative); if negative, test is invalid",
                      "Step 1: Incubate patient red cells with polyspecific AHG that binds IgG and C3Positive test: Patient red cells visually agglutinate",
                      "Positive test: Patient red cells visually agglutinate",
                      "Step 2: If step 1 is positive, incubate patient red cells with monospecific AHG: (1) anti-IgG only and (2) anti-C3 onlyPositive test: Patient red cells visually agglutinatePositive agglutination with anti-IgG reagent implies IgG is coating patient red cells, and eluate procedure is subsequently performed",
                      "Positive test: Patient red cells visually agglutinate",
                      "Positive agglutination with anti-IgG reagent implies IgG is coating patient red cells, and eluate procedure is subsequently performed",
                      "Control steps6% albumin or saline without AHG (negative control): If positive, test is invalid as it implies spontaneous red cell agglutinationCheck red cells (positive control): Used to validate that AHG reagent is actually working (when results are negative); if negative, test is invalid",
                      "6% albumin or saline without AHG (negative control): If positive, test is invalid as it implies spontaneous red cell agglutination",
                      "Check red cells (positive control): Used to validate that AHG reagent is actually working (when results are negative); if negative, test is invalid"
                    ]
                  },
                  {
                    "text": "Eluate: Defines red cell specificity of IgG antibody detected in positive DATAntibodies are removed/separated from red cell using various techniquesAcid elution is commonly used to identify warm autoantibodies and alloantibodiesChemical/organic solvents are used for warm autoantibodies and alloantibodiesFreeze-thaw techniques are used for ABO hemolytic disease of fetus and newbornHeat techniques are used for IgM detection and ABO hemolytic disease of fetus and newbornRemoved antibodies are then used for antibody identification using same techniques used to test plasma (indirect antiglobulin techniques)Results of eluate are helpful in distinguishing between hemolytic transfusion reactions, drug-induced hemolysis, and warm immune hemolysis",
                    "sub_points": [
                      "Antibodies are removed/separated from red cell using various techniquesAcid elution is commonly used to identify warm autoantibodies and alloantibodiesChemical/organic solvents are used for warm autoantibodies and alloantibodiesFreeze-thaw techniques are used for ABO hemolytic disease of fetus and newbornHeat techniques are used for IgM detection and ABO hemolytic disease of fetus and newborn",
                      "Acid elution is commonly used to identify warm autoantibodies and alloantibodies",
                      "Chemical/organic solvents are used for warm autoantibodies and alloantibodies",
                      "Freeze-thaw techniques are used for ABO hemolytic disease of fetus and newborn",
                      "Heat techniques are used for IgM detection and ABO hemolytic disease of fetus and newborn",
                      "Removed antibodies are then used for antibody identification using same techniques used to test plasma (indirect antiglobulin techniques)Results of eluate are helpful in distinguishing between hemolytic transfusion reactions, drug-induced hemolysis, and warm immune hemolysis",
                      "Results of eluate are helpful in distinguishing between hemolytic transfusion reactions, drug-induced hemolysis, and warm immune hemolysis"
                    ]
                  }
                ],
                "Interpretation of Test Results": [
                  {
                    "text": "Causes of positive DATClinically significant causesWarm autoimmune hemolytic anemiaDrug-induced hemolytic anemia (all forms)Acute or delayed hemolytic transfusion reactionsCold agglutinin diseaseParoxysmal cold hemoglobinuriaHemolytic disease of fetus and newbornPassenger lymphocyte syndromePassively transfused clinically significant antibodies (causes hemolysis) in plasma (from plasma/platelets, Rh immune globulin, or IVIG)Clinically insignificant causes (false-positives)Healthy individuals sometimes have positive DATs without evidence of hemolysis (1:1000-14,000 of healthy donors have positive test)Hospitalized patients sometimes have positive DATs without evidence of hemolysis (1:6-100 have positive test)Associated diseases: Sickle cell disease, β-thalassemia, renal disease, multiple myeloma, autoimmune disorders, HIV, etc.Passively transfused antibodies in plasma (from plasma, Rh immune globulin, or IVIG)—rarely can be significant (see above)",
                    "sub_points": [
                      "Clinically significant causesWarm autoimmune hemolytic anemiaDrug-induced hemolytic anemia (all forms)Acute or delayed hemolytic transfusion reactionsCold agglutinin diseaseParoxysmal cold hemoglobinuriaHemolytic disease of fetus and newbornPassenger lymphocyte syndromePassively transfused clinically significant antibodies (causes hemolysis) in plasma (from plasma/platelets, Rh immune globulin, or IVIG)",
                      "Warm autoimmune hemolytic anemia",
                      "Drug-induced hemolytic anemia (all forms)",
                      "Acute or delayed hemolytic transfusion reactions",
                      "Cold agglutinin disease",
                      "Paroxysmal cold hemoglobinuria",
                      "Hemolytic disease of fetus and newborn",
                      "Passenger lymphocyte syndrome",
                      "Passively transfused clinically significant antibodies (causes hemolysis) in plasma (from plasma/platelets, Rh immune globulin, or IVIG)",
                      "Clinically insignificant causes (false-positives)Healthy individuals sometimes have positive DATs without evidence of hemolysis (1:1000-14,000 of healthy donors have positive test)Hospitalized patients sometimes have positive DATs without evidence of hemolysis (1:6-100 have positive test)Associated diseases: Sickle cell disease, β-thalassemia, renal disease, multiple myeloma, autoimmune disorders, HIV, etc.Passively transfused antibodies in plasma (from plasma, Rh immune globulin, or IVIG)—rarely can be significant (see above)",
                      "Healthy individuals sometimes have positive DATs without evidence of hemolysis (1:1000-14,000 of healthy donors have positive test)",
                      "Hospitalized patients sometimes have positive DATs without evidence of hemolysis (1:6-100 have positive test)Associated diseases: Sickle cell disease, β-thalassemia, renal disease, multiple myeloma, autoimmune disorders, HIV, etc.",
                      "Associated diseases: Sickle cell disease, β-thalassemia, renal disease, multiple myeloma, autoimmune disorders, HIV, etc.",
                      "Passively transfused antibodies in plasma (from plasma, Rh immune globulin, or IVIG)—rarely can be significant (see above)"
                    ]
                  },
                  {
                    "text": "Causes of false-negative DATImmune-mediated hemolysis is from IgA antibodyImmune-mediated hemolysis is from IgG or IgM antibody that is low titer or weak agglutininTest was done incorrectlyIncorrect washingResuspensionDelayed testing (sample sat around for too long)",
                    "sub_points": [
                      "Immune-mediated hemolysis is from IgA antibody",
                      "Immune-mediated hemolysis is from IgG or IgM antibody that is low titer or weak agglutinin",
                      "Test was done incorrectlyIncorrect washingResuspensionDelayed testing (sample sat around for too long)",
                      "Incorrect washing",
                      "Resuspension",
                      "Delayed testing (sample sat around for too long)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Antibody Panels for Identification of Alloantibodies and Autoantibodies": {
            "name": "Antibody Panels for Identification of Alloantibodies and Autoantibodies",
            "url": "https://app.pathprimer.com/document/fdb9267a-137b-4ded-8ac9-4848401a3223/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Identification of antibody to RBC antigen requires testing of patient's plasma against panel of selected RBCs"
                  },
                  {
                    "text": "Systematic approach is required for correct antibody panel interpretation"
                  }
                ]
              },
              "OVERVIEW": {
                "Antibody Identification Panel (General)": [
                  {
                    "text": "Identification of antibody to RBC antigen requires testing of patient's plasma against panel of selected RBC samples"
                  },
                  {
                    "text": "Typically, 8-14 reagent RBCs are used, with known antigenic composition for major blood groupsRh, Kell, Kidd, Duffy, and MNS are known for each RBC used and represented in panelReagent RBCs are usually from commercial supplierRBCs are usually blood group O to avoid influence of anti-A or anti-B in patient sampleCells are specifically selected to allow for identification of single antibody specificity with exclusion of most others",
                    "sub_points": [
                      "Rh, Kell, Kidd, Duffy, and MNS are known for each RBC used and represented in panel",
                      "Reagent RBCs are usually from commercial supplier",
                      "RBCs are usually blood group O to avoid influence of anti-A or anti-B in patient sample",
                      "Cells are specifically selected to allow for identification of single antibody specificity with exclusion of most others"
                    ]
                  }
                ],
                "Panel Testing Specifics": [
                  {
                    "text": "For panel test, it is common to use same methodology that was used for antibody screen test (tube, gel, or solid phase)"
                  },
                  {
                    "text": "Panel test has 3 phasesImmediate spin phaseLooking for agglutination at room temperature helps detect IgM or cold-reacting antibodies (anti-M, N, P1, Lea, Leb)Many omit this phase because most antibodies detected at room temperature are not clinically significantClinically significant anti-Vel and IgM anti-Fya are important exceptions here37°C phaseLooking for agglutination after 37°C incubation, but before addition of AHG reagent (Coombs reagent), helps detect IgG antibodies that can cause direct agglutination (anti-D, E, K, or Jk can do this)Many omit this phase, because most antibodies detected here will also be detected after addition of AHG reagentAHG (Coombs) phaseLooking for agglutination after 37°C incubation and after addition of AHG reagent (Coombs reagent) detects most of clinically significant antibodies present in patient plasmaImportant note: Automated techniques only detect antibodies in this phase",
                    "sub_points": [
                      "Immediate spin phaseLooking for agglutination at room temperature helps detect IgM or cold-reacting antibodies (anti-M, N, P1, Lea, Leb)Many omit this phase because most antibodies detected at room temperature are not clinically significantClinically significant anti-Vel and IgM anti-Fya are important exceptions here",
                      "Looking for agglutination at room temperature helps detect IgM or cold-reacting antibodies (anti-M, N, P1, Lea, Leb)",
                      "Many omit this phase because most antibodies detected at room temperature are not clinically significantClinically significant anti-Vel and IgM anti-Fya are important exceptions here",
                      "Clinically significant anti-Vel and IgM anti-Fya are important exceptions here",
                      "37°C phaseLooking for agglutination after 37°C incubation, but before addition of AHG reagent (Coombs reagent), helps detect IgG antibodies that can cause direct agglutination (anti-D, E, K, or Jk can do this)Many omit this phase, because most antibodies detected here will also be detected after addition of AHG reagent",
                      "Looking for agglutination after 37°C incubation, but before addition of AHG reagent (Coombs reagent), helps detect IgG antibodies that can cause direct agglutination (anti-D, E, K, or Jk can do this)",
                      "Many omit this phase, because most antibodies detected here will also be detected after addition of AHG reagent",
                      "AHG (Coombs) phaseLooking for agglutination after 37°C incubation and after addition of AHG reagent (Coombs reagent) detects most of clinically significant antibodies present in patient plasmaImportant note: Automated techniques only detect antibodies in this phase",
                      "Looking for agglutination after 37°C incubation and after addition of AHG reagent (Coombs reagent) detects most of clinically significant antibodies present in patient plasma",
                      "Important note: Automated techniques only detect antibodies in this phase"
                    ]
                  },
                  {
                    "text": "Use of selected cell panelsNot necessary to reconfirm previously identified antibodiesSelecting cells known negative for previously detected antibodies allows for detection of new alloantibodies while reducing amount of testing required",
                    "sub_points": [
                      "Not necessary to reconfirm previously identified antibodies",
                      "Selecting cells known negative for previously detected antibodies allows for detection of new alloantibodies while reducing amount of testing required"
                    ]
                  },
                  {
                    "text": "Complex antibody identification may require use of additional tools described in detail in other sectionsEnhancement media (e.g., PEG or LISS)Enzyme or chemical treatment (e.g., Ficin or DTT)Neutralization (e.g., urine or saliva)Adsorption (e.g., autoadsorption or alloadsorption)Prewarming techniqueRequires warming both patient's serum and reagent RBCs to 37°C before mixing them togetherHelpful in removing cold antibodies that react at AHG phase due to reactivity carried over from room temperature phase of testing",
                    "sub_points": [
                      "Enhancement media (e.g., PEG or LISS)",
                      "Enzyme or chemical treatment (e.g., Ficin or DTT)",
                      "Neutralization (e.g., urine or saliva)",
                      "Adsorption (e.g., autoadsorption or alloadsorption)",
                      "Prewarming techniqueRequires warming both patient's serum and reagent RBCs to 37°C before mixing them togetherHelpful in removing cold antibodies that react at AHG phase due to reactivity carried over from room temperature phase of testing",
                      "Requires warming both patient's serum and reagent RBCs to 37°C before mixing them together",
                      "Helpful in removing cold antibodies that react at AHG phase due to reactivity carried over from room temperature phase of testing"
                    ]
                  }
                ],
                "Antibody Panel Identification": [
                  {
                    "text": "Interpretation of panel resultsAgglutination is interpreted based on reaction strength and given number from 0 (no agglutination) to 4+ (strongest agglutination reaction)Positive results may be from clinically insignificant sources, and negative results may miss rare, clinically significant, antibodies",
                    "sub_points": [
                      "Agglutination is interpreted based on reaction strength and given number from 0 (no agglutination) to 4+ (strongest agglutination reaction)",
                      "Positive results may be from clinically insignificant sources, and negative results may miss rare, clinically significant, antibodies"
                    ]
                  },
                  {
                    "text": "How to read panelStep 1: Check patient historySome previous conditions increase risk for red cell alloantibodiesPrevious pregnancyCertain diseases (e.g., mononucleosis or sickle cell disease)Previous transplantPrevious red cell transfusionsCertain medications, such as IVIG, RhIg, or new anti-CD38 (Daratumumab), increase chance for false-positive resultsPatient anemia may have immune cause, and clinical significance of panel results should be weighed against current clinical presentationStep 2: Review autocontrol (patient red cells tested against patient plasma)Positive autocontrol could imply autoantibody, alloantibody to recently transfused red cell unit, or drug-related antibodyWhen all cells, including autocontrol, are positive, warm autoantibody is likely (check direct antiglobulin test result for confirmation)Step 3: Use common rule-out methodologyStart with panel red cells where no reaction is seenExclude antibodies when antigen is present (in homozygous form) on RBC but no reaction is seenPractical note: Kell (K) can be ruled out when heterozygous (Kk cells) RBC shows no agglutinationNext, review panel red cells where agglutination is presentUniform reaction strength usually means one antibody is presentVariable reaction strengths means more than one antibody is present or one antibody presents with dosage (stronger agglutination with homozygous cell: Common antigens with dosage include Kidd, Duffy, Rh, and MNS antigens)Reactions that differ by phase (immediate spin vs. AHG phase) might imply multiple antibodies of different type (cold-IgM vs. warm-IgG antibody) is presentStep 4: To ensure that reactions are not due to chance, conclusive antibody identification requires that 2-3 cells are positive that have antigen in question, and 2-3 cells are negative that lack antigen in questionIf this criteria cannot be met, additional panel cells should be tested for confirmatory purposes",
                    "sub_points": [
                      "Step 1: Check patient historySome previous conditions increase risk for red cell alloantibodiesPrevious pregnancyCertain diseases (e.g., mononucleosis or sickle cell disease)Previous transplantPrevious red cell transfusionsCertain medications, such as IVIG, RhIg, or new anti-CD38 (Daratumumab), increase chance for false-positive resultsPatient anemia may have immune cause, and clinical significance of panel results should be weighed against current clinical presentation",
                      "Some previous conditions increase risk for red cell alloantibodiesPrevious pregnancyCertain diseases (e.g., mononucleosis or sickle cell disease)Previous transplantPrevious red cell transfusions",
                      "Previous pregnancy",
                      "Certain diseases (e.g., mononucleosis or sickle cell disease)",
                      "Previous transplant",
                      "Previous red cell transfusions",
                      "Certain medications, such as IVIG, RhIg, or new anti-CD38 (Daratumumab), increase chance for false-positive results",
                      "Patient anemia may have immune cause, and clinical significance of panel results should be weighed against current clinical presentation",
                      "Step 2: Review autocontrol (patient red cells tested against patient plasma)Positive autocontrol could imply autoantibody, alloantibody to recently transfused red cell unit, or drug-related antibodyWhen all cells, including autocontrol, are positive, warm autoantibody is likely (check direct antiglobulin test result for confirmation)",
                      "Positive autocontrol could imply autoantibody, alloantibody to recently transfused red cell unit, or drug-related antibody",
                      "When all cells, including autocontrol, are positive, warm autoantibody is likely (check direct antiglobulin test result for confirmation)",
                      "Step 3: Use common rule-out methodologyStart with panel red cells where no reaction is seenExclude antibodies when antigen is present (in homozygous form) on RBC but no reaction is seenPractical note: Kell (K) can be ruled out when heterozygous (Kk cells) RBC shows no agglutinationNext, review panel red cells where agglutination is presentUniform reaction strength usually means one antibody is presentVariable reaction strengths means more than one antibody is present or one antibody presents with dosage (stronger agglutination with homozygous cell: Common antigens with dosage include Kidd, Duffy, Rh, and MNS antigens)Reactions that differ by phase (immediate spin vs. AHG phase) might imply multiple antibodies of different type (cold-IgM vs. warm-IgG antibody) is present",
                      "Start with panel red cells where no reaction is seenExclude antibodies when antigen is present (in homozygous form) on RBC but no reaction is seenPractical note: Kell (K) can be ruled out when heterozygous (Kk cells) RBC shows no agglutination",
                      "Exclude antibodies when antigen is present (in homozygous form) on RBC but no reaction is seen",
                      "Practical note: Kell (K) can be ruled out when heterozygous (Kk cells) RBC shows no agglutination",
                      "Next, review panel red cells where agglutination is presentUniform reaction strength usually means one antibody is presentVariable reaction strengths means more than one antibody is present or one antibody presents with dosage (stronger agglutination with homozygous cell: Common antigens with dosage include Kidd, Duffy, Rh, and MNS antigens)Reactions that differ by phase (immediate spin vs. AHG phase) might imply multiple antibodies of different type (cold-IgM vs. warm-IgG antibody) is present",
                      "Uniform reaction strength usually means one antibody is present",
                      "Variable reaction strengths means more than one antibody is present or one antibody presents with dosage (stronger agglutination with homozygous cell: Common antigens with dosage include Kidd, Duffy, Rh, and MNS antigens)",
                      "Reactions that differ by phase (immediate spin vs. AHG phase) might imply multiple antibodies of different type (cold-IgM vs. warm-IgG antibody) is present",
                      "Step 4: To ensure that reactions are not due to chance, conclusive antibody identification requires that 2-3 cells are positive that have antigen in question, and 2-3 cells are negative that lack antigen in questionIf this criteria cannot be met, additional panel cells should be tested for confirmatory purposes",
                      "If this criteria cannot be met, additional panel cells should be tested for confirmatory purposes"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Anti-human globulin (AHG)"
                  },
                  {
                    "text": "Dithiothreitol (DTT)"
                  },
                  {
                    "text": "Low-ionic-strength solution (LISS)"
                  },
                  {
                    "text": "Polyethylene glycol (PEG)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Molecular DNA-Based Blood Group Typing": {
            "name": "Molecular DNA-Based Blood Group Typing",
            "url": "https://app.pathprimer.com/document/bb09302f-0830-41bc-9756-66552d6087e7/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Use of molecular methods for blood group typing can be especially beneficial in patients who have been recently transfused or have autoantibodies"
                  },
                  {
                    "text": "Molecular methods have become increasingly automated but can only predict patient's actual blood group phenotype"
                  }
                ]
              },
              "OVERVIEW": {
                "Identification": [
                  {
                    "text": "Patient red cell blood group antigen identification can be very importantCan help determine if patient lacks antigen that corresponds to tentatively identified antibodyCan help avoid transfusion of incompatible antigens in cases where antibody detection is limited",
                    "sub_points": [
                      "Can help determine if patient lacks antigen that corresponds to tentatively identified antibody",
                      "Can help avoid transfusion of incompatible antigens in cases where antibody detection is limited"
                    ]
                  }
                ],
                "Benefits of Molecular Methods": [
                  {
                    "text": "Use of molecular methods for blood group typing is especially beneficial in certain situationsWhen patient has been recently transfusedWhen patient's red cells are heavily coated with IgG",
                    "sub_points": [
                      "When patient has been recently transfused",
                      "When patient's red cells are heavily coated with IgG"
                    ]
                  }
                ],
                "Limitations": [
                  {
                    "text": "Use of molecular methods for blood group typing remains somewhat limitedMutations exist where molecular results do not predict actual red cell serology (e.g., rare or new alleles, inactivating mutations, etc.)genotype does not always equal phenotypeStem cell transplant recipients can have red cell alleles that genetically differ between donor and recipientGenes that code for enzymes (i.e., ABO) are complex and often require gene sequencing",
                    "sub_points": [
                      "Mutations exist where molecular results do not predict actual red cell serology (e.g., rare or new alleles, inactivating mutations, etc.)genotype does not always equal phenotype",
                      "genotype does not always equal phenotype",
                      "Stem cell transplant recipients can have red cell alleles that genetically differ between donor and recipient",
                      "Genes that code for enzymes (i.e., ABO) are complex and often require gene sequencing"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Dithiothreitol (DTT)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  },
                  {
                    "text": "Single nucleotide gene polymorphism (SNP)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Blood Group Typing by Serology (Gold Standard Test)": [
                  {
                    "text": "Requires suspension of patient RBCs as well as reagent antisera that is specific for allele of interest"
                  },
                  {
                    "text": "Red cell agglutination after incubation implies that patient has red cell antigen of interestBlood group serology post-transfusion (interpret these results with caution)Pre-transfusion blood specimens, if available, are preferable for testingCentrifugation of fresh post-transfusion (best after 3 days post-transfusion) sample may allow for improved blood group typing, due to density differences between new (patient) and older (transfused) red cellsBlood group serology in patients with strong warm/cold autoantibodiesSerology may be possible if antibody can be removed from red cell (interpret these results with caution)DTT or warm saline washes for IgM cold antibodiesGentle heat elution, treatment with chloroquine diphosphate, or treatment with acid glycine/EDTA for IgG warm antibodies",
                    "sub_points": [
                      "Blood group serology post-transfusion (interpret these results with caution)Pre-transfusion blood specimens, if available, are preferable for testingCentrifugation of fresh post-transfusion (best after 3 days post-transfusion) sample may allow for improved blood group typing, due to density differences between new (patient) and older (transfused) red cells",
                      "Pre-transfusion blood specimens, if available, are preferable for testing",
                      "Centrifugation of fresh post-transfusion (best after 3 days post-transfusion) sample may allow for improved blood group typing, due to density differences between new (patient) and older (transfused) red cells",
                      "Blood group serology in patients with strong warm/cold autoantibodiesSerology may be possible if antibody can be removed from red cell (interpret these results with caution)DTT or warm saline washes for IgM cold antibodiesGentle heat elution, treatment with chloroquine diphosphate, or treatment with acid glycine/EDTA for IgG warm antibodies",
                      "Serology may be possible if antibody can be removed from red cell (interpret these results with caution)DTT or warm saline washes for IgM cold antibodiesGentle heat elution, treatment with chloroquine diphosphate, or treatment with acid glycine/EDTA for IgG warm antibodies",
                      "DTT or warm saline washes for IgM cold antibodies",
                      "Gentle heat elution, treatment with chloroquine diphosphate, or treatment with acid glycine/EDTA for IgG warm antibodies"
                    ]
                  }
                ],
                "Blood Group Typing by Molecular Methods": [
                  {
                    "text": "Most blood group antigens result from SNPs inherited in mendelian mannerABO and Rh genes are much more complex and make genetic interpretations of predicted phenotype much more difficultResults of molecular blood group typing techniques are reported as predicted red cell phenotype",
                    "sub_points": [
                      "ABO and Rh genes are much more complex and make genetic interpretations of predicted phenotype much more difficult",
                      "Results of molecular blood group typing techniques are reported as predicted red cell phenotype"
                    ]
                  },
                  {
                    "text": "Common manual methodsAllele-specific PCRTwo reactions are performed, with primers specific for each of 2 allelesPCR-restriction fragment length polymorphismUseful for alleles when polymorphism in question has loss or gain of restriction enzyme recognition siteGene sequencing (exon specific or cDNA methods)Useful to determine novel alleles or mutations",
                    "sub_points": [
                      "Allele-specific PCRTwo reactions are performed, with primers specific for each of 2 alleles",
                      "Two reactions are performed, with primers specific for each of 2 alleles",
                      "PCR-restriction fragment length polymorphismUseful for alleles when polymorphism in question has loss or gain of restriction enzyme recognition site",
                      "Useful for alleles when polymorphism in question has loss or gain of restriction enzyme recognition site",
                      "Gene sequencing (exon specific or cDNA methods)Useful to determine novel alleles or mutations",
                      "Useful to determine novel alleles or mutations"
                    ]
                  },
                  {
                    "text": "Common automated molecular methodsReal-time PCRAutomated technique that uses sequence-specific fluorescent probes (TacMan) that bind to target SNP of interestTarget locus of interest is amplified; DNA polymerase used encounters bound TacMan and degrades itDegraded TacMan allows reporter to fluoresce, allowing qualitative and quantitative analysis of allele of interestAmount of fluorescence is directly proportional to amount of PCR product obtainedBead multiplex assayAutomated technique that uses multiple fluorescent beads with allele-specific capture probes to target multiple different patient SNPsAmplified patient DNA fragments are incubated with these beads and are allowed to anneal and elongate to probes using labeled nucleotidesBeads and associated signals are analyzed by flow cytometer",
                    "sub_points": [
                      "Real-time PCRAutomated technique that uses sequence-specific fluorescent probes (TacMan) that bind to target SNP of interestTarget locus of interest is amplified; DNA polymerase used encounters bound TacMan and degrades itDegraded TacMan allows reporter to fluoresce, allowing qualitative and quantitative analysis of allele of interestAmount of fluorescence is directly proportional to amount of PCR product obtained",
                      "Automated technique that uses sequence-specific fluorescent probes (TacMan) that bind to target SNP of interest",
                      "Target locus of interest is amplified; DNA polymerase used encounters bound TacMan and degrades itDegraded TacMan allows reporter to fluoresce, allowing qualitative and quantitative analysis of allele of interestAmount of fluorescence is directly proportional to amount of PCR product obtained",
                      "Degraded TacMan allows reporter to fluoresce, allowing qualitative and quantitative analysis of allele of interest",
                      "Amount of fluorescence is directly proportional to amount of PCR product obtained",
                      "Bead multiplex assayAutomated technique that uses multiple fluorescent beads with allele-specific capture probes to target multiple different patient SNPsAmplified patient DNA fragments are incubated with these beads and are allowed to anneal and elongate to probes using labeled nucleotidesBeads and associated signals are analyzed by flow cytometer",
                      "Automated technique that uses multiple fluorescent beads with allele-specific capture probes to target multiple different patient SNPs",
                      "Amplified patient DNA fragments are incubated with these beads and are allowed to anneal and elongate to probes using labeled nucleotides",
                      "Beads and associated signals are analyzed by flow cytometer"
                    ]
                  },
                  {
                    "text": "Current transfusion service applications of molecular blood group methodsDetermining blood group in recently transfused patientDetermining blood group in patient with immunoglobulin coated red cellsDetermining Rh/D status of patient when unclear (especially pregnant patient)Determining allo-antibodies versus auto-antibodies when antibody specificity is notedDetermining blood groups for patients with sickle cell disease who need chronic transfusion therapyDetermining blood groups for fetus in utero by amniocentesis (for risk determination of hemolytic disease of fetus and newborn)Determining patient with Mcleod syndrome",
                    "sub_points": [
                      "Determining blood group in recently transfused patient",
                      "Determining blood group in patient with immunoglobulin coated red cells",
                      "Determining Rh/D status of patient when unclear (especially pregnant patient)",
                      "Determining allo-antibodies versus auto-antibodies when antibody specificity is noted",
                      "Determining blood groups for patients with sickle cell disease who need chronic transfusion therapy",
                      "Determining blood groups for fetus in utero by amniocentesis (for risk determination of hemolytic disease of fetus and newborn)",
                      "Determining patient with Mcleod syndrome"
                    ]
                  },
                  {
                    "text": "Current donor center applications of molecular blood group methodsTyping of antigens where no commercial serology reagents exist (e.g., Dombrock)Determine D type of donorsScreening donors for rare antigens or specific antigen combinations",
                    "sub_points": [
                      "Typing of antigens where no commercial serology reagents exist (e.g., Dombrock)",
                      "Determine D type of donors",
                      "Screening donors for rare antigens or specific antigen combinations"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Compatibility Testing and Selection of Compatible Red Blood Cell Units": {
            "name": "Compatibility Testing and Selection of Compatible Red Blood Cell Units",
            "url": "https://app.pathprimer.com/document/0fbefa89-d803-4ca0-a645-585b23711365/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Compatibility testing involves crossmatch, which helps avoid ABO-incompatible and non-ABO red cell antigen-incompatible transfusions"
                  },
                  {
                    "text": "Major crossmatch methods are AHG, IS, and electronic"
                  },
                  {
                    "text": "Blood components should ideally be ABO-identical with transfusion recipient; when this is not possible, compatible units need to be selected"
                  }
                ]
              },
              "OVERVIEW": {
                "Compatibility Testing": [
                  {
                    "text": "Objective of compatibility testing is to demonstrate compatibility between antigens on donor blood product and recipient plasma before transfusion occurs"
                  },
                  {
                    "text": "Compatibility testing with patient is needed for blood components containing ≥ 2 mL of red cellsRBC unitsWhole bloodGranulocyte units",
                    "sub_points": [
                      "RBC units",
                      "Whole blood",
                      "Granulocyte units"
                    ]
                  },
                  {
                    "text": "Compatibility testing may be performed serologically or electronically (in specific situations)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Antihuman globulin (AHG)"
                  },
                  {
                    "text": "Immediate spin (IS)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Compatibility Testing (Crossmatch)": [
                  {
                    "text": "Major vs. minor crossmatchMajor crossmatch is incubation of patient plasma with donor RBCs to determine incompatibility of donor RBCs with recipient plasma antibodiesMinor crossmatch is incubation of patient RBCs with donor plasma to determine incompatibility of recipient RBCs with donor plasma antibodiesNot required or often performedWas used for whole-blood compatibility testing due to potential risk of incompatible donor plasma antibodies",
                    "sub_points": [
                      "Major crossmatch is incubation of patient plasma with donor RBCs to determine incompatibility of donor RBCs with recipient plasma antibodies",
                      "Minor crossmatch is incubation of patient RBCs with donor plasma to determine incompatibility of recipient RBCs with donor plasma antibodiesNot required or often performedWas used for whole-blood compatibility testing due to potential risk of incompatible donor plasma antibodies",
                      "Not required or often performed",
                      "Was used for whole-blood compatibility testing due to potential risk of incompatible donor plasma antibodies"
                    ]
                  },
                  {
                    "text": "Major crossmatch methodsAHG crossmatchRequired for patients with past or current history of non-ABO alloantibodiesUsed to detect incompatibility between patient's plasma and non-ABO and ABO antigens on donor RBCsAgglutination or hemolysis constitutes positive (incompatible) test resultAHG crossmatch can be performed using tube, gel, or solid phase methodologiesIS crossmatchDesigned to detect ABO incompatibility onlyDetects plasma antibodies that react at room temperatureAgglutination or hemolysis constitutes positive (incompatible) test resultMay detect clinically insignificant cold autoantibodies or rouleauxAdequate crossmatch method if patient has no previous history of clinically significant antibody and current antibody screen is negativeElectronic crossmatchAcceptable alternative to IS crossmatch for patients with no previous or current history of clinically significant antibodiesDesigned to prevent ABO incompatibilitySimilar to IS crossmatchTransfusion service can perform computer confirmation of ABO compatibility without any serologic testing whenTransfusion service has FDA-approved computer system that is validated on sitePatient/recipient has 2 determinations of ABO group on record in blood bank (one of which is current sample), negative antibody screen, and no past history of clinically significant antibodiesTransfusion service has method to verify correct entry of data before release of blood componentApproved computer system contains logic to alert user to discrepancies between donor and recipient ABO/RhApproved computer system contains and retains adequate donor (ID number, component name, ABO/Rh type) and patient information (ABO/Rh type, antibody screen results, compatibility results)",
                    "sub_points": [
                      "AHG crossmatchRequired for patients with past or current history of non-ABO alloantibodiesUsed to detect incompatibility between patient's plasma and non-ABO and ABO antigens on donor RBCsAgglutination or hemolysis constitutes positive (incompatible) test resultAHG crossmatch can be performed using tube, gel, or solid phase methodologies",
                      "Required for patients with past or current history of non-ABO alloantibodies",
                      "Used to detect incompatibility between patient's plasma and non-ABO and ABO antigens on donor RBCsAgglutination or hemolysis constitutes positive (incompatible) test resultAHG crossmatch can be performed using tube, gel, or solid phase methodologies",
                      "Agglutination or hemolysis constitutes positive (incompatible) test result",
                      "AHG crossmatch can be performed using tube, gel, or solid phase methodologies",
                      "IS crossmatchDesigned to detect ABO incompatibility onlyDetects plasma antibodies that react at room temperatureAgglutination or hemolysis constitutes positive (incompatible) test resultMay detect clinically insignificant cold autoantibodies or rouleauxAdequate crossmatch method if patient has no previous history of clinically significant antibody and current antibody screen is negative",
                      "Designed to detect ABO incompatibility only",
                      "Detects plasma antibodies that react at room temperatureAgglutination or hemolysis constitutes positive (incompatible) test resultMay detect clinically insignificant cold autoantibodies or rouleaux",
                      "Agglutination or hemolysis constitutes positive (incompatible) test result",
                      "May detect clinically insignificant cold autoantibodies or rouleaux",
                      "Adequate crossmatch method if patient has no previous history of clinically significant antibody and current antibody screen is negative",
                      "Electronic crossmatchAcceptable alternative to IS crossmatch for patients with no previous or current history of clinically significant antibodiesDesigned to prevent ABO incompatibilitySimilar to IS crossmatchTransfusion service can perform computer confirmation of ABO compatibility without any serologic testing whenTransfusion service has FDA-approved computer system that is validated on sitePatient/recipient has 2 determinations of ABO group on record in blood bank (one of which is current sample), negative antibody screen, and no past history of clinically significant antibodiesTransfusion service has method to verify correct entry of data before release of blood componentApproved computer system contains logic to alert user to discrepancies between donor and recipient ABO/RhApproved computer system contains and retains adequate donor (ID number, component name, ABO/Rh type) and patient information (ABO/Rh type, antibody screen results, compatibility results)",
                      "Acceptable alternative to IS crossmatch for patients with no previous or current history of clinically significant antibodies",
                      "Designed to prevent ABO incompatibilitySimilar to IS crossmatch",
                      "Similar to IS crossmatch",
                      "Transfusion service can perform computer confirmation of ABO compatibility without any serologic testing whenTransfusion service has FDA-approved computer system that is validated on sitePatient/recipient has 2 determinations of ABO group on record in blood bank (one of which is current sample), negative antibody screen, and no past history of clinically significant antibodiesTransfusion service has method to verify correct entry of data before release of blood componentApproved computer system contains logic to alert user to discrepancies between donor and recipient ABO/RhApproved computer system contains and retains adequate donor (ID number, component name, ABO/Rh type) and patient information (ABO/Rh type, antibody screen results, compatibility results)",
                      "Transfusion service has FDA-approved computer system that is validated on site",
                      "Patient/recipient has 2 determinations of ABO group on record in blood bank (one of which is current sample), negative antibody screen, and no past history of clinically significant antibodies",
                      "Transfusion service has method to verify correct entry of data before release of blood component",
                      "Approved computer system contains logic to alert user to discrepancies between donor and recipient ABO/Rh",
                      "Approved computer system contains and retains adequate donor (ID number, component name, ABO/Rh type) and patient information (ABO/Rh type, antibody screen results, compatibility results)"
                    ]
                  },
                  {
                    "text": "Labeling and release of blood components after crossmatchAt time of issue, following must occurFinal check of records is performed to ensure that all recipient information and transfusion requirements are consistent and correctTag or label is attached securely to unit with at least2 independent recipient identifiers (i.e., name and medical record number)Donor unit numberCompatibility testing results (if done)Confirmation that identifying information on request, records, and components matchConfirmation that unit color, integrity (no leaks), and outdate are acceptable",
                    "sub_points": [
                      "At time of issue, following must occurFinal check of records is performed to ensure that all recipient information and transfusion requirements are consistent and correctTag or label is attached securely to unit with at least2 independent recipient identifiers (i.e., name and medical record number)Donor unit numberCompatibility testing results (if done)Confirmation that identifying information on request, records, and components matchConfirmation that unit color, integrity (no leaks), and outdate are acceptable",
                      "Final check of records is performed to ensure that all recipient information and transfusion requirements are consistent and correct",
                      "Tag or label is attached securely to unit with at least2 independent recipient identifiers (i.e., name and medical record number)Donor unit numberCompatibility testing results (if done)",
                      "2 independent recipient identifiers (i.e., name and medical record number)",
                      "Donor unit number",
                      "Compatibility testing results (if done)",
                      "Confirmation that identifying information on request, records, and components match",
                      "Confirmation that unit color, integrity (no leaks), and outdate are acceptable"
                    ]
                  },
                  {
                    "text": "Special compatibility situationsEmergency bloodIn emergency situations, crossmatch does not need to be done and pretransfusion testing does not need to be completed before issuing bloodRecords must contain signed statement from ordering physician indicating that clinical situation was sufficiently urgent to bypass testingTag must clearly indicate that compatibility test was not completed at time of issuePretransfusion tests and compatibility tests must be completed as soon as possible after release of unitIf incompatibility is detected, ordering physician and transfusion service medical director should be immediately notifiedGroup O, D negative red cells are preferred when patient is woman of childbearing age (< 50 years old)ABO and D compatible units can be used if current blood sample has been completedNeonatesIf clinically significant, unexpected antibodies are not present, it is unnecessary to crossmatch RBC units for initial or subsequent transfusionsIf clinically significant antibodies of maternal origin are present, crossmatching is not required if antigen-negative blood is transfused",
                    "sub_points": [
                      "Emergency bloodIn emergency situations, crossmatch does not need to be done and pretransfusion testing does not need to be completed before issuing bloodRecords must contain signed statement from ordering physician indicating that clinical situation was sufficiently urgent to bypass testingTag must clearly indicate that compatibility test was not completed at time of issuePretransfusion tests and compatibility tests must be completed as soon as possible after release of unitIf incompatibility is detected, ordering physician and transfusion service medical director should be immediately notifiedGroup O, D negative red cells are preferred when patient is woman of childbearing age (< 50 years old)ABO and D compatible units can be used if current blood sample has been completed",
                      "In emergency situations, crossmatch does not need to be done and pretransfusion testing does not need to be completed before issuing bloodRecords must contain signed statement from ordering physician indicating that clinical situation was sufficiently urgent to bypass testingTag must clearly indicate that compatibility test was not completed at time of issuePretransfusion tests and compatibility tests must be completed as soon as possible after release of unitIf incompatibility is detected, ordering physician and transfusion service medical director should be immediately notified",
                      "Records must contain signed statement from ordering physician indicating that clinical situation was sufficiently urgent to bypass testing",
                      "Tag must clearly indicate that compatibility test was not completed at time of issue",
                      "Pretransfusion tests and compatibility tests must be completed as soon as possible after release of unit",
                      "If incompatibility is detected, ordering physician and transfusion service medical director should be immediately notified",
                      "Group O, D negative red cells are preferred when patient is woman of childbearing age (< 50 years old)ABO and D compatible units can be used if current blood sample has been completed",
                      "ABO and D compatible units can be used if current blood sample has been completed",
                      "NeonatesIf clinically significant, unexpected antibodies are not present, it is unnecessary to crossmatch RBC units for initial or subsequent transfusionsIf clinically significant antibodies of maternal origin are present, crossmatching is not required if antigen-negative blood is transfused",
                      "If clinically significant, unexpected antibodies are not present, it is unnecessary to crossmatch RBC units for initial or subsequent transfusions",
                      "If clinically significant antibodies of maternal origin are present, crossmatching is not required if antigen-negative blood is transfused"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Red Cell Component Selection": [
                  {
                    "text": "ABO compatibilityBlood components should ideally be ABO-identical with transfusion recipientWhen this is not possible, compatible units need to be selectedIn blood components containing ≥ 2 mL of red cells, donor red cells must be compatible with recipient's plasma",
                    "sub_points": [
                      "Blood components should ideally be ABO-identical with transfusion recipientWhen this is not possible, compatible units need to be selected",
                      "When this is not possible, compatible units need to be selected",
                      "In blood components containing ≥ 2 mL of red cells, donor red cells must be compatible with recipient's plasma"
                    ]
                  },
                  {
                    "text": "D compatibilityRBC-containing components should be matched for D-antigen (red cell, granulocyte, whole blood, and platelets)D-positive RBC-containing units can be considered for D-negative patients whenMedical urgency outweighs risk of anti-D formation (inadequate time to get D-negative product)Patient is not woman of childbearing age or patient who will need long-term/ongoing transfusion supportRisk of anti-D formation is lowApheresis platelet components have low riskPatients undergoing chemotherapy for malignancy have reduced riskRh factor immunoglobulin can be used in some situations to prevent anti-D formationHemolysis can result if exposed to large volume of D-positive red cells",
                    "sub_points": [
                      "RBC-containing components should be matched for D-antigen (red cell, granulocyte, whole blood, and platelets)",
                      "D-positive RBC-containing units can be considered for D-negative patients whenMedical urgency outweighs risk of anti-D formation (inadequate time to get D-negative product)Patient is not woman of childbearing age or patient who will need long-term/ongoing transfusion supportRisk of anti-D formation is lowApheresis platelet components have low riskPatients undergoing chemotherapy for malignancy have reduced risk",
                      "Medical urgency outweighs risk of anti-D formation (inadequate time to get D-negative product)",
                      "Patient is not woman of childbearing age or patient who will need long-term/ongoing transfusion support",
                      "Risk of anti-D formation is lowApheresis platelet components have low riskPatients undergoing chemotherapy for malignancy have reduced risk",
                      "Apheresis platelet components have low risk",
                      "Patients undergoing chemotherapy for malignancy have reduced risk",
                      "Rh factor immunoglobulin can be used in some situations to prevent anti-D formationHemolysis can result if exposed to large volume of D-positive red cells",
                      "Hemolysis can result if exposed to large volume of D-positive red cells"
                    ]
                  },
                  {
                    "text": "Other red cell antigensUsually not needed in nonalloimmunized patientsIn patients with known alloantibodies, corresponding antigen-negative units selected for compatibility testingProphylactic antigen matching (C, c, E, e, K, k) is often used for specific populationsSuch as patients with sickle cell disease",
                    "sub_points": [
                      "Usually not needed in nonalloimmunized patientsIn patients with known alloantibodies, corresponding antigen-negative units selected for compatibility testing",
                      "In patients with known alloantibodies, corresponding antigen-negative units selected for compatibility testing",
                      "Prophylactic antigen matching (C, c, E, e, K, k) is often used for specific populationsSuch as patients with sickle cell disease",
                      "Such as patients with sickle cell disease"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Adsorptions, Elutions, and Neutralizations": {
            "name": "Adsorptions, Elutions, and Neutralizations",
            "url": "https://app.pathprimer.com/document/acb46b54-090e-43dd-8a33-276fe617420d/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Additional techniques may be needed to define red cell antigen or antibody specificityAdsorption techniques remove serum antibodiesElution techniques remove antibodies that adhere to red cellsEnzymes and other substances can enhance, neutralize, or destroy red cell antigens/antibodies for diagnostic purposes",
                    "sub_points": [
                      "Adsorption techniques remove serum antibodies",
                      "Elution techniques remove antibodies that adhere to red cells",
                      "Enzymes and other substances can enhance, neutralize, or destroy red cell antigens/antibodies for diagnostic purposes"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Difficult Pretransfusion Testing Issues May Require Additional Specialized Techniques": [
                  {
                    "text": "AdsorptionProcess whereby antibody can be removed from serum sample onto red cells that express corresponding antigenAdsorption can be used for several purposesSeparating multiple antibodies present in single serum sampleRemoving autoantibodies to permit detection of underlying alloantibodiesRemoving unwanted antibodies from sample being prepared for reagent useConfirming presence of specific antigen or specificity of specific antibodyTechnique can use patient red cells (autoadsorption) or red cells with defined specificities (alloadsorption)",
                    "sub_points": [
                      "Process whereby antibody can be removed from serum sample onto red cells that express corresponding antigen",
                      "Adsorption can be used for several purposesSeparating multiple antibodies present in single serum sampleRemoving autoantibodies to permit detection of underlying alloantibodiesRemoving unwanted antibodies from sample being prepared for reagent useConfirming presence of specific antigen or specificity of specific antibody",
                      "Separating multiple antibodies present in single serum sample",
                      "Removing autoantibodies to permit detection of underlying alloantibodies",
                      "Removing unwanted antibodies from sample being prepared for reagent use",
                      "Confirming presence of specific antigen or specificity of specific antibody",
                      "Technique can use patient red cells (autoadsorption) or red cells with defined specificities (alloadsorption)"
                    ]
                  },
                  {
                    "text": "ElutionProcess whereby red cells are safely dissociated from attached red cell antibodies for further red cell or antibody testingMultiple techniques have been described, and no single method is best for all situationsHeat or freeze-thaw elution techniques are best for detection of HDFNAcid or organic solvent techniques are best for warm-reactive alloantibodies or autoantibodiesElution can be used for several purposesInvestigation of positive DAT (when IgG is detected)Concentration and purification of red cell antibodiesPreparation of antibody-free red cells for phenotyping or autoadsorptions (see above)",
                    "sub_points": [
                      "Process whereby red cells are safely dissociated from attached red cell antibodies for further red cell or antibody testing",
                      "Multiple techniques have been described, and no single method is best for all situationsHeat or freeze-thaw elution techniques are best for detection of HDFNAcid or organic solvent techniques are best for warm-reactive alloantibodies or autoantibodies",
                      "Heat or freeze-thaw elution techniques are best for detection of HDFN",
                      "Acid or organic solvent techniques are best for warm-reactive alloantibodies or autoantibodies",
                      "Elution can be used for several purposesInvestigation of positive DAT (when IgG is detected)Concentration and purification of red cell antibodiesPreparation of antibody-free red cells for phenotyping or autoadsorptions (see above)",
                      "Investigation of positive DAT (when IgG is detected)",
                      "Concentration and purification of red cell antibodies",
                      "Preparation of antibody-free red cells for phenotyping or autoadsorptions (see above)"
                    ]
                  },
                  {
                    "text": "Enhancement or neutralizationAddition of compounds to IAT can help remove or enhance certain antibodies for identification purposesEnzymesExamples: Ficin (from figs), papain (from papaya), bromelain (from pineapple)Cleaves RBC surface antigens (sialoglycoproteins) and can either destroy antigen or enhance reactivity to that antigenUseful in difficult antibody identificationsNeutralizing substancesActs by inhibiting activity of specific antibodiesUseful in difficult antibody identificationsSolutions that can denature red cell antigensThese solutions are often used to dissociate antibodies from red cell antigens for future red cell or antibody testing (not for their denaturing ability)0.01 M DTT is used to identify Ig type of antibodyExample: DTT can be used to remove anti-CD38 (i.e., daratumumab) from red cells for IAT testing, but Kell antibodies cannot be ruled out as resultLectinsExtracts from plants or seeds that react with certain RBC antigensUseful in diagnosis of polyagglutination",
                    "sub_points": [
                      "Addition of compounds to IAT can help remove or enhance certain antibodies for identification purposesEnzymesExamples: Ficin (from figs), papain (from papaya), bromelain (from pineapple)Cleaves RBC surface antigens (sialoglycoproteins) and can either destroy antigen or enhance reactivity to that antigenUseful in difficult antibody identificationsNeutralizing substancesActs by inhibiting activity of specific antibodiesUseful in difficult antibody identificationsSolutions that can denature red cell antigensThese solutions are often used to dissociate antibodies from red cell antigens for future red cell or antibody testing (not for their denaturing ability)0.01 M DTT is used to identify Ig type of antibodyExample: DTT can be used to remove anti-CD38 (i.e., daratumumab) from red cells for IAT testing, but Kell antibodies cannot be ruled out as resultLectinsExtracts from plants or seeds that react with certain RBC antigensUseful in diagnosis of polyagglutination",
                      "EnzymesExamples: Ficin (from figs), papain (from papaya), bromelain (from pineapple)Cleaves RBC surface antigens (sialoglycoproteins) and can either destroy antigen or enhance reactivity to that antigenUseful in difficult antibody identifications",
                      "Examples: Ficin (from figs), papain (from papaya), bromelain (from pineapple)",
                      "Cleaves RBC surface antigens (sialoglycoproteins) and can either destroy antigen or enhance reactivity to that antigen",
                      "Useful in difficult antibody identifications",
                      "Neutralizing substancesActs by inhibiting activity of specific antibodiesUseful in difficult antibody identifications",
                      "Acts by inhibiting activity of specific antibodies",
                      "Useful in difficult antibody identifications",
                      "Solutions that can denature red cell antigensThese solutions are often used to dissociate antibodies from red cell antigens for future red cell or antibody testing (not for their denaturing ability)0.01 M DTT is used to identify Ig type of antibodyExample: DTT can be used to remove anti-CD38 (i.e., daratumumab) from red cells for IAT testing, but Kell antibodies cannot be ruled out as result",
                      "These solutions are often used to dissociate antibodies from red cell antigens for future red cell or antibody testing (not for their denaturing ability)",
                      "0.01 M DTT is used to identify Ig type of antibody",
                      "Example: DTT can be used to remove anti-CD38 (i.e., daratumumab) from red cells for IAT testing, but Kell antibodies cannot be ruled out as result",
                      "LectinsExtracts from plants or seeds that react with certain RBC antigensUseful in diagnosis of polyagglutination",
                      "Extracts from plants or seeds that react with certain RBC antigens",
                      "Useful in diagnosis of polyagglutination"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  },
                  {
                    "text": "Dithiothreitol (DTT)"
                  },
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Indirect antiglobulin test (IAT)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pretransfusion Orders, Patient Specimens, and Issuing of Blood Products": {
            "name": "Pretransfusion Orders, Patient Specimens, and Issuing of Blood Products",
            "url": "https://app.pathprimer.com/document/3e1ef932-e810-4cd1-8f54-6da2fc726cf1/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Correct patient identification is critical for pretransfusion orders, patient specimens, and blood product issuing"
                  },
                  {
                    "text": "Type and screen differs from type and crossmatch in that only in type and crossmatch is unit assigned to patient"
                  }
                ]
              },
              "OVERVIEW": {
                "Pretransfusion Testing": [
                  {
                    "text": "Requires highly controlled process that maximizes patient and recipient safetyPretransfusion orders and blood product issuing protocols require correct identification of patient and patient specimensPretransfusion blood specimens have defined rules regarding how samples are collected and stored",
                    "sub_points": [
                      "Pretransfusion orders and blood product issuing protocols require correct identification of patient and patient specimens",
                      "Pretransfusion blood specimens have defined rules regarding how samples are collected and stored"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Pretransfusion Orders": [
                  {
                    "text": "Requests for blood may be submitted in oral, electronic, or written format"
                  },
                  {
                    "text": "Requests must contain sufficient information for accurate patient identificationAt least 2 patient identifiers are requiredi.e., patient's first and last name, hospital ID number, date of birth, patient driver's license number, photo ID, etc.Age and gender of patientKind and amount of component requestedSpecial transfusion requests, such as need for irradiationName of authorized ordering provider",
                    "sub_points": [
                      "At least 2 patient identifiers are requiredi.e., patient's first and last name, hospital ID number, date of birth, patient driver's license number, photo ID, etc.",
                      "i.e., patient's first and last name, hospital ID number, date of birth, patient driver's license number, photo ID, etc.",
                      "Age and gender of patient",
                      "Kind and amount of component requested",
                      "Special transfusion requests, such as need for irradiation",
                      "Name of authorized ordering provider"
                    ]
                  },
                  {
                    "text": "Hospitals are required to have written policy defining acceptance criteria for transfusion requests"
                  },
                  {
                    "text": "One of 2 types of pretransfusion orders are possibleType and screen requestTests performedABO/D typeAntibody screenAntibody panel (if needed)Test not performedCrossmatchUsed when transfusion need is not urgentPatient specimen is stored for future crossmatching if need arisesType and cross requestTests performedABO/D typeAntibody screenAntibody panel (if needed)Donor unit selectionRed cell crossmatchUsed when transfusion need is known or highly likelyLimitation: Selected unit is removed from general inventory and may not be available for use by other patients in timely manner",
                    "sub_points": [
                      "Type and screen requestTests performedABO/D typeAntibody screenAntibody panel (if needed)Test not performedCrossmatchUsed when transfusion need is not urgentPatient specimen is stored for future crossmatching if need arises",
                      "Tests performedABO/D typeAntibody screenAntibody panel (if needed)",
                      "ABO/D type",
                      "Antibody screen",
                      "Antibody panel (if needed)",
                      "Test not performedCrossmatch",
                      "Crossmatch",
                      "Used when transfusion need is not urgentPatient specimen is stored for future crossmatching if need arises",
                      "Patient specimen is stored for future crossmatching if need arises",
                      "Type and cross requestTests performedABO/D typeAntibody screenAntibody panel (if needed)Donor unit selectionRed cell crossmatchUsed when transfusion need is known or highly likelyLimitation: Selected unit is removed from general inventory and may not be available for use by other patients in timely manner",
                      "Tests performedABO/D typeAntibody screenAntibody panel (if needed)Donor unit selectionRed cell crossmatch",
                      "ABO/D type",
                      "Antibody screen",
                      "Antibody panel (if needed)",
                      "Donor unit selection",
                      "Red cell crossmatch",
                      "Used when transfusion need is known or highly likely",
                      "Limitation: Selected unit is removed from general inventory and may not be available for use by other patients in timely manner"
                    ]
                  }
                ],
                "Patient Specimen Requirements": [
                  {
                    "text": "Pretransfusion testing samples can be performed on either plasma or serumUse of grossly hemolyzed or lipemic specimens should be avoided",
                    "sub_points": [
                      "Use of grossly hemolyzed or lipemic specimens should be avoided"
                    ]
                  },
                  {
                    "text": "Specimen must be appropriately labeled for acceptance by blood bankNecessary informationTwo independent (clearly labeled) patient identifiersDate and time of collectionName of phlebotomist (e.g., phlebotomist initials on samples)Any ambiguity regarding sample or identifiers on specimen will result in specimen being rejected for testing",
                    "sub_points": [
                      "Necessary informationTwo independent (clearly labeled) patient identifiersDate and time of collectionName of phlebotomist (e.g., phlebotomist initials on samples)",
                      "Two independent (clearly labeled) patient identifiers",
                      "Date and time of collection",
                      "Name of phlebotomist (e.g., phlebotomist initials on samples)",
                      "Any ambiguity regarding sample or identifiers on specimen will result in specimen being rejected for testing"
                    ]
                  },
                  {
                    "text": "Information on pretransfusion orders must match identifiers on specimen itself, or specimen will be rejected"
                  },
                  {
                    "text": "Patient's blood specimen and samples of selected donor RBC must be stored in monitored refrigerator for at least 7 days after transfusion"
                  },
                  {
                    "text": "If specimen is to be used for crossmatching, it must have been collected within 3 days of requested transfusion eventExceptions to 3-day rulePatients with no transfusion or pregnancy in past 3 monthsRequests for plasma, platelets, or cryoprecipitate transfusions when ABO and D-typing are already on record",
                    "sub_points": [
                      "Exceptions to 3-day rulePatients with no transfusion or pregnancy in past 3 monthsRequests for plasma, platelets, or cryoprecipitate transfusions when ABO and D-typing are already on record",
                      "Patients with no transfusion or pregnancy in past 3 months",
                      "Requests for plasma, platelets, or cryoprecipitate transfusions when ABO and D-typing are already on record"
                    ]
                  }
                ],
                "Issuing of Blood Products": [
                  {
                    "text": "Required by transfusion service prior to any blood components being issued from blood bank for patientPlacement of tag or label with information on blood componentTwo independent patient identifiersDonor ID numberCompatibility testing results (if done)Final check of records is performed to verify details prior to release of blood product for patientTwo unique and correct patient identifiersPatient's ABO and D typeDonor unit ID numberDonor ABO and D typeResults of crossmatch (if done)Date and time of blood unit issueDonor unit's expiration date and timeSpecial transfusion requirements for unit (if applicable), such as use of irradiation or antigen-matchingInformation on blood request, medical records, and blood component all matchUnit must be inspected before issue and must have normal color, appearance, and not be leakingFinal identification of transfusion recipient and blood component is responsibility of transfusionist after blood has been issuedTwo-person verification process is usually required (Joint Commission requirement)Must verify agreement between patient at bedside and identifying information on forms, tags, and labels of unit about to be transfused",
                    "sub_points": [
                      "Placement of tag or label with information on blood componentTwo independent patient identifiersDonor ID numberCompatibility testing results (if done)",
                      "Two independent patient identifiers",
                      "Donor ID number",
                      "Compatibility testing results (if done)",
                      "Final check of records is performed to verify details prior to release of blood product for patientTwo unique and correct patient identifiersPatient's ABO and D typeDonor unit ID numberDonor ABO and D typeResults of crossmatch (if done)Date and time of blood unit issueDonor unit's expiration date and timeSpecial transfusion requirements for unit (if applicable), such as use of irradiation or antigen-matching",
                      "Two unique and correct patient identifiers",
                      "Patient's ABO and D type",
                      "Donor unit ID number",
                      "Donor ABO and D type",
                      "Results of crossmatch (if done)",
                      "Date and time of blood unit issue",
                      "Donor unit's expiration date and time",
                      "Special transfusion requirements for unit (if applicable), such as use of irradiation or antigen-matching",
                      "Information on blood request, medical records, and blood component all match",
                      "Unit must be inspected before issue and must have normal color, appearance, and not be leaking",
                      "Final identification of transfusion recipient and blood component is responsibility of transfusionist after blood has been issuedTwo-person verification process is usually required (Joint Commission requirement)Must verify agreement between patient at bedside and identifying information on forms, tags, and labels of unit about to be transfused",
                      "Two-person verification process is usually required (Joint Commission requirement)",
                      "Must verify agreement between patient at bedside and identifying information on forms, tags, and labels of unit about to be transfused"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bedside Transfusion Practice": {
            "name": "Bedside Transfusion Practice",
            "url": "https://app.pathprimer.com/document/05e5ac03-74dd-4b76-9e05-7fd544615c7f/lesson/140612b2-190f-42b4-8166-e1649bb21d01",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Transfusion: Very common medical procedure, but offers significant risk for acute hemolysis if performed incorrectly or if given to wrong patientRoughly two-thirds of transfusion errors are associated with incorrect blood recipient identification at patient's bedside",
                    "sub_points": [
                      "Roughly two-thirds of transfusion errors are associated with incorrect blood recipient identification at patient's bedside"
                    ]
                  },
                  {
                    "text": "Hospitals are required to have established procedures for transfusing blood components, including use of infusion devices, as well as recognition and reporting adverse events (American Association of Blood Banks Standards, 30th ed, 5.28, 7.5)Systematic bedside check of patient and blood product ensures identity and proper matching of transfusions prior to blood administrationTransfusionists must keep records of each transfusion and monitor patient for transfusion reactions",
                    "sub_points": [
                      "Systematic bedside check of patient and blood product ensures identity and proper matching of transfusions prior to blood administration",
                      "Transfusionists must keep records of each transfusion and monitor patient for transfusion reactions"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Bedside Blood Check": [
                  {
                    "text": "Joint Commission and AABB require bedside check of patient and blood product to endure identity and proper matchingHospitals often require 2-person verificationVerification must positively identify recipient and match issued blood products to recipient through 2 independent identifiers (AABB Standards, 30th ed, 5.28.4)Product donor identification number (DIN), recipient and product ABO and Rh, cross-match testing interpretation, special transfusion requirements (if any), and product expiration date are all also verified (AABB Standards, 30th ed, 5.28.3)Bar-coded identification bracelets, radiofrequency identification devices, and handheld computers that relay information from bedside to transfusion service can be used to help in this process",
                    "sub_points": [
                      "Hospitals often require 2-person verificationVerification must positively identify recipient and match issued blood products to recipient through 2 independent identifiers (AABB Standards, 30th ed, 5.28.4)Product donor identification number (DIN), recipient and product ABO and Rh, cross-match testing interpretation, special transfusion requirements (if any), and product expiration date are all also verified (AABB Standards, 30th ed, 5.28.3)Bar-coded identification bracelets, radiofrequency identification devices, and handheld computers that relay information from bedside to transfusion service can be used to help in this process",
                      "Verification must positively identify recipient and match issued blood products to recipient through 2 independent identifiers (AABB Standards, 30th ed, 5.28.4)",
                      "Product donor identification number (DIN), recipient and product ABO and Rh, cross-match testing interpretation, special transfusion requirements (if any), and product expiration date are all also verified (AABB Standards, 30th ed, 5.28.3)",
                      "Bar-coded identification bracelets, radiofrequency identification devices, and handheld computers that relay information from bedside to transfusion service can be used to help in this process"
                    ]
                  }
                ],
                "Transfusion Process": [
                  {
                    "text": "Premedication (before transfusion)Antipyretics (acetaminophen), antihistamines (diphenhydramine and assorted H2-blockers), meperidine, and corticosteroids are commonly used but have not been shown to be helpful in preventing transfusion reactions",
                    "sub_points": [
                      "Antipyretics (acetaminophen), antihistamines (diphenhydramine and assorted H2-blockers), meperidine, and corticosteroids are commonly used but have not been shown to be helpful in preventing transfusion reactions"
                    ]
                  },
                  {
                    "text": "Transfusion accessCellular blood products should generally be transfused through 20-gauge or larger venous accessBlood components must be administered through sterile infusion sets that have filter designed to retain harmful particles/clots (AABB Standards, 30th ed, 5.28.8)Infusion sets are generally acceptable to use for up to 4 hours, for multiple compatible blood productsInfusion set filters are generally 170-260 micronBlood components can ONLY be transfused with 0.9% sodium chloride or 5% human albumin (other fluids can cause hemolysis)Blood warmers can be used to prevent hypothermia or cardiac dysrhythmia, but must be able to maintain temperature < 42°C (due to hemolysis risk)",
                    "sub_points": [
                      "Cellular blood products should generally be transfused through 20-gauge or larger venous access",
                      "Blood components must be administered through sterile infusion sets that have filter designed to retain harmful particles/clots (AABB Standards, 30th ed, 5.28.8)Infusion sets are generally acceptable to use for up to 4 hours, for multiple compatible blood productsInfusion set filters are generally 170-260 micronBlood components can ONLY be transfused with 0.9% sodium chloride or 5% human albumin (other fluids can cause hemolysis)Blood warmers can be used to prevent hypothermia or cardiac dysrhythmia, but must be able to maintain temperature < 42°C (due to hemolysis risk)",
                      "Infusion sets are generally acceptable to use for up to 4 hours, for multiple compatible blood products",
                      "Infusion set filters are generally 170-260 micron",
                      "Blood components can ONLY be transfused with 0.9% sodium chloride or 5% human albumin (other fluids can cause hemolysis)",
                      "Blood warmers can be used to prevent hypothermia or cardiac dysrhythmia, but must be able to maintain temperature < 42°C (due to hemolysis risk)"
                    ]
                  },
                  {
                    "text": "Transfusion rate and monitoringRBC transfusions should be started at slow rate (1-2 mL per min) for first 15 minutes to assess patient tolerance of unit; then increased to 4-5 mL per minute to ensure product is finished within 4 hoursPlasma and platelet components can generally be started at rate of 5 mL per minuteRecipient vital signs should be taken before starting transfusion, within 5-15 minutes of starting transfusion, during transfusion according to hospital policy, and finally at conclusion of transfusionAdverse event monitoring and reportingWhen transfusion reaction is suspected, transfusion should be stopped immediatelyPatient is assessed, vital signs recorded, and any clinical needs addressedPatient and blood identifiers are verified once again to evaluate for incorrect transfusionInfusion set is changed and venous access is kept open with normal salineBlood bank is alerted to suspected reaction and appropriate follow-up lab tests are completedPatient's medical record should contain records of the followingTransfusion ordersPatient consent to receive bloodBlood products administered (including date and time)Pretransfusion and posttransfusion vital signsTransfusionist identificationAdverse effects of transfusion",
                    "sub_points": [
                      "RBC transfusions should be started at slow rate (1-2 mL per min) for first 15 minutes to assess patient tolerance of unit; then increased to 4-5 mL per minute to ensure product is finished within 4 hours",
                      "Plasma and platelet components can generally be started at rate of 5 mL per minute",
                      "Recipient vital signs should be taken before starting transfusion, within 5-15 minutes of starting transfusion, during transfusion according to hospital policy, and finally at conclusion of transfusion",
                      "Adverse event monitoring and reportingWhen transfusion reaction is suspected, transfusion should be stopped immediatelyPatient is assessed, vital signs recorded, and any clinical needs addressedPatient and blood identifiers are verified once again to evaluate for incorrect transfusionInfusion set is changed and venous access is kept open with normal salineBlood bank is alerted to suspected reaction and appropriate follow-up lab tests are completed",
                      "When transfusion reaction is suspected, transfusion should be stopped immediately",
                      "Patient is assessed, vital signs recorded, and any clinical needs addressed",
                      "Patient and blood identifiers are verified once again to evaluate for incorrect transfusion",
                      "Infusion set is changed and venous access is kept open with normal saline",
                      "Blood bank is alerted to suspected reaction and appropriate follow-up lab tests are completed",
                      "Patient's medical record should contain records of the followingTransfusion ordersPatient consent to receive bloodBlood products administered (including date and time)Pretransfusion and posttransfusion vital signsTransfusionist identificationAdverse effects of transfusion",
                      "Transfusion orders",
                      "Patient consent to receive blood",
                      "Blood products administered (including date and time)",
                      "Pretransfusion and posttransfusion vital signs",
                      "Transfusionist identification",
                      "Adverse effects of transfusion"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Red Blood Cell Antigens": {
        "name": "Red Blood Cell Antigens",
        "url": "https://app.pathprimer.com/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
        "topics": {
          "ABO Blood Group System": {
            "name": "ABO Blood Group System",
            "url": "https://app.pathprimer.com/document/b669df16-7ebb-40a6-8514-eff00b01218c/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "ABO is most significant blood group for transfusion due to high risk of acute hemolysis with incompatible transfusion"
                  },
                  {
                    "text": "ABO blood group is highly polymorphic; genotyping is not approved by FDA for compatibility testing"
                  },
                  {
                    "text": "Occurrence and location of A, B, and O (H) antigens are controlled by 3 glucosyltransferase genes:H,Se, andABO"
                  }
                ]
              },
              "OVERVIEW": {
                "ABO IsMostSignificant Blood Group for Transfusion Practice": [
                  {
                    "text": "ABO typing and compatibility testing are foundation of pretransfusion testing and pretransplantation testing"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Single nucleotide polymorphism (SNP)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Venous thromboembolism (VTE)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biology of ABO": [
                  {
                    "text": "ABO is carbohydrate-based blood antigen system that consists of A, B, and H antigensGroup O individuals express precursor H antigen but lack A and B antigensBoth group A and group B individuals express H antigen",
                    "sub_points": [
                      "Group O individuals express precursor H antigen but lack A and B antigens",
                      "Both group A and group B individuals express H antigen"
                    ]
                  },
                  {
                    "text": "Organisms of familyEnterobacteriaceaehave ABO-like structures on their lipopolysaccharide coats"
                  },
                  {
                    "text": "ABO antigens are monosaccharides added to oligosaccharide precursor chains present on glycolipids and glycoproteinsType 1 precursor chains are present on secreted proteinsType 2 precursor chains are present on RBCs",
                    "sub_points": [
                      "Type 1 precursor chains are present on secreted proteins",
                      "Type 2 precursor chains are present on RBCs"
                    ]
                  },
                  {
                    "text": "A, B, and H antigens are synthesized in a stepwise fashion by glycosyltransferases in Golgi apparatus"
                  },
                  {
                    "text": "ABO antigens are detected on embryonic/fetal RBC by 5-6 weeks of gestationQuantity of ABO antigens on cord RBCs is less than adults (approximately 1/3) because of immaturity of type 2 chain precursors on cord red cellsInfants have simpler, linear ABH chains resulting in weaker antigen expressionABO antigen reaches adult levels of expression (> 2 million antigens per RBC) in children by 2-4 yr old",
                    "sub_points": [
                      "Quantity of ABO antigens on cord RBCs is less than adults (approximately 1/3) because of immaturity of type 2 chain precursors on cord red cellsInfants have simpler, linear ABH chains resulting in weaker antigen expression",
                      "Infants have simpler, linear ABH chains resulting in weaker antigen expression",
                      "ABO antigen reaches adult levels of expression (> 2 million antigens per RBC) in children by 2-4 yr old"
                    ]
                  },
                  {
                    "text": "ABO antigens are detected on RBCs, endothelium, and epithelium of lung, gut, and genitourinary tract"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Polymerase Chain Reaction (PCR)": [
                  {
                    "text": "ABO system is not well suited to SNP-based polymorphism detection, as can be used for many other antigen systemsExtensive sequence heterogeneity underlies major ABO alleles that produce normal blood groups A, B, AB, and O> 100 different alleles of ABO gene have been described, including > 50 O allelesAllele can have SNP background that appears to encode A or BMissense mutation would result in inactive glycosyltransferase and instead allele encodes OSanger sequencing or next-generation sequencing better suited for accurate ABO genotyping but not approved by FDA for compatibility testing at this time",
                    "sub_points": [
                      "Extensive sequence heterogeneity underlies major ABO alleles that produce normal blood groups A, B, AB, and O",
                      "> 100 different alleles of ABO gene have been described, including > 50 O allelesAllele can have SNP background that appears to encode A or BMissense mutation would result in inactive glycosyltransferase and instead allele encodes O",
                      "Allele can have SNP background that appears to encode A or BMissense mutation would result in inactive glycosyltransferase and instead allele encodes O",
                      "Missense mutation would result in inactive glycosyltransferase and instead allele encodes O",
                      "Sanger sequencing or next-generation sequencing better suited for accurate ABO genotyping but not approved by FDA for compatibility testing at this time"
                    ]
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Genetics and Biochemistry of ABO": [
                  {
                    "text": "Occurrence and location of A, B, and O (H) antigens controlled by 3 glucosyltransferase genes:H,Se,ABO"
                  },
                  {
                    "text": "Se(FUT2)is fucosyltransferase that forms H antigen on secreted proteinsBase for A and B antigens in secretionsFUT2alleles areSeandseSecodes for fucosyltransferase that adds terminal fucose to type 1 precursor chain to create H antigen on proteins secreted by epithelial cellsABO glucosyltransferases can add A and B antigens to type 1 chains expressing H antigenseis amorph alleleDoes not code for transferase enzyme",
                    "sub_points": [
                      "Base for A and B antigens in secretions",
                      "FUT2alleles areSeandse",
                      "Secodes for fucosyltransferase that adds terminal fucose to type 1 precursor chain to create H antigen on proteins secreted by epithelial cellsABO glucosyltransferases can add A and B antigens to type 1 chains expressing H antigen",
                      "ABO glucosyltransferases can add A and B antigens to type 1 chains expressing H antigen",
                      "seis amorph alleleDoes not code for transferase enzyme",
                      "Does not code for transferase enzyme"
                    ]
                  },
                  {
                    "text": "H (FUT1)gene is fucosyltransferase that forms H antigen on type 2 chainsBase for building A and B antigens on RBCFUT1alleles areHandhHcodes for fucosyltransferase that adds terminal fucose to type 2 precursor chain to create H antigen on RBChis amorph alleleDoes not code for transferase enzymeExtremely rare and causes Bombay phenotype",
                    "sub_points": [
                      "Base for building A and B antigens on RBC",
                      "FUT1alleles areHandh",
                      "Hcodes for fucosyltransferase that adds terminal fucose to type 2 precursor chain to create H antigen on RBC",
                      "his amorph alleleDoes not code for transferase enzymeExtremely rare and causes Bombay phenotype",
                      "Does not code for transferase enzyme",
                      "Extremely rare and causes Bombay phenotype"
                    ]
                  },
                  {
                    "text": "ABO glycosyltransferase adds sugar to H antigens to produce A and B antigensCodominant A and B alleles and 1 amorph recessive O allele4 major ABO phenotypes: A, B, AB, and OA allele codes for enzyme that attachesN-acetyl-D-galactosamine (GalNAc) to terminal galactose on type 1 or type 2 chain expressing H antigenB allele codes for enzyme that attaches D-galactose (Gal) to terminal galactose on type 1 or type 2 chain expressing H antigenO allele does not code for functional enzyme (nonsense mutation)Only H antigen is expressed and no additional sugars are addedMost common O alleles are deletions leading to frameshift and truncated inactive enzymeSubgroups of A allele80% of A alleles are A1, 20% are A2, and < 1% are other A subgroupsA1 allele is most efficient and results in most A copies per RBC (and consequently less residual H antigen)A2 is qualitatively and quantitatively different from A1Less A antigen is present on RBC membrane and there are structural differencesConsequently, A2 individuals can form anti-A1 antibodiesAnti-A1 is more commonly seen in A2B individualsAnti-A1 rarely results in hemolysis of transfused A1 RBCsDolichos bifloruslectin agglutinates A1 RBCs but not A2 or other subgroupsCan be used to resolve ABO typing discrepancies due to A2 with anti-A1 antibodiesB subgroups are very rareA and B glycosyltransferases act on H substrateIn absence of H, ABO glycosyltransferases cannot add sugar to oligosaccharide chainA1 is produced by most efficient enzyme, followed by B and A2Amount of residual H present on RBC varies by ABO type and follows the pattern O > A2 > B > A2B > A1 > A1B",
                    "sub_points": [
                      "Codominant A and B alleles and 1 amorph recessive O allele",
                      "4 major ABO phenotypes: A, B, AB, and O",
                      "A allele codes for enzyme that attachesN-acetyl-D-galactosamine (GalNAc) to terminal galactose on type 1 or type 2 chain expressing H antigen",
                      "B allele codes for enzyme that attaches D-galactose (Gal) to terminal galactose on type 1 or type 2 chain expressing H antigen",
                      "O allele does not code for functional enzyme (nonsense mutation)Only H antigen is expressed and no additional sugars are addedMost common O alleles are deletions leading to frameshift and truncated inactive enzyme",
                      "Only H antigen is expressed and no additional sugars are added",
                      "Most common O alleles are deletions leading to frameshift and truncated inactive enzyme",
                      "Subgroups of A allele80% of A alleles are A1, 20% are A2, and < 1% are other A subgroupsA1 allele is most efficient and results in most A copies per RBC (and consequently less residual H antigen)A2 is qualitatively and quantitatively different from A1Less A antigen is present on RBC membrane and there are structural differencesConsequently, A2 individuals can form anti-A1 antibodiesAnti-A1 is more commonly seen in A2B individualsAnti-A1 rarely results in hemolysis of transfused A1 RBCsDolichos bifloruslectin agglutinates A1 RBCs but not A2 or other subgroupsCan be used to resolve ABO typing discrepancies due to A2 with anti-A1 antibodies",
                      "80% of A alleles are A1, 20% are A2, and < 1% are other A subgroups",
                      "A1 allele is most efficient and results in most A copies per RBC (and consequently less residual H antigen)",
                      "A2 is qualitatively and quantitatively different from A1Less A antigen is present on RBC membrane and there are structural differences",
                      "Less A antigen is present on RBC membrane and there are structural differences",
                      "Consequently, A2 individuals can form anti-A1 antibodiesAnti-A1 is more commonly seen in A2B individualsAnti-A1 rarely results in hemolysis of transfused A1 RBCs",
                      "Anti-A1 is more commonly seen in A2B individuals",
                      "Anti-A1 rarely results in hemolysis of transfused A1 RBCs",
                      "Dolichos bifloruslectin agglutinates A1 RBCs but not A2 or other subgroupsCan be used to resolve ABO typing discrepancies due to A2 with anti-A1 antibodies",
                      "Can be used to resolve ABO typing discrepancies due to A2 with anti-A1 antibodies",
                      "B subgroups are very rare",
                      "A and B glycosyltransferases act on H substrateIn absence of H, ABO glycosyltransferases cannot add sugar to oligosaccharide chain",
                      "In absence of H, ABO glycosyltransferases cannot add sugar to oligosaccharide chain",
                      "A1 is produced by most efficient enzyme, followed by B and A2Amount of residual H present on RBC varies by ABO type and follows the pattern O > A2 > B > A2B > A1 > A1B",
                      "Amount of residual H present on RBC varies by ABO type and follows the pattern O > A2 > B > A2B > A1 > A1B"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Applications of ABO System": [
                  {
                    "text": "Transfusion of ABO-incompatible RBCs can cause acute intravascular hemolysis, renal failure due to free hemoglobin, and deathABO was first blood system to be identified in 1901 and ismostsignificant for transfusion practiceK. Landsteiner won 1930 Nobel Prize in Physiology/MedicineTransfusion without regard to ABO would be incompatible in approximately 1/3 of casesABO antigens are present on endotheliumTransplant of ABO-incompatible organs associated with acute humoral rejection",
                    "sub_points": [
                      "ABO was first blood system to be identified in 1901 and ismostsignificant for transfusion practiceK. Landsteiner won 1930 Nobel Prize in Physiology/Medicine",
                      "K. Landsteiner won 1930 Nobel Prize in Physiology/Medicine",
                      "Transfusion without regard to ABO would be incompatible in approximately 1/3 of cases",
                      "ABO antigens are present on endotheliumTransplant of ABO-incompatible organs associated with acute humoral rejection",
                      "Transplant of ABO-incompatible organs associated with acute humoral rejection"
                    ]
                  },
                  {
                    "text": "vWF levels are approximately 25% higher in individuals who are a blood group other than OPresence of ABH structures in vWF N-linked oligosaccharides provides molecular basis for ABO regulation of vWF levelsData suggest that carbohydrate content (ABH-bearing structures of vWF) protects vWF from proteolytic degradation by ADAMTS13Prevalence of non-O blood group is significantly higher in patients with VTE compared with controlsRisk of venous thrombosis is increased approximately 2-fold in non-group O individualsAdditive effect on VTE risk is observed when inherited thrombophilic condition is associated with non-O blood groupWeaker association exists between non-O blood type and arterial thrombosis",
                    "sub_points": [
                      "Presence of ABH structures in vWF N-linked oligosaccharides provides molecular basis for ABO regulation of vWF levelsData suggest that carbohydrate content (ABH-bearing structures of vWF) protects vWF from proteolytic degradation by ADAMTS13",
                      "Data suggest that carbohydrate content (ABH-bearing structures of vWF) protects vWF from proteolytic degradation by ADAMTS13",
                      "Prevalence of non-O blood group is significantly higher in patients with VTE compared with controls",
                      "Risk of venous thrombosis is increased approximately 2-fold in non-group O individualsAdditive effect on VTE risk is observed when inherited thrombophilic condition is associated with non-O blood groupWeaker association exists between non-O blood type and arterial thrombosis",
                      "Additive effect on VTE risk is observed when inherited thrombophilic condition is associated with non-O blood group",
                      "Weaker association exists between non-O blood type and arterial thrombosis"
                    ]
                  },
                  {
                    "text": "ABO and infectious diseaseHelicobacter pylorihas approximately 5-fold increased binding affinity for O Leb compared with A LebGroup O patients tend to have less severePlasmodium falciparummalaria than group A individuals due to smaller intravascular RBC rosettes in type O patients, leading to less severe vaso-occlusion",
                    "sub_points": [
                      "Helicobacter pylorihas approximately 5-fold increased binding affinity for O Leb compared with A Leb",
                      "Group O patients tend to have less severePlasmodium falciparummalaria than group A individuals due to smaller intravascular RBC rosettes in type O patients, leading to less severe vaso-occlusion"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bombay and Para-Bombay Phenotypes": {
            "name": "Bombay and Para-Bombay Phenotypes",
            "url": "https://app.pathprimer.com/document/1c03e5ae-6952-4248-bf28-47940c43f29e/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Bombay phenotypeHomozygosity forhandse(amorph allele forFUT2) leading to lack of H substance on RBC membranes and secretionsPotent alloanti-H antibodies are formed that render Bombay individuals compatible only with other Bombay individualsAutosomal recessive and associated with consanguinity",
                    "sub_points": [
                      "Homozygosity forhandse(amorph allele forFUT2) leading to lack of H substance on RBC membranes and secretions",
                      "Potent alloanti-H antibodies are formed that render Bombay individuals compatible only with other Bombay individuals",
                      "Autosomal recessive and associated with consanguinity"
                    ]
                  },
                  {
                    "text": "Para-Bombay phenotypeHomozygosity forhbut with at least 1 functionalFUT2allele (Se) leading to presence of H substance in secretions/tissues and some adsorption of soluble H substance onto RBC membranesForm naturally occurring anti-H antibodies",
                    "sub_points": [
                      "Homozygosity forhbut with at least 1 functionalFUT2allele (Se) leading to presence of H substance in secretions/tissues and some adsorption of soluble H substance onto RBC membranes",
                      "Form naturally occurring anti-H antibodies"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Bombay Phenotype Is Very Rare and Is Associated With Consanguinity": [
                  {
                    "text": "Frequency of Bombay and para-Bombay phenotypes varies1:1 million in Europe, 1:10,000 in India, and 1:1000 on Reunion Island",
                    "sub_points": [
                      "1:1 million in Europe, 1:10,000 in India, and 1:1000 on Reunion Island"
                    ]
                  },
                  {
                    "text": "In Chinese, frequency of Bombay and para-Bombay phenotypes is approximately 1 per 10,000 (or 0.01%)Para-Bombay phenotype is more common than Bombay phenotype",
                    "sub_points": [
                      "Para-Bombay phenotype is more common than Bombay phenotype"
                    ]
                  },
                  {
                    "text": "hhgenotype atFUT1locus is associated with formation of potent alloanti-H that renders Bombay individuals compatible only with other Bombay individuals"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Basis of Bombay and Para-Bombay Phenotypes": [
                  {
                    "text": "H (FUT1) gene is fucosyltransferase that forms H antigen on type 2 chainsBase for building A and B antigens on RBC",
                    "sub_points": [
                      "Base for building A and B antigens on RBC"
                    ]
                  },
                  {
                    "text": "FUT1alleles areHandhHcodes for fucosyltransferase that adds terminal fucose to type 2 precursor chain to create H antigen on RBChis amorph alleleDoes not code for transferase enzymeIndividuals homozygous forhcannot fucosylate type 2 chains, preventing formation of A or B sugars on RBC",
                    "sub_points": [
                      "Hcodes for fucosyltransferase that adds terminal fucose to type 2 precursor chain to create H antigen on RBC",
                      "his amorph alleleDoes not code for transferase enzyme",
                      "Does not code for transferase enzyme",
                      "Individuals homozygous forhcannot fucosylate type 2 chains, preventing formation of A or B sugars on RBC"
                    ]
                  },
                  {
                    "text": "Bombay phenotypeIndividuals homozygous forhand homozygous forse(amorph allele forFUT2) do not have any H substance on either RBCs or secretionsThey also lack any A or B substance on either RBCs or secretionsResults of ABO typing of individuals homozygous forhare identical to group O individualsFront typeTheir cells do not react with either anti-A or anti-BBack typeTheir plasma reacts with A1 cells and B cellsThese individuals have \"Bombay\" (or Oh) phenotypePhenotype was originally described in Bombay, IndiaRBCs from these individuals do not react withUlex europaeuslectin (anti-H)Because Bombay individuals arese/se, they also type as Le(b-)These individuals produce a potent naturally occurring anti-H (reactive at room temperature and 37°C) and have pan-reactive antibody screens with high-frequency antigen patternAlthough Bombay individuals initially type as O, all type O RBCs are incompatible with their plasmaResults of antibody screening are positive and reagent RBC panel is pan-reactiveBombay individuals can receive packed RBC transfusion only from other Bombay individuals",
                    "sub_points": [
                      "Individuals homozygous forhand homozygous forse(amorph allele forFUT2) do not have any H substance on either RBCs or secretionsThey also lack any A or B substance on either RBCs or secretions",
                      "They also lack any A or B substance on either RBCs or secretions",
                      "Results of ABO typing of individuals homozygous forhare identical to group O individualsFront typeTheir cells do not react with either anti-A or anti-BBack typeTheir plasma reacts with A1 cells and B cells",
                      "Front typeTheir cells do not react with either anti-A or anti-B",
                      "Their cells do not react with either anti-A or anti-B",
                      "Back typeTheir plasma reacts with A1 cells and B cells",
                      "Their plasma reacts with A1 cells and B cells",
                      "These individuals have \"Bombay\" (or Oh) phenotypePhenotype was originally described in Bombay, India",
                      "Phenotype was originally described in Bombay, India",
                      "RBCs from these individuals do not react withUlex europaeuslectin (anti-H)",
                      "Because Bombay individuals arese/se, they also type as Le(b-)",
                      "These individuals produce a potent naturally occurring anti-H (reactive at room temperature and 37°C) and have pan-reactive antibody screens with high-frequency antigen patternAlthough Bombay individuals initially type as O, all type O RBCs are incompatible with their plasmaResults of antibody screening are positive and reagent RBC panel is pan-reactive",
                      "Although Bombay individuals initially type as O, all type O RBCs are incompatible with their plasma",
                      "Results of antibody screening are positive and reagent RBC panel is pan-reactive",
                      "Bombay individuals can receive packed RBC transfusion only from other Bombay individuals"
                    ]
                  },
                  {
                    "text": "Para-Bombay phenotypeIndividuals homozygous forhbut with at least 1 functionalFUT2allele (Se) produce H substance on secretions/tissuesTheir RBCs contain a small amount of soluble HBased on these individuals' ABO genotype, they can express minimal amount of ABH antigen on RBC surfaceThis is usually either undetectable or causes only weak reactions by typical immunohematology methodsPara-Bombay individuals make A &/or B substance in their tissues/secretions consistent with their ABO genotypeTheir ABO front type is likely to appear to be group O, but their ABO back type is consistent with their ABOThat is, if their ABO genotype was AO, they do not have anti-A in their back typeThese individuals naturally produce a potent anti-H (reactive at room temperature and 37°C) and have pan-reactive antibody screens with high-frequency antigen pattern",
                    "sub_points": [
                      "Individuals homozygous forhbut with at least 1 functionalFUT2allele (Se) produce H substance on secretions/tissuesTheir RBCs contain a small amount of soluble H",
                      "Their RBCs contain a small amount of soluble H",
                      "Based on these individuals' ABO genotype, they can express minimal amount of ABH antigen on RBC surfaceThis is usually either undetectable or causes only weak reactions by typical immunohematology methodsPara-Bombay individuals make A &/or B substance in their tissues/secretions consistent with their ABO genotypeTheir ABO front type is likely to appear to be group O, but their ABO back type is consistent with their ABOThat is, if their ABO genotype was AO, they do not have anti-A in their back type",
                      "This is usually either undetectable or causes only weak reactions by typical immunohematology methods",
                      "Para-Bombay individuals make A &/or B substance in their tissues/secretions consistent with their ABO genotype",
                      "Their ABO front type is likely to appear to be group O, but their ABO back type is consistent with their ABOThat is, if their ABO genotype was AO, they do not have anti-A in their back type",
                      "That is, if their ABO genotype was AO, they do not have anti-A in their back type",
                      "These individuals naturally produce a potent anti-H (reactive at room temperature and 37°C) and have pan-reactive antibody screens with high-frequency antigen pattern"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Anti-H Antibodies": [
                  {
                    "text": "Alloanti-HAnti-H in Bombay and para-Bombay individuals is clinically significant and associated with acute hemolytic transfusion reactionsSimilar to anti-A or anti-B, it is predominantly an IgM antibodyThis antibody reacts with all cells but Bombay or para-Bombay cells",
                    "sub_points": [
                      "Anti-H in Bombay and para-Bombay individuals is clinically significant and associated with acute hemolytic transfusion reactions",
                      "Similar to anti-A or anti-B, it is predominantly an IgM antibody",
                      "This antibody reacts with all cells but Bombay or para-Bombay cells"
                    ]
                  },
                  {
                    "text": "Autoanti-HPeople withHalleles can form autoanti-HThis phenomenon is most common in group A1 individuals due to their highly efficient transformation of H substance into A substanceAutoanti-H is IgM antibody that is generally reactive at room temperature only and is generally not clinically significantPatients with autoanti-H that is reactive at 37°C should generally be transfused with type-specific RBCsThat is, given that most of these people are A1, they should receive group A packed RBCs rather than group O",
                    "sub_points": [
                      "People withHalleles can form autoanti-H",
                      "This phenomenon is most common in group A1 individuals due to their highly efficient transformation of H substance into A substance",
                      "Autoanti-H is IgM antibody that is generally reactive at room temperature only and is generally not clinically significant",
                      "Patients with autoanti-H that is reactive at 37°C should generally be transfused with type-specific RBCsThat is, given that most of these people are A1, they should receive group A packed RBCs rather than group O",
                      "That is, given that most of these people are A1, they should receive group A packed RBCs rather than group O"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rh and RhAG Blood Group Systems": {
            "name": "Rh and RhAG Blood Group Systems",
            "url": "https://app.pathprimer.com/document/b1814071-cc03-4e02-8d55-29ad8e2113e4/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Blood Group Antigens": [
                  {
                    "text": "Rh blood system is second only to ABO in terms of importance in transfusion medicine, as D antigen is one of most immunogenic of all RBC antigens"
                  },
                  {
                    "text": "\"Rh positive\" and \"Rh negative\" refer to RhD positive and RhD negative, respectively"
                  },
                  {
                    "text": "Rh negative phenotype is absence of RhD protein"
                  },
                  {
                    "text": "Individuals with weak D express less RhD protein on RBC membrane and do not generally form alloanti-D when exposed to Rh positive components"
                  },
                  {
                    "text": "Individuals with partial D express \"part\" of RhD protein and can form alloanti-D when exposed to Rh positive components"
                  },
                  {
                    "text": "C/c and E/e are due to polymorphisms inRHCEgene"
                  },
                  {
                    "text": "Alloantibodies to D, E, e, C, and c are clinically significant causing hemolytic transfusion reactions and HDFN"
                  },
                  {
                    "text": "RHAGis necessary for expression of all Rh antigens, and lack ofRHAGleads to a Rh null phenotype"
                  },
                  {
                    "text": "Lack of RhAG causes stomatocytosis and hemolytic anemia"
                  }
                ]
              },
              "OVERVIEW": {
                "Rh Blood Group System": [
                  {
                    "text": "Rh blood system is second only to ABO in terms of importance in transfusion medicineD antigen is one of most immunogenic of all RBC antigens",
                    "sub_points": [
                      "D antigen is one of most immunogenic of all RBC antigens"
                    ]
                  },
                  {
                    "text": "Rh blood group system comprises > 50 antigens"
                  },
                  {
                    "text": "Due to their close linkage,RHDandRHCEare inherited as 1 haplotype"
                  }
                ],
                "RhAG Blood Group System": [
                  {
                    "text": "RhAG constitutes its own blood group system"
                  },
                  {
                    "text": "RhAG is necessary for expression of all Rh antigens, as RhAG forms a complex with RhD and RhCE"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Antihuman globulin (AHG)"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Rh Blood System": [
                  {
                    "text": "Rh proteins are expressed only on RBCs and WBCs and are present on fetal RBCs at adult strength"
                  },
                  {
                    "text": "Rh system is most complex of 34 human blood group systemsIncludes 48 antigens16 are \"polymorphic,\" frequently associated with alloimmunization (not low or high prevalence)",
                    "sub_points": [
                      "Includes 48 antigens16 are \"polymorphic,\" frequently associated with alloimmunization (not low or high prevalence)",
                      "16 are \"polymorphic,\" frequently associated with alloimmunization (not low or high prevalence)"
                    ]
                  },
                  {
                    "text": "Major Rh antigens are D, C/c, and E/ePresent on 2 proteins: RhD and RhCETransmembrane proteins with approximately 97% homologyRHDandRHCEare products of gene duplication",
                    "sub_points": [
                      "Present on 2 proteins: RhD and RhCE",
                      "Transmembrane proteins with approximately 97% homology",
                      "RHDandRHCEare products of gene duplication"
                    ]
                  },
                  {
                    "text": "Due to their close linkage,RHDandRHCEare inherited as 1 haplotype"
                  },
                  {
                    "text": "Function of RhD and RhCE proteins is unclear"
                  }
                ],
                "RhD": [
                  {
                    "text": "D antigen is unusual in transfusion medicineNot derived from polymorphismDerived from presence or absence of RhD protein",
                    "sub_points": [
                      "Not derived from polymorphism",
                      "Derived from presence or absence of RhD protein"
                    ]
                  },
                  {
                    "text": "As D antigen is made up of entire protein, it has numerous epitopes"
                  },
                  {
                    "text": "\"Rh positive\" and \"Rh negative\" refer to RhD positive and RhD negative, respectively"
                  },
                  {
                    "text": "Rh negative phenotype is absence of RhD proteinGene deletion is most common cause of RhD negative status in whitesIndividuals of African descent often have inactivating mutations causing RhD negative statusAsians are rarely RhD negative (1%-5%)Asians who are RhD negative have inactivating mutations",
                    "sub_points": [
                      "Gene deletion is most common cause of RhD negative status in whites",
                      "Individuals of African descent often have inactivating mutations causing RhD negative status",
                      "Asians are rarely RhD negative (1%-5%)Asians who are RhD negative have inactivating mutations",
                      "Asians who are RhD negative have inactivating mutations"
                    ]
                  },
                  {
                    "text": "RHDhas > 275 alleles"
                  },
                  {
                    "text": "Antibodies to RhDTypically IgG but may have IgM componentClinically significant causing hemolytic transfusion reactions and potentially severe HDFNApproximately 20% of hospitalized Rh negative patients form alloanti-D after exposure to RhD positive componentsApproximately 80% of healthy individuals form alloanti-D after exposure to RhD positive componentsEnzyme treatment of reagent RBCs on antibody panels enhances reactivity",
                    "sub_points": [
                      "Typically IgG but may have IgM component",
                      "Clinically significant causing hemolytic transfusion reactions and potentially severe HDFN",
                      "Approximately 20% of hospitalized Rh negative patients form alloanti-D after exposure to RhD positive components",
                      "Approximately 80% of healthy individuals form alloanti-D after exposure to RhD positive components",
                      "Enzyme treatment of reagent RBCs on antibody panels enhances reactivity"
                    ]
                  }
                ],
                "D Variants: Weak D, DEL, and Partial D": [
                  {
                    "text": "Weak DDefined as expression of D antigen at low enough level that weak (≤ 2+) or no agglutination is seen on testing with typical monoclonal anti-D reagentDetected by incubating tube with patient cells and anti-D reagent (containing anti-D IgG) at 37°C for 15-60 min, washing, and adding AHG to enhance agglutinationNewer monoclonal reagents are able to detect presence weak D without addition of AHGPrevalence of serologic weak D phenotypes varies by race and ethnicity0.2%-1% of whites and approximately 1% of ethnic ChineseCaused by various different point mutations inRHDgene that cause amino acid changes on intracellular or transmembrane portion of protein leading to inefficient processing of protein from endoplasmic reticulum to cell surfaceLess RhD is present on RBC membrane, but protein itself is unchangedWeak D patients generally do not produce anti-D when exposed to D positive RBCsPatients with most common forms of weak D can generally receive D positive RBCs without risk of immunizationBlood donors must be tested for weak D",
                    "sub_points": [
                      "Defined as expression of D antigen at low enough level that weak (≤ 2+) or no agglutination is seen on testing with typical monoclonal anti-D reagent",
                      "Detected by incubating tube with patient cells and anti-D reagent (containing anti-D IgG) at 37°C for 15-60 min, washing, and adding AHG to enhance agglutination",
                      "Newer monoclonal reagents are able to detect presence weak D without addition of AHG",
                      "Prevalence of serologic weak D phenotypes varies by race and ethnicity0.2%-1% of whites and approximately 1% of ethnic Chinese",
                      "0.2%-1% of whites and approximately 1% of ethnic Chinese",
                      "Caused by various different point mutations inRHDgene that cause amino acid changes on intracellular or transmembrane portion of protein leading to inefficient processing of protein from endoplasmic reticulum to cell surface",
                      "Less RhD is present on RBC membrane, but protein itself is unchanged",
                      "Weak D patients generally do not produce anti-D when exposed to D positive RBCs",
                      "Patients with most common forms of weak D can generally receive D positive RBCs without risk of immunization",
                      "Blood donors must be tested for weak D"
                    ]
                  },
                  {
                    "text": "DEL phenotypeD antigen is expressed at such low density that even weak D testing is negativeD is not detected serologically unless adsorption and elution studies are performedFound more commonly among persons of Asian ancestry10%-30% of RhD negative Asians",
                    "sub_points": [
                      "D antigen is expressed at such low density that even weak D testing is negative",
                      "D is not detected serologically unless adsorption and elution studies are performed",
                      "Found more commonly among persons of Asian ancestry10%-30% of RhD negative Asians",
                      "10%-30% of RhD negative Asians"
                    ]
                  },
                  {
                    "text": "Partial DDefined as loss of D epitopesGenerally due to gene conversion betweenRHDandRHCE\"Part\" of RhD protein is expressedAssociated with amino acid substitutions in RhD protein on extracellular surface of RhD protein, leading to lack of common D epitopesMore common in individuals of African descentIndividuals with partial D can make alloanti-D when exposed to RhD RBCsBlood typing reagents frequently include 2 different D typing antisera to increase odds of identifying partial D (i.e., if D typing results are positive with 1 reagent and negative with another)Partial D phenotypes have been given names with Roman numerals and lettersDIIIa, DVI, DBT, and DFRRhD genotyping is preferred method for identifying partial D phenotype",
                    "sub_points": [
                      "Defined as loss of D epitopesGenerally due to gene conversion betweenRHDandRHCE",
                      "Generally due to gene conversion betweenRHDandRHCE",
                      "\"Part\" of RhD protein is expressed",
                      "Associated with amino acid substitutions in RhD protein on extracellular surface of RhD protein, leading to lack of common D epitopes",
                      "More common in individuals of African descent",
                      "Individuals with partial D can make alloanti-D when exposed to RhD RBCs",
                      "Blood typing reagents frequently include 2 different D typing antisera to increase odds of identifying partial D (i.e., if D typing results are positive with 1 reagent and negative with another)",
                      "Partial D phenotypes have been given names with Roman numerals and lettersDIIIa, DVI, DBT, and DFR",
                      "DIIIa, DVI, DBT, and DFR",
                      "RhD genotyping is preferred method for identifying partial D phenotype"
                    ]
                  }
                ],
                "RhCE": [
                  {
                    "text": "C/c polymorphism is associated with Ser103Pro on extracellular face of RhCE, among 3 other polymorphisms in transmembrane portions"
                  },
                  {
                    "text": "E/e polymorphism is due to Pro226Ala in RhCE"
                  },
                  {
                    "text": "In individuals of African descent, altered RHCE genes are present that encode partial e antigensRh variants can greatly complicate identification of compatible RBC units",
                    "sub_points": [
                      "Rh variants can greatly complicate identification of compatible RBC units"
                    ]
                  },
                  {
                    "text": "f is compound antigen when c and e are expressed on same haplotype/protein"
                  },
                  {
                    "text": "V and VS are low-frequency antigens associated with polymorphisms of RHCE that are common in African Americans and rare in whites"
                  },
                  {
                    "text": "G is antigen common to both D and C"
                  },
                  {
                    "text": "RHCEhas > 50 alleles"
                  },
                  {
                    "text": "AntibodiesTypically IgG but may have an IgM componentClinically significant causing both hemolytic transfusion reactions and HDFNAnti-c can cause severe HDFNAnti-C, anti-E, anti-e usually cause no to mild HDFNEnzyme treatment of reagent RBCs on antibody panels enhances reactivity",
                    "sub_points": [
                      "Typically IgG but may have an IgM component",
                      "Clinically significant causing both hemolytic transfusion reactions and HDFNAnti-c can cause severe HDFNAnti-C, anti-E, anti-e usually cause no to mild HDFN",
                      "Anti-c can cause severe HDFN",
                      "Anti-C, anti-E, anti-e usually cause no to mild HDFN",
                      "Enzyme treatment of reagent RBCs on antibody panels enhances reactivity"
                    ]
                  }
                ],
                "RHAG Blood Group System": [
                  {
                    "text": "RHAGis approximately 40% homologous withRHDandRHCE"
                  },
                  {
                    "text": "Necessary for expression of all Rh antigensForms complex with RhD and RhCE that is inserted in RBC membrane",
                    "sub_points": [
                      "Forms complex with RhD and RhCE that is inserted in RBC membrane"
                    ]
                  },
                  {
                    "text": "Appears to be involved with RBC ammonia/ammonium transport"
                  },
                  {
                    "text": "Lack of RhAG causes stomatocytosis and hemolytic anemia (due to cation transport defect) and have Rh null phenotype"
                  },
                  {
                    "text": "Exposure of Rh null patients to non-Rh null RBC can lead to alloimmunization to all Rh antigens"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rh Phenotypes and Terminology Systems": {
            "name": "Rh Phenotypes and Terminology Systems",
            "url": "https://app.pathprimer.com/document/6cfae3f4-471d-4c32-8d8e-828a132e82b2/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Blood Group Antigens": [
                  {
                    "text": "\"Rh positive\" refers to presence of D antigen, and \"Rh negative\" refers to absence of D antigen; there is no \"d\" antigen"
                  },
                  {
                    "text": "Modified Weiner haplotype terminology is useful shorthand in blood bank"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Rh Terminology": [
                  {
                    "text": "\"Rh positive\" refers to presence of D antigen, and \"Rh negative\" refers to absence of D antigenThere is no \"d\" antigen",
                    "sub_points": [
                      "There is no \"d\" antigen"
                    ]
                  },
                  {
                    "text": "Fisher-Race terminology was based on hypothesis of 3 closely linked genes: D, C/c, and E/e"
                  },
                  {
                    "text": "Weiner terminology was based on hypothesis of 1 gene encoding all 3 commonly significant antigens: C/c, E/e, D"
                  },
                  {
                    "text": "Modified Weiner haplotype terminology is useful shorthand in blood bank\"R\" always refers to D whether it is Ro, R1, R2, or the very rare Rz\"r\" always refers to d or lack of D\"0\" refers to having no C or E\"1\" or ' always refers to C\"2\" or \" always refers to E",
                    "sub_points": [
                      "\"R\" always refers to D whether it is Ro, R1, R2, or the very rare Rz",
                      "\"r\" always refers to d or lack of D",
                      "\"0\" refers to having no C or E",
                      "\"1\" or ' always refers to C",
                      "\"2\" or \" always refers to E"
                    ]
                  },
                  {
                    "text": "Very rare haplotypes that have both C and E in single haplotype are given letters from the end of the alphabet (z and y)"
                  },
                  {
                    "text": "Following is conversion of modified Weiner haplotype terminology into Fisher-Race terminologyR1 = DCeR2 = DcER0 = DceRz = DCEr = cer' = Cer'' = cEry = CE",
                    "sub_points": [
                      "R1 = DCe",
                      "R2 = DcE",
                      "R0 = Dce",
                      "Rz = DCE",
                      "r = ce",
                      "r' = Ce",
                      "r'' = cE",
                      "ry = CE"
                    ]
                  },
                  {
                    "text": "Rank order of Rh haplotypes by frequency and their racial differencesWhites: R1 > r > R2Blacks: Ro > r > R1 > R2Asians and Native Americans: R1 > R2R1 always comes before R2r comes second",
                    "sub_points": [
                      "Whites: R1 > r > R2",
                      "Blacks: Ro > r > R1 > R2",
                      "Asians and Native Americans: R1 > R2",
                      "R1 always comes before R2",
                      "r comes second"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Kell Blood Group System": {
            "name": "Kell Blood Group System",
            "url": "https://app.pathprimer.com/document/66d96ff0-85a8-43fe-a6f8-e17a2fdb0727/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Blood Group Antigens": [
                  {
                    "text": "K is relatively low-frequency antigen, present in 10% of the population; k is high-frequency antigen"
                  },
                  {
                    "text": "K and k (Cellano) are antithetical antigens that differ by 1 amino acid"
                  },
                  {
                    "text": "K is considered most immunogenic RBC antigen outside of ABO; its higher immunogenicity but lower antibody frequency compared with Rh is caused by relative rarity of K antigen"
                  },
                  {
                    "text": "Antibodies to K may suppress erythropoiesis at progenitor level, leading to fetal hypoproliferative anemia (less erythroblastosis), which can persist after birth"
                  },
                  {
                    "text": "McLeod phenotype is X-linked disease defined by acanthocytosis, shortened RBC survival, late-onset neuromuscular defects (chorea, areflexia, skeletal muscle atrophy, cardiomyopathy), and increased serum CK"
                  }
                ]
              },
              "OVERVIEW": {
                "Kell Is Single-Pass Glycoprotein in Red Blood Cell Membrane": [
                  {
                    "text": "Anti-K antibodies are associated with severe HDFNUnique hypoproliferative anemia due to early expression of K on fetal erythroid precursorsOrigin of pediatric/obstetric mnemonic \"Kell kills\"",
                    "sub_points": [
                      "Unique hypoproliferative anemia due to early expression of K on fetal erythroid precursors",
                      "Origin of pediatric/obstetric mnemonic \"Kell kills\""
                    ]
                  },
                  {
                    "text": "McLeod phenotype is extremely rare, X-linked syndrome involving neuromuscular defects and hemolytic anemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Dithiothreitol (DTT)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Chronic granulomatous disease (CGD)"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Kell and Kx Blood Group Systems": [
                  {
                    "text": "Two membrane proteins that appear early in erythropoiesisAlso present on many other tissues",
                    "sub_points": [
                      "Also present on many other tissues"
                    ]
                  },
                  {
                    "text": "KellKell is membrane zinc endopeptidase that cleaves/activates endothelin-3Exact function in vivo unknown35 antigens including K/k, Kp(a)/Kp(b), Js(a)/Js(b)Numerous disulfide bonds in KellThis explains sensitivity of antigen system to reducing agents (DTT, β-mercaptoethanol)Kell system antigens resistant to enzyme treatmentK and k (Cellano) are antithetical antigens that differ by 1 amino acidK is relatively low-frequency antigenPresent in 10% of populationk is high-frequency antigenKp(a) and Kp(b) are antithetical antigens that differ by 1 amino acidKp(a) is low-frequency antigenSeen almost exclusively in whitesKp(b) is high-frequency antigenKp(a) is almost never found on same haplotype as KJs(a) and Js(b) are antithetical antigens that differ by 1 amino acidJs(a) is low-frequency antigenSeen almost exclusively in blacksJs(b) is high-frequency antigenK0 RBC lacks Kell protein and is caused by homozygosity (or compound heterozygosity) for variousKELmutationsK0 phenotype is rare and can lead to formation of high-frequency antibodyDoes not have apparent clinical phenotypeAntibodies against Kell systemAnti-Kell antibodies can cause severe transfusion reactions and HDFNGenerally IgG, rarely binds complementMost common non-ABO antibody after RhK considered most immunogenic RBC antigen outside of ABO; its higher immunogenicity but lower antibody frequency compared with Rh is caused by relative rarity of K antigenK-negative recipient transfused with K-positive packed RBC unit makes anti-K 1 in 10 timesAntibodies to K may suppress erythropoiesis at progenitor levelLeads to fetal hypoproliferative anemia (less erythroblastosis), which can persist after birthCompared with antibodies against Rh system, lower titers are used for anti-K for triggering increased monitoring with fetal middle cerebral artery DopplersAnti-K titer of 4 or 8 is generally considered critical titer, whereas critical titer of other clinically significant antibodies is generally 16Anti-Kell HDFN is not well monitored by amniotic fluid bilirubin, as HDFN due to anti-K is associated with lower plasma and amniotic fluid bilirubin (caused by suppression of early erythropoiesis)Antibody made by K0 individuals is called anti-Ku and reacts with all cells except K0Due to rarity of K0 cells, K0 individuals are encouraged to pursue autologous donation and storage",
                    "sub_points": [
                      "Kell is membrane zinc endopeptidase that cleaves/activates endothelin-3Exact function in vivo unknown",
                      "Exact function in vivo unknown",
                      "35 antigens including K/k, Kp(a)/Kp(b), Js(a)/Js(b)",
                      "Numerous disulfide bonds in KellThis explains sensitivity of antigen system to reducing agents (DTT, β-mercaptoethanol)Kell system antigens resistant to enzyme treatment",
                      "This explains sensitivity of antigen system to reducing agents (DTT, β-mercaptoethanol)",
                      "Kell system antigens resistant to enzyme treatment",
                      "K and k (Cellano) are antithetical antigens that differ by 1 amino acidK is relatively low-frequency antigenPresent in 10% of populationk is high-frequency antigen",
                      "K is relatively low-frequency antigenPresent in 10% of populationk is high-frequency antigen",
                      "Present in 10% of population",
                      "k is high-frequency antigen",
                      "Kp(a) and Kp(b) are antithetical antigens that differ by 1 amino acidKp(a) is low-frequency antigenSeen almost exclusively in whitesKp(b) is high-frequency antigenKp(a) is almost never found on same haplotype as K",
                      "Kp(a) is low-frequency antigenSeen almost exclusively in whites",
                      "Seen almost exclusively in whites",
                      "Kp(b) is high-frequency antigen",
                      "Kp(a) is almost never found on same haplotype as K",
                      "Js(a) and Js(b) are antithetical antigens that differ by 1 amino acidJs(a) is low-frequency antigenSeen almost exclusively in blacksJs(b) is high-frequency antigen",
                      "Js(a) is low-frequency antigenSeen almost exclusively in blacks",
                      "Seen almost exclusively in blacks",
                      "Js(b) is high-frequency antigen",
                      "K0 RBC lacks Kell protein and is caused by homozygosity (or compound heterozygosity) for variousKELmutationsK0 phenotype is rare and can lead to formation of high-frequency antibodyDoes not have apparent clinical phenotype",
                      "K0 phenotype is rare and can lead to formation of high-frequency antibodyDoes not have apparent clinical phenotype",
                      "Does not have apparent clinical phenotype",
                      "Antibodies against Kell systemAnti-Kell antibodies can cause severe transfusion reactions and HDFNGenerally IgG, rarely binds complementMost common non-ABO antibody after RhK considered most immunogenic RBC antigen outside of ABO; its higher immunogenicity but lower antibody frequency compared with Rh is caused by relative rarity of K antigenK-negative recipient transfused with K-positive packed RBC unit makes anti-K 1 in 10 timesAntibodies to K may suppress erythropoiesis at progenitor levelLeads to fetal hypoproliferative anemia (less erythroblastosis), which can persist after birthCompared with antibodies against Rh system, lower titers are used for anti-K for triggering increased monitoring with fetal middle cerebral artery DopplersAnti-K titer of 4 or 8 is generally considered critical titer, whereas critical titer of other clinically significant antibodies is generally 16Anti-Kell HDFN is not well monitored by amniotic fluid bilirubin, as HDFN due to anti-K is associated with lower plasma and amniotic fluid bilirubin (caused by suppression of early erythropoiesis)Antibody made by K0 individuals is called anti-Ku and reacts with all cells except K0Due to rarity of K0 cells, K0 individuals are encouraged to pursue autologous donation and storage",
                      "Anti-Kell antibodies can cause severe transfusion reactions and HDFNGenerally IgG, rarely binds complementMost common non-ABO antibody after RhK considered most immunogenic RBC antigen outside of ABO; its higher immunogenicity but lower antibody frequency compared with Rh is caused by relative rarity of K antigenK-negative recipient transfused with K-positive packed RBC unit makes anti-K 1 in 10 times",
                      "Generally IgG, rarely binds complement",
                      "Most common non-ABO antibody after Rh",
                      "K considered most immunogenic RBC antigen outside of ABO; its higher immunogenicity but lower antibody frequency compared with Rh is caused by relative rarity of K antigen",
                      "K-negative recipient transfused with K-positive packed RBC unit makes anti-K 1 in 10 times",
                      "Antibodies to K may suppress erythropoiesis at progenitor levelLeads to fetal hypoproliferative anemia (less erythroblastosis), which can persist after birthCompared with antibodies against Rh system, lower titers are used for anti-K for triggering increased monitoring with fetal middle cerebral artery DopplersAnti-K titer of 4 or 8 is generally considered critical titer, whereas critical titer of other clinically significant antibodies is generally 16Anti-Kell HDFN is not well monitored by amniotic fluid bilirubin, as HDFN due to anti-K is associated with lower plasma and amniotic fluid bilirubin (caused by suppression of early erythropoiesis)",
                      "Leads to fetal hypoproliferative anemia (less erythroblastosis), which can persist after birth",
                      "Compared with antibodies against Rh system, lower titers are used for anti-K for triggering increased monitoring with fetal middle cerebral artery Dopplers",
                      "Anti-K titer of 4 or 8 is generally considered critical titer, whereas critical titer of other clinically significant antibodies is generally 16",
                      "Anti-Kell HDFN is not well monitored by amniotic fluid bilirubin, as HDFN due to anti-K is associated with lower plasma and amniotic fluid bilirubin (caused by suppression of early erythropoiesis)",
                      "Antibody made by K0 individuals is called anti-Ku and reacts with all cells except K0Due to rarity of K0 cells, K0 individuals are encouraged to pursue autologous donation and storage",
                      "Due to rarity of K0 cells, K0 individuals are encouraged to pursue autologous donation and storage"
                    ]
                  },
                  {
                    "text": "KxXKis only gene and antigen in Kx blood group systemXK and Kell are linked by single disulfide bondXK protein carries Ku antigen, a cryptic antigen exposed only when Kell protein is not normally expressedMcLeod phenotypeVery rare X-linked conditionCaused by deletions and mutations inXK﻿gene﻿Larger deletions on X chromosome cause loss of bothXKandCYBBgenes, resulting in McLeod syndrome with concurrent CGDCells lack Kx antigen, causing decreased expression of Kell system antigens (including Km antigen)McLeod phenotype is X-linked diseaseDefined by acanthocytosis, shortened RBC survival, late-onset neuromuscular defects (chorea, areflexia, skeletal muscle atrophy, cardiomyopathy), increased serum creatine kinaseAntibodies against Kx/Kell systemPatients with McLeod phenotype without CGD produce anti-Km (compatible with McLeod RBC and K0 RBC)Patients with McLeod phenotype with CGD produce anti-Km and anti-Kx (compatible with McLeod RBC only)Due to rarity of McLeod cells, McLeod individuals are encouraged to pursue autologous donation and storage",
                    "sub_points": [
                      "XKis only gene and antigen in Kx blood group systemXK and Kell are linked by single disulfide bondXK protein carries Ku antigen, a cryptic antigen exposed only when Kell protein is not normally expressed",
                      "XK and Kell are linked by single disulfide bond",
                      "XK protein carries Ku antigen, a cryptic antigen exposed only when Kell protein is not normally expressed",
                      "McLeod phenotypeVery rare X-linked conditionCaused by deletions and mutations inXK﻿gene﻿Larger deletions on X chromosome cause loss of bothXKandCYBBgenes, resulting in McLeod syndrome with concurrent CGDCells lack Kx antigen, causing decreased expression of Kell system antigens (including Km antigen)McLeod phenotype is X-linked diseaseDefined by acanthocytosis, shortened RBC survival, late-onset neuromuscular defects (chorea, areflexia, skeletal muscle atrophy, cardiomyopathy), increased serum creatine kinase",
                      "Very rare X-linked condition",
                      "Caused by deletions and mutations inXK﻿gene﻿Larger deletions on X chromosome cause loss of bothXKandCYBBgenes, resulting in McLeod syndrome with concurrent CGD",
                      "Larger deletions on X chromosome cause loss of bothXKandCYBBgenes, resulting in McLeod syndrome with concurrent CGD",
                      "Cells lack Kx antigen, causing decreased expression of Kell system antigens (including Km antigen)",
                      "McLeod phenotype is X-linked diseaseDefined by acanthocytosis, shortened RBC survival, late-onset neuromuscular defects (chorea, areflexia, skeletal muscle atrophy, cardiomyopathy), increased serum creatine kinase",
                      "Defined by acanthocytosis, shortened RBC survival, late-onset neuromuscular defects (chorea, areflexia, skeletal muscle atrophy, cardiomyopathy), increased serum creatine kinase",
                      "Antibodies against Kx/Kell systemPatients with McLeod phenotype without CGD produce anti-Km (compatible with McLeod RBC and K0 RBC)Patients with McLeod phenotype with CGD produce anti-Km and anti-Kx (compatible with McLeod RBC only)Due to rarity of McLeod cells, McLeod individuals are encouraged to pursue autologous donation and storage",
                      "Patients with McLeod phenotype without CGD produce anti-Km (compatible with McLeod RBC and K0 RBC)",
                      "Patients with McLeod phenotype with CGD produce anti-Km and anti-Kx (compatible with McLeod RBC only)",
                      "Due to rarity of McLeod cells, McLeod individuals are encouraged to pursue autologous donation and storage"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Kidd Blood Group System": {
            "name": "Kidd Blood Group System",
            "url": "https://app.pathprimer.com/document/1b1b2f78-566f-4199-8fdf-c9b93f16600d/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Clinically significant blood group system consisting of 2 main allelic antigens: Jka and Jkb"
                  },
                  {
                    "text": "Associated with delayed hemolytic transfusion reactions"
                  },
                  {
                    "text": "Both intravascular and extravascular hemolysis can be seen"
                  },
                  {
                    "text": "Antibodies are frequently transient and can be difficult to detect on routine pretransfusion testing"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Antigens": [
                  {
                    "text": "Found on transmembrane glycoprotein expressed predominantly on red blood cells, and endothelial cells of vasa recta in renal medullaFunctions as urea transporter",
                    "sub_points": [
                      "Functions as urea transporter"
                    ]
                  },
                  {
                    "text": "Two main antithetical allelic antigens: Jka and JkbExpressed codominantlyDiffer by a single amino substitution",
                    "sub_points": [
                      "Expressed codominantly",
                      "Differ by a single amino substitution"
                    ]
                  },
                  {
                    "text": "Three common phenotypesJk(a+b-)Jk(a-b+)Jk(a-b-)",
                    "sub_points": [
                      "Jk(a+b-)",
                      "Jk(a-b+)",
                      "Jk(a-b-)"
                    ]
                  },
                  {
                    "text": "Null phenotype is rare, but may be seen in Asian and Polynesian populationsNot associated with clinical syndrome, but null individuals have decreased ability to concentrate urineLack high-frequency Kidd antigen Jk3",
                    "sub_points": [
                      "Not associated with clinical syndrome, but null individuals have decreased ability to concentrate urine",
                      "Lack high-frequency Kidd antigen Jk3"
                    ]
                  },
                  {
                    "text": "Weak expression of Kidd antigen; detectable only by molecular methods; has been described"
                  }
                ],
                "Antibodies": [
                  {
                    "text": "Anti-Kidd antibodies are potentially clinically significant"
                  },
                  {
                    "text": "Mainly IgG, but may be partially IgMIgG1 or IgG3 isotypes may be formed, leading to activation of complement and consequent intravascular hemolysis",
                    "sub_points": [
                      "IgG1 or IgG3 isotypes may be formed, leading to activation of complement and consequent intravascular hemolysis"
                    ]
                  },
                  {
                    "text": "Most commonly detected at antihuman globulin phase of testing"
                  },
                  {
                    "text": "Frequently transient, leading to difficulty in detection during routine pretransfusion testing"
                  },
                  {
                    "text": "Dosage effect is seen due to weak avidity and low titerIncreased reactivity seen with homozygous cells compared with heterozygous cells",
                    "sub_points": [
                      "Increased reactivity seen with homozygous cells compared with heterozygous cells"
                    ]
                  },
                  {
                    "text": "Reactivity is enhanced by enzyme treatment with ficin and papain"
                  }
                ],
                "Clinical Significance": [
                  {
                    "text": "Common cause of mild to moderate delayed hemolytic transfusion reactions"
                  },
                  {
                    "text": "Intravascular hemolysis (in addition to extravascular hemolysis) may be present"
                  },
                  {
                    "text": "Can cause mild hemolytic disease of fetus and newborn"
                  },
                  {
                    "text": "Brisk anamnestic response with rapid intravascular and extravascular hemolysis may be seen after transfusion of crossmatch-compatible red blood cells due to undetectable anti-Kidd antibodies on pretransfusion testingTransfusion reaction work-up on posttransfusion patient sample demonstrates the followingPositive crossmatch with transfused red blood cellsIdentification of anti-Kidd antibody on reagent red cell panelPositive direct antiglobulin testing with IgG and complementIdentification of anti-Kidd antibody in eluate",
                    "sub_points": [
                      "Transfusion reaction work-up on posttransfusion patient sample demonstrates the followingPositive crossmatch with transfused red blood cellsIdentification of anti-Kidd antibody on reagent red cell panelPositive direct antiglobulin testing with IgG and complementIdentification of anti-Kidd antibody in eluate",
                      "Positive crossmatch with transfused red blood cells",
                      "Identification of anti-Kidd antibody on reagent red cell panel",
                      "Positive direct antiglobulin testing with IgG and complement",
                      "Identification of anti-Kidd antibody in eluate"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "MNSs Blood Group System": {
            "name": "MNSs Blood Group System",
            "url": "https://app.pathprimer.com/document/cbd6940a-96d3-4a18-85e6-0947e2efe7e7/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Blood group system consisting of 5 main antigens: M, N, S, s, and U"
                  },
                  {
                    "text": "Anti-M and anti-N are generally clinically insignificant"
                  },
                  {
                    "text": "Anti-S, anti-s, and anti-U are clinically significant; generally associated with delayed hemolytic transfusion reactions"
                  },
                  {
                    "text": "U- RBC units are very rare (< 1% of black blood donors); frequently frozen units"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Antigens": [
                  {
                    "text": "MNSs blood group system includes more than 40 antigens with carbohydrate and peptide epitopes"
                  },
                  {
                    "text": "Major antigens are M, N, S, s, and U (universal antigen)"
                  },
                  {
                    "text": "Present on glycophorin A and glycophorin B, which are expressed on red blood cells and on renal endothelial and epithelial cells"
                  },
                  {
                    "text": "Glycophorins are receptors for viruses, bacteria, and malarial parasitePlasmodium falciparumGlycophorin null RBCs are resistant toPlasmodium falciparuminfection ﻿in vitro﻿",
                    "sub_points": [
                      "Glycophorin null RBCs are resistant toPlasmodium falciparuminfection ﻿in vitro﻿"
                    ]
                  },
                  {
                    "text": "Glycophorin ACarries M and N antithetical codominantly expressed antigensNull phenotype lack high-incidence antigen Ena",
                    "sub_points": [
                      "Carries M and N antithetical codominantly expressed antigens",
                      "Null phenotype lack high-incidence antigen Ena"
                    ]
                  },
                  {
                    "text": "Glycophorin BCarries S and s antithetical codominantly expressed antigensCarries high-frequency antigen UU- phenotype is seen only in individuals of African descentU- individuals lack glycophorin B and, therefore, always lack S and s antigensS- s- individuals do not always lack U antigen; approximately 16% express variant formHas N-like peptide at amino terminus",
                    "sub_points": [
                      "Carries S and s antithetical codominantly expressed antigens",
                      "Carries high-frequency antigen U",
                      "U- phenotype is seen only in individuals of African descentU- individuals lack glycophorin B and, therefore, always lack S and s antigensS- s- individuals do not always lack U antigen; approximately 16% express variant form",
                      "U- individuals lack glycophorin B and, therefore, always lack S and s antigens",
                      "S- s- individuals do not always lack U antigen; approximately 16% express variant form",
                      "Has N-like peptide at amino terminus"
                    ]
                  }
                ],
                "Antibodies": [
                  {
                    "text": "Anti-MPrimarily IgM, but may have IgG componentGenerally, cold-reacting antibodies are formed, but may react at all phases (immediate spin, 37°C, and antihuman globulin) of testingAntibodies reacting at 37°C may be clinically significant and M negative; crossmatch compatible RBCs should be providedCan be naturally occurringOften show dosage effect with increased reactivity to homozygous cells on reagent red cell panelsSensitive to enzyme treatment",
                    "sub_points": [
                      "Primarily IgM, but may have IgG component",
                      "Generally, cold-reacting antibodies are formed, but may react at all phases (immediate spin, 37°C, and antihuman globulin) of testingAntibodies reacting at 37°C may be clinically significant and M negative; crossmatch compatible RBCs should be provided",
                      "Antibodies reacting at 37°C may be clinically significant and M negative; crossmatch compatible RBCs should be provided",
                      "Can be naturally occurring",
                      "Often show dosage effect with increased reactivity to homozygous cells on reagent red cell panels",
                      "Sensitive to enzyme treatment"
                    ]
                  },
                  {
                    "text": "Anti-NPrimarily IgM and cold reactingCan be naturally occurringOften show dosage effect with increased reactivity to homozygous cells on reagent red cell panelsSensitive to enzyme treatmentAuto-anti-N is associated with exposure to hemodialysis equipment sterilized with formaldehydeCan cause warm autoimmune hemolytic anemia",
                    "sub_points": [
                      "Primarily IgM and cold reacting",
                      "Can be naturally occurring",
                      "Often show dosage effect with increased reactivity to homozygous cells on reagent red cell panels",
                      "Sensitive to enzyme treatment",
                      "Auto-anti-N is associated with exposure to hemodialysis equipment sterilized with formaldehydeCan cause warm autoimmune hemolytic anemia",
                      "Can cause warm autoimmune hemolytic anemia"
                    ]
                  },
                  {
                    "text": "Anti-S and anti-sPrimarily IgG antibodies and may fix complementVariable sensitivity for enzyme treatment with ficin and papainReactive at antihuman globulin phase of testingOften show dosage effect with increased reactivity to homozygous cells on reagent red cell panelsGenerally causes extravascular hemolysis",
                    "sub_points": [
                      "Primarily IgG antibodies and may fix complement",
                      "Variable sensitivity for enzyme treatment with ficin and papain",
                      "Reactive at antihuman globulin phase of testing",
                      "Often show dosage effect with increased reactivity to homozygous cells on reagent red cell panels",
                      "Generally causes extravascular hemolysis"
                    ]
                  },
                  {
                    "text": "Anti-UPrimarily IgG antibodiesReactive at antihuman globulin phase of testingResistant to enzyme treatmentGenerally causes extravascular hemolysis",
                    "sub_points": [
                      "Primarily IgG antibodies",
                      "Reactive at antihuman globulin phase of testing",
                      "Resistant to enzyme treatment",
                      "Generally causes extravascular hemolysis"
                    ]
                  }
                ],
                "Clinical Significance": [
                  {
                    "text": "Anti-S, anti-s, and anti-U are clinically significantAssociated with mild to severe hemolytic transfusion reactions and mild to severe hemolytic disease of fetus and newborn",
                    "sub_points": [
                      "Associated with mild to severe hemolytic transfusion reactions and mild to severe hemolytic disease of fetus and newborn"
                    ]
                  },
                  {
                    "text": "Anti-M is usually clinically insignificant, but has occasionally been associated with generally mild hemolytic transfusion reactions and mild hemolytic disease of fetus and newborn when reactive at 37°C and at antihuman globulin phases of testing"
                  },
                  {
                    "text": "Anti-N is very rare; usually clinically insignificant"
                  },
                  {
                    "text": "Rare U- blood must be provided to individuals with anti-U antibodies< 1% of black donors are U-",
                    "sub_points": [
                      "< 1% of black donors are U-"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Duffy Blood Group System": {
            "name": "Duffy Blood Group System",
            "url": "https://app.pathprimer.com/document/c21c5d49-d981-4644-b9b7-b9c435c1908b/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Clinically significant blood group system consisting of 2 main antigens, Fya and Fyb"
                  },
                  {
                    "text": "Associated with mild to severe hemolytic transfusion reactions"
                  },
                  {
                    "text": "Associated with mild to severe hemolytic disease of fetus and newborn"
                  },
                  {
                    "text": "Receptor forPlasmodium vivaxandPlasmodium knowlesimalarial parasites"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Duffy antigen receptor for chemokines (DARC)"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Antigens": [
                  {
                    "text": "Found on transmembrane glycoprotein DARCExpressed on red blood cells, Purkinje cells, and on endothelial cells in multiple organ systems",
                    "sub_points": [
                      "Expressed on red blood cells, Purkinje cells, and on endothelial cells in multiple organ systems"
                    ]
                  },
                  {
                    "text": "Fya and Fyb are 2 main antithetical allelesExpressed codominantlyDiffer by single amino acid",
                    "sub_points": [
                      "Expressed codominantly",
                      "Differ by single amino acid"
                    ]
                  },
                  {
                    "text": "Four main phenotypes are seenFy(a+b-)Fy(a-b+)Fy(a+b+)Fy(a-b-)",
                    "sub_points": [
                      "Fy(a+b-)",
                      "Fy(a-b+)",
                      "Fy(a+b+)",
                      "Fy(a-b-)"
                    ]
                  },
                  {
                    "text": "Fy3 is high-frequency antigen on DARC"
                  },
                  {
                    "text": "DARC is receptor for malarial parasitesPlasmodium vivaxandPlasmodium knowlesi"
                  },
                  {
                    "text": "Homozygous inheritance of single nucleic acid substitution within GATA box of erythroid-specific promoter ofFYgene leads to Fy(a-b-) red blood cell phenotype in individuals of African ancestryThese individuals are resistant to infection byPlasmodium vivaxandPlasmodium knowlesiAlmost 100% of West Africans are Fy(a-b-) due to inheritance of this mutationMutation affects expression of Fyb but not Fya on RBCs, but does not affect expression on other tissues",
                    "sub_points": [
                      "These individuals are resistant to infection byPlasmodium vivaxandPlasmodium knowlesi",
                      "Almost 100% of West Africans are Fy(a-b-) due to inheritance of this mutation",
                      "Mutation affects expression of Fyb but not Fya on RBCs, but does not affect expression on other tissues"
                    ]
                  }
                ],
                "Antibodies": [
                  {
                    "text": "Almost always IgG, rarely IgM, and do not fix complement"
                  },
                  {
                    "text": "Anti-Fya is more common than anti-Fyb"
                  },
                  {
                    "text": "Detectable at antihuman globulin phase of testing"
                  },
                  {
                    "text": "Can cause extravascular hemolysis"
                  },
                  {
                    "text": "Dosage effect can be seenIncreased reactivity seen with homozygous cells compared with heterozygous cells",
                    "sub_points": [
                      "Increased reactivity seen with homozygous cells compared with heterozygous cells"
                    ]
                  },
                  {
                    "text": "Reactivity destroyed by enzyme treatment with papain and ficin"
                  }
                ],
                "Clinical Significance": [
                  {
                    "text": "Cause of mild to severe hemolytic transfusion reactions"
                  },
                  {
                    "text": "Cause of mild to severe hemolytic disease of fetus and newborn"
                  },
                  {
                    "text": "Fy(a-b-) individuals are resistant to infection by malarial parasitesPlasmodium vivaxandPlasmodium knowlesi"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lewis Blood Group System": {
            "name": "Lewis Blood Group System",
            "url": "https://app.pathprimer.com/document/39f52945-e9eb-475a-bc43-1c99ba744795/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "FUT3 (Le) is fucosyltransferase that adds fucose toN-acetylgalactosamine to type 1 precursor chains to create Le antigen on secreted proteins"
                  },
                  {
                    "text": "Le(a) and Le(b) antigens are product of interplay ofLe (FUT3)andSe (FUT2)genes → Le(a) and Le(b) are not alleles"
                  },
                  {
                    "text": "Le expression on RBCs is often greatly reduced during pregnancy; this is thought to be due to increased plasma volume with increased circulating lipoprotein mass causing passive elution of Le antigen off of RBC"
                  }
                ]
              },
              "OVERVIEW": {
                "Lewis Blood Group System": [
                  {
                    "text": "Antigens Lea and Leb are produced by 2 different enzymes, FUT3 and FUT2"
                  },
                  {
                    "text": "Lea is precursor molecule for Leb"
                  },
                  {
                    "text": "Antibodies to Lewis antigens are generally IgM and clinically insignificant"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Hemolytic disease of fetus and newborn (HDFN)"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "Anti-Lewis Antibodies": [
                  {
                    "text": "Anti-Le antibodies are generally IgM and are naturally occurringReact at room temperatureRarely anti-Le antibodies react at 37°C and can cause in vitro hemolysisPatients need to be issued crossmatch compatible bloodAnti-Le antibodies are most often detected in Le(a-b-) patients.Le expression on RBCs is often greatly reduced during pregnancyThought to be due to increased plasma volume with increased circulating lipoprotein mass causing passive elution of Le antigen off of RBCPregnant women may type as Le(a-b-)Can be associated with transient development of anti-Le antibodiesCan show mixture of anti-Le(a), anti-Le(b), anti-Le(ab) reactionsCan sometimes show ABO effect reacting with combinations of A &/or B antigens and Le antigensAnti-ALe(b) is antibody that reacts strongly only with type A Le(b+) cellsLewis antigen is enhanced by enzymesPapain, ficinLewis antibodies are neutralized by secretions (i.e., saliva) or by transfused plasmaLewis antibodies are not associated with HDFN",
                    "sub_points": [
                      "React at room temperature",
                      "Rarely anti-Le antibodies react at 37°C and can cause in vitro hemolysisPatients need to be issued crossmatch compatible blood",
                      "Patients need to be issued crossmatch compatible blood",
                      "Anti-Le antibodies are most often detected in Le(a-b-) patients.Le expression on RBCs is often greatly reduced during pregnancyThought to be due to increased plasma volume with increased circulating lipoprotein mass causing passive elution of Le antigen off of RBCPregnant women may type as Le(a-b-)Can be associated with transient development of anti-Le antibodiesCan show mixture of anti-Le(a), anti-Le(b), anti-Le(ab) reactionsCan sometimes show ABO effect reacting with combinations of A &/or B antigens and Le antigensAnti-ALe(b) is antibody that reacts strongly only with type A Le(b+) cells",
                      "Le expression on RBCs is often greatly reduced during pregnancyThought to be due to increased plasma volume with increased circulating lipoprotein mass causing passive elution of Le antigen off of RBC",
                      "Thought to be due to increased plasma volume with increased circulating lipoprotein mass causing passive elution of Le antigen off of RBC",
                      "Pregnant women may type as Le(a-b-)Can be associated with transient development of anti-Le antibodies",
                      "Can be associated with transient development of anti-Le antibodies",
                      "Can show mixture of anti-Le(a), anti-Le(b), anti-Le(ab) reactions",
                      "Can sometimes show ABO effect reacting with combinations of A &/or B antigens and Le antigensAnti-ALe(b) is antibody that reacts strongly only with type A Le(b+) cells",
                      "Anti-ALe(b) is antibody that reacts strongly only with type A Le(b+) cells",
                      "Lewis antigen is enhanced by enzymesPapain, ficin",
                      "Papain, ficin",
                      "Lewis antibodies are neutralized by secretions (i.e., saliva) or by transfused plasma",
                      "Lewis antibodies are not associated with HDFN"
                    ]
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Lea and Leb Antigens": [
                  {
                    "text": "Lea and Leb are synthesized on type 1 glycoproteins and secreted by epithelial cells"
                  },
                  {
                    "text": "These antigens may be free in plasma, may be bound to lipoproteins, or are adsorbed onto RBC membranes"
                  },
                  {
                    "text": "Le antigens are not intrinsic to RBCApproximately 1/3 of blood Le substance is on RBCApproximately 2/3 are in plasma",
                    "sub_points": [
                      "Approximately 1/3 of blood Le substance is on RBC",
                      "Approximately 2/3 are in plasma"
                    ]
                  },
                  {
                    "text": "Lea and Leb are produced by 2 different fucosyltransferases"
                  },
                  {
                    "text": "Lea antigenCreated by addition of fucose toN-acetylgalactosamine by FUT3FUT3 is encoded by the geneLEResulting phenotype is Le(a+b-)leallele is amorphDoes not code for transferase enzymeNo Le antigen in secretions",
                    "sub_points": [
                      "Created by addition of fucose toN-acetylgalactosamine by FUT3",
                      "FUT3 is encoded by the geneLE",
                      "Resulting phenotype is Le(a+b-)",
                      "leallele is amorphDoes not code for transferase enzymeNo Le antigen in secretions",
                      "Does not code for transferase enzyme",
                      "No Le antigen in secretions"
                    ]
                  },
                  {
                    "text": "Leb antigenCreated by addition of fucose to terminal galactose by FUT2Fucose is H antigen in secretions and base for formation of A and B antigens in secretionsIndividuals with at least 1 Se allele are called \"secretors\"They are able to form H antigen on secreted proteins in saliva, plasma, other secretionsApproximately 80% of Caucasians are secretorsFUT2 is encoded by geneSEseis amorph alleleDoes not code for transferase enzymese/seindividuals do not form A, B, H antigen in secretionsFUT3 must add fucose toN-acetylgalactosamine for FUT2 to add fucose to terminal galactoseThis converts phenotype Le(a+b-) to Le(a-b+)Creation of Leb antigen requires functional FUT2 and FUT3WithoutLEgene and FUT3 enzyme, individuals have Le(a-b-) phenotype with or without presence ofSEgene and FUT2 enzyme",
                    "sub_points": [
                      "Created by addition of fucose to terminal galactose by FUT2",
                      "Fucose is H antigen in secretions and base for formation of A and B antigens in secretionsIndividuals with at least 1 Se allele are called \"secretors\"They are able to form H antigen on secreted proteins in saliva, plasma, other secretionsApproximately 80% of Caucasians are secretors",
                      "Individuals with at least 1 Se allele are called \"secretors\"They are able to form H antigen on secreted proteins in saliva, plasma, other secretions",
                      "They are able to form H antigen on secreted proteins in saliva, plasma, other secretions",
                      "Approximately 80% of Caucasians are secretors",
                      "FUT2 is encoded by geneSE",
                      "seis amorph alleleDoes not code for transferase enzymese/seindividuals do not form A, B, H antigen in secretions",
                      "Does not code for transferase enzyme",
                      "se/seindividuals do not form A, B, H antigen in secretions",
                      "FUT3 must add fucose toN-acetylgalactosamine for FUT2 to add fucose to terminal galactose",
                      "This converts phenotype Le(a+b-) to Le(a-b+)",
                      "Creation of Leb antigen requires functional FUT2 and FUT3",
                      "WithoutLEgene and FUT3 enzyme, individuals have Le(a-b-) phenotype with or without presence ofSEgene and FUT2 enzyme"
                    ]
                  },
                  {
                    "text": "Le and Se antigens are not well expressed on cord RBCsNeonates type as Le(a-b-)Accurate Lewis phenotype is not developed until 5-6 yr oldLe(a) is made before Le(b)Le enzyme levels reach adult levels before Se",
                    "sub_points": [
                      "Neonates type as Le(a-b-)",
                      "Accurate Lewis phenotype is not developed until 5-6 yr old",
                      "Le(a) is made before Le(b)Le enzyme levels reach adult levels before Se",
                      "Le enzyme levels reach adult levels before Se"
                    ]
                  },
                  {
                    "text": "Lewis antigens are enhanced by enzyme (i.e., ficin, papain) treatment"
                  },
                  {
                    "text": "Le antigen levels on RBCs may decrease with pregnancy"
                  }
                ],
                "Lewis Inheritance and Expression Patterns": [
                  {
                    "text": "SEse/SESEandleleexpress FUT2 but not FUT3 → Le(a-b-)"
                  },
                  {
                    "text": "SEse/SESEandLEle/LELEexpress both FUT2 and FUT3 → Le(a-b+)"
                  },
                  {
                    "text": "seseandLEle/LELEexpress FUT3 but not FUT2 → Le(a+b-)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Lewis System Outside of Transfusion Medicine": [
                  {
                    "text": "H on type 1 chains and Le(b) are receptors for some strains ofHelicobacter pyloriType O secretors are more prone to peptic ulcer disease",
                    "sub_points": [
                      "Type O secretors are more prone to peptic ulcer disease"
                    ]
                  },
                  {
                    "text": "H on type 1 chains and Le(b) are also receptors forNorovirus"
                  },
                  {
                    "text": "Sialylated Lewis antigens are ligands for E-selectin and markers for carcinomasCA19-9 is synonymous with sialyl-Le(a)Antigen sialyl-Le(a) is secreted by pancreatic and biliary epithelial cells and can be elevated in pancreatic cancer, pancreatitis, and biliary obstructionConcentration of tumor marker CA 19-9 is influenced by patient'sSeandLegenotype",
                    "sub_points": [
                      "CA19-9 is synonymous with sialyl-Le(a)Antigen sialyl-Le(a) is secreted by pancreatic and biliary epithelial cells and can be elevated in pancreatic cancer, pancreatitis, and biliary obstructionConcentration of tumor marker CA 19-9 is influenced by patient'sSeandLegenotype",
                      "Antigen sialyl-Le(a) is secreted by pancreatic and biliary epithelial cells and can be elevated in pancreatic cancer, pancreatitis, and biliary obstruction",
                      "Concentration of tumor marker CA 19-9 is influenced by patient'sSeandLegenotype"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "I, P, and GLOB Blood Group Systems": {
            "name": "I, P, and GLOB Blood Group Systems",
            "url": "https://app.pathprimer.com/document/13574b1a-e5ab-4706-9f83-2fe349e12347/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Blood Group Antigens": [
                  {
                    "text": "Ii blood group system has two antigens - I and iI is a branched carbohydrate structure found on adult RBCs, tissues, and secretionsi is a linear carbohydrate structure found on fetal and infant RBCs, tissues, and secretionsi antigen becomes I antigen with increasing age as carbohydrate structures become increasingly branchedAntibodies to these antigens are IgM and typically clinically insignificant",
                    "sub_points": [
                      "I is a branched carbohydrate structure found on adult RBCs, tissues, and secretions",
                      "i is a linear carbohydrate structure found on fetal and infant RBCs, tissues, and secretions",
                      "i antigen becomes I antigen with increasing age as carbohydrate structures become increasingly branched",
                      "Antibodies to these antigens are IgM and typically clinically insignificant"
                    ]
                  },
                  {
                    "text": "Pk, P, and LKE are all high-incidence antigens expressed on nearly all RBC"
                  },
                  {
                    "text": "Autoanti-P is associated with paroxysmal cold hemaglobinuria"
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Ii Blood Group System": [
                  {
                    "text": "Carbohydrate antigens found on oligosaccharide chains on tissue and RBCs"
                  },
                  {
                    "text": "i antigenFormed by disaccharide units linked in a straight chainFound on fetal and infant RBCs, tissues, and secretionsIncreased expression of an acetyl-glucosamine transferase during the six years of life leads to increased branching and formation of the I antigenMutations in the gene for acetyl-glucosamine transferase can lead to rare adult i phenotype",
                    "sub_points": [
                      "Formed by disaccharide units linked in a straight chain",
                      "Found on fetal and infant RBCs, tissues, and secretions",
                      "Increased expression of an acetyl-glucosamine transferase during the six years of life leads to increased branching and formation of the I antigen",
                      "Mutations in the gene for acetyl-glucosamine transferase can lead to rare adult i phenotype"
                    ]
                  },
                  {
                    "text": "I antigenFormed by branched disaccharide unitsFound on RBCs, tissues, and secretions of older children and adults",
                    "sub_points": [
                      "Formed by branched disaccharide units",
                      "Found on RBCs, tissues, and secretions of older children and adults"
                    ]
                  },
                  {
                    "text": "AntibodiesIgM antibodies (or cold agglutinins) that are generally low titer and react optimally at 4 degrees CAnti-I reacts most strongly with adult RBCsAnti-i reacts most strongly with cord bloodPresent in the plasma of all adults at low titers and are usually benignReactivity enhanced by enzyme treatmentPrewarm technique or performing all testing at 37 degrees C can be used when anti-I antibodies interfere with pretransfusion testingRabbit erythrocyte stroma (REST) can also remove cold agglutininsAdults with i phenotype can form alloanti-IAlloanti-I is generally clinically insignificantRarely associated with hemolytic transfusion reactions when reactive at 37 degreesAnti-IH antibodies, most commonly formed by Group A1 individuals, react with H and I antigens and can rarely cause hemolytic transfusion reactions when reactive at 37 degrees C",
                    "sub_points": [
                      "IgM antibodies (or cold agglutinins) that are generally low titer and react optimally at 4 degrees CAnti-I reacts most strongly with adult RBCsAnti-i reacts most strongly with cord blood",
                      "Anti-I reacts most strongly with adult RBCs",
                      "Anti-i reacts most strongly with cord blood",
                      "Present in the plasma of all adults at low titers and are usually benign",
                      "Reactivity enhanced by enzyme treatment",
                      "Prewarm technique or performing all testing at 37 degrees C can be used when anti-I antibodies interfere with pretransfusion testing",
                      "Rabbit erythrocyte stroma (REST) can also remove cold agglutinins",
                      "Adults with i phenotype can form alloanti-IAlloanti-I is generally clinically insignificantRarely associated with hemolytic transfusion reactions when reactive at 37 degrees",
                      "Alloanti-I is generally clinically insignificant",
                      "Rarely associated with hemolytic transfusion reactions when reactive at 37 degrees",
                      "Anti-IH antibodies, most commonly formed by Group A1 individuals, react with H and I antigens and can rarely cause hemolytic transfusion reactions when reactive at 37 degrees C"
                    ]
                  },
                  {
                    "text": "Cold Agglutinin DiseaseOccurs when autoanti-I antobodies have broad thermal amplitude (reactive at 37 degrees C) and are high titerAcute and transient cold agglutinin disease is associated with infectionsAnti-i is associated with Epstein Barr virus (EBV) infectionAnti-I is associated with mycoplasma infectionChronic cold agglutinin disease is associated with clonal B cell expansion (CLL, B cell lymphomas)",
                    "sub_points": [
                      "Occurs when autoanti-I antobodies have broad thermal amplitude (reactive at 37 degrees C) and are high titer",
                      "Acute and transient cold agglutinin disease is associated with infectionsAnti-i is associated with Epstein Barr virus (EBV) infectionAnti-I is associated with mycoplasma infection",
                      "Anti-i is associated with Epstein Barr virus (EBV) infection",
                      "Anti-I is associated with mycoplasma infection",
                      "Chronic cold agglutinin disease is associated with clonal B cell expansion (CLL, B cell lymphomas)"
                    ]
                  }
                ],
                "P1PK and GLOB Blood Group Systems": [
                  {
                    "text": "The synthesis of Pk, P, and P1 antigens originates from step-wise addition of sugars to lactosylceramide"
                  },
                  {
                    "text": "Downstream products of lactosylceramide modification follow two pathways:Globo family (Pk-->P-->LKE)Pk, P, and LKE are all high-incidence antigens expressed on nearly all RBCPk and P antigens are widely expressed on tissuesP is receptor for parvovirus B19Pk is receptor for Shiga toxinP1/P/Pk are all receptors for fibriated E. coliNeolacto/paragloboside family (P1)P1 antigen is restricted to RBC",
                    "sub_points": [
                      "Globo family (Pk-->P-->LKE)Pk, P, and LKE are all high-incidence antigens expressed on nearly all RBCPk and P antigens are widely expressed on tissuesP is receptor for parvovirus B19Pk is receptor for Shiga toxinP1/P/Pk are all receptors for fibriated E. coli",
                      "Pk, P, and LKE are all high-incidence antigens expressed on nearly all RBC",
                      "Pk and P antigens are widely expressed on tissues",
                      "P is receptor for parvovirus B19",
                      "Pk is receptor for Shiga toxin",
                      "P1/P/Pk are all receptors for fibriated E. coli",
                      "Neolacto/paragloboside family (P1)P1 antigen is restricted to RBC",
                      "P1 antigen is restricted to RBC"
                    ]
                  },
                  {
                    "text": "Lack of P1, Pk, and P antigens is called p phenotype"
                  },
                  {
                    "text": "Lack of P is called Pk phenotype"
                  },
                  {
                    "text": "AntibodiesAnti-P1, anti-P, and anti-P1PPk antibodiesNatural anti-P1 found in ~25% of P2 individuals, titers are elevated in bird handlers and those with hydatid cyst disease (Echinococcus)Anti-P1 is a cold-reactive IgM that is generally naturally occurringAnti-P1 is neutralized by hydatid cyst fluid and pigeon egg whites,P1 expression is variable in donors, therefore anti-P1 can show unexpected pattern in identification panelsp phenotype individuals can form natural anti-PP1Pk which is clinically significant and is associated with spontaneous abortions in affected mothersPk phenotype individuals can form natural alloanti-P which is clinically significantAutoanti-P antibodyDonath-Landsteiner biphasic hemolysin seen in paroxysmal cold hemoglobinuriaHistorically associated with syphilis but more commonly seen in children today after upper respiratory and gastrointestinal infectionsBinds to RBCs in the cold, fixes complement, and dissociates in warmer areas of the bodyCauses a positive direct antiglobulin test (DAT) with complementHemolysis occurs after exposure to colder temperatures",
                    "sub_points": [
                      "Anti-P1, anti-P, and anti-P1PPk antibodiesNatural anti-P1 found in ~25% of P2 individuals, titers are elevated in bird handlers and those with hydatid cyst disease (Echinococcus)Anti-P1 is a cold-reactive IgM that is generally naturally occurringAnti-P1 is neutralized by hydatid cyst fluid and pigeon egg whites,P1 expression is variable in donors, therefore anti-P1 can show unexpected pattern in identification panelsp phenotype individuals can form natural anti-PP1Pk which is clinically significant and is associated with spontaneous abortions in affected mothersPk phenotype individuals can form natural alloanti-P which is clinically significant",
                      "Natural anti-P1 found in ~25% of P2 individuals, titers are elevated in bird handlers and those with hydatid cyst disease (Echinococcus)",
                      "Anti-P1 is a cold-reactive IgM that is generally naturally occurring",
                      "Anti-P1 is neutralized by hydatid cyst fluid and pigeon egg whites,",
                      "P1 expression is variable in donors, therefore anti-P1 can show unexpected pattern in identification panels",
                      "p phenotype individuals can form natural anti-PP1Pk which is clinically significant and is associated with spontaneous abortions in affected mothers",
                      "Pk phenotype individuals can form natural alloanti-P which is clinically significant",
                      "Autoanti-P antibodyDonath-Landsteiner biphasic hemolysin seen in paroxysmal cold hemoglobinuriaHistorically associated with syphilis but more commonly seen in children today after upper respiratory and gastrointestinal infectionsBinds to RBCs in the cold, fixes complement, and dissociates in warmer areas of the bodyCauses a positive direct antiglobulin test (DAT) with complementHemolysis occurs after exposure to colder temperatures",
                      "Donath-Landsteiner biphasic hemolysin seen in paroxysmal cold hemoglobinuria",
                      "Historically associated with syphilis but more commonly seen in children today after upper respiratory and gastrointestinal infections",
                      "Binds to RBCs in the cold, fixes complement, and dissociates in warmer areas of the body",
                      "Causes a positive direct antiglobulin test (DAT) with complement",
                      "Hemolysis occurs after exposure to colder temperatures"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Other Blood Group Systems, Collections, and Series": {
            "name": "Other Blood Group Systems, Collections, and Series",
            "url": "https://app.pathprimer.com/document/a443947d-f556-44a3-bb53-a4a6742ffd2d/lesson/22ee60f7-2748-47fa-b7e7-3785ad271a98",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Blood group systems: Antigens controlled at a single gene locus or by 2 or more very closely linked homologous genes"
                  },
                  {
                    "text": "Blood group collections: Serologically, biochemically, or genetically related antigens"
                  },
                  {
                    "text": "Blood group series: Antigens that do not fit within a blood group system or collection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemolytic disease of the fetus and newborn (HDFN)"
                  },
                  {
                    "text": "Hemolytic transfusion reaction (HTR)"
                  },
                  {
                    "text": "Indirect antiglobulin testing (IAT)"
                  },
                  {
                    "text": "International Society for Blood Transfusion (ISBT)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Blood group systems: According to ISBT, these are antigens controlled at a single gene locus or by 2 or more very closely linked homologous genes with little or no observable recombination between them"
                  },
                  {
                    "text": "Blood group collections: According to ISBT, these are serologically, biochemically, or genetically related antigens"
                  },
                  {
                    "text": "Blood group series: Include antigens that do not fit within a blood group system or collection700 series includes low-frequency antigens (incidence < 1%)901 series includes high-frequency antigens (incidence > 90%)",
                    "sub_points": [
                      "700 series includes low-frequency antigens (incidence < 1%)",
                      "901 series includes high-frequency antigens (incidence > 90%)"
                    ]
                  }
                ]
              },
              "BLOOD GROUP ANTIGENS": {
                "Dombrock System": [
                  {
                    "text": "Includes 5 antigens: Doa, Dob, and high-prevalence antigens Gya, Hy, and Joa"
                  },
                  {
                    "text": "Antibodies to antigens of Dombrock system are IgG and reactive at IAT"
                  },
                  {
                    "text": "Anti-Gya may be produced by individuals with Dombrock null phenotype"
                  },
                  {
                    "text": "Anti-Doa and -Dob antibodiesWeakly reactiveOften difficult to detectHave been associated with acute HTRs, delayed hemolysis, and HDFN",
                    "sub_points": [
                      "Weakly reactive",
                      "Often difficult to detect",
                      "Have been associated with acute HTRs, delayed hemolysis, and HDFN"
                    ]
                  },
                  {
                    "text": "Anti-Gya, -Hy, and -Joa antibodies have been associated with delayed hemolysis"
                  }
                ],
                "Lutheran System": [
                  {
                    "text": "Contains more than 20 antigens located on B-CAM adhesion glycoproteins"
                  },
                  {
                    "text": "Major antigens are Lua and LubLua: Low-incidence antigen; anti-Lua antibodies are rarely considered clinically significantLub: High-incidence antigen; anti-Lub antibodies have been implicated in mild HTRs and mild HDFN",
                    "sub_points": [
                      "Lua: Low-incidence antigen; anti-Lua antibodies are rarely considered clinically significant",
                      "Lub: High-incidence antigen; anti-Lub antibodies have been implicated in mild HTRs and mild HDFN"
                    ]
                  },
                  {
                    "text": "Lutheran antigens are poorly developed at birth"
                  }
                ],
                "Diego System": [
                  {
                    "text": "Includes 2 pairs of antithetical antigens — Dia/Dib and Wra/Wrb — and 22 low-frequency antigensAntigens are located on band 3, a chloride-bicarbonate exchanger in red blood cell membraneDia: Low-frequency antigenDib: High-frequency antigen, except in some North and South American populations",
                    "sub_points": [
                      "Antigens are located on band 3, a chloride-bicarbonate exchanger in red blood cell membrane",
                      "Dia: Low-frequency antigen",
                      "Dib: High-frequency antigen, except in some North and South American populations"
                    ]
                  },
                  {
                    "text": "Anti-Dia and -Dib antibodies have been associated with HTRs and HDFN"
                  },
                  {
                    "text": "Anti-Wra is relatively common, can be IgG or IgM, does not require sensitization, and is rarely associated with HTRs or HDFN"
                  },
                  {
                    "text": "Anti-Wrb is rarely detected in pretransfusion testing, but may be clinically significant"
                  }
                ],
                "Colton System": [
                  {
                    "text": "Includes antithetical antigens Coa/Cob, which are located on aquaporin-1Coa: High-frequency antigenCob: Low-frequency antigen",
                    "sub_points": [
                      "Coa: High-frequency antigen",
                      "Cob: Low-frequency antigen"
                    ]
                  },
                  {
                    "text": "Colton antibodies usually IgG and reactive at IAT, and have been implicated in HTRs and HDFN"
                  }
                ],
                "Knops System": [
                  {
                    "text": "Includes multiple high-incidence antigens located on complement receptor on red blood cells"
                  },
                  {
                    "text": "Antibodies to these antigens demonstrate variable (but often weak) reactivity, but may be reactive even at high dilutions"
                  },
                  {
                    "text": "Antibodies to these antigens are not clinically significant"
                  }
                ],
                "Chido/Rogers System": [
                  {
                    "text": "Includes 2 high-incidence antigens — Ch and Rg — located on complement"
                  },
                  {
                    "text": "Antigens adsorb onto red blood cell membrane"
                  },
                  {
                    "text": "Antibodies to these antigens are not clinically significant and are neutralized by plasma"
                  }
                ],
                "Xg System": [
                  {
                    "text": "Xga is located on CD99, which is an adhesion molecule"
                  },
                  {
                    "text": "Gene for this antigen is on X chromosome"
                  },
                  {
                    "text": "Antibodies to Xga may be naturally occurring and are not generally considered clinically significant"
                  }
                ],
                "Cost Collection": [
                  {
                    "text": "Include Csa and Csb antigens"
                  },
                  {
                    "text": "Antibodies to these antigens are generally considered not clinically significant"
                  }
                ],
                "901 series": [
                  {
                    "text": "Includes high-incidence antigens found in > 90% of individuals in most populations tested"
                  },
                  {
                    "text": "ExamplesBg (Bennett-Goodspeed) antigensCorrespond to human leukocyte antigens (HLAs)Bga corresponds to HLA-B7Bgb corresponds to HLA-B17Bgc corresponds to HLA-A28Variable expression on red blood cellsSda antigenAntigen located on carbohydrates with variable expression on red blood cellsExpression may decrease during pregnancyAnti-Sda antibodies are generally not clinically significant and are neutralized by urine",
                    "sub_points": [
                      "Bg (Bennett-Goodspeed) antigensCorrespond to human leukocyte antigens (HLAs)Bga corresponds to HLA-B7Bgb corresponds to HLA-B17Bgc corresponds to HLA-A28Variable expression on red blood cells",
                      "Correspond to human leukocyte antigens (HLAs)Bga corresponds to HLA-B7Bgb corresponds to HLA-B17Bgc corresponds to HLA-A28",
                      "Bga corresponds to HLA-B7",
                      "Bgb corresponds to HLA-B17",
                      "Bgc corresponds to HLA-A28",
                      "Variable expression on red blood cells",
                      "Sda antigenAntigen located on carbohydrates with variable expression on red blood cellsExpression may decrease during pregnancyAnti-Sda antibodies are generally not clinically significant and are neutralized by urine",
                      "Antigen located on carbohydrates with variable expression on red blood cells",
                      "Expression may decrease during pregnancy",
                      "Anti-Sda antibodies are generally not clinically significant and are neutralized by urine"
                    ]
                  }
                ],
                "700 series": [
                  {
                    "text": "Includes low-incidence antigens found in < 1% of individuals in most populations tested"
                  },
                  {
                    "text": "ExamplesBoxHJKJensenRasmussenReid",
                    "sub_points": [
                      "Box",
                      "HJK",
                      "Jensen",
                      "Rasmussen",
                      "Reid"
                    ]
                  },
                  {
                    "text": "Antibodies to these antigens rarely cause problems during red blood cell transfusions due to their low incidence"
                  },
                  {
                    "text": "Antibodies to some of these antigens have been reported to cause HDFN"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Human Leukocyte, Human Neutrophil, and Human Platelet Antigens": {
        "name": "Human Leukocyte, Human Neutrophil, and Human Platelet Antigens",
        "url": "https://app.pathprimer.com/lesson/a5794d1b-1525-43b9-873e-1c8c648c5d7d",
        "topics": {
          "Human Platelet Antigens": {
            "name": "Human Platelet Antigens",
            "url": "https://app.pathprimer.com/document/8bb83509-fe5d-4e12-a845-e87c9208a0d0/lesson/a5794d1b-1525-43b9-873e-1c8c648c5d7d",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Development of alloantibodies against HPAs is possible after exposure to antigens due to transfusion or pregnancy"
                  },
                  {
                    "text": "Alloantibody formation against HPAs can be related to many causes of thrombocytopenia"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "HPAs are platelet-specific antigens that have primary role in forming clots, in addition to other roles"
                  },
                  {
                    "text": "Thirty-two HPAs have been identified, of which 12 are categorized in 6 biallelic pairs\"a\" antigen of each pair is high-incidence antigen\"b\" antigen of each pair is low-incidence antigenRemaining 20 unpaired antigens are all low frequency",
                    "sub_points": [
                      "\"a\" antigen of each pair is high-incidence antigen",
                      "\"b\" antigen of each pair is low-incidence antigen",
                      "Remaining 20 unpaired antigens are all low frequency"
                    ]
                  },
                  {
                    "text": "Development of alloantibodies against HPAs is possible after exposure to antigens due to transfusion or pregnancy"
                  },
                  {
                    "text": "Alloantibody formation against HPAs can be related to many causes of thrombocytopeniaNAITPTPPlatelet refractoriness",
                    "sub_points": [
                      "NAIT",
                      "PTP",
                      "Platelet refractoriness"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Human platelet antigens (HPA)"
                  },
                  {
                    "text": "Neonatal alloimmune thrombocytopenia (NAIT)"
                  },
                  {
                    "text": "Post-transfusion purpura (PTP)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Neonatal Alloimmune Thrombocytopenia": [
                  {
                    "text": "NAIT causes thrombocytopenia in fetus/neonate secondary to maternal alloantibodies against platelet-specific antigens that she is lackingPaternal HPAs inherited by fetus",
                    "sub_points": [
                      "Paternal HPAs inherited by fetus"
                    ]
                  },
                  {
                    "text": "Thrombocytopenia in NAIT can lead to bleeding complications/fetal demise"
                  },
                  {
                    "text": "Most cases are related to alloantibodies against HPA-1a (75-80%)Anti HPA-5b is second most common cause",
                    "sub_points": [
                      "Anti HPA-5b is second most common cause"
                    ]
                  },
                  {
                    "text": "Treatment for NAITWashed maternal platelets are historic product of choice but are logistically difficult to obtainAntigen-negative platelets if availableRandom donor platelets may be used if matched platelets are unavailable",
                    "sub_points": [
                      "Washed maternal platelets are historic product of choice but are logistically difficult to obtain",
                      "Antigen-negative platelets if available",
                      "Random donor platelets may be used if matched platelets are unavailable"
                    ]
                  }
                ],
                "Post-transfusion purpura": [
                  {
                    "text": "PTP is caused by alloantibodies against HPAs in transfused blood products (usually RBCs) or patients sensitized during pregnancy"
                  },
                  {
                    "text": "Causes self-limited destruction of transfused and native platelets"
                  }
                ],
                "Platelet Refractoriness": [
                  {
                    "text": "HPAs may cause refractoriness to platelet transfusionAnti HPA-1a and Anti HPA-5b are most commonly implicated alloantibodies",
                    "sub_points": [
                      "Anti HPA-1a and Anti HPA-5b are most commonly implicated alloantibodies"
                    ]
                  },
                  {
                    "text": "Platelet refractoriness due to HPAs may also be seen in patients with Glanzmann thrombasthenia and Bernard-Soulier syndrome"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Human Neutrophil Antigens": {
            "name": "Human Neutrophil Antigens",
            "url": "https://app.pathprimer.com/document/87717e5b-712c-4ba0-bc2b-1fa3cccbd5b4/lesson/a5794d1b-1525-43b9-873e-1c8c648c5d7d",
            "content": {
              "OVERVIEW": {
                "General": [
                  {
                    "text": "Human neutrophil antigens (HNAs) consist of 7 antigens in a 5-antigen system"
                  },
                  {
                    "text": "Antibodies to HNAs are developed through exposure during pregnancy or transfusion"
                  },
                  {
                    "text": "HNA antibodies have been implicated in the followingNANTRALIPost-hematopoietic progenitor cell transplant neutropeniaAIN",
                    "sub_points": [
                      "NAN",
                      "TRALI",
                      "Post-hematopoietic progenitor cell transplant neutropenia",
                      "AIN"
                    ]
                  },
                  {
                    "text": "Laboratory testingAntibody detectionGranulocyte agglutinationGranulocyte immunofluorescenceAntigen typing is primarily performed by molecular methods",
                    "sub_points": [
                      "Antibody detectionGranulocyte agglutinationGranulocyte immunofluorescence",
                      "Granulocyte agglutination",
                      "Granulocyte immunofluorescence",
                      "Antigen typing is primarily performed by molecular methods"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Human neutrophil antigen (HNA)"
                  },
                  {
                    "text": "Chronic benign neutropenia of infancy (a.k.a. primary autoimmune neutropenia, or AIN)"
                  },
                  {
                    "text": "Neonatal alloimmune neutropenia (NAN)"
                  },
                  {
                    "text": "Transfusion-related acute lung injury (TRALI)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Antibody Disease Associations": [
                  {
                    "text": "HNA-1aTRALINANAIN",
                    "sub_points": [
                      "TRALI",
                      "NAN",
                      "AIN"
                    ]
                  },
                  {
                    "text": "HNA-1bNANAIN",
                    "sub_points": [
                      "NAN",
                      "AIN"
                    ]
                  },
                  {
                    "text": "HNA-2TRALINANNeutropenia in marrow transplant recipients",
                    "sub_points": [
                      "TRALI",
                      "NAN",
                      "Neutropenia in marrow transplant recipients"
                    ]
                  },
                  {
                    "text": "HNA-3aFatal TRALI",
                    "sub_points": [
                      "Fatal TRALI"
                    ]
                  },
                  {
                    "text": "HNA-4aNAN",
                    "sub_points": [
                      "NAN"
                    ]
                  },
                  {
                    "text": "HNA-5aNAN",
                    "sub_points": [
                      "NAN"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Human Leukocyte Antigens": {
            "name": "Human Leukocyte Antigens",
            "url": "https://app.pathprimer.com/document/486d08b8-7924-449d-a19f-095daf4369aa/lesson/a5794d1b-1525-43b9-873e-1c8c648c5d7d",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "In transplant medicine, human leukocyte antigens (HLAs) play an important role in transfusion"
                  },
                  {
                    "text": "Detection of HLA antibodies is involved in appropriate solid organ transplant selection, solid organ rejection, platelet refractoriness, and transfusion-associated acute lung injury (TRALI)"
                  },
                  {
                    "text": "HLA frequencies vary by racial/ethnic group; certain alleles are more often associated with other alleles"
                  },
                  {
                    "text": "HLA typing allows for matching of appropriate stem cell donor and recipient pairs"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Definitions": [
                  {
                    "text": "HLA antigens: Glycoproteins on body's cell surfaces involved in initiation of immune responsesPresent on surface of B lymphocytes, activated T cells, macrophages, monocytes, dendritic cells, platelets, and nucleated cellsConsist of 2 classesHLA Class I: HLA-A, B, CHLA Class II: HLA-DR, DQ, DP",
                    "sub_points": [
                      "Present on surface of B lymphocytes, activated T cells, macrophages, monocytes, dendritic cells, platelets, and nucleated cells",
                      "Consist of 2 classesHLA Class I: HLA-A, B, CHLA Class II: HLA-DR, DQ, DP",
                      "HLA Class I: HLA-A, B, C",
                      "HLA Class II: HLA-DR, DQ, DP"
                    ]
                  }
                ],
                "HLA Inheritance": [
                  {
                    "text": "Follows mendelian geneticsOne HLA haplotype is inherited from each parent",
                    "sub_points": [
                      "One HLA haplotype is inherited from each parent"
                    ]
                  },
                  {
                    "text": "25% chance of siblings being HLA identicalChance of finding matched sibling increases with number of siblings",
                    "sub_points": [
                      "Chance of finding matched sibling increases with number of siblings"
                    ]
                  }
                ],
                "HLA Matching": [
                  {
                    "text": "Hematopoietic stem cell (HSC)Transplant registries list HLA types of volunteer cord blood and HSC donorsBest match is 10 out of 10 allele match (HLA-A, B, C, DR B1, DQ B1)10 out of 10 matched transplant shows improved outcomesDecreased mortalityDecreased graft-versus-host diseaseDecreased rejection",
                    "sub_points": [
                      "Transplant registries list HLA types of volunteer cord blood and HSC donors",
                      "Best match is 10 out of 10 allele match (HLA-A, B, C, DR B1, DQ B1)10 out of 10 matched transplant shows improved outcomesDecreased mortalityDecreased graft-versus-host diseaseDecreased rejection",
                      "10 out of 10 matched transplant shows improved outcomesDecreased mortalityDecreased graft-versus-host diseaseDecreased rejection",
                      "Decreased mortality",
                      "Decreased graft-versus-host disease",
                      "Decreased rejection"
                    ]
                  },
                  {
                    "text": "Cord blood (CB)CB is matched at alleles HLA-A, B, DR B1 (4-6 allele match)",
                    "sub_points": [
                      "CB is matched at alleles HLA-A, B, DR B1 (4-6 allele match)"
                    ]
                  },
                  {
                    "text": "Solid organRequired to type for HLA-A, B, DR antigensHowever, only sensitized renal transplant recipients are matchedDegree of HLA match is associated with graft survival",
                    "sub_points": [
                      "Required to type for HLA-A, B, DR antigensHowever, only sensitized renal transplant recipients are matched",
                      "However, only sensitized renal transplant recipients are matched",
                      "Degree of HLA match is associated with graft survival"
                    ]
                  }
                ],
                "HLA Antibodies": [
                  {
                    "text": "HLA antibodies develop through various means of exposure to foreign antigensBlood transfusionPregnancyTransplant",
                    "sub_points": [
                      "Blood transfusion",
                      "Pregnancy",
                      "Transplant"
                    ]
                  },
                  {
                    "text": "Possible associations with HLA antibodiesIncreased time to transplantIncreased risk of transplant rejectionGraft failure in HSC transplantTransfusion reactions, including FNHTR, TRALI, TA-GVHD, and TRIM",
                    "sub_points": [
                      "Increased time to transplant",
                      "Increased risk of transplant rejection",
                      "Graft failure in HSC transplant",
                      "Transfusion reactions, including FNHTR, TRALI, TA-GVHD, and TRIM"
                    ]
                  }
                ],
                "Disease Associations": [
                  {
                    "text": "Association of certain HLA phenotypes with disease processes or illness has been known for yearsHLA phenotypes have been linked to autoimmune disorders, infectious diseases (viral and microbial), drug sensitivity reactions, and cancer",
                    "sub_points": [
                      "HLA phenotypes have been linked to autoimmune disorders, infectious diseases (viral and microbial), drug sensitivity reactions, and cancer"
                    ]
                  },
                  {
                    "text": "HLA antigens are usually associated with autoimmune diseases with a relapsing remitting courseSome HLA antigens may be protective against certain illnesses",
                    "sub_points": [
                      "Some HLA antigens may be protective against certain illnesses"
                    ]
                  },
                  {
                    "text": "Relationship may be causative or simply associative and may infer risk or be related to course &/or severity of illnessCausative association is known for celiac diseaseStrong associations are also knownRheumatoid arthritisInsulin dependent diabetes mellitusAnkylosing spondylitis drug hypersensitivity reactionsNarcolepsyClass I associationsAnkylosing spondylitis (HLA B27)Behçet syndrome (HLA B51)Subacute thyroiditis (HLA B35)Uveitis (HLA B27)Class II associationsCeliac disease (HLA DQ2, DQ8)Crohn disease (HLA DRB1)Graves disease (HLA DR17, DQ2)Type I diabetes (HLA DQ3)Multiple sclerosis (HLA DR15, DQ6)Narcolepsy (HLA DQ6)Rheumatoid arthritis (HLA DR4)",
                    "sub_points": [
                      "Causative association is known for celiac disease",
                      "Strong associations are also knownRheumatoid arthritisInsulin dependent diabetes mellitusAnkylosing spondylitis drug hypersensitivity reactionsNarcolepsy",
                      "Rheumatoid arthritis",
                      "Insulin dependent diabetes mellitus",
                      "Ankylosing spondylitis drug hypersensitivity reactions",
                      "Narcolepsy",
                      "Class I associationsAnkylosing spondylitis (HLA B27)Behçet syndrome (HLA B51)Subacute thyroiditis (HLA B35)Uveitis (HLA B27)",
                      "Ankylosing spondylitis (HLA B27)",
                      "Behçet syndrome (HLA B51)",
                      "Subacute thyroiditis (HLA B35)",
                      "Uveitis (HLA B27)",
                      "Class II associationsCeliac disease (HLA DQ2, DQ8)Crohn disease (HLA DRB1)Graves disease (HLA DR17, DQ2)Type I diabetes (HLA DQ3)Multiple sclerosis (HLA DR15, DQ6)Narcolepsy (HLA DQ6)Rheumatoid arthritis (HLA DR4)",
                      "Celiac disease (HLA DQ2, DQ8)",
                      "Crohn disease (HLA DRB1)",
                      "Graves disease (HLA DR17, DQ2)",
                      "Type I diabetes (HLA DQ3)",
                      "Multiple sclerosis (HLA DR15, DQ6)",
                      "Narcolepsy (HLA DQ6)",
                      "Rheumatoid arthritis (HLA DR4)"
                    ]
                  }
                ],
                "HLA Laboratory Testing": [
                  {
                    "text": "Serologic methods for HLA antigen typingMicrocytotoxic assayMixed lymphocyte cytotoxicity",
                    "sub_points": [
                      "Microcytotoxic assay",
                      "Mixed lymphocyte cytotoxicity"
                    ]
                  },
                  {
                    "text": "Molecular methods for HLA antigen typing, PCR based (low resolution, high resolution, allelic resolution)Sequence-specific oligonucleotide probe hybridizationSequence-specific primersSequence-based typing",
                    "sub_points": [
                      "Sequence-specific oligonucleotide probe hybridization",
                      "Sequence-specific primers",
                      "Sequence-based typing"
                    ]
                  },
                  {
                    "text": "Antibody detectionSolid phase assays: HLA antigen-coated beads or particlesDetection of antibody bonding using fluorescently labeled anti-human globulin",
                    "sub_points": [
                      "Solid phase assays: HLA antigen-coated beads or particles",
                      "Detection of antibody bonding using fluorescently labeled anti-human globulin"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Blood Products": {
        "name": "Blood Products",
        "url": "https://app.pathprimer.com/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
        "topics": {
          "Red Blood Cell Components": {
            "name": "Red Blood Cell Components",
            "url": "https://app.pathprimer.com/document/d83686d5-e9fd-4215-bc47-e989cba93d51/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "RBC transfusion is indicated to increase O₂ carrying capacity and decrease signs/symptoms of anemia"
                  },
                  {
                    "text": "Adults are often transfused 1 unit of PRBC at time regardless of body weight, with typical dose 1-2 units"
                  },
                  {
                    "text": "One unit of PRBC is expected to raise Hgb 1 g/dL (or raise Hct 3%)"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Transfusion of PRBC is considered in patients under certain conditionsAcute symptomatic anemiaTrauma with massive hemorrhageCritically ill patients who need increased oxygen-carrying capacity",
                    "sub_points": [
                      "Acute symptomatic anemia",
                      "Trauma with massive hemorrhage",
                      "Critically ill patients who need increased oxygen-carrying capacity"
                    ]
                  },
                  {
                    "text": "Patient's Hgb level and compensatory response to decreased hemoglobin levels should be considered before decision to transfuse is made"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "2,3-diphosphoglycerate (2,3-DPG)"
                  },
                  {
                    "text": "Hematocrit (Hct)"
                  },
                  {
                    "text": "Hemoglobin (Hgb)"
                  },
                  {
                    "text": "Nitric oxide (NO)"
                  },
                  {
                    "text": "Oxygen partial pressure (PO₂)"
                  },
                  {
                    "text": "Packed red blood cells (PRBC)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications": [
                  {
                    "text": "RBC transfusion is indicated to increase oxygen-carrying capacity and decrease signs/symptoms of anemia"
                  },
                  {
                    "text": "Patients become anemic in various waysLoss of red cells (hemorrhage)Decreased RBC productionIncreased RBC clearanceIncreased destruction of RBC",
                    "sub_points": [
                      "Loss of red cells (hemorrhage)",
                      "Decreased RBC production",
                      "Increased RBC clearance",
                      "Increased destruction of RBC"
                    ]
                  },
                  {
                    "text": "Transfusion of RBC is also indicated for red cell exchange and in patients undergoing radiation therapy"
                  }
                ],
                "Transfusion Triggers/Guidelines": [
                  {
                    "text": "At this time, no uniform red cell transfusion trigger exists"
                  },
                  {
                    "text": "Medical decisions about RBC transfusion must be tailored to patient; however, restrictive \"trigger\" of 7-8 g/dL is supported by several studies"
                  },
                  {
                    "text": "Compared with higher hemoglobin thresholds, hemoglobin threshold of 7 or 8 g/dL for hemodynamically stable critically ill adults is associated with fewer RBC units transfused and without adverse association with mortality, cardiac morbidity, functional recovery, and length of stay"
                  },
                  {
                    "text": "It can generally be stated that almost all adult patients with Hgb < 6 g/dL require transfusion, while almost none with Hgb > 10 g/dL have such requirement"
                  },
                  {
                    "text": "In addition to Hgb triggers, red cell transfusion guidelines focus on condition/clinical status of patient"
                  }
                ],
                "Indications for transfusion of PRBC at Hgb > 8 g/dL": [
                  {
                    "text": "Indications for transfusion at higher hemoglobins include unstable cardiac disease and myocardial infarction"
                  },
                  {
                    "text": "In these patient populations, 9-10 g/dL may still be considered acceptable transfusion trigger"
                  }
                ],
                "Blood Group Compatibility": [
                  {
                    "text": "Patients should be transfused with crossmatched ABO type-specific or compatible PRBC"
                  },
                  {
                    "text": "Patients with history of alloantibody should receive antigen-negative units"
                  },
                  {
                    "text": "In addition, PRBC transfusions should be Rh-compatible"
                  },
                  {
                    "text": "In cases of emergent transfusion or unknown Rh status, Rh-negative products should be issued"
                  }
                ],
                "Dose": [
                  {
                    "text": "Adults are often transfused 1 unit of PRBC at time regardless of body weight, with typical dose 1-2 units"
                  },
                  {
                    "text": "One unit of PRBC is expected to raise Hgb 1 g/dL (or raise Hct 3%)"
                  }
                ],
                "Contraindications": [
                  {
                    "text": "Correction of iron deficiency"
                  },
                  {
                    "text": "Nutritional supplementation"
                  },
                  {
                    "text": "Volume expansion"
                  },
                  {
                    "text": "Asymptomatic chronic anemia"
                  },
                  {
                    "text": "To speed recovery"
                  },
                  {
                    "text": "To shorten wound healing"
                  },
                  {
                    "text": "To provide sense of well being"
                  }
                ]
              },
              "LIMITATIONS": {
                "Adverse Reactions": [
                  {
                    "text": "Hemolytic transfusion reactions/other transfusion reactions"
                  },
                  {
                    "text": "Alloimmunization"
                  },
                  {
                    "text": "Infectious disease transmission"
                  }
                ],
                "Red Blood Cell Storage Lesion": [
                  {
                    "text": "Several different biochemical and structural changes occur in stored PRBCs"
                  },
                  {
                    "text": "Free hemoglobin, lactate, and potassium increase over time during storage"
                  },
                  {
                    "text": "Proinflammatory cytokines accumulate in nonleukoreduced PRBC units during storage"
                  },
                  {
                    "text": "2,3-DPG levels decrease rapidly, leading to lower oxygen release at given PO₂ during storage"
                  },
                  {
                    "text": "RBC morphology changes to echinocytes and spherechinocytes during storage"
                  },
                  {
                    "text": "Fall in ATP content of RBCs occurs during storage"
                  },
                  {
                    "text": "Stored PRBC have reduced NO bioavailability, possibly leading to reduced hypoxia-induced vasodilation"
                  },
                  {
                    "text": "Fresh PRBC are usually defined as PRBC units within 5-7 days of collection"
                  },
                  {
                    "text": "Mean storage duration for PRBCs in United States is 17.9 days"
                  },
                  {
                    "text": "Practically, few PRBCs are transfused after 35 days of storage (for PRBC units with additive solution)"
                  },
                  {
                    "text": "Advantages of transfusing fresh PRBCImproved post-transfusion RBC survivalImproved oxygen transport in first 24 hours due to higher 2,3-DPG levelsDecreased potassium loadObservational studies suggest that older PRBC transfusion is associated with increased mortalityHowever, high-quality randomized controlled trials have not shown that age of blood causes differences in outcome",
                    "sub_points": [
                      "Improved post-transfusion RBC survival",
                      "Improved oxygen transport in first 24 hours due to higher 2,3-DPG levels",
                      "Decreased potassium load",
                      "Observational studies suggest that older PRBC transfusion is associated with increased mortality",
                      "However, high-quality randomized controlled trials have not shown that age of blood causes differences in outcome"
                    ]
                  },
                  {
                    "text": "Patients who are candidates for fresh PRBCLimited high-quality evidence that old versus fresh PRBCs affect patient outcomeTherefore, fresh PRBC (< 5 days) should be limited to neonates or patients who are very sensitive to potassiumAs alternative to issuing fresh PRBC, any PRBC unit can be washed to remove excess potassium",
                    "sub_points": [
                      "Limited high-quality evidence that old versus fresh PRBCs affect patient outcome",
                      "Therefore, fresh PRBC (< 5 days) should be limited to neonates or patients who are very sensitive to potassium",
                      "As alternative to issuing fresh PRBC, any PRBC unit can be washed to remove excess potassium"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Plasma Components": {
            "name": "Plasma Components",
            "url": "https://app.pathprimer.com/document/4be007aa-c675-492a-b6c1-c127718301ef/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Most common reasons plasma is transfused are to correct multiple clotting factor deficiencies seen in hemorrhage or to prevent bleeding"
                  },
                  {
                    "text": "Various plasma products (FFP, FP24, thawed plasma) are available and can generally be used interchangeably"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Typical dose of plasma is 10-20 mL/kg patient body weight or 2-4 U in adult patients"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Plasma is liquid portion of whole bloodContains soluble clotting factors, vitamin K-dependent clotting factors, hormones, and vitamins",
                    "sub_points": [
                      "Contains soluble clotting factors, vitamin K-dependent clotting factors, hormones, and vitamins"
                    ]
                  },
                  {
                    "text": "Most common reasons plasma is transfusedTo correct multiple clotting factor deficiencies seen in hemorrhageTo prevent bleeding",
                    "sub_points": [
                      "To correct multiple clotting factor deficiencies seen in hemorrhage",
                      "To prevent bleeding"
                    ]
                  },
                  {
                    "text": "Various plasma products (FFP, FP24, thawed plasma) are available and can generally be used interchangeablyFP24 has decreased levels of factor V and factor VIII",
                    "sub_points": [
                      "FP24 has decreased levels of factor V and factor VIII"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Plasma frozen within 24 hr (FP24)"
                  },
                  {
                    "text": "von Willebrand factor (vWF)"
                  },
                  {
                    "text": "Intracranial hemorrhage (ICH)"
                  },
                  {
                    "text": "International normalized ratio (INR)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Transfusion-related acute lung injury (TRALI)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Description": [
                  {
                    "text": "Acellular, fluid component of blood"
                  },
                  {
                    "text": "Contains soluble clotting factors, fibrinogen, vWF"
                  },
                  {
                    "text": "Contains approximately 1 IU/mL of each clotting factor"
                  }
                ]
              },
              "PRETRANSFUSION LABORATORY TESTING": {
                "ABO Group": [
                  {
                    "text": "Transfused plasma should be ABO compatible"
                  },
                  {
                    "text": "Crossmatching is not performed before administration"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Plasma Transfusion": [
                  {
                    "text": "Evidence-based guidelines for plasma transfusion are weakData are insufficient to make sound recommendations for many clinical scenarios",
                    "sub_points": [
                      "Data are insufficient to make sound recommendations for many clinical scenarios"
                    ]
                  },
                  {
                    "text": "Abnormal coagulation tests do not adequately predict risk of hemorrhage"
                  },
                  {
                    "text": "Sensitive testing techniques detect mild decreases in coagulation factor activity before decreases are clinically significant"
                  },
                  {
                    "text": "Attempts to correct mild coagulation study abnormalities before surgery are often unsuccessful"
                  },
                  {
                    "text": "There is no plasma transfusion trigger based on laboratory studies"
                  }
                ],
                "Indications": [
                  {
                    "text": "Plasma transfused as component of massive transfusion protocols"
                  },
                  {
                    "text": "Reversal of warfarin anticoagulation in patients with ICH, bleeding, INR > 9 requiring surgery"
                  },
                  {
                    "text": "Replacement fluid for plasma exchange"
                  },
                  {
                    "text": "Congenital deficiencies of procoagulants when factor specific concentrates are unavailable"
                  },
                  {
                    "text": "Multiple coagulation factor deficiencies"
                  },
                  {
                    "text": "DIC"
                  },
                  {
                    "text": "Liver failure"
                  }
                ],
                "Contraindications": [
                  {
                    "text": "Prophylactic transfusion (risks outweigh benefits)"
                  },
                  {
                    "text": "Correction of mild increases in INR"
                  },
                  {
                    "text": "Immunodeficiency"
                  },
                  {
                    "text": "Burns"
                  },
                  {
                    "text": "To speed wound healing"
                  },
                  {
                    "text": "Volume expansion"
                  },
                  {
                    "text": "To replenish nutrients"
                  }
                ],
                "Dosage": [
                  {
                    "text": "Ability to form clots occurs with coagulation factor levels of approximately 30%-40%"
                  },
                  {
                    "text": "Typical dose of plasma is 10-20 mL/kg patient body weight or 2-4 U in adult patients"
                  },
                  {
                    "text": "Typical dose of plasma should increase coagulation factor levels by 20%-30%"
                  },
                  {
                    "text": "When transfusing plasma, half-life of factor being replaced should be considered"
                  },
                  {
                    "text": "Factors with shorter half-lives may require more frequent dosing"
                  },
                  {
                    "text": "Plasma transfusion should occur immediately before procedures to help ensure hemostasis"
                  }
                ],
                "Preparation and Storage": [
                  {
                    "text": "Stored at -18°C or less for up to 1 yr"
                  },
                  {
                    "text": "Thawed at 30°C-37°C (approximately 20 min to thaw)"
                  },
                  {
                    "text": "Must be transfused immediately or stored at 1°C-6°C"
                  },
                  {
                    "text": "If stored for > 24 hr, FFP and FP24 become thawed plasma"
                  },
                  {
                    "text": "Thawed plasma has shelf-life of 5 days at 1°C-6°C from time of initial thawing"
                  }
                ],
                "Other Plasma Products": [
                  {
                    "text": "Cryoprecipitate-reduced plasmaSupernatant expressed after manufacture of cryoprecipitateDeficient in factors VIII and XIII, vWF, fibrinogen, cryoglobulin, and fibronectinOnly indication is for plasma exchange or transfusion for patients with TTP",
                    "sub_points": [
                      "Supernatant expressed after manufacture of cryoprecipitate",
                      "Deficient in factors VIII and XIII, vWF, fibrinogen, cryoglobulin, and fibronectin",
                      "Only indication is for plasma exchange or transfusion for patients with TTP"
                    ]
                  },
                  {
                    "text": "Solvent/detergent plasmaManufactured from pooled plasma and treated with solvent/detergentSolvent/detergent treatment inactivates lipid-enveloped viruses, including HIV, hepatitis B, and hepatitis CStored at -18°C or colder for up to 1 yrContain approximately 50% of protein S and 10% less clotting factors compared with FFP and FP24FDA-approved product",
                    "sub_points": [
                      "Manufactured from pooled plasma and treated with solvent/detergent",
                      "Solvent/detergent treatment inactivates lipid-enveloped viruses, including HIV, hepatitis B, and hepatitis C",
                      "Stored at -18°C or colder for up to 1 yr",
                      "Contain approximately 50% of protein S and 10% less clotting factors compared with FFP and FP24",
                      "FDA-approved product"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Risks of Plasma Transfusion": [
                  {
                    "text": "Fluid overload"
                  },
                  {
                    "text": "TRALI"
                  },
                  {
                    "text": "Infectious disease transmission"
                  },
                  {
                    "text": "Allergic reaction"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Components": {
            "name": "Platelet Components",
            "url": "https://app.pathprimer.com/document/6900b0a4-d2ba-4cea-a79b-9e6f84d0c6f7/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Platelet count of ≤ 10,000/μL is accepted threshold to decrease risk of hemorrhage for patients requiring chemotherapy or undergoing HPC transplant"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Prophylactic platelet transfusion is used to prevent potential bleeding in thrombocytopenic patients and patients with platelet dysfunction; most platelets are transfused prophylactically to reduce risk for spontaneous bleeding after chemotherapy or HPC transplant"
                  },
                  {
                    "text": "Transfusion of dose of platelets should increase counts by 30,000-60,000/μL"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Platelet count of ≤ 10,000/μL is accepted threshold to decrease risk of hemorrhage for patients requiring chemotherapy or undergoing HPC transplant"
                  },
                  {
                    "text": "Platelet deficiency or dysfunction can lead to bleeding and hemorrhage"
                  },
                  {
                    "text": "Signs of thrombocytopenia/platelet dysfunctionPetechiaeBruisingMucous membrane bleeding",
                    "sub_points": [
                      "Petechiae",
                      "Bruising",
                      "Mucous membrane bleeding"
                    ]
                  },
                  {
                    "text": "Many other established platelet transfusion thresholds are available depending on clinical situation"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hematopoietic progenitor cell (HPC)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  },
                  {
                    "text": "Idiopathic (autoimmune) thrombocytopenia (ITP)"
                  },
                  {
                    "text": "Heparin-induced thrombocytopenia (HIT)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications": [
                  {
                    "text": "Prophylactic transfusionProphylactic platelet transfusion is used to prevent potential bleeding in thrombocytopenic patients and patients with platelet dysfunctionMost platelets are transfused prophylactically to reduce risk for spontaneous bleeding in patients after chemotherapy or HPC transplantProphylaxis with low-dose platelets (half of apheresis platelet) provides hemostasis that is equal to standard-dose or high-dose platelets in patients with therapy-induced hypoproliferative thrombocytopeniaIn nonbleeding patients, risk of spontaneous hemorrhage is low when platelet count is > 10,000/μLHigher threshold may be indicated in patients with fever or sepsisInvasive procedures may require higher platelet counts> 50,000/μL for lumbar puncture, central line insertion, thoracentesis, liver biopsy, transbronchial biopsy> 100,000/μL for procedures involving eye, brain, or major surgery",
                    "sub_points": [
                      "Prophylactic platelet transfusion is used to prevent potential bleeding in thrombocytopenic patients and patients with platelet dysfunctionMost platelets are transfused prophylactically to reduce risk for spontaneous bleeding in patients after chemotherapy or HPC transplant",
                      "Most platelets are transfused prophylactically to reduce risk for spontaneous bleeding in patients after chemotherapy or HPC transplant",
                      "Prophylaxis with low-dose platelets (half of apheresis platelet) provides hemostasis that is equal to standard-dose or high-dose platelets in patients with therapy-induced hypoproliferative thrombocytopenia",
                      "In nonbleeding patients, risk of spontaneous hemorrhage is low when platelet count is > 10,000/μL",
                      "Higher threshold may be indicated in patients with fever or sepsis",
                      "Invasive procedures may require higher platelet counts> 50,000/μL for lumbar puncture, central line insertion, thoracentesis, liver biopsy, transbronchial biopsy> 100,000/μL for procedures involving eye, brain, or major surgery",
                      "> 50,000/μL for lumbar puncture, central line insertion, thoracentesis, liver biopsy, transbronchial biopsy",
                      "> 100,000/μL for procedures involving eye, brain, or major surgery"
                    ]
                  },
                  {
                    "text": "Therapeutic transfusionAdministration of platelets to treat actively bleeding patients with platelet counts < 50,000/μLTransfusion of dose of platelets should increase counts by 30,000-60,000/μL",
                    "sub_points": [
                      "Administration of platelets to treat actively bleeding patients with platelet counts < 50,000/μL",
                      "Transfusion of dose of platelets should increase counts by 30,000-60,000/μL"
                    ]
                  },
                  {
                    "text": "Platelet function abnormalitiesAlternative treatment optionsAnemic patientUremic patientPatient has taken medications that cause platelet dysfunctionPlatelet transfusion should be considered in patients with platelet function abnormalities if treatment of underlying cause is unsuccessful",
                    "sub_points": [
                      "Alternative treatment optionsAnemic patientUremic patientPatient has taken medications that cause platelet dysfunction",
                      "Anemic patient",
                      "Uremic patient",
                      "Patient has taken medications that cause platelet dysfunction",
                      "Platelet transfusion should be considered in patients with platelet function abnormalities if treatment of underlying cause is unsuccessful"
                    ]
                  }
                ],
                "Contraindications": [
                  {
                    "text": "TTP"
                  },
                  {
                    "text": "ITP"
                  },
                  {
                    "text": "HIT"
                  }
                ],
                "Dosing": [
                  {
                    "text": "Optimal platelet dose is unknown"
                  },
                  {
                    "text": "Standard adult dose is 3-4 x 10¹¹This dose can be achieved by transfusion of1 apheresis unitPool of 4-6 random donor platelets",
                    "sub_points": [
                      "This dose can be achieved by transfusion of1 apheresis unitPool of 4-6 random donor platelets",
                      "1 apheresis unit",
                      "Pool of 4-6 random donor platelets"
                    ]
                  }
                ],
                "ABO Group Compatibility": [
                  {
                    "text": "ABO compatible platelets are usually transfused"
                  },
                  {
                    "text": "When platelet supply is limited, platelets may be transfused without regard to ABO group"
                  },
                  {
                    "text": "Transfusion of ABO incompatible platelets should be avoided in neonates and pediatric patientsTransfused volume represents greater proportion of patient's plasma volume",
                    "sub_points": [
                      "Transfused volume represents greater proportion of patient's plasma volume"
                    ]
                  },
                  {
                    "text": "Volume reduction or washing of platelet products can prevent transfusion of large amounts of incompatible plasma"
                  },
                  {
                    "text": "Risks of transfusion of ABO incompatible plateletsDecreased platelet incrementHemolysis of recipient RBCs, especially in group O donors with high-titer anti-A &/or anti-BPositive DAT",
                    "sub_points": [
                      "Decreased platelet increment",
                      "Hemolysis of recipient RBCs, especially in group O donors with high-titer anti-A &/or anti-B",
                      "Positive DAT"
                    ]
                  }
                ],
                "Rh Type Compatibility": [
                  {
                    "text": "D antigen is not present on surface of plateletsMay be present on residual RBCs present in platelet product",
                    "sub_points": [
                      "May be present on residual RBCs present in platelet product"
                    ]
                  },
                  {
                    "text": "RhD may be present on residual RBCs in platelet productMay result in alloimmunization in susceptible recipients",
                    "sub_points": [
                      "May result in alloimmunization in susceptible recipients"
                    ]
                  },
                  {
                    "text": "Rh(D)-negative platelets are given to Rh(D)-negative recipients"
                  },
                  {
                    "text": "Rh(D)-positive platelets may be transfused to Rh(D)-negative patients when platelet supply is limited"
                  },
                  {
                    "text": "If Rh-negative platelet products are unavailable, anti-D antibody formation can be prevented by administering Rh immunoglobulin"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cryoprecipitate and Fibrinogen Concentrates": {
            "name": "Cryoprecipitate and Fibrinogen Concentrates",
            "url": "https://app.pathprimer.com/document/f5e443f5-ca11-468d-8f4a-9fbbc4515d30/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Cryoprecipitate and fibrinogen concentrates provide concentrated source of fibrinogen for transfusion"
                  }
                ],
                "Laboratory Regulation": [
                  {
                    "text": "Require that each unit of cryoprecipitate contain at least 150 mg of fibrinogen and 80 IU of factor VIII"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Cryoprecipitate is prepared from human FFP by thawing at 1-6 °C"
                  },
                  {
                    "text": "Precipitate formed is stored as cryoprecipitated AHF/cryoprecipitate"
                  },
                  {
                    "text": "Provides concentrated source of fibrinogen for transfusion"
                  },
                  {
                    "text": "Cryoprecipitate contents80-100 units of factor VIIIvon Willebrand factor150 mg fibrinogenFactor XIIIFibronectin",
                    "sub_points": [
                      "80-100 units of factor VIII",
                      "von Willebrand factor",
                      "150 mg fibrinogen",
                      "Factor XIII",
                      "Fibronectin"
                    ]
                  },
                  {
                    "text": "Human fibrinogen concentrates are prepared from pooled human plasma that is virally inactivatedHave replaced cryoprecipitate in Europe",
                    "sub_points": [
                      "Have replaced cryoprecipitate in Europe"
                    ]
                  },
                  {
                    "text": "In United States, fibrinogen concentrates are FDA approved for use in treatment of fibrinogen deficiency and dysfibrinogenemia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antihemophilic factor (AHF)"
                  },
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Primary Indications": [
                  {
                    "text": "Hypofibrinogenemia (fibrinogen < 100 mg/dL), most common use"
                  },
                  {
                    "text": "Acute disseminated intravascular coagulation"
                  },
                  {
                    "text": "Reversal of thrombolytic therapy"
                  },
                  {
                    "text": "Massive transfusion"
                  },
                  {
                    "text": "Localized fibrinolysis during surgeries involving tissues that activate plasminogenProstateSalivary glandsUrothelium",
                    "sub_points": [
                      "Prostate",
                      "Salivary glands",
                      "Urothelium"
                    ]
                  },
                  {
                    "text": "Impaired production of fibrinogenAdvanced liver diseaseCongenital hypofibrinogenemiaAfibrinogenemiaDysfibrinogenemia",
                    "sub_points": [
                      "Advanced liver disease",
                      "Congenital hypofibrinogenemia",
                      "Afibrinogenemia",
                      "Dysfibrinogenemia"
                    ]
                  },
                  {
                    "text": "Renal failure (uremic coagulopathy) with abnormal bleeding when medical therapies and desmopressin/dialysis are contraindicated or ineffective"
                  }
                ],
                "Contraindications": [
                  {
                    "text": "Should not be used when recombinant or virally inactivated products are available, e.g., treatment of von Willebrand disease or hemophilia A"
                  },
                  {
                    "text": "Treatment of bleeding without evidence of hypofibrinogenemia"
                  },
                  {
                    "text": "Reversal of warfarin therapy"
                  },
                  {
                    "text": "Hepatic coagulopathy"
                  }
                ],
                "Transfusion of Cryoprecipitate": [
                  {
                    "text": "Units of cryoprecipitate contain negligible amounts of RBCs and isohemagglutinins and do not need to be crossmatched"
                  },
                  {
                    "text": "However, ABO-compatible components may be preferred, especially in neonates because of their small plasma volume"
                  },
                  {
                    "text": "If large volume of ABO-incompatible cryoprecipitate is used, potential for recipient to develop positive DAT and mild hemolysis (rare)"
                  },
                  {
                    "text": "Rh type does not need to be considered when using cryoprecipitate"
                  }
                ],
                "Cryoprecipitate Dosing": [
                  {
                    "text": "Typical single cryoprecipitate dose consists of pool of 5 or 10 unitsEach unit should increase fibrinogen levels by 50 mg/dL per 10 kg body weight",
                    "sub_points": [
                      "Each unit should increase fibrinogen levels by 50 mg/dL per 10 kg body weight"
                    ]
                  },
                  {
                    "text": "Average unit contains approximately 250 mg of fibrinogen"
                  },
                  {
                    "text": "Dose may be calculated using formulaDose (units) = [desired fibrinogen increment (mg/dL) x plasma volume] / 250 gm/unit",
                    "sub_points": [
                      "Dose (units) = [desired fibrinogen increment (mg/dL) x plasma volume] / 250 gm/unit"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards": [
                  {
                    "text": "Require that each unit of cryoprecipitate contain at least 150 mg of fibrinogen and 80 IU of factor VIII"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Granulocytes": {
            "name": "Granulocytes",
            "url": "https://app.pathprimer.com/document/49377769-30d9-4e2f-bfdf-6891babd13fd/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Patients with prolonged neutropenia in setting of bacterial or fungal infection unresponsive to appropriate antimicrobial therapy may benefit from granulocyte transfusion"
                  },
                  {
                    "text": "Granulocyte concentrates are collected by apheresis from donors who qualify for whole-blood donation, are ABO-Rh compatible with recipient, and have negative infectious disease history"
                  }
                ]
              },
              "OVERVIEW": {
                "Definitions": [
                  {
                    "text": "Granulocytes are white blood cells containing granules with nonspecific antimicrobial activity that function as part of innate immune system"
                  },
                  {
                    "text": "Decreased granulocyte count (neutropenia) is associated with increased risk of infection"
                  },
                  {
                    "text": "Patients with prolonged neutropenia in the setting of bacterial or fungal infection unresponsive to appropriate antimicrobial therapy may benefit from granulocyte transfusion"
                  },
                  {
                    "text": "Granulocyte concentrates are collected by apheresis from donors with the following characteristicsQualify for whole-blood donationAre ABO-Rh compatible with recipientHave negative history of infectious disease",
                    "sub_points": [
                      "Qualify for whole-blood donation",
                      "Are ABO-Rh compatible with recipient",
                      "Have negative history of infectious disease"
                    ]
                  },
                  {
                    "text": "Granulocyte concentrates must be transfused within 24 hr from collection time"
                  },
                  {
                    "text": "Evidence regarding efficacy of granulocyte transfusions is mixedRecent study reported no significant benefit",
                    "sub_points": [
                      "Recent study reported no significant benefit"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Absolute neutrophil count (ANC)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Infectious disease marker (IDM)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Cytomegalovirus (CMV)"
                  },
                  {
                    "text": "Human leukocyte antigen (HLA)"
                  },
                  {
                    "text": "Transfusion associated-graft-vs.-host disease (TA-GVHD)"
                  },
                  {
                    "text": "Complete blood count (CBC)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications": [
                  {
                    "text": "ANC < 500 cells/μL with expected bone marrow recovery"
                  },
                  {
                    "text": "Clinical, laboratory, or radiographic evidence of fungal or bacterial infection"
                  },
                  {
                    "text": "Absence of response to antimicrobial/antifungal treatmentPreferably minimum of 48 hr of appropriate treatment",
                    "sub_points": [
                      "Preferably minimum of 48 hr of appropriate treatment"
                    ]
                  },
                  {
                    "text": "Patient populationsPediatric and adult patients with sepsis and severe neutropenia resulting from chemotherapy or after hematopoietic progenitor cell transplantPatients with chronic granulomatous disease with deep-seated abscesses or fungal infections not responsive to appropriate antimicrobial therapyNeonatal sepsisNot commonly used today with advent of more potent antibiotics",
                    "sub_points": [
                      "Pediatric and adult patients with sepsis and severe neutropenia resulting from chemotherapy or after hematopoietic progenitor cell transplant",
                      "Patients with chronic granulomatous disease with deep-seated abscesses or fungal infections not responsive to appropriate antimicrobial therapy",
                      "Neonatal sepsisNot commonly used today with advent of more potent antibiotics",
                      "Not commonly used today with advent of more potent antibiotics"
                    ]
                  },
                  {
                    "text": "Prophylactic granulocyte transfusion not indicated"
                  }
                ],
                "Technical aspects": [
                  {
                    "text": "DonorsStimulated with corticosteroids with or without G-CSF 12 hr before collection to increase yieldStimulation by G-CSF or dexamethasone may cause mild symptoms in donorsArthralgiasBone painHeadacheFatigueInsomniaDonor history of hypertension, diabetes, cataracts, and peptic ulcer disease should be considered before stimulation with corticosteroidsDonors with recent IDM testing are preferred as products are emergently releasedResults of IDM testing are often received after transfusion",
                    "sub_points": [
                      "Stimulated with corticosteroids with or without G-CSF 12 hr before collection to increase yieldStimulation by G-CSF or dexamethasone may cause mild symptoms in donorsArthralgiasBone painHeadacheFatigueInsomniaDonor history of hypertension, diabetes, cataracts, and peptic ulcer disease should be considered before stimulation with corticosteroids",
                      "Stimulation by G-CSF or dexamethasone may cause mild symptoms in donorsArthralgiasBone painHeadacheFatigueInsomnia",
                      "Arthralgias",
                      "Bone pain",
                      "Headache",
                      "Fatigue",
                      "Insomnia",
                      "Donor history of hypertension, diabetes, cataracts, and peptic ulcer disease should be considered before stimulation with corticosteroids",
                      "Donors with recent IDM testing are preferred as products are emergently releasedResults of IDM testing are often received after transfusion",
                      "Results of IDM testing are often received after transfusion"
                    ]
                  },
                  {
                    "text": "ProductCollected via apheresis with average volume of 200 mLMust be ABO compatible and crossmatched with recipientGranulocytes contain > 2 mL of RBCsMust be CMV seronegative if patient requires CMV-reduced-risk transfusionsMust be HLA compatible for patients with anti-HLA antibodiesMust be irradiated due to risk of TA-GVHDMustnotbe leukoreducedMust be transfused within 24 hrIdeally transfused within 6 hr of collectionStored at 20°C-24°C unagitated1 × 10¹⁰ granulocytes must be present in > 75% tested unitsHigher doses are more efficaciousOptimal therapeutic dose is not established",
                    "sub_points": [
                      "Collected via apheresis with average volume of 200 mL",
                      "Must be ABO compatible and crossmatched with recipientGranulocytes contain > 2 mL of RBCs",
                      "Granulocytes contain > 2 mL of RBCs",
                      "Must be CMV seronegative if patient requires CMV-reduced-risk transfusions",
                      "Must be HLA compatible for patients with anti-HLA antibodies",
                      "Must be irradiated due to risk of TA-GVHD",
                      "Mustnotbe leukoreduced",
                      "Must be transfused within 24 hrIdeally transfused within 6 hr of collection",
                      "Ideally transfused within 6 hr of collection",
                      "Stored at 20°C-24°C unagitated",
                      "1 × 10¹⁰ granulocytes must be present in > 75% tested unitsHigher doses are more efficaciousOptimal therapeutic dose is not established",
                      "Higher doses are more efficacious",
                      "Optimal therapeutic dose is not established"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Monitor ANC with daily CBC with differential"
                  },
                  {
                    "text": "Monitor changes in underlying infection with microbial cultures or imaging"
                  },
                  {
                    "text": "Requires close surveillance of vital signs, oxygenation, and symptoms after transfusionDue to increased occurrence of transfusion reactions compared with other blood components",
                    "sub_points": [
                      "Due to increased occurrence of transfusion reactions compared with other blood components"
                    ]
                  },
                  {
                    "text": "Development of fever and chills is common during or after granulocyte transfusion"
                  },
                  {
                    "text": "Pulmonary reactions including dyspnea, decreased oxygen saturation, and worsening pulmonary infiltrates may be seen"
                  },
                  {
                    "text": "Severe reactions including pulmonary reactions, TA-GVHD, HLA alloimmunization, or transfusion-transmitted infection rarely occur"
                  },
                  {
                    "text": "Administration of amphotericin should be separated from granulocyte transfusion by a minimum of 12 hr due to increased risk of reactions"
                  },
                  {
                    "text": "Efficacy of granulocyte transfusions in clinical trials is mixedResolving Infection in people with Neutropenia with Granulocytes (RING) published results in 2015 on efficacy of transfusing G-CSF-stimulated granulocytes at 14 clinical sitesNo statistical benefit was identified, but study was limited by low power",
                    "sub_points": [
                      "Resolving Infection in people with Neutropenia with Granulocytes (RING) published results in 2015 on efficacy of transfusing G-CSF-stimulated granulocytes at 14 clinical sites",
                      "No statistical benefit was identified, but study was limited by low power"
                    ]
                  }
                ],
                "Future Research": [
                  {
                    "text": "Determining efficacy and benefit vs. risks"
                  },
                  {
                    "text": "Identifying patient populations that would benefit, including demographics and clinical history"
                  },
                  {
                    "text": "Identifying minimum efficacious dose"
                  },
                  {
                    "text": "Improving collection process"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards": [
                  {
                    "text": "Donor RBCs must be ABO compatible with recipient's plasma"
                  },
                  {
                    "text": "Donor RBCs must be crossmatched with recipient's plasma if > 2 mL of RBCs are present"
                  },
                  {
                    "text": "Must not be transfused through leukocyte reduction filter or microaggregate filter"
                  },
                  {
                    "text": "1 × 10¹⁰ granulocytes must be present in > 75% tested units"
                  },
                  {
                    "text": "Stored at 20°C-24°C and expire at 24 hrShould be transfused as soon as possible after collection",
                    "sub_points": [
                      "Should be transfused as soon as possible after collection"
                    ]
                  }
                ],
                "FDA": [
                  {
                    "text": "Granulocytes are not FDA-licensed product"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prothrombin Complex Concentrates and Recombinant Activated Factor VII": {
            "name": "Prothrombin Complex Concentrates and Recombinant Activated Factor VII",
            "url": "https://app.pathprimer.com/document/be5b67e0-6cf8-436f-a7b5-5871ae573fcf/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "PCCs are made by separating vitamin K-dependent coagulation factors (factor II, factor VII, factor IX, and factor X) from plasma"
                  },
                  {
                    "text": "Factor VIIa is recombinant form of factor VII that was historically approved to treat bleeding/surgical patients with hemophilia and inhibitors to factor VIII or factor IX and was subsequently approved for treatment of congenital factor VII deficiency"
                  },
                  {
                    "text": "Recombinant factor VIIa has been used in treatment of hemorrhage secondary to multiple causes, including trauma, cardiothoracic surgery, and intra/postoperative bleeding"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Heparin-induced thrombocytopenia (HIT)"
                  },
                  {
                    "text": "International normalized ratio (INR)"
                  },
                  {
                    "text": "Prothrombin complex concentrates (PCC)"
                  },
                  {
                    "text": "Tissue factor (TF)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Prothrombin Complex Concentrates": [
                  {
                    "text": "General informationPCCs are made by separating vitamin K-dependent coagulation factors (factor II, factor VII, factor IX, and factor X) from plasmaPCCs are defined as 3 factor PCCs or 4 factor PCCs based on levels of factor VII they containFour factor PCCs contain higher factor VII levelsPCCs may also contain Protein C, Protein S, Protein Z, antithrombin, and heparinIncreasing levels of factors II, VII, IX, and X increase factor Xa level leading to thrombin formationOlder PCCs were associated with high risk of thrombosis due to infusion of activated procoagulantsNewer PCCs avoid manufacture with activated factors, making them available for wider clinical usePCCs provide benefitsRapid correction of INRInfusion of less volumeDecreased transfusion reaction risk",
                    "sub_points": [
                      "PCCs are made by separating vitamin K-dependent coagulation factors (factor II, factor VII, factor IX, and factor X) from plasma",
                      "PCCs are defined as 3 factor PCCs or 4 factor PCCs based on levels of factor VII they contain",
                      "Four factor PCCs contain higher factor VII levels",
                      "PCCs may also contain Protein C, Protein S, Protein Z, antithrombin, and heparin",
                      "Increasing levels of factors II, VII, IX, and X increase factor Xa level leading to thrombin formation",
                      "Older PCCs were associated with high risk of thrombosis due to infusion of activated procoagulants",
                      "Newer PCCs avoid manufacture with activated factors, making them available for wider clinical use",
                      "PCCs provide benefitsRapid correction of INRInfusion of less volumeDecreased transfusion reaction risk",
                      "Rapid correction of INR",
                      "Infusion of less volume",
                      "Decreased transfusion reaction risk"
                    ]
                  },
                  {
                    "text": "IndicationsPCCs are FDA approved for certain usesHemophilia with inhibitorsWarfarin reversal with bleeding/invasive procedures/surgery",
                    "sub_points": [
                      "PCCs are FDA approved for certain usesHemophilia with inhibitorsWarfarin reversal with bleeding/invasive procedures/surgery",
                      "Hemophilia with inhibitors",
                      "Warfarin reversal with bleeding/invasive procedures/surgery"
                    ]
                  },
                  {
                    "text": "ContraindicationsPatients with history of thromboembolic events in past 3 monthsPatients with HIT",
                    "sub_points": [
                      "Patients with history of thromboembolic events in past 3 months",
                      "Patients with HIT"
                    ]
                  },
                  {
                    "text": "RisksThromboembolic events pose biggest risk of PCC useRisk of thrombosis may depend on PCC prothrombin contentConcurrent plasma transfusion can decrease prothrombotic risk",
                    "sub_points": [
                      "Thromboembolic events pose biggest risk of PCC use",
                      "Risk of thrombosis may depend on PCC prothrombin content",
                      "Concurrent plasma transfusion can decrease prothrombotic risk"
                    ]
                  }
                ],
                "Factor VIIa": [
                  {
                    "text": "General informationFactor VIIa is recombinant form of factor VII that was historically approved to treat bleeding/surgical patients with hemophilia and inhibitors to factor VIII or factor IXSubsequently approved for treatment of congenital factor VII deficiencyRecombinant factor VIIa has been used in treatment of hemorrhage secondary to multiple causesTraumaCardiothoracic surgeryIntra/postoperative bleedingDespite off-label usage, there is not strong evidence of efficacy in these clinical settingsRisks versus benefits must be carefully considered before use in off-label clinical settings",
                    "sub_points": [
                      "Factor VIIa is recombinant form of factor VII that was historically approved to treat bleeding/surgical patients with hemophilia and inhibitors to factor VIII or factor IX",
                      "Subsequently approved for treatment of congenital factor VII deficiency",
                      "Recombinant factor VIIa has been used in treatment of hemorrhage secondary to multiple causesTraumaCardiothoracic surgeryIntra/postoperative bleeding",
                      "Trauma",
                      "Cardiothoracic surgery",
                      "Intra/postoperative bleeding",
                      "Despite off-label usage, there is not strong evidence of efficacy in these clinical settings",
                      "Risks versus benefits must be carefully considered before use in off-label clinical settings"
                    ]
                  },
                  {
                    "text": "Mechanism of actionFactor VIIa forms complex with TF, then activates common pathway of coagulation cascadeFactor VIIa also binds activated platelets concentrating factor Xa to sites of tissue injury",
                    "sub_points": [
                      "Factor VIIa forms complex with TF, then activates common pathway of coagulation cascade",
                      "Factor VIIa also binds activated platelets concentrating factor Xa to sites of tissue injury"
                    ]
                  },
                  {
                    "text": "IndicationsHemophilia with inhibitorsFactor VII deficiencyRapid reversal of warfarin anticoagulation with bleeding (off label)Acquired hemophiliaTrauma/massive transfusion (less effective in cases of acidosis/hypothermia; off label)Liver transplant (off label)Glanzmann thrombasthenia with platelet refractoriness (off label)Open heart surgery with refractory microvascular bleeding (off label)Irreversible antiplatelet agents with refractory bleeding (off label)",
                    "sub_points": [
                      "Hemophilia with inhibitors",
                      "Factor VII deficiency",
                      "Rapid reversal of warfarin anticoagulation with bleeding (off label)",
                      "Acquired hemophilia",
                      "Trauma/massive transfusion (less effective in cases of acidosis/hypothermia; off label)",
                      "Liver transplant (off label)",
                      "Glanzmann thrombasthenia with platelet refractoriness (off label)",
                      "Open heart surgery with refractory microvascular bleeding (off label)",
                      "Irreversible antiplatelet agents with refractory bleeding (off label)"
                    ]
                  },
                  {
                    "text": "Factor VIIa is contraindicated in patients with increased risk of thrombosis"
                  },
                  {
                    "text": "RisksIncreased risk of thrombotic events, including stroke and myocardial infarction, with use of factor VIIaHowever, thrombotic events are rarely reported when factor VIIa is used for FDA-approved indications",
                    "sub_points": [
                      "Increased risk of thrombotic events, including stroke and myocardial infarction, with use of factor VIIa",
                      "However, thrombotic events are rarely reported when factor VIIa is used for FDA-approved indications"
                    ]
                  },
                  {
                    "text": "DosageFactor VIIa deficiency: 15-30 μg/kg every 4-6 hoursHemophilia with inhibitors: 90 μg/kg as neededAcquired hemophilia: 70-90 μg/kg every 2-3 hoursWarfarin anticoagulation: 15-20 μg/kgVaries for off-label use",
                    "sub_points": [
                      "Factor VIIa deficiency: 15-30 μg/kg every 4-6 hours",
                      "Hemophilia with inhibitors: 90 μg/kg as needed",
                      "Acquired hemophilia: 70-90 μg/kg every 2-3 hours",
                      "Warfarin anticoagulation: 15-20 μg/kg",
                      "Varies for off-label use"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Rh Immune Globulin": {
            "name": "Rh Immune Globulin",
            "url": "https://app.pathprimer.com/document/1c903b07-9f87-458d-b126-4a7c01b42b4e/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Rh immune globulin (RhIg): Human plasma-derived IgG anti-D that prevents alloimmunization to D antigenUsed in D-antigen-negative women for prevention of hemolytic disease of the fetus and newborn",
                    "sub_points": [
                      "Used in D-antigen-negative women for prevention of hemolytic disease of the fetus and newborn"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Dose of 300 mcg RhIg protects against 15 ml RBC or 30 ml WB"
                  }
                ]
              },
              "OVERVIEW": {
                "Definition": [
                  {
                    "text": "Rh immune globulin (RhIg): Human plasma-derived IgG anti-D that prevents alloimmunization to D antigenUsesPrevention of hemolytic disease of the fetus and newborn in D-antigen-negative womenPrevention of alloimmunization in D-negative recipients transfused with D-positive blood productsAdministration of RhIg may be considered in D-negative women of childbearing ageTreatment of immune thrombocytopenic purpuraRhIg can be used in treatment of ITP in patients with intact spleens who are D positiveAvailable doses300 mcg50 mcg",
                    "sub_points": [
                      "UsesPrevention of hemolytic disease of the fetus and newborn in D-antigen-negative womenPrevention of alloimmunization in D-negative recipients transfused with D-positive blood productsAdministration of RhIg may be considered in D-negative women of childbearing ageTreatment of immune thrombocytopenic purpuraRhIg can be used in treatment of ITP in patients with intact spleens who are D positive",
                      "Prevention of hemolytic disease of the fetus and newborn in D-antigen-negative women",
                      "Prevention of alloimmunization in D-negative recipients transfused with D-positive blood productsAdministration of RhIg may be considered in D-negative women of childbearing age",
                      "Administration of RhIg may be considered in D-negative women of childbearing age",
                      "Treatment of immune thrombocytopenic purpuraRhIg can be used in treatment of ITP in patients with intact spleens who are D positive",
                      "RhIg can be used in treatment of ITP in patients with intact spleens who are D positive",
                      "Available doses300 mcg50 mcg",
                      "300 mcg",
                      "50 mcg"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  },
                  {
                    "text": "Fetal maternal hemorrhage (FMH)"
                  },
                  {
                    "text": "Immune thrombocytopenic purpura (ITP)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Total blood volume (TBV)"
                  },
                  {
                    "text": "Whole blood (WB)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications": [
                  {
                    "text": "Should be administered to D-negative women at 28 weeks' estimated gestational age and postpartum in D-negative women who deliver D-positive, weak-D-positive, or untested infant"
                  },
                  {
                    "text": "Should be administered within 72 hours of delivery, or as soon as possible within 28 days"
                  },
                  {
                    "text": "Other indicationsInvasive procedures (amniocentesis, cordocentesis, chorionic villous sampling)External versionEctopic pregnancyAbortionAbdominal trauma in D-negative women",
                    "sub_points": [
                      "Invasive procedures (amniocentesis, cordocentesis, chorionic villous sampling)",
                      "External version",
                      "Ectopic pregnancy",
                      "Abortion",
                      "Abdominal trauma in D-negative women"
                    ]
                  },
                  {
                    "text": "RhIg is not indicated inPreviously immunized D-negative womenD-negative women who give birth to D-positive infantsD-positive women",
                    "sub_points": [
                      "Previously immunized D-negative women",
                      "D-negative women who give birth to D-positive infants",
                      "D-positive women"
                    ]
                  }
                ],
                "Rosette Test": [
                  {
                    "text": "Screening test for detection of large FMHShould be performed at delivery of D-positive infant to D-negative mother",
                    "sub_points": [
                      "Should be performed at delivery of D-positive infant to D-negative mother"
                    ]
                  },
                  {
                    "text": "DescriptionMaternal blood sample is incubated with anti-D and D-positive indicator cellsIf D-positive cells are present rosettes are formedIf Rosette test result is negative, 300 mcg dose of RhIg should be administered300 mcg RhIg protects against 15 ml RBC or 30 ml WBFalse-positives or false-negatives may occur if mother or infant has weak D phenotypePositive rosette test result indicates presence of large FMH and must be followed by quantitative test (Kleihauer-Betke, flow cytometry) to determine appropriate RhIg dose",
                    "sub_points": [
                      "Maternal blood sample is incubated with anti-D and D-positive indicator cells",
                      "If D-positive cells are present rosettes are formed",
                      "If Rosette test result is negative, 300 mcg dose of RhIg should be administered300 mcg RhIg protects against 15 ml RBC or 30 ml WB",
                      "300 mcg RhIg protects against 15 ml RBC or 30 ml WB",
                      "False-positives or false-negatives may occur if mother or infant has weak D phenotype",
                      "Positive rosette test result indicates presence of large FMH and must be followed by quantitative test (Kleihauer-Betke, flow cytometry) to determine appropriate RhIg dose"
                    ]
                  }
                ],
                "Quantitative Test": [
                  {
                    "text": "Kleihauer-BetkeBased on resistance of fetal RBCs to acid elutionThin smear of maternal blood is treated with acid and then counterstained2000 cells are counted and amount of FMH is calculatedFormula to calculate FMH(# fetal cells/2000) X TBV ml = ml fetal WB",
                    "sub_points": [
                      "Based on resistance of fetal RBCs to acid elution",
                      "Thin smear of maternal blood is treated with acid and then counterstained",
                      "2000 cells are counted and amount of FMH is calculatedFormula to calculate FMH(# fetal cells/2000) X TBV ml = ml fetal WB",
                      "Formula to calculate FMH(# fetal cells/2000) X TBV ml = ml fetal WB",
                      "(# fetal cells/2000) X TBV ml = ml fetal WB"
                    ]
                  },
                  {
                    "text": "Determination of RhIg doseFetal WB ml/30 ml = # RhIg vialsRound # of RhIg vials to nearest whole number, then add 1 to determine final RhIg dose",
                    "sub_points": [
                      "Fetal WB ml/30 ml = # RhIg vials",
                      "Round # of RhIg vials to nearest whole number, then add 1 to determine final RhIg dose"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Interference with Blood Bank Testing": [
                  {
                    "text": "RhIg administration can cause positive screen in recipient"
                  },
                  {
                    "text": "Differentiation between passive anti-D and alloimmunizationTiters of anti-D due to RhIg administration are rarely > 4RhIg is IgG antibody; anti-D caused by immunization will have IgM component and may be detected in saline phase of testing",
                    "sub_points": [
                      "Titers of anti-D due to RhIg administration are rarely > 4",
                      "RhIg is IgG antibody; anti-D caused by immunization will have IgM component and may be detected in saline phase of testing"
                    ]
                  },
                  {
                    "text": "Neonate may have positive DAT without evidence of hemolysis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Coagulation Factors": {
            "name": "Coagulation Factors",
            "url": "https://app.pathprimer.com/document/e9414e47-d24d-400f-952a-8043f2552b46/lesson/677ac826-276f-4971-b285-fac6f7d06bce",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Treatment of major bleeding"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "Patients with congenital factor deficiencies historically were treated with plasma or cryoprecipitate transfusion"
                  },
                  {
                    "text": "Newer human-derived products with decreased infectious disease risk are available for treatment of specific factor deficiencies"
                  },
                  {
                    "text": "These products are manufactured using pooled donor-derived plasma that undergoes plasma purification and pathogen inactivation"
                  },
                  {
                    "text": "Nucleic acid testing (NAT) for infectious disease markers in these productsHIVHepatitis CHepatitis BHepatitis AHuman T-lymphotropic virus (HTLV) I/IIWest Nile virusParvovirus",
                    "sub_points": [
                      "HIV",
                      "Hepatitis C",
                      "Hepatitis B",
                      "Hepatitis A",
                      "Human T-lymphotropic virus (HTLV) I/II",
                      "West Nile virus",
                      "Parvovirus"
                    ]
                  },
                  {
                    "text": "Despite improvements in human-derived coagulation factors, most patients with coagulation factor deficiencies are treated with recombinant coagulation factors"
                  },
                  {
                    "text": "Coagulation factor products include factor VIII, factor IX, factor VII, von Willebrand factor (vWF), fibrinogen, factor XIII, antithrombin III, protein C and prothrombin complex concentrates"
                  }
                ],
                "Treatment of Factor Deficiencies": [
                  {
                    "text": "Goal of treatment is to stop/prevent spontaneous bleeding and prevent excessive bleeding during surgery/procedures."
                  },
                  {
                    "text": "Treatment is based on multiple factorsPatient factor deficiencyAvailable productsDosingHalf-lifePharmacologic characteristicsLevel of factor deficiency: mild, moderate, severeCoagulation factor activity levelsPatient bleedingRisk of bleedingDuration of bleeding",
                    "sub_points": [
                      "Patient factor deficiency",
                      "Available productsDosingHalf-lifePharmacologic characteristics",
                      "Dosing",
                      "Half-life",
                      "Pharmacologic characteristics",
                      "Level of factor deficiency: mild, moderate, severe",
                      "Coagulation factor activity levels",
                      "Patient bleedingRisk of bleedingDuration of bleeding",
                      "Risk of bleeding",
                      "Duration of bleeding"
                    ]
                  },
                  {
                    "text": "Factor activity levels should be determined before and after treatment to optimize therapy"
                  },
                  {
                    "text": "Testing method to assess factor levels/activityClotting time assaysChromogenic assaysAntigenic assays (enzyme-linked immunosorbent assay [ELISA], immunoturbidimetry)Functional assays (ristocetin cofactor activity)",
                    "sub_points": [
                      "Clotting time assays",
                      "Chromogenic assays",
                      "Antigenic assays (enzyme-linked immunosorbent assay [ELISA], immunoturbidimetry)",
                      "Functional assays (ristocetin cofactor activity)"
                    ]
                  }
                ],
                "Factor VIII and Factor IX Dosing": [
                  {
                    "text": "Coagulation factor concentrate dosing based onWeightPlasma volumeBleeding riskDesired factor levelFactor half-lifeFactor VIIIWeight in kg x (desired factor level/2) = required dose (IU)Factor IXWeight in kg x desired factor level = required dose (IU)",
                    "sub_points": [
                      "Weight",
                      "Plasma volume",
                      "Bleeding risk",
                      "Desired factor level",
                      "Factor half-life",
                      "Factor VIIIWeight in kg x (desired factor level/2) = required dose (IU)",
                      "Weight in kg x (desired factor level/2) = required dose (IU)",
                      "Factor IXWeight in kg x desired factor level = required dose (IU)",
                      "Weight in kg x desired factor level = required dose (IU)"
                    ]
                  },
                  {
                    "text": "Maintenance factor doses are given at rate to keep factor levels at desired threshold based on clinical situation/risk of bleeding"
                  }
                ],
                "von Willebrand Disease": [
                  {
                    "text": "von Willebrand disease (vWD) is most common inherited bleeding disorderCharacterized by quantitative or qualitative deficiency in vWF",
                    "sub_points": [
                      "Characterized by quantitative or qualitative deficiency in vWF"
                    ]
                  },
                  {
                    "text": "Treatment of minor bleedingIntranasal or intravenous DDAVP for persistent bleedingAntifibrinolytics",
                    "sub_points": [
                      "Intranasal or intravenous DDAVP for persistent bleeding",
                      "Antifibrinolytics"
                    ]
                  },
                  {
                    "text": "Treatment of major bleeding/surgeryGoal is maintenance of normal vWF levels during surgery and for 1-2 days postoperativelyFactor VIII levels should be kept at 50% for 1 week after surgery/procedure and at 30% during 2nd postoperative week.",
                    "sub_points": [
                      "Goal is maintenance of normal vWF levels during surgery and for 1-2 days postoperatively",
                      "Factor VIII levels should be kept at 50% for 1 week after surgery/procedure and at 30% during 2nd postoperative week."
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Blood Product Modifications": {
        "name": "Blood Product Modifications",
        "url": "https://app.pathprimer.com/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
        "topics": {
          "Leukoreduced and CMV Reduced-Risk Blood Products": {
            "name": "Leukoreduced and CMV Reduced-Risk Blood Products",
            "url": "https://app.pathprimer.com/document/4438fa58-0a7d-4009-9ca4-aecaae8675ff/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "CMV seronegative products are donated by donors who are seronegative for IgG and IgM antibodies to CMV"
                  },
                  {
                    "text": "Leukoreduced products are considered to be \"CMV safe\""
                  },
                  {
                    "text": "Leukoreduced products reduce specific risksTransfusion-transmitted CMVHLA alloimmunizationFebrile nonhemolytic transfusion reactionsTransfusion-related immunomodulation",
                    "sub_points": [
                      "Transfusion-transmitted CMV",
                      "HLA alloimmunization",
                      "Febrile nonhemolytic transfusion reactions",
                      "Transfusion-related immunomodulation"
                    ]
                  },
                  {
                    "text": "Leukoreduced red blood cells and apheresis platelets must contain < 5 x 10⁶ leukocytes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cytomegalovirus (CMV)"
                  },
                  {
                    "text": "Hematopoietic progenitor cell (HPC)"
                  },
                  {
                    "text": "Transfusion-transmitted CMV (TT-CMV)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "CMV": [
                  {
                    "text": "Lipid enveloped DNA virus in herpes virus family"
                  },
                  {
                    "text": "Transmission is through body fluids"
                  },
                  {
                    "text": "Causes mild illness in immunocompetent individuals with fever, sore throat, and fatigue"
                  },
                  {
                    "text": "Occasionally causes infectious mononucleosis or hepatitis"
                  },
                  {
                    "text": "CMV can establish latency in multiple tissues and reactivate"
                  },
                  {
                    "text": "CMV seroprevalence is estimated to be 40-60% in general population"
                  },
                  {
                    "text": "Some patient populations are at risk of serious complicationsPneumonitisHepatitisColitisPolyradiculitisTransverse myelitisEncephalitisRetinitis",
                    "sub_points": [
                      "Pneumonitis",
                      "Hepatitis",
                      "Colitis",
                      "Polyradiculitis",
                      "Transverse myelitis",
                      "Encephalitis",
                      "Retinitis"
                    ]
                  },
                  {
                    "text": "High-risk populations include patients with specific conditionsSolid-organ malignancyLymphomaLeukemiaRenal failure on hemodialysisSolid organ and HPC transplant recipientsPatients on immunosuppressive regimensHIV-positive patients",
                    "sub_points": [
                      "Solid-organ malignancy",
                      "Lymphoma",
                      "Leukemia",
                      "Renal failure on hemodialysis",
                      "Solid organ and HPC transplant recipients",
                      "Patients on immunosuppressive regimens",
                      "HIV-positive patients"
                    ]
                  },
                  {
                    "text": "CMV can be transmitted vertically from pregnant woman to fetus, potentially leading to congenital infection"
                  },
                  {
                    "text": "Congenital infection can lead to low birth weight, seizures, microcephaly, and hepatosplenomegaly and may be fatal in some cases"
                  }
                ],
                "Transfusion-Transmitted CMV": [
                  {
                    "text": "Cellular blood components can transmit CMVRed blood cellsPlateletsGranulocytes",
                    "sub_points": [
                      "Red blood cells",
                      "Platelets",
                      "Granulocytes"
                    ]
                  },
                  {
                    "text": "CMV resides within WBCs in product"
                  },
                  {
                    "text": "Immunocompromised patients at high risk of transfusion-transmitted infectionSeronegative recipients of seronegative allogeneic or autologous HPC transplantsSeronegative recipients of seronegative solid organ transplantsFetusesPremature low-birth-weight infants born to seronegative mothersSeronegative HIV patientsPatients with inherited immunodeficiency",
                    "sub_points": [
                      "Seronegative recipients of seronegative allogeneic or autologous HPC transplants",
                      "Seronegative recipients of seronegative solid organ transplants",
                      "Fetuses",
                      "Premature low-birth-weight infants born to seronegative mothers",
                      "Seronegative HIV patients",
                      "Patients with inherited immunodeficiency"
                    ]
                  },
                  {
                    "text": "These patients should receive CMV reduced-risk blood products"
                  },
                  {
                    "text": "CMV infection in seronegative immunocompromised patients can lead to major morbidity and mortality"
                  }
                ],
                "CMV Reduced-Risk Products": [
                  {
                    "text": "Cellular blood components collected from CMV seronegative blood donors"
                  },
                  {
                    "text": "Leukoreduced blood components"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "CMV Seronegative Blood Components": [
                  {
                    "text": "Donor serum is tested for IgM and IgG antibodies to CMVSolid phase immunofluorescence assaysEnzyme immunoassaysLatex particle agglutinationSolid phase red cell adherence assays",
                    "sub_points": [
                      "Solid phase immunofluorescence assays",
                      "Enzyme immunoassays",
                      "Latex particle agglutination",
                      "Solid phase red cell adherence assays"
                    ]
                  },
                  {
                    "text": "Donors may be able to transmit virus via transfusion during window period or time between CMV exposure and time to positive test result"
                  },
                  {
                    "text": "Window period between infection and positive serology for CMV is about 6-8 weeks"
                  },
                  {
                    "text": "Use of CMV seronegative blood components decreases but does not eliminate risk of TT-CMV"
                  },
                  {
                    "text": "Estimated residual risk of TT-CMV using seronegative blood components is about 1-2% in at-risk populations"
                  }
                ],
                "Leukoreduction": [
                  {
                    "text": "Unit of whole blood normally contains ≥ 1-10 x 10⁹ leukocytes"
                  },
                  {
                    "text": "Leukoreduced products must contain < 5 x 10⁶ leukocytes"
                  },
                  {
                    "text": "Leukoreduction methodsWhole blood-derived componentsFilter-based: In-line as part of whole blood collection setFilter-based: BedsideApheresis-derived componentsFilter-based: In-line as part of apheresis disposable kitDirect, in-process leukoreduction: Some plateletpheresis and plasmapheresis collections are inherently associated with contamination by < 5 x 10⁶ leukocytes",
                    "sub_points": [
                      "Whole blood-derived componentsFilter-based: In-line as part of whole blood collection setFilter-based: Bedside",
                      "Filter-based: In-line as part of whole blood collection set",
                      "Filter-based: Bedside",
                      "Apheresis-derived componentsFilter-based: In-line as part of apheresis disposable kitDirect, in-process leukoreduction: Some plateletpheresis and plasmapheresis collections are inherently associated with contamination by < 5 x 10⁶ leukocytes",
                      "Filter-based: In-line as part of apheresis disposable kit",
                      "Direct, in-process leukoreduction: Some plateletpheresis and plasmapheresis collections are inherently associated with contamination by < 5 x 10⁶ leukocytes"
                    ]
                  },
                  {
                    "text": "Leukoreduction filters remove WBCs by pore size and charge exclusion"
                  },
                  {
                    "text": "Leukoreduction can be performed prestorage or at bedsidePrestorage leukoreduction is preferred to bedside leukoreductionPrevents cytokine release by donor WBC during storage",
                    "sub_points": [
                      "Prestorage leukoreduction is preferred to bedside leukoreduction",
                      "Prevents cytokine release by donor WBC during storage"
                    ]
                  },
                  {
                    "text": "AdvantagesDecreases risk of febrile nonhemolytic transfusion reactionsDecreased risk of transfusion-related immunomodulationDecreases risk of transfusion-transmitted CMVDecreases risk of human leukocyte antigen (HLA) alloimmunization",
                    "sub_points": [
                      "Decreases risk of febrile nonhemolytic transfusion reactions",
                      "Decreased risk of transfusion-related immunomodulation",
                      "Decreases risk of transfusion-transmitted CMV",
                      "Decreases risk of human leukocyte antigen (HLA) alloimmunization"
                    ]
                  },
                  {
                    "text": "DisadvantagesNot tested for CMV seronegativityCMV may be present in plasma during early infectionRisk of CMV transmission is about 2-3%",
                    "sub_points": [
                      "Not tested for CMV seronegativityCMV may be present in plasma during early infectionRisk of CMV transmission is about 2-3%",
                      "CMV may be present in plasma during early infection",
                      "Risk of CMV transmission is about 2-3%"
                    ]
                  },
                  {
                    "text": "Leukoreduced cellular products often referred to as \"CMV-safe\""
                  },
                  {
                    "text": "Granulocytes should never be leukoreduced"
                  },
                  {
                    "text": "Most common cause of leukoreduction failure is sickle cell trait"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards": [
                  {
                    "text": "Leukocyte-reduced blood and blood components must contain less than 5 x 10⁶ leukocytes for red blood cells and apheresis platelets"
                  },
                  {
                    "text": "Must contain less than 8.3 x 10⁵ leukocytes for whole blood-derived platelets"
                  },
                  {
                    "text": "Validation and quality control must demonstrate that at least 95% of units tested meet these criteria"
                  }
                ],
                "FDA": [
                  {
                    "text": "Requires at least 85% recovery of original RBC or platelet content"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Irradiated Blood Products": {
            "name": "Irradiated Blood Products",
            "url": "https://app.pathprimer.com/document/36b89632-1c40-4eff-a016-ec5086bc327a/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Irradiated blood products are indicated for prevention of TA-GVHD in susceptible patientsTA-GVHD: Rare, but usually fatal, complication of blood transfusionIrradiation damages DNA of lymphocytes, preventing lymphocyte proliferation and engraftment in host, resulting in TA-GVHDOnly cellular blood products (RBCs, platelets, granulocytes, whole blood, and fresh plasma) have viable T lymphocytes and are irradiated to prevent TA-GVHD",
                    "sub_points": [
                      "TA-GVHD: Rare, but usually fatal, complication of blood transfusionIrradiation damages DNA of lymphocytes, preventing lymphocyte proliferation and engraftment in host, resulting in TA-GVHD",
                      "Irradiation damages DNA of lymphocytes, preventing lymphocyte proliferation and engraftment in host, resulting in TA-GVHD",
                      "Only cellular blood products (RBCs, platelets, granulocytes, whole blood, and fresh plasma) have viable T lymphocytes and are irradiated to prevent TA-GVHD"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Transfusion-associated graft-versus-host disease (TA-GVHD)"
                  },
                  {
                    "text": "Gray (Gy)"
                  },
                  {
                    "text": "centiGray (cGy)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "General": [
                  {
                    "text": "TA-GVHD: Rare complication of transfusion (approximately 1 per 2,000,000 cellular products transfused)Almost uniformly fatal; successful treatment is rare",
                    "sub_points": [
                      "Almost uniformly fatal; successful treatment is rare"
                    ]
                  },
                  {
                    "text": "Immunosuppressed patients are at risk for developing TA-GVHD"
                  },
                  {
                    "text": "If done properly, irradiation of cellular blood components eliminates risk of TA-GVHDBlood irradiators are regulated by United States Nuclear Regulatory Commission",
                    "sub_points": [
                      "Blood irradiators are regulated by United States Nuclear Regulatory Commission"
                    ]
                  }
                ],
                "Indications": [
                  {
                    "text": "Differences in opinion exist around indications for irradiation; however, indications accepted by most authorities are listed hereHematopoietic progenitor cell transplant recipientsHodgkin diseasePatients with history of purine analog treatment (fludarabine, cladribine, deoxycoformycin)Patients receiving HLA-matched plateletsPatients receiving transfusion from blood relativesGranulocyte transfusionsIntrauterine transfusionsTreatment with anti-CD52 (Campath) or other medications or antibodies affecting T lymphocyte function or numberPatients with congenital immunodeficiencies",
                    "sub_points": [
                      "Hematopoietic progenitor cell transplant recipients",
                      "Hodgkin disease",
                      "Patients with history of purine analog treatment (fludarabine, cladribine, deoxycoformycin)",
                      "Patients receiving HLA-matched platelets",
                      "Patients receiving transfusion from blood relatives",
                      "Granulocyte transfusions",
                      "Intrauterine transfusions",
                      "Treatment with anti-CD52 (Campath) or other medications or antibodies affecting T lymphocyte function or number",
                      "Patients with congenital immunodeficiencies"
                    ]
                  },
                  {
                    "text": "Transfusion services must have policy stating populations identified as at-risk and requiring irradiated cellular blood products"
                  },
                  {
                    "text": "Universal irradiation is performed at some institutions due to high risk of fatality from TA-GVHD, low risk of transfusing irradiated cellular blood products, and relative low cost of irradiation"
                  }
                ],
                "Risks of Irradiation": [
                  {
                    "text": "Potassium release"
                  },
                  {
                    "text": "Decreased RBC recovery"
                  }
                ],
                "Irradiation not indicated": [
                  {
                    "text": "Patients with HIV/AIDS"
                  },
                  {
                    "text": "Solid organ transplantation"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB Standards": [
                  {
                    "text": "Irradiation dose shall be 25 Gy (2500 cGy) to center of container"
                  },
                  {
                    "text": "Minimum irradiation dose to any other area shall be 15 Gy (1500 cGy)"
                  },
                  {
                    "text": "Method must ensure that irradiation has occurredMethod must also be used to indicate that irradiation occurred",
                    "sub_points": [
                      "Method must also be used to indicate that irradiation occurred"
                    ]
                  },
                  {
                    "text": "Outdate of irradiated red cells is 28 days or original outdate, whichever is sooner"
                  },
                  {
                    "text": "Irradiated platelets maintain their original outdate"
                  }
                ],
                "Additional Requirements": [
                  {
                    "text": "Maximum dose of irradiation should be no more than 50 Gy (5000 cGy)"
                  }
                ]
              },
              "SPECIMENS": {
                "Products That May Be Irradiated": [
                  {
                    "text": "Cellular blood products"
                  },
                  {
                    "text": "Whole blood (WB)"
                  },
                  {
                    "text": "Packed red blood cells (PRBC)"
                  },
                  {
                    "text": "Platelets"
                  },
                  {
                    "text": "Granulocytes"
                  },
                  {
                    "text": "Liquid plasma"
                  }
                ],
                "Products That Do Not Require Irradiation": [
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Hematopoietic progenitor cells must NOT be irradiated"
                  }
                ]
              },
              "PROCESSING": {
                "Methods": [
                  {
                    "text": "Sources of irradiation can be gamma rays and x-rays"
                  },
                  {
                    "text": "Cellular blood products are irradiated by exposure to cesium-137, cobalt-60, or x-rays"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Washed Blood Products": {
            "name": "Washed Blood Products",
            "url": "https://app.pathprimer.com/document/00bfbfd6-7e13-45ed-9bbb-fa89bdfbd3cf/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Washing: Blood product modification that involves adding up to 2 L of saline to blood product, and centrifugation to remove liquid supernatantLiquid portion of blood product replaced with salineRemoves 99% of plasma proteins﻿Also removes free hemoglobin, cytokines, and potassiumAnticoagulant-preservative solutions removed",
                    "sub_points": [
                      "Liquid portion of blood product replaced with saline",
                      "Removes 99% of plasma proteins﻿Also removes free hemoglobin, cytokines, and potassium",
                      "Also removes free hemoglobin, cytokines, and potassium",
                      "Anticoagulant-preservative solutions removed"
                    ]
                  },
                  {
                    "text": "Possible indicationsCases of severe allergic reactionIn large-volume transfusions for pediatric patients, to remove potassium",
                    "sub_points": [
                      "Cases of severe allergic reaction",
                      "In large-volume transfusions for pediatric patients, to remove potassium"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Products That May Be Washed": [
                  {
                    "text": "Red blood cells (RBCs)Red cells are washed with up to 2 L of salineMay cause loss of red cell mass up to 20% and cause shear stress on red cellsLeads to increased plasma-free hemoglobinDecreases storage time to 24 hours at 1°C-6°C, if washed in open systemAll frozen RBCs must be washed after thawing to remove cryoprotectant glycerol",
                    "sub_points": [
                      "Red cells are washed with up to 2 L of saline",
                      "May cause loss of red cell mass up to 20% and cause shear stress on red cellsLeads to increased plasma-free hemoglobin",
                      "Leads to increased plasma-free hemoglobin",
                      "Decreases storage time to 24 hours at 1°C-6°C, if washed in open system",
                      "All frozen RBCs must be washed after thawing to remove cryoprotectant glycerol"
                    ]
                  },
                  {
                    "text": "PlateletsMay cause platelet activation and loss of up to 30% of plateletsMay lead to decreased platelet aggregation and functionEffect is decrease in fresh plateletsDecreases storage time to 4 hours at room temperature",
                    "sub_points": [
                      "May cause platelet activation and loss of up to 30% of plateletsMay lead to decreased platelet aggregation and functionEffect is decrease in fresh platelets",
                      "May lead to decreased platelet aggregation and functionEffect is decrease in fresh platelets",
                      "Effect is decrease in fresh platelets",
                      "Decreases storage time to 4 hours at room temperature"
                    ]
                  }
                ],
                "Indications for Washed Products (RBCs and Platelets)": [
                  {
                    "text": "Prevention of severe allergic/anaphylactic reactionsIgA deficiencyHaptoglobin deficiencyComplement deficiency (C3, C4)",
                    "sub_points": [
                      "IgA deficiency",
                      "Haptoglobin deficiency",
                      "Complement deficiency (C3, C4)"
                    ]
                  },
                  {
                    "text": "Transfusion of incompatible plasmaTransfusion of group O platelets to group A or group B recipients",
                    "sub_points": [
                      "Transfusion of group O platelets to group A or group B recipients"
                    ]
                  },
                  {
                    "text": "Prevention of hyperkalemiaLarge-volume or rapid transfusions to pediatric patientsTransfusion of older irradiated red cell units",
                    "sub_points": [
                      "Large-volume or rapid transfusions to pediatric patients",
                      "Transfusion of older irradiated red cell units"
                    ]
                  },
                  {
                    "text": "Neonatal alloimmune thrombocytopenia (NAIT)Maternal platelets are washed to remove antibody, causing platelet destruction",
                    "sub_points": [
                      "Maternal platelets are washed to remove antibody, causing platelet destruction"
                    ]
                  },
                  {
                    "text": "Removal of anticoagulant additive solutions"
                  },
                  {
                    "text": "Removal of plasma proteins to prevent severe allergic reactions in patients"
                  },
                  {
                    "text": "Patients with T activationNaturally occurring IgM anti-T binds to T-cryptantigen exposed by removal of N-acetylneuraminic acid from RBC membrane by bacterial neuraminidaseMay be seen in patients with necrotizing enterocolitis, sepsis, or hemolytic uremic syndrome, and in pediatric patients withStreptococcal pneumoniainfection",
                    "sub_points": [
                      "Naturally occurring IgM anti-T binds to T-cryptantigen exposed by removal of N-acetylneuraminic acid from RBC membrane by bacterial neuraminidase",
                      "May be seen in patients with necrotizing enterocolitis, sepsis, or hemolytic uremic syndrome, and in pediatric patients withStreptococcal pneumoniainfection"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Products That Can Not Be Washed": [
                  {
                    "text": "Cryoprecipitate"
                  },
                  {
                    "text": "Plasma"
                  }
                ],
                "Laboratory": [
                  {
                    "text": "Washing products is time consuming; may lead to delays in issuing"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "AABB StandardsWashed red cells must be prepared by method known to ensure that volume of compatible solution used will remove almost all plasma",
                    "sub_points": [
                      "Washed red cells must be prepared by method known to ensure that volume of compatible solution used will remove almost all plasma"
                    ]
                  }
                ],
                "Storage, Transportation, and Expiration": [
                  {
                    "text": "Washed RBCs are stored at 1°C-6°C"
                  },
                  {
                    "text": "Washed RBCs expire in 24 hours"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Volume-Reduced Products": {
            "name": "Volume-Reduced Products",
            "url": "https://app.pathprimer.com/document/898cfedc-d50d-4c72-94d4-4e02cbb9854e/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Volume reduction removes part of liquid portion of cellular blood product (RBCs, platelets, HPCs)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Prevention of hyperkalemia in at-risk patients"
                  },
                  {
                    "text": "Prevention of volume overload in at-risk patients"
                  },
                  {
                    "text": "Out-of-group ABO platelet transfusions"
                  }
                ]
              },
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Volume reduction removes portion of liquid supernatant of cellular blood product (RBCs, platelets, HPCs)Removes most of anticoagulant-preservative solutionResults in more concentrated blood product",
                    "sub_points": [
                      "Removes most of anticoagulant-preservative solution",
                      "Results in more concentrated blood product"
                    ]
                  },
                  {
                    "text": "Processing involves centrifugation with expression of supernatant"
                  },
                  {
                    "text": "Primarily used to prevent volume overload in susceptible patient populations, patients at risk of TACO, or patients with transfusion-associated dyspnea"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "Hematopoietic progenitor cells (HPCs)"
                  },
                  {
                    "text": "Transfusion-associated circulatory overload (TACO)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Volume Reduction of RBCs": [
                  {
                    "text": "Centrifugation of RBC unit and removal of supernatant"
                  },
                  {
                    "text": "Inverted gravity sedimentation with removal of supernatant"
                  },
                  {
                    "text": "Hematocrit of volume-reduced RBC units is ~ 70-90%"
                  }
                ],
                "Volume Reduction of Platelets": [
                  {
                    "text": "Performed via centrifugation of platelet component and removal of supernatant"
                  },
                  {
                    "text": "Platelets must rest without agitation after centrifugation to prevent aggregation"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Components that may be volume reduced": [
                  {
                    "text": "RBCs"
                  },
                  {
                    "text": "Platelets"
                  },
                  {
                    "text": "HPCs"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Indications for Volume-Reduced RBCs": [
                  {
                    "text": "Prevention of volume overload in at-risk patient populationsLow-birthweight infantsPatients with inadequate renal or cardiovascular function",
                    "sub_points": [
                      "Low-birthweight infants",
                      "Patients with inadequate renal or cardiovascular function"
                    ]
                  },
                  {
                    "text": "Prevention of hyperkalemia in at-risk patientsLarge-volume transfusions (> 20 mL/kg transfused)Transfusion via central venous catheter with tip near right atrium",
                    "sub_points": [
                      "Large-volume transfusions (> 20 mL/kg transfused)",
                      "Transfusion via central venous catheter with tip near right atrium"
                    ]
                  },
                  {
                    "text": "Decrease in febrile nonhemolytic transfusion reactionsDecreases cytokine levels accumulated during storage of nonleukoreduced products",
                    "sub_points": [
                      "Decreases cytokine levels accumulated during storage of nonleukoreduced products"
                    ]
                  },
                  {
                    "text": "Aliquoted RBC units for neonates"
                  }
                ],
                "Indications for Volume-Reduced Platelets": [
                  {
                    "text": "Transfusion of out-of-group platelets (group O to group A or group B) to remove incompatible ABO IgM antibodies"
                  },
                  {
                    "text": "Decrease in febrile nonhemolytic transfusion reactions due to decrease in cytokine levels accumulated during storage of nonleukoreduced products"
                  },
                  {
                    "text": "Transfusion of volume-reduced platelets should be limited to infants at risk for volume overload"
                  }
                ],
                "Indications for Volume-Reduced HPCs": [
                  {
                    "text": "Minor ABO incompatibility between donor and recipient, to remove donor anti-ABO antibodies"
                  }
                ]
              },
              "LIMITATIONS": {
                "Adverse Effects": [
                  {
                    "text": "Red cells are not harmed by volume reductions"
                  },
                  {
                    "text": "Platelet outdate is shortened to 4 hours"
                  },
                  {
                    "text": "May result in loss of platelets, clumping, and dysfunction due to platelet activation and aggregation"
                  },
                  {
                    "text": "May lead to delay in component issuing"
                  }
                ]
              },
              "QUALITY": {
                "Expiration of Volume-Reduced Components": [
                  {
                    "text": "Red cells: 24 hours"
                  },
                  {
                    "text": "Platelets: 4 hours"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pathogen Reduction Technologies": {
            "name": "Pathogen Reduction Technologies",
            "url": "https://app.pathprimer.com/document/4b8d9c83-67fe-48da-ad60-fe6a30248202/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "In effort to further improve blood safety, PIT has potential to produce profound shift in overall approach to blood safety, with ability to inactivate contaminating infectious agents and reduce need for expensive implementation of screening tests for emerging pathogens"
                  },
                  {
                    "text": "Most used treatment of FFP or FP24 involves combination of detergent and nonvolatile solvent to disturb lipid-enveloped viruses"
                  },
                  {
                    "text": "All PITs currently available effectively inactivate most pathogens"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Terminology": [
                  {
                    "text": "AbbreviationsHuman immunodeficiency virus (HIV)Pathogen inactivation technology (PIT)Solvent-detergent (SD)US Food and Drug Administration (FDA)Hepatitis B virus (HBV)Hepatitis C virus (HCV)Transfusion-related acute lung injury (TRALI)Fresh frozen plasma (FFP)Ultraviolet (UV)Pathogen reduction technology (PRT)Red blood cell (RBC)Transfusion-associated graft-vs.-host disease (TA-GVHD)Infectious disease marker (IDM)Cytomegalovirus (CMV)Frozen plasma at 24 hr (FP24)",
                    "sub_points": [
                      "Human immunodeficiency virus (HIV)",
                      "Pathogen inactivation technology (PIT)",
                      "Solvent-detergent (SD)",
                      "US Food and Drug Administration (FDA)",
                      "Hepatitis B virus (HBV)",
                      "Hepatitis C virus (HCV)",
                      "Transfusion-related acute lung injury (TRALI)",
                      "Fresh frozen plasma (FFP)",
                      "Ultraviolet (UV)",
                      "Pathogen reduction technology (PRT)",
                      "Red blood cell (RBC)",
                      "Transfusion-associated graft-vs.-host disease (TA-GVHD)",
                      "Infectious disease marker (IDM)",
                      "Cytomegalovirus (CMV)",
                      "Frozen plasma at 24 hr (FP24)"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "Risk of transfusion-transmitted disease has been a major focus of blood collection agencies since the 1980s with the discovery of HIV"
                  },
                  {
                    "text": "Although large reductions in risk of transfusion-associated infection have occurred, there are other agents potentially transmitted in blood with either no screening tests or no defined guidelines for screening"
                  },
                  {
                    "text": "PIT has potential to produce profound shift in overall approach to blood safety with ability to inactivate contaminating infectious agents"
                  }
                ],
                "Pathogen Inactivation Technologies": [
                  {
                    "text": "SD plasmaOnly FDA-approved product is Octoplas from OctapharmaPooled plasma treated with combination of detergent and nonvolatile solvent to inactivate enveloped viruses by disrupting lipid bilayers of plasma membrane of cells/organisms and lipid coat of enveloped viruses (HBV, HCV, and HIV)Not a viable option for use in cellular products because solvent-detergent has direct negative effect on cellular membranesIndicationsReplacement of multiple coagulation factors in patients with acquired deficiencies such as liver disease or preoperatively for patients undergoing liver transplant or cardiac surgeryPlasma exchange in patients with thrombotic thrombocytopenic purpuraHypothesized to reduce or eliminate risk of TRALI due to dilution of antibodiesCoagulation factor levels consistent within each batchAll factors > 0.5 IU/mLExceptions protein S and α₂-antiplasmin, which are > 0.4 IU/mLProtein S and α₂-antiplasmin (also known as plasmin inhibitor) are labile to SD treatment",
                    "sub_points": [
                      "Only FDA-approved product is Octoplas from Octapharma",
                      "Pooled plasma treated with combination of detergent and nonvolatile solvent to inactivate enveloped viruses by disrupting lipid bilayers of plasma membrane of cells/organisms and lipid coat of enveloped viruses (HBV, HCV, and HIV)",
                      "Not a viable option for use in cellular products because solvent-detergent has direct negative effect on cellular membranes",
                      "IndicationsReplacement of multiple coagulation factors in patients with acquired deficiencies such as liver disease or preoperatively for patients undergoing liver transplant or cardiac surgeryPlasma exchange in patients with thrombotic thrombocytopenic purpura",
                      "Replacement of multiple coagulation factors in patients with acquired deficiencies such as liver disease or preoperatively for patients undergoing liver transplant or cardiac surgery",
                      "Plasma exchange in patients with thrombotic thrombocytopenic purpura",
                      "Hypothesized to reduce or eliminate risk of TRALI due to dilution of antibodies",
                      "Coagulation factor levels consistent within each batchAll factors > 0.5 IU/mLExceptions protein S and α₂-antiplasmin, which are > 0.4 IU/mLProtein S and α₂-antiplasmin (also known as plasmin inhibitor) are labile to SD treatment",
                      "All factors > 0.5 IU/mL",
                      "Exceptions protein S and α₂-antiplasmin, which are > 0.4 IU/mLProtein S and α₂-antiplasmin (also known as plasmin inhibitor) are labile to SD treatment",
                      "Protein S and α₂-antiplasmin (also known as plasmin inhibitor) are labile to SD treatment"
                    ]
                  },
                  {
                    "text": "Methylene blueNot currently approved by FDAPrimarily used in treatment of FFPPhotoreactive methylene blue has high affinity for nucleic acids and surface structure of viruses to inactivate most viruses and bacteriaConcerns for mutagenic effects of methylene blue have prompted development of additional filtration steps to remove residual dye before transfusion",
                    "sub_points": [
                      "Not currently approved by FDA",
                      "Primarily used in treatment of FFP",
                      "Photoreactive methylene blue has high affinity for nucleic acids and surface structure of viruses to inactivate most viruses and bacteria",
                      "Concerns for mutagenic effects of methylene blue have prompted development of additional filtration steps to remove residual dye before transfusion"
                    ]
                  },
                  {
                    "text": "Riboflavin/UV lightPhotoactivation of riboflavin (vitamin B2) inactivates pathogens by damaging nucleic acids and production of reactive oxygen intermediatesMirasol PRTToxicity of riboflavin is of less concern than other photoactivating agentsMirasol PRT for pathogen reduction is currently used in Europe for plasma and plateletsTrials underway in United States and Europe for RBCs",
                    "sub_points": [
                      "Photoactivation of riboflavin (vitamin B2) inactivates pathogens by damaging nucleic acids and production of reactive oxygen intermediatesMirasol PRT",
                      "Mirasol PRT",
                      "Toxicity of riboflavin is of less concern than other photoactivating agents",
                      "Mirasol PRT for pathogen reduction is currently used in Europe for plasma and plateletsTrials underway in United States and Europe for RBCs",
                      "Trials underway in United States and Europe for RBCs"
                    ]
                  },
                  {
                    "text": "Amotosalen/UVThe Intercept system uses compound amotosalen, a psoralen compound, which intercalates between nucleotide bases of RNA and DNA on UV light activation preventing nucleic acid replicationResidual amotosalen and its photoactive products have not shown any mutagenic, phototoxic, or genotoxic effectsAmotosalen/UV treatment is approved by FDA and has been investigated for use in frozen plasma and platelet products",
                    "sub_points": [
                      "The Intercept system uses compound amotosalen, a psoralen compound, which intercalates between nucleotide bases of RNA and DNA on UV light activation preventing nucleic acid replication",
                      "Residual amotosalen and its photoactive products have not shown any mutagenic, phototoxic, or genotoxic effects",
                      "Amotosalen/UV treatment is approved by FDA and has been investigated for use in frozen plasma and platelet products"
                    ]
                  }
                ],
                "Benefits of Pathogen Inactivation Technologies": [
                  {
                    "text": "PITs currently available inactivate most pathogens"
                  },
                  {
                    "text": "Reduced transmission of infectious agents"
                  },
                  {
                    "text": "Reduced potential of transmission of emerging infectious agents"
                  },
                  {
                    "text": "Decreased risk of TA-GVHD"
                  },
                  {
                    "text": "Decreased transfusion reactions"
                  },
                  {
                    "text": "Reduced need for IDM testing"
                  },
                  {
                    "text": "Potential extension of platelet outdate"
                  },
                  {
                    "text": "Replacement of CMV testing (Intercept)"
                  },
                  {
                    "text": "Replacement of irradiation (Intercept)"
                  }
                ],
                "Risks of Pathogen Inactivation Technologies": [
                  {
                    "text": "Recipient reactions"
                  },
                  {
                    "text": "Decreased effectiveness of component therapy"
                  },
                  {
                    "text": "PITs do not inactivate prions"
                  },
                  {
                    "text": "Potential of shortened storage period for packed RBCs"
                  },
                  {
                    "text": "Reduction of α₂-antiplasmin and protein S and risk of thrombosis (SD plasma)"
                  },
                  {
                    "text": "Loss of coagulation factors (amotosalen and riboflavin PIT)"
                  }
                ],
                "Pathogen Inactivation Technologies by Component": [
                  {
                    "text": "PlasmaIntercept (FDA approved): UVA + amatosalenMirasol-UV + riboflavinTheraflex-methylene blueOctaplas (FDA approved)",
                    "sub_points": [
                      "Intercept (FDA approved): UVA + amatosalen",
                      "Mirasol-UV + riboflavin",
                      "Theraflex-methylene blue",
                      "Octaplas (FDA approved)"
                    ]
                  },
                  {
                    "text": "PlateletsIntercept (FDA approved)MirasolTheraflex",
                    "sub_points": [
                      "Intercept (FDA approved)",
                      "Mirasol",
                      "Theraflex"
                    ]
                  },
                  {
                    "text": "RBCsFrangible anchor-linker effector compound",
                    "sub_points": [
                      "Frangible anchor-linker effector compound"
                    ]
                  },
                  {
                    "text": "Whole bloodMirasol",
                    "sub_points": [
                      "Mirasol"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Frozen Blood Products": {
            "name": "Frozen Blood Products",
            "url": "https://app.pathprimer.com/document/3a90a18d-e94b-4f98-a03b-32a1902136d9/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Red blood cell (RBC) units are frozen to increase storage time to 10 years"
                  },
                  {
                    "text": "Frozen RBC units usually have either rare combinations of antigens or lack high-incidence antigens"
                  },
                  {
                    "text": "Frozen inventories of rare units are maintained by the American Rare Donor Program and the International Blood Group Reference Laboratory"
                  },
                  {
                    "text": "Rejuvenation allows for increased shelf life of red cells units for either 24 hours at 1°C-6°C, or frozen up to 10 years"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Cryopreservation of RBCs": [
                  {
                    "text": "RBCs are frozen using glycerol as cryoprotectantGlycerolHyperosmotic and crosses RBC membranePrevents loss of intracellular water into extracellular fluid and resultant cellular dehydrationMay be added in either high or low concentrations prior to freezing",
                    "sub_points": [
                      "GlycerolHyperosmotic and crosses RBC membranePrevents loss of intracellular water into extracellular fluid and resultant cellular dehydrationMay be added in either high or low concentrations prior to freezing",
                      "Hyperosmotic and crosses RBC membrane",
                      "Prevents loss of intracellular water into extracellular fluid and resultant cellular dehydration",
                      "May be added in either high or low concentrations prior to freezing"
                    ]
                  },
                  {
                    "text": "RBC units frozen using high glycerol freezing method are slowly frozen in -80°C mechanical freezers and stored at -65°CThis method is more commonly used by blood centers, as it does not require use of liquid nitrogen",
                    "sub_points": [
                      "This method is more commonly used by blood centers, as it does not require use of liquid nitrogen"
                    ]
                  },
                  {
                    "text": "RBC units frozen using low glycerol freezing method are rapidly frozen in liquid nitrogen and stored at -120°C"
                  },
                  {
                    "text": "Frozen RBC units have shelf life of 10 yearsShelf life of very rare units may be extended beyond 10 years after medical review and approval",
                    "sub_points": [
                      "Shelf life of very rare units may be extended beyond 10 years after medical review and approval"
                    ]
                  },
                  {
                    "text": "Aliquot of frozen RBC unit must be frozen separately to allow for performance of additional donor screening/testing"
                  }
                ],
                "Rejuvenation": [
                  {
                    "text": "FDA-approved rejuvenation solution contains pyruvate, inosine, phosphate, and adenine"
                  },
                  {
                    "text": "Restores 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP) levels"
                  },
                  {
                    "text": "Rejuvenation solution may be added between 3 days of collection and 3 days post-expiration"
                  },
                  {
                    "text": "Recommended that rejuvenation solution is added after 14 days of collection to prevent supraphysiologic levels 2,3-DPG"
                  },
                  {
                    "text": "Rejuvenated citrate-phosphate-dextrose (CPD) and citrate-phosphate-dextrose-adenine-1 (CPDA-1) RBC units must either be washed and transfused within 24 hours or stored frozen for up to 10 years"
                  },
                  {
                    "text": "Rejuvenated CPD/AS-1 RBC units must be frozen; may be stored for up to 3 years"
                  },
                  {
                    "text": "Rejuvenation solution should not be infused into patient"
                  },
                  {
                    "text": "Deglycerolized rejuvenated RBCs must be stored at 1°C-6°C and transfused within 24 hours"
                  }
                ],
                "Thawing and Deglycerolization": [
                  {
                    "text": "Frozen units are thawed in 37°C hot water bath or dry warmer with gentle agitation"
                  },
                  {
                    "text": "Thawed units are washed with sodium chloride solutions to remove all glycerol prior to transfusionFinal storage solution is 0.9% sodium chloride with 0.2% dextrose",
                    "sub_points": [
                      "Final storage solution is 0.9% sodium chloride with 0.2% dextrose"
                    ]
                  },
                  {
                    "text": "Washing process is gradual, to prevent hemolysisIf unit is washed in open system, shelf life is 24 hours at 1°C-6°CIf unit is washed in closed system, cells are resuspended in AS-3 and may be stored for up to 14 days at 1°C-6°C",
                    "sub_points": [
                      "If unit is washed in open system, shelf life is 24 hours at 1°C-6°C",
                      "If unit is washed in closed system, cells are resuspended in AS-3 and may be stored for up to 14 days at 1°C-6°C"
                    ]
                  }
                ],
                "Refreezing of Thawed RBCs": [
                  {
                    "text": "Exceptionally rare units that were accidentally thawed, or thawed and unused, may be refrozen"
                  }
                ],
                "Indications": [
                  {
                    "text": "Rare units are frozen to maintain inventories for patients with antibodies who require transfusionUnits that are negative for high-incidence antigensUnits with rare phenotypes",
                    "sub_points": [
                      "Units that are negative for high-incidence antigens",
                      "Units with rare phenotypes"
                    ]
                  },
                  {
                    "text": "American Rare Donor Program and the International Blood Group Reference Laboratory assist hospital blood banks and blood donor centers in identifying and procuring rare donor units"
                  },
                  {
                    "text": "Autologous units may be frozen to prolong storage timeFrequently done by patients with multiple alloantibodies or antibodies to high-frequency antigens",
                    "sub_points": [
                      "Frequently done by patients with multiple alloantibodies or antibodies to high-frequency antigens"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Volume Losses": [
                  {
                    "text": "Significant red cell volume may be lost during freezing and washing processes"
                  }
                ],
                "Hemolysis": [
                  {
                    "text": "RBCs obtained from donors with sickle cell trait hemolyze during deglycerolization process"
                  },
                  {
                    "text": "Specialized washing procedures prevent hemolysis in these units, but are not widely available"
                  },
                  {
                    "text": "Most blood centers screen units for sickle cell trait prior to freezing"
                  }
                ]
              },
              "QUALITY": {
                "Quality Control and Assurance": [
                  {
                    "text": "Volume of RBCs in final washed deglycerolized unit should be monitored"
                  },
                  {
                    "text": "Last wash solution should be inspected visually for evidence of hemolysis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Platelet Additive Solutions": {
            "name": "Platelet Additive Solutions",
            "url": "https://app.pathprimer.com/document/c37a35a8-bcdf-43b4-b46e-5f767c9eb503/lesson/f1c60ef3-13ba-4703-9f1c-8030d821b444",
            "content": {
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "Platelet additive solutions (PAS) are isotonic electrolyte plasma substitutes used in storage of platelet products"
                  },
                  {
                    "text": "PAS were developed in 1980s and have been available in other countries for many years"
                  },
                  {
                    "text": "In United States, platelets are primarily stored in anticoagulated plasma at 20°C-24°C"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA) approved Intersol, a platelet additive solution, in 2009Intersol platelets contain 65% PAS and 35% plasma",
                    "sub_points": [
                      "Intersol platelets contain 65% PAS and 35% plasma"
                    ]
                  },
                  {
                    "text": "Platelet additive solution Isoplate was approved by FDA for storage of apheresis platelet products collected by Trima in 2013Isoplate products contain 65% PAS and 35% plasma",
                    "sub_points": [
                      "Isoplate products contain 65% PAS and 35% plasma"
                    ]
                  }
                ],
                "Contents of Platelet Additive Solutions": [
                  {
                    "text": "PAS are named by category, PAS A through PAS G, based on their contents"
                  },
                  {
                    "text": "PAS are composed of NaCl, sodium acetate (source of energy), sodium citrate, and phosphate (maintenance of pH)"
                  },
                  {
                    "text": "Newer formulations also contain magnesium and potassium"
                  },
                  {
                    "text": "PAS platelet products generally contain 20%-50% plasma and 50%-80% PAS"
                  },
                  {
                    "text": "Due to decreased amounts of plasma, coagulation factor levels are lower"
                  }
                ],
                "Characteristics of Platelets Stored in Platelet Additive Solutions": [
                  {
                    "text": "Use of PAS does not affect collection procedures, storage containers, platelet count, or storage volume"
                  },
                  {
                    "text": "No difference in bleeding outcome, number of transfusions, or transfusion interval between patients transfused with PAS platelets and platelets stored in plasma"
                  },
                  {
                    "text": "Platelet recovery and survival vary based on PAS type"
                  },
                  {
                    "text": "PAS platelets are stored at 20°C-24°C with agitation for 5 days"
                  }
                ],
                "Benefits": [
                  {
                    "text": "Improve platelet storage conditions, survival, and function"
                  },
                  {
                    "text": "Increased shelf life"
                  },
                  {
                    "text": "Increased plasma available for manufacturer"
                  },
                  {
                    "text": "Use in pathogen inactivation"
                  },
                  {
                    "text": "Decrease in reactions caused by plasma transfusionPrevention of acute hemolytic transfusion reactions (reduction of transfusion of ABO-incompatible plasma)Decreased rates of allergic transfusion reactionsDecreased risk of transfusion-related acute lung injury (TRALI)Potential decreased risk of transfusion-associated circulatory overload (TACO)Potential decrease in febrile nonhemolytic transfusion reactions",
                    "sub_points": [
                      "Prevention of acute hemolytic transfusion reactions (reduction of transfusion of ABO-incompatible plasma)",
                      "Decreased rates of allergic transfusion reactions",
                      "Decreased risk of transfusion-related acute lung injury (TRALI)",
                      "Potential decreased risk of transfusion-associated circulatory overload (TACO)",
                      "Potential decrease in febrile nonhemolytic transfusion reactions"
                    ]
                  }
                ],
                "Future of Platelet Additive Solutions Products": [
                  {
                    "text": "PAS that can be used with 5%-20% plasma"
                  },
                  {
                    "text": "Addition of glucose,calcium, and bicarbonateGlucose to affect platelet metabolismCalcium to maintain potassium ion gradient across platelet membraneBicarbonate to raise pH",
                    "sub_points": [
                      "Glucose to affect platelet metabolism",
                      "Calcium to maintain potassium ion gradient across platelet membrane",
                      "Bicarbonate to raise pH"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Specific Clinical Settings": {
        "name": "Specific Clinical Settings",
        "url": "https://app.pathprimer.com/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
        "topics": {
          "Neonatal and Pediatric Patients": {
            "name": "Neonatal and Pediatric Patients",
            "url": "https://app.pathprimer.com/document/324bb377-ec3c-43d6-afae-7566bb8f705d/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Pediatric patients require specialized transfusion care due to differences in size, immune status, and physiology when compared with adults"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "Pediatric patients require specialized transfusion care due to differences in size, immune status, and physiology when compared with adults"
                  }
                ],
                "Neonates (1-4 months)": [
                  {
                    "text": "Red Cell Transfusions in NeonatesPacked red blood cells (PRBC) are transfused to neonates under certain conditionsTreatment of symptomatic anemiaBlood loss of > 10% blood volumeHgb < 13 grams/dL in first 24 hours post-deliveryIndicationsNo clearly defined universal recommendationsGuidelines are based on clinical experience due to lack of data/clinical studiesDose10-15 mL/kg body weightAt this dose, expected increase in Hgb is 2-3 g/dL",
                    "sub_points": [
                      "Packed red blood cells (PRBC) are transfused to neonates under certain conditionsTreatment of symptomatic anemiaBlood loss of > 10% blood volumeHgb < 13 grams/dL in first 24 hours post-delivery",
                      "Treatment of symptomatic anemia",
                      "Blood loss of > 10% blood volume",
                      "Hgb < 13 grams/dL in first 24 hours post-delivery",
                      "IndicationsNo clearly defined universal recommendationsGuidelines are based on clinical experience due to lack of data/clinical studies",
                      "No clearly defined universal recommendations",
                      "Guidelines are based on clinical experience due to lack of data/clinical studies",
                      "Dose10-15 mL/kg body weightAt this dose, expected increase in Hgb is 2-3 g/dL",
                      "10-15 mL/kg body weight",
                      "At this dose, expected increase in Hgb is 2-3 g/dL"
                    ]
                  },
                  {
                    "text": "Compatibility TestingABO group, Rh type (reverse type not required)Antibody screen (plasma/serum from mother or infant)Before issuing non group O red blood cells (RBC), testing to detect passively acquired anti-A and anti-B must be performed to ensure transfusion compatibilityIf unexpected antibody (alloantibody) is detected, antigen-negative or crossmatch-compatible units should be transfused until antibody is no longer detectedCrossmatch not requiredRepeat ABO, Rh not necessary during single hospitalization",
                    "sub_points": [
                      "ABO group, Rh type (reverse type not required)",
                      "Antibody screen (plasma/serum from mother or infant)Before issuing non group O red blood cells (RBC), testing to detect passively acquired anti-A and anti-B must be performed to ensure transfusion compatibilityIf unexpected antibody (alloantibody) is detected, antigen-negative or crossmatch-compatible units should be transfused until antibody is no longer detected",
                      "Before issuing non group O red blood cells (RBC), testing to detect passively acquired anti-A and anti-B must be performed to ensure transfusion compatibility",
                      "If unexpected antibody (alloantibody) is detected, antigen-negative or crossmatch-compatible units should be transfused until antibody is no longer detected",
                      "Crossmatch not required",
                      "Repeat ABO, Rh not necessary during single hospitalization"
                    ]
                  },
                  {
                    "text": "Special Procedures in NeonatesExchange transfusions are performed to treat hyperbilirubinemia in patients who fail phototherapy or in removal of chemicals, toxins, or other drugsRequirement for Exchange TransfusionReconstituted whole blood (ABO compatible PRBC in compatible fresh frozen plasma [FFP])Citrate phosphate dextrose adenine (CPDA-1) PRBC, < 7 days oldHgb S negativeCytomegalovirus (CMV) risk reducedIrradiated (immediately prior to transfusion)",
                    "sub_points": [
                      "Exchange transfusions are performed to treat hyperbilirubinemia in patients who fail phototherapy or in removal of chemicals, toxins, or other drugs",
                      "Requirement for Exchange TransfusionReconstituted whole blood (ABO compatible PRBC in compatible fresh frozen plasma [FFP])Citrate phosphate dextrose adenine (CPDA-1) PRBC, < 7 days oldHgb S negativeCytomegalovirus (CMV) risk reducedIrradiated (immediately prior to transfusion)",
                      "Reconstituted whole blood (ABO compatible PRBC in compatible fresh frozen plasma [FFP])",
                      "Citrate phosphate dextrose adenine (CPDA-1) PRBC, < 7 days old",
                      "Hgb S negative",
                      "Cytomegalovirus (CMV) risk reduced",
                      "Irradiated (immediately prior to transfusion)"
                    ]
                  },
                  {
                    "text": "Platelet Transfusion SupportMost common hemostatic abnormality in infants is thrombocytopeniaTherapeutic Platelet TransfusionPlatelets are transfused for platelet counts < 50,000 with active bleedingHowever, ill, preterm infants may bleed at higher platelet countsProphylactic Platelet TransfusionPrevention of intraventricular hemorrhageDose5-10 mL/kg body weightIncreases platelet count by 50,000-100,000ABOPlatelet transfusions should be ABO-specific when availability allowsPlasma in platelet products should be compatibleWashing or volume reduction can remove incompatible plasma if necessary",
                    "sub_points": [
                      "Most common hemostatic abnormality in infants is thrombocytopenia",
                      "Therapeutic Platelet TransfusionPlatelets are transfused for platelet counts < 50,000 with active bleedingHowever, ill, preterm infants may bleed at higher platelet counts",
                      "Platelets are transfused for platelet counts < 50,000 with active bleeding",
                      "However, ill, preterm infants may bleed at higher platelet counts",
                      "Prophylactic Platelet TransfusionPrevention of intraventricular hemorrhage",
                      "Prevention of intraventricular hemorrhage",
                      "Dose5-10 mL/kg body weightIncreases platelet count by 50,000-100,000",
                      "5-10 mL/kg body weight",
                      "Increases platelet count by 50,000-100,000",
                      "ABOPlatelet transfusions should be ABO-specific when availability allowsPlasma in platelet products should be compatibleWashing or volume reduction can remove incompatible plasma if necessary",
                      "Platelet transfusions should be ABO-specific when availability allows",
                      "Plasma in platelet products should be compatible",
                      "Washing or volume reduction can remove incompatible plasma if necessary"
                    ]
                  },
                  {
                    "text": "Plasma TransfusionFFP is transfused to correct coagulation factor deficiencies, hemorrhagic disease of newborn, and vitamin K deficiencyDose10-15 mL/kg body weightDose is expected to increase coagulation factor activity levels by 15-20%",
                    "sub_points": [
                      "FFP is transfused to correct coagulation factor deficiencies, hemorrhagic disease of newborn, and vitamin K deficiency",
                      "Dose10-15 mL/kg body weightDose is expected to increase coagulation factor activity levels by 15-20%",
                      "10-15 mL/kg body weight",
                      "Dose is expected to increase coagulation factor activity levels by 15-20%"
                    ]
                  },
                  {
                    "text": "CryoprecipitateCryoprecipitate is used for treatment of decreased/dysfunctional fibrinogenCan be used for factor XIII deficiency if recombinant factor is not availableDoseOne unit in newbornsABOABO compatible cryoprecipitate should be transfused",
                    "sub_points": [
                      "Cryoprecipitate is used for treatment of decreased/dysfunctional fibrinogen",
                      "Can be used for factor XIII deficiency if recombinant factor is not available",
                      "DoseOne unit in newborns",
                      "One unit in newborns",
                      "ABOABO compatible cryoprecipitate should be transfused",
                      "ABO compatible cryoprecipitate should be transfused"
                    ]
                  }
                ],
                "Special Products, Pediatric Transfusion": [
                  {
                    "text": "Aliquots/syringesDecrease blood exposuresDecrease blood waste",
                    "sub_points": [
                      "Decrease blood exposures",
                      "Decrease blood waste"
                    ]
                  },
                  {
                    "text": "CMV-negative or CMV risk reduced"
                  },
                  {
                    "text": "Dedicated units"
                  },
                  {
                    "text": "Irradiation"
                  },
                  {
                    "text": "CPDA-1 unitsAdditive solution (AS) units are safe in small volume transfusions",
                    "sub_points": [
                      "Additive solution (AS) units are safe in small volume transfusions"
                    ]
                  }
                ],
                "Pediatric Therapies": [
                  {
                    "text": "Extracorporeal membrane oxygenation (ECMO)ECMO allows venous blood to be circulated through instrument for CO₂ exchangeUsed in patients with heart and/or lung dysfunctionBlood requirements1-2 ABO crossmatch-compatible units PRBCHbg S negative< 7 days oldCMV risk reducedIrradiatedOne unit of group-specific FFPPlatelets are transfused to maintain platelet counts between 80,000-150,000",
                    "sub_points": [
                      "ECMO allows venous blood to be circulated through instrument for CO₂ exchange",
                      "Used in patients with heart and/or lung dysfunction",
                      "Blood requirements1-2 ABO crossmatch-compatible units PRBCHbg S negative< 7 days oldCMV risk reducedIrradiatedOne unit of group-specific FFPPlatelets are transfused to maintain platelet counts between 80,000-150,000",
                      "1-2 ABO crossmatch-compatible units PRBCHbg S negative< 7 days oldCMV risk reducedIrradiated",
                      "Hbg S negative",
                      "< 7 days old",
                      "CMV risk reduced",
                      "Irradiated",
                      "One unit of group-specific FFP",
                      "Platelets are transfused to maintain platelet counts between 80,000-150,000"
                    ]
                  }
                ],
                "Pediatric Transfusion, > 4 months": [
                  {
                    "text": "Transfusion in patients older than 4 months of age is similar to transfusion in adults"
                  },
                  {
                    "text": "Special considerationsPatient blood volumeNormal pediatric hemoglobin levelsPatient's ability to tolerate blood loss",
                    "sub_points": [
                      "Patient blood volume",
                      "Normal pediatric hemoglobin levels",
                      "Patient's ability to tolerate blood loss"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemolytic Disease of the Fetus and Newborn": {
            "name": "Hemolytic Disease of the Fetus and Newborn",
            "url": "https://app.pathprimer.com/document/5a53dc6b-5414-4d44-9add-76561994d8fd/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "HDFN is caused by development of IgG red cell antibodies from maternal exposure to fetal red cell antigens that cross placental barrier and can lead to destruction of fetal red cell precursors and circulating red cells"
                  },
                  {
                    "text": "Prevention of alloimmunization to Rh-D antigen in Rh-negative mothers can be prevented with administration of RhIG at 28 weeks' gestation and following birth; this drug binds circulating fetal RBCs that contain Rh-D antigen, preventing mother's body from recognizing antigen and forming antibody to it"
                  },
                  {
                    "text": "More than 50 specificities of RBC antibodies have been implicated in HDFN, with most cases of severe anemia caused by anti-D, anti-c (Rh system), or anti-Kell"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Hemolytic disease of the fetus and newborn (HDFN) is caused by development of IgG red cell antibodies from maternal exposure to fetal red cell antigens that cross placental barrier"
                  },
                  {
                    "text": "Can lead to destruction of fetal red cell precursors and circulating red cells"
                  },
                  {
                    "text": "Maternally derived red cell antibodies can have dire consequences to fetus in utero due to red cell destruction and anemia and infant postnatally from hemolysis and hyperbilirubinemia following birth"
                  },
                  {
                    "text": "Prevention of alloimmunization to Rh-D antigen in Rh-negative mothers can be prevented with administration of Rh immunoglobulin (RhIG) at 28 weeks gestation and following birth"
                  },
                  {
                    "text": "Rh immunoglobulin binds circulating fetal red blood cells (RBCs) containing Rh-D antigen, preventing mother's body from recognizing antigen and forming antibody to it"
                  },
                  {
                    "text": "HDFN caused by Anti-KImportant cause of HDFN occurring in mothers sensitized through transfusion or prior pregnancyIn addition to red cell hemolysis, Anti-K in HDFN leads to destruction of fetal K antigen positive erythropoietic precursors, resulting in severe anemiaHDFN due to Anti-K can be clinically significant at low titers due to presence of Kell antigen on red cell precursors",
                    "sub_points": [
                      "Important cause of HDFN occurring in mothers sensitized through transfusion or prior pregnancy",
                      "In addition to red cell hemolysis, Anti-K in HDFN leads to destruction of fetal K antigen positive erythropoietic precursors, resulting in severe anemia",
                      "HDFN due to Anti-K can be clinically significant at low titers due to presence of Kell antigen on red cell precursors"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "IncidenceMore than 50 specificities of RBC antibodies have been implicated in HDFN, with most cases of severe anemia caused by anti-D, anti-c (Rh system), or anti-KellSince advent of RhIG, most common form of HDFN in western world is ABO incompatibility in babies born to type O mothers due to anti-A, B IgG presentHowever, clinical presentation is mild with hyperbilirubinemia in absence of anemia, most likely due to low numbers of A and B antigens on surface of fetal RBCsIntroduction of RhIG reduced incidence of Rh-D alloimmunization from 14% (about rate of Rh-D negative women) to 0.1%Despite RhIG administration, 6.7 of 1000 live births in United States are affected by Rh-D alloimmunization, most likely from inadvertent failure to administer RhIG, inadequate prenatal care, or antenatal sensitization prior to 28 weeksHowever, only about half of all infants positive for cognate antigen that mother has developed red cell antibody to are affected in utero",
                    "sub_points": [
                      "More than 50 specificities of RBC antibodies have been implicated in HDFN, with most cases of severe anemia caused by anti-D, anti-c (Rh system), or anti-Kell",
                      "Since advent of RhIG, most common form of HDFN in western world is ABO incompatibility in babies born to type O mothers due to anti-A, B IgG present",
                      "However, clinical presentation is mild with hyperbilirubinemia in absence of anemia, most likely due to low numbers of A and B antigens on surface of fetal RBCs",
                      "Introduction of RhIG reduced incidence of Rh-D alloimmunization from 14% (about rate of Rh-D negative women) to 0.1%",
                      "Despite RhIG administration, 6.7 of 1000 live births in United States are affected by Rh-D alloimmunization, most likely from inadvertent failure to administer RhIG, inadequate prenatal care, or antenatal sensitization prior to 28 weeks",
                      "However, only about half of all infants positive for cognate antigen that mother has developed red cell antibody to are affected in utero"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Neonates affected by severe HDFN present in variety of ways, many of which are considered emergencies"
                  },
                  {
                    "text": "HDFN is considered in neonates with following presentationRapidly developing unconjugated hyperbilirubinemia (bilirubin levels may be lower in Anti-K HDFN)Positive direct antiglobulin test (DAT)Positive maternal antibody screenSevere anemiaHydrops fetalisHemolysis detected on peripheral blood smear",
                    "sub_points": [
                      "Rapidly developing unconjugated hyperbilirubinemia (bilirubin levels may be lower in Anti-K HDFN)",
                      "Positive direct antiglobulin test (DAT)",
                      "Positive maternal antibody screen",
                      "Severe anemia",
                      "Hydrops fetalis",
                      "Hemolysis detected on peripheral blood smear"
                    ]
                  },
                  {
                    "text": "In utero, classic signs of anemia due to HDFN include hydrops fetalis (fluid accumulation around lungs, abdomen, brain, etc.) and anemia"
                  },
                  {
                    "text": "Fetuses do not have hyperbilirubinemia, as bilirubin is transported across placenta and metabolized by mother’s liver"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Intrauterine transfusion is indicated in fetuses with elevated middle cerebral artery (MCA) Doppler and radiographic evidence of anemia"
                  },
                  {
                    "text": "Packed RBCs used for transfusion in HDFNAntigen-negative to corresponding antibody detected in motherO negativeWashed to remove anti-A and anti-B in plasmaIrradiated to prevent transfusion-associated graft-versus-host diseaseHemoglobin S negativeCytomegalovirus-safe (leukoreduced and/or cytomegalovirus IgG negative)",
                    "sub_points": [
                      "Antigen-negative to corresponding antibody detected in mother",
                      "O negative",
                      "Washed to remove anti-A and anti-B in plasma",
                      "Irradiated to prevent transfusion-associated graft-versus-host disease",
                      "Hemoglobin S negative",
                      "Cytomegalovirus-safe (leukoreduced and/or cytomegalovirus IgG negative)"
                    ]
                  },
                  {
                    "text": "Exchange transfusion in neonates involves removal of neonatal blood that is incompatible with maternal antibody and replacement with antigen-negative whole blood units"
                  },
                  {
                    "text": "Process effectively corrects anemia; removes maternal antibody and bilirubin"
                  },
                  {
                    "text": "Exchange transfusion is indicated in neonates if there is severe anemia (< 10 g/dL) at birth and/or severe hyperbilirubinemia (> 340 mmol/L)"
                  },
                  {
                    "text": "Phototherapy is effective for treatment of neonates with HDN to reduce burden of bilirubin through photactivation using white light"
                  },
                  {
                    "text": "Due to its safety profile and noninvasive nature, it is considered viable option and effective alternative to exchange transfusion in selected cases"
                  },
                  {
                    "text": "Use of intravenous immunoglobulin (IVIG) as adjuvant therapy in neonates has recently been studied with decreased need for exchange transfusion in these patients, though evidence is still in favor of exchange transfusion in neonates with severe presentations"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Neonatal hemolysis due to HDFN must be distinguished from other causes of hyperbilirubinemia in this patient populationRBC membrane disordersHyperbilirubinemia with negative DAT and abnormal peripheral blood smearLook for family history; most common disorder is hereditary spherocytosisCan confirm with red cell dye-binding studies or membrane electrophoresisRBC enzyme defectsGlucose-6-phosphate dehydrogenase (G6PD) deficiency is most common inherited red cell enzyme deficiency presenting with neonatal hyperbilirubinemiaG6PD deficiency is X-linked and has high prevalence in central Africa and MediterraneanClues to this diagnosis besides neonatal unconjugated hyperbilirubinemiaNegative DATEthnic originGender (male)Normal peripheral blood smearHemoglobinopathiesHemoglobinopathies, with exception of α-thalassemia, most often do not present in neonatal periodα-thalassemia major, caused by deletion of all 4 α-globin genes, often presents similarly to HDFN in utero mid-trimester with hydrops fetalis and severe fetal anemiaSeen most commonly in babies born to parents coming from Southeast Asia or Middle EastNeonates with α-thalassemia who survive birth develop marked anemia and hydrops that rapidly progresses to hyperbilirubinemiaReview of parents' peripheral blood smear should reveal hypochromic, microcytic red cells, as both parents are carriers of 2 α-globin gene deletionsDiagnosis is confirmed by hemoglobin electrophoresis or high-performance liquid chromatography",
                    "sub_points": [
                      "RBC membrane disordersHyperbilirubinemia with negative DAT and abnormal peripheral blood smearLook for family history; most common disorder is hereditary spherocytosisCan confirm with red cell dye-binding studies or membrane electrophoresis",
                      "Hyperbilirubinemia with negative DAT and abnormal peripheral blood smear",
                      "Look for family history; most common disorder is hereditary spherocytosis",
                      "Can confirm with red cell dye-binding studies or membrane electrophoresis",
                      "RBC enzyme defectsGlucose-6-phosphate dehydrogenase (G6PD) deficiency is most common inherited red cell enzyme deficiency presenting with neonatal hyperbilirubinemiaG6PD deficiency is X-linked and has high prevalence in central Africa and MediterraneanClues to this diagnosis besides neonatal unconjugated hyperbilirubinemiaNegative DATEthnic originGender (male)Normal peripheral blood smear",
                      "Glucose-6-phosphate dehydrogenase (G6PD) deficiency is most common inherited red cell enzyme deficiency presenting with neonatal hyperbilirubinemia",
                      "G6PD deficiency is X-linked and has high prevalence in central Africa and Mediterranean",
                      "Clues to this diagnosis besides neonatal unconjugated hyperbilirubinemiaNegative DATEthnic originGender (male)Normal peripheral blood smear",
                      "Negative DAT",
                      "Ethnic origin",
                      "Gender (male)",
                      "Normal peripheral blood smear",
                      "HemoglobinopathiesHemoglobinopathies, with exception of α-thalassemia, most often do not present in neonatal periodα-thalassemia major, caused by deletion of all 4 α-globin genes, often presents similarly to HDFN in utero mid-trimester with hydrops fetalis and severe fetal anemiaSeen most commonly in babies born to parents coming from Southeast Asia or Middle EastNeonates with α-thalassemia who survive birth develop marked anemia and hydrops that rapidly progresses to hyperbilirubinemiaReview of parents' peripheral blood smear should reveal hypochromic, microcytic red cells, as both parents are carriers of 2 α-globin gene deletionsDiagnosis is confirmed by hemoglobin electrophoresis or high-performance liquid chromatography",
                      "Hemoglobinopathies, with exception of α-thalassemia, most often do not present in neonatal period",
                      "α-thalassemia major, caused by deletion of all 4 α-globin genes, often presents similarly to HDFN in utero mid-trimester with hydrops fetalis and severe fetal anemiaSeen most commonly in babies born to parents coming from Southeast Asia or Middle East",
                      "Seen most commonly in babies born to parents coming from Southeast Asia or Middle East",
                      "Neonates with α-thalassemia who survive birth develop marked anemia and hydrops that rapidly progresses to hyperbilirubinemia",
                      "Review of parents' peripheral blood smear should reveal hypochromic, microcytic red cells, as both parents are carriers of 2 α-globin gene deletions",
                      "Diagnosis is confirmed by hemoglobin electrophoresis or high-performance liquid chromatography"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Microscopy": [
                  {
                    "text": "Histological featuresPeripheral blood examination in neonates with significant hemolysis due to HDNRBC fragmentsSpherocytesIncreased numbers of nucleated RBCs and reticulocytes (low reticulocyte count may be observed in anti-K HDFN)Polychromasia (due to increased RNA content)",
                    "sub_points": [
                      "Peripheral blood examination in neonates with significant hemolysis due to HDNRBC fragmentsSpherocytesIncreased numbers of nucleated RBCs and reticulocytes (low reticulocyte count may be observed in anti-K HDFN)Polychromasia (due to increased RNA content)",
                      "RBC fragments",
                      "Spherocytes",
                      "Increased numbers of nucleated RBCs and reticulocytes (low reticulocyte count may be observed in anti-K HDFN)",
                      "Polychromasia (due to increased RNA content)"
                    ]
                  }
                ],
                "Blood Bank/Clinical Testing": [
                  {
                    "text": "When clinically significant antibody is detected in woman’s first pregnancy, maternal antibody titers are performed each month until 24 weeks' gestation"
                  },
                  {
                    "text": "Most laboratories and obstetricians consider titer of 1:32 clinically relevant, except for anti-Kell, which can cause HDFN regardless of titer"
                  },
                  {
                    "text": "Once maternal antibody reaches critical threshold, maternal fetal medicine physicians will begin weekly screening of fetal MCA flow, with increased velocities indicating severe anemia, requiring treatment"
                  },
                  {
                    "text": "All neonates at risk should have cord blood hemoglobin, DAT, and bilirubin performed to establish diagnosis and assess need for therapy"
                  },
                  {
                    "text": "Following affected pregnancy, genotype studies on mother and father can be performed to assess risk in future pregnancies"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fetal and Neonatal Alloimmune Thrombocytopenia": {
            "name": "Fetal and Neonatal Alloimmune Thrombocytopenia",
            "url": "https://app.pathprimer.com/document/75117194-5143-4919-a376-559045a1f987/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "FNAIT causes transient thrombocytopenia in fetus/neonate due to presence of maternal alloantibodies against fetal platelet-specific antigens"
                  },
                  {
                    "text": "HPA-1a causes 75-80% of FNAIT in white patients"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Fetal and neonatal alloimmune thrombocytopenia (FNAIT) causes transient thrombocytopenia in fetus/neonate due to presence of maternal alloantibodies against fetal platelet-specific antigens or human platelet antigens (HPA)"
                  },
                  {
                    "text": "Mother exposed to paternal HPAs that she lacks has potential to become immunized, developing HPA antibodies"
                  },
                  {
                    "text": "IgG alloantibody crosses placenta and binds to fetal platelets, leading to increased platelet destruction/clearance and causing thrombocytopenia"
                  },
                  {
                    "text": "All HPAs have been implicated in FNAIT, but cause may differ based on allele frequency found in different racial/ethnic populationsHPA-1a causes 75-80% of FNAIT in white patients2.5% of white people are HPA-1a-negativeHPA-5b causes 10% of FNAIT and is second most common causeHPA-1b causes 4% of casesHPA-3a causes 2% of casesHPA-4 is responsible for 80% of FNAIT in Asians",
                    "sub_points": [
                      "HPA-1a causes 75-80% of FNAIT in white patients2.5% of white people are HPA-1a-negative",
                      "2.5% of white people are HPA-1a-negative",
                      "HPA-5b causes 10% of FNAIT and is second most common cause",
                      "HPA-1b causes 4% of cases",
                      "HPA-3a causes 2% of cases",
                      "HPA-4 is responsible for 80% of FNAIT in Asians"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "IncidenceFNAIT occurs in 1 in 1000 live births (most common cause of thrombocytopenia in newborns)",
                    "sub_points": [
                      "FNAIT occurs in 1 in 1000 live births (most common cause of thrombocytopenia in newborns)"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Clinical presentation of FNAIT varies, ranging from thrombocytopenia without bleeding to fetal demise"
                  },
                  {
                    "text": "Most cases are asymptomaticOften go undetected unless complete blood count is drawn for another clinical reason (i.e., sepsis)",
                    "sub_points": [
                      "Often go undetected unless complete blood count is drawn for another clinical reason (i.e., sepsis)"
                    ]
                  },
                  {
                    "text": "FNAIT occurs in first pregnancy in about 25% of cases, with most clinical signs evident in full-term neonates"
                  },
                  {
                    "text": "SignsThrombocytopenia in utero/within first 24-72 hours of birth, platelet count < 50,000/microliter, with or without bleedingPetechiaeEcchymosisMelenaHematomaHematuriaHematemesisHemoptysisIntracranial hemorrhage (ICH)50-57% of cases occur prenatallyFetal demise",
                    "sub_points": [
                      "Thrombocytopenia in utero/within first 24-72 hours of birth, platelet count < 50,000/microliter, with or without bleeding",
                      "Petechiae",
                      "Ecchymosis",
                      "Melena",
                      "Hematoma",
                      "Hematuria",
                      "Hematemesis",
                      "Hemoptysis",
                      "Intracranial hemorrhage (ICH)50-57% of cases occur prenatally",
                      "50-57% of cases occur prenatally",
                      "Fetal demise"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Goal of FNAIT treatment is prevention of hemorrhage, particularly intracranial hemorrhage, which can lead to neurologic dysfunction and death"
                  },
                  {
                    "text": "AntenatalNo screening tests are currently usedConsider history of prior pregnancies, including history of intracranial hemorrhage and fetal age at time of occurrence and fetal demise due to hemorrhageSeverity of prior affected pregnancies is predictive of severity of FNAIT in future pregnanciesMaternal intravenous immunoglobulin (IVIG) with or without prednisone can be used in at-risk pregnanciesIntrauterine transfusion of HPA-negative plateletsElective cesarean section",
                    "sub_points": [
                      "No screening tests are currently used",
                      "Consider history of prior pregnancies, including history of intracranial hemorrhage and fetal age at time of occurrence and fetal demise due to hemorrhage",
                      "Severity of prior affected pregnancies is predictive of severity of FNAIT in future pregnancies",
                      "Maternal intravenous immunoglobulin (IVIG) with or without prednisone can be used in at-risk pregnancies",
                      "Intrauterine transfusion of HPA-negative platelets",
                      "Elective cesarean section"
                    ]
                  },
                  {
                    "text": "PostnatalTreatment must occur prior to final diagnosisPhysical examinationHead ultrasonographyIVIG with or without corticosteroidsPlatelet transfusion for platelet counts < 30,000/microliter in asymptomatic neonate or < 100,000/microliter in presence of ICHAntigen-negative plateletsWashed maternal plateletsUntested platelets",
                    "sub_points": [
                      "Treatment must occur prior to final diagnosisPhysical examinationHead ultrasonographyIVIG with or without corticosteroidsPlatelet transfusion for platelet counts < 30,000/microliter in asymptomatic neonate or < 100,000/microliter in presence of ICHAntigen-negative plateletsWashed maternal plateletsUntested platelets",
                      "Physical examination",
                      "Head ultrasonography",
                      "IVIG with or without corticosteroids",
                      "Platelet transfusion for platelet counts < 30,000/microliter in asymptomatic neonate or < 100,000/microliter in presence of ICHAntigen-negative plateletsWashed maternal plateletsUntested platelets",
                      "Antigen-negative platelets",
                      "Washed maternal platelets",
                      "Untested platelets"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other causes of thrombocytopenia in neonate should be consideredInfectionMaternal hypertensionChronic hypoxiaNecrotizing enterocolitisThrombosisInherited thrombocytopeniaMaternal immune thrombocytopeniaBone marrow failure syndromes",
                    "sub_points": [
                      "Infection",
                      "Maternal hypertension",
                      "Chronic hypoxia",
                      "Necrotizing enterocolitis",
                      "Thrombosis",
                      "Inherited thrombocytopenia",
                      "Maternal immune thrombocytopenia",
                      "Bone marrow failure syndromes"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Diagnosis": [
                  {
                    "text": "Diagnosis depends on detection of presence of maternal HPA alloantibody in serum to corresponding paternal HPAPaternal and maternal genotyping using PCR can be performed to determine HPA type and zygositySerologic testing can be performed for antibody detectionMonoclonal antibody immobilization of platelet antigens (MAIPA) assayModified antigen capture enzyme-linked immunosorbent assay (MACE)Flow cytometry for antibody detection",
                    "sub_points": [
                      "Paternal and maternal genotyping using PCR can be performed to determine HPA type and zygosity",
                      "Serologic testing can be performed for antibody detectionMonoclonal antibody immobilization of platelet antigens (MAIPA) assayModified antigen capture enzyme-linked immunosorbent assay (MACE)",
                      "Monoclonal antibody immobilization of platelet antigens (MAIPA) assay",
                      "Modified antigen capture enzyme-linked immunosorbent assay (MACE)",
                      "Flow cytometry for antibody detection"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Patients with Hemoglobinopathies": {
            "name": "Patients with Hemoglobinopathies",
            "url": "https://app.pathprimer.com/document/42ff6d6d-0424-44fd-b109-b22d9000fda2/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Patients with hemoglobinopathies are unique subset of patients who require specialized transfusion support"
                  },
                  {
                    "text": "In patients with sickle cell, PRBC are transfused to improve oxygen carrying capacity by increasing Hgb A concentration, decreasing red cell sickling and blood viscosity"
                  },
                  {
                    "text": "Thalassemia patients are transfused on a regular basis, every 2-5 weeks, to increase Hgb levels to 13-14 g/dL and maintain Hgb levels at 9-10 g/dL"
                  },
                  {
                    "text": "Patients with sickle cell and thalassemia commonly receive phenotype matched (C, E, and K) blood to decrease risk of alloimmunization"
                  },
                  {
                    "text": "Patients with sickle cell anemia have higher risk of alloimmunization (18-50%)"
                  },
                  {
                    "text": "Thalassemia patients have alloimmunization risk of 5-11%"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Hemoglobinopathies": [
                  {
                    "text": "Patients with hemoglobinopathies are unique subset of patients who require specialized transfusion support"
                  },
                  {
                    "text": "Sickle cell anemia and thalassemia patients commonly require transfusion"
                  },
                  {
                    "text": "Special considerations for these patients includeNeed for phenotype matched bloodChronic transfusion supportIncreased risk of alloantibody formationRed cell exchange proceduresPotential for hematopoietic stem cell transplant",
                    "sub_points": [
                      "Need for phenotype matched blood",
                      "Chronic transfusion support",
                      "Increased risk of alloantibody formation",
                      "Red cell exchange procedures",
                      "Potential for hematopoietic stem cell transplant"
                    ]
                  }
                ],
                "Sickle Cell Disease": [
                  {
                    "text": "Inherited anemia affecting ~ 100,000 AmericansCaused by point mutation in beta globin gene replacing glutamine with valine at position 6Low oxygen tension causes sickling of red cells leading to hemolysis, splenic sequestration and other complications",
                    "sub_points": [
                      "Caused by point mutation in beta globin gene replacing glutamine with valine at position 6",
                      "Low oxygen tension causes sickling of red cells leading to hemolysis, splenic sequestration and other complications"
                    ]
                  },
                  {
                    "text": "Transfusion in sickle cell diseasePRBC are transfused to improve oxygen carrying capacity by increasing the Hgb A concentration, decreasing red cell sickling and blood viscosity, thereby decreasing microvascular vaso-occlusive effect of sickled red cellsAcute severe anemia (secondary to splenic sequestration, transient red cell aplasia, or hemolysis) or vaso-occlusive event can be managed with red cell transfusion to replete hemoglobin A levels and decrease proportion of hemoglobin SChronic transfusions may be beneficial in suppressing red cell production to maintain lower levels of hemoglobin SPRBC modificationsCommonly phenotype matched for (C, E, and K) to decrease risk of alloimmunizationExtended phenotype matching for Duffy and Kidd antigens may be indicated in patients who have made alloantibodiesHgb S negativeLeukoreducedTransfusions may be acute or chronic, simple or exchangeDecision to perform simple or exchange transfusion is based on clinical scenario and balance of risk to benefitsIndicationsAcuteAcute chest syndromeMultiorgan failureSplenic sequestrationAcute strokeSymptomatic anemiaAplastic crisisFat embolism syndromePreoperative transfusionSevere hepatic crisisChronicPrevention of stroke in at-risk patients (abnormal transcranial Doppler results)Hgb S complications in pregnancyPotential indications for transfusion include frequent pain crises, priapism and recurrent acute chest syndromeTransfusion not indicatedAcute pain crisis (treat with hydration and pain management)Leg ulcersPregnancyMicroalbuminuria",
                    "sub_points": [
                      "PRBC are transfused to improve oxygen carrying capacity by increasing the Hgb A concentration, decreasing red cell sickling and blood viscosity, thereby decreasing microvascular vaso-occlusive effect of sickled red cellsAcute severe anemia (secondary to splenic sequestration, transient red cell aplasia, or hemolysis) or vaso-occlusive event can be managed with red cell transfusion to replete hemoglobin A levels and decrease proportion of hemoglobin SChronic transfusions may be beneficial in suppressing red cell production to maintain lower levels of hemoglobin S",
                      "Acute severe anemia (secondary to splenic sequestration, transient red cell aplasia, or hemolysis) or vaso-occlusive event can be managed with red cell transfusion to replete hemoglobin A levels and decrease proportion of hemoglobin S",
                      "Chronic transfusions may be beneficial in suppressing red cell production to maintain lower levels of hemoglobin S",
                      "PRBC modificationsCommonly phenotype matched for (C, E, and K) to decrease risk of alloimmunizationExtended phenotype matching for Duffy and Kidd antigens may be indicated in patients who have made alloantibodiesHgb S negativeLeukoreduced",
                      "Commonly phenotype matched for (C, E, and K) to decrease risk of alloimmunizationExtended phenotype matching for Duffy and Kidd antigens may be indicated in patients who have made alloantibodies",
                      "Extended phenotype matching for Duffy and Kidd antigens may be indicated in patients who have made alloantibodies",
                      "Hgb S negative",
                      "Leukoreduced",
                      "Transfusions may be acute or chronic, simple or exchangeDecision to perform simple or exchange transfusion is based on clinical scenario and balance of risk to benefits",
                      "Decision to perform simple or exchange transfusion is based on clinical scenario and balance of risk to benefits",
                      "IndicationsAcuteAcute chest syndromeMultiorgan failureSplenic sequestrationAcute strokeSymptomatic anemiaAplastic crisisFat embolism syndromePreoperative transfusionSevere hepatic crisisChronicPrevention of stroke in at-risk patients (abnormal transcranial Doppler results)Hgb S complications in pregnancy",
                      "AcuteAcute chest syndromeMultiorgan failureSplenic sequestrationAcute strokeSymptomatic anemiaAplastic crisisFat embolism syndromePreoperative transfusionSevere hepatic crisis",
                      "Acute chest syndrome",
                      "Multiorgan failure",
                      "Splenic sequestration",
                      "Acute stroke",
                      "Symptomatic anemia",
                      "Aplastic crisis",
                      "Fat embolism syndrome",
                      "Preoperative transfusion",
                      "Severe hepatic crisis",
                      "ChronicPrevention of stroke in at-risk patients (abnormal transcranial Doppler results)Hgb S complications in pregnancy",
                      "Prevention of stroke in at-risk patients (abnormal transcranial Doppler results)",
                      "Hgb S complications in pregnancy",
                      "Potential indications for transfusion include frequent pain crises, priapism and recurrent acute chest syndrome",
                      "Transfusion not indicatedAcute pain crisis (treat with hydration and pain management)Leg ulcersPregnancyMicroalbuminuria",
                      "Acute pain crisis (treat with hydration and pain management)",
                      "Leg ulcers",
                      "Pregnancy",
                      "Microalbuminuria"
                    ]
                  },
                  {
                    "text": "Transfusion risks in sickle cell diseasePatients with sickle cell anemia have higher risk of alloimmunization (18-50%)Autoantibody formation\"Hyperhemolytic\" transfusion syndrome (1-4% of transfused SCD patients)Iron overloadHigh number of donor exposures",
                    "sub_points": [
                      "Patients with sickle cell anemia have higher risk of alloimmunization (18-50%)",
                      "Autoantibody formation",
                      "\"Hyperhemolytic\" transfusion syndrome (1-4% of transfused SCD patients)",
                      "Iron overload",
                      "High number of donor exposures"
                    ]
                  },
                  {
                    "text": "Alloimmunization in sickle cell diseaseMajor complication in patients with sickle cell disease, causing difficulty in obtaining compatible units as well as possible transfusion reactionsFactors affecting alloimmunization include antigen exposures, antigen disparity between donor and recipient population, and level of antigen matching for non ABO and D antigensAlloimmunization against the Rh antigens, D, C, and E and against Kell antigen are the most common antibodies identified across multiple studiesThese correlate well with antigenic frequency differences of donors, primarily European ancestry, compared to SCD patients, primarily of African ancestryOne strategy to decrease red cell alloimmunization in SCD is matching units for C, E, and K antigensMore expanded phenotype matching would additionally screen for Fya and Jkb",
                    "sub_points": [
                      "Major complication in patients with sickle cell disease, causing difficulty in obtaining compatible units as well as possible transfusion reactions",
                      "Factors affecting alloimmunization include antigen exposures, antigen disparity between donor and recipient population, and level of antigen matching for non ABO and D antigens",
                      "Alloimmunization against the Rh antigens, D, C, and E and against Kell antigen are the most common antibodies identified across multiple studies",
                      "These correlate well with antigenic frequency differences of donors, primarily European ancestry, compared to SCD patients, primarily of African ancestry",
                      "One strategy to decrease red cell alloimmunization in SCD is matching units for C, E, and K antigens",
                      "More expanded phenotype matching would additionally screen for Fya and Jkb"
                    ]
                  }
                ],
                "Thalassemia": [
                  {
                    "text": "Thalassemias result from mutations in alpha or beta globin gene leading to abnormal globin synthesis, defective erythropoiesis, RBC membrane damage and hemolysis"
                  },
                  {
                    "text": "Transfusion in thalassemiaPatients with severe thalassemia are transfusion dependent and require chronic transfusion of PRBCThalassemia patients are transfused on a regular basis, every 2-5 weeks, to increase Hgb levels to 13-14 g/dL and maintain Hgb levels at 9-10 g/dLMaintenance of hemoglobin at these levels prevents abnormal growth/development, decreased extramedullary hematopoiesis, bone marrow expansion and gastrointestinal iron absorptionPRBCs should be phenotype matched (C, E, K) and leukoreducedIndicationsGrowth retardationFailure to thriveSymptomatic anemiaHypersplenismFacial/skeletal bone changesRisks of TransfusionIncreased risk of alloimmunization (5-11%)Iron overload",
                    "sub_points": [
                      "Patients with severe thalassemia are transfusion dependent and require chronic transfusion of PRBC",
                      "Thalassemia patients are transfused on a regular basis, every 2-5 weeks, to increase Hgb levels to 13-14 g/dL and maintain Hgb levels at 9-10 g/dL",
                      "Maintenance of hemoglobin at these levels prevents abnormal growth/development, decreased extramedullary hematopoiesis, bone marrow expansion and gastrointestinal iron absorption",
                      "PRBCs should be phenotype matched (C, E, K) and leukoreduced",
                      "IndicationsGrowth retardationFailure to thriveSymptomatic anemiaHypersplenismFacial/skeletal bone changes",
                      "Growth retardation",
                      "Failure to thrive",
                      "Symptomatic anemia",
                      "Hypersplenism",
                      "Facial/skeletal bone changes",
                      "Risks of TransfusionIncreased risk of alloimmunization (5-11%)Iron overload",
                      "Increased risk of alloimmunization (5-11%)",
                      "Iron overload"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Patients Post-Transplantation": {
            "name": "Patients Post-Transplantation",
            "url": "https://app.pathprimer.com/document/6369f9c3-c2aa-4f98-a354-b7d1afea3138/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Patients who have received HPC transplant have unique transfusion requirements"
                  },
                  {
                    "text": "Decisions about appropriate products to transfuse may depend on stage of transplant"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Transfusion in Transplantation": [
                  {
                    "text": "Patients who have received hematopoietic progenitor cell (HPC) transplant have unique transfusion requirements due to many factorsUnderlying conditionImmunosuppressive regimensABO group mismatchAlloantibodiesTransfusion of passenger lymphocytes",
                    "sub_points": [
                      "Underlying condition",
                      "Immunosuppressive regimens",
                      "ABO group mismatch",
                      "Alloantibodies",
                      "Transfusion of passenger lymphocytes"
                    ]
                  },
                  {
                    "text": "ABO group is not barrier to receiving HPC transplantABO mismatch between patient and donor plays role in transfusion supportABO mismatch occurs in 25-50% of transplantsAllogeneic HPC transplant ABO compatibility categoriesABO compatibleMajor ABO incompatibilityMinor ABO incompatibilityBidirectional ABO incompatibility",
                    "sub_points": [
                      "ABO mismatch between patient and donor plays role in transfusion supportABO mismatch occurs in 25-50% of transplants",
                      "ABO mismatch occurs in 25-50% of transplants",
                      "Allogeneic HPC transplant ABO compatibility categoriesABO compatibleMajor ABO incompatibilityMinor ABO incompatibilityBidirectional ABO incompatibility",
                      "ABO compatible",
                      "Major ABO incompatibility",
                      "Minor ABO incompatibility",
                      "Bidirectional ABO incompatibility"
                    ]
                  },
                  {
                    "text": "Major ABO incompatibilityThere are naturally occurring antibodies in recipient against donor ABO antigensRisks of major incompatibilityPotential hemolysis of red blood cells (RBCs) infused in HPC productThis risk can be decreased by minimizing number of red cells collected, red cell depletion of HPC products, and freezing of HPC productsContinued recipient production of antibodies leading to destruction of engrafting erythroid cells, delaying red cell engraftment and increasing recipient red cell transfusion requirements",
                    "sub_points": [
                      "There are naturally occurring antibodies in recipient against donor ABO antigens",
                      "Risks of major incompatibilityPotential hemolysis of red blood cells (RBCs) infused in HPC productThis risk can be decreased by minimizing number of red cells collected, red cell depletion of HPC products, and freezing of HPC productsContinued recipient production of antibodies leading to destruction of engrafting erythroid cells, delaying red cell engraftment and increasing recipient red cell transfusion requirements",
                      "Potential hemolysis of red blood cells (RBCs) infused in HPC productThis risk can be decreased by minimizing number of red cells collected, red cell depletion of HPC products, and freezing of HPC products",
                      "This risk can be decreased by minimizing number of red cells collected, red cell depletion of HPC products, and freezing of HPC products",
                      "Continued recipient production of antibodies leading to destruction of engrafting erythroid cells, delaying red cell engraftment and increasing recipient red cell transfusion requirements"
                    ]
                  },
                  {
                    "text": "Minor ABO incompatibilityThere are donor naturally occurring antibodies against recipient red cell antigens.Risks of minor incompatibilityHemolysis of recipient red cells during HPC infusion and with continued production of isoagglutinins by infused lymphocytes (passenger lymphocyte syndrome)Passenger lymphocyte syndrome occurs 5-16 days after transplant and can be treated with red cell exchange",
                    "sub_points": [
                      "There are donor naturally occurring antibodies against recipient red cell antigens.",
                      "Risks of minor incompatibilityHemolysis of recipient red cells during HPC infusion and with continued production of isoagglutinins by infused lymphocytes (passenger lymphocyte syndrome)Passenger lymphocyte syndrome occurs 5-16 days after transplant and can be treated with red cell exchange",
                      "Hemolysis of recipient red cells during HPC infusion and with continued production of isoagglutinins by infused lymphocytes (passenger lymphocyte syndrome)",
                      "Passenger lymphocyte syndrome occurs 5-16 days after transplant and can be treated with red cell exchange"
                    ]
                  },
                  {
                    "text": "Bidirectional ABO incompatibilityPatients are at risk of complications seen in major and minor incompatibilityComplicationsHemolysisDelayed red cell engraftmentPure red cell aplasia (PRCA)",
                    "sub_points": [
                      "Patients are at risk of complications seen in major and minor incompatibility",
                      "ComplicationsHemolysisDelayed red cell engraftmentPure red cell aplasia (PRCA)",
                      "Hemolysis",
                      "Delayed red cell engraftment",
                      "Pure red cell aplasia (PRCA)"
                    ]
                  },
                  {
                    "text": "Alloantibodies to antigens other than ABO should be considered in donor selection and transfusion support"
                  },
                  {
                    "text": "Transfusion support of HPC transplant recipientsTransfusion service must keep detailed records of HPC recipient's pretransplant ABO group and donor's ABO groupDecisions about appropriate products to transfuse may also depend on stage of transplantPreparative periodRecipient compatible blood products are transfusedPostengraftment periodWhen recipient antibodies are no longer detected, donor compatible blood products can be transfusedIf either donor or recipient is Rh negative, Rh-negative red cells should be transfusedTransfusion of Rh-negative platelets is preferredHPC transplant patients require irradiated, CMV-risk-reduced (CMV-negative or leukoreduced) blood productsAutologous HPC transplant recipients also require irradiated, CMV-risk-reduced transfusionsABO mismatch is not a concernPatient who is refractory to platelets may also require HLA-matched or crossmatched platelets",
                    "sub_points": [
                      "Transfusion service must keep detailed records of HPC recipient's pretransplant ABO group and donor's ABO group",
                      "Decisions about appropriate products to transfuse may also depend on stage of transplantPreparative periodRecipient compatible blood products are transfusedPostengraftment periodWhen recipient antibodies are no longer detected, donor compatible blood products can be transfused",
                      "Preparative periodRecipient compatible blood products are transfused",
                      "Recipient compatible blood products are transfused",
                      "Postengraftment periodWhen recipient antibodies are no longer detected, donor compatible blood products can be transfused",
                      "When recipient antibodies are no longer detected, donor compatible blood products can be transfused",
                      "If either donor or recipient is Rh negative, Rh-negative red cells should be transfusedTransfusion of Rh-negative platelets is preferred",
                      "Transfusion of Rh-negative platelets is preferred",
                      "HPC transplant patients require irradiated, CMV-risk-reduced (CMV-negative or leukoreduced) blood products",
                      "Autologous HPC transplant recipients also require irradiated, CMV-risk-reduced transfusionsABO mismatch is not a concern",
                      "ABO mismatch is not a concern",
                      "Patient who is refractory to platelets may also require HLA-matched or crossmatched platelets"
                    ]
                  },
                  {
                    "text": "Solid-organ transplantTransfusion services provide transfusion support to recipients of solid-organ transplantBlood banks can provide blood group testing, reference laboratory testing, performance of titers, and apheresis supportConsideration of donor and recipient blood group is important in transfusion support of organ transplant recipientsIf possible, ABO identical RBCs should be selected for transfusionGroup O packed RBCs can be transfused to patients at risk of passenger lymphocyte syndromePlasma-containing blood products should be compatible with both donor and recipientSolid-organ transplant recipients may require leukoreduced, CMV-negative, or irradiated blood productsIrradiated blood products not usually recommended",
                    "sub_points": [
                      "Transfusion services provide transfusion support to recipients of solid-organ transplantBlood banks can provide blood group testing, reference laboratory testing, performance of titers, and apheresis support",
                      "Blood banks can provide blood group testing, reference laboratory testing, performance of titers, and apheresis support",
                      "Consideration of donor and recipient blood group is important in transfusion support of organ transplant recipients",
                      "If possible, ABO identical RBCs should be selected for transfusion",
                      "Group O packed RBCs can be transfused to patients at risk of passenger lymphocyte syndrome",
                      "Plasma-containing blood products should be compatible with both donor and recipient",
                      "Solid-organ transplant recipients may require leukoreduced, CMV-negative, or irradiated blood productsIrradiated blood products not usually recommended",
                      "Irradiated blood products not usually recommended"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Patients on Antithrombotic Therapy": {
            "name": "Patients on Antithrombotic Therapy",
            "url": "https://app.pathprimer.com/document/eff3b451-4a4c-4cb4-aafb-42d041bbe33b/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Medications used for prevention of future thrombosis may lead to increased bleeding risk, requiring reversal and/or transfusion"
                  },
                  {
                    "text": "These include medications used for prophylaxis of both venous and arterial thrombosis"
                  },
                  {
                    "text": "Need for transfusion depends on availability of reversal agents and risk of bleeding"
                  },
                  {
                    "text": "Decision to discontinue therapy must be weighed against increased risks of thrombosis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "People with history of venous thrombosis may require prolonged treatment with antithrombotic therapies"
                  },
                  {
                    "text": "These medications prevent future thrombosis; however, they may cause increased bleeding risk requiring reversal and/or transfusion"
                  },
                  {
                    "text": "Newer agents provide benefits of rapid onset of action and decreased need for therapeutic monitoringHowever, lack of reversal agents and data on management of bleeding are downsides",
                    "sub_points": [
                      "However, lack of reversal agents and data on management of bleeding are downsides"
                    ]
                  },
                  {
                    "text": "Antithrombotic medicationsWarfarinHeparinFondaparinuxFactor Xa inhibitorsThrombin inhibitors",
                    "sub_points": [
                      "Warfarin",
                      "Heparin",
                      "Fondaparinux",
                      "Factor Xa inhibitors",
                      "Thrombin inhibitors"
                    ]
                  },
                  {
                    "text": "Arterial thrombosis prophylaxis is required for patients at risk of arterial thrombosis, including patients with coronary artery disease and history of myocardial infarction"
                  },
                  {
                    "text": "Medications used in prevention of arterial thrombosisAspirinAdenosine diphosphate (ADP) receptor inhibitorsGPIIb/IIIa inhibitors",
                    "sub_points": [
                      "Aspirin",
                      "Adenosine diphosphate (ADP) receptor inhibitors",
                      "GPIIb/IIIa inhibitors"
                    ]
                  }
                ],
                "Warfarin": [
                  {
                    "text": "Warfarin is vitamin K inhibitor, which affects levels of Vitamin K-dependent coagulation factorsFactor II, factor VII, factor IX, factor X, protein C, and protein S",
                    "sub_points": [
                      "Factor II, factor VII, factor IX, factor X, protein C, and protein S"
                    ]
                  },
                  {
                    "text": "Warfarin therapy is monitored by measuring INRINR 2-3 is therapeutic",
                    "sub_points": [
                      "INR 2-3 is therapeutic"
                    ]
                  },
                  {
                    "text": "Warfarin reversal can be necessary in patients with supratherapeutic INR and bleeding or patients scheduled for surgery or invasive procedures"
                  },
                  {
                    "text": "Options for warfarin reversal depend on how rapidly warfarin reversal is needed and INR level"
                  },
                  {
                    "text": "Therapeutic optionsVitamin KProthrombin complex concentrates (PCC)Plasma transfusion10-20 mL/kg body weight with goal of INR < 1.5",
                    "sub_points": [
                      "Vitamin K",
                      "Prothrombin complex concentrates (PCC)",
                      "Plasma transfusion10-20 mL/kg body weight with goal of INR < 1.5",
                      "10-20 mL/kg body weight with goal of INR < 1.5"
                    ]
                  },
                  {
                    "text": "Recommended that warfarin therapy be discontinued 5 days prior to surgery, with heparin bridging if necessary"
                  }
                ],
                "Heparin": [
                  {
                    "text": "Heparins increase antithrombin activity, deactivating factor IIa and factor Xa"
                  },
                  {
                    "text": "Unfractionated heparin therapy is monitored by partial thromboplastin time (PTT) measurements or by anti Xa assays (less available)"
                  },
                  {
                    "text": "Heparin therapy can be reversed with protamine sulfate given at 1 mg per 100 U heparin administered during past 4 hours"
                  },
                  {
                    "text": "Due to heparin's short half life, active reversal is not often necessary"
                  },
                  {
                    "text": "Low-molecular-weight heparins do not require routine laboratory monitoring and can also be reversed with protamine sulfate"
                  }
                ],
                "Oral Anticoagulants": [
                  {
                    "text": "Factor Xa inhibitorsFactor Xa inhibitors do not require routine laboratory monitoringDo not have reversal agent; bleeding while on these medications requires supportive care with transfusion of packed red blood cells and fresh frozen plasmaPCC treatment may be useful in bleeding patients on some factor Xa inhibitors",
                    "sub_points": [
                      "Factor Xa inhibitors do not require routine laboratory monitoring",
                      "Do not have reversal agent; bleeding while on these medications requires supportive care with transfusion of packed red blood cells and fresh frozen plasma",
                      "PCC treatment may be useful in bleeding patients on some factor Xa inhibitors"
                    ]
                  },
                  {
                    "text": "Direct thrombin inhibitors (DTI)DTI are small molecules that inhibit factor IIa used in treatment of patients with atrial fibrillationDTI do not require routine laboratory monitoringIn bleeding patients on DTI, medication should be discontinued and supportive transfusion provided as neededIdarucizumab, monoclonal antibody fragment with structural similarities to thrombin, is available for reversal of dabigatran (pradaxa)Additional factor Xa inhibitor antidotes are being developed and will be available in future",
                    "sub_points": [
                      "DTI are small molecules that inhibit factor IIa used in treatment of patients with atrial fibrillation",
                      "DTI do not require routine laboratory monitoring",
                      "In bleeding patients on DTI, medication should be discontinued and supportive transfusion provided as needed",
                      "Idarucizumab, monoclonal antibody fragment with structural similarities to thrombin, is available for reversal of dabigatran (pradaxa)",
                      "Additional factor Xa inhibitor antidotes are being developed and will be available in future"
                    ]
                  },
                  {
                    "text": "Due to short half-lives of many oral anticoagulants, discontinuation of drug may quickly reverse anticoagulant effects"
                  },
                  {
                    "text": "Prescribed potential reversal procedures depend on particular oral anticoagulantHemodialysis/hemofiltrationPCC",
                    "sub_points": [
                      "Hemodialysis/hemofiltration",
                      "PCC"
                    ]
                  }
                ],
                "Antiplatelet Agents": [
                  {
                    "text": "Aspirin (ASA)Patients on ASA therapy should discontinue ASA use 1 week to 10 days prior to surgery or invasive proceduresPlatelet transfusion may be indicated in actively bleeding patients on ASA therapy",
                    "sub_points": [
                      "Patients on ASA therapy should discontinue ASA use 1 week to 10 days prior to surgery or invasive procedures",
                      "Platelet transfusion may be indicated in actively bleeding patients on ASA therapy"
                    ]
                  },
                  {
                    "text": "ADP receptor inhibitorsADP receptor inhibitors include clopidogrel, prasugrel, ticlopidine, and ticagrelorMany of these medications are irreversible inhibitors of ADP receptor and inhibit platelet function for 7-10 daysPlatelets transfused prior to clearance of ADP inhibitors will also become inactiveIn patients with increased risk of bleeding, clopidogrel therapy should be discontinued 5 days before surgery and ASA therapy maintained",
                    "sub_points": [
                      "ADP receptor inhibitors include clopidogrel, prasugrel, ticlopidine, and ticagrelor",
                      "Many of these medications are irreversible inhibitors of ADP receptor and inhibit platelet function for 7-10 days",
                      "Platelets transfused prior to clearance of ADP inhibitors will also become inactive",
                      "In patients with increased risk of bleeding, clopidogrel therapy should be discontinued 5 days before surgery and ASA therapy maintained"
                    ]
                  },
                  {
                    "text": "GPIIa/IIIB inhibitorsGPIIb/IIIa inhibitors block platelet fibrinogen receptor and include abciximab, eptifibatide, and tirofibanBinding to fibrinogen receptor is reversible; platelet function returns 24-48 hours post last doseIn emergency situations/hemorrhaging, patient platelet transfusion can be therapeutic",
                    "sub_points": [
                      "GPIIb/IIIa inhibitors block platelet fibrinogen receptor and include abciximab, eptifibatide, and tirofiban",
                      "Binding to fibrinogen receptor is reversible; platelet function returns 24-48 hours post last dose",
                      "In emergency situations/hemorrhaging, patient platelet transfusion can be therapeutic"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Patients with Platelet Transfusion Refractoriness": {
            "name": "Patients with Platelet Transfusion Refractoriness",
            "url": "https://app.pathprimer.com/document/b7633237-6cae-445b-a98a-9ce4a9f84e41/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Inadequate platelet increment after repeated platelet transfusion, usually determined by 1 hr (10-60 min) after CCI"
                  },
                  {
                    "text": "Platelet refractoriness defined as 1-hr CCI of < 5000-7500 on > 1 occasion"
                  },
                  {
                    "text": "Most common causes of platelet transfusion refractoriness are nonimmune"
                  },
                  {
                    "text": "Leukoreduction of blood products decreases risk of HLA alloimmunization"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Inadequate platelet increment after repeated platelet transfusion, usually determined by 1 hr (10-60 min) after corrected count increment (CCI)Platelet refractoriness defined as 1-hr CCI of < 5000-7500 on > 1 occasion",
                    "sub_points": [
                      "Platelet refractoriness defined as 1-hr CCI of < 5000-7500 on > 1 occasion"
                    ]
                  },
                  {
                    "text": "Refractoriness occurs in 20%-70% of patients who require multiple platelet transfusions"
                  },
                  {
                    "text": "Platelet refractoriness is particular issue for hematology/oncology and hematopoietic progenitor cell (HPC) transplant patients"
                  },
                  {
                    "text": "Reasons that patients become refractory to platelet transfusion are commonly multifactorial and can include immune and nonimmune causes"
                  },
                  {
                    "text": "Most common causes are nonimmune"
                  },
                  {
                    "text": "Most common immune cause is presence of human leukocyte antigen (HLA) class I alloantibodies"
                  },
                  {
                    "text": "HLA alloantibodies are formed due to exposure to HLA antigens through pregnancy or transfusion"
                  },
                  {
                    "text": "Nonimmune causesBleedingInadequate platelet doseFeverInfectionSplenomegalyDisseminated intravascular coagulopathy (DIC)Liver dysfunctionMedicationsAllogeneic stem cell transplantGraft-vs.-host diseaseAge of platelet productChemotherapyIrradiationThrombotic thrombocytopenic purpura (TTP)",
                    "sub_points": [
                      "Bleeding",
                      "Inadequate platelet dose",
                      "Fever",
                      "Infection",
                      "Splenomegaly",
                      "Disseminated intravascular coagulopathy (DIC)",
                      "Liver dysfunction",
                      "Medications",
                      "Allogeneic stem cell transplant",
                      "Graft-vs.-host disease",
                      "Age of platelet product",
                      "Chemotherapy",
                      "Irradiation",
                      "Thrombotic thrombocytopenic purpura (TTP)"
                    ]
                  },
                  {
                    "text": "Immune causesHLA class I antibodiesHuman platelet antigen (HPA) antibodiesABO antibodiesDrug-induced antibodiesAntibodies to plasma proteins",
                    "sub_points": [
                      "HLA class I antibodies",
                      "Human platelet antigen (HPA) antibodies",
                      "ABO antibodies",
                      "Drug-induced antibodies",
                      "Antibodies to plasma proteins"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Evaluation of refractory patients should includeKnowledge of etiology of thrombocytopenia and underlying illness, patient medications, presence/severity of active bleeding, and need for further platelet transfusionTesting should be performed to determine1-hr post-transfusion platelet countIdentification of presence of HLA &/or HPA antibodiesIdentification of patient HLA type if plan to transfuse HLA matched platelets",
                    "sub_points": [
                      "Knowledge of etiology of thrombocytopenia and underlying illness, patient medications, presence/severity of active bleeding, and need for further platelet transfusion",
                      "Testing should be performed to determine1-hr post-transfusion platelet countIdentification of presence of HLA &/or HPA antibodiesIdentification of patient HLA type if plan to transfuse HLA matched platelets",
                      "1-hr post-transfusion platelet count",
                      "Identification of presence of HLA &/or HPA antibodies",
                      "Identification of patient HLA type if plan to transfuse HLA matched platelets"
                    ]
                  },
                  {
                    "text": "Platelet crossmatchingPatient's serum is crossmatched with multiple donor platelets to obtain compatible unitsCrossmatching allows selection of compatible platelets without need to know HLA or HPA type",
                    "sub_points": [
                      "Patient's serum is crossmatched with multiple donor platelets to obtain compatible units",
                      "Crossmatching allows selection of compatible platelets without need to know HLA or HPA type"
                    ]
                  },
                  {
                    "text": "HLA matchingHLA matching involves selection of platelets with HLA class I type similar to patientUnits are selected based on HLA gradeGrades A through B2U provide best transfusion resultsA: HLA identicalB: 3 antigen matched, 1 antigen unknownB1X: 1 cross-reactive groupB2UX: 1 cross-reactive group, 1 unknown antigenC: 1 mismatched antigenD: ≥ 2 mismatched antigensR: random plateletSelection of platelets may include obtaining donor platelets lacking antigen that patient has formed antibodies against",
                    "sub_points": [
                      "HLA matching involves selection of platelets with HLA class I type similar to patientUnits are selected based on HLA gradeGrades A through B2U provide best transfusion resultsA: HLA identicalB: 3 antigen matched, 1 antigen unknownB1X: 1 cross-reactive groupB2UX: 1 cross-reactive group, 1 unknown antigenC: 1 mismatched antigenD: ≥ 2 mismatched antigensR: random platelet",
                      "Units are selected based on HLA grade",
                      "Grades A through B2U provide best transfusion resultsA: HLA identicalB: 3 antigen matched, 1 antigen unknownB1X: 1 cross-reactive groupB2UX: 1 cross-reactive group, 1 unknown antigenC: 1 mismatched antigenD: ≥ 2 mismatched antigensR: random platelet",
                      "A: HLA identical",
                      "B: 3 antigen matched, 1 antigen unknown",
                      "B1X: 1 cross-reactive group",
                      "B2UX: 1 cross-reactive group, 1 unknown antigen",
                      "C: 1 mismatched antigen",
                      "D: ≥ 2 mismatched antigens",
                      "R: random platelet",
                      "Selection of platelets may include obtaining donor platelets lacking antigen that patient has formed antibodies against"
                    ]
                  },
                  {
                    "text": "Directed donation from relativesDirected donation can be considered if patient has HPA antibodies or has failed to get appropriate increment with HLA-matched or crossmatched plateletsDirected donations should be avoided if family member is potential stem cell donor for patient",
                    "sub_points": [
                      "Directed donation can be considered if patient has HPA antibodies or has failed to get appropriate increment with HLA-matched or crossmatched platelets",
                      "Directed donations should be avoided if family member is potential stem cell donor for patient"
                    ]
                  }
                ],
                "Prevention": [
                  {
                    "text": "Leukoreduction of blood products decreases risk of HLA alloimmunization"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Testing": [
                  {
                    "text": "Detection of HLA antibodiesPanel reactive antibody (> 20% probable HLA refractoriness)Enzyme-linked immunosorbent assay (ELISA)Flow cytometry",
                    "sub_points": [
                      "Panel reactive antibody (> 20% probable HLA refractoriness)",
                      "Enzyme-linked immunosorbent assay (ELISA)",
                      "Flow cytometry"
                    ]
                  },
                  {
                    "text": "Detection of HPA antibodiesELISAIndirect platelet immunofluorescence testing",
                    "sub_points": [
                      "ELISA",
                      "Indirect platelet immunofluorescence testing"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Massive Transfusion": {
            "name": "Massive Transfusion",
            "url": "https://app.pathprimer.com/document/ea2af1fc-94f7-4d7c-b7c0-d67e67de7912/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Massive transfusion is generally defined as transfusion of 10 or more units of PRBC in 24 hours or replacement of one half of TBV in 3 hours"
                  },
                  {
                    "text": "Practice patterns have changed over past decade from laboratory-based component transfusion to prophylactic transfusion favoring early plasma transfusion with similar ratios of plasma to PRBC units"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "Multiple definitions of massive transfusion exist, based on amount of blood lost or replaced within certain amount of time"
                  },
                  {
                    "text": "Generally defined as transfusion of 10 or more units of packed red blood cells (PRBC) in 24 hours or replacement of one half of total blood volume (TBV) in 3 hours"
                  },
                  {
                    "text": "Massive transfusion is usually mentioned in relation to trauma settings; however, it can be necessary in many clinical settingsObstetricsLiverCardiovascular surgeriesSpinal surgeries",
                    "sub_points": [
                      "Obstetrics",
                      "Liver",
                      "Cardiovascular surgeries",
                      "Spinal surgeries"
                    ]
                  },
                  {
                    "text": "Signs and symptoms of blood lossTachycardia/palpitationsIncreased respiratory rateHypotensionAltered mental statusDecreased urinary outputDecreased central venous pressurePallorDecreased arterial pressure",
                    "sub_points": [
                      "Tachycardia/palpitations",
                      "Increased respiratory rate",
                      "Hypotension",
                      "Altered mental status",
                      "Decreased urinary output",
                      "Decreased central venous pressure",
                      "Pallor",
                      "Decreased arterial pressure"
                    ]
                  },
                  {
                    "text": "For emergency situations when type and screen/crossmatch not availableGroup O uncrossmatched PRBCs are available for transfusionGroup AB (alternatively Group A) plasmaWomen of childbearing age (< 50 years) should receive Rh-negative blood productsMen and women > 50 years can receive Rh-positive blood productsType and screen should be performed as soon as possible and products switched to type-specific",
                    "sub_points": [
                      "Group O uncrossmatched PRBCs are available for transfusion",
                      "Group AB (alternatively Group A) plasma",
                      "Women of childbearing age (< 50 years) should receive Rh-negative blood products",
                      "Men and women > 50 years can receive Rh-positive blood products",
                      "Type and screen should be performed as soon as possible and products switched to type-specific"
                    ]
                  }
                ],
                "Massive Transfusion Protocols": [
                  {
                    "text": "Large amounts of crystalloid are less commonly used in massive transfusion patients with early institution of plasma and platelet infusion to improve morbidity and treat coagulopathy of trauma"
                  },
                  {
                    "text": "This change in practice led to development of massive transfusion protocols (MTP)"
                  },
                  {
                    "text": "Practice patterns have changed over past decade from laboratory-based component transfusion to prophylactic transfusion favoring early plasma transfusion with similar ratios of plasma to PRBC unitsOptimal ratios are unknownIn practice, 1:1:1 ratio of RBC:plasma:platelet is used",
                    "sub_points": [
                      "Optimal ratios are unknown",
                      "In practice, 1:1:1 ratio of RBC:plasma:platelet is used"
                    ]
                  },
                  {
                    "text": "Massive transfusion protocols in obstetrics may require higher levels of fibrinogen, > 400 mg/dL, and transfusion of cryoprecipitate"
                  },
                  {
                    "text": "Massive transfusion protocols should be written to include specific proceduresNotification of blood bankBlood product contents/ratioLaboratory tests to performUse of hemostatic medications, factor VIIa, tranexamic acid, prothrombin complex concentratesSwitching from D-negative to D-positive transfusionIssuing incompatible plasmaProviding antigen-negative units in patients with alloantibodies",
                    "sub_points": [
                      "Notification of blood bank",
                      "Blood product contents/ratio",
                      "Laboratory tests to perform",
                      "Use of hemostatic medications, factor VIIa, tranexamic acid, prothrombin complex concentrates",
                      "Switching from D-negative to D-positive transfusion",
                      "Issuing incompatible plasma",
                      "Providing antigen-negative units in patients with alloantibodies"
                    ]
                  }
                ],
                "Massive Transfusion Risks/Complications": [
                  {
                    "text": "Coagulopathy"
                  },
                  {
                    "text": "Hypothermia"
                  },
                  {
                    "text": "Hyperkalemia"
                  },
                  {
                    "text": "Citrate toxicity"
                  },
                  {
                    "text": "Hypocalcemia"
                  },
                  {
                    "text": "Acidosis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Patient Blood Management": {
            "name": "Patient Blood Management",
            "url": "https://app.pathprimer.com/document/23855efe-4783-4946-8fda-7505531fa8cd/lesson/c2e1be50-29ed-4c67-aa79-6a68b7bfc070",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "PBM programs are collaborative, comprehensive, evidence-based programs aimed at ensuring appropriate blood utilization and optimizing patient care"
                  },
                  {
                    "text": "Successful PBM programs require input from physicians, nurses, administrators, laboratory personnel, and information technologists"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "General Information": [
                  {
                    "text": "Patient blood management (PBM) programs are collaborative, comprehensive, evidence-based programs aimed at ensuring appropriate blood utilization and optimizing patient care"
                  },
                  {
                    "text": "Risks of transfusion and costs associated with blood have popularized PBM programs"
                  },
                  {
                    "text": "Successful programs require input from physicians, nurses, administrators, laboratory personnel, and information technologists"
                  }
                ],
                "Topics Addressed by Patient Blood Management Programs": [
                  {
                    "text": "Risks of transfusionRisk of infection vs. potential benefits of transfusion",
                    "sub_points": [
                      "Risk of infection vs. potential benefits of transfusion"
                    ]
                  },
                  {
                    "text": "Informed consent for transfusionIncluding information on alternative therapies",
                    "sub_points": [
                      "Including information on alternative therapies"
                    ]
                  },
                  {
                    "text": "Evidence-based transfusion guidelines"
                  },
                  {
                    "text": "Audits of transfusion with physician/specialty feedback"
                  },
                  {
                    "text": "Use of computer order entry systems to guide transfusion practice"
                  },
                  {
                    "text": "Costs"
                  },
                  {
                    "text": "Blood supply"
                  }
                ],
                "Patient Blood Management Strategies": [
                  {
                    "text": "Preoperative/preprocedure treatment of anemia"
                  },
                  {
                    "text": "Intraoperative strategies to reduce blood loss"
                  },
                  {
                    "text": "Use of postoperative therapies that decrease need for transfusion"
                  },
                  {
                    "text": "Blood utilization review"
                  },
                  {
                    "text": "Clinician education"
                  },
                  {
                    "text": "Combination of strategies can be used in surgical and medical patients to decrease allogeneic transfusion"
                  },
                  {
                    "text": "Inappropriate blood transfusions should be avoided throughout course of patient carePreoperative strategies should be performed approximately 1 month before surgeryDiagnosis and treatment of anemiaIron, vitamin B12, folate replacement, erythropoietinCoagulation evaluationLimitation of phlebotomyLimitation of crystalloid infusionAutologous blood donation (4-6 weeks before surgery)Intraoperative/perioperative strategiesImplementation of surgical techniques that minimize intraoperative bleedingAcute normovolemic hemodilution (ANH)ANH involves whole-blood collection, replacement of patient's blood volume with crystalloid or colloid solutions, and return of collected blood to patient at end of surgeryBenefits of ANH are dilution of patient blood (blood lost has lower hematocrit) and ability to reinfuse product containing active platelets and coagulation factorsANH should be avoided in patients with history of cardiac ischemia, pulmonary obstructive disease, coagulation abnormalities, and hemolytic illnessesIntraoperative blood recoveryIntraoperative blood recovery involves collection of shed blood from surgical field, centrifugation, and reinfusion of washed red cellsRelative contraindications of this technique are cases with potential bacterial contamination, cancer surgeries, and obstetric bleedingHemostatic medications can decrease blood lossAminocaproic acidTranexamic acidDDAVPTopical hemostaticsRecombinant factor VIIaPostoperativePostoperative blood recoveryShed blood is collected from patient drains/wounds, washed or filtered, and transfused to patientEach patient should be carefully evaluated to determine need for transfusion and if possible 1 U of packed RBCs should be transfused at a timeAdditional postoperative PBM strategiesDecrease iatrogenic blood loss by ordering only necessary laboratory testsRemove central lines as soon as possibleUse point of care testing",
                    "sub_points": [
                      "Preoperative strategies should be performed approximately 1 month before surgeryDiagnosis and treatment of anemiaIron, vitamin B12, folate replacement, erythropoietinCoagulation evaluationLimitation of phlebotomyLimitation of crystalloid infusionAutologous blood donation (4-6 weeks before surgery)",
                      "Diagnosis and treatment of anemiaIron, vitamin B12, folate replacement, erythropoietin",
                      "Iron, vitamin B12, folate replacement, erythropoietin",
                      "Coagulation evaluation",
                      "Limitation of phlebotomy",
                      "Limitation of crystalloid infusion",
                      "Autologous blood donation (4-6 weeks before surgery)",
                      "Intraoperative/perioperative strategiesImplementation of surgical techniques that minimize intraoperative bleedingAcute normovolemic hemodilution (ANH)ANH involves whole-blood collection, replacement of patient's blood volume with crystalloid or colloid solutions, and return of collected blood to patient at end of surgeryBenefits of ANH are dilution of patient blood (blood lost has lower hematocrit) and ability to reinfuse product containing active platelets and coagulation factorsANH should be avoided in patients with history of cardiac ischemia, pulmonary obstructive disease, coagulation abnormalities, and hemolytic illnessesIntraoperative blood recoveryIntraoperative blood recovery involves collection of shed blood from surgical field, centrifugation, and reinfusion of washed red cellsRelative contraindications of this technique are cases with potential bacterial contamination, cancer surgeries, and obstetric bleedingHemostatic medications can decrease blood lossAminocaproic acidTranexamic acidDDAVPTopical hemostaticsRecombinant factor VIIa",
                      "Implementation of surgical techniques that minimize intraoperative bleeding",
                      "Acute normovolemic hemodilution (ANH)ANH involves whole-blood collection, replacement of patient's blood volume with crystalloid or colloid solutions, and return of collected blood to patient at end of surgeryBenefits of ANH are dilution of patient blood (blood lost has lower hematocrit) and ability to reinfuse product containing active platelets and coagulation factorsANH should be avoided in patients with history of cardiac ischemia, pulmonary obstructive disease, coagulation abnormalities, and hemolytic illnesses",
                      "ANH involves whole-blood collection, replacement of patient's blood volume with crystalloid or colloid solutions, and return of collected blood to patient at end of surgery",
                      "Benefits of ANH are dilution of patient blood (blood lost has lower hematocrit) and ability to reinfuse product containing active platelets and coagulation factors",
                      "ANH should be avoided in patients with history of cardiac ischemia, pulmonary obstructive disease, coagulation abnormalities, and hemolytic illnesses",
                      "Intraoperative blood recoveryIntraoperative blood recovery involves collection of shed blood from surgical field, centrifugation, and reinfusion of washed red cellsRelative contraindications of this technique are cases with potential bacterial contamination, cancer surgeries, and obstetric bleeding",
                      "Intraoperative blood recovery involves collection of shed blood from surgical field, centrifugation, and reinfusion of washed red cells",
                      "Relative contraindications of this technique are cases with potential bacterial contamination, cancer surgeries, and obstetric bleeding",
                      "Hemostatic medications can decrease blood lossAminocaproic acidTranexamic acidDDAVPTopical hemostaticsRecombinant factor VIIa",
                      "Aminocaproic acid",
                      "Tranexamic acid",
                      "DDAVP",
                      "Topical hemostatics",
                      "Recombinant factor VIIa",
                      "PostoperativePostoperative blood recoveryShed blood is collected from patient drains/wounds, washed or filtered, and transfused to patientEach patient should be carefully evaluated to determine need for transfusion and if possible 1 U of packed RBCs should be transfused at a timeAdditional postoperative PBM strategiesDecrease iatrogenic blood loss by ordering only necessary laboratory testsRemove central lines as soon as possibleUse point of care testing",
                      "Postoperative blood recoveryShed blood is collected from patient drains/wounds, washed or filtered, and transfused to patientEach patient should be carefully evaluated to determine need for transfusion and if possible 1 U of packed RBCs should be transfused at a time",
                      "Shed blood is collected from patient drains/wounds, washed or filtered, and transfused to patient",
                      "Each patient should be carefully evaluated to determine need for transfusion and if possible 1 U of packed RBCs should be transfused at a time",
                      "Additional postoperative PBM strategiesDecrease iatrogenic blood loss by ordering only necessary laboratory testsRemove central lines as soon as possibleUse point of care testing",
                      "Decrease iatrogenic blood loss by ordering only necessary laboratory tests",
                      "Remove central lines as soon as possible",
                      "Use point of care testing"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Transfusion Complications": {
        "name": "Transfusion Complications",
        "url": "https://app.pathprimer.com/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
        "topics": {
          "Approach to Suspected Transfusion Reaction": {
            "name": "Approach to Suspected Transfusion Reaction",
            "url": "https://app.pathprimer.com/document/e9020332-6f42-4b1e-80f7-8e61e701179a/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Systematic medical review of reported transfusion reaction can clarify etiology of most adverse transfusion events"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Five-Step Approach to Transfusion Reactions": [
                  {
                    "text": "Step 1: Make sure transfusion is halted and all necessary materials have been receivedTransfusion should be immediately halted in all suspected transfusion reactionsReaction should be reported to blood bank for evaluation, with submission of offending unit and appropriate post-reaction blood and urine samples (see Transfusion Reaction Work-Up)",
                    "sub_points": [
                      "Transfusion should be immediately halted in all suspected transfusion reactions",
                      "Reaction should be reported to blood bank for evaluation, with submission of offending unit and appropriate post-reaction blood and urine samples (see Transfusion Reaction Work-Up)"
                    ]
                  },
                  {
                    "text": "Step 2: Review reaction history in detailSystematic approach to all reported transfusion reactions improves likelihood of accurate diagnosisImportant clinical information to obtain with every casePatient diagnosis (Why are they in hospital or receiving transfusion?)History of previous transfusion reactions (Has this happened before?)Transfusion premedication (What and how much?)Reaction timing (including how much of unit was given before unit was stopped, and timing of transfusion until reaction was noted)Reaction symptoms (What did patient feel?)Reaction vitals and physical exam findings (pre-reaction vitals are helpful to compare with reaction vitals reported)Medications used to treat reaction (What and how much?)Reaction resolution (Did patient get better? Require increased medical care, e.g., intubation? Expire?)",
                    "sub_points": [
                      "Systematic approach to all reported transfusion reactions improves likelihood of accurate diagnosis",
                      "Important clinical information to obtain with every casePatient diagnosis (Why are they in hospital or receiving transfusion?)History of previous transfusion reactions (Has this happened before?)Transfusion premedication (What and how much?)Reaction timing (including how much of unit was given before unit was stopped, and timing of transfusion until reaction was noted)Reaction symptoms (What did patient feel?)Reaction vitals and physical exam findings (pre-reaction vitals are helpful to compare with reaction vitals reported)Medications used to treat reaction (What and how much?)Reaction resolution (Did patient get better? Require increased medical care, e.g., intubation? Expire?)",
                      "Patient diagnosis (Why are they in hospital or receiving transfusion?)",
                      "History of previous transfusion reactions (Has this happened before?)",
                      "Transfusion premedication (What and how much?)",
                      "Reaction timing (including how much of unit was given before unit was stopped, and timing of transfusion until reaction was noted)",
                      "Reaction symptoms (What did patient feel?)",
                      "Reaction vitals and physical exam findings (pre-reaction vitals are helpful to compare with reaction vitals reported)",
                      "Medications used to treat reaction (What and how much?)",
                      "Reaction resolution (Did patient get better? Require increased medical care, e.g., intubation? Expire?)"
                    ]
                  },
                  {
                    "text": "Step 3: Narrow diagnosis and determine if additional tests are neededDifferential diagnosis of most acute transfusion reactions can be simplified by determining dominant reported patient symptomIf fever predominates, hemolytic transfusion reactions, transfusion-related sepsis, febrile non-hemolytic transfusion reactions, and underlying medical conditions are favoredPatient underlying diagnosisFever during transfusion in patient with known sepsis or neutropenic fever increases chance that underlying medical condition contributedTiming of feverFevers that develop early during transfusion may favor significant hemolytic transfusion reactions and transfusion-related sepsisSeverity of feverHigh spiking fevers (103°F) favor significant transfusion-related sepsisChanges in blood pressureHypertension: Often seen in febrile non-hemolytic transfusion reactionsHypotension: Can be seen in significant hemolytic transfusion reactions and transfusion-related sepsisResults of direct antiglobulin test (DAT) and unit clerical checkThis should be done on all cases of fever in context of red cell transfusionNegative result strongly suggests that hemolysis was not cause of fever (favors other causes)Results of post-reaction blood cultures (if suspected based on other symptoms)Positive blood culture from both patient and transfused unit where organism identified is same in both is strong evidence for transfusion-related sepsisIf shortness of breath with hypoxia predominates, transfusion-related acute lung injury (TRALI), transfusion-associated cardiac overload (TACO), and anaphylaxis are favoredHistory of significant heart or renal diseaseKnown history of patient volume status issues increases risk of symptomatic cardiac overload from transfusionPatient ageOlder patients are more at risk for cardiac overload eventsTransfusion infusion rateIn non-bleeding patients, rapid infusion rates increase risk of symptomatic cardiac overloadChanges in blood pressureHypertension: Favors TACOHypotension: Favors TRALI or anaphylaxisRespiratory exam findingsWheezing favors anaphylaxisCrackles or visible pink frothy sputum favors TRALI/TACOResults of chest x-ray (should be done in all cases of transfusion-associated events involving dyspnea/hypoxia)Bilateral pulmonary edema favors TRALI/TACO over anaphylaxisCardiomegaly favors TACO over TRALI/anaphylaxisResponse to medical therapyNoted clinical improvement with diuretic favors TACO (not TRALI)Noted clinical improvement with epinephrine or steroids favors anaphylaxis (not TRALI)If pruritus or hives predominate, allergic transfusion reaction is favoredTemporally associate medications or eventsPatient may be allergic to something else that was givenSymptom severity is important to clarify (not all hives are created equal)Periorbital or perioral edema is concerning for more severe allergic reactionReported shortness of breath or wheezing is concerning for more severe reactionReported decreases in blood pressure are concerning for more severe reactionResponse to medical therapyNoted clinical improvement with simple antihistamine (i.e., benadryl) favors mild reactionReactions that require steroids for symptomatic relief are more severe",
                    "sub_points": [
                      "Differential diagnosis of most acute transfusion reactions can be simplified by determining dominant reported patient symptom",
                      "If fever predominates, hemolytic transfusion reactions, transfusion-related sepsis, febrile non-hemolytic transfusion reactions, and underlying medical conditions are favoredPatient underlying diagnosisFever during transfusion in patient with known sepsis or neutropenic fever increases chance that underlying medical condition contributedTiming of feverFevers that develop early during transfusion may favor significant hemolytic transfusion reactions and transfusion-related sepsisSeverity of feverHigh spiking fevers (103°F) favor significant transfusion-related sepsisChanges in blood pressureHypertension: Often seen in febrile non-hemolytic transfusion reactionsHypotension: Can be seen in significant hemolytic transfusion reactions and transfusion-related sepsisResults of direct antiglobulin test (DAT) and unit clerical checkThis should be done on all cases of fever in context of red cell transfusionNegative result strongly suggests that hemolysis was not cause of fever (favors other causes)Results of post-reaction blood cultures (if suspected based on other symptoms)Positive blood culture from both patient and transfused unit where organism identified is same in both is strong evidence for transfusion-related sepsis",
                      "Patient underlying diagnosisFever during transfusion in patient with known sepsis or neutropenic fever increases chance that underlying medical condition contributed",
                      "Fever during transfusion in patient with known sepsis or neutropenic fever increases chance that underlying medical condition contributed",
                      "Timing of feverFevers that develop early during transfusion may favor significant hemolytic transfusion reactions and transfusion-related sepsis",
                      "Fevers that develop early during transfusion may favor significant hemolytic transfusion reactions and transfusion-related sepsis",
                      "Severity of feverHigh spiking fevers (103°F) favor significant transfusion-related sepsis",
                      "High spiking fevers (103°F) favor significant transfusion-related sepsis",
                      "Changes in blood pressureHypertension: Often seen in febrile non-hemolytic transfusion reactionsHypotension: Can be seen in significant hemolytic transfusion reactions and transfusion-related sepsis",
                      "Hypertension: Often seen in febrile non-hemolytic transfusion reactions",
                      "Hypotension: Can be seen in significant hemolytic transfusion reactions and transfusion-related sepsis",
                      "Results of direct antiglobulin test (DAT) and unit clerical checkThis should be done on all cases of fever in context of red cell transfusionNegative result strongly suggests that hemolysis was not cause of fever (favors other causes)",
                      "This should be done on all cases of fever in context of red cell transfusion",
                      "Negative result strongly suggests that hemolysis was not cause of fever (favors other causes)",
                      "Results of post-reaction blood cultures (if suspected based on other symptoms)Positive blood culture from both patient and transfused unit where organism identified is same in both is strong evidence for transfusion-related sepsis",
                      "Positive blood culture from both patient and transfused unit where organism identified is same in both is strong evidence for transfusion-related sepsis",
                      "If shortness of breath with hypoxia predominates, transfusion-related acute lung injury (TRALI), transfusion-associated cardiac overload (TACO), and anaphylaxis are favoredHistory of significant heart or renal diseaseKnown history of patient volume status issues increases risk of symptomatic cardiac overload from transfusionPatient ageOlder patients are more at risk for cardiac overload eventsTransfusion infusion rateIn non-bleeding patients, rapid infusion rates increase risk of symptomatic cardiac overloadChanges in blood pressureHypertension: Favors TACOHypotension: Favors TRALI or anaphylaxisRespiratory exam findingsWheezing favors anaphylaxisCrackles or visible pink frothy sputum favors TRALI/TACOResults of chest x-ray (should be done in all cases of transfusion-associated events involving dyspnea/hypoxia)Bilateral pulmonary edema favors TRALI/TACO over anaphylaxisCardiomegaly favors TACO over TRALI/anaphylaxisResponse to medical therapyNoted clinical improvement with diuretic favors TACO (not TRALI)Noted clinical improvement with epinephrine or steroids favors anaphylaxis (not TRALI)",
                      "History of significant heart or renal diseaseKnown history of patient volume status issues increases risk of symptomatic cardiac overload from transfusion",
                      "Known history of patient volume status issues increases risk of symptomatic cardiac overload from transfusion",
                      "Patient ageOlder patients are more at risk for cardiac overload events",
                      "Older patients are more at risk for cardiac overload events",
                      "Transfusion infusion rateIn non-bleeding patients, rapid infusion rates increase risk of symptomatic cardiac overload",
                      "In non-bleeding patients, rapid infusion rates increase risk of symptomatic cardiac overload",
                      "Changes in blood pressureHypertension: Favors TACOHypotension: Favors TRALI or anaphylaxis",
                      "Hypertension: Favors TACO",
                      "Hypotension: Favors TRALI or anaphylaxis",
                      "Respiratory exam findingsWheezing favors anaphylaxisCrackles or visible pink frothy sputum favors TRALI/TACO",
                      "Wheezing favors anaphylaxis",
                      "Crackles or visible pink frothy sputum favors TRALI/TACO",
                      "Results of chest x-ray (should be done in all cases of transfusion-associated events involving dyspnea/hypoxia)Bilateral pulmonary edema favors TRALI/TACO over anaphylaxisCardiomegaly favors TACO over TRALI/anaphylaxis",
                      "Bilateral pulmonary edema favors TRALI/TACO over anaphylaxis",
                      "Cardiomegaly favors TACO over TRALI/anaphylaxis",
                      "Response to medical therapyNoted clinical improvement with diuretic favors TACO (not TRALI)Noted clinical improvement with epinephrine or steroids favors anaphylaxis (not TRALI)",
                      "Noted clinical improvement with diuretic favors TACO (not TRALI)",
                      "Noted clinical improvement with epinephrine or steroids favors anaphylaxis (not TRALI)",
                      "If pruritus or hives predominate, allergic transfusion reaction is favoredTemporally associate medications or eventsPatient may be allergic to something else that was givenSymptom severity is important to clarify (not all hives are created equal)Periorbital or perioral edema is concerning for more severe allergic reactionReported shortness of breath or wheezing is concerning for more severe reactionReported decreases in blood pressure are concerning for more severe reactionResponse to medical therapyNoted clinical improvement with simple antihistamine (i.e., benadryl) favors mild reactionReactions that require steroids for symptomatic relief are more severe",
                      "Temporally associate medications or eventsPatient may be allergic to something else that was given",
                      "Patient may be allergic to something else that was given",
                      "Symptom severity is important to clarify (not all hives are created equal)Periorbital or perioral edema is concerning for more severe allergic reactionReported shortness of breath or wheezing is concerning for more severe reactionReported decreases in blood pressure are concerning for more severe reaction",
                      "Periorbital or perioral edema is concerning for more severe allergic reaction",
                      "Reported shortness of breath or wheezing is concerning for more severe reaction",
                      "Reported decreases in blood pressure are concerning for more severe reaction",
                      "Response to medical therapyNoted clinical improvement with simple antihistamine (i.e., benadryl) favors mild reactionReactions that require steroids for symptomatic relief are more severe",
                      "Noted clinical improvement with simple antihistamine (i.e., benadryl) favors mild reaction",
                      "Reactions that require steroids for symptomatic relief are more severe"
                    ]
                  },
                  {
                    "text": "Step 4: Decide if you need to quarantine any units or notify your blood providerQuarantine/notify after suspected septic transfusion reaction when blood products from same donor are availableQuarantine/notify after suspected TRALI reaction when blood products from same donor are available",
                    "sub_points": [
                      "Quarantine/notify after suspected septic transfusion reaction when blood products from same donor are available",
                      "Quarantine/notify after suspected TRALI reaction when blood products from same donor are available"
                    ]
                  },
                  {
                    "text": "Step 5: Decide if patient is safe to receive future transfusionsCan be considered under certain circumstancesPatient cannot wait due to medical needReaction or likely diagnosis is benign (i.e., febrile non-hemolytic transfusion reactions)Etiology is clear, or preventive steps have been taken to reduce future riskExample (1) using C-negative blood in patient with new anti-CExample (2) volume reducing or washing products for severe/recurrent allergic transfusion reactionsChance of similar reaction with new product is lowi.e., chance that second product is also bacterially contaminated is very low",
                    "sub_points": [
                      "Can be considered under certain circumstancesPatient cannot wait due to medical needReaction or likely diagnosis is benign (i.e., febrile non-hemolytic transfusion reactions)Etiology is clear, or preventive steps have been taken to reduce future riskExample (1) using C-negative blood in patient with new anti-CExample (2) volume reducing or washing products for severe/recurrent allergic transfusion reactionsChance of similar reaction with new product is lowi.e., chance that second product is also bacterially contaminated is very low",
                      "Patient cannot wait due to medical need",
                      "Reaction or likely diagnosis is benign (i.e., febrile non-hemolytic transfusion reactions)",
                      "Etiology is clear, or preventive steps have been taken to reduce future riskExample (1) using C-negative blood in patient with new anti-CExample (2) volume reducing or washing products for severe/recurrent allergic transfusion reactions",
                      "Example (1) using C-negative blood in patient with new anti-C",
                      "Example (2) volume reducing or washing products for severe/recurrent allergic transfusion reactions",
                      "Chance of similar reaction with new product is lowi.e., chance that second product is also bacterially contaminated is very low",
                      "i.e., chance that second product is also bacterially contaminated is very low"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Work-up of Suspected Transfusion Reaction": {
            "name": "Laboratory Work-up of Suspected Transfusion Reaction",
            "url": "https://app.pathprimer.com/document/a2546c00-082f-4547-b26b-af5559adeb9c/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Diagnosis": [
                  {
                    "text": "Hospital procedures for managing suspected transfusion reactions vary, but all require minimum evaluation to exclude possibility of hemolytic transfusion reaction"
                  },
                  {
                    "text": "Transfusion reaction work-up usually requires unit and tubing, posttransfusion blood sample from patient, and report documenting reaction symptoms"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Hospital procedures for managing suspected transfusion reactions varyAll require minimum standard evaluation to exclude possibility of hemolytic transfusion reaction",
                    "sub_points": [
                      "All require minimum standard evaluation to exclude possibility of hemolytic transfusion reaction"
                    ]
                  },
                  {
                    "text": "Transfusion reaction work-up usually requiresUnit, tubing, transfusion set with associated IV solutions and transfusion record paperwork (which documents VS and reaction signs/symptoms) be sent to transfusion serviceTo perform clerical check of component bag, label, paperwork and patient sample to confirm no clerical error occurredTo confirm that no inappropriate fluids were used (i.e., dextrose)To evaluate clinical details regarding transfusion reaction eventRemaining blood component with tubing may be utilized for culturer/Gram stain if indicatedPosttransfusion blood sample from transfusion recipientTo repeat ABO testing to reconfirm patient ABO typeTo perform visual check of pre- and posttransfusion specimens for evidence of hemolysisIf hemolysis is present, plasma color is darker orange-red and not clear yellowMay not be visible if hemoglobin is < 50 mg/dLTo perform DAT (direct antiglobulin test) to determine if antibodies or complement are attached or coating posttransfusion red cellsIf result is positive, most recent pretransfusion sample will be used for comparisonReport of findings given to blood bank supervisor and medical director who may request additional studies/tests be performedMay also request quarantine of co-components generated from same donor collection, or impose future transfusion restrictions/instructions for patientAdditional reaction-specific effortsTransfusion related lung injury (TRALI): Report reaction to blood provider so thatAny known units in inventory from same donor are quarantinedPatient and donor are tested for possible HLA, HNA antibodies",
                    "sub_points": [
                      "Unit, tubing, transfusion set with associated IV solutions and transfusion record paperwork (which documents VS and reaction signs/symptoms) be sent to transfusion serviceTo perform clerical check of component bag, label, paperwork and patient sample to confirm no clerical error occurredTo confirm that no inappropriate fluids were used (i.e., dextrose)To evaluate clinical details regarding transfusion reaction eventRemaining blood component with tubing may be utilized for culturer/Gram stain if indicated",
                      "To perform clerical check of component bag, label, paperwork and patient sample to confirm no clerical error occurred",
                      "To confirm that no inappropriate fluids were used (i.e., dextrose)",
                      "To evaluate clinical details regarding transfusion reaction event",
                      "Remaining blood component with tubing may be utilized for culturer/Gram stain if indicated",
                      "Posttransfusion blood sample from transfusion recipientTo repeat ABO testing to reconfirm patient ABO typeTo perform visual check of pre- and posttransfusion specimens for evidence of hemolysisIf hemolysis is present, plasma color is darker orange-red and not clear yellowMay not be visible if hemoglobin is < 50 mg/dLTo perform DAT (direct antiglobulin test) to determine if antibodies or complement are attached or coating posttransfusion red cellsIf result is positive, most recent pretransfusion sample will be used for comparison",
                      "To repeat ABO testing to reconfirm patient ABO type",
                      "To perform visual check of pre- and posttransfusion specimens for evidence of hemolysisIf hemolysis is present, plasma color is darker orange-red and not clear yellowMay not be visible if hemoglobin is < 50 mg/dL",
                      "If hemolysis is present, plasma color is darker orange-red and not clear yellow",
                      "May not be visible if hemoglobin is < 50 mg/dL",
                      "To perform DAT (direct antiglobulin test) to determine if antibodies or complement are attached or coating posttransfusion red cellsIf result is positive, most recent pretransfusion sample will be used for comparison",
                      "If result is positive, most recent pretransfusion sample will be used for comparison",
                      "Report of findings given to blood bank supervisor and medical director who may request additional studies/tests be performedMay also request quarantine of co-components generated from same donor collection, or impose future transfusion restrictions/instructions for patient",
                      "May also request quarantine of co-components generated from same donor collection, or impose future transfusion restrictions/instructions for patient",
                      "Additional reaction-specific effortsTransfusion related lung injury (TRALI): Report reaction to blood provider so thatAny known units in inventory from same donor are quarantinedPatient and donor are tested for possible HLA, HNA antibodies",
                      "Transfusion related lung injury (TRALI): Report reaction to blood provider so thatAny known units in inventory from same donor are quarantinedPatient and donor are tested for possible HLA, HNA antibodies",
                      "Any known units in inventory from same donor are quarantined",
                      "Patient and donor are tested for possible HLA, HNA antibodies"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Febrile Nonhemolytic Transfusion Reaction": {
            "name": "Febrile Nonhemolytic Transfusion Reaction",
            "url": "https://app.pathprimer.com/document/c24123f6-d3b2-423e-8e6e-3c0edea4747a/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Common, mild reaction to blood productsPresents with fever &/or chills/rigors during or within 4 hours of transfusion",
                    "sub_points": [
                      "Presents with fever &/or chills/rigors during or within 4 hours of transfusion"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Febrile nonhemolytic reactions are diagnosis of exclusion"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Fever from transfusion is likely multifactorial and can be triggered by various possible mechanismsRelease of cytokines IL-1, IL-6, and TNF-alpha is final common pathway for fever production from transfusionDonor white cells are stimulated by recipient preformed antibodies to release cytokines posttransfusion (more likely in nonleukoreduced products)Immune complexes formed between recipient antibodies and donor white cells lead to release of cytokines from recipient macrophages (more likely in nonleukoreduced products)Passive receipt of preformed donor cytokines in plasma of a unit (more likely in leukoreduced products)",
                    "sub_points": [
                      "Release of cytokines IL-1, IL-6, and TNF-alpha is final common pathway for fever production from transfusionDonor white cells are stimulated by recipient preformed antibodies to release cytokines posttransfusion (more likely in nonleukoreduced products)Immune complexes formed between recipient antibodies and donor white cells lead to release of cytokines from recipient macrophages (more likely in nonleukoreduced products)Passive receipt of preformed donor cytokines in plasma of a unit (more likely in leukoreduced products)",
                      "Donor white cells are stimulated by recipient preformed antibodies to release cytokines posttransfusion (more likely in nonleukoreduced products)",
                      "Immune complexes formed between recipient antibodies and donor white cells lead to release of cytokines from recipient macrophages (more likely in nonleukoreduced products)",
                      "Passive receipt of preformed donor cytokines in plasma of a unit (more likely in leukoreduced products)"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Prior to leukoreduction, fever was most common transfusion reaction"
                  },
                  {
                    "text": "Post-leukoreduction, fever still common but now less common than allergic reactions (about 2:100 units)Fever risk from red cell products: 0.2-6.8%Nonleukocyte reduced > leukocyte reducedFever risk from platelets: 0.1-2.2%Nonleukocyte reduced > leukocyte reducedOld platelets (4-5 days) > fresh platelets (< 4 days)Fever risk from plasma: 0.02%",
                    "sub_points": [
                      "Fever risk from red cell products: 0.2-6.8%Nonleukocyte reduced > leukocyte reduced",
                      "Nonleukocyte reduced > leukocyte reduced",
                      "Fever risk from platelets: 0.1-2.2%Nonleukocyte reduced > leukocyte reducedOld platelets (4-5 days) > fresh platelets (< 4 days)",
                      "Nonleukocyte reduced > leukocyte reduced",
                      "Old platelets (4-5 days) > fresh platelets (< 4 days)",
                      "Fever risk from plasma: 0.02%"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Fever (change in > 1°C or 1.8°F)"
                  },
                  {
                    "text": "Chills/rigors (may be only presenting symptom)"
                  },
                  {
                    "text": "Occurs during or within 4 hours of transfusionOften presents late in transfusion due to its dose-dependent etiologyReaction severity usually mild",
                    "sub_points": [
                      "Often presents late in transfusion due to its dose-dependent etiology",
                      "Reaction severity usually mild"
                    ]
                  },
                  {
                    "text": "Tachycardia and increases in blood pressure can be seen"
                  },
                  {
                    "text": "Headache/nausea can be associated"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Stop transfusion and file transfusion reaction report (to exclude hemolysis)"
                  },
                  {
                    "text": "Use standard antipyreticsPremedication with antipyretic is often used clinically, but is likely to be ineffective and has potential to mask fever related to more serious cause",
                    "sub_points": [
                      "Premedication with antipyretic is often used clinically, but is likely to be ineffective and has potential to mask fever related to more serious cause"
                    ]
                  }
                ],
                "Prevention": [
                  {
                    "text": "Prestorage leukoreduction is effective at removing white cells that can cause cytokine release and lead to fever"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Hemolytic transfusion reaction must be ruled out before accepting/considering diagnosis of febrile nonhemolytic transfusion reaction (FNHTR)"
                  },
                  {
                    "text": "Transfusion related: Hemolytic transfusion reaction, sepsis, or transfusion-related acute lung injury (TRALI)"
                  },
                  {
                    "text": "Nontransfusion related: Underlying illness or medications (often most likely cause)"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Currently no tests available to help diagnose FNHTRDiagnosis of exclusion",
                    "sub_points": [
                      "Diagnosis of exclusion"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Delayed Hemolytic and Delayed Serologic Transfusion Reactions": {
            "name": "Delayed Hemolytic and Delayed Serologic Transfusion Reactions",
            "url": "https://app.pathprimer.com/document/07d5fb9a-bdf0-4376-b1cd-166aeda5e7fd/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "DSTR and DHTR are caused by re-activation of a minor red cell antibody"
                  },
                  {
                    "text": "Severity of these reactions differs widely, but many cases are asymptomatic"
                  },
                  {
                    "text": "Treatment: Supportive care and use of red cells lacking the incompatible antigen"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Most often caused by re-exposure to incompatible minor red cell antigensAnti-E, -Fya, and -Jka are most frequently identified in key studiesPrimary exposure is typically not clinically significant",
                    "sub_points": [
                      "Anti-E, -Fya, and -Jka are most frequently identified in key studies",
                      "Primary exposure is typically not clinically significant"
                    ]
                  },
                  {
                    "text": "Delayed serologic transfusion reactions (DSTR)Defined by rapid serologic rise of minor red cell antibody, but no evidence of red cell hemolysis",
                    "sub_points": [
                      "Defined by rapid serologic rise of minor red cell antibody, but no evidence of red cell hemolysis"
                    ]
                  },
                  {
                    "text": "Delayed hemolytic transfusion reactions (DHTR)Result from same red cell antibody, but cause extravascular hemolysis (most common) or intravascular hemolysis (less common) of incompatible red cellsAntibodies coat incompatible red cells, resulting in splenic phagocyte removal and release of their metabolized contents (e.g., bilirubin)Severity of these hemolytic reactions is due to thermal range, antibody specificity, and IgG subclass of offending antibodyHemolysis most likely seen with antibodies that react at body temperature (37°C) in vitro",
                    "sub_points": [
                      "Result from same red cell antibody, but cause extravascular hemolysis (most common) or intravascular hemolysis (less common) of incompatible red cells",
                      "Antibodies coat incompatible red cells, resulting in splenic phagocyte removal and release of their metabolized contents (e.g., bilirubin)",
                      "Severity of these hemolytic reactions is due to thermal range, antibody specificity, and IgG subclass of offending antibodyHemolysis most likely seen with antibodies that react at body temperature (37°C) in vitro",
                      "Hemolysis most likely seen with antibodies that react at body temperature (37°C) in vitro"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Overall incidence is 1:1500 unitsIncidence of DSTR is 4x greater than DHTRIncidence of DSTR and DHTR are greater using gel test than polyethylene glycol indirect antiglobulin test (PEG IAT), due to differences in test sensitivity",
                    "sub_points": [
                      "Incidence of DSTR is 4x greater than DHTR",
                      "Incidence of DSTR and DHTR are greater using gel test than polyethylene glycol indirect antiglobulin test (PEG IAT), due to differences in test sensitivity"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Symptoms or signs develop 3-28 days after exposure to incompatible transfusionIncompatible unit may have been serologically compatible originallyMany delayed reactions have no evidence of clinical symptoms, just detection of new red cell antibody",
                    "sub_points": [
                      "Incompatible unit may have been serologically compatible originally",
                      "Many delayed reactions have no evidence of clinical symptoms, just detection of new red cell antibody"
                    ]
                  },
                  {
                    "text": "Evidence of hemolysisUnexpected drop in hemoglobinLess than expected posttransfusion increment in hemoglobinFever, with or without chillsUnexpected rise in bilirubin, with or without jaundiceMalaiseBack painRenal failurePain crisis or hyperhemolysis in patients with sickle cell disease",
                    "sub_points": [
                      "Unexpected drop in hemoglobin",
                      "Less than expected posttransfusion increment in hemoglobin",
                      "Fever, with or without chills",
                      "Unexpected rise in bilirubin, with or without jaundice",
                      "Malaise",
                      "Back pain",
                      "Renal failure",
                      "Pain crisis or hyperhemolysis in patients with sickle cell disease"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Most reactions do not require specific treatment"
                  },
                  {
                    "text": "All future red cell transfusions need to lack antigen to which patient is now sensitized"
                  },
                  {
                    "text": "Serious reactions (e.g., jaundice or renal failure) should be treated supportively"
                  }
                ],
                "Prevention": [
                  {
                    "text": "While difficult to prevent such reactions, all blood banks are required to permanently retain complete information regarding previously identified red cell antibodiesGood transfusion and pregnancy history are critical in providing compatible red cell units",
                    "sub_points": [
                      "Good transfusion and pregnancy history are critical in providing compatible red cell units"
                    ]
                  },
                  {
                    "text": "Whenever possible, all red cell units provided should avoid documented patient red cell antibodies"
                  },
                  {
                    "text": "All transfused red cell units should be crossmatch-compatible at IAT phase of testing in absence of emergent transfusion"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Clinical symptoms could be caused by underlying medical conditions (e.g., infection or bleeding)"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Indirect antiglobulin test (IAT) (antibody screen/antibody panel)Positive with a \"new\" red cell antibody",
                    "sub_points": [
                      "Positive with a \"new\" red cell antibody"
                    ]
                  },
                  {
                    "text": "Direct antiglobulin test (DAT)Positive with IgG &/or C3Eluate will be positive with new red cell alloantibodyDAT may be positive for up to 300 days posttransfusion",
                    "sub_points": [
                      "Positive with IgG &/or C3Eluate will be positive with new red cell alloantibodyDAT may be positive for up to 300 days posttransfusion",
                      "Eluate will be positive with new red cell alloantibody",
                      "DAT may be positive for up to 300 days posttransfusion"
                    ]
                  },
                  {
                    "text": "Other lab findings suggestive of DHTRElevated reticulocyte % or countElevated unconjugated bilirubinElevated urine urobilinogenIf intravascular hemolysisElevated lactate dehydrogenase (LDH), hemoglobinuria, and decreased haptoglobin",
                    "sub_points": [
                      "Elevated reticulocyte % or count",
                      "Elevated unconjugated bilirubin",
                      "Elevated urine urobilinogen",
                      "If intravascular hemolysisElevated lactate dehydrogenase (LDH), hemoglobinuria, and decreased haptoglobin",
                      "Elevated lactate dehydrogenase (LDH), hemoglobinuria, and decreased haptoglobin"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Complications of Massive Transfusion": {
            "name": "Complications of Massive Transfusion",
            "url": "https://app.pathprimer.com/document/c347990f-f77f-4bee-9db7-ce2c70da30a1/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Massive transfusion: Commonly defined as transfusion of ≥ 10 red blood cell (RBC) products within 24 hours"
                  },
                  {
                    "text": "Rapid infusion of blood products can lead to various complications, including hypocalcemia, hyperkalemia, hypothermia, hypocoagulable state, and alloimmunization"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Massive transfusion: Commonly defined as transfusion of ≥ 10 red blood cell (RBC) products within 24 hours"
                  },
                  {
                    "text": "Rapid infusion of blood products can lead to various transfusion-specific complications, including hypocalcemia, hyperkalemia, hypothermia, hypocoagulable state, acidosis, and alloimmunization (described below)HypocalcemiaCausesStandard blood products contain sodium citrate as part of the preservative, which binds plasma calcium when receivedSymptomsParaesthesias, nausea, hyperventilation, tetany, abnormal cardiac functionMassive transfusion patient most likely is unable to report symptoms; thus, emesis, hyperventilation, tetany, abnormal cardiac function may be only symptoms seenTests for detectionAbnormally low ionized calcium levelPrevention &/or treatmentProvide IV calcium gluconate or calcium chloride during massive transfusion eventHyperkalemiaCausesPlasma potassium increases in stored RBCs over timePotassium is 27 mmol/l at day 0 (fresh red cell unit) and 50 mmol/l at day 42 (older red cell unit)SymptomsCardiac arrhythmiasTests for detectionEKG abnormalities: Peaked T wavesAbnormally high potassium levelPrevention &/or treatmentFresh red cells have less free potassium than older stored red cells (washing of red cells takes too long)Potassium-lowering medications: Insulin or salbutamolHypothermiaCausesRBC units are stored at 1-6°C; rapid infusion of these stored products can lower body temperatureSymptomsMetabolic acidosis, bleeding diathesis, cardiac arrhythmiaTests for detectionStandard body temperature (thermometer); body core temperature below 35.0°CPrevention &/or treatmentBlood products can be infused through blood warmerOther metabolic or coagulation changes can be treated supportivelyHypocoagulable stateCausesRBC products have very little platelet and plasma content (platelet count falls to ~ 50,000/uL and fibrinogen falls to ~ 100mg/dL after 2 blood volumes of red cells)SymptomsContinued bleeding despite adequate hemostasisTests for detectionStandard labs: PT/PTT/INR/fibrinogenThromboelastogram (TEG)Prevention &/or treatmentAdequate use of platelet and plasma transfusions in context of massive transfusionMassive transfusion protocols useful for this purposeAlloimmunizationCausesMassive transfusions often occur in situations where compatible blood is (1) not available based on the urgent need, or (2) not established due to lack of patient sampleMany hospitals allow for use of Rh-positive units even when patient known to be Rh negativeSymptomsDelayed hemolytic transfusion reactionHemolytic disease of fetus or newborn can occur in women of child-bearing ageTests for detectionFuture direct antiglobulin test (DAT) or indirect antiglobulin test (IAT) turns positivePrevention &/or treatmentDifficult in all cases due to urgency and available information during massive transfusion situationProvide only O-negative red cell units to female of child-bearing age (if possible)",
                    "sub_points": [
                      "HypocalcemiaCausesStandard blood products contain sodium citrate as part of the preservative, which binds plasma calcium when receivedSymptomsParaesthesias, nausea, hyperventilation, tetany, abnormal cardiac functionMassive transfusion patient most likely is unable to report symptoms; thus, emesis, hyperventilation, tetany, abnormal cardiac function may be only symptoms seenTests for detectionAbnormally low ionized calcium levelPrevention &/or treatmentProvide IV calcium gluconate or calcium chloride during massive transfusion event",
                      "CausesStandard blood products contain sodium citrate as part of the preservative, which binds plasma calcium when received",
                      "Standard blood products contain sodium citrate as part of the preservative, which binds plasma calcium when received",
                      "SymptomsParaesthesias, nausea, hyperventilation, tetany, abnormal cardiac functionMassive transfusion patient most likely is unable to report symptoms; thus, emesis, hyperventilation, tetany, abnormal cardiac function may be only symptoms seen",
                      "Paraesthesias, nausea, hyperventilation, tetany, abnormal cardiac function",
                      "Massive transfusion patient most likely is unable to report symptoms; thus, emesis, hyperventilation, tetany, abnormal cardiac function may be only symptoms seen",
                      "Tests for detectionAbnormally low ionized calcium level",
                      "Abnormally low ionized calcium level",
                      "Prevention &/or treatmentProvide IV calcium gluconate or calcium chloride during massive transfusion event",
                      "Provide IV calcium gluconate or calcium chloride during massive transfusion event",
                      "HyperkalemiaCausesPlasma potassium increases in stored RBCs over timePotassium is 27 mmol/l at day 0 (fresh red cell unit) and 50 mmol/l at day 42 (older red cell unit)SymptomsCardiac arrhythmiasTests for detectionEKG abnormalities: Peaked T wavesAbnormally high potassium levelPrevention &/or treatmentFresh red cells have less free potassium than older stored red cells (washing of red cells takes too long)Potassium-lowering medications: Insulin or salbutamol",
                      "CausesPlasma potassium increases in stored RBCs over timePotassium is 27 mmol/l at day 0 (fresh red cell unit) and 50 mmol/l at day 42 (older red cell unit)",
                      "Plasma potassium increases in stored RBCs over time",
                      "Potassium is 27 mmol/l at day 0 (fresh red cell unit) and 50 mmol/l at day 42 (older red cell unit)",
                      "SymptomsCardiac arrhythmias",
                      "Cardiac arrhythmias",
                      "Tests for detectionEKG abnormalities: Peaked T wavesAbnormally high potassium level",
                      "EKG abnormalities: Peaked T waves",
                      "Abnormally high potassium level",
                      "Prevention &/or treatmentFresh red cells have less free potassium than older stored red cells (washing of red cells takes too long)Potassium-lowering medications: Insulin or salbutamol",
                      "Fresh red cells have less free potassium than older stored red cells (washing of red cells takes too long)",
                      "Potassium-lowering medications: Insulin or salbutamol",
                      "HypothermiaCausesRBC units are stored at 1-6°C; rapid infusion of these stored products can lower body temperatureSymptomsMetabolic acidosis, bleeding diathesis, cardiac arrhythmiaTests for detectionStandard body temperature (thermometer); body core temperature below 35.0°CPrevention &/or treatmentBlood products can be infused through blood warmerOther metabolic or coagulation changes can be treated supportively",
                      "CausesRBC units are stored at 1-6°C; rapid infusion of these stored products can lower body temperature",
                      "RBC units are stored at 1-6°C; rapid infusion of these stored products can lower body temperature",
                      "SymptomsMetabolic acidosis, bleeding diathesis, cardiac arrhythmia",
                      "Metabolic acidosis, bleeding diathesis, cardiac arrhythmia",
                      "Tests for detectionStandard body temperature (thermometer); body core temperature below 35.0°C",
                      "Standard body temperature (thermometer); body core temperature below 35.0°C",
                      "Prevention &/or treatmentBlood products can be infused through blood warmerOther metabolic or coagulation changes can be treated supportively",
                      "Blood products can be infused through blood warmer",
                      "Other metabolic or coagulation changes can be treated supportively",
                      "Hypocoagulable stateCausesRBC products have very little platelet and plasma content (platelet count falls to ~ 50,000/uL and fibrinogen falls to ~ 100mg/dL after 2 blood volumes of red cells)SymptomsContinued bleeding despite adequate hemostasisTests for detectionStandard labs: PT/PTT/INR/fibrinogenThromboelastogram (TEG)Prevention &/or treatmentAdequate use of platelet and plasma transfusions in context of massive transfusionMassive transfusion protocols useful for this purpose",
                      "CausesRBC products have very little platelet and plasma content (platelet count falls to ~ 50,000/uL and fibrinogen falls to ~ 100mg/dL after 2 blood volumes of red cells)",
                      "RBC products have very little platelet and plasma content (platelet count falls to ~ 50,000/uL and fibrinogen falls to ~ 100mg/dL after 2 blood volumes of red cells)",
                      "SymptomsContinued bleeding despite adequate hemostasis",
                      "Continued bleeding despite adequate hemostasis",
                      "Tests for detectionStandard labs: PT/PTT/INR/fibrinogenThromboelastogram (TEG)",
                      "Standard labs: PT/PTT/INR/fibrinogen",
                      "Thromboelastogram (TEG)",
                      "Prevention &/or treatmentAdequate use of platelet and plasma transfusions in context of massive transfusionMassive transfusion protocols useful for this purpose",
                      "Adequate use of platelet and plasma transfusions in context of massive transfusion",
                      "Massive transfusion protocols useful for this purpose",
                      "AlloimmunizationCausesMassive transfusions often occur in situations where compatible blood is (1) not available based on the urgent need, or (2) not established due to lack of patient sampleMany hospitals allow for use of Rh-positive units even when patient known to be Rh negativeSymptomsDelayed hemolytic transfusion reactionHemolytic disease of fetus or newborn can occur in women of child-bearing ageTests for detectionFuture direct antiglobulin test (DAT) or indirect antiglobulin test (IAT) turns positivePrevention &/or treatmentDifficult in all cases due to urgency and available information during massive transfusion situationProvide only O-negative red cell units to female of child-bearing age (if possible)",
                      "CausesMassive transfusions often occur in situations where compatible blood is (1) not available based on the urgent need, or (2) not established due to lack of patient sampleMany hospitals allow for use of Rh-positive units even when patient known to be Rh negative",
                      "Massive transfusions often occur in situations where compatible blood is (1) not available based on the urgent need, or (2) not established due to lack of patient sample",
                      "Many hospitals allow for use of Rh-positive units even when patient known to be Rh negative",
                      "SymptomsDelayed hemolytic transfusion reactionHemolytic disease of fetus or newborn can occur in women of child-bearing age",
                      "Delayed hemolytic transfusion reaction",
                      "Hemolytic disease of fetus or newborn can occur in women of child-bearing age",
                      "Tests for detectionFuture direct antiglobulin test (DAT) or indirect antiglobulin test (IAT) turns positive",
                      "Future direct antiglobulin test (DAT) or indirect antiglobulin test (IAT) turns positive",
                      "Prevention &/or treatmentDifficult in all cases due to urgency and available information during massive transfusion situationProvide only O-negative red cell units to female of child-bearing age (if possible)",
                      "Difficult in all cases due to urgency and available information during massive transfusion situation",
                      "Provide only O-negative red cell units to female of child-bearing age (if possible)"
                    ]
                  },
                  {
                    "text": "\"Triad of death\"Comprises1) Ongoing bleeding2) Hypothermia3) AcidosisLeads to critical loss in coagulation function, ongoing blood loss, decompensated shock, and death﻿",
                    "sub_points": [
                      "Comprises1) Ongoing bleeding2) Hypothermia3) Acidosis",
                      "1) Ongoing bleeding",
                      "2) Hypothermia",
                      "3) Acidosis",
                      "Leads to critical loss in coagulation function, ongoing blood loss, decompensated shock, and death﻿"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Hemolytic Transfusion Reactions": {
            "name": "Acute Hemolytic Transfusion Reactions",
            "url": "https://app.pathprimer.com/document/ed8482bb-c35b-449f-ac6a-bc09b6307794/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Most acute hemolytic reactions are due to erroneous transfusion of ABO-incompatible red cells into patient with naturally occurring anti-A or anti-B antibodies"
                  },
                  {
                    "text": "Transfusion of minor incompatible red cell antigens can also produce these reactions (Kell, Rh, Duffy, Kidd)"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Prompt blood bank evaluation is critical for diagnosis of acute hemolytic reactions, as offending antibody &/or transfusion error can often be detected"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Most reactions are due to erroneous transfusion of ABO-incompatible red cells into patient with naturally occurring anti-A or anti-B antibodiesTransfusion of minor incompatible red cell antigens can also produce these reactions (Kell, Rh, Duffy, Kidd)Transfusion of incompatible plasma or platelets can rarely provide enough antibodies to lead to patient red cell hemolysis",
                    "sub_points": [
                      "Transfusion of minor incompatible red cell antigens can also produce these reactions (Kell, Rh, Duffy, Kidd)",
                      "Transfusion of incompatible plasma or platelets can rarely provide enough antibodies to lead to patient red cell hemolysis"
                    ]
                  },
                  {
                    "text": "IgM, IgG1, and IgG3 antibodies effectively bind complement (C1q) and initiate complement cascadeFormation of complement membrane attack complex (C5-9) results in intravascular red cell lysisFormation of C3a and C5a induces release of histamines and other proinflammatory cytokinesLeads to fever, hypotension, and potentially disseminated intravascular coagulation (DIC)",
                    "sub_points": [
                      "Formation of complement membrane attack complex (C5-9) results in intravascular red cell lysis",
                      "Formation of C3a and C5a induces release of histamines and other proinflammatory cytokinesLeads to fever, hypotension, and potentially disseminated intravascular coagulation (DIC)",
                      "Leads to fever, hypotension, and potentially disseminated intravascular coagulation (DIC)"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "IncidenceABO-incompatible transfusions1 in 38,000-100,000 red cell transfusions1 in 2000-46,176 incompatible plasma transfusionsDeaths from ABO-incompatible transfusions1 in 1.5 million",
                    "sub_points": [
                      "ABO-incompatible transfusions1 in 38,000-100,000 red cell transfusions1 in 2000-46,176 incompatible plasma transfusions",
                      "1 in 38,000-100,000 red cell transfusions",
                      "1 in 2000-46,176 incompatible plasma transfusions",
                      "Deaths from ABO-incompatible transfusions1 in 1.5 million",
                      "1 in 1.5 million"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Occurs within 24 hr of incompatible transfusion"
                  },
                  {
                    "text": "Patient signs and symptomsChills/rigorsFeverBack/flank painHypotensionHemoglobinuriaEpistaxisOliguria or anuriaRenal failureDICPain or oozing at infusion siteSense of doom",
                    "sub_points": [
                      "Chills/rigors",
                      "Fever",
                      "Back/flank pain",
                      "Hypotension",
                      "Hemoglobinuria",
                      "Epistaxis",
                      "Oliguria or anuria",
                      "Renal failure",
                      "DIC",
                      "Pain or oozing at infusion site",
                      "Sense of doom"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "When symptoms are presentStopping transfusion is critical",
                    "sub_points": [
                      "Stopping transfusion is critical"
                    ]
                  },
                  {
                    "text": "When diagnosis is madeTransfer to intensive care unit may be helpfulManage hypotensionLow-dose dopamine and infusion of colloid or crystalloid fluidsManage renal functionDiuretic to maintain urine output at ≥ 30-100 mL/hrManage DICPlasma/fresh frozen plasma, platelets, or cryoprecipitate to manage bleeding or derangement in coagulation or platelet studies",
                    "sub_points": [
                      "Transfer to intensive care unit may be helpful",
                      "Manage hypotensionLow-dose dopamine and infusion of colloid or crystalloid fluids",
                      "Low-dose dopamine and infusion of colloid or crystalloid fluids",
                      "Manage renal functionDiuretic to maintain urine output at ≥ 30-100 mL/hr",
                      "Diuretic to maintain urine output at ≥ 30-100 mL/hr",
                      "Manage DICPlasma/fresh frozen plasma, platelets, or cryoprecipitate to manage bleeding or derangement in coagulation or platelet studies",
                      "Plasma/fresh frozen plasma, platelets, or cryoprecipitate to manage bleeding or derangement in coagulation or platelet studies"
                    ]
                  },
                  {
                    "text": "Avoid offending antibody in future transfusions"
                  }
                ],
                "Prevention": [
                  {
                    "text": "Minimize sources of mistransfusion (wrong unit given to wrong patient)Laboratory error represents only 30% of errors leading to mistransfusionMost are bedside errors in labeling or patient identification",
                    "sub_points": [
                      "Laboratory error represents only 30% of errors leading to mistransfusionMost are bedside errors in labeling or patient identification",
                      "Most are bedside errors in labeling or patient identification"
                    ]
                  },
                  {
                    "text": "Strict adherence to transfusion administration guidelines"
                  },
                  {
                    "text": "Ensure future products, postdiagnosis, are appropriately compatible"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Transfusion of improperly stored or transfused red cellThermal hemolysis, mechanical hemolysis, or osmolar hemolysis",
                    "sub_points": [
                      "Thermal hemolysis, mechanical hemolysis, or osmolar hemolysis"
                    ]
                  },
                  {
                    "text": "Underlying medical conditionsSickle cell diseaseMicroangiopathic hemolytic anemias (i.e., thrombotic thrombocytopenic purpura)Implanted circulatory devicesCan cause mechanical hemolysis",
                    "sub_points": [
                      "Sickle cell disease",
                      "Microangiopathic hemolytic anemias (i.e., thrombotic thrombocytopenic purpura)",
                      "Implanted circulatory devicesCan cause mechanical hemolysis",
                      "Can cause mechanical hemolysis"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Blood bankDirect antiglobulin test (DAT) positive for IgG &/or C3 using patient's posttransfusion blood sampleEluate from positive DAT shows positivity for specific antibody (anti-A, anti-B, or another new antibody)Patient's plasma may be discolored because of presence of hemolysisUnit returned to blood bank will not match what was originally sent to that patient if wrong unit was issued to wrong patientPosttransfusion blood sample from patient reveals different ABO blood type from what was previously documented if blood typing was performed on mislabeled or misdrawn blood sample",
                    "sub_points": [
                      "Direct antiglobulin test (DAT) positive for IgG &/or C3 using patient's posttransfusion blood sampleEluate from positive DAT shows positivity for specific antibody (anti-A, anti-B, or another new antibody)",
                      "Eluate from positive DAT shows positivity for specific antibody (anti-A, anti-B, or another new antibody)",
                      "Patient's plasma may be discolored because of presence of hemolysis",
                      "Unit returned to blood bank will not match what was originally sent to that patient if wrong unit was issued to wrong patient",
                      "Posttransfusion blood sample from patient reveals different ABO blood type from what was previously documented if blood typing was performed on mislabeled or misdrawn blood sample"
                    ]
                  },
                  {
                    "text": "Non-blood bankEvidence of hemolysisElevated lactate dehydrogenase (LDH)Elevated bilirubinDecreased haptoglobinHemoglobinuriaEvidence of DICDecreased platelet countDecreased fibrinogenIncreased prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR)Evidence of renal failureElevated creatinineElevated blood urea nitrogen (BUN)",
                    "sub_points": [
                      "Evidence of hemolysisElevated lactate dehydrogenase (LDH)Elevated bilirubinDecreased haptoglobinHemoglobinuria",
                      "Elevated lactate dehydrogenase (LDH)",
                      "Elevated bilirubin",
                      "Decreased haptoglobin",
                      "Hemoglobinuria",
                      "Evidence of DICDecreased platelet countDecreased fibrinogenIncreased prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR)",
                      "Decreased platelet count",
                      "Decreased fibrinogen",
                      "Increased prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR)",
                      "Evidence of renal failureElevated creatinineElevated blood urea nitrogen (BUN)",
                      "Elevated creatinine",
                      "Elevated blood urea nitrogen (BUN)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Transfusion-Associated Sepsis": {
            "name": "Transfusion-Associated Sepsis",
            "url": "https://app.pathprimer.com/document/eeb0a28e-b825-46cc-8ac7-e43053cec1ab/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Overall risk of sepsis is 1 per 15,000-100,000 units, but risk differs significantly by blood product"
                  },
                  {
                    "text": "Fatalities from contaminated blood products are mostly from platelets"
                  },
                  {
                    "text": "Rules for prevention currently evolving"
                  }
                ]
              },
              "OVERVIEW": {
                "Because of success of viral testing, bacterial pathogens are most common cause of transfusion-transmitted infections": [
                  {
                    "text": "IncidenceOverall risk of sepsis is 1 per 15,000-100,000 units, but risk differs significantly by blood productRed cells1 per 250,000 unitsPlatelets1 per 25,000 units if from whole blood1 per 108,000 if from apheresisPlasmaRareCryoprecipitateRareFatalities from contaminated blood products are mostly from plateletsStaphylococcus aureusandEscherichia coliare most common pathogens to result in death",
                    "sub_points": [
                      "Overall risk of sepsis is 1 per 15,000-100,000 units, but risk differs significantly by blood productRed cells1 per 250,000 unitsPlatelets1 per 25,000 units if from whole blood1 per 108,000 if from apheresisPlasmaRareCryoprecipitateRare",
                      "Red cells1 per 250,000 units",
                      "1 per 250,000 units",
                      "Platelets1 per 25,000 units if from whole blood1 per 108,000 if from apheresis",
                      "1 per 25,000 units if from whole blood",
                      "1 per 108,000 if from apheresis",
                      "PlasmaRare",
                      "Rare",
                      "CryoprecipitateRare",
                      "Rare",
                      "Fatalities from contaminated blood products are mostly from plateletsStaphylococcus aureusandEscherichia coliare most common pathogens to result in death",
                      "Staphylococcus aureusandEscherichia coliare most common pathogens to result in death"
                    ]
                  },
                  {
                    "text": "Clinical presentation during or within 4 hr of transfusionFever (increase of 2°C [4°F])HypotensionRigorsTachycardiaDyspneaNausea/emesisShock or multisystem organ failureDisseminated intravascular coagulation (DIC)",
                    "sub_points": [
                      "Fever (increase of 2°C [4°F])",
                      "Hypotension",
                      "Rigors",
                      "Tachycardia",
                      "Dyspnea",
                      "Nausea/emesis",
                      "Shock or multisystem organ failure",
                      "Disseminated intravascular coagulation (DIC)"
                    ]
                  },
                  {
                    "text": "PathophysiologyInflammatory response due to exposure to bolus of bacteriaBacteria fromDonor blood (i.e.,Streptococcus bovisif patient has colonic polyp)Donor skin due to improper phlebotomy techniquesContaminated or faulty collection bagsContaminated water bath (for thawing plasma or cryoprecipitate)Preformed endotoxin from gram-negative bacteriaLeads to rapid release of proinflammatory mediatorsCan lead to more severe reaction and shorter time to symptom onsetTriggers release of interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-αTriggers release of nitric oxideActivates complement and coagulation pathwaysKey bacteria by blood productRed cells: Offer cold but iron-rich environmentYersinia enterocolitica,Pseudomonasspp.,Serratiaspp.Although rare, these gram-negative organisms lead to mortality 70% of the time when presentYersiniaresponsible for 60% of reported casesPlatelets: Offer room-temperature and oxygen- and nutrient-rich environmentMost common: Skin flora, includingStaphylococcus epidermidis, coagulase-negative staphylococci, diphtheroid bacteria,Streptococcusspp.Most commonly fatal:S. aureus,Klebsiella pneumoniae,E. coliPlasma/cryoprecipitate: Usually obtained from contaminated water bathMost common:Burkholderia cepacia,Pseudomonas aeruginosa",
                    "sub_points": [
                      "Inflammatory response due to exposure to bolus of bacteriaBacteria fromDonor blood (i.e.,Streptococcus bovisif patient has colonic polyp)Donor skin due to improper phlebotomy techniquesContaminated or faulty collection bagsContaminated water bath (for thawing plasma or cryoprecipitate)",
                      "Bacteria fromDonor blood (i.e.,Streptococcus bovisif patient has colonic polyp)Donor skin due to improper phlebotomy techniquesContaminated or faulty collection bagsContaminated water bath (for thawing plasma or cryoprecipitate)",
                      "Donor blood (i.e.,Streptococcus bovisif patient has colonic polyp)",
                      "Donor skin due to improper phlebotomy techniques",
                      "Contaminated or faulty collection bags",
                      "Contaminated water bath (for thawing plasma or cryoprecipitate)",
                      "Preformed endotoxin from gram-negative bacteriaLeads to rapid release of proinflammatory mediatorsCan lead to more severe reaction and shorter time to symptom onsetTriggers release of interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-αTriggers release of nitric oxideActivates complement and coagulation pathways",
                      "Leads to rapid release of proinflammatory mediators",
                      "Can lead to more severe reaction and shorter time to symptom onset",
                      "Triggers release of interleukin (IL)-1, IL-6, IL-8, and tumor necrosis factor (TNF)-α",
                      "Triggers release of nitric oxide",
                      "Activates complement and coagulation pathways",
                      "Key bacteria by blood productRed cells: Offer cold but iron-rich environmentYersinia enterocolitica,Pseudomonasspp.,Serratiaspp.Although rare, these gram-negative organisms lead to mortality 70% of the time when presentYersiniaresponsible for 60% of reported casesPlatelets: Offer room-temperature and oxygen- and nutrient-rich environmentMost common: Skin flora, includingStaphylococcus epidermidis, coagulase-negative staphylococci, diphtheroid bacteria,Streptococcusspp.Most commonly fatal:S. aureus,Klebsiella pneumoniae,E. coliPlasma/cryoprecipitate: Usually obtained from contaminated water bathMost common:Burkholderia cepacia,Pseudomonas aeruginosa",
                      "Red cells: Offer cold but iron-rich environmentYersinia enterocolitica,Pseudomonasspp.,Serratiaspp.Although rare, these gram-negative organisms lead to mortality 70% of the time when presentYersiniaresponsible for 60% of reported cases",
                      "Yersinia enterocolitica,Pseudomonasspp.,Serratiaspp.",
                      "Although rare, these gram-negative organisms lead to mortality 70% of the time when present",
                      "Yersiniaresponsible for 60% of reported cases",
                      "Platelets: Offer room-temperature and oxygen- and nutrient-rich environmentMost common: Skin flora, includingStaphylococcus epidermidis, coagulase-negative staphylococci, diphtheroid bacteria,Streptococcusspp.Most commonly fatal:S. aureus,Klebsiella pneumoniae,E. coli",
                      "Most common: Skin flora, includingStaphylococcus epidermidis, coagulase-negative staphylococci, diphtheroid bacteria,Streptococcusspp.",
                      "Most commonly fatal:S. aureus,Klebsiella pneumoniae,E. coli",
                      "Plasma/cryoprecipitate: Usually obtained from contaminated water bathMost common:Burkholderia cepacia,Pseudomonas aeruginosa",
                      "Most common:Burkholderia cepacia,Pseudomonas aeruginosa"
                    ]
                  },
                  {
                    "text": "DiagnosisGram stain and culture of suspected blood productCulturing of unit segments suboptimal and often results in false-negative diagnosisIf no blood is left in unit, culture broth or sterile saline can be infused in bag and testedBlood Gram stain and culture from patient before start of antibioticsObtain blood culture from site opposite from transfusion access point",
                    "sub_points": [
                      "Gram stain and culture of suspected blood productCulturing of unit segments suboptimal and often results in false-negative diagnosisIf no blood is left in unit, culture broth or sterile saline can be infused in bag and tested",
                      "Culturing of unit segments suboptimal and often results in false-negative diagnosis",
                      "If no blood is left in unit, culture broth or sterile saline can be infused in bag and tested",
                      "Blood Gram stain and culture from patient before start of antibioticsObtain blood culture from site opposite from transfusion access point",
                      "Obtain blood culture from site opposite from transfusion access point"
                    ]
                  },
                  {
                    "text": "Differential diagnosisFebrile nonhemolytic transfusion reactionAcute hemolytic transfusion reactionTransfusion-related acute lung injury (TRALI)Underlying medical illness",
                    "sub_points": [
                      "Febrile nonhemolytic transfusion reaction",
                      "Acute hemolytic transfusion reaction",
                      "Transfusion-related acute lung injury (TRALI)",
                      "Underlying medical illness"
                    ]
                  },
                  {
                    "text": "TreatmentPrompt use of broad-spectrum antibioticsSupportive care for hypotension, DIC, or shockStop transfusion as soon as symptoms develop",
                    "sub_points": [
                      "Prompt use of broad-spectrum antibiotics",
                      "Supportive care for hypotension, DIC, or shock",
                      "Stop transfusion as soon as symptoms develop"
                    ]
                  },
                  {
                    "text": "PreventionQuarantine of blood products from same donor can prevent future septic eventsBlood providers are required to adequately test platelet products for bacteriaPlatelet products are cultured after collection and released only if culture remains negative for 12-24 hr (depending on blood provider)Additional bacterial testing before transfusion of a day 4 or 5 platelet product will be required in the futureMost fatal reactions occur when bacteria reach a concentration of 10⁵ colony-forming units (CFU)/mL, which occurs most often after day 2-5 of storage (after unit has been released for transfusion)Use of U.S. Food and Drug Administration (FDA)-approved pathogen inactivation systemsRoutine testing of red cells, plasma, and cryoprecipitate not required",
                    "sub_points": [
                      "Quarantine of blood products from same donor can prevent future septic events",
                      "Blood providers are required to adequately test platelet products for bacteriaPlatelet products are cultured after collection and released only if culture remains negative for 12-24 hr (depending on blood provider)Additional bacterial testing before transfusion of a day 4 or 5 platelet product will be required in the futureMost fatal reactions occur when bacteria reach a concentration of 10⁵ colony-forming units (CFU)/mL, which occurs most often after day 2-5 of storage (after unit has been released for transfusion)",
                      "Platelet products are cultured after collection and released only if culture remains negative for 12-24 hr (depending on blood provider)",
                      "Additional bacterial testing before transfusion of a day 4 or 5 platelet product will be required in the futureMost fatal reactions occur when bacteria reach a concentration of 10⁵ colony-forming units (CFU)/mL, which occurs most often after day 2-5 of storage (after unit has been released for transfusion)",
                      "Most fatal reactions occur when bacteria reach a concentration of 10⁵ colony-forming units (CFU)/mL, which occurs most often after day 2-5 of storage (after unit has been released for transfusion)",
                      "Use of U.S. Food and Drug Administration (FDA)-approved pathogen inactivation systems",
                      "Routine testing of red cells, plasma, and cryoprecipitate not required"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Transfusion-Related Acute Lung Injury": {
            "name": "Transfusion-Related Acute Lung Injury",
            "url": "https://app.pathprimer.com/document/ad743cfe-8c78-4dec-988c-8a4f8e1578c4/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "TRALI is leading cause of transfusion-related mortality reported to FDA"
                  },
                  {
                    "text": "TRALI is clinical diagnosis"
                  },
                  {
                    "text": "TRALI is inflammatory pulmonary edema, but mechanism is not fully understood"
                  },
                  {
                    "text": "Treatment is supportive; many patients improve after 48-96 hr"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-related acute lung injury (TRALI) manifests with acute hypoxia and is leading cause of transfusion-associated mortality in the United States": [
                  {
                    "text": "IncidenceOccurs in approximately 1 per 7500 unitsLeading cause of transfusion-related mortality reported to U.S. Food and Drug Administration (FDA)Death occurs in 15%-20% of casesRemaining 80%-85% of cases improve within 48-96 hrRisk highest in plasma units historicallyMitigation strategies have reduced risk to that of platelet or red cell units",
                    "sub_points": [
                      "Occurs in approximately 1 per 7500 units",
                      "Leading cause of transfusion-related mortality reported to U.S. Food and Drug Administration (FDA)Death occurs in 15%-20% of casesRemaining 80%-85% of cases improve within 48-96 hr",
                      "Death occurs in 15%-20% of cases",
                      "Remaining 80%-85% of cases improve within 48-96 hr",
                      "Risk highest in plasma units historicallyMitigation strategies have reduced risk to that of platelet or red cell units",
                      "Mitigation strategies have reduced risk to that of platelet or red cell units"
                    ]
                  },
                  {
                    "text": "Signs and symptomsRespiratory distress with hypoxemiaDyspneaTachypneaFeverTachycardiaHypotension",
                    "sub_points": [
                      "Respiratory distress with hypoxemia",
                      "Dyspnea",
                      "Tachypnea",
                      "Fever",
                      "Tachycardia",
                      "Hypotension"
                    ]
                  },
                  {
                    "text": "PathophysiologyTRALI is inflammatory pulmonary edemaMechanism not fully understoodDonor antibodies to human leukocyte antigen (HLA) class 1, HLA class 2, or human neutrophil antigen (HNA) reported in most TRALI casesDonor cytokines or bioactive lipids also associated with TRALI reactions\"Two-hit\" hypothesisRecipient leukocytes (neutrophils) are primed to be activated due to patient's preexisting illnessTransfused donor antibodies attach to and activate primed leukocytesImmune complexes between donor antibodies and soluble antigens may also be recognized by Fc receptors on these same leukocytes, leading to similar activationActivated leukocytes release mediators that result in increased permeability of pulmonary microvasculature",
                    "sub_points": [
                      "TRALI is inflammatory pulmonary edemaMechanism not fully understood",
                      "Mechanism not fully understood",
                      "Donor antibodies to human leukocyte antigen (HLA) class 1, HLA class 2, or human neutrophil antigen (HNA) reported in most TRALI cases",
                      "Donor cytokines or bioactive lipids also associated with TRALI reactions",
                      "\"Two-hit\" hypothesisRecipient leukocytes (neutrophils) are primed to be activated due to patient's preexisting illnessTransfused donor antibodies attach to and activate primed leukocytesImmune complexes between donor antibodies and soluble antigens may also be recognized by Fc receptors on these same leukocytes, leading to similar activationActivated leukocytes release mediators that result in increased permeability of pulmonary microvasculature",
                      "Recipient leukocytes (neutrophils) are primed to be activated due to patient's preexisting illness",
                      "Transfused donor antibodies attach to and activate primed leukocytesImmune complexes between donor antibodies and soluble antigens may also be recognized by Fc receptors on these same leukocytes, leading to similar activation",
                      "Immune complexes between donor antibodies and soluble antigens may also be recognized by Fc receptors on these same leukocytes, leading to similar activation",
                      "Activated leukocytes release mediators that result in increased permeability of pulmonary microvasculature"
                    ]
                  },
                  {
                    "text": "DiagnosisTRALI is diagnosed based on clinical and radiographic findings and exclusion of other causesDiagnostic criteriaPresence of acute lung injuryAcute onsetHypoxemia defined as SpO₂ < 90% on room air, PaO₂/FIO₂ < 300, or clinical evidence of hypoxemiaNew or worsening bilateral infiltrates of alveolar or interstitial spaceswithoutcardiomegalyNo evidence of left atrial hypertensionNo preexisting acute lung injury before transfusionSymptoms occur during or within 6 hr of transfusionNo temporal relationship to alternative risk factor for acute lung injuryIf all criteria are met except for presence of temporal relationship to alternative risk factor for acute lung injury, criteria for possible TRALI are metOther clinical findingsFrothy pink secretions on intubationRalesDiminished breath soundsLaboratory findingsTransient leukopeniaNeutropeniaMonocytopeniaHypocomplementemia",
                    "sub_points": [
                      "TRALI is diagnosed based on clinical and radiographic findings and exclusion of other causes",
                      "Diagnostic criteriaPresence of acute lung injuryAcute onsetHypoxemia defined as SpO₂ < 90% on room air, PaO₂/FIO₂ < 300, or clinical evidence of hypoxemiaNew or worsening bilateral infiltrates of alveolar or interstitial spaceswithoutcardiomegalyNo evidence of left atrial hypertensionNo preexisting acute lung injury before transfusionSymptoms occur during or within 6 hr of transfusionNo temporal relationship to alternative risk factor for acute lung injury",
                      "Presence of acute lung injuryAcute onsetHypoxemia defined as SpO₂ < 90% on room air, PaO₂/FIO₂ < 300, or clinical evidence of hypoxemiaNew or worsening bilateral infiltrates of alveolar or interstitial spaceswithoutcardiomegalyNo evidence of left atrial hypertension",
                      "Acute onset",
                      "Hypoxemia defined as SpO₂ < 90% on room air, PaO₂/FIO₂ < 300, or clinical evidence of hypoxemia",
                      "New or worsening bilateral infiltrates of alveolar or interstitial spaceswithoutcardiomegaly",
                      "No evidence of left atrial hypertension",
                      "No preexisting acute lung injury before transfusion",
                      "Symptoms occur during or within 6 hr of transfusion",
                      "No temporal relationship to alternative risk factor for acute lung injury",
                      "If all criteria are met except for presence of temporal relationship to alternative risk factor for acute lung injury, criteria for possible TRALI are met",
                      "Other clinical findingsFrothy pink secretions on intubationRalesDiminished breath sounds",
                      "Frothy pink secretions on intubation",
                      "Rales",
                      "Diminished breath sounds",
                      "Laboratory findingsTransient leukopeniaNeutropeniaMonocytopeniaHypocomplementemia",
                      "Transient leukopenia",
                      "Neutropenia",
                      "Monocytopenia",
                      "Hypocomplementemia"
                    ]
                  },
                  {
                    "text": "Differential diagnosisTransfusion-associatedTransfusion-associated circulatory overload (TACO) is very similar clinicallyAnaphylaxis, sepsis, and hemolysis can have dyspnea and hypoxiaUnderlying medical conditions that can resemble TRALIAspiration pneumoniaToxic inhalationSevere sepsisShockTraumaBurn injuryCardiopulmonary bypass complicationsDrug overdoses",
                    "sub_points": [
                      "Transfusion-associatedTransfusion-associated circulatory overload (TACO) is very similar clinicallyAnaphylaxis, sepsis, and hemolysis can have dyspnea and hypoxia",
                      "Transfusion-associated circulatory overload (TACO) is very similar clinically",
                      "Anaphylaxis, sepsis, and hemolysis can have dyspnea and hypoxia",
                      "Underlying medical conditions that can resemble TRALIAspiration pneumoniaToxic inhalationSevere sepsisShockTraumaBurn injuryCardiopulmonary bypass complicationsDrug overdoses",
                      "Aspiration pneumonia",
                      "Toxic inhalation",
                      "Severe sepsis",
                      "Shock",
                      "Trauma",
                      "Burn injury",
                      "Cardiopulmonary bypass complications",
                      "Drug overdoses"
                    ]
                  },
                  {
                    "text": "Treatment and managementStop transfusion as soon as symptoms developRule out hemolysis by sending transfusion reaction work-upSupport airway and blood pressure with oxygen/mechanical ventilation and pressors if neededQuarantine units from implicated donorInform blood center",
                    "sub_points": [
                      "Stop transfusion as soon as symptoms develop",
                      "Rule out hemolysis by sending transfusion reaction work-up",
                      "Support airway and blood pressure with oxygen/mechanical ventilation and pressors if needed",
                      "Quarantine units from implicated donorInform blood center",
                      "Inform blood center"
                    ]
                  },
                  {
                    "text": "PreventionDonor of suspected TRALI reaction should be tested for HLA or HNA antibodies and compared with patientPresence of anti-HLA antibodies in donor and presence of cognate HLA antigen in recipient support clinical diagnosis of TRALIDonor should be deferred from plasma/platelet donations if positive for HLA/HNA antibodiesReduce TRALI risk in generalUse predominantly male plasma donorsUse predominantly male platelet donorsUse female donors who have no pregnancy history or test negative for HLA/HNA antibodiesUse platelet additive solutionsMost recent American Associations of Blood Banks (AABB) Standards require implementation of TRALI mitigation strategiesAABB Standard 5.4.1.2 states: “Plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies”",
                    "sub_points": [
                      "Donor of suspected TRALI reaction should be tested for HLA or HNA antibodies and compared with patientPresence of anti-HLA antibodies in donor and presence of cognate HLA antigen in recipient support clinical diagnosis of TRALIDonor should be deferred from plasma/platelet donations if positive for HLA/HNA antibodies",
                      "Presence of anti-HLA antibodies in donor and presence of cognate HLA antigen in recipient support clinical diagnosis of TRALI",
                      "Donor should be deferred from plasma/platelet donations if positive for HLA/HNA antibodies",
                      "Reduce TRALI risk in generalUse predominantly male plasma donorsUse predominantly male platelet donorsUse female donors who have no pregnancy history or test negative for HLA/HNA antibodiesUse platelet additive solutions",
                      "Use predominantly male plasma donors",
                      "Use predominantly male platelet donors",
                      "Use female donors who have no pregnancy history or test negative for HLA/HNA antibodies",
                      "Use platelet additive solutions",
                      "Most recent American Associations of Blood Banks (AABB) Standards require implementation of TRALI mitigation strategiesAABB Standard 5.4.1.2 states: “Plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies”",
                      "AABB Standard 5.4.1.2 states: “Plasma and whole blood for allogeneic transfusion shall be from males, females who have not been pregnant, or females who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies”"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Allergic Transfusion Reactions": {
            "name": "Allergic Transfusion Reactions",
            "url": "https://app.pathprimer.com/document/3200983c-7eae-4f42-a989-f0924fc786a3/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Risk of allergic reaction differs by blood product used, but occurs at rate of about 1 in 100 units overall"
                  },
                  {
                    "text": "Occurs due to interaction between blood proteins and recipient IgE molecules"
                  },
                  {
                    "text": "Treated with standard allergy medications (e.g., antihistamines)"
                  }
                ]
              },
              "OVERVIEW": {
                "Allergic Transfusion Reactions Very Common; Can Occur With Any Blood Product": [
                  {
                    "text": "Clinical featuresIncidenceRisk differs by blood product used, but occurs at rate of about 1 in 100 units overallRed blood cells (RBCs): 0.03-0.1%Platelets: 0.3-6%Plasma: 1-3%Risk of anaphylaxis is less common1 in 20,000-47,000 unitsRisk in IgA-deficient patients: 1 in 50,000Signs and symptomsCan occur up to 2-3 hours after transfusionMild allergy: Itching (pruritus), hives (urticaria), flushing (erythema), angioedemaSevere allergy: Upper/lower airway obstruction (wheezing, hoarseness, stridor), dyspnea, profound hypotension, tachycardia, arrhythmias, cardiac arrestDiagnosisBased mainly on symptoms and timing with transfusionUnexpected severe allergic reactions may signify IgA deficiency (found in 1 in 200 individuals)Tests for IgA levels and anti-IgA can be doneUnexpected severe allergic reactions may signify deficiency in C3, C4, or haptoglobinTesting for plasma levels of haptoglobin, C3, or C4 can be done",
                    "sub_points": [
                      "IncidenceRisk differs by blood product used, but occurs at rate of about 1 in 100 units overallRed blood cells (RBCs): 0.03-0.1%Platelets: 0.3-6%Plasma: 1-3%Risk of anaphylaxis is less common1 in 20,000-47,000 unitsRisk in IgA-deficient patients: 1 in 50,000",
                      "Risk differs by blood product used, but occurs at rate of about 1 in 100 units overallRed blood cells (RBCs): 0.03-0.1%Platelets: 0.3-6%Plasma: 1-3%",
                      "Red blood cells (RBCs): 0.03-0.1%",
                      "Platelets: 0.3-6%",
                      "Plasma: 1-3%",
                      "Risk of anaphylaxis is less common1 in 20,000-47,000 unitsRisk in IgA-deficient patients: 1 in 50,000",
                      "1 in 20,000-47,000 units",
                      "Risk in IgA-deficient patients: 1 in 50,000",
                      "Signs and symptomsCan occur up to 2-3 hours after transfusionMild allergy: Itching (pruritus), hives (urticaria), flushing (erythema), angioedemaSevere allergy: Upper/lower airway obstruction (wheezing, hoarseness, stridor), dyspnea, profound hypotension, tachycardia, arrhythmias, cardiac arrest",
                      "Can occur up to 2-3 hours after transfusion",
                      "Mild allergy: Itching (pruritus), hives (urticaria), flushing (erythema), angioedema",
                      "Severe allergy: Upper/lower airway obstruction (wheezing, hoarseness, stridor), dyspnea, profound hypotension, tachycardia, arrhythmias, cardiac arrest",
                      "DiagnosisBased mainly on symptoms and timing with transfusionUnexpected severe allergic reactions may signify IgA deficiency (found in 1 in 200 individuals)Tests for IgA levels and anti-IgA can be doneUnexpected severe allergic reactions may signify deficiency in C3, C4, or haptoglobinTesting for plasma levels of haptoglobin, C3, or C4 can be done",
                      "Based mainly on symptoms and timing with transfusion",
                      "Unexpected severe allergic reactions may signify IgA deficiency (found in 1 in 200 individuals)Tests for IgA levels and anti-IgA can be done",
                      "Tests for IgA levels and anti-IgA can be done",
                      "Unexpected severe allergic reactions may signify deficiency in C3, C4, or haptoglobinTesting for plasma levels of haptoglobin, C3, or C4 can be done",
                      "Testing for plasma levels of haptoglobin, C3, or C4 can be done"
                    ]
                  },
                  {
                    "text": "PathophysiologyType 1 hypersensitivity reaction to component in blood product (likely in plasma of a unit)Offending protein (whatever it is) binds to IgE molecules on mast cells and basophils, leading to release of histamines, cytokines, and chemokinesIgA deficiency85-90% of IgA-deficient individuals are asymptomatic; its relationship with anaphylaxis remains somewhat unclearAbsolute vs. relative deficiency: IgA-deficient patients can have either very low IgA levels that standard tests cannot detect (relative deficiency) or essentially no IgA (absolute deficiency, defined as < 0.05 mg/dl)Recent retrospective studies suggest that both absolute and relative IgA deficiency patients can be at risk for severe allergic reactionsHaptoglobin deficiencyCan be seen in Japanese populations",
                    "sub_points": [
                      "Type 1 hypersensitivity reaction to component in blood product (likely in plasma of a unit)Offending protein (whatever it is) binds to IgE molecules on mast cells and basophils, leading to release of histamines, cytokines, and chemokinesIgA deficiency85-90% of IgA-deficient individuals are asymptomatic; its relationship with anaphylaxis remains somewhat unclearAbsolute vs. relative deficiency: IgA-deficient patients can have either very low IgA levels that standard tests cannot detect (relative deficiency) or essentially no IgA (absolute deficiency, defined as < 0.05 mg/dl)Recent retrospective studies suggest that both absolute and relative IgA deficiency patients can be at risk for severe allergic reactionsHaptoglobin deficiencyCan be seen in Japanese populations",
                      "Offending protein (whatever it is) binds to IgE molecules on mast cells and basophils, leading to release of histamines, cytokines, and chemokines",
                      "IgA deficiency85-90% of IgA-deficient individuals are asymptomatic; its relationship with anaphylaxis remains somewhat unclearAbsolute vs. relative deficiency: IgA-deficient patients can have either very low IgA levels that standard tests cannot detect (relative deficiency) or essentially no IgA (absolute deficiency, defined as < 0.05 mg/dl)Recent retrospective studies suggest that both absolute and relative IgA deficiency patients can be at risk for severe allergic reactions",
                      "85-90% of IgA-deficient individuals are asymptomatic; its relationship with anaphylaxis remains somewhat unclear",
                      "Absolute vs. relative deficiency: IgA-deficient patients can have either very low IgA levels that standard tests cannot detect (relative deficiency) or essentially no IgA (absolute deficiency, defined as < 0.05 mg/dl)",
                      "Recent retrospective studies suggest that both absolute and relative IgA deficiency patients can be at risk for severe allergic reactions",
                      "Haptoglobin deficiencyCan be seen in Japanese populations",
                      "Can be seen in Japanese populations"
                    ]
                  },
                  {
                    "text": "Treatment and preventionTreatment of mild allergyStop transfusion and administer diphenhydramine or other antihistamineAfter mild symptoms resolve, okay to continue transfusionTreatment of moderate/severe allergyStop transfusionSupport airwayIntubation may be requiredBlood pressure (pressors may be needed)With severe reactionsAdminister diphenhydramine (or other antihistamine) and oral/IV steroids, if necessaryWith anaphylaxisUrgently administer epinephrine (0.01 mg/kg) up to every 5 minutes as long as symptoms continuePreventionPlasma reduction or washing of blood products does reduce incidence of allergic reactionsIgA-deficient products can be used for IgA-deficient patients (specifically for plasma needs)Prophylactic use of antihistamines or steroids have not been shown to reduce incidence of allergic transfusion symptoms",
                    "sub_points": [
                      "Treatment of mild allergyStop transfusion and administer diphenhydramine or other antihistamineAfter mild symptoms resolve, okay to continue transfusion",
                      "Stop transfusion and administer diphenhydramine or other antihistamine",
                      "After mild symptoms resolve, okay to continue transfusion",
                      "Treatment of moderate/severe allergyStop transfusionSupport airwayIntubation may be requiredBlood pressure (pressors may be needed)With severe reactionsAdminister diphenhydramine (or other antihistamine) and oral/IV steroids, if necessaryWith anaphylaxisUrgently administer epinephrine (0.01 mg/kg) up to every 5 minutes as long as symptoms continue",
                      "Stop transfusion",
                      "Support airwayIntubation may be requiredBlood pressure (pressors may be needed)",
                      "Intubation may be required",
                      "Blood pressure (pressors may be needed)",
                      "With severe reactionsAdminister diphenhydramine (or other antihistamine) and oral/IV steroids, if necessary",
                      "Administer diphenhydramine (or other antihistamine) and oral/IV steroids, if necessary",
                      "With anaphylaxisUrgently administer epinephrine (0.01 mg/kg) up to every 5 minutes as long as symptoms continue",
                      "Urgently administer epinephrine (0.01 mg/kg) up to every 5 minutes as long as symptoms continue",
                      "PreventionPlasma reduction or washing of blood products does reduce incidence of allergic reactionsIgA-deficient products can be used for IgA-deficient patients (specifically for plasma needs)Prophylactic use of antihistamines or steroids have not been shown to reduce incidence of allergic transfusion symptoms",
                      "Plasma reduction or washing of blood products does reduce incidence of allergic reactions",
                      "IgA-deficient products can be used for IgA-deficient patients (specifically for plasma needs)",
                      "Prophylactic use of antihistamines or steroids have not been shown to reduce incidence of allergic transfusion symptoms"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Transfusion-Associated Cardiac Overload": {
            "name": "Transfusion-Associated Cardiac Overload",
            "url": "https://app.pathprimer.com/document/52d362c0-7b91-43b0-a91d-ee47ed0f0d70/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "TACO is due to inability of recipient to compensate for volume of transfused product"
                  },
                  {
                    "text": "Cardiogenic form of pulmonary edema"
                  },
                  {
                    "text": "Reaction is highly underreported and may be most common transfusion reaction"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-associated cardiac overload is due to inability of the recipient to compensate for the volume of a transfused product; it is highly underreported and may be the most common transfusion reaction": [
                  {
                    "text": "IncidenceOccurs at an estimated rate of 1-8 per 100 unitsMay be more common in very young or elderly patients and patients with previously documented heart diseaseIs highly underreportedResponsible for 20%-30% of transfusion-related fatalities",
                    "sub_points": [
                      "Occurs at an estimated rate of 1-8 per 100 unitsMay be more common in very young or elderly patients and patients with previously documented heart diseaseIs highly underreported",
                      "May be more common in very young or elderly patients and patients with previously documented heart disease",
                      "Is highly underreported",
                      "Responsible for 20%-30% of transfusion-related fatalities"
                    ]
                  },
                  {
                    "text": "Signs and symptomsOccurs during or up to 6 hr after transfusionDyspneaOrthopneaCoughChest tightnessHypoxia &/or cyanosisHypertensionWidened pulse pressureHeadacheCongestive heart failure",
                    "sub_points": [
                      "Occurs during or up to 6 hr after transfusion",
                      "Dyspnea",
                      "Orthopnea",
                      "Cough",
                      "Chest tightness",
                      "Hypoxia &/or cyanosis",
                      "Hypertension",
                      "Widened pulse pressure",
                      "Headache",
                      "Congestive heart failure"
                    ]
                  },
                  {
                    "text": "PathophysiologyCardiogenic pulmonary edemaFluid backs up in lungs when left heart cannot pump transfused fluid out to aorta fast enoughCaused by transfused product having too much volume or being infused too fast",
                    "sub_points": [
                      "Cardiogenic pulmonary edemaFluid backs up in lungs when left heart cannot pump transfused fluid out to aorta fast enoughCaused by transfused product having too much volume or being infused too fast",
                      "Fluid backs up in lungs when left heart cannot pump transfused fluid out to aorta fast enough",
                      "Caused by transfused product having too much volume or being infused too fast"
                    ]
                  },
                  {
                    "text": "DiagnosisPhysical examinationLung crackles/ralesElevated jugular venous pressure (JVP)Audible S₃ gallopRadiologyNew/worsening alveolar or interstitial edemaKerley B linesPleural effusionsCardiomegalyEvidence of left heart failureLaboratory testsN-terminal prohormone brain natriuretic protein (NT-proBNP) may be elevatedClinical historyEvidence of positive fluid balanceRenal diseaseKnown heart diseaseResponse to therapyPatient has documented improvement after use of diuretics",
                    "sub_points": [
                      "Physical examinationLung crackles/ralesElevated jugular venous pressure (JVP)Audible S₃ gallop",
                      "Lung crackles/rales",
                      "Elevated jugular venous pressure (JVP)",
                      "Audible S₃ gallop",
                      "RadiologyNew/worsening alveolar or interstitial edemaKerley B linesPleural effusionsCardiomegalyEvidence of left heart failure",
                      "New/worsening alveolar or interstitial edema",
                      "Kerley B lines",
                      "Pleural effusions",
                      "Cardiomegaly",
                      "Evidence of left heart failure",
                      "Laboratory testsN-terminal prohormone brain natriuretic protein (NT-proBNP) may be elevated",
                      "N-terminal prohormone brain natriuretic protein (NT-proBNP) may be elevated",
                      "Clinical historyEvidence of positive fluid balanceRenal diseaseKnown heart disease",
                      "Evidence of positive fluid balance",
                      "Renal disease",
                      "Known heart disease",
                      "Response to therapyPatient has documented improvement after use of diuretics",
                      "Patient has documented improvement after use of diuretics"
                    ]
                  },
                  {
                    "text": "Differential diagnosisTransfusion-related acute lung injury (TRALI) and transfusion-associated cardiac overload (TACO) are clinically very similarSepsis, anaphylaxis, and intravascular hemolysis can also have symptoms of respiratory distress",
                    "sub_points": [
                      "Transfusion-related acute lung injury (TRALI) and transfusion-associated cardiac overload (TACO) are clinically very similar",
                      "Sepsis, anaphylaxis, and intravascular hemolysis can also have symptoms of respiratory distress"
                    ]
                  },
                  {
                    "text": "ManagementImmediately stop transfusionRule out hemolysis with blood bank work-upSupport airway via oxygen supplementation or intubation if necessaryDiuretics to remove excess fluid",
                    "sub_points": [
                      "Immediately stop transfusion",
                      "Rule out hemolysis with blood bank work-up",
                      "Support airway via oxygen supplementation or intubation if necessary",
                      "Diuretics to remove excess fluid"
                    ]
                  },
                  {
                    "text": "PreventionTransfuse blood products as slowly as possible (infuse 1 product over 4 hr)Split future blood products into 2, and infuse each over 4 hr",
                    "sub_points": [
                      "Transfuse blood products as slowly as possible (infuse 1 product over 4 hr)",
                      "Split future blood products into 2, and infuse each over 4 hr"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Transfusion-Associated Graft-vs.-Host Disease": {
            "name": "Transfusion-Associated Graft-vs.-Host Disease",
            "url": "https://app.pathprimer.com/document/bf0a9d54-29ca-4952-a2ec-06802c7eb2d1/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "TA-GVHD is rare, severe, delayed transfusion reaction that is universally fatal"
                  },
                  {
                    "text": "Prevention is via irradiation or pathogen inactivation of cellular blood products"
                  }
                ]
              },
              "OVERVIEW": {
                "Transfusion-associated graft-vs.-host disease (TA-GVHD) is a rare, but severe delayed transfusion reaction": [
                  {
                    "text": "IncidenceTA-GVHD is rare but almost universally fatalIn adults, death occurs within 3 weeks of symptom onset in > 95% of cases",
                    "sub_points": [
                      "TA-GVHD is rare but almost universally fatal",
                      "In adults, death occurs within 3 weeks of symptom onset in > 95% of cases"
                    ]
                  },
                  {
                    "text": "PathophysiologyCaused by persistence and activity of incompatible donor allogeneic white cells in transfusion recipients after transfusion of cellular blood productSusceptible individuals are unable to recognize and destroy foreign transfused white cells from circulation for the following reasonsSevere immunosuppressionPlanned or inadvertent human leukocyte antigen (HLA) matching of transfused productIncompatible white cells mount immune response against host similar to that of acute GVHDPhase 1: Conditioning phaseInherent underlying tissue damage in patient leads to cytokine/inflammatory-rich environmentPhase 2: Afferent phaseForeign antigen presentation by host tissues leads to donor T-cell activation, differentiation, and proliferationPhase 3: Efferent phaseActivated donor T cells destroy host tissues due to HLA incompatibility between host and transfused T cells",
                    "sub_points": [
                      "Caused by persistence and activity of incompatible donor allogeneic white cells in transfusion recipients after transfusion of cellular blood productSusceptible individuals are unable to recognize and destroy foreign transfused white cells from circulation for the following reasonsSevere immunosuppressionPlanned or inadvertent human leukocyte antigen (HLA) matching of transfused product",
                      "Susceptible individuals are unable to recognize and destroy foreign transfused white cells from circulation for the following reasonsSevere immunosuppressionPlanned or inadvertent human leukocyte antigen (HLA) matching of transfused product",
                      "Severe immunosuppression",
                      "Planned or inadvertent human leukocyte antigen (HLA) matching of transfused product",
                      "Incompatible white cells mount immune response against host similar to that of acute GVHDPhase 1: Conditioning phaseInherent underlying tissue damage in patient leads to cytokine/inflammatory-rich environmentPhase 2: Afferent phaseForeign antigen presentation by host tissues leads to donor T-cell activation, differentiation, and proliferationPhase 3: Efferent phaseActivated donor T cells destroy host tissues due to HLA incompatibility between host and transfused T cells",
                      "Phase 1: Conditioning phaseInherent underlying tissue damage in patient leads to cytokine/inflammatory-rich environment",
                      "Inherent underlying tissue damage in patient leads to cytokine/inflammatory-rich environment",
                      "Phase 2: Afferent phaseForeign antigen presentation by host tissues leads to donor T-cell activation, differentiation, and proliferation",
                      "Foreign antigen presentation by host tissues leads to donor T-cell activation, differentiation, and proliferation",
                      "Phase 3: Efferent phaseActivated donor T cells destroy host tissues due to HLA incompatibility between host and transfused T cells",
                      "Activated donor T cells destroy host tissues due to HLA incompatibility between host and transfused T cells"
                    ]
                  },
                  {
                    "text": "Signs and symptoms begin 2 days to 6 weeks after offending transfusionClinical syndrome: Skin, gastrointestinal (GI) system, liver, bone marrow all involvedFever/chillsMaculopapular rash/erythemaUsually starts on face and trunk and spreads to extremitiesHepatomegalyJaundiceDiarrheaNausea/emesisPostoperative erythrodermaVariant of TA-GVHD (less severe)Seen in JapanManifests as erythema in immunocompetent patient who received blood products that are inadvertently highly HLA similarLaboratory findingsLiver dysfunctionElevated aspartate aminotransferase (AST)Elevated alanine aminotransferase (ALT)PancytopeniaCan lead to bleeding, sepsis, and multiorgan failure when severeClassic GVHD findings on skin or liver biopsy",
                    "sub_points": [
                      "Clinical syndrome: Skin, gastrointestinal (GI) system, liver, bone marrow all involvedFever/chillsMaculopapular rash/erythemaUsually starts on face and trunk and spreads to extremitiesHepatomegalyJaundiceDiarrheaNausea/emesisPostoperative erythrodermaVariant of TA-GVHD (less severe)Seen in JapanManifests as erythema in immunocompetent patient who received blood products that are inadvertently highly HLA similar",
                      "Fever/chills",
                      "Maculopapular rash/erythemaUsually starts on face and trunk and spreads to extremities",
                      "Usually starts on face and trunk and spreads to extremities",
                      "Hepatomegaly",
                      "Jaundice",
                      "Diarrhea",
                      "Nausea/emesis",
                      "Postoperative erythrodermaVariant of TA-GVHD (less severe)Seen in JapanManifests as erythema in immunocompetent patient who received blood products that are inadvertently highly HLA similar",
                      "Variant of TA-GVHD (less severe)",
                      "Seen in Japan",
                      "Manifests as erythema in immunocompetent patient who received blood products that are inadvertently highly HLA similar",
                      "Laboratory findingsLiver dysfunctionElevated aspartate aminotransferase (AST)Elevated alanine aminotransferase (ALT)PancytopeniaCan lead to bleeding, sepsis, and multiorgan failure when severeClassic GVHD findings on skin or liver biopsy",
                      "Liver dysfunctionElevated aspartate aminotransferase (AST)Elevated alanine aminotransferase (ALT)",
                      "Elevated aspartate aminotransferase (AST)",
                      "Elevated alanine aminotransferase (ALT)",
                      "PancytopeniaCan lead to bleeding, sepsis, and multiorgan failure when severe",
                      "Can lead to bleeding, sepsis, and multiorgan failure when severe",
                      "Classic GVHD findings on skin or liver biopsy"
                    ]
                  },
                  {
                    "text": "DiagnosisPresence of clinical and laboratory findings consistent with GVHDDonor lymphocyte DNA (polymerase chain [PCR]-based HLA typing) in patient's peripheral blood or tissue biopsy can confirm diagnosis",
                    "sub_points": [
                      "Presence of clinical and laboratory findings consistent with GVHD",
                      "Donor lymphocyte DNA (polymerase chain [PCR]-based HLA typing) in patient's peripheral blood or tissue biopsy can confirm diagnosis"
                    ]
                  },
                  {
                    "text": "Differential diagnosisActual GVHDSevere viral infectionAdverse drug reaction",
                    "sub_points": [
                      "Actual GVHD",
                      "Severe viral infection",
                      "Adverse drug reaction"
                    ]
                  },
                  {
                    "text": "TreatmentLargely palliativeMost treatments unsuccessfulTA-GVHD is nearly 100% fatal",
                    "sub_points": [
                      "Largely palliative",
                      "Most treatments unsuccessfulTA-GVHD is nearly 100% fatal",
                      "TA-GVHD is nearly 100% fatal"
                    ]
                  },
                  {
                    "text": "PreventionKey to prevention is recognition of at-risk populationsPrevention for individuals at riskIrradiation of blood productsPathogen inactivation of blood products (if available)Risk factors for TA-GVHDBlood product ageYounger blood products have more viable white cellsWhite cell doseProducts that are not leukocyte reduced may provide greater riskBlood product typeAll cellular products (not fresh frozen plasma [FFP]) can cause TA-GVHDGranulocyte products have greatest risk, as they are given fresh and have (intentionally) high white cell countDirected donor products have higher risk because of HLA similarity with recipientPatient susceptibility: Patient populations at increased risk that should receive irradiated productsPatients with congenital immunodeficiency syndromesStem cell transplant candidate or recipientPatients with Hodgkin or non-Hodgkin lymphomasPatients with aplastic anemia on ATGPatients on purine analogue (fludarabine) or anti-CD52 (alemtuzumab) medicationsPremature or low-birth-weight infantsChildren with congenital heart diseases (if secondary to DiGeorge syndrome)",
                    "sub_points": [
                      "Key to prevention is recognition of at-risk populations",
                      "Prevention for individuals at riskIrradiation of blood productsPathogen inactivation of blood products (if available)",
                      "Irradiation of blood products",
                      "Pathogen inactivation of blood products (if available)",
                      "Risk factors for TA-GVHDBlood product ageYounger blood products have more viable white cellsWhite cell doseProducts that are not leukocyte reduced may provide greater riskBlood product typeAll cellular products (not fresh frozen plasma [FFP]) can cause TA-GVHDGranulocyte products have greatest risk, as they are given fresh and have (intentionally) high white cell countDirected donor products have higher risk because of HLA similarity with recipientPatient susceptibility: Patient populations at increased risk that should receive irradiated productsPatients with congenital immunodeficiency syndromesStem cell transplant candidate or recipientPatients with Hodgkin or non-Hodgkin lymphomasPatients with aplastic anemia on ATGPatients on purine analogue (fludarabine) or anti-CD52 (alemtuzumab) medicationsPremature or low-birth-weight infantsChildren with congenital heart diseases (if secondary to DiGeorge syndrome)",
                      "Blood product ageYounger blood products have more viable white cells",
                      "Younger blood products have more viable white cells",
                      "White cell doseProducts that are not leukocyte reduced may provide greater risk",
                      "Products that are not leukocyte reduced may provide greater risk",
                      "Blood product typeAll cellular products (not fresh frozen plasma [FFP]) can cause TA-GVHDGranulocyte products have greatest risk, as they are given fresh and have (intentionally) high white cell countDirected donor products have higher risk because of HLA similarity with recipient",
                      "All cellular products (not fresh frozen plasma [FFP]) can cause TA-GVHD",
                      "Granulocyte products have greatest risk, as they are given fresh and have (intentionally) high white cell count",
                      "Directed donor products have higher risk because of HLA similarity with recipient",
                      "Patient susceptibility: Patient populations at increased risk that should receive irradiated productsPatients with congenital immunodeficiency syndromesStem cell transplant candidate or recipientPatients with Hodgkin or non-Hodgkin lymphomasPatients with aplastic anemia on ATGPatients on purine analogue (fludarabine) or anti-CD52 (alemtuzumab) medicationsPremature or low-birth-weight infantsChildren with congenital heart diseases (if secondary to DiGeorge syndrome)",
                      "Patients with congenital immunodeficiency syndromes",
                      "Stem cell transplant candidate or recipient",
                      "Patients with Hodgkin or non-Hodgkin lymphomas",
                      "Patients with aplastic anemia on ATG",
                      "Patients on purine analogue (fludarabine) or anti-CD52 (alemtuzumab) medications",
                      "Premature or low-birth-weight infants",
                      "Children with congenital heart diseases (if secondary to DiGeorge syndrome)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Posttransfusion Purpura": {
            "name": "Posttransfusion Purpura",
            "url": "https://app.pathprimer.com/document/079c0474-5b01-461e-89c0-f18e51636fae/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Posttransfusion purpura (PTP) is a rare delayed transfusion reaction that causes a profound thrombocytopenia"
                  },
                  {
                    "text": "After 2-14 days from a transfusion, anti-HPA-1a (or other HPA antibody) leads to destruction of both transfused (alloimmune) and native (autoimmune) platelets"
                  }
                ]
              },
              "OVERVIEW": {
                "Rare Delayed Transfusion Reaction That Causes Profound Thrombocytopenia": [
                  {
                    "text": "IncidencePosttransfusion purpura (PTP) most commonly occurs in previously pregnant womenRisk is 1 in 50,000-100,000 units",
                    "sub_points": [
                      "Posttransfusion purpura (PTP) most commonly occurs in previously pregnant women",
                      "Risk is 1 in 50,000-100,000 units"
                    ]
                  },
                  {
                    "text": "PathophysiologyPatient who has previously formed a platelet alloantibody (most commonly anti-HPA-1a) is re-exposed to the antigen via a blood product (red cell, plasma, or platelet product)Same alloantibody that can cause neonatal alloimmune thrombocytopenia (NAIT)In 2-14 days posttransfusion, anti-HPA-1a (or other HPA antibody) increases in titer and begins to remove any incompatible platelets from circulationAllo-anti-HPA-1a also gains ability to remove patient's own platelets (becomes an autoantibody of sorts) by an unclear mechanismAntibody cross-reacts with autologous platelets; or, donor-derived incompatible HPA-1a is adsorbed on to autologous platelets; or, reactivated anti-HPA-1a has an autoimmune component",
                    "sub_points": [
                      "Patient who has previously formed a platelet alloantibody (most commonly anti-HPA-1a) is re-exposed to the antigen via a blood product (red cell, plasma, or platelet product)Same alloantibody that can cause neonatal alloimmune thrombocytopenia (NAIT)",
                      "Same alloantibody that can cause neonatal alloimmune thrombocytopenia (NAIT)",
                      "In 2-14 days posttransfusion, anti-HPA-1a (or other HPA antibody) increases in titer and begins to remove any incompatible platelets from circulation",
                      "Allo-anti-HPA-1a also gains ability to remove patient's own platelets (becomes an autoantibody of sorts) by an unclear mechanismAntibody cross-reacts with autologous platelets; or, donor-derived incompatible HPA-1a is adsorbed on to autologous platelets; or, reactivated anti-HPA-1a has an autoimmune component",
                      "Antibody cross-reacts with autologous platelets; or, donor-derived incompatible HPA-1a is adsorbed on to autologous platelets; or, reactivated anti-HPA-1a has an autoimmune component"
                    ]
                  },
                  {
                    "text": "Signs and symptomsSymptoms start to develop 2-14 days after offending transfusionFebrile nonhemolytic transfusion reaction often occurs with offending transfusionSymptoms can includePurpuric rashBruisingMucosal bleedingRisk of major bleeding is 30%Risk of death is 10%",
                    "sub_points": [
                      "Symptoms start to develop 2-14 days after offending transfusionFebrile nonhemolytic transfusion reaction often occurs with offending transfusion",
                      "Febrile nonhemolytic transfusion reaction often occurs with offending transfusion",
                      "Symptoms can includePurpuric rashBruisingMucosal bleeding",
                      "Purpuric rash",
                      "Bruising",
                      "Mucosal bleeding",
                      "Risk of major bleeding is 30%",
                      "Risk of death is 10%"
                    ]
                  },
                  {
                    "text": "DiagnosisPlatelet count reveals a profound thrombocytopenia (< 10,000/uL)Patient testing reveals antibodies to platelet antigens (anti-HPA-1a most common, but many others have been reported)Patient testing reveals that these antibodies are alloantibodies, as they differ from patient's phenotype (using HPA molecular genotyping)",
                    "sub_points": [
                      "Platelet count reveals a profound thrombocytopenia (< 10,000/uL)",
                      "Patient testing reveals antibodies to platelet antigens (anti-HPA-1a most common, but many others have been reported)",
                      "Patient testing reveals that these antibodies are alloantibodies, as they differ from patient's phenotype (using HPA molecular genotyping)"
                    ]
                  },
                  {
                    "text": "Differential diagnosisCan mimic other immune thrombocytopenias: Autoimmune thrombocytopenia, drug-induced thrombocytopenia, disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia (HIT), or thrombotic thrombocytopenic purpura (TTP)",
                    "sub_points": [
                      "Can mimic other immune thrombocytopenias: Autoimmune thrombocytopenia, drug-induced thrombocytopenia, disseminated intravascular coagulation (DIC), heparin-induced thrombocytopenia (HIT), or thrombotic thrombocytopenic purpura (TTP)"
                    ]
                  },
                  {
                    "text": "TreatmentEven without treatment, disease is self-limited and platelet count recovers in about 21 daysPrimary treatment is high-dose intravenous immunoglobulin (IVIG), with or without steroids85% respond to this treatment in 3-5 daysSteroids alone are ineffectiveSplenectomy can be used in refractory casesPlatelets that lack offending antigen have been tried, but the autoantibody properties of PTP (described in pathophysiology) lead to decreased survival of these platelets",
                    "sub_points": [
                      "Even without treatment, disease is self-limited and platelet count recovers in about 21 days",
                      "Primary treatment is high-dose intravenous immunoglobulin (IVIG), with or without steroids85% respond to this treatment in 3-5 daysSteroids alone are ineffective",
                      "85% respond to this treatment in 3-5 days",
                      "Steroids alone are ineffective",
                      "Splenectomy can be used in refractory cases",
                      "Platelets that lack offending antigen have been tried, but the autoantibody properties of PTP (described in pathophysiology) lead to decreased survival of these platelets"
                    ]
                  },
                  {
                    "text": "PreventionUniversal leukoreduction of blood products may be helpfulRecurrence of PTP is rare",
                    "sub_points": [
                      "Universal leukoreduction of blood products may be helpful",
                      "Recurrence of PTP is rare"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Iron Overload": {
            "name": "Iron Overload",
            "url": "https://app.pathprimer.com/document/b00d25b1-b9bd-4396-8c4b-0ca4970496e6/lesson/aa715dff-d73d-43ea-8e46-ac7f6f50b0d3",
            "content": {
              "OVERVIEW": {
                "General Information": [
                  {
                    "text": "Iron overload can be primary or secondaryPrimary: Disorders include hemochromatosis and β-thalassemiaSecondary: Seen in patients requiring chronic transfusion (i.e., sickle cell anemia, β-thalassemia major, myelodysplastic syndrome)Secondary iron overload may be seen after transfusion of > 50-100 units of packed red blood cells (PRBC)",
                    "sub_points": [
                      "Primary: Disorders include hemochromatosis and β-thalassemia",
                      "Secondary: Seen in patients requiring chronic transfusion (i.e., sickle cell anemia, β-thalassemia major, myelodysplastic syndrome)Secondary iron overload may be seen after transfusion of > 50-100 units of packed red blood cells (PRBC)",
                      "Secondary iron overload may be seen after transfusion of > 50-100 units of packed red blood cells (PRBC)"
                    ]
                  },
                  {
                    "text": "Iron is absorbed at rates of 1-2 mg/day"
                  },
                  {
                    "text": "Chronic transfusion leads to increased iron infusion, which the body is unable to excrete"
                  },
                  {
                    "text": "Hepcidin regulates iron hemostasis by binding iron to prevent its transport into plasma, causing iron degradation"
                  },
                  {
                    "text": "Iron overload secondary to transfusion may cause significant morbidity"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemoglobin (Hb)"
                  },
                  {
                    "text": "Iron (Fe)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Iron Homeostasis": [
                  {
                    "text": "Hepcidin is primary regulator of iron homeostasisIncreased hepcidin levels lead to decreased iron absorption from gastrointestinal tract and decreased release of iron from macrophagesHepcidin binds to ferroportin (iron export protein found on duodenal enterocytes and macrophages), causing internalization and degradationHepcidin is regulated by iron levels, hypoxia, inflammation, and erythropoiesis",
                    "sub_points": [
                      "Increased hepcidin levels lead to decreased iron absorption from gastrointestinal tract and decreased release of iron from macrophages",
                      "Hepcidin binds to ferroportin (iron export protein found on duodenal enterocytes and macrophages), causing internalization and degradation",
                      "Hepcidin is regulated by iron levels, hypoxia, inflammation, and erythropoiesis"
                    ]
                  },
                  {
                    "text": "Normally, iron circulates bound to transferrin or ferritin"
                  },
                  {
                    "text": "Non-transferrin-bound iron accumulates with decreased hepcidin levels and excess transfused iron"
                  },
                  {
                    "text": "Excess non-transferrin-bound iron leads to generation of free radicals and end organ damage"
                  }
                ]
              },
              "BLOOD COMPONENTS": {
                "Packed Red Blood Cells": [
                  {
                    "text": "PRBCs contain 200-250 mg of iron"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Features": [
                  {
                    "text": "Effects of iron deposition in organsCardiomyopathyArrhythmiasDiabetesLiver dysfunction (cirrhosis)ArthropathyHypothyroidism",
                    "sub_points": [
                      "Cardiomyopathy",
                      "Arrhythmias",
                      "Diabetes",
                      "Liver dysfunction (cirrhosis)",
                      "Arthropathy",
                      "Hypothyroidism"
                    ]
                  }
                ],
                "Diagnosis": [
                  {
                    "text": "Measure ferritin levels"
                  },
                  {
                    "text": "MRI of heart and liver"
                  },
                  {
                    "text": "Liver biopsy"
                  }
                ],
                "Management": [
                  {
                    "text": "Primary iron overload treatment: Therapeutic phlebotomy"
                  },
                  {
                    "text": "Secondary iron overload treatment: Iron chelation therapyOralDeferasiroxDeferiproneParenteralDeferoxamine",
                    "sub_points": [
                      "OralDeferasiroxDeferiprone",
                      "Deferasirox",
                      "Deferiprone",
                      "ParenteralDeferoxamine",
                      "Deferoxamine"
                    ]
                  }
                ],
                "General": [
                  {
                    "text": "Total body iron in average man: 3-3.5 g"
                  },
                  {
                    "text": "Body iron supplies are used to make hemoglobin"
                  },
                  {
                    "text": "Daily iron absorption (to meet iron replacement needs): 1-2 mg"
                  },
                  {
                    "text": "No mechanism exists for iron excretion"
                  }
                ],
                "Patients at Risk Due to Transfusion": [
                  {
                    "text": "Sickle cell anemia"
                  },
                  {
                    "text": "Thalassemia"
                  },
                  {
                    "text": "Other chronically transfused patientsMyelodysplastic syndromeAplastic anemiaHemolytic anemia",
                    "sub_points": [
                      "Myelodysplastic syndrome",
                      "Aplastic anemia",
                      "Hemolytic anemia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Autoimmune Hemolytic Anemias": {
        "name": "Autoimmune Hemolytic Anemias",
        "url": "https://app.pathprimer.com/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
        "topics": {
          "Clinical Significance and Work-up of Positive Direct Antiglobulin Test": {
            "name": "Clinical Significance and Work-up of Positive Direct Antiglobulin Test",
            "url": "https://app.pathprimer.com/document/ed630cc0-6589-4df8-8e5e-a15031dbb3a2/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Knowledge of DAT IgG, C3, and eluate results can define likely cause of immune-mediated hemolytic process"
                  }
                ]
              },
              "OVERVIEW": {
                "DAT Can Be Powerful Tool in Suspected Immune-Mediated Hemolytic Anemia": [
                  {
                    "text": "Patient history is critical for diagnosisEvidence of in-vivo hemolysis (i.e., anemia and reticulocytosis)History of recent transfusionHelpful if considering delayed or acute hemolytic transfusion reactionMedication use history (specifically antibiotics)Helpful if considering drug-induced hemolytic processHistory of organ or bone marrow transplantPassenger lymphocytes can make anti-A, B, or other red cell antibodiesRecent use of IVIGSome doses have clinically relevant titers of anti-A, B, or D that can cause hemolysis",
                    "sub_points": [
                      "Evidence of in-vivo hemolysis (i.e., anemia and reticulocytosis)",
                      "History of recent transfusionHelpful if considering delayed or acute hemolytic transfusion reaction",
                      "Helpful if considering delayed or acute hemolytic transfusion reaction",
                      "Medication use history (specifically antibiotics)Helpful if considering drug-induced hemolytic process",
                      "Helpful if considering drug-induced hemolytic process",
                      "History of organ or bone marrow transplantPassenger lymphocytes can make anti-A, B, or other red cell antibodies",
                      "Passenger lymphocytes can make anti-A, B, or other red cell antibodies",
                      "Recent use of IVIGSome doses have clinically relevant titers of anti-A, B, or D that can cause hemolysis",
                      "Some doses have clinically relevant titers of anti-A, B, or D that can cause hemolysis"
                    ]
                  },
                  {
                    "text": "Reasonable differential diagnosis can be formed using known common reaction profiles once DAT and eluate are performed"
                  },
                  {
                    "text": "Positive DAT (false-positive) can be seen in those without evidence of hemolytic anemiaInterpretation of positive DAT must be taken in contextNegative DAT (false-negative) can be seen in some rare cases of true immune-mediated hemolysisExamplesIgA-mediated hemolysisLow-affinity IgG-mediated hemolysisSpecial techniques at immunohematology reference labs can sometimes identify these rare antibodiesFlow cytometryDirect PEG testOther specialized methods",
                    "sub_points": [
                      "Interpretation of positive DAT must be taken in context",
                      "Negative DAT (false-negative) can be seen in some rare cases of true immune-mediated hemolysisExamplesIgA-mediated hemolysisLow-affinity IgG-mediated hemolysisSpecial techniques at immunohematology reference labs can sometimes identify these rare antibodiesFlow cytometryDirect PEG testOther specialized methods",
                      "ExamplesIgA-mediated hemolysisLow-affinity IgG-mediated hemolysis",
                      "IgA-mediated hemolysis",
                      "Low-affinity IgG-mediated hemolysis",
                      "Special techniques at immunohematology reference labs can sometimes identify these rare antibodiesFlow cytometryDirect PEG testOther specialized methods",
                      "Flow cytometry",
                      "Direct PEG test",
                      "Other specialized methods"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Direct antiglobulin test (DAT)"
                  },
                  {
                    "text": "Intravenous immune globulin (IVIG)"
                  },
                  {
                    "text": "Polyethylene glycol (PEG)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Warm Autoimmune Hemolytic Anemia": {
            "name": "Warm Autoimmune Hemolytic Anemia",
            "url": "https://app.pathprimer.com/document/38ca655d-4f7d-41b5-ad84-fd94bdaf828d/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Warm autoimmune hemolytic anemia (WAIHA) is caused by warm reactive (reactive at 37°C) red cell autoantibody (IgG, most commonly, but can be IgM or IgA)"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Diagnosis is made by finding of positive direct antiglobulin (Coomb) test (DAT) and positive eluate (all cells positive)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Caused by warm reactive (reactive at 37°C) red cell autoantibody (IgG, most commonly, but can be IgM or IgA)"
                  },
                  {
                    "text": "Autoantibodies mediate either intravascular hemolysis by complement lytic complex (C5b-C9) or, more often, extravascular destruction of red cells in spleen by macrophage-phagocytic system"
                  },
                  {
                    "text": "Can be primary (idiopathic) or secondary: About 50% of all cases are secondarySecondary associated causesMalignanciesMonoclonal gammopathiesCLLSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaHodgkin diseaseOvarian teratomaSome solid tumorsInfectionsEpstein-Barr virusCytomegalovirusParvovirus (B19)VaricellaHIVMycoplasmaBrucellosisLeishmaniasisAutoimmune diseasesSystemic lupus erythematosusAntiphospholipid syndromeInflammatory bowel diseases (ulcerative colitis/Crohn disease)Allogeneic hematopoietic stem cell transplantations",
                    "sub_points": [
                      "Secondary associated causesMalignanciesMonoclonal gammopathiesCLLSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaHodgkin diseaseOvarian teratomaSome solid tumorsInfectionsEpstein-Barr virusCytomegalovirusParvovirus (B19)VaricellaHIVMycoplasmaBrucellosisLeishmaniasisAutoimmune diseasesSystemic lupus erythematosusAntiphospholipid syndromeInflammatory bowel diseases (ulcerative colitis/Crohn disease)Allogeneic hematopoietic stem cell transplantations",
                      "MalignanciesMonoclonal gammopathiesCLLSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaHodgkin diseaseOvarian teratomaSome solid tumors",
                      "Monoclonal gammopathies",
                      "CLL",
                      "Splenic marginal zone lymphoma",
                      "Angioimmunoblastic T-cell lymphoma",
                      "Hodgkin disease",
                      "Ovarian teratoma",
                      "Some solid tumors",
                      "InfectionsEpstein-Barr virusCytomegalovirusParvovirus (B19)VaricellaHIVMycoplasmaBrucellosisLeishmaniasis",
                      "Epstein-Barr virus",
                      "Cytomegalovirus",
                      "Parvovirus (B19)",
                      "Varicella",
                      "HIV",
                      "Mycoplasma",
                      "Brucellosis",
                      "Leishmaniasis",
                      "Autoimmune diseasesSystemic lupus erythematosusAntiphospholipid syndromeInflammatory bowel diseases (ulcerative colitis/Crohn disease)",
                      "Systemic lupus erythematosus",
                      "Antiphospholipid syndrome",
                      "Inflammatory bowel diseases (ulcerative colitis/Crohn disease)",
                      "Allogeneic hematopoietic stem cell transplantations"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Incidence: About 0.8/100,000/year"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Fatigue"
                  },
                  {
                    "text": "Jaundice"
                  },
                  {
                    "text": "Signs of immune hemolysisAnemiaReticulocytosisHyperbilirubinemiaElevated serum LDH",
                    "sub_points": [
                      "Anemia",
                      "Reticulocytosis",
                      "Hyperbilirubinemia",
                      "Elevated serum LDH"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Medical managementFirst-line therapy: Prednisone (1-2 mg/kg/day) is used and continued/adjusted until adequate response is attainedSecond-line therapiesRituximabSplenectomyRefractory cases may benefit from other therapiesIntravenous immunoglobulinCyclophosphamideVincristineAzathioprinemTOR inhibitorNewer monoclonal antibodies such as alemtuzumabTherapeutic plasma exchange may be considered in cases with fulminant hemolysis that are unresponsive to RBC transfusions (ASFA category III)",
                    "sub_points": [
                      "First-line therapy: Prednisone (1-2 mg/kg/day) is used and continued/adjusted until adequate response is attained",
                      "Second-line therapiesRituximabSplenectomy",
                      "Rituximab",
                      "Splenectomy",
                      "Refractory cases may benefit from other therapiesIntravenous immunoglobulinCyclophosphamideVincristineAzathioprinemTOR inhibitorNewer monoclonal antibodies such as alemtuzumab",
                      "Intravenous immunoglobulin",
                      "Cyclophosphamide",
                      "Vincristine",
                      "Azathioprine",
                      "mTOR inhibitor",
                      "Newer monoclonal antibodies such as alemtuzumab",
                      "Therapeutic plasma exchange may be considered in cases with fulminant hemolysis that are unresponsive to RBC transfusions (ASFA category III)"
                    ]
                  },
                  {
                    "text": "Transfusion managementDuration of survival of transfused red cells is about same as that of patient's own red cells (which is reduced anyway due to antibody)Use of ABO-D compatible, crossmatch incompatible, red cell units may be necessary and acceptable to maintain adequate oxygen deliverySelection of prophylactic red cell antigen matched units (matching for C, c, E, e, and K) in these cases may be helpful in reducing risk of future alloimmunization",
                    "sub_points": [
                      "Duration of survival of transfused red cells is about same as that of patient's own red cells (which is reduced anyway due to antibody)Use of ABO-D compatible, crossmatch incompatible, red cell units may be necessary and acceptable to maintain adequate oxygen delivery",
                      "Use of ABO-D compatible, crossmatch incompatible, red cell units may be necessary and acceptable to maintain adequate oxygen delivery",
                      "Selection of prophylactic red cell antigen matched units (matching for C, c, E, e, and K) in these cases may be helpful in reducing risk of future alloimmunization"
                    ]
                  }
                ],
                "Prevention": [
                  {
                    "text": "None"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis is generally good but depends, in part, on whether disease is primary or secondary"
                  },
                  {
                    "text": "Exact rate of patients remaining in chronic remission after end of first-line steroid therapy is unknown; estimated to be around 20%Chronic remission can be achieved post splenectomy in about 38-82% of patients; and possibly cure 20% of cases",
                    "sub_points": [
                      "Chronic remission can be achieved post splenectomy in about 38-82% of patients; and possibly cure 20% of cases"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other forms of warm immune hemolytic anemias should be considered (if DAT is positive)Drug-induced hemolytic anemiaPassenger lymphocyte syndromeEvans syndrome",
                    "sub_points": [
                      "Drug-induced hemolytic anemia",
                      "Passenger lymphocyte syndrome",
                      "Evans syndrome"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Positive DAT (Coomb) test provides strong evidence for diagnosisMay be positive to IgG only (20% of cases) or IgG and complement (67% of cases)Caveat: DAT-negative forms of WAIHA have been reported and can be due to low affinity antibodies or non-IgG-related anemia (i.e., IgA)",
                    "sub_points": [
                      "May be positive to IgG only (20% of cases) or IgG and complement (67% of cases)",
                      "Caveat: DAT-negative forms of WAIHA have been reported and can be due to low affinity antibodies or non-IgG-related anemia (i.e., IgA)"
                    ]
                  },
                  {
                    "text": "EluateMost commonly, antibody is reactive with all red cells tested, including patient's own red cellsAutoantibody may have specificity, most commonly for antigen of Rh system (D, C, E, c, e)",
                    "sub_points": [
                      "Most commonly, antibody is reactive with all red cells tested, including patient's own red cells",
                      "Autoantibody may have specificity, most commonly for antigen of Rh system (D, C, E, c, e)"
                    ]
                  },
                  {
                    "text": "Red cell adsorption techniquesUseful for detecting underlying clinically significant alloantibodies in patient with strong autoantibody who needs red cell transfusionAutoadsorption: Best technique for patients with WAIHA who have not been transfused recently (not in past 3 months)Alloadsorption: Best technique for patients with WAIHA who have been transfused recently (3 months or less)",
                    "sub_points": [
                      "Useful for detecting underlying clinically significant alloantibodies in patient with strong autoantibody who needs red cell transfusionAutoadsorption: Best technique for patients with WAIHA who have not been transfused recently (not in past 3 months)Alloadsorption: Best technique for patients with WAIHA who have been transfused recently (3 months or less)",
                      "Autoadsorption: Best technique for patients with WAIHA who have not been transfused recently (not in past 3 months)",
                      "Alloadsorption: Best technique for patients with WAIHA who have been transfused recently (3 months or less)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cold Agglutinin Disease": {
            "name": "Cold Agglutinin Disease",
            "url": "https://app.pathprimer.com/document/64750fad-2939-49e7-9bfa-f9884f08f1a4/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Cold agglutinin disease (CAD) results from clinically significant IgM cold autoantibodies (cold agglutinin): Anti-I, i, and Pr"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "C3 positive direct antiglobulin test is helpful in supporting diagnosis"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Cold agglutinin disease (CAD) results from clinically significant IgM cold autoantibodies (cold agglutinin)Antibody is usually present at high titer (> 1:10,000)Antibody is usually reactive at warm temperatures (> 30 °C)Antigen can usually bind complementAntibody usually has specificity for I (common), i, or Pr (rare) antigens on red cells",
                    "sub_points": [
                      "Antibody is usually present at high titer (> 1:10,000)",
                      "Antibody is usually reactive at warm temperatures (> 30 °C)",
                      "Antigen can usually bind complement",
                      "Antibody usually has specificity for I (common), i, or Pr (rare) antigens on red cells"
                    ]
                  },
                  {
                    "text": "Cause of autoantibody formation is unknown, but there are some theoriesImmune dysfunctionAntigen sharing between infectious agents and RBCs (molecular mimicry)Infection-induced antigen changes on red cells",
                    "sub_points": [
                      "Immune dysfunction",
                      "Antigen sharing between infectious agents and RBCs (molecular mimicry)",
                      "Infection-induced antigen changes on red cells"
                    ]
                  },
                  {
                    "text": "CAD results from IgM binding complement on red cell, leading to activation of classic complement pathway (MAC complex) and intravascular hemolysis in vivo"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Idiopathic CADSeen mostly in elderly patients",
                    "sub_points": [
                      "Seen mostly in elderly patients"
                    ]
                  },
                  {
                    "text": "Secondary CADSeen mostly in children and young adultsMalignancy associationsCAD is usually chronic when malignancy-associatedMonoclonal gammopathiesChronic leukemiasSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaLymphoplasmacytic lymphomaSome solid tumorsInfectious associationsCAD is usually acute and transient when infection-associatedViral causesEpstein-Barr virus (mononucleosis)CytomegalovirusVaricellaRubellaHIVBacterial causesMycoplasmaBrucella",
                    "sub_points": [
                      "Seen mostly in children and young adults",
                      "Malignancy associationsCAD is usually chronic when malignancy-associatedMonoclonal gammopathiesChronic leukemiasSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaLymphoplasmacytic lymphomaSome solid tumors",
                      "CAD is usually chronic when malignancy-associatedMonoclonal gammopathiesChronic leukemiasSplenic marginal zone lymphomaAngioimmunoblastic T-cell lymphomaLymphoplasmacytic lymphomaSome solid tumors",
                      "Monoclonal gammopathies",
                      "Chronic leukemias",
                      "Splenic marginal zone lymphoma",
                      "Angioimmunoblastic T-cell lymphoma",
                      "Lymphoplasmacytic lymphoma",
                      "Some solid tumors",
                      "Infectious associationsCAD is usually acute and transient when infection-associatedViral causesEpstein-Barr virus (mononucleosis)CytomegalovirusVaricellaRubellaHIVBacterial causesMycoplasmaBrucella",
                      "CAD is usually acute and transient when infection-associated",
                      "Viral causesEpstein-Barr virus (mononucleosis)CytomegalovirusVaricellaRubellaHIV",
                      "Epstein-Barr virus (mononucleosis)",
                      "Cytomegalovirus",
                      "Varicella",
                      "Rubella",
                      "HIV",
                      "Bacterial causesMycoplasmaBrucella",
                      "Mycoplasma",
                      "Brucella"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Mild to severe anemia (exacerbated by exposure to cold)"
                  },
                  {
                    "text": "Cold sensitivity"
                  },
                  {
                    "text": "Cold-dependent acrocyanosis"
                  },
                  {
                    "text": "Acral numbness"
                  },
                  {
                    "text": "Livido reticularis or organ ischemia"
                  },
                  {
                    "text": "In cases of severe anemiaMalaiseFeverJaundiceAbdominal painShortness of breathHemoglobinuria",
                    "sub_points": [
                      "Malaise",
                      "Fever",
                      "Jaundice",
                      "Abdominal pain",
                      "Shortness of breath",
                      "Hemoglobinuria"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Cold avoidance (keep environment warm)"
                  },
                  {
                    "text": "Treat underlying infectious or malignant disease"
                  },
                  {
                    "text": "Immune-suppressing medications tend to be less effective in this disease (i.e., steroids, splenectomy)However, rituximab may be helpful",
                    "sub_points": [
                      "However, rituximab may be helpful"
                    ]
                  },
                  {
                    "text": "Red cell transfusion support (if severe anemia)Blood warmer can be used to modulate infusion temperature of red cell unit",
                    "sub_points": [
                      "Blood warmer can be used to modulate infusion temperature of red cell unit"
                    ]
                  },
                  {
                    "text": "Therapeutic plasma exchange can be of benefit in life-threatening cases (ASFA category II), with immune-modulating therapy"
                  }
                ],
                "Prevention": [
                  {
                    "text": "None"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Usually has good prognosis, but can be severe and life-threatening (due to intravascular hemolysis)"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other immune (direct antiglobulin test) positive hemolytic anemiasParoxysmal cold hemoglobinuriaMixed autoimmune hemolytic anemiaDrug-induced hemolytic anemiaHemolytic transfusion reactionPassenger lymphocyte syndromeEvans syndromeWarm autoimmune hemolytic anemia",
                    "sub_points": [
                      "Paroxysmal cold hemoglobinuria",
                      "Mixed autoimmune hemolytic anemia",
                      "Drug-induced hemolytic anemia",
                      "Hemolytic transfusion reaction",
                      "Passenger lymphocyte syndrome",
                      "Evans syndrome",
                      "Warm autoimmune hemolytic anemia"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Direct antiglobulin testUsually positive with C3 only (no IgG detected)",
                    "sub_points": [
                      "Usually positive with C3 only (no IgG detected)"
                    ]
                  },
                  {
                    "text": "Cold antibody identificationDetermining specificity of cold antibody can help support diagnosis and allow for additional testing",
                    "sub_points": [
                      "Determining specificity of cold antibody can help support diagnosis and allow for additional testing"
                    ]
                  },
                  {
                    "text": "Cold antibody titer and thermal amplitude testingIn ambiguous cases, determining concentration of antibody (clinically significant titer is > 1:10,000) and temperature when it is reactive (clinically significant titer is > 30 °C) can help support diagnosis",
                    "sub_points": [
                      "In ambiguous cases, determining concentration of antibody (clinically significant titer is > 1:10,000) and temperature when it is reactive (clinically significant titer is > 30 °C) can help support diagnosis"
                    ]
                  },
                  {
                    "text": "General pretransfusion testing (finding other antibodies in context of CAD)Prewarming of patient samples may help mitigate reactivity of cold antibody and reveal underlying alloantibodies for transfusion supportPretreating of patient samples with DTT can also be used to remove IgM (breaks disulfide bonds)",
                    "sub_points": [
                      "Prewarming of patient samples may help mitigate reactivity of cold antibody and reveal underlying alloantibodies for transfusion support",
                      "Pretreating of patient samples with DTT can also be used to remove IgM (breaks disulfide bonds)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Paroxysmal Cold Hemoglobinuria": {
            "name": "Paroxysmal Cold Hemoglobinuria",
            "url": "https://app.pathprimer.com/document/00f108d1-b525-41fc-9fd1-7cc64561e7cc/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "PCH is defined by presence of clinically significant IgG biphasic-hemolysin (anti-P, most commonly)"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Positive Donath-Landsteiner test is diagnostic gold standard"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Paroxysmal cold hemoglobinuria (PCH) was first described by Donath and Landsteiner in 1904Originally associated with secondary and tertiary syphilis (pre-antibiotic therapy)",
                    "sub_points": [
                      "Originally associated with secondary and tertiary syphilis (pre-antibiotic therapy)"
                    ]
                  },
                  {
                    "text": "Defined by presence of clinically significant IgG biphasic-hemolysin (anti-P, most commonly)Antibody binds red cells at cooler body temperaturesAt body temperature, intravascular hemolysis occurs via complement-mediated processIntravascular hemolysis leads to hemoglobinuria and jaundice associated with disease",
                    "sub_points": [
                      "Antibody binds red cells at cooler body temperatures",
                      "At body temperature, intravascular hemolysis occurs via complement-mediated process",
                      "Intravascular hemolysis leads to hemoglobinuria and jaundice associated with disease"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Primarily presents in children and has median age of 5 years, with range of 1-82 years"
                  },
                  {
                    "text": "Incidence is estimated to be 0.001/100,000 per year in boys and 0.005/100,000 per year in girls"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Most cases of PCH are classically severe but transient, and condition spontaneously resolves in days to weeks without recurrenceClassically presents 1-2 weeks after respiratory tract infectionCan be associated with some forms of non-Hodgkin lymphoma",
                    "sub_points": [
                      "Classically presents 1-2 weeks after respiratory tract infection",
                      "Can be associated with some forms of non-Hodgkin lymphoma"
                    ]
                  },
                  {
                    "text": "Common presenting symptomsAnemiaFeverHemoglobinuriaJaundicePallorPalpable liver/spleenAbdominal pain",
                    "sub_points": [
                      "Anemia",
                      "Fever",
                      "Hemoglobinuria",
                      "Jaundice",
                      "Pallor",
                      "Palpable liver/spleen",
                      "Abdominal pain"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Transfusion support"
                  },
                  {
                    "text": "Medical management is of unclear benefit, and number of therapies have been triedCorticosteroidsAzathioprineRituximabSplenectomy",
                    "sub_points": [
                      "Corticosteroids",
                      "Azathioprine",
                      "Rituximab",
                      "Splenectomy"
                    ]
                  }
                ],
                "Prevention": [
                  {
                    "text": "None currently"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall prognosis of acute PCH is good, though deaths have been reported in severe cases"
                  },
                  {
                    "text": "Effectiveness of medical interventions is difficult to evaluate due to low incidence of disease and transient nature of disease process"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other causes of immune (direct antiglobulin test-positive) hemolysisWarm autoimmune hemolytic anemiaCold agglutinin diseaseDrug-induced hemolytic anemia",
                    "sub_points": [
                      "Warm autoimmune hemolytic anemia",
                      "Cold agglutinin disease",
                      "Drug-induced hemolytic anemia"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "Direct antiglobulin testWill be positive for C3 only in most cases",
                    "sub_points": [
                      "Will be positive for C3 only in most cases"
                    ]
                  },
                  {
                    "text": "Donath-Landsteiner test (diagnostic gold standard)Will demonstrate red cell lysis only after incubating patient sample with normal test red cells at 4°C and then warming that sample to 37°C",
                    "sub_points": [
                      "Will demonstrate red cell lysis only after incubating patient sample with normal test red cells at 4°C and then warming that sample to 37°C"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Drug-Induced Hemolytic Anemias": {
            "name": "Drug-Induced Hemolytic Anemias",
            "url": "https://app.pathprimer.com/document/68539380-c5cb-419b-a121-ca74741f6b99/lesson/133b6aea-f98f-495d-bcd8-9059a1f736c8",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Drug-induced hemolytic anemia is a rare condition defined by antibody that forms against red cells as result of drug exposure"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Direct antiglobulin test is key diagnostic test and is usually IgG positive and eluate negative (when drug is absent)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Some drugs bind loosely or firmly to red cell membrane; this interaction leads to unique antibody production (usually IgG)Three types of antibodies are possibleAntibody is specific for drug only (red cell is removed only when drug is bound to red cell)Antibody is specific to predominantly red cell membrane (red cell can be removed with or without drug bound to red cell)Antibody is specific for combination of drug and red cell membrane components (red cell can be removed when drug and red cell are associated)",
                    "sub_points": [
                      "Three types of antibodies are possibleAntibody is specific for drug only (red cell is removed only when drug is bound to red cell)Antibody is specific to predominantly red cell membrane (red cell can be removed with or without drug bound to red cell)Antibody is specific for combination of drug and red cell membrane components (red cell can be removed when drug and red cell are associated)",
                      "Antibody is specific for drug only (red cell is removed only when drug is bound to red cell)",
                      "Antibody is specific to predominantly red cell membrane (red cell can be removed with or without drug bound to red cell)",
                      "Antibody is specific for combination of drug and red cell membrane components (red cell can be removed when drug and red cell are associated)"
                    ]
                  },
                  {
                    "text": "These antibodies mediate either intravascular hemolysis by terminal complement lytic complex (C5b-C9) or extravascular destruction in spleen by macrophage-phagocytic system"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Incidence is rare; 1:1 million people"
                  },
                  {
                    "text": "Most common associated drugs include piperacillin, ceftriaxone, and cefotetanOf note, single prophylactic dose of cefotetan is enough to cause severe hemolytic anemia",
                    "sub_points": [
                      "Of note, single prophylactic dose of cefotetan is enough to cause severe hemolytic anemia"
                    ]
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Fatigue"
                  },
                  {
                    "text": "Jaundice"
                  },
                  {
                    "text": "Symptoms and signs of hemolysisAnemiaReticulocytosisHyperbilirubinemiaElevated serum LDH",
                    "sub_points": [
                      "Anemia",
                      "Reticulocytosis",
                      "Hyperbilirubinemia",
                      "Elevated serum LDH"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Stop offending drug (usually enough to cause remission of hemolysis)"
                  },
                  {
                    "text": "Transfusion support: Useful to support oxygen-carrying capacity when hemolysis is severePatient's serum should be tested for unexpected alloantibodies by routine techniques",
                    "sub_points": [
                      "Patient's serum should be tested for unexpected alloantibodies by routine techniques"
                    ]
                  },
                  {
                    "text": "Use of steroids may be helpful in some severe cases (e.g., in fludarabine-induced cases)"
                  }
                ],
                "Prevention": [
                  {
                    "text": "None known"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Generally good after cessation of drug"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Other types of direct antiglobulin test (DAT)-positive immune hemolytic anemiasWarm autoimmune hemolytic anemia (if eluate is positive)Cold agglutinin disease or paroxysmal cold hemoglobinuria (if DAT is positive for C3 only)",
                    "sub_points": [
                      "Warm autoimmune hemolytic anemia (if eluate is positive)",
                      "Cold agglutinin disease or paroxysmal cold hemoglobinuria (if DAT is positive for C3 only)"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "DAT (Coomb test)Drug-independent immune hemolytic anemia (do not require drug to be detected)Can be indistinguishable from warm autoimmune hemolytic anemiaWill have positive DAT for IgG and +/-C3, and will have eluate that will be positive with all cellsTemporal relationship to offending drug may be all you have to make this diagnosisExamples: Methyldopa and fludarabineDrug-dependent immune hemolytic anemia (require drug to be detected)Antibodies can react to drug-treated red cells (e.g., penicillin and some cephalosporin antibodies)Will have positive DAT for IgG and +/-C3, and will have negative eluate when drug is not present (pre-treated red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sampleAntibodies can react to untreated red cells in presence of drug in solution (e.g., quinine and ceftriaxone antibodies)Will have positive DAT for +/-IgG and +/-C3 (C3+ may be all you see here), and will have negative eluate when drug is not present (drug in solution with red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample",
                    "sub_points": [
                      "Drug-independent immune hemolytic anemia (do not require drug to be detected)Can be indistinguishable from warm autoimmune hemolytic anemiaWill have positive DAT for IgG and +/-C3, and will have eluate that will be positive with all cellsTemporal relationship to offending drug may be all you have to make this diagnosisExamples: Methyldopa and fludarabine",
                      "Can be indistinguishable from warm autoimmune hemolytic anemiaWill have positive DAT for IgG and +/-C3, and will have eluate that will be positive with all cellsTemporal relationship to offending drug may be all you have to make this diagnosis",
                      "Will have positive DAT for IgG and +/-C3, and will have eluate that will be positive with all cells",
                      "Temporal relationship to offending drug may be all you have to make this diagnosis",
                      "Examples: Methyldopa and fludarabine",
                      "Drug-dependent immune hemolytic anemia (require drug to be detected)Antibodies can react to drug-treated red cells (e.g., penicillin and some cephalosporin antibodies)Will have positive DAT for IgG and +/-C3, and will have negative eluate when drug is not present (pre-treated red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sampleAntibodies can react to untreated red cells in presence of drug in solution (e.g., quinine and ceftriaxone antibodies)Will have positive DAT for +/-IgG and +/-C3 (C3+ may be all you see here), and will have negative eluate when drug is not present (drug in solution with red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample",
                      "Antibodies can react to drug-treated red cells (e.g., penicillin and some cephalosporin antibodies)Will have positive DAT for IgG and +/-C3, and will have negative eluate when drug is not present (pre-treated red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample",
                      "Will have positive DAT for IgG and +/-C3, and will have negative eluate when drug is not present (pre-treated red cells)",
                      "For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample",
                      "Antibodies can react to untreated red cells in presence of drug in solution (e.g., quinine and ceftriaxone antibodies)Will have positive DAT for +/-IgG and +/-C3 (C3+ may be all you see here), and will have negative eluate when drug is not present (drug in solution with red cells)For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample",
                      "Will have positive DAT for +/-IgG and +/-C3 (C3+ may be all you see here), and will have negative eluate when drug is not present (drug in solution with red cells)",
                      "For best diagnosis, samples of actual drug/pure drug used for patient should be sent with patient's blood sample"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Therapeutic Apheresis": {
        "name": "Therapeutic Apheresis",
        "url": "https://app.pathprimer.com/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
        "topics": {
          "Overview of Therapeutic Apheresis": {
            "name": "Overview of Therapeutic Apheresis",
            "url": "https://app.pathprimer.com/document/47c6408d-a3f7-4a1e-a97b-d0377d4b9a46/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Therapeutic apheresis is defined as treatment of diseases through removal or manipulation of blood components"
                  },
                  {
                    "text": "Therapeutic apheresis procedures are defined by location of pathologic substance"
                  }
                ]
              },
              "OVERVIEW": {
                "Apheresis Is Term Derived From Greek WordAphairesis, Which Means\"to Remove Forcibly\"": [
                  {
                    "text": "Common uses of apheresis technologyTo collect blood components (donor apheresis)To remove pathologic substances (therapeutic apheresis)",
                    "sub_points": [
                      "To collect blood components (donor apheresis)",
                      "To remove pathologic substances (therapeutic apheresis)"
                    ]
                  },
                  {
                    "text": "Therapeutic apheresis is defined as treatment of diseases through removal or manipulation of blood componentsThere must be good understanding of disease pathology to suggest clear rationale for therapeutic apheresisAbnormality should be meaningfully corrected by therapeutic apheresisThere must be strong clinical evidence that therapeutic apheresis provides meaningful benefit",
                    "sub_points": [
                      "There must be good understanding of disease pathology to suggest clear rationale for therapeutic apheresis",
                      "Abnormality should be meaningfully corrected by therapeutic apheresis",
                      "There must be strong clinical evidence that therapeutic apheresis provides meaningful benefit"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Therapeutic Apheresis Procedures Are Defined by Location of Pathologic or Manipulated Substance": [
                  {
                    "text": "Plasma = therapeutic plasma exchange or selective adsorption"
                  },
                  {
                    "text": "Red blood cells (RBCs) = red cell exchange"
                  },
                  {
                    "text": "White blood cells = leukapheresis or photopheresis"
                  },
                  {
                    "text": "Platelets = thrombocytapheresis"
                  }
                ],
                "Volume to Exchange Depends on What Is Being Removed and Size of Patient": [
                  {
                    "text": "Typical apheresis procedures process 1-1.5 plasma volumesIntravascular substances: 36.8% of substance remains after single plasma volume procedure (e.g., IgM antibodies)Mixed intravascular/extravascular substances: 60.6% of substance remains after single plasma volume procedure (e.g., IgG antibodies)RBCs: when 1 blood volume is exchanged, 63.2% of red cells are removedMore than 1.5 plasma volumes is rarely indicated because substance removal by apheresis becomes less efficient",
                    "sub_points": [
                      "Intravascular substances: 36.8% of substance remains after single plasma volume procedure (e.g., IgM antibodies)",
                      "Mixed intravascular/extravascular substances: 60.6% of substance remains after single plasma volume procedure (e.g., IgG antibodies)",
                      "RBCs: when 1 blood volume is exchanged, 63.2% of red cells are removed",
                      "More than 1.5 plasma volumes is rarely indicated because substance removal by apheresis becomes less efficient"
                    ]
                  },
                  {
                    "text": "Duration of typical apheresis procedures depends partly on plasma volume processedLarger plasma volumes/larger patients require increased processing or procedure timePlasma volume = total blood volume (Nadler formula) x (1 - hematocrit)Plasma volume depends on patient weight, height, and hematocritVolume calculations usually overestimate obese patients and underestimate muscular patientsTotal red cell volume = total blood volume (Nadler formula) x hematocrit",
                    "sub_points": [
                      "Larger plasma volumes/larger patients require increased processing or procedure timePlasma volume = total blood volume (Nadler formula) x (1 - hematocrit)Plasma volume depends on patient weight, height, and hematocritVolume calculations usually overestimate obese patients and underestimate muscular patientsTotal red cell volume = total blood volume (Nadler formula) x hematocrit",
                      "Plasma volume = total blood volume (Nadler formula) x (1 - hematocrit)Plasma volume depends on patient weight, height, and hematocritVolume calculations usually overestimate obese patients and underestimate muscular patients",
                      "Plasma volume depends on patient weight, height, and hematocrit",
                      "Volume calculations usually overestimate obese patients and underestimate muscular patients",
                      "Total red cell volume = total blood volume (Nadler formula) x hematocrit"
                    ]
                  },
                  {
                    "text": "Extracorporeal volumeAmount of blood that is outside of patient during apheresis procedure (usually 131-284 mL)Volume depends on type of procedure, apheresis system used (Spectra vs. Optia), and ancillary equipment (i.e., use of blood warmer)Total extracorporeal volume shouldnotexceed 15% of total blood volume or RBC volumeIf exceeded (seen mostly in pediatric patients), priming machine with RBCs or albumin is needed to prevent hypovolemia",
                    "sub_points": [
                      "Amount of blood that is outside of patient during apheresis procedure (usually 131-284 mL)Volume depends on type of procedure, apheresis system used (Spectra vs. Optia), and ancillary equipment (i.e., use of blood warmer)",
                      "Volume depends on type of procedure, apheresis system used (Spectra vs. Optia), and ancillary equipment (i.e., use of blood warmer)",
                      "Total extracorporeal volume shouldnotexceed 15% of total blood volume or RBC volumeIf exceeded (seen mostly in pediatric patients), priming machine with RBCs or albumin is needed to prevent hypovolemia",
                      "If exceeded (seen mostly in pediatric patients), priming machine with RBCs or albumin is needed to prevent hypovolemia"
                    ]
                  }
                ],
                "Frequency and Number of Procedures Needed Depend on What Is Being Removed and Clinical Indication": [
                  {
                    "text": "Intravascular substances (IgM) favor fewer procedures"
                  },
                  {
                    "text": "Mixed intravascular/extravascular substances (IgG) favor more procedures"
                  },
                  {
                    "text": "Clinical recovery is most important in many diseasesNumber of procedures driven by clinical response",
                    "sub_points": [
                      "Number of procedures driven by clinical response"
                    ]
                  }
                ],
                "Many Therapeutic Apheresis Procedures Require Replacement Fluid": [
                  {
                    "text": "Replacement fluids are needed when > 15% of patient's plasma volume, or red cells, is removed during procedureChoice of fluid based on underlying diagnosis, patient's comorbidities, and bleeding risk",
                    "sub_points": [
                      "Choice of fluid based on underlying diagnosis, patient's comorbidities, and bleeding risk"
                    ]
                  },
                  {
                    "text": "Each fluid type has risks and benefits"
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "AABB and American Society for Apheresis Standards and Guidelines": [
                  {
                    "text": "Therapeutic apheresis clinical privileging"
                  },
                  {
                    "text": "Therapeutic apheresis required clinical documentation"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Guidelines and Indications for Therapeutic Apheresis": {
            "name": "Guidelines and Indications for Therapeutic Apheresis",
            "url": "https://app.pathprimer.com/document/c11f4e62-82d6-4ffc-9bd9-4a0ce3a5fa08/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Currently, there are numerous (157) published indications for therapeutic apheresis according to 2019 ASFA guidelines"
                  },
                  {
                    "text": "ASFA guidelines use category and grading system to report clinical efficacy of therapeutic apheresis for each indication"
                  }
                ]
              },
              "OVERVIEW": {
                "Apheresis Therapy": [
                  {
                    "text": "Very few clinical trials have been performed regarding apheresis therapy, and study quality is generally limited"
                  },
                  {
                    "text": "Due to limited evidence and diverse clinical utility, expert consensus guidelines are required to guide apheresis therapy and protocols"
                  },
                  {
                    "text": "Apheresis specialists often use guidelines provided by ASFAGuidelines updated every 3 yearsCurrent is 5th version (2019)Each disease for which pheresis has been studied is provided category and grade based on expert review of literatureGuideline category describes how effective apheresis therapy is for given disease; 4 categories exist (I-IV)Guideline grade reveals strength of literature in support of given category; 6 grades exist (1A-1C and 2A-2C)Currently, there are numerous (157) published indications for apheresis according to these guidelinesTherapeutic apheresis procedures evaluated in ASFA guidelines includeImmunoadsorption pheresisTPEErythrocytapheresisRBC exchangeThrombocytapheresisLeukocytapheresisLipoprotein apheresisFiltration-based selective apheresisECPHVPRheopheresis",
                    "sub_points": [
                      "Guidelines updated every 3 yearsCurrent is 5th version (2019)",
                      "Current is 5th version (2019)",
                      "Each disease for which pheresis has been studied is provided category and grade based on expert review of literatureGuideline category describes how effective apheresis therapy is for given disease; 4 categories exist (I-IV)Guideline grade reveals strength of literature in support of given category; 6 grades exist (1A-1C and 2A-2C)Currently, there are numerous (157) published indications for apheresis according to these guidelinesTherapeutic apheresis procedures evaluated in ASFA guidelines includeImmunoadsorption pheresisTPEErythrocytapheresisRBC exchangeThrombocytapheresisLeukocytapheresisLipoprotein apheresisFiltration-based selective apheresisECPHVPRheopheresis",
                      "Guideline category describes how effective apheresis therapy is for given disease; 4 categories exist (I-IV)",
                      "Guideline grade reveals strength of literature in support of given category; 6 grades exist (1A-1C and 2A-2C)",
                      "Currently, there are numerous (157) published indications for apheresis according to these guidelines",
                      "Therapeutic apheresis procedures evaluated in ASFA guidelines includeImmunoadsorption pheresisTPEErythrocytapheresisRBC exchangeThrombocytapheresisLeukocytapheresisLipoprotein apheresisFiltration-based selective apheresisECPHVPRheopheresis",
                      "Immunoadsorption pheresis",
                      "TPE",
                      "Erythrocytapheresis",
                      "RBC exchange",
                      "Thrombocytapheresis",
                      "Leukocytapheresis",
                      "Lipoprotein apheresis",
                      "Filtration-based selective apheresis",
                      "ECP",
                      "HVP",
                      "Rheopheresis"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "American Society for Apheresis (ASFA)"
                  },
                  {
                    "text": "Therapeutic plasma exchange (TPE)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Extracorporeal photopheresis (ECP)"
                  },
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  },
                  {
                    "text": "High-volume plasma (HVP)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Apheresis Instrumentation and Methodology": {
            "name": "Apheresis Instrumentation and Methodology",
            "url": "https://app.pathprimer.com/document/14a1686a-c678-4717-974e-943f5734c809/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Current apheresis devices allow separation of whole blood into component fractions"
                  },
                  {
                    "text": "Separation of whole blood can be accomplished by filtration &/or centrifugation"
                  },
                  {
                    "text": "Typical apheresis machines require large, rigid, 2-lumen catheters"
                  }
                ]
              },
              "OVERVIEW": {
                "Current Apheresis Devices Allow Separation of Whole Blood into Component Fractions by Density or Size": [
                  {
                    "text": "Remove desired blood fraction"
                  },
                  {
                    "text": "Return remaining fractions by in-line automated technology"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  },
                  {
                    "text": "Acid citrate dextrose (ACD)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Separation of Whole Blood Can Be Accomplished by Filtration &/or Centrifugation": [
                  {
                    "text": "Apheresis by centrifugation methodsRapid rotational forces separate whole blood by densityMost dense: red cellsMid-density (in order of decreasing density): neocytes (young red cells), granulocytes, mononuclear cells, plateletsLeast dense: plasmaSeparation of blood components by rapid rotational forces can be achieved by intermittent flow or continuous flow methodsIntermittent flow centrifugationBlood is processed in discrete batchesExtracorporeal photopheresis procedures are most often performed using intermittent flow centrifugation (i.e., Therakos system)Continuous flow centrifugationBlood is processed in ongoing mannerTherapeutic apheresis procedures are most often performed using continuous flow centrifugation (i.e., COBE Spectra or Spectra Optia)",
                    "sub_points": [
                      "Rapid rotational forces separate whole blood by densityMost dense: red cellsMid-density (in order of decreasing density): neocytes (young red cells), granulocytes, mononuclear cells, plateletsLeast dense: plasma",
                      "Most dense: red cells",
                      "Mid-density (in order of decreasing density): neocytes (young red cells), granulocytes, mononuclear cells, platelets",
                      "Least dense: plasma",
                      "Separation of blood components by rapid rotational forces can be achieved by intermittent flow or continuous flow methodsIntermittent flow centrifugationBlood is processed in discrete batchesExtracorporeal photopheresis procedures are most often performed using intermittent flow centrifugation (i.e., Therakos system)Continuous flow centrifugationBlood is processed in ongoing mannerTherapeutic apheresis procedures are most often performed using continuous flow centrifugation (i.e., COBE Spectra or Spectra Optia)",
                      "Intermittent flow centrifugationBlood is processed in discrete batchesExtracorporeal photopheresis procedures are most often performed using intermittent flow centrifugation (i.e., Therakos system)",
                      "Blood is processed in discrete batches",
                      "Extracorporeal photopheresis procedures are most often performed using intermittent flow centrifugation (i.e., Therakos system)",
                      "Continuous flow centrifugationBlood is processed in ongoing mannerTherapeutic apheresis procedures are most often performed using continuous flow centrifugation (i.e., COBE Spectra or Spectra Optia)",
                      "Blood is processed in ongoing manner",
                      "Therapeutic apheresis procedures are most often performed using continuous flow centrifugation (i.e., COBE Spectra or Spectra Optia)"
                    ]
                  },
                  {
                    "text": "Apheresis by filtration methodsUses membrane filters that separate blood on the basis of differences in particle size or affinity for specific blood component (i.e., LDL)Therapeutic cholesterol (LDL) reduction techniques use continuous flow filtration machines (i.e., Kaneka Liposorber System)",
                    "sub_points": [
                      "Uses membrane filters that separate blood on the basis of differences in particle size or affinity for specific blood component (i.e., LDL)Therapeutic cholesterol (LDL) reduction techniques use continuous flow filtration machines (i.e., Kaneka Liposorber System)",
                      "Therapeutic cholesterol (LDL) reduction techniques use continuous flow filtration machines (i.e., Kaneka Liposorber System)"
                    ]
                  },
                  {
                    "text": "Filtration and centrifugation technologies differ in many waysStandard blood flow rateRequired anticoagulation",
                    "sub_points": [
                      "Standard blood flow rate",
                      "Required anticoagulation"
                    ]
                  }
                ],
                "Flow Rates Required by These Instruments Require Anticoagulation": [
                  {
                    "text": "Anticoagulation is required in all apheresis instruments to maintain flow through plastic tubing and blood-containing elements of device"
                  },
                  {
                    "text": "Heparin or citrate (ACD) may be usedCitrate is more commonCitrate prevents coagulation by binding ionized calciumCitrate is metabolized much more quickly than heparinRisk of patient bleeding is lowerHeparin prevents coagulation by potentiating activity of antithrombinHeparin has half-life of 90 min0.5-2 IU/mL needed for anticoagulation",
                    "sub_points": [
                      "Citrate is more common",
                      "Citrate prevents coagulation by binding ionized calciumCitrate is metabolized much more quickly than heparinRisk of patient bleeding is lower",
                      "Citrate is metabolized much more quickly than heparin",
                      "Risk of patient bleeding is lower",
                      "Heparin prevents coagulation by potentiating activity of antithrombinHeparin has half-life of 90 min0.5-2 IU/mL needed for anticoagulation",
                      "Heparin has half-life of 90 min",
                      "0.5-2 IU/mL needed for anticoagulation"
                    ]
                  }
                ],
                "Flow Rates Required by These Instruments Require Specific and Unique Vascular Access": [
                  {
                    "text": "Peripheral veins can be used for procedure access17-gauge draw line and 18-gauge return line required",
                    "sub_points": [
                      "17-gauge draw line and 18-gauge return line required"
                    ]
                  },
                  {
                    "text": "Central venous catheters may be requiredBeneficial for patients without adequate peripheral veins or for patients needing multiple frequent proceduresMust have rigid walls and at least 2 lumens for procedureSuggested lumen size differs by patient weightCatheter location influenced by duration of treatmentSubclavian or internal jugularTreatments that require many weeksFemoralTreatments that require days (due to increased infection risk)",
                    "sub_points": [
                      "Beneficial for patients without adequate peripheral veins or for patients needing multiple frequent procedures",
                      "Must have rigid walls and at least 2 lumens for procedureSuggested lumen size differs by patient weight",
                      "Suggested lumen size differs by patient weight",
                      "Catheter location influenced by duration of treatmentSubclavian or internal jugularTreatments that require many weeksFemoralTreatments that require days (due to increased infection risk)",
                      "Subclavian or internal jugularTreatments that require many weeks",
                      "Treatments that require many weeks",
                      "FemoralTreatments that require days (due to increased infection risk)",
                      "Treatments that require days (due to increased infection risk)"
                    ]
                  }
                ],
                "Suggested Catheter Size for Patients by Weight (kg), Including Pediatrics": [
                  {
                    "text": "≤ 3 kg: 5F, 2 single-lumen"
                  },
                  {
                    "text": "3-10 kg: 7F, double-lumen"
                  },
                  {
                    "text": "10-20 kg: 8F or 9F, double-lumen"
                  },
                  {
                    "text": "20-50 kg: 9F or 10F, double-lumen"
                  },
                  {
                    "text": "> 50 kg: 11.5F, 12F, or 13.5F, double-lumen"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Appropriate Course of Plasma Exchange": {
            "name": "Appropriate Course of Plasma Exchange",
            "url": "https://app.pathprimer.com/document/df2e4509-ed4e-41cd-8035-1db6b00ef26a/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Appropriate course of plasma exchange is complex and requires understanding of disease process, clinical endpoints for therapy, behavior of the component being removed, and patient"
                  }
                ]
              },
              "OVERVIEW": {
                "Determining Appropriate Course of Plasma Exchange Is Complex and Requires Careful Clinical Evaluation of Patient": [
                  {
                    "text": "Consider the following in every caseRationale: Can plasma exchange effectively remove disease-causing agent?Consider results of published clinical trials or ASFA guidelines as guidanceImpact: Can plasma exchange cause harm to patient? Do benefits outweigh risks?Comorbidities, such as severe heart disease, may make apheresis dangerous for patientTherapeutic medications that are predominantly in plasma (e.g., rituximab or IVIG) are removed by apheresisTechnical issues: How will the procedure best be done?AnticoagulationCitrate or heparin could be consideredCitrate is favored in most situationsReplacement fluidSaline, albumin, or plasma could be usedAlbumin is favored in most situationsVascular accessPeripheral veins or placement of central venous catheter could be usedProcessed volume1 or 1.5 volumes could be considered1 plasma volume is standardTherapeutic plan: How many procedures will be needed and for how long?Clinical and laboratory endpoints: How will effect of plasma exchange be evaluated?Timing and locations: When and where should procedure be initiated?Timing: Procedure could be started right away as an emergency or over the next few days or weeksLocation: Common locations are hospitals and outpatient apheresis clinics",
                    "sub_points": [
                      "Rationale: Can plasma exchange effectively remove disease-causing agent?Consider results of published clinical trials or ASFA guidelines as guidance",
                      "Consider results of published clinical trials or ASFA guidelines as guidance",
                      "Impact: Can plasma exchange cause harm to patient? Do benefits outweigh risks?Comorbidities, such as severe heart disease, may make apheresis dangerous for patientTherapeutic medications that are predominantly in plasma (e.g., rituximab or IVIG) are removed by apheresis",
                      "Comorbidities, such as severe heart disease, may make apheresis dangerous for patient",
                      "Therapeutic medications that are predominantly in plasma (e.g., rituximab or IVIG) are removed by apheresis",
                      "Technical issues: How will the procedure best be done?AnticoagulationCitrate or heparin could be consideredCitrate is favored in most situationsReplacement fluidSaline, albumin, or plasma could be usedAlbumin is favored in most situationsVascular accessPeripheral veins or placement of central venous catheter could be usedProcessed volume1 or 1.5 volumes could be considered1 plasma volume is standard",
                      "AnticoagulationCitrate or heparin could be consideredCitrate is favored in most situations",
                      "Citrate or heparin could be considered",
                      "Citrate is favored in most situations",
                      "Replacement fluidSaline, albumin, or plasma could be usedAlbumin is favored in most situations",
                      "Saline, albumin, or plasma could be used",
                      "Albumin is favored in most situations",
                      "Vascular accessPeripheral veins or placement of central venous catheter could be used",
                      "Peripheral veins or placement of central venous catheter could be used",
                      "Processed volume1 or 1.5 volumes could be considered1 plasma volume is standard",
                      "1 or 1.5 volumes could be considered",
                      "1 plasma volume is standard",
                      "Therapeutic plan: How many procedures will be needed and for how long?",
                      "Clinical and laboratory endpoints: How will effect of plasma exchange be evaluated?",
                      "Timing and locations: When and where should procedure be initiated?Timing: Procedure could be started right away as an emergency or over the next few days or weeksLocation: Common locations are hospitals and outpatient apheresis clinics",
                      "Timing: Procedure could be started right away as an emergency or over the next few days or weeks",
                      "Location: Common locations are hospitals and outpatient apheresis clinics"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "American Society for Apheresis (ASFA)"
                  },
                  {
                    "text": "Intravenous immunoglobulin (IVIG)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Timing and Frequency of Plasma Exchange Procedures Depend on the Following": [
                  {
                    "text": "Diagnosis for which plasma exchange is requested"
                  },
                  {
                    "text": "Time it takes removed component of interest to re-equilibrate into intravascular spaceRe-equilibration of IgG typically occurs within 2 daysFive to six 1 plasma volume exchanges over 2 weeks for IgG removal (every other day) usually achieves 70%-85% reduction in IgGRemoval of IgM is more robustOnly 1 or 2 treatments may be needed for clinical impact",
                    "sub_points": [
                      "Re-equilibration of IgG typically occurs within 2 daysFive to six 1 plasma volume exchanges over 2 weeks for IgG removal (every other day) usually achieves 70%-85% reduction in IgG",
                      "Five to six 1 plasma volume exchanges over 2 weeks for IgG removal (every other day) usually achieves 70%-85% reduction in IgG",
                      "Removal of IgM is more robustOnly 1 or 2 treatments may be needed for clinical impact",
                      "Only 1 or 2 treatments may be needed for clinical impact"
                    ]
                  },
                  {
                    "text": "Need to minimize risk of bleeding as a result of depletion of clotting factors, especially fibrinogen63% of fibrinogen is removed after 1 plasma volume exchangeOnly 65% recovers after 48 hrUse of plasma with exchange as replacement fluid minimizes this risk",
                    "sub_points": [
                      "63% of fibrinogen is removed after 1 plasma volume exchangeOnly 65% recovers after 48 hr",
                      "Only 65% recovers after 48 hr",
                      "Use of plasma with exchange as replacement fluid minimizes this risk"
                    ]
                  },
                  {
                    "text": "Goal of plasma exchange therapyResponse to therapy may be laboratory target (platelet count in TTP) or clinical response (neurologic diseases)",
                    "sub_points": [
                      "Response to therapy may be laboratory target (platelet count in TTP) or clinical response (neurologic diseases)"
                    ]
                  },
                  {
                    "text": "Severity of presenting illnessDaily treatments are favored during more severe illnesses",
                    "sub_points": [
                      "Daily treatments are favored during more severe illnesses"
                    ]
                  }
                ],
                "Replacement Fluid Used During Exchange Procedures Depend on the Following": [
                  {
                    "text": "Bleeding riskPatients who are currently bleeding (pulmonary hemorrhage in Goodpasture syndrome) or who are at risk for bleeding (future surgery) will need plasma replacement",
                    "sub_points": [
                      "Patients who are currently bleeding (pulmonary hemorrhage in Goodpasture syndrome) or who are at risk for bleeding (future surgery) will need plasma replacement"
                    ]
                  },
                  {
                    "text": "Procedure frequency5% albumin is most commonly used replacement fluid for most plasma exchange indications, when done every other dayPlasma may be needed for procedures that occur daily",
                    "sub_points": [
                      "5% albumin is most commonly used replacement fluid for most plasma exchange indications, when done every other day",
                      "Plasma may be needed for procedures that occur daily"
                    ]
                  },
                  {
                    "text": "Underlying diagnosisUse of plasma in TTP is therapeutic because it replaces deficient ADAMTS13 protein",
                    "sub_points": [
                      "Use of plasma in TTP is therapeutic because it replaces deficient ADAMTS13 protein"
                    ]
                  },
                  {
                    "text": "Patient allergic historyAllergic symptoms are more common when using plasmaPlasma use should be avoided when possible in patients with history of allergic symptoms to plasma-containing products",
                    "sub_points": [
                      "Allergic symptoms are more common when using plasma",
                      "Plasma use should be avoided when possible in patients with history of allergic symptoms to plasma-containing products"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Therapeutic Plasma Exchange": {
            "name": "Therapeutic Plasma Exchange",
            "url": "https://app.pathprimer.com/document/2ee9e9c0-2800-4db1-a0eb-18230c6a59f4/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "In TPE, whole blood of patient is removed by apheresis device, and plasma of patient is separated and removed"
                  },
                  {
                    "text": "TPE is used for plasma antibody (rarely immune complex) removal and removal of plasma-prevalent drugs, paraproteins, lipoproteins, and other molecules for therapeutic purposes"
                  }
                ]
              },
              "OVERVIEW": {
                "": [
                  {
                    "text": "In general, TPE is used for plasma antibody (rarely immune complex) removal"
                  },
                  {
                    "text": "Plasma-prevalent drugs, paraproteins, lipoproteins, and other molecules can also be removed for therapeutic purposes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Therapeutic plasma exchange (TPE)"
                  },
                  {
                    "text": "Fresh frozen plasma (FFP)"
                  },
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP)"
                  },
                  {
                    "text": "Plasma volume (PV)"
                  },
                  {
                    "text": "Intravenous immunoglobulin (IVIG)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Methods for Therapeutic Plasma Exchange Procedures": [
                  {
                    "text": "Can be performed by centrifugation or membrane filtration and by continuous or intermittent flow techniques"
                  },
                  {
                    "text": "Commonly used TPE devices include Spectra and Optia (continuous flow centrifugation devices)"
                  }
                ],
                "Replacement Fluids and Anticoagulants for Therapeutic Plasma Exchange": [
                  {
                    "text": "Standard replacement fluidsOptions include 5% albumin, 0.9% normal saline, and plasma (FFP)Albumin/saline combinations used for many standard TPE proceduresAlbumin replacement only used for many standard TPE proceduresEspecially when patient is volume sensitive and may not tolerate salinePlasma with or without albumin used when bleeding risk is great or when therapeutically neededADAMTS13 replacement in patients with TTP",
                    "sub_points": [
                      "Options include 5% albumin, 0.9% normal saline, and plasma (FFP)Albumin/saline combinations used for many standard TPE proceduresAlbumin replacement only used for many standard TPE proceduresEspecially when patient is volume sensitive and may not tolerate salinePlasma with or without albumin used when bleeding risk is great or when therapeutically neededADAMTS13 replacement in patients with TTP",
                      "Albumin/saline combinations used for many standard TPE procedures",
                      "Albumin replacement only used for many standard TPE proceduresEspecially when patient is volume sensitive and may not tolerate saline",
                      "Especially when patient is volume sensitive and may not tolerate saline",
                      "Plasma with or without albumin used when bleeding risk is great or when therapeutically neededADAMTS13 replacement in patients with TTP",
                      "ADAMTS13 replacement in patients with TTP"
                    ]
                  },
                  {
                    "text": "Standard anticoagulantsCitrate and heparin can be used to prevent coagulation in circuit of machineAnticoagulant used is often device dependent",
                    "sub_points": [
                      "Citrate and heparin can be used to prevent coagulation in circuit of machine",
                      "Anticoagulant used is often device dependent"
                    ]
                  }
                ],
                "Volume Exchanged for Therapeutic Plasma Exchange Procedures": [
                  {
                    "text": "Efficacy of TPE depends onPatient PVThe larger the patient, the more plasma needs to be removedDistribution of pathologic substance being removed (amount accessible in intravascular space)Synthesis and equilibrium rate of substance to be removed",
                    "sub_points": [
                      "Patient PVThe larger the patient, the more plasma needs to be removed",
                      "The larger the patient, the more plasma needs to be removed",
                      "Distribution of pathologic substance being removed (amount accessible in intravascular space)",
                      "Synthesis and equilibrium rate of substance to be removed"
                    ]
                  },
                  {
                    "text": "Most TPE procedures are 1 or 1.5 PV procedures65% of substance is removed after 1 PV75% of substance is removed after 1.5 PVMost standard models do not predict meaningful additional benefit for procedures that process > 1.5 PV",
                    "sub_points": [
                      "65% of substance is removed after 1 PV",
                      "75% of substance is removed after 1.5 PV",
                      "Most standard models do not predict meaningful additional benefit for procedures that process > 1.5 PV"
                    ]
                  }
                ],
                "Timing and Frequency of Therapeutic Plasma Exchange Procedures": [
                  {
                    "text": "Standard protocols require > 1 procedure and are spaced to occur every other dayThis maximizes re-equilibration between intravascular and extravascular spaces for pathologic substance and minimizes risk for bleeding1 PV TPE performed 5-6 times achieves 70%-85% reduction in pathologic IgG",
                    "sub_points": [
                      "This maximizes re-equilibration between intravascular and extravascular spaces for pathologic substance and minimizes risk for bleeding",
                      "1 PV TPE performed 5-6 times achieves 70%-85% reduction in pathologic IgG"
                    ]
                  },
                  {
                    "text": "Pathologic substances that are predominantly in intravascular space (e.g., IgM molecules) require fewer procedures due to better procedure efficiency"
                  }
                ],
                "Established Complications From Therapeutic Plasma Exchange Procedures": [
                  {
                    "text": "Citrate toxicity is most commonHypotension and allergic reactions have been reportedPatients with liver disease do not metabolize citrate wellPatients must be monitored carefully for toxicity symptomsInfusions of calcium (intravenous calcium gluconate or chloride) are often used to reduce risk of toxicity symptoms during procedure",
                    "sub_points": [
                      "Hypotension and allergic reactions have been reported",
                      "Patients with liver disease do not metabolize citrate wellPatients must be monitored carefully for toxicity symptoms",
                      "Patients must be monitored carefully for toxicity symptoms",
                      "Infusions of calcium (intravenous calcium gluconate or chloride) are often used to reduce risk of toxicity symptoms during procedure"
                    ]
                  },
                  {
                    "text": "All plasma components are removed by TPECoagulation factors and platelet counts decrease (increases bleeding risk)Most removed factors are replaced endogenously within 2-4 days after procedureLaboratory tests immediately postprocedure are not advised, as it often takes 24 hr to re-establish equilibrium between intravascular and extravascular spacesPlasma or cryoprecipitate can be used as replacement fluid or after procedure to reduce bleeding risk",
                    "sub_points": [
                      "Coagulation factors and platelet counts decrease (increases bleeding risk)",
                      "Most removed factors are replaced endogenously within 2-4 days after procedure",
                      "Laboratory tests immediately postprocedure are not advised, as it often takes 24 hr to re-establish equilibrium between intravascular and extravascular spaces",
                      "Plasma or cryoprecipitate can be used as replacement fluid or after procedure to reduce bleeding risk"
                    ]
                  },
                  {
                    "text": "Plasma-predominant therapeutic medications are removedAdditional doses may be neededCommon examples are diltiazem, rituximab, IVIG, ceftriaxone, propranolol, verapamil, vincristine",
                    "sub_points": [
                      "Additional doses may be needed",
                      "Common examples are diltiazem, rituximab, IVIG, ceftriaxone, propranolol, verapamil, vincristine"
                    ]
                  }
                ],
                "Indications for Therapeutic Plasma Exchange": [
                  {
                    "text": "Use of TPE is highly diverse with well-established, evidence-based indications for which TPE is considered first-line therapy"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Therapeutic Erythrocytapheresis": {
            "name": "Therapeutic Erythrocytapheresis",
            "url": "https://app.pathprimer.com/document/6b739d02-7a76-4ba6-b57f-d24d91c599ba/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "In therapeutic erythrocytapheresis and RCE, whole blood of patient is removed by apheresis device, and RBCs of patient are separated and either removed or replaced with donor RBCs"
                  },
                  {
                    "text": "Required volume exchanged for erythrocytapheresis/RCE procedures is determined by desired FCR and hematocrit"
                  },
                  {
                    "text": "Therapeutic erythrocytapheresis removes RBCs and replaces RBCs with albumin or saline, lowering hemoglobin and hematocrit"
                  },
                  {
                    "text": "RCE replaces patient RBCs with donor RBCs for therapeutic benefit"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red cell exchange (RCE)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Fraction of cells remaining (FCR)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Methods for Erythrocytapheresis/Red Cell Exchange Procedures": [
                  {
                    "text": "Can be performed by manual or centrifugation methods"
                  },
                  {
                    "text": "Commonly used erythrocytapheresis devices include Spectra and Optia (continuous flow centrifugation devices)"
                  }
                ],
                "Replacement Fluids and Anticoagulants for Erythrocytapheresis/Red Cell Exchange Procedures": [
                  {
                    "text": "For RCEs, leukoreduced ABO- and D- compatible RBCs should be usedFor patients with sickle cell disease, these units are also Hemoglobin S negative and often matched for C, E, and K red cell antigens",
                    "sub_points": [
                      "For patients with sickle cell disease, these units are also Hemoglobin S negative and often matched for C, E, and K red cell antigens"
                    ]
                  },
                  {
                    "text": "For erythrocytapheresis, replacement options include 5% albumin &/or 0.9% normal saline"
                  },
                  {
                    "text": "Citrate and heparin can be further used to prevent coagulation in circuit of machine"
                  }
                ],
                "Volume Exchanged for Erythrocytapheresis/Red Cell Exchange Procedures": [
                  {
                    "text": "Determined by desired FCR: Percentage of patient RBCs remaining after procedureIn sickle cell disease, typical procedure goal is to reduce hemoglobin S to 30%Assuming 100% hemoglobin S, FCR would need to be 30%",
                    "sub_points": [
                      "In sickle cell disease, typical procedure goal is to reduce hemoglobin S to 30%Assuming 100% hemoglobin S, FCR would need to be 30%",
                      "Assuming 100% hemoglobin S, FCR would need to be 30%"
                    ]
                  },
                  {
                    "text": "Most apheresis devices also require determining final desired hematocrit for procedureIn sickle cell disease, typical procedure goal is hematocrit of 30%",
                    "sub_points": [
                      "In sickle cell disease, typical procedure goal is hematocrit of 30%"
                    ]
                  }
                ],
                "Timing and Frequency of Erythrocytapheresis/Red Cell Exchange Procedures": [
                  {
                    "text": "Standard protocols usually require only 1 procedure for acute therapeutic benefit"
                  },
                  {
                    "text": "In sickle cell disease and in hemochromatosis, routine procedures may be needed every few weeks to maintain target hematocrit, hemoglobin S, or ferritin target"
                  }
                ],
                "Established Complications From Erythrocytapheresis/Red Cell Exchange Procedures": [
                  {
                    "text": "Reactions can occur from infusion of donor RBCsReactions can include hemolysis, fever, acute lung injury, and allergic reactions",
                    "sub_points": [
                      "Reactions can include hemolysis, fever, acute lung injury, and allergic reactions"
                    ]
                  },
                  {
                    "text": "Citrate toxicity can also occur"
                  }
                ],
                "Indications for Erythrocytapheresis/Red Cell Exchange": [
                  {
                    "text": "Babesiosis"
                  },
                  {
                    "text": "Hereditary hemachromatosis"
                  },
                  {
                    "text": "Polycythemia vera"
                  },
                  {
                    "text": "Sickle cell disease"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Therapeutic Cytapheresis": {
            "name": "Therapeutic Cytapheresis",
            "url": "https://app.pathprimer.com/document/784e9adb-7e0f-43ee-ad8a-396eed9a7815/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "In therapeutic cytapheresis, whole blood of patient is removed by apheresis device, and cells of patient are separated and removed"
                  },
                  {
                    "text": "Common procedures include thrombocytapheresis and leukocytapheresis"
                  }
                ]
              },
              "OVERVIEW": {
                "Therapeutic Cytapheresis Is Procedure in Which Whole Blood of Patient Is Removed by Apheresis Device and Cells of Patient Are Separated and Removed": [
                  {
                    "text": "Thrombocytapheresis: Therapeutic cytapheresis procedure in which platelets are removedApheresis device returns remainder of patient’s blood with or without addition of replacement fluid such as colloid &/or crystalloid solution",
                    "sub_points": [
                      "Apheresis device returns remainder of patient’s blood with or without addition of replacement fluid such as colloid &/or crystalloid solution"
                    ]
                  },
                  {
                    "text": "Leukocytapheresis: Therapeutic cytapheresis procedure in which WBCs (e.g., leukemic blasts or granulocytes) are removedApheresis device returns remainder of patient’s blood with or without addition of replacement fluid such as colloid &/or crystalloid solution",
                    "sub_points": [
                      "Apheresis device returns remainder of patient’s blood with or without addition of replacement fluid such as colloid &/or crystalloid solution"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Total blood volume (TBV)"
                  },
                  {
                    "text": "Hydroxyethyl starch (HES)"
                  },
                  {
                    "text": "Disseminated intravascular coagulation (DIC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Methods for Cytapheresis Procedures": [
                  {
                    "text": "Can be performed by centrifugation or membrane filtration and by continuous or intermittent flow techniques"
                  },
                  {
                    "text": "Commonly used devices include Spectra and Optia (continuous flow centrifugation devices)"
                  }
                ],
                "Replacement Fluids and Anticoagulants for Cytapheresis Procedures": [
                  {
                    "text": "Replacement fluid is not routinely used in platelet or WBC reduction procedures, as < 15% of patient's TBV is removed5% albumin is suggested as standard replacement fluid in cases where > 15% of patient's TBV is removed, such as in pediatric patients",
                    "sub_points": [
                      "5% albumin is suggested as standard replacement fluid in cases where > 15% of patient's TBV is removed, such as in pediatric patients"
                    ]
                  },
                  {
                    "text": "Citrate is anticoagulant of choice for these proceduresHeparin can cause platelet clumping in apheresis circuit",
                    "sub_points": [
                      "Heparin can cause platelet clumping in apheresis circuit"
                    ]
                  },
                  {
                    "text": "Donor red cell transfusions may be needed with some cytapheresis proceduresSome patients who need procedure may be pancytopenic",
                    "sub_points": [
                      "Some patients who need procedure may be pancytopenic"
                    ]
                  }
                ],
                "Volume Exchanged for Cytapheresis Procedures": [
                  {
                    "text": "Thrombocytapheresis: 1.5-2 blood volume exchanges are often used, resulting in 30%-60% reduction in platelet count"
                  },
                  {
                    "text": "Leukocytapheresis: 1.5-2 blood volume exchanges are often used, resulting in 30%-60% reduction in WBC countEfficacy of WBC removal may be enhanced by 6% HESUse of 6% HES is particularly helpful in patients with chronic myeloid leukemias without renal or heart disease",
                    "sub_points": [
                      "Efficacy of WBC removal may be enhanced by 6% HES",
                      "Use of 6% HES is particularly helpful in patients with chronic myeloid leukemias without renal or heart disease"
                    ]
                  }
                ],
                "Timing and Frequency of Cytapheresis Procedures": [
                  {
                    "text": "Procedures are often requested on urgent basis for patients who are symptomatic"
                  },
                  {
                    "text": "Usually only 1 procedure is needed for therapeutic benefit, but additional days can be used as needed until symptoms resolve"
                  }
                ],
                "Established Complications From Cytapheresis Procedures": [
                  {
                    "text": "Citrate toxicity, hypotension, and allergic reactions have been reported"
                  },
                  {
                    "text": "In procedures where red cells are lost (i.e., leukocytapheresis), red cell transfusion midway through procedure may be needed due to worsening anemia"
                  }
                ],
                "Indications for Cytapheresis": [
                  {
                    "text": "Thrombocytosis: Platelet count > 450,000/μLPrimary thrombocytosis (10% of cases)Thromboembolic risk greatest when platelet count is > 600,000/μLPrimary thrombocytosis (10% of cases)Bleeding risk is greatest when platelet count is > 1,500,000/μLPatients develop acquired von Willebrand syndromeSecondary thrombocytosis (90% of cases)Approximately 4% develop bleeding or thrombotic complications when platelet count is > 1,000,000/μLPheresis is used as bridge to definitive therapy and is not definitive treatment",
                    "sub_points": [
                      "Primary thrombocytosis (10% of cases)Thromboembolic risk greatest when platelet count is > 600,000/μL",
                      "Thromboembolic risk greatest when platelet count is > 600,000/μL",
                      "Primary thrombocytosis (10% of cases)Bleeding risk is greatest when platelet count is > 1,500,000/μLPatients develop acquired von Willebrand syndrome",
                      "Bleeding risk is greatest when platelet count is > 1,500,000/μLPatients develop acquired von Willebrand syndrome",
                      "Patients develop acquired von Willebrand syndrome",
                      "Secondary thrombocytosis (90% of cases)Approximately 4% develop bleeding or thrombotic complications when platelet count is > 1,000,000/μL",
                      "Approximately 4% develop bleeding or thrombotic complications when platelet count is > 1,000,000/μL",
                      "Pheresis is used as bridge to definitive therapy and is not definitive treatment"
                    ]
                  },
                  {
                    "text": "Leukocytosis: WBC > 50,000-100,000/μLHyperleukocytosis: Increased WBCs lead to hyperviscosity and can cause cerebrovascular symptoms (confusion), pulmonary complications, and DICPheresis is used as bridge to chemotherapy and is not definitive treatment",
                    "sub_points": [
                      "Hyperleukocytosis: Increased WBCs lead to hyperviscosity and can cause cerebrovascular symptoms (confusion), pulmonary complications, and DIC",
                      "Pheresis is used as bridge to chemotherapy and is not definitive treatment"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Other Apheresis Methodologies": {
            "name": "Other Apheresis Methodologies",
            "url": "https://app.pathprimer.com/document/7864aa86-b951-4ea3-9def-dbb1e5cc6c21/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Multiple different apheresis methodologies have been developed to enhance therapeutic benefits of devices that separate blood into components"
                  },
                  {
                    "text": "ECP and LDL apheresis are commonly used alternative apheresis modalities"
                  }
                ]
              },
              "OVERVIEW": {
                "Multiple Different Apheresis Methodologies Have Been Developed to Enhance Therapeutic Benefits of Devices That Separate Blood into Components": [
                  {
                    "text": "ECP: Therapeutic procedure in which buffy coat is separated from patient’s blood, treated extracorporeally with photoactive compound (e.g., psoralens), exposed to UVA light, and reinfused to patient during same procedure"
                  },
                  {
                    "text": "LDL apheresis: Selective removal of LDLs from blood with return of remaining components"
                  },
                  {
                    "text": "Adsorptive cytapheresis: Therapeutic procedure in which blood of patient is passed through device that contains column or filter that selectively adsorbs activated monocytes and granulocytes, allowing remaining leukocytes and other blood components to be returned to patientTherapeutic examples: Inflammatory bowel disease, psoriasis, vasculitis",
                    "sub_points": [
                      "Therapeutic examples: Inflammatory bowel disease, psoriasis, vasculitis"
                    ]
                  },
                  {
                    "text": "β₂-Microglobulin column pheresis: β₂-Microglobulin apheresis column contains porous cellulose beads specifically designed to bind to β₂-microglobulin as patient’s blood passes over beadsTherapeutic example: Amyloidosis",
                    "sub_points": [
                      "Therapeutic example: Amyloidosis"
                    ]
                  },
                  {
                    "text": "HVP exchange: Exchange of 15% of ideal body weight (representing 8-12 L); patient plasma is removed at rate of 1-2 L/hr with replacement with plasma in equivalent volumeTherapeutic example: Acute liver failure",
                    "sub_points": [
                      "Therapeutic example: Acute liver failure"
                    ]
                  },
                  {
                    "text": "IA: Therapeutic procedure in which plasma of patient, after separation from blood, is passed through medical device that has capacity to remove immunoglobulins by specifically binding them to active component (e.g., staphylococcal protein A) of deviceTherapeutic examples: Coagulation factor inhibitors, cryoglobulinemia, dilated cardiomyopathy, immune thrombocytopenia",
                    "sub_points": [
                      "Therapeutic examples: Coagulation factor inhibitors, cryoglobulinemia, dilated cardiomyopathy, immune thrombocytopenia"
                    ]
                  },
                  {
                    "text": "Rheopheresis: Therapeutic procedure in which blood of patient is passed through medical device that separates high-molecular-weight plasma components to reduce plasma viscosity and red cell aggregationTherapeutic examples: Age-related macular degeneration, sudden sensorineural hearing loss",
                    "sub_points": [
                      "Therapeutic examples: Age-related macular degeneration, sudden sensorineural hearing loss"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Extracorporeal photopheresis (ECP)"
                  },
                  {
                    "text": "Ultraviolet A (UVA)"
                  },
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  },
                  {
                    "text": "High-volume plasma (HVP)"
                  },
                  {
                    "text": "Immunoadsorption (IA)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "American Society for Apheresis (ASFA)"
                  },
                  {
                    "text": "Angiotensin-converting enzyme (ACE)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Extracorporeal Photopheresis": [
                  {
                    "text": "Method for procedureInvolves ex vivo exposure of peripheral blood mononuclear cells and T lymphocytes to photoreactive 8-methoxypsoralen and UVA light8-Methoxypsoralen intercalates into cellular DNAAfter exposure to UVA light, is susceptible to apoptosisExposed cells are reinfused into patient for therapeutic benefitReinfused cells trigger disease-modifying cytokines, stimulate monocytes, induce cytotoxic T-cell response and T-cell apoptosis",
                    "sub_points": [
                      "Involves ex vivo exposure of peripheral blood mononuclear cells and T lymphocytes to photoreactive 8-methoxypsoralen and UVA light8-Methoxypsoralen intercalates into cellular DNAAfter exposure to UVA light, is susceptible to apoptosis",
                      "8-Methoxypsoralen intercalates into cellular DNAAfter exposure to UVA light, is susceptible to apoptosis",
                      "After exposure to UVA light, is susceptible to apoptosis",
                      "Exposed cells are reinfused into patient for therapeutic benefitReinfused cells trigger disease-modifying cytokines, stimulate monocytes, induce cytotoxic T-cell response and T-cell apoptosis",
                      "Reinfused cells trigger disease-modifying cytokines, stimulate monocytes, induce cytotoxic T-cell response and T-cell apoptosis"
                    ]
                  },
                  {
                    "text": "Devices for ECP proceduresOnly 2 devices are approved by FDA in United StatesTherakos UVAR (intermittent flow)Therakos CellEx (continuous flow)",
                    "sub_points": [
                      "Only 2 devices are approved by FDA in United StatesTherakos UVAR (intermittent flow)Therakos CellEx (continuous flow)",
                      "Therakos UVAR (intermittent flow)",
                      "Therakos CellEx (continuous flow)"
                    ]
                  },
                  {
                    "text": "AnticoagulationHeparin is standard for these procedures",
                    "sub_points": [
                      "Heparin is standard for these procedures"
                    ]
                  },
                  {
                    "text": "Common adverse events (generally safe and well tolerated)Patients with elevated triglycerides or bilirubin levels may have diminished procedure efficacy due to sensor interface difficulties/reduced UVA light exposureHypotension, pruritus, and low-grade fevers may occurPatients should avoid sun exposure for 24 hr",
                    "sub_points": [
                      "Patients with elevated triglycerides or bilirubin levels may have diminished procedure efficacy due to sensor interface difficulties/reduced UVA light exposure",
                      "Hypotension, pruritus, and low-grade fevers may occur",
                      "Patients should avoid sun exposure for 24 hr"
                    ]
                  },
                  {
                    "text": "Protocol and indications for ECPStandard treatments include 2 consecutive days every 1-4 weeks with goal of symptomatic improvementOnly FDA-approved indication is cutaneous T-cell lymphomaASFA 2016 category I and II uses for ECPCardiac transplantation cellular rejectionErythrodermic cutaneous T-cell lymphomaAcute and chronic graft-vs.-host diseaseBronchiolitis obliterans syndrome post-lung transplant",
                    "sub_points": [
                      "Standard treatments include 2 consecutive days every 1-4 weeks with goal of symptomatic improvement",
                      "Only FDA-approved indication is cutaneous T-cell lymphomaASFA 2016 category I and II uses for ECPCardiac transplantation cellular rejectionErythrodermic cutaneous T-cell lymphomaAcute and chronic graft-vs.-host diseaseBronchiolitis obliterans syndrome post-lung transplant",
                      "ASFA 2016 category I and II uses for ECPCardiac transplantation cellular rejectionErythrodermic cutaneous T-cell lymphomaAcute and chronic graft-vs.-host diseaseBronchiolitis obliterans syndrome post-lung transplant",
                      "Cardiac transplantation cellular rejection",
                      "Erythrodermic cutaneous T-cell lymphoma",
                      "Acute and chronic graft-vs.-host disease",
                      "Bronchiolitis obliterans syndrome post-lung transplant"
                    ]
                  }
                ],
                "LDL Apheresis": [
                  {
                    "text": "Method for procedureInvolves selective removal of apolipoprotein-containing and lipoprotein (a) lipoproteins using IA system",
                    "sub_points": [
                      "Involves selective removal of apolipoprotein-containing and lipoprotein (a) lipoproteins using IA system"
                    ]
                  },
                  {
                    "text": "Devices for LDL apheresis proceduresOnly 2 devices are approved by FDA in United StatesLiposorber: Uses dextran sulfate (negatively charged) columns to selectively remove LDL (positively charged)Typically 3 plasma volumes processed per procedure, leading to 56%-65% reduction in LDL per procedurePlasmat Secura: Uses infusion of acidic heparin (pH 4.84) to selectively remove LDL (forms insoluble precipitate at acidic pH)67% reduction in LDL per procedure is expectedACE inhibitor drugs are specifically contraindicated for this device for reasons similar to other therapeutic plasma exchange devices",
                    "sub_points": [
                      "Only 2 devices are approved by FDA in United StatesLiposorber: Uses dextran sulfate (negatively charged) columns to selectively remove LDL (positively charged)Typically 3 plasma volumes processed per procedure, leading to 56%-65% reduction in LDL per procedurePlasmat Secura: Uses infusion of acidic heparin (pH 4.84) to selectively remove LDL (forms insoluble precipitate at acidic pH)67% reduction in LDL per procedure is expectedACE inhibitor drugs are specifically contraindicated for this device for reasons similar to other therapeutic plasma exchange devices",
                      "Liposorber: Uses dextran sulfate (negatively charged) columns to selectively remove LDL (positively charged)Typically 3 plasma volumes processed per procedure, leading to 56%-65% reduction in LDL per procedure",
                      "Typically 3 plasma volumes processed per procedure, leading to 56%-65% reduction in LDL per procedure",
                      "Plasmat Secura: Uses infusion of acidic heparin (pH 4.84) to selectively remove LDL (forms insoluble precipitate at acidic pH)67% reduction in LDL per procedure is expectedACE inhibitor drugs are specifically contraindicated for this device for reasons similar to other therapeutic plasma exchange devices",
                      "67% reduction in LDL per procedure is expected",
                      "ACE inhibitor drugs are specifically contraindicated for this device for reasons similar to other therapeutic plasma exchange devices"
                    ]
                  },
                  {
                    "text": "AnticoagulationHeparin is standard for these procedures",
                    "sub_points": [
                      "Heparin is standard for these procedures"
                    ]
                  },
                  {
                    "text": "Common adverse events (generally safe and well tolerated)Overall adverse event rate is 11%Postprocedure bleeding (from heparin), emesis, hypoglycemia, hypotensionSome LDL apheresis systems have been found to result in significant removal of vitamin B12, transferrin, and ferritinMay cause anemia, requiring supplementation of vitamin B12 and iron",
                    "sub_points": [
                      "Overall adverse event rate is 11%Postprocedure bleeding (from heparin), emesis, hypoglycemia, hypotension",
                      "Postprocedure bleeding (from heparin), emesis, hypoglycemia, hypotension",
                      "Some LDL apheresis systems have been found to result in significant removal of vitamin B12, transferrin, and ferritinMay cause anemia, requiring supplementation of vitamin B12 and iron",
                      "May cause anemia, requiring supplementation of vitamin B12 and iron"
                    ]
                  },
                  {
                    "text": "Protocol and indications for LDL apheresisTreatment is lifelongFrequency of procedures determined by how quickly plasma LDL rebounds for each patientThis process is mainly indicated currently for treatment of patients with familial hypercholesterolemia who cannot be managed with diet and maximum drug therapyASFA 2016 category I and II uses for LDL apheresisFamilial hypercholesterolemia (homozygous and heterozygous forms)Lipoprotein (a) hyperlipoproteinemiaPeripheral vascular diseasesPhytanic acid storage disease (Refsum disease)",
                    "sub_points": [
                      "Treatment is lifelongFrequency of procedures determined by how quickly plasma LDL rebounds for each patient",
                      "Frequency of procedures determined by how quickly plasma LDL rebounds for each patient",
                      "This process is mainly indicated currently for treatment of patients with familial hypercholesterolemia who cannot be managed with diet and maximum drug therapyASFA 2016 category I and II uses for LDL apheresisFamilial hypercholesterolemia (homozygous and heterozygous forms)Lipoprotein (a) hyperlipoproteinemiaPeripheral vascular diseasesPhytanic acid storage disease (Refsum disease)",
                      "ASFA 2016 category I and II uses for LDL apheresisFamilial hypercholesterolemia (homozygous and heterozygous forms)Lipoprotein (a) hyperlipoproteinemiaPeripheral vascular diseasesPhytanic acid storage disease (Refsum disease)",
                      "Familial hypercholesterolemia (homozygous and heterozygous forms)",
                      "Lipoprotein (a) hyperlipoproteinemia",
                      "Peripheral vascular diseases",
                      "Phytanic acid storage disease (Refsum disease)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Thrombotic Thrombocytopenic Purpura": {
            "name": "Thrombotic Thrombocytopenic Purpura",
            "url": "https://app.pathprimer.com/document/800249a9-8485-4294-945d-47e8f96356d2/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Thrombotic thrombocytopenic purpura (TTP): Caused by severe deficiency of ADAMTS13, often caused by an autoantibody"
                  },
                  {
                    "text": "Plasma exchange removes anti-ADAMTS13 autoantibody and replaces ADAMTS13Has reduced mortality of this disease to < 10%",
                    "sub_points": [
                      "Has reduced mortality of this disease to < 10%"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Disease process is driven by severe deficiency of ADAMTS13 (a disintegrin and metalloprotease), which specifically cleaves ultra-large von Willebrand factor (ULVWF) multimers"
                  },
                  {
                    "text": "Uncontrolled, ULVWF strings form in microcirculation, resulting in thrombocytopenia due to platelet deposition and leading to microvascular obstruction (ischemia) and mechanical damage to red blood cells (anemia)"
                  },
                  {
                    "text": "Congenital and acquired forms of the disease existAcquired formsAssociated with autoantibody against ADAMTS13IgG4 is the most common anti-ADAMTS13 IgG subclassCongenital formsAssociated with diminished or absent production of ADAMTS13",
                    "sub_points": [
                      "Acquired formsAssociated with autoantibody against ADAMTS13IgG4 is the most common anti-ADAMTS13 IgG subclass",
                      "Associated with autoantibody against ADAMTS13",
                      "IgG4 is the most common anti-ADAMTS13 IgG subclass",
                      "Congenital formsAssociated with diminished or absent production of ADAMTS13",
                      "Associated with diminished or absent production of ADAMTS13"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Annual incidence: 0.37 per 100,000"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Classic pentadThrombocytopeniaMicroangiopathic hemolytic anemia (MAHA)Mental status changesRenal failureFever (usually not seen clinically)",
                    "sub_points": [
                      "Thrombocytopenia",
                      "Microangiopathic hemolytic anemia (MAHA)",
                      "Mental status changes",
                      "Renal failure",
                      "Fever (usually not seen clinically)"
                    ]
                  },
                  {
                    "text": "10-40% report infection or flu-like symptoms in the weeks preceding diagnosis"
                  },
                  {
                    "text": "Clinical findings of unexplained thrombocytopenia and MAHA are usually sufficient to clinically diagnose TTP todayAlthough platelet counts can be very low (< 10K), patients with TTP have thrombotic (stroke/MI) rather than hemorrhagic tendencies (can see increased troponins or ST elevation)",
                    "sub_points": [
                      "Although platelet counts can be very low (< 10K), patients with TTP have thrombotic (stroke/MI) rather than hemorrhagic tendencies (can see increased troponins or ST elevation)"
                    ]
                  },
                  {
                    "text": "General MAHA signs and symptoms includeAnemia and thrombocytopeniaMucocutaneous bleeding or purpura when platelets fall < 20KIncrease in lactate dehydrogenase (LDH)Fall in haptoglobinSchistocytes on peripheral blood smearHemoglobinemia and hemoglobinuriaRenal dysfunction in rare cases (increased creatinine/BUN)",
                    "sub_points": [
                      "Anemia and thrombocytopeniaMucocutaneous bleeding or purpura when platelets fall < 20K",
                      "Mucocutaneous bleeding or purpura when platelets fall < 20K",
                      "Increase in lactate dehydrogenase (LDH)",
                      "Fall in haptoglobin",
                      "Schistocytes on peripheral blood smear",
                      "Hemoglobinemia and hemoglobinuria",
                      "Renal dysfunction in rare cases (increased creatinine/BUN)"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Plasma exchange (use 100% plasma: FFP or cryo-poor plasma)Plasma exchange removes anti-ADAMTS13 autoantibody and replaces ADAMTS13Considered category I (first line) indication for plasma exchange according to American Society for Apheresis (ASFA)Treatment is usually initiated urgently within 4-8 hours of diagnostic suspicion (considered a medical emergency)Plasma infusions can be given until plasma exchange can be initiated, if not rapidly availablePlasma exchange is generally performed daily (usually 7-8 days) until platelet count is > 150 x 109 per liter, and LDH is near normal for 2-3 consecutive days",
                    "sub_points": [
                      "Plasma exchange removes anti-ADAMTS13 autoantibody and replaces ADAMTS13Considered category I (first line) indication for plasma exchange according to American Society for Apheresis (ASFA)",
                      "Considered category I (first line) indication for plasma exchange according to American Society for Apheresis (ASFA)",
                      "Treatment is usually initiated urgently within 4-8 hours of diagnostic suspicion (considered a medical emergency)Plasma infusions can be given until plasma exchange can be initiated, if not rapidly available",
                      "Plasma infusions can be given until plasma exchange can be initiated, if not rapidly available",
                      "Plasma exchange is generally performed daily (usually 7-8 days) until platelet count is > 150 x 109 per liter, and LDH is near normal for 2-3 consecutive days"
                    ]
                  },
                  {
                    "text": "Medical (medication) managementCorticosteroids are often used as primary adjunct to plasma exchange (1 mg per kg of body weight, per day)Rituximab is often used to treat refractory/relapsing casesUse is now increasing for this as primary adjunct therapeutic agentCyclosporine, azathioprine, vincristine, and splenectomy can also be used in refractory cases",
                    "sub_points": [
                      "Corticosteroids are often used as primary adjunct to plasma exchange (1 mg per kg of body weight, per day)",
                      "Rituximab is often used to treat refractory/relapsing casesUse is now increasing for this as primary adjunct therapeutic agent",
                      "Use is now increasing for this as primary adjunct therapeutic agent",
                      "Cyclosporine, azathioprine, vincristine, and splenectomy can also be used in refractory cases"
                    ]
                  },
                  {
                    "text": "Blood product usePlatelets should only be transfused for potential life-threatening bleeding (otherwise it should be avoided)Transfusion of RBCs can be used to treat associated anemia",
                    "sub_points": [
                      "Platelets should only be transfused for potential life-threatening bleeding (otherwise it should be avoided)",
                      "Transfusion of RBCs can be used to treat associated anemia"
                    ]
                  }
                ],
                "Prevention": [
                  {
                    "text": "In congenital cases, routine/scheduled transfusions of FFP have been prophylactically used in some patients to maintain normal ADAMTS13 levels at times of risk"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Plasma exchange has decreased overall mortality of idiopathic TTP from almost uniformly fatal to < 10%"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Disseminated intravascular coagulation"
                  },
                  {
                    "text": "Severe malignant hypertension"
                  },
                  {
                    "text": "Pernicious anemia (vitamin B12 deficiency)"
                  },
                  {
                    "text": "Hemolytic uremic syndrome"
                  },
                  {
                    "text": "Posttransplant or drug-induced thrombotic microangiopathy"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Analytic Techniques": [
                  {
                    "text": "ADAMTS13 enzyme activity level assayTTP is associated with severe (< 10%) plasma deficiency in ADAMTS13 activity",
                    "sub_points": [
                      "TTP is associated with severe (< 10%) plasma deficiency in ADAMTS13 activity"
                    ]
                  },
                  {
                    "text": "ADAMTS13 autoantibody (inhibitor) assayDetection of autoantibody (inhibitor) against ADAMTS13 is strong evidence for acquired form of TTP (does not rule out congenital form)",
                    "sub_points": [
                      "Detection of autoantibody (inhibitor) against ADAMTS13 is strong evidence for acquired form of TTP (does not rule out congenital form)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Complications of Apheresis": {
            "name": "Complications of Apheresis",
            "url": "https://app.pathprimer.com/document/b36c6ebb-8ae9-459c-8b6a-5a60ddcda66d/lesson/55a695f2-eb15-4253-b7e2-b8432eec0e0c",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Plasma exchange is well tolerated in most cases, and adverse events are rare"
                  },
                  {
                    "text": "Adverse events can occur because of pheresis catheter, replacement fluid, or procedure itself"
                  }
                ]
              },
              "OVERVIEW": {
                "Complications From Plasma Exchange Procedures Can Be Related to Vascular Access, Replacement Fluid, or Procedure Itself": [
                  {
                    "text": "Plasma exchange procedures generally well tolerated4%-12% overall mild reaction rateCitrate-related reactions most common (3%), followed by vasovagal (0.2%), vascular access (0.2%), and plasma-related (0.1%) eventsSerious complications occur in 1.5% of all procedures",
                    "sub_points": [
                      "4%-12% overall mild reaction rate",
                      "Citrate-related reactions most common (3%), followed by vasovagal (0.2%), vascular access (0.2%), and plasma-related (0.1%) events",
                      "Serious complications occur in 1.5% of all procedures"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Tissue plasminogen activator (t-PA)"
                  },
                  {
                    "text": "Intravenous (IV)"
                  },
                  {
                    "text": "Electrocardiogram (ECG)"
                  },
                  {
                    "text": "Angiotensin-converting enzyme (ACE)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Adverse Effects From Vascular Access": [
                  {
                    "text": "SepsisEtiologyPoor technique associated with line placement, care, or maintenanceSigns and symptomsFeverHypotensionPositive blood cultureTreatmentRemove and replace infected lineAntibiotics",
                    "sub_points": [
                      "EtiologyPoor technique associated with line placement, care, or maintenance",
                      "Poor technique associated with line placement, care, or maintenance",
                      "Signs and symptomsFeverHypotensionPositive blood culture",
                      "Fever",
                      "Hypotension",
                      "Positive blood culture",
                      "TreatmentRemove and replace infected lineAntibiotics",
                      "Remove and replace infected line",
                      "Antibiotics"
                    ]
                  },
                  {
                    "text": "ThrombosisEtiologyTurbulent catheter flow activating platelets and coagulation factorsSigns and symptomsCatheter cannot be flushedHigh-pressure alarms indicate suboptimal flowProcedure cannot be completedTreatmentAdjust or remove lineThrombolytic agents (i.e., t-PA/alteplase) before starting pheresis",
                    "sub_points": [
                      "EtiologyTurbulent catheter flow activating platelets and coagulation factors",
                      "Turbulent catheter flow activating platelets and coagulation factors",
                      "Signs and symptomsCatheter cannot be flushedHigh-pressure alarms indicate suboptimal flowProcedure cannot be completed",
                      "Catheter cannot be flushed",
                      "High-pressure alarms indicate suboptimal flow",
                      "Procedure cannot be completed",
                      "TreatmentAdjust or remove lineThrombolytic agents (i.e., t-PA/alteplase) before starting pheresis",
                      "Adjust or remove line",
                      "Thrombolytic agents (i.e., t-PA/alteplase) before starting pheresis"
                    ]
                  }
                ],
                "Adverse Effects From Replacement Fluids": [
                  {
                    "text": "Allergic reactionsEtiologySensitivity to certain albumin preparations, hydroxyethyl starch, plasma, or ethylene oxide (cleaning agent)Signs and symptomsItchingUrticariaFacial edemaWheezingShortness of breathHypotensionTreatmentDiphenhydramine (if mild)IV methylprednisolone (if moderate)Subcutaneous epinephrine (if severe)Trying different fluid formulations may help prevent future reactionsConsider repeated priming of apheresis tubing on future procedures to wash out ethylene oxide",
                    "sub_points": [
                      "EtiologySensitivity to certain albumin preparations, hydroxyethyl starch, plasma, or ethylene oxide (cleaning agent)",
                      "Sensitivity to certain albumin preparations, hydroxyethyl starch, plasma, or ethylene oxide (cleaning agent)",
                      "Signs and symptomsItchingUrticariaFacial edemaWheezingShortness of breathHypotension",
                      "Itching",
                      "Urticaria",
                      "Facial edema",
                      "Wheezing",
                      "Shortness of breath",
                      "Hypotension",
                      "TreatmentDiphenhydramine (if mild)IV methylprednisolone (if moderate)Subcutaneous epinephrine (if severe)Trying different fluid formulations may help prevent future reactionsConsider repeated priming of apheresis tubing on future procedures to wash out ethylene oxide",
                      "Diphenhydramine (if mild)",
                      "IV methylprednisolone (if moderate)",
                      "Subcutaneous epinephrine (if severe)",
                      "Trying different fluid formulations may help prevent future reactions",
                      "Consider repeated priming of apheresis tubing on future procedures to wash out ethylene oxide"
                    ]
                  },
                  {
                    "text": "Transfusion reactions (nonallergic)When blood products are used as replacement fluids (i.e., plasma), patient is at risk for all known infectious and noninfectious reactionsReactions should be evaluated and treated similar to any transfusion reaction",
                    "sub_points": [
                      "When blood products are used as replacement fluids (i.e., plasma), patient is at risk for all known infectious and noninfectious reactions",
                      "Reactions should be evaluated and treated similar to any transfusion reaction"
                    ]
                  }
                ],
                "Adverse Effects From Apheresis Procedure": [
                  {
                    "text": "Hypocalcemia (most common adverse event)EtiologyTemporary reduction in plasma ionized calcium by exposure to procedure provided citrate (which is calcium binder)Signs and symptomsParesthesiasCircumoral tinglingVibration sensation of jaw or bed/chairAbdominal painNausea/emesisDiarrheaChest tightnessHypotensionProlonged Q-T interval on ECGTetanyTreatmentPause procedure to allow natural metabolism of citrateSlow citrate infusion rate by decreasing the whole blood flow rate or increasing whole blood-to-acid citrate dextrose ratioAdminister IV calcium gluconate or chlorideAdd calcium gluconate to colloid or crystalloid replacement fluidCitrate toxicity risk higher in small-sized patients, patients with hepatic dysfunction, or when plasma is used as replacement fluid",
                    "sub_points": [
                      "EtiologyTemporary reduction in plasma ionized calcium by exposure to procedure provided citrate (which is calcium binder)",
                      "Temporary reduction in plasma ionized calcium by exposure to procedure provided citrate (which is calcium binder)",
                      "Signs and symptomsParesthesiasCircumoral tinglingVibration sensation of jaw or bed/chairAbdominal painNausea/emesisDiarrheaChest tightnessHypotensionProlonged Q-T interval on ECGTetany",
                      "Paresthesias",
                      "Circumoral tingling",
                      "Vibration sensation of jaw or bed/chair",
                      "Abdominal pain",
                      "Nausea/emesis",
                      "Diarrhea",
                      "Chest tightness",
                      "Hypotension",
                      "Prolonged Q-T interval on ECG",
                      "Tetany",
                      "TreatmentPause procedure to allow natural metabolism of citrateSlow citrate infusion rate by decreasing the whole blood flow rate or increasing whole blood-to-acid citrate dextrose ratioAdminister IV calcium gluconate or chlorideAdd calcium gluconate to colloid or crystalloid replacement fluid",
                      "Pause procedure to allow natural metabolism of citrate",
                      "Slow citrate infusion rate by decreasing the whole blood flow rate or increasing whole blood-to-acid citrate dextrose ratio",
                      "Administer IV calcium gluconate or chloride",
                      "Add calcium gluconate to colloid or crystalloid replacement fluid",
                      "Citrate toxicity risk higher in small-sized patients, patients with hepatic dysfunction, or when plasma is used as replacement fluid"
                    ]
                  },
                  {
                    "text": "Sensation of coldEtiologyReplacement fluids are returned to patient cooler than body temperatureSigns and symptomsChills/rigorsTreatmentProphylactic use of a blood warmer or warmed blankets",
                    "sub_points": [
                      "EtiologyReplacement fluids are returned to patient cooler than body temperature",
                      "Replacement fluids are returned to patient cooler than body temperature",
                      "Signs and symptomsChills/rigors",
                      "Chills/rigors",
                      "TreatmentProphylactic use of a blood warmer or warmed blankets",
                      "Prophylactic use of a blood warmer or warmed blankets"
                    ]
                  },
                  {
                    "text": "AnxietyEtiologyUnderlying anxiety diagnosisProcedural anxietySigns and symptomsTachycardiaHyperventilationHypertension or hypotensionTingling of fingers and toesDiaphoresisTreatmentBreathe into paper bagTrendelenburg position and bolus of normal saline/albumin for hypotensionAnxiolytic medications",
                    "sub_points": [
                      "EtiologyUnderlying anxiety diagnosisProcedural anxiety",
                      "Underlying anxiety diagnosis",
                      "Procedural anxiety",
                      "Signs and symptomsTachycardiaHyperventilationHypertension or hypotensionTingling of fingers and toesDiaphoresis",
                      "Tachycardia",
                      "Hyperventilation",
                      "Hypertension or hypotension",
                      "Tingling of fingers and toes",
                      "Diaphoresis",
                      "TreatmentBreathe into paper bagTrendelenburg position and bolus of normal saline/albumin for hypotensionAnxiolytic medications",
                      "Breathe into paper bag",
                      "Trendelenburg position and bolus of normal saline/albumin for hypotension",
                      "Anxiolytic medications"
                    ]
                  },
                  {
                    "text": "Vasovagal reactionEtiologyUnderlying anxiety diagnosisProcedural anxietySight of bloodSigns and symptomsBradycardiaHypotensionDiaphoresisPallorLoss of consciousness and nausea/emesisTreatmentTrendelenburg position and bolus of normal saline/albumin for hypotensionCold moist towels on forehead and neck",
                    "sub_points": [
                      "EtiologyUnderlying anxiety diagnosisProcedural anxietySight of blood",
                      "Underlying anxiety diagnosis",
                      "Procedural anxiety",
                      "Sight of blood",
                      "Signs and symptomsBradycardiaHypotensionDiaphoresisPallorLoss of consciousness and nausea/emesis",
                      "Bradycardia",
                      "Hypotension",
                      "Diaphoresis",
                      "Pallor",
                      "Loss of consciousness and nausea/emesis",
                      "TreatmentTrendelenburg position and bolus of normal saline/albumin for hypotensionCold moist towels on forehead and neck",
                      "Trendelenburg position and bolus of normal saline/albumin for hypotension",
                      "Cold moist towels on forehead and neck"
                    ]
                  },
                  {
                    "text": "HypovolemiaEtiologyProviding too much crystalloid replacement fluid in volume-sensitive patientProviding isovolemic procedure in volume-sensitive patientProviding plasma exchange to patient on antihypertensive medications (e.g., β-blockers)Signs and symptomsHypotensionDiaphoresisDizzinessLightheadednessNauseaTachycardiaTreatmentHalt procedureTrendelenburg position and bolus of normal saline/albumin for hypotensionPrevention for future proceduresIncrease percent albumin used in procedureAlter procedure such that patient is volume-up at the endHold antihypertensive medications on procedure days until after procedure is done",
                    "sub_points": [
                      "EtiologyProviding too much crystalloid replacement fluid in volume-sensitive patientProviding isovolemic procedure in volume-sensitive patientProviding plasma exchange to patient on antihypertensive medications (e.g., β-blockers)",
                      "Providing too much crystalloid replacement fluid in volume-sensitive patient",
                      "Providing isovolemic procedure in volume-sensitive patient",
                      "Providing plasma exchange to patient on antihypertensive medications (e.g., β-blockers)",
                      "Signs and symptomsHypotensionDiaphoresisDizzinessLightheadednessNauseaTachycardia",
                      "Hypotension",
                      "Diaphoresis",
                      "Dizziness",
                      "Lightheadedness",
                      "Nausea",
                      "Tachycardia",
                      "TreatmentHalt procedureTrendelenburg position and bolus of normal saline/albumin for hypotension",
                      "Halt procedure",
                      "Trendelenburg position and bolus of normal saline/albumin for hypotension",
                      "Prevention for future proceduresIncrease percent albumin used in procedureAlter procedure such that patient is volume-up at the endHold antihypertensive medications on procedure days until after procedure is done",
                      "Increase percent albumin used in procedure",
                      "Alter procedure such that patient is volume-up at the end",
                      "Hold antihypertensive medications on procedure days until after procedure is done"
                    ]
                  },
                  {
                    "text": "ACE inhibitor reactionsEtiologyUnclear, but involves generation and accumulation of excess bradykinin and leads to profound vasodilation in patientHypothesis 1: Activation of contact pathway in apheresis circuit leads to generation and accumulation of bradykininsHypothesis 2: Prekallikrein activator in albumin is activated during procedure and leads to generation and accumulation of bradykininsSigns and symptomsHypotensionFlushingFeelings of doomTreatment and managementHold apheresis for 24-48 hr after last ACE inhibitor dose",
                    "sub_points": [
                      "EtiologyUnclear, but involves generation and accumulation of excess bradykinin and leads to profound vasodilation in patientHypothesis 1: Activation of contact pathway in apheresis circuit leads to generation and accumulation of bradykininsHypothesis 2: Prekallikrein activator in albumin is activated during procedure and leads to generation and accumulation of bradykinins",
                      "Unclear, but involves generation and accumulation of excess bradykinin and leads to profound vasodilation in patient",
                      "Hypothesis 1: Activation of contact pathway in apheresis circuit leads to generation and accumulation of bradykinins",
                      "Hypothesis 2: Prekallikrein activator in albumin is activated during procedure and leads to generation and accumulation of bradykinins",
                      "Signs and symptomsHypotensionFlushingFeelings of doom",
                      "Hypotension",
                      "Flushing",
                      "Feelings of doom",
                      "Treatment and managementHold apheresis for 24-48 hr after last ACE inhibitor dose",
                      "Hold apheresis for 24-48 hr after last ACE inhibitor dose"
                    ]
                  },
                  {
                    "text": "Removal of necessary blood components (if not replaced by plasma in replacement fluid)Plasma-based medications, clotting factors, and platelets all are removed by apheresisWhen clinically significant, these changes may increase infection or bleeding riskTreatment and managementIncrease drug dosages or avoid during apheresisProvide plasma or cryoprecipitate transfusions to mitigate risk",
                    "sub_points": [
                      "Plasma-based medications, clotting factors, and platelets all are removed by apheresis",
                      "When clinically significant, these changes may increase infection or bleeding risk",
                      "Treatment and managementIncrease drug dosages or avoid during apheresisProvide plasma or cryoprecipitate transfusions to mitigate risk",
                      "Increase drug dosages or avoid during apheresis",
                      "Provide plasma or cryoprecipitate transfusions to mitigate risk"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Cellular Therapy and Tissue Banking": {
        "name": "Cellular Therapy and Tissue Banking",
        "url": "https://app.pathprimer.com/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
        "topics": {
          "Overview of Cellular Therapy": {
            "name": "Overview of Cellular Therapy",
            "url": "https://app.pathprimer.com/document/b8a4bb81-6be7-4e95-b6e2-b36f314efbe9/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Cellular therapy is use of viable cells and tissues for treatment of disease"
                  },
                  {
                    "text": "FDA regulates collection, manufacturing, and distribution of human cellular and tissue based products"
                  }
                ]
              },
              "OVERVIEW": {
                "Cellular Therapy": [
                  {
                    "text": "Use of viable cells and tissues for treatment of disease"
                  },
                  {
                    "text": "Blood transfusions were 1st successful form of cell therapy"
                  },
                  {
                    "text": "All cellular therapy products must address product safety, quality, identity, potency, and purity"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Donor typesAutologous: Donor that provide their own cellsSyngeneic: Donor that provides cells to genetically identical recipient (i.e., identical twin)Allogeneic: Donor that provides cells to genetically different/distinct recipientXenogeneic: Nonhuman animal provides cells to human recipient",
                    "sub_points": [
                      "Autologous: Donor that provide their own cells",
                      "Syngeneic: Donor that provides cells to genetically identical recipient (i.e., identical twin)",
                      "Allogeneic: Donor that provides cells to genetically different/distinct recipient",
                      "Xenogeneic: Nonhuman animal provides cells to human recipient"
                    ]
                  },
                  {
                    "text": "Cell typesHomologous cells: Cellular products that are used to repair, construct, replace, or supplement recipient's cells and perform same function between recipient and donore.g., hematopoietic progenitor cell product (HPC) for bone marrow transplantNonhomologous cells: Cellular products that are used to repair, construct, replace, or supplement recipient's cells but perform different function between recipient and donore.g., hematopoietic progenitor cell product (HPC) to repair cardiac muscle",
                    "sub_points": [
                      "Homologous cells: Cellular products that are used to repair, construct, replace, or supplement recipient's cells and perform same function between recipient and donore.g., hematopoietic progenitor cell product (HPC) for bone marrow transplant",
                      "e.g., hematopoietic progenitor cell product (HPC) for bone marrow transplant",
                      "Nonhomologous cells: Cellular products that are used to repair, construct, replace, or supplement recipient's cells but perform different function between recipient and donore.g., hematopoietic progenitor cell product (HPC) to repair cardiac muscle",
                      "e.g., hematopoietic progenitor cell product (HPC) to repair cardiac muscle"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Good Tissue Practices": [
                  {
                    "text": "Designed to ensure quality product and to prevent spread of communicable diseases"
                  },
                  {
                    "text": "Donor eligibility qualificationsDonors must be evaluated by physical exam and assessed for risk factors associated with communicable diseasesDonors must be tested for communicable diseases: HIV, Hepatitis B and C, HTLV, syphilis, west nile virus,Trypanosoma cruzi, and cytomegalovirus (if tissue is viable leukocyte-rich)",
                    "sub_points": [
                      "Donors must be evaluated by physical exam and assessed for risk factors associated with communicable diseases",
                      "Donors must be tested for communicable diseases: HIV, Hepatitis B and C, HTLV, syphilis, west nile virus,Trypanosoma cruzi, and cytomegalovirus (if tissue is viable leukocyte-rich)"
                    ]
                  },
                  {
                    "text": "Purity and potencyAssays must be used to identify cell type of interest and the viability of donor cells collected",
                    "sub_points": [
                      "Assays must be used to identify cell type of interest and the viability of donor cells collected"
                    ]
                  },
                  {
                    "text": "Microbial contaminationProducts must be collected using aseptic techniqueFinal product should be assayed for bacterial or fungal contamination (endotoxin and mycoplasma assays are also required for 351 products)",
                    "sub_points": [
                      "Products must be collected using aseptic technique",
                      "Final product should be assayed for bacterial or fungal contamination (endotoxin and mycoplasma assays are also required for 351 products)"
                    ]
                  }
                ],
                "Sources of Cells": [
                  {
                    "text": "Cellular therapies have been developed using either stem cells or adult tissue specific differentiated cellsStem cells: Cells that have capacity for self renewalMultipotent: Stem cells that have limited spectrum of differentiationPluripotent: Stem cells that have capacity to differentiate into any cell typeDifferentiated cells: Cells that have no capacity for self renewal",
                    "sub_points": [
                      "Stem cells: Cells that have capacity for self renewalMultipotent: Stem cells that have limited spectrum of differentiationPluripotent: Stem cells that have capacity to differentiate into any cell type",
                      "Multipotent: Stem cells that have limited spectrum of differentiation",
                      "Pluripotent: Stem cells that have capacity to differentiate into any cell type",
                      "Differentiated cells: Cells that have no capacity for self renewal"
                    ]
                  },
                  {
                    "text": "Examples of FDA-approved cell therapiesAutologous cultured chondrocytes for cartilage repairAutologous fibroblasts for improvement of nasolabial foldsAutologous cellular immunotherapy for hormone refractory prostate cancerHPC products (including umbilical cord blood) for bone marrow reconstitution",
                    "sub_points": [
                      "Autologous cultured chondrocytes for cartilage repair",
                      "Autologous fibroblasts for improvement of nasolabial folds",
                      "Autologous cellular immunotherapy for hormone refractory prostate cancer",
                      "HPC products (including umbilical cord blood) for bone marrow reconstitution"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA": [
                  {
                    "text": "Regulates collection, manufacturing, and distribution of human cellular and tissue based products21 CFR Part 1271: Regulations designed to prevent introduction, transmission, or spread of communicable diseaseRequires qualification of donor eligibilityRequires use of good tissue practices (cGTP) during tissue procurement, manufacture, and distributionRequires testing for bacterial or fungal contaminationPHS Act 361: Additional regulations for cellular therapy products that are minimally manipulated or intended for homologous useThese products do not require FDA approval prior to marketingPHS Act 351: Additional regulations for cellular therapy products that are manipulated or genetically modified post collection, or intended for use in recipients other than donorUse of these products require FDA approval via investigational new drug (IND) applicationFDA must review clinical safety and efficacy data prior to approval for marketing these productsRequire more strict production requirements (called good manufacturing processes cGMP)",
                    "sub_points": [
                      "21 CFR Part 1271: Regulations designed to prevent introduction, transmission, or spread of communicable diseaseRequires qualification of donor eligibilityRequires use of good tissue practices (cGTP) during tissue procurement, manufacture, and distributionRequires testing for bacterial or fungal contamination",
                      "Requires qualification of donor eligibility",
                      "Requires use of good tissue practices (cGTP) during tissue procurement, manufacture, and distribution",
                      "Requires testing for bacterial or fungal contamination",
                      "PHS Act 361: Additional regulations for cellular therapy products that are minimally manipulated or intended for homologous useThese products do not require FDA approval prior to marketing",
                      "These products do not require FDA approval prior to marketing",
                      "PHS Act 351: Additional regulations for cellular therapy products that are manipulated or genetically modified post collection, or intended for use in recipients other than donorUse of these products require FDA approval via investigational new drug (IND) applicationFDA must review clinical safety and efficacy data prior to approval for marketing these productsRequire more strict production requirements (called good manufacturing processes cGMP)",
                      "Use of these products require FDA approval via investigational new drug (IND) application",
                      "FDA must review clinical safety and efficacy data prior to approval for marketing these products",
                      "Require more strict production requirements (called good manufacturing processes cGMP)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Bone Marrow Derived Hematopoietic Progenitor Cell Products": {
            "name": "Bone Marrow Derived Hematopoietic Progenitor Cell Products",
            "url": "https://app.pathprimer.com/document/e1e7e979-c8a4-490d-8d67-5e029f07f524/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Bone marrow is site of hematopoiesis and therefore a source of hematopoietic stem cells"
                  },
                  {
                    "text": "Bone marrow derived hematopoietic progenitor cell products can be used for marrow reconstitution of stem cells post-transplant"
                  }
                ]
              },
              "OVERVIEW": {
                "Hematopoietic Stem Cell Products Are Primitive Pluripotent Cells Capable of Self-Renewal and Differentiation": [
                  {
                    "text": "Cells can differentiate into lymphocytes, monocytes, granulocytes, erythrocytes, platelets"
                  },
                  {
                    "text": "Cells are capable of reconstituting functions of normal bone marrow when transplanted into patient"
                  },
                  {
                    "text": "In vivo, cells are typically concentrated in bone marrow"
                  },
                  {
                    "text": "Cells are typically identified by presence of surface CD34 using flow cytometry"
                  }
                ],
                "Marrow Harvest Is Invasive Procedure Performed Under Sterile Conditions in Operating Room Under Anesthesia": [
                  {
                    "text": "Blood loss is commonMany patients require blood transfusions",
                    "sub_points": [
                      "Many patients require blood transfusions"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hematopoietic stem cell (HSC)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Graft-vs.-host disease (GVHD)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Dimethyl sulfoxide (DMSO)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hematopoietic Stem Cell Products Can Be Used for Numerous Immune and Nonimmune Diseases": [
                  {
                    "text": "Bone marrow and peripheral blood derived stem cell products can be used for same indications"
                  },
                  {
                    "text": "Bone marrow and peripheral blood derived stem cell products can be used for both autologous and allogeneic transplantsAutologous transplantsMarrow products may be preferred when graft vs. tumor effect is not needed, such as for hemoglobinopathies, or when the patient cannot tolerate G-CSFAllogeneic transplantsMarrow products may be preferred when recipient risk is high for GVHD",
                    "sub_points": [
                      "Autologous transplantsMarrow products may be preferred when graft vs. tumor effect is not needed, such as for hemoglobinopathies, or when the patient cannot tolerate G-CSF",
                      "Marrow products may be preferred when graft vs. tumor effect is not needed, such as for hemoglobinopathies, or when the patient cannot tolerate G-CSF",
                      "Allogeneic transplantsMarrow products may be preferred when recipient risk is high for GVHD",
                      "Marrow products may be preferred when recipient risk is high for GVHD"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Autologous and Allogeneic Donor Eligibility Requirements": [
                  {
                    "text": "Similar to donor eligibility requirements seen for peripheral donors"
                  },
                  {
                    "text": "Care should be taken to ensure that donor can medically tolerate marrow collection procedureDonor must be able to tolerate volume loss associated with marrow harvest (young or small donors may be unsuitable)Total collection volume limited by donor's sizeMaximum collection volume set by Be The Match Registry is 20 mL/kgDonor must be healthy enough for invasive procedureNo severe heart disease if possibleDonor must be able to tolerate anesthesiaDonor should not have had radiation therapy to pelvisSome patients with malignancies may be ineligible",
                    "sub_points": [
                      "Donor must be able to tolerate volume loss associated with marrow harvest (young or small donors may be unsuitable)Total collection volume limited by donor's sizeMaximum collection volume set by Be The Match Registry is 20 mL/kg",
                      "Total collection volume limited by donor's size",
                      "Maximum collection volume set by Be The Match Registry is 20 mL/kg",
                      "Donor must be healthy enough for invasive procedureNo severe heart disease if possible",
                      "No severe heart disease if possible",
                      "Donor must be able to tolerate anesthesia",
                      "Donor should not have had radiation therapy to pelvisSome patients with malignancies may be ineligible",
                      "Some patients with malignancies may be ineligible"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Marrow Collection": [
                  {
                    "text": "Harvest technique varies considerably depending on institution practicePerformed under sterile conditions with anesthesia11- to 14-gauge needle on syringe flushed with anticoagulant is inserted into posterior iliac crest and 5 mL of marrow is aspiratedAspirate is collected into large collection bag with anticoagulantMid-collection nucleated cell count sometimes is used to determine adequacy of procedureProcess is repeated at different posterior iliac crest sites until target collection volume is achieved",
                    "sub_points": [
                      "Performed under sterile conditions with anesthesia",
                      "11- to 14-gauge needle on syringe flushed with anticoagulant is inserted into posterior iliac crest and 5 mL of marrow is aspirated",
                      "Aspirate is collected into large collection bag with anticoagulant",
                      "Mid-collection nucleated cell count sometimes is used to determine adequacy of procedure",
                      "Process is repeated at different posterior iliac crest sites until target collection volume is achieved"
                    ]
                  },
                  {
                    "text": "Target marrow collection totalsDose of total nucleated cells requested is based on recipient weight.Engraftment requires minimum of 2-3 x 10⁸ nucleated cells/kg body weightUsually 10-15 mg/kg recipient body weight",
                    "sub_points": [
                      "Dose of total nucleated cells requested is based on recipient weight.",
                      "Engraftment requires minimum of 2-3 x 10⁸ nucleated cells/kg body weightUsually 10-15 mg/kg recipient body weight",
                      "Usually 10-15 mg/kg recipient body weight"
                    ]
                  },
                  {
                    "text": "Common adverse events during and after procedureAnemia76% of bone marrow donors require transfusion of RBCsAny allogeneic red cell or platelet units used should be irradiated to prevent blood leukocytes from contaminating graftPain at harvest siteFatigueInsomniaNauseaDizzinessAnorexiaAll events usually resolve by 1 month postprocedure",
                    "sub_points": [
                      "Anemia76% of bone marrow donors require transfusion of RBCsAny allogeneic red cell or platelet units used should be irradiated to prevent blood leukocytes from contaminating graft",
                      "76% of bone marrow donors require transfusion of RBCs",
                      "Any allogeneic red cell or platelet units used should be irradiated to prevent blood leukocytes from contaminating graft",
                      "Pain at harvest site",
                      "Fatigue",
                      "Insomnia",
                      "Nausea",
                      "Dizziness",
                      "Anorexia",
                      "All events usually resolve by 1 month postprocedure"
                    ]
                  }
                ],
                "Postcollection Processing": [
                  {
                    "text": "Bone marrow collections are large-volume products compared with apheresis productsRBC reduction and plasma reduction often needed",
                    "sub_points": [
                      "RBC reduction and plasma reduction often needed"
                    ]
                  },
                  {
                    "text": "Bone marrow collections require postcollection filtration and sedimentation to remove bone spicules, fat, and clots in collection bag"
                  },
                  {
                    "text": "RBC reduction, plasma reduction, and CD34+ enrichment otherwise performed in manner similar to peripheral blood derived hematopoietic progenitor cell products"
                  }
                ],
                "Product Storage": [
                  {
                    "text": "DMSO is added at concentrations of 5%-10% to prevent ice crystal formation"
                  },
                  {
                    "text": "DMSO stem cell product is cooled at 1°C-2°C/min to storage temperature of -70°C to -196°C depending on storage type"
                  }
                ],
                "Marrow Collection Processing Outcomes": [
                  {
                    "text": "Minimum number of cells needed for transplantation is 2 x 10⁶ CD34+ cells/kg5 x 10⁶ CD34+ cells/kg is desirable",
                    "sub_points": [
                      "5 x 10⁶ CD34+ cells/kg is desirable"
                    ]
                  },
                  {
                    "text": "Time to stem cell engraftment is longer for bone marrow derived hematopoietic progenitor cell products than for peripheral blood derived hematopoietic progenitor cell productsNeutrophil engraftment: 21 daysPlatelet engraftment: 21-22 days",
                    "sub_points": [
                      "Neutrophil engraftment: 21 days",
                      "Platelet engraftment: 21-22 days"
                    ]
                  },
                  {
                    "text": "In recipients of myeloablative transplants from unrelated donors, survival is equivalent using bone marrow vs. peripheral blood products"
                  },
                  {
                    "text": "Marrow grafts are associated with less chronic GVHD but more graft failuresMarrow products may be preferred in pediatric transplants",
                    "sub_points": [
                      "Marrow products may be preferred in pediatric transplants"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Tests used are similar to tests for peripheral blood stem cell productsTotal nucleated cell count/kg recipient body weightCD34+ cells/kg recipient body weightWBC viability assaysSterility testingFunctional assays (clonogenic assay)",
                    "sub_points": [
                      "Total nucleated cell count/kg recipient body weight",
                      "CD34+ cells/kg recipient body weight",
                      "WBC viability assays",
                      "Sterility testing",
                      "Functional assays (clonogenic assay)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Peripheral Blood Derived Hematopoietic Progenitor Cell Products": {
            "name": "Peripheral Blood Derived Hematopoietic Progenitor Cell Products",
            "url": "https://app.pathprimer.com/document/b1a42907-852e-467e-b752-ab025118ab7e/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Peripheral blood HSC collection is most common procedure for HSC donation"
                  },
                  {
                    "text": "Peripheral blood HSC collections generally require patient stem cell mobilization using G-CSF and an apheresis machine"
                  }
                ]
              },
              "OVERVIEW": {
                "Hematopoietic Stem Cell Products": [
                  {
                    "text": "Primitive pluripotent cells capable of self-renewal and differentiation"
                  },
                  {
                    "text": "Cells can differentiate into lymphocytes, monocytes, granulocytes, erythrocytes, and platelets"
                  },
                  {
                    "text": "Cells are capable of reconstituting functions of normal bone marrow when transplanted into patient"
                  },
                  {
                    "text": "In vivo, these cells are typically concentrated in bone marrow"
                  },
                  {
                    "text": "Cells are typically identified by presence of surface CD34 using flow cytometry"
                  }
                ],
                "Peripheral Blood Hematopoietic Stem Cell Collection": [
                  {
                    "text": "Most common procedure for hematopoietic stem cell donation"
                  },
                  {
                    "text": "Performed on outpatient basis"
                  },
                  {
                    "text": "Generally well tolerated"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hematopoietic stem cell (HSC)"
                  },
                  {
                    "text": "Graft-vs.-host disease (GVHD)"
                  },
                  {
                    "text": "Human leukocyte antigen (HLA)"
                  },
                  {
                    "text": "Cytomegalovirus (CMV)"
                  },
                  {
                    "text": "Human T-lymphotropic virus (HTLV)"
                  },
                  {
                    "text": "US Food and Drug Administration (FDA)"
                  },
                  {
                    "text": "Foundation for the Accreditation of Cellular Therapy (FACT)"
                  },
                  {
                    "text": "National Marrow Donor Program (NMDP)"
                  },
                  {
                    "text": "Granulocyte colony-stimulating factor (G-CSF)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Dimethyl sulfoxide (DMSO)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hematopoietic Stem Cell Products": [
                  {
                    "text": "Used for numerous immune and nonimmune diseases"
                  },
                  {
                    "text": "Use of stem cells differs significantly by recipient age"
                  },
                  {
                    "text": "Decision to perform transplant using HSC products is highly complexRequires integration of patient goals, disease prognosis and progression, transplant type",
                    "sub_points": [
                      "Requires integration of patient goals, disease prognosis and progression, transplant type"
                    ]
                  },
                  {
                    "text": "Current transplant typesAutologous transplantationPredominantly used to rescue patient bone marrow after high-dose cancer chemotherapyAntitumor effect comes from pretransplant chemotherapy, not from HSCsPatients donate HSCs for their own useNo risk of GVHD, graft rejection, or infectious disease transmissionDonors are often illHistory of chemotherapy &/or radiation may affect ability to collect adequate numbers of stem cellsAllogeneic transplantationPredominantly used to treat malignant conditions where there is known therapeutic benefit from receiving donor stem cells (graft-vs.-tumor effect)In children, allogeneic transplantation is required to replace deficient cellular machinery (cure the disease)Product may come from matched-unrelated donor or matched-related (parent, sibling, child) donorRisk of GVHD, graft rejection, and infectious disease transmissionHistocompatibility considerationsHLA matching has important impact on patient outcomes: 5-10% decrease in survival with each mismatchRelated donors preferred over nonrelated allogeneic donors (all things being equal)Other factors improving outcome: Donor male gender, young age, no pregnancy history, ABO matching, CMV negative status",
                    "sub_points": [
                      "Autologous transplantationPredominantly used to rescue patient bone marrow after high-dose cancer chemotherapyAntitumor effect comes from pretransplant chemotherapy, not from HSCsPatients donate HSCs for their own useNo risk of GVHD, graft rejection, or infectious disease transmissionDonors are often illHistory of chemotherapy &/or radiation may affect ability to collect adequate numbers of stem cells",
                      "Predominantly used to rescue patient bone marrow after high-dose cancer chemotherapyAntitumor effect comes from pretransplant chemotherapy, not from HSCs",
                      "Antitumor effect comes from pretransplant chemotherapy, not from HSCs",
                      "Patients donate HSCs for their own use",
                      "No risk of GVHD, graft rejection, or infectious disease transmission",
                      "Donors are often illHistory of chemotherapy &/or radiation may affect ability to collect adequate numbers of stem cells",
                      "History of chemotherapy &/or radiation may affect ability to collect adequate numbers of stem cells",
                      "Allogeneic transplantationPredominantly used to treat malignant conditions where there is known therapeutic benefit from receiving donor stem cells (graft-vs.-tumor effect)In children, allogeneic transplantation is required to replace deficient cellular machinery (cure the disease)Product may come from matched-unrelated donor or matched-related (parent, sibling, child) donorRisk of GVHD, graft rejection, and infectious disease transmissionHistocompatibility considerationsHLA matching has important impact on patient outcomes: 5-10% decrease in survival with each mismatchRelated donors preferred over nonrelated allogeneic donors (all things being equal)Other factors improving outcome: Donor male gender, young age, no pregnancy history, ABO matching, CMV negative status",
                      "Predominantly used to treat malignant conditions where there is known therapeutic benefit from receiving donor stem cells (graft-vs.-tumor effect)In children, allogeneic transplantation is required to replace deficient cellular machinery (cure the disease)",
                      "In children, allogeneic transplantation is required to replace deficient cellular machinery (cure the disease)",
                      "Product may come from matched-unrelated donor or matched-related (parent, sibling, child) donor",
                      "Risk of GVHD, graft rejection, and infectious disease transmission",
                      "Histocompatibility considerationsHLA matching has important impact on patient outcomes: 5-10% decrease in survival with each mismatchRelated donors preferred over nonrelated allogeneic donors (all things being equal)Other factors improving outcome: Donor male gender, young age, no pregnancy history, ABO matching, CMV negative status",
                      "HLA matching has important impact on patient outcomes: 5-10% decrease in survival with each mismatch",
                      "Related donors preferred over nonrelated allogeneic donors (all things being equal)",
                      "Other factors improving outcome: Donor male gender, young age, no pregnancy history, ABO matching, CMV negative status"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "Autologous Donor Eligibility Requirements": [
                  {
                    "text": "AABB standards require general health assessment before donation"
                  },
                  {
                    "text": "AABB standards require testing for HIV-1 and HIV-2, hepatitis B and C, syphilis, HTLV I/II, and CMV to assess cryopreservation contamination risk only"
                  }
                ],
                "Allogeneic Donor Eligibility Requirements": [
                  {
                    "text": "FDA regulates allogeneic hematopoietic progenitor cell collections (21 CFR Part 1271)Requires careful donor screening to assess and identify relevant communicable diseasesCompletion of questionnaireComplete physical examinationReview of patient medical recordsInfectious disease testingHIV-1 and HIV-2, hepatitis B and C, syphilis, HTLV I/II, West Nile virus, Chagas disease, CMVPositive infectious diseases tests do not absolutely prevent use of collected donor stem cellsUse of these \"ineligible\" products is at discretion of physician and based on medical urgency/need",
                    "sub_points": [
                      "Requires careful donor screening to assess and identify relevant communicable diseasesCompletion of questionnaireComplete physical examinationReview of patient medical recordsInfectious disease testingHIV-1 and HIV-2, hepatitis B and C, syphilis, HTLV I/II, West Nile virus, Chagas disease, CMV",
                      "Completion of questionnaire",
                      "Complete physical examination",
                      "Review of patient medical records",
                      "Infectious disease testingHIV-1 and HIV-2, hepatitis B and C, syphilis, HTLV I/II, West Nile virus, Chagas disease, CMV",
                      "HIV-1 and HIV-2, hepatitis B and C, syphilis, HTLV I/II, West Nile virus, Chagas disease, CMV",
                      "Positive infectious diseases tests do not absolutely prevent use of collected donor stem cellsUse of these \"ineligible\" products is at discretion of physician and based on medical urgency/need",
                      "Use of these \"ineligible\" products is at discretion of physician and based on medical urgency/need"
                    ]
                  },
                  {
                    "text": "Administration of allogeneic products is governed by standards set by accreditation bodiesAABBFACTNMDP",
                    "sub_points": [
                      "AABB",
                      "FACT",
                      "NMDP"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Peripheral Blood Collection": [
                  {
                    "text": "HSCs need to be mobilized into patient/donor peripheral blood using G-CSF (5-20 μg/kg/day) and plerixafor (if poor mobilizer)Side effects of G-CSF mobilization are bone pain, myalgia, headache, insomnia, or rarely splenic ruptureMaximum CD34 cell concentration is usually reached after day 3-5 of marrow stimulation",
                    "sub_points": [
                      "Side effects of G-CSF mobilization are bone pain, myalgia, headache, insomnia, or rarely splenic rupture",
                      "Maximum CD34 cell concentration is usually reached after day 3-5 of marrow stimulation"
                    ]
                  },
                  {
                    "text": "Collection is performed using apheresis device (usually a Spectra or Optia machine)Access for apheresis collection can be obtained via peripheral veins or central venous access (i.e., Mahurkar catheter)Side effects of apheresis collectionSeen in 20% of donorsCitrate toxicity, nausea, fatigue, chills, blood pressure changes, allergic reactions, syncopeCollection targets can usually be achieved after 1-2 collection procedures",
                    "sub_points": [
                      "Access for apheresis collection can be obtained via peripheral veins or central venous access (i.e., Mahurkar catheter)",
                      "Side effects of apheresis collectionSeen in 20% of donorsCitrate toxicity, nausea, fatigue, chills, blood pressure changes, allergic reactions, syncope",
                      "Seen in 20% of donors",
                      "Citrate toxicity, nausea, fatigue, chills, blood pressure changes, allergic reactions, syncope",
                      "Collection targets can usually be achieved after 1-2 collection procedures"
                    ]
                  },
                  {
                    "text": "Apheresis HSC product volume is usually 300-600 mL before processing"
                  }
                ],
                "Postcollection Processing": [
                  {
                    "text": "ABO product compatibilityRBCs are in apheresis stem cell productMajor incompatibilityWhen recipient has antibodies to donor RBC antigens (e.g., O recipient and A donor)Hemolytic reactions can be reduced or prevented by red cell reducing stem cell product to < 30 mL of red cell volume post collectionCan cause hemolytic transfusion reactions, delayed hemolysis, or pure red cell aplasia post transplantMinor incompatibilityWhen donor has antibodies to recipient RBC antigens (e.g., A recipient and O donor)Hemolytic reactions can be reduced or prevented by plasma reducing stem cell product postcollectionBidirectional incompatibilityWhen recipientanddonor have antibodies to recipientanddonor RBC antigens (e.g., A recipient and B donor)",
                    "sub_points": [
                      "RBCs are in apheresis stem cell product",
                      "Major incompatibilityWhen recipient has antibodies to donor RBC antigens (e.g., O recipient and A donor)Hemolytic reactions can be reduced or prevented by red cell reducing stem cell product to < 30 mL of red cell volume post collectionCan cause hemolytic transfusion reactions, delayed hemolysis, or pure red cell aplasia post transplant",
                      "When recipient has antibodies to donor RBC antigens (e.g., O recipient and A donor)",
                      "Hemolytic reactions can be reduced or prevented by red cell reducing stem cell product to < 30 mL of red cell volume post collection",
                      "Can cause hemolytic transfusion reactions, delayed hemolysis, or pure red cell aplasia post transplant",
                      "Minor incompatibilityWhen donor has antibodies to recipient RBC antigens (e.g., A recipient and O donor)Hemolytic reactions can be reduced or prevented by plasma reducing stem cell product postcollection",
                      "When donor has antibodies to recipient RBC antigens (e.g., A recipient and O donor)",
                      "Hemolytic reactions can be reduced or prevented by plasma reducing stem cell product postcollection",
                      "Bidirectional incompatibilityWhen recipientanddonor have antibodies to recipientanddonor RBC antigens (e.g., A recipient and B donor)",
                      "When recipientanddonor have antibodies to recipientanddonor RBC antigens (e.g., A recipient and B donor)"
                    ]
                  },
                  {
                    "text": "Plasma and RBC reductionHelpful to reduce/prevent reactions from ABO incompatibilityPlasma can be reduced by simple centrifugationRBC reduction requires use of hydroxyethyl starch &/or centrifugationMay be complicated by loss of CD34+ cells during process",
                    "sub_points": [
                      "Helpful to reduce/prevent reactions from ABO incompatibility",
                      "Plasma can be reduced by simple centrifugation",
                      "RBC reduction requires use of hydroxyethyl starch &/or centrifugationMay be complicated by loss of CD34+ cells during process",
                      "May be complicated by loss of CD34+ cells during process"
                    ]
                  },
                  {
                    "text": "CD34+ cell enrichment/T-cell depletionAnti-CD34+ labeled magnetic beads can be used to capture CD34+ stem cells over other WBCs or tumor cellsT-cell depletion may decrease risk of GVHDTumor cell depletion removes tumor cells from HSC products to prevent potential relapse",
                    "sub_points": [
                      "Anti-CD34+ labeled magnetic beads can be used to capture CD34+ stem cells over other WBCs or tumor cells",
                      "T-cell depletion may decrease risk of GVHD",
                      "Tumor cell depletion removes tumor cells from HSC products to prevent potential relapse"
                    ]
                  }
                ],
                "Product Storage": [
                  {
                    "text": "DMSO is added at concentrations of 5-10% to prevent ice crystal formation"
                  },
                  {
                    "text": "DMSO stem cell product is cooled at 1-2 °C/min to storage temperature of -70 °C to -196 °C depending on storage typeStem cell products are most often stored in vapor phase liquid nitrogen (-150 °C)",
                    "sub_points": [
                      "Stem cell products are most often stored in vapor phase liquid nitrogen (-150 °C)"
                    ]
                  }
                ],
                "Peripheral Blood Collection Processing Outcomes": [
                  {
                    "text": "Minimum number of cells needed for transplantation is 2 x 10⁶ CD34+ cells/kg5 x 10⁶ CD34+ cells/kg is desirable",
                    "sub_points": [
                      "5 x 10⁶ CD34+ cells/kg is desirable"
                    ]
                  },
                  {
                    "text": "Time to stem cell engraftment is shorter for peripheral blood derived hematopoietic progenitor cell products than marrow derived hematopoietic progenitor cell productsNeutrophil engraftment is 14-15 daysPlatelet engraftment is 13-14 days",
                    "sub_points": [
                      "Neutrophil engraftment is 14-15 days",
                      "Platelet engraftment is 13-14 days"
                    ]
                  },
                  {
                    "text": "Patient overall and disease-free survival may be better with peripheral blood-derived hematopoietic progenitor cell products than marrow derived hematopoietic progenitor cell productsOutcome studies differ based on patient populationPeripherally collected stem cells are associated with greater risk for chronic GVHD but fewer graft failures",
                    "sub_points": [
                      "Outcome studies differ based on patient population",
                      "Peripherally collected stem cells are associated with greater risk for chronic GVHD but fewer graft failures"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "Quality testing aimed at characterizing safety, purity, potency, and stability of productQuality measures usedTotal nucleated cell count/kg recipient body weightCD34+ cells/kg recipient body weightDetermined by flow cytometryWBC viabilityUsing trypan blue, acridine orange, or 7-aminoactinomycin DSterility testingUsing automated microbial detection systemFunctional assay (clonogenic assay)Results of assay correlate well with speed of product engraftment",
                    "sub_points": [
                      "Quality measures usedTotal nucleated cell count/kg recipient body weightCD34+ cells/kg recipient body weightDetermined by flow cytometryWBC viabilityUsing trypan blue, acridine orange, or 7-aminoactinomycin DSterility testingUsing automated microbial detection systemFunctional assay (clonogenic assay)Results of assay correlate well with speed of product engraftment",
                      "Total nucleated cell count/kg recipient body weight",
                      "CD34+ cells/kg recipient body weightDetermined by flow cytometry",
                      "Determined by flow cytometry",
                      "WBC viabilityUsing trypan blue, acridine orange, or 7-aminoactinomycin D",
                      "Using trypan blue, acridine orange, or 7-aminoactinomycin D",
                      "Sterility testingUsing automated microbial detection system",
                      "Using automated microbial detection system",
                      "Functional assay (clonogenic assay)Results of assay correlate well with speed of product engraftment",
                      "Results of assay correlate well with speed of product engraftment"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cord Blood Banking": {
            "name": "Cord Blood Banking",
            "url": "https://app.pathprimer.com/document/8f9e7f3c-4908-4bfa-9406-dac4d9f046e5/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Cord blood is rich in hematopoietic stem cells (HSC) and serves as alternative source of stem cells for patients who do not have matched related donors"
                  },
                  {
                    "text": "Cord blood banks are regulated by FDA, and standards are issued by American Association of Blood Banks (AABB) and Foundation for the Accreditation of Cellular Therapy (FACT) organizations"
                  }
                ]
              },
              "OVERVIEW": {
                "Cord Blood (the Product)": [
                  {
                    "text": "Cord blood: Blood remaining in placenta and umbilical cord after a birthOne unit: Product collected from single placenta/umbilical cord",
                    "sub_points": [
                      "One unit: Product collected from single placenta/umbilical cord"
                    ]
                  },
                  {
                    "text": "Rich in HSCs; alternative source of stem cells for patients who do not have matched related donorsFirst transplant using cord blood occurred in 1988; since then 30,000 transplants have been performedCurrent usesStem cell transplants (for leukemia, lymphoma, inherited immune deficiencies, hemoglobinopathies, etc.)Regenerative medicine techniques (research)AdvantagesRich source of HSCEasy to collect, with minimal risk to mother and newbornRich diversity of HLA and ABO types (large potential donor pool)No established expiration date (when cryopreserved)Lower risk of viral infections in comparison to adult donorsContains immunologically naive lymphocytes, so HLA matching may be less critical for these cellsLess risk for graft-versus-host disease (GVHD)DisadvantagesVolume collected may not contain adequate number of cells for adult/larger patient transplantLonger predicted engraftment time than peripheral blood or bone marrow productsEngraftment is associated with longer times to transfusion independence and increased recipient infection riskSecond donations are not possible (one-time collection)Transmission of congenital or genetic diseases is possible",
                    "sub_points": [
                      "First transplant using cord blood occurred in 1988; since then 30,000 transplants have been performed",
                      "Current usesStem cell transplants (for leukemia, lymphoma, inherited immune deficiencies, hemoglobinopathies, etc.)Regenerative medicine techniques (research)",
                      "Stem cell transplants (for leukemia, lymphoma, inherited immune deficiencies, hemoglobinopathies, etc.)",
                      "Regenerative medicine techniques (research)",
                      "AdvantagesRich source of HSCEasy to collect, with minimal risk to mother and newbornRich diversity of HLA and ABO types (large potential donor pool)No established expiration date (when cryopreserved)Lower risk of viral infections in comparison to adult donorsContains immunologically naive lymphocytes, so HLA matching may be less critical for these cellsLess risk for graft-versus-host disease (GVHD)",
                      "Rich source of HSC",
                      "Easy to collect, with minimal risk to mother and newborn",
                      "Rich diversity of HLA and ABO types (large potential donor pool)",
                      "No established expiration date (when cryopreserved)",
                      "Lower risk of viral infections in comparison to adult donors",
                      "Contains immunologically naive lymphocytes, so HLA matching may be less critical for these cellsLess risk for graft-versus-host disease (GVHD)",
                      "Less risk for graft-versus-host disease (GVHD)",
                      "DisadvantagesVolume collected may not contain adequate number of cells for adult/larger patient transplantLonger predicted engraftment time than peripheral blood or bone marrow productsEngraftment is associated with longer times to transfusion independence and increased recipient infection riskSecond donations are not possible (one-time collection)Transmission of congenital or genetic diseases is possible",
                      "Volume collected may not contain adequate number of cells for adult/larger patient transplant",
                      "Longer predicted engraftment time than peripheral blood or bone marrow productsEngraftment is associated with longer times to transfusion independence and increased recipient infection risk",
                      "Engraftment is associated with longer times to transfusion independence and increased recipient infection risk",
                      "Second donations are not possible (one-time collection)",
                      "Transmission of congenital or genetic diseases is possible"
                    ]
                  }
                ],
                "Cord Blood Bank (the Process)": [
                  {
                    "text": "Type of banksPrivateFor-profit companies that facilitate storage of cord blood for personal or family useUse of cord blood as \"biological insurance\" is discouraged by American Academy of Pediatrics (citing lack of evidence)DirectedCord blood donations where recipient is known or related to donor or donor's familyPublicCord blood donations where recipient can be any suitable patient, unrelated to donor",
                    "sub_points": [
                      "PrivateFor-profit companies that facilitate storage of cord blood for personal or family useUse of cord blood as \"biological insurance\" is discouraged by American Academy of Pediatrics (citing lack of evidence)",
                      "For-profit companies that facilitate storage of cord blood for personal or family useUse of cord blood as \"biological insurance\" is discouraged by American Academy of Pediatrics (citing lack of evidence)",
                      "Use of cord blood as \"biological insurance\" is discouraged by American Academy of Pediatrics (citing lack of evidence)",
                      "DirectedCord blood donations where recipient is known or related to donor or donor's family",
                      "Cord blood donations where recipient is known or related to donor or donor's family",
                      "PublicCord blood donations where recipient can be any suitable patient, unrelated to donor",
                      "Cord blood donations where recipient can be any suitable patient, unrelated to donor"
                    ]
                  },
                  {
                    "text": "Collection processMother must give informed consent for testing and collection of cord bloodTiming of this process is important, as it effects collection volume and risk for clottingCord blood flows by gravity from umbilical vein into collection bag with CPDA (anticoagulant) post-venipunctureIn utero collectionsPerformed by obstetrician during third stage of labor, after delivery of childEx utero collectionsPerformed after third stage of labor, after delivery of placenta by trained collection personnel member (clinical team is not involved)",
                    "sub_points": [
                      "Mother must give informed consent for testing and collection of cord blood",
                      "Timing of this process is important, as it effects collection volume and risk for clottingCord blood flows by gravity from umbilical vein into collection bag with CPDA (anticoagulant) post-venipuncture",
                      "Cord blood flows by gravity from umbilical vein into collection bag with CPDA (anticoagulant) post-venipuncture",
                      "In utero collectionsPerformed by obstetrician during third stage of labor, after delivery of child",
                      "Performed by obstetrician during third stage of labor, after delivery of child",
                      "Ex utero collectionsPerformed after third stage of labor, after delivery of placenta by trained collection personnel member (clinical team is not involved)",
                      "Performed after third stage of labor, after delivery of placenta by trained collection personnel member (clinical team is not involved)"
                    ]
                  },
                  {
                    "text": "ProcessingMust occur within 48 hours of collectionGoal is to remove maximum red cells and plasma before storageThis process is often automated",
                    "sub_points": [
                      "Must occur within 48 hours of collection",
                      "Goal is to remove maximum red cells and plasma before storageThis process is often automated",
                      "This process is often automated"
                    ]
                  },
                  {
                    "text": "Required testingDonor cord blood eligibility is dictated by FDA regulations 21 CFR 1271Based on risk factors assessed on maternal questionnaire, review of medical records, and results of infectious disease testsCord blood units with positive tests for HIV, HTLV, or hepatitis should be discardedInfectious diseases (should be negative for all)Cultures are taken from product to rule out bacterial and fungal contaminationHIV (both antibody to HIV 1 and 2, and nucleic acid test)Hepatitis B (anticore antibody, surface antigen, and nucleic acid testing)Hepatitis C (antibody and nucleic acid testing)Human T-lymphocyte virus (antibody for HTLV I and II)Syphilis screeningChagas (Trypanosoma cruzi) antibodyWest Nile virus (nucleic acid testing)Potency evaluationMany cord banks have predefined cut-off collection volumes &/or cell counts to select products for cryopreservation and storageTotal nucleated cell count: Number of nucleated cells counted both before and after processingCD34+ count and viability: Number of CD34+ stem cells, determined via flow cytometry prior to cryopreservationIdentity typingShould be tested twice (before processing and before use)ABO and DHLA (typing for -A, -B, and -DR are required)Hemoglobinopathy screening (HbS)",
                    "sub_points": [
                      "Donor cord blood eligibility is dictated by FDA regulations 21 CFR 1271Based on risk factors assessed on maternal questionnaire, review of medical records, and results of infectious disease testsCord blood units with positive tests for HIV, HTLV, or hepatitis should be discarded",
                      "Based on risk factors assessed on maternal questionnaire, review of medical records, and results of infectious disease tests",
                      "Cord blood units with positive tests for HIV, HTLV, or hepatitis should be discarded",
                      "Infectious diseases (should be negative for all)Cultures are taken from product to rule out bacterial and fungal contaminationHIV (both antibody to HIV 1 and 2, and nucleic acid test)Hepatitis B (anticore antibody, surface antigen, and nucleic acid testing)Hepatitis C (antibody and nucleic acid testing)Human T-lymphocyte virus (antibody for HTLV I and II)Syphilis screeningChagas (Trypanosoma cruzi) antibodyWest Nile virus (nucleic acid testing)",
                      "Cultures are taken from product to rule out bacterial and fungal contamination",
                      "HIV (both antibody to HIV 1 and 2, and nucleic acid test)",
                      "Hepatitis B (anticore antibody, surface antigen, and nucleic acid testing)",
                      "Hepatitis C (antibody and nucleic acid testing)",
                      "Human T-lymphocyte virus (antibody for HTLV I and II)",
                      "Syphilis screening",
                      "Chagas (Trypanosoma cruzi) antibody",
                      "West Nile virus (nucleic acid testing)",
                      "Potency evaluationMany cord banks have predefined cut-off collection volumes &/or cell counts to select products for cryopreservation and storageTotal nucleated cell count: Number of nucleated cells counted both before and after processingCD34+ count and viability: Number of CD34+ stem cells, determined via flow cytometry prior to cryopreservation",
                      "Many cord banks have predefined cut-off collection volumes &/or cell counts to select products for cryopreservation and storageTotal nucleated cell count: Number of nucleated cells counted both before and after processingCD34+ count and viability: Number of CD34+ stem cells, determined via flow cytometry prior to cryopreservation",
                      "Total nucleated cell count: Number of nucleated cells counted both before and after processing",
                      "CD34+ count and viability: Number of CD34+ stem cells, determined via flow cytometry prior to cryopreservation",
                      "Identity typingShould be tested twice (before processing and before use)ABO and DHLA (typing for -A, -B, and -DR are required)",
                      "Should be tested twice (before processing and before use)ABO and DHLA (typing for -A, -B, and -DR are required)",
                      "ABO and D",
                      "HLA (typing for -A, -B, and -DR are required)",
                      "Hemoglobinopathy screening (HbS)"
                    ]
                  },
                  {
                    "text": "Storage and shipping parametersCord blood cells are added to 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogenCord blood is shipped in validated packaging that can maintain controlled low temperature (-196°C) for 5-7 days",
                    "sub_points": [
                      "Cord blood cells are added to 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen",
                      "Cord blood is shipped in validated packaging that can maintain controlled low temperature (-196°C) for 5-7 days"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA Considers Cord Blood a Biological Drug": [
                  {
                    "text": "Donor cord blood eligibility is dictated by FDA regulations 21 CFR 1271"
                  }
                ],
                "Standards and Accreditation": [
                  {
                    "text": "Issued by AABB and FACT organizations"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hematopoietic Progenitor Cell Infusion": {
            "name": "Hematopoietic Progenitor Cell Infusion",
            "url": "https://app.pathprimer.com/document/e3bd71c4-4236-4774-9e6b-be50fac031bd/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hematopoietic progenitor cell infusion process is simple, but multiple, mostly mild complications can occur from red cells, granulocytes, plasma proteins, and DSMO in product"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Classic Clinical Findings": [
                  {
                    "text": "Hematopoietic progenitor cell infusion process is simple, but multiple complications can occurInfusion processProduct and patient must be identified correctly at bedsideProduct is infused using intravenous (IV) drip directly into central line, typically without needle or pumpPatient vital signs should be measured before infusion, immediately after infusion, and 1 hr after infusion at a minimumTo maximize infusion of stem cells, bag and IV tubing can be flushed with saline into patient after bag emptiesProduct is infused as fast as patient can tolerateAssociated adverse eventsMost common reported side effects during infusion are mildCoughThroat tickleNausea/emesisReactions associated with infusion can be very similar to reactions seen with other blood product transfusionsCardiac overloadAllergic reactionFebrile nonhemolytic reactionSepsisABO incompatibility is major contributor to adverse eventsHemolytic reactions can occur when donor and recipient ABO type is differentMajor ABO mismatches (recipient has antibodies against donor red cells) are most likely to cause immediate acute hemolytic reactionsAdverse symptoms from hemolysis: fever, back pain, chills, blood pressure changes, renal dysfunction, pain at infusion site, sense of doom, hemoglobinemia, hemoglobinuria, disseminated intravascular coagulationRisk is reduced as much as possible by use of red cell and plasma reduction techniques after collectionEffects from dimethyl sulfoxide (DMSO) (5%-10%)Common adverse symptoms: pruritus, urticaria, flushing, wheezing, fever, nausea, emesis, cough, headacheRisk reduced by use of smaller volume products or post-thaw washed/diluted larger volume productsProphylactic medications/treatments commonly used with stem cell infusionAggressive IV hydration before and after infusion with use of diuretics, antiemetics, antipyretics, and antihistaminesTransplant physician and cell therapy laboratory should be notified of unexpected or moderate/severe reaction to infusionCause of reaction should be determined with direct antiglobulin test, antibody titer, Gram stain, or bacterial blood cultureData on patient longer term clinical outcomes, such as time to engraftment, should also be reviewed regularly as quality improvement measure",
                    "sub_points": [
                      "Infusion processProduct and patient must be identified correctly at bedsideProduct is infused using intravenous (IV) drip directly into central line, typically without needle or pumpPatient vital signs should be measured before infusion, immediately after infusion, and 1 hr after infusion at a minimumTo maximize infusion of stem cells, bag and IV tubing can be flushed with saline into patient after bag emptiesProduct is infused as fast as patient can tolerate",
                      "Product and patient must be identified correctly at bedside",
                      "Product is infused using intravenous (IV) drip directly into central line, typically without needle or pumpPatient vital signs should be measured before infusion, immediately after infusion, and 1 hr after infusion at a minimum",
                      "Patient vital signs should be measured before infusion, immediately after infusion, and 1 hr after infusion at a minimum",
                      "To maximize infusion of stem cells, bag and IV tubing can be flushed with saline into patient after bag empties",
                      "Product is infused as fast as patient can tolerate",
                      "Associated adverse eventsMost common reported side effects during infusion are mildCoughThroat tickleNausea/emesisReactions associated with infusion can be very similar to reactions seen with other blood product transfusionsCardiac overloadAllergic reactionFebrile nonhemolytic reactionSepsisABO incompatibility is major contributor to adverse eventsHemolytic reactions can occur when donor and recipient ABO type is differentMajor ABO mismatches (recipient has antibodies against donor red cells) are most likely to cause immediate acute hemolytic reactionsAdverse symptoms from hemolysis: fever, back pain, chills, blood pressure changes, renal dysfunction, pain at infusion site, sense of doom, hemoglobinemia, hemoglobinuria, disseminated intravascular coagulationRisk is reduced as much as possible by use of red cell and plasma reduction techniques after collectionEffects from dimethyl sulfoxide (DMSO) (5%-10%)Common adverse symptoms: pruritus, urticaria, flushing, wheezing, fever, nausea, emesis, cough, headacheRisk reduced by use of smaller volume products or post-thaw washed/diluted larger volume productsProphylactic medications/treatments commonly used with stem cell infusionAggressive IV hydration before and after infusion with use of diuretics, antiemetics, antipyretics, and antihistaminesTransplant physician and cell therapy laboratory should be notified of unexpected or moderate/severe reaction to infusionCause of reaction should be determined with direct antiglobulin test, antibody titer, Gram stain, or bacterial blood cultureData on patient longer term clinical outcomes, such as time to engraftment, should also be reviewed regularly as quality improvement measure",
                      "Most common reported side effects during infusion are mildCoughThroat tickleNausea/emesis",
                      "Cough",
                      "Throat tickle",
                      "Nausea/emesis",
                      "Reactions associated with infusion can be very similar to reactions seen with other blood product transfusionsCardiac overloadAllergic reactionFebrile nonhemolytic reactionSepsis",
                      "Cardiac overload",
                      "Allergic reaction",
                      "Febrile nonhemolytic reaction",
                      "Sepsis",
                      "ABO incompatibility is major contributor to adverse eventsHemolytic reactions can occur when donor and recipient ABO type is differentMajor ABO mismatches (recipient has antibodies against donor red cells) are most likely to cause immediate acute hemolytic reactionsAdverse symptoms from hemolysis: fever, back pain, chills, blood pressure changes, renal dysfunction, pain at infusion site, sense of doom, hemoglobinemia, hemoglobinuria, disseminated intravascular coagulationRisk is reduced as much as possible by use of red cell and plasma reduction techniques after collection",
                      "Hemolytic reactions can occur when donor and recipient ABO type is different",
                      "Major ABO mismatches (recipient has antibodies against donor red cells) are most likely to cause immediate acute hemolytic reactions",
                      "Adverse symptoms from hemolysis: fever, back pain, chills, blood pressure changes, renal dysfunction, pain at infusion site, sense of doom, hemoglobinemia, hemoglobinuria, disseminated intravascular coagulation",
                      "Risk is reduced as much as possible by use of red cell and plasma reduction techniques after collection",
                      "Effects from dimethyl sulfoxide (DMSO) (5%-10%)Common adverse symptoms: pruritus, urticaria, flushing, wheezing, fever, nausea, emesis, cough, headacheRisk reduced by use of smaller volume products or post-thaw washed/diluted larger volume products",
                      "Common adverse symptoms: pruritus, urticaria, flushing, wheezing, fever, nausea, emesis, cough, headache",
                      "Risk reduced by use of smaller volume products or post-thaw washed/diluted larger volume products",
                      "Prophylactic medications/treatments commonly used with stem cell infusionAggressive IV hydration before and after infusion with use of diuretics, antiemetics, antipyretics, and antihistamines",
                      "Aggressive IV hydration before and after infusion with use of diuretics, antiemetics, antipyretics, and antihistamines",
                      "Transplant physician and cell therapy laboratory should be notified of unexpected or moderate/severe reaction to infusionCause of reaction should be determined with direct antiglobulin test, antibody titer, Gram stain, or bacterial blood cultureData on patient longer term clinical outcomes, such as time to engraftment, should also be reviewed regularly as quality improvement measure",
                      "Cause of reaction should be determined with direct antiglobulin test, antibody titer, Gram stain, or bacterial blood culture",
                      "Data on patient longer term clinical outcomes, such as time to engraftment, should also be reviewed regularly as quality improvement measure"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tissue Banking": {
            "name": "Tissue Banking",
            "url": "https://app.pathprimer.com/document/80e28fe6-f607-401d-afb4-d7d51150152e/lesson/ec2e7fd6-d4ac-4359-a526-7abb6a803f18",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Tissue bank regulation is similar to blood bank regulation"
                  },
                  {
                    "text": "Tissue storage conditions differ depending on nature of tissue, method of preservation, and type of packaging"
                  }
                ]
              },
              "OVERVIEW": {
                "Tissue Banks": [
                  {
                    "text": "30,000 donors provide > 2 million tissue grafts for transplantation yearlyBone, tendon, and cornea are most commonMultiple specialties use stored human tissueOrthopedicsPlastic surgeryUrologyNeurologySports medicineTrauma",
                    "sub_points": [
                      "Bone, tendon, and cornea are most common",
                      "Multiple specialties use stored human tissueOrthopedicsPlastic surgeryUrologyNeurologySports medicineTrauma",
                      "Orthopedics",
                      "Plastic surgery",
                      "Urology",
                      "Neurology",
                      "Sports medicine",
                      "Trauma"
                    ]
                  },
                  {
                    "text": "Donor eligibilityDeferral criteria is similar to criteria used for blood donorsDonor travel (infection-endemic areas) and medical history (high-risk behaviors) are evaluated using medical records, autopsy records, and next-of-kin interviewInfectious disease testing should be negative (required)Hepatitis B (surface antigen and core antibody)Hepatitis C (antibody and nucleic acid testing)HIV (antibody for HIV-1 and HIV-2, and nucleic acid testing)HTLV (HTLV I and HTLV II antibodies)Syphilis (nontreponema- or treponema-specific assay)",
                    "sub_points": [
                      "Deferral criteria is similar to criteria used for blood donorsDonor travel (infection-endemic areas) and medical history (high-risk behaviors) are evaluated using medical records, autopsy records, and next-of-kin interviewInfectious disease testing should be negative (required)Hepatitis B (surface antigen and core antibody)Hepatitis C (antibody and nucleic acid testing)HIV (antibody for HIV-1 and HIV-2, and nucleic acid testing)HTLV (HTLV I and HTLV II antibodies)Syphilis (nontreponema- or treponema-specific assay)",
                      "Donor travel (infection-endemic areas) and medical history (high-risk behaviors) are evaluated using medical records, autopsy records, and next-of-kin interview",
                      "Infectious disease testing should be negative (required)Hepatitis B (surface antigen and core antibody)Hepatitis C (antibody and nucleic acid testing)HIV (antibody for HIV-1 and HIV-2, and nucleic acid testing)HTLV (HTLV I and HTLV II antibodies)Syphilis (nontreponema- or treponema-specific assay)",
                      "Hepatitis B (surface antigen and core antibody)",
                      "Hepatitis C (antibody and nucleic acid testing)",
                      "HIV (antibody for HIV-1 and HIV-2, and nucleic acid testing)",
                      "HTLV (HTLV I and HTLV II antibodies)",
                      "Syphilis (nontreponema- or treponema-specific assay)"
                    ]
                  },
                  {
                    "text": "Tissue procurement and processingMost tissues are procured from deceased donors within 24 hours of death after consent is obtained from legal designated authorityTissue is obtained using aseptic surgical techniquesTissues are processed in controlled environment in facility designed to prevent contamination",
                    "sub_points": [
                      "Most tissues are procured from deceased donors within 24 hours of death after consent is obtained from legal designated authority",
                      "Tissue is obtained using aseptic surgical techniques",
                      "Tissues are processed in controlled environment in facility designed to prevent contamination"
                    ]
                  }
                ]
              },
              "LABORATORY REGULATION": {
                "FDA Regulates Activities of Tissue Banks": [
                  {
                    "text": "Code of Federal Regulations (CFR) Title 21, parts 1270 and 12711271 concerns the followingTissue bank registrationRules for donor eligibilityAppropriate processing and storage (good tissue practice, or GTP)1271 rules do not apply to facilities that only receive, store, and dispense tissue1271 rules concern only nonvascularized tissues (i.e., bone, ligament, tendon)",
                    "sub_points": [
                      "1271 concerns the followingTissue bank registrationRules for donor eligibilityAppropriate processing and storage (good tissue practice, or GTP)",
                      "Tissue bank registration",
                      "Rules for donor eligibility",
                      "Appropriate processing and storage (good tissue practice, or GTP)",
                      "1271 rules do not apply to facilities that only receive, store, and dispense tissue",
                      "1271 rules concern only nonvascularized tissues (i.e., bone, ligament, tendon)"
                    ]
                  },
                  {
                    "text": "Standards for tissue-dispensing services (not 2171 applicable)Regulatory oversight of tissue banks is governed by multiple voluntary organizationsJoint CommissionAmerican Association of Blood Banks (AABB)College of American Pathologists (CAP)Association of periOperative Registered Nurses (AORN)American Association of Tissue Banks (AATB)Eye Bank Association of America (EBAA)",
                    "sub_points": [
                      "Regulatory oversight of tissue banks is governed by multiple voluntary organizationsJoint CommissionAmerican Association of Blood Banks (AABB)College of American Pathologists (CAP)Association of periOperative Registered Nurses (AORN)American Association of Tissue Banks (AATB)Eye Bank Association of America (EBAA)",
                      "Joint Commission",
                      "American Association of Blood Banks (AABB)",
                      "College of American Pathologists (CAP)",
                      "Association of periOperative Registered Nurses (AORN)",
                      "American Association of Tissue Banks (AATB)",
                      "Eye Bank Association of America (EBAA)"
                    ]
                  },
                  {
                    "text": "Accreditation of tissue-dispensing servicesAATB and EBAA offer tissue bank–specific accreditationTissue banks are not required to be in blood bankSuccessful accreditation is dependent upon clear rules and procedures (similar to blood bank rules and regulations)Tissue orderingTissue receivingTissue storageTissue distribution and trackingInvestigating adverse eventsTissue-related recalls, complaints, and lookback investigations",
                    "sub_points": [
                      "AATB and EBAA offer tissue bank–specific accreditation",
                      "Tissue banks are not required to be in blood bank",
                      "Successful accreditation is dependent upon clear rules and procedures (similar to blood bank rules and regulations)Tissue orderingTissue receivingTissue storageTissue distribution and trackingInvestigating adverse eventsTissue-related recalls, complaints, and lookback investigations",
                      "Tissue ordering",
                      "Tissue receiving",
                      "Tissue storage",
                      "Tissue distribution and tracking",
                      "Investigating adverse events",
                      "Tissue-related recalls, complaints, and lookback investigations"
                    ]
                  },
                  {
                    "text": "Required tissue storage conditions and compatibility issuesIn general, bone and soft tissue allografts do not need to be matched for HLA or ABOAppropriate storage conditions depend on nature of tissue, method of preservation, and type of packagingContinuous temperature monitoring is required for refrigerated and frozen products",
                    "sub_points": [
                      "In general, bone and soft tissue allografts do not need to be matched for HLA or ABO",
                      "Appropriate storage conditions depend on nature of tissue, method of preservation, and type of packagingContinuous temperature monitoring is required for refrigerated and frozen products",
                      "Continuous temperature monitoring is required for refrigerated and frozen products"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}